<SEC-DOCUMENT>0001493152-23-022805.txt : 20230628
<SEC-HEADER>0001493152-23-022805.hdr.sgml : 20230628
<ACCEPTANCE-DATETIME>20230628171551
ACCESSION NUMBER:		0001493152-23-022805
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		129
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230628
DATE AS OF CHANGE:		20230628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EUDA Health Holdings Ltd
		CENTRAL INDEX KEY:			0001847846
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HEALTH SERVICES [8000]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0731

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40678
		FILM NUMBER:		231053170

	BUSINESS ADDRESS:	
		STREET 1:		C/O 6 EU TONG SEN STREET
		STREET 2:		#08-13 THE CENTRAL
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			059817
		BUSINESS PHONE:		65 67880388

	MAIL ADDRESS:	
		STREET 1:		C/O 6 EU TONG SEN STREET
		STREET 2:		#08-13 THE CENTRAL
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			059817

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	8i Acquisition 2 Corp.
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:EUDA="http://euda.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_EUDA_euda.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001847846 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_SGD_0_iso4217%2D%2DSGD -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001847846</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0021" name="dei:EntityIncorporationStateCountryCode">D8</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ForwardPurchaseReceivables" contextRef="AsOf2021-12-31" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:OtherReceivablesNonCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:LoanToThirdParty" contextRef="AsOf2022-12-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ShortTermLoansThirdParties" contextRef="AsOf2022-12-31" id="xdx2ixbrl0125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:PromissoryNote" contextRef="AsOf2021-12-31" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ConvertibleNotesRelatedParties" contextRef="AsOf2021-12-31" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:AccountsPayableRelatedParty" contextRef="AsOf2022-12-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2021-12-31" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0195" name="us-gaap:CommonStockSharesAuthorizedUnlimited">Unlimited</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0197" name="us-gaap:CommonStockSharesAuthorizedUnlimited">Unlimited</ix:nonNumeric>
  <ix:nonFraction name="EUDA:EarnoutSharePayment" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueCapitalContributions" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueCapitalContributions" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueCapitalContributions" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:EarnoutPayment" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesReceivableCurrent" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ProceedsFromReverseRecapitalization" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:RepaymentsToShorttermLoansThirdParties" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ConversionOfDebtIntoPromissoryNote" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ConversionOfDebtsIntoConvertibleNotes" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ForgivenessOfDebtByRelatedParty" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:IssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2021-12-31_currency_MYR" id="xdx2ixbrl0804" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2021-12-31_currency_MYR" id="xdx2ixbrl0807" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_currency_MYR" id="xdx2ixbrl0816" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_currency_MYR" id="xdx2ixbrl0819" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2021-12-31" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0868" decimals="0" unitRef="USD">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1015" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:DivestmentReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl1207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:OtherReceivablesNetNonCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2021-12-31" id="xdx2ixbrl1227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2020-12-31" id="xdx2ixbrl1229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:AllowanceForDoubtfulOtherReceivableRecoveries" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:AllowanceForDoubtfulOtherReceivableWriteOffs" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2022-12-31" id="xdx2ixbrl1239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2021-12-31" id="xdx2ixbrl1241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember" id="xdx2ixbrl1347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl1349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember" id="xdx2ixbrl1351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember" id="xdx2ixbrl1352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl1353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestIncomeRelatedParty" contextRef="From2022-01-012022-12-31_custom_PTTotalPrimaIndonesiaMember" id="xdx2ixbrl1401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" id="xdx2ixbrl1431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" id="xdx2ixbrl1445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" id="xdx2ixbrl1468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" id="xdx2ixbrl1493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" id="xdx2ixbrl1514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" id="xdx2ixbrl1526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" id="xdx2ixbrl1538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" id="xdx2ixbrl1550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_ConvertibleNotesThirdPartiesMember" id="xdx2ixbrl1554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" id="xdx2ixbrl1566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" id="xdx2ixbrl1578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_custom_ConvertibleNotesRelatedPartiesMember" id="xdx2ixbrl1582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_UGDigitalSdnBhdMember" id="xdx2ixbrl1621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_ZukihealthSDNMember" id="xdx2ixbrl1627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_JenniferGohMember" id="xdx2ixbrl1630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_FrescoInvestmentPteLtdMember" id="xdx2ixbrl1633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember" id="xdx2ixbrl1637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember" id="xdx2ixbrl1646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember" id="xdx2ixbrl1649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_JamieFanWeiZhiMember" id="xdx2ixbrl1655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_WatermarkDevelopmentsLtdMember" id="xdx2ixbrl1668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_WilkeServicesLtdMember" id="xdx2ixbrl1670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_MountLockeLimitedMember" id="xdx2ixbrl1674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_UGDigitalSdnBhdMember" id="xdx2ixbrl1677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1753" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1755" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1757" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ClassOfWarrantOrRightOutstandingForfeited" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1767" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1769" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:ClassOfWarrantOrRightOutstandingExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1771" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1773" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="EUDA:DeferredTaxAssetsLeaseLiabilityNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2022-12-31" id="xdx2ixbrl1906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" id="xdx2ixbrl1909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31" id="xdx2ixbrl1984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember" id="xdx2ixbrl1988" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" id="xdx2ixbrl2046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="euda-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">EUDA:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">EUDA:RedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-24</xbrli:startDate>
        <xbrli:endDate>2021-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-24_custom_EUDAPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-24</xbrli:startDate>
        <xbrli:endDate>2021-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-01_custom_SuperGatewayGroupLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-01_custom_SuperGatewayGroupLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAHealthLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EUDAHealthLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAHealthLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EUDAPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitekVietnamPrivateLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitekVietnamPrivateLimitedLiabilityCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TheGoodClinicPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDADoctorPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EUDADoctorPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDADoctorPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHillPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgeHillPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHillPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgeHealthLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitechPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ZukitechPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitechPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SuperGatewayGroupLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UniversalGatewayInternationalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UniversalGatewayInternationalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:MelanaInternationalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MelanaInternationalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:MelanaInternationalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TriGlobalSecurityPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TriGlobalSecurityPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TriGlobalSecurityPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UGDigitechPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UGDigitechPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UGDigitechPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:NosweatFitnessCompanyPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:NosweatFitnessCompanyPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TrueCoverPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TrueCoverPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TrueCoverPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KRDigitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukihealthSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ZukihealthSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukihealthSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-012022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-01</xbrli:startDate>
        <xbrli:endDate>2022-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-19_custom_KRDigitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-192022-04-19_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-19</xbrli:startDate>
        <xbrli:endDate>2022-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-15_custom_KRDigitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-152022-04-15_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-15</xbrli:startDate>
        <xbrli:endDate>2022-04-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_currency_SGD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_currency_SGD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_currency_VND">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:VND</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_currency_VND">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:VND</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_currency_MYR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MYR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_currency_MYR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MYR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CentralProvidentFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:CentralProvidentFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SkillDevelopmentLevyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SocialInsuranceFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SocialInsuranceFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SocialInsuranceFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SocialInsuranceFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSubTotalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServiceCommonAreaManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceCommonAreaManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServiceCommonAreaManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceCommonAreaManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServiceSecurityManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceSecurityManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServiceSecurityManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceSecurityManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServicesCommonAreaManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesCommonAreaManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServicesCommonAreaManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesCommonAreaManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServicesSecurityManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesSecurityManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServicesSecurityManagementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesSecurityManagementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ProductMangementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductMangementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ProductMangementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductMangementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-162022-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-16</xbrli:startDate>
        <xbrli:endDate>2022-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-162022-11-17_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-16</xbrli:startDate>
        <xbrli:endDate>2022-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-162022-11-17_custom_SecondAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SecondAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-16</xbrli:startDate>
        <xbrli:endDate>2022-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17_custom_SecondAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SecondAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17_custom_BusinessCombinationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:BusinessCombinationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17_custom_SharePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SharePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-162022-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-16</xbrli:startDate>
        <xbrli:endDate>2022-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-02_custom_SEMAAgreementMember_custom_TheGoodClinicPrivateLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-272022-03-02_custom_SEMAAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-27</xbrli:startDate>
        <xbrli:endDate>2022-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SEMAAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MelanaInternationalPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TriGlobalSecurityPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MelanaInternationalPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TriGlobalSecurityPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-082022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-08</xbrli:startDate>
        <xbrli:endDate>2022-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-082022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-08</xbrli:startDate>
        <xbrli:endDate>2022-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-09_us-gaap_ForwardContractsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-192020-11-20_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-19</xbrli:startDate>
        <xbrli:endDate>2020-11-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PTTotalPrimaIndonesiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-202019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-20</xbrli:startDate>
        <xbrli:endDate>2019-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-142023-02-15_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-14</xbrli:startDate>
        <xbrli:endDate>2023-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SettlementAgreementMember_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KRHillCapitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KRHillCapitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KRHillCapitalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KRHillCapitalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgeMedicalPtdLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeMedicalPtdLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KentRidgeMedicalPtdLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeMedicalPtdLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UGDigitalSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:UGDigitalSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UGDigitalSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:UGDigitalSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_JanicLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JanicLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_JanicLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JanicLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ZukihealthSDNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:ZukihealthSDNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ZukihealthSDNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:ZukihealthSDNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_JenniferGohMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JenniferGohMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_JenniferGohMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JenniferGohMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FrescoInvestmentPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:FrescoInvestmentPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_FrescoInvestmentPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:FrescoInvestmentPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CadenceHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CadenceHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CheeYinMehMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CheeYinMehMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CheeYinMehMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CheeYinMehMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_JamieFanWeiZhiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JamieFanWeiZhiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_JamieFanWeiZhiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JamieFanWeiZhiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KelvinChenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KelvinChenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgeHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KentRidgeHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_KentRidgePacificPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_KentRidgePacificPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WatermarkDevelopmentsLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WatermarkDevelopmentsLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WatermarkDevelopmentsLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WatermarkDevelopmentsLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WilkeServicesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WilkeServicesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WilkeServicesLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WilkeServicesLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MountLockeLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:MountLockeLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MountLockeLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:MountLockeLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-20_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-17_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-302022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-30</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-242022-07-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-24</xbrli:startDate>
        <xbrli:endDate>2022-07-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-162022-11-17_custom_EightIHoldingsTwoPtdLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-16</xbrli:startDate>
        <xbrli:endDate>2022-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PublicWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EUDA:PublicWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PrivateWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EUDA:PrivateWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TriggeringEventOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">EUDA:TriggeringEventOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TriggeringEventTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">EUDA:TriggeringEventTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_VN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_SG">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SeventyFivePercentageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FiftyPercentageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SingaporeSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">EUDA:SingaporeSubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SingaporeSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">EUDA:SingaporeSubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_country_VN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_country_VN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:OneVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:VendorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:VendorTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:OneVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_InterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_InterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MedicalServicesMember36611421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConsolidatedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:ConsolidatedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MedicalServicesMember36611453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConsolidatedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:ConsolidatedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PropertyManagementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CorporateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PropertyManagementServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-092023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-09</xbrli:startDate>
        <xbrli:endDate>2023-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:AlfredLimMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:AlfredLimMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanSecondLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-242023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanSecondLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-24</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanFirstLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanFirstLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanThirdLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanThirdLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-15</xbrli:startDate>
        <xbrli:endDate>2023-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-15</xbrli:startDate>
        <xbrli:endDate>2023-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_JamesTanMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:JamesTanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_ShineLinkMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:ShineLinkMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_MenoraMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:MenoraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_EightiHoldingMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:EightiHoldingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:ChenSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-15</xbrli:startDate>
        <xbrli:endDate>2023-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:SellerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:SellerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001847846</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="SGD">
      <xbrli:measure>iso4217:SGD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000188" toRefs="Footnote000220"></ix:relationship>
  <ix:relationship fromRefs="Fact000189" toRefs="Footnote000220"></ix:relationship>
  <ix:relationship fromRefs="Fact000679" toRefs="Footnote000764"></ix:relationship>
  <ix:relationship fromRefs="Fact000753" toRefs="Footnote000769"></ix:relationship>
  <ix:relationship fromRefs="Fact000759" toRefs="Footnote000769"></ix:relationship>
  <ix:relationship fromRefs="Fact000803" toRefs="Footnote000820"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0804" toRefs="Footnote000820"></ix:relationship>
  <ix:relationship fromRefs="Fact000815" toRefs="Footnote000820"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0816" toRefs="Footnote000820"></ix:relationship>
  <ix:relationship fromRefs="Fact001165" toRefs="Footnote001173"></ix:relationship>
  <ix:relationship fromRefs="Fact001166" toRefs="Footnote001173"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1207" toRefs="Footnote001242"></ix:relationship>
  <ix:relationship fromRefs="Fact001208" toRefs="Footnote001242"></ix:relationship>
  <ix:relationship fromRefs="Fact001409" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001411" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001413" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001415" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001417" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001419" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001421" toRefs="Footnote001450"></ix:relationship>
  <ix:relationship fromRefs="Fact001462" toRefs="Footnote001479"></ix:relationship>
  <ix:relationship fromRefs="Fact001485" toRefs="Footnote001494"></ix:relationship>
  <ix:relationship fromRefs="Fact001556" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="Fact001558" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="Fact001560" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="Fact001562" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="Fact001564" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1566" toRefs="Footnote001583"></ix:relationship>
  <ix:relationship fromRefs="Fact001568" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="Fact001570" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="Fact001572" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="Fact001574" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="Fact001576" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1578" toRefs="Footnote001586"></ix:relationship>
  <ix:relationship fromRefs="Fact001594" toRefs="Footnote001608"></ix:relationship>
  <ix:relationship fromRefs="Fact001595" toRefs="Footnote001608"></ix:relationship>
  <ix:relationship fromRefs="Fact001600" toRefs="Footnote001609"></ix:relationship>
  <ix:relationship fromRefs="Fact001601" toRefs="Footnote001609"></ix:relationship>
  <ix:relationship fromRefs="Fact001636" toRefs="Footnote001644"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1637" toRefs="Footnote001644"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1670" toRefs="Footnote001684"></ix:relationship>
  <ix:relationship fromRefs="Fact001671" toRefs="Footnote001684"></ix:relationship>
  <ix:relationship fromRefs="Fact001872" toRefs="Footnote001886"></ix:relationship>
  <ix:relationship fromRefs="Fact001873" toRefs="Footnote001886"></ix:relationship>
  <ix:relationship fromRefs="Fact001881" toRefs="Footnote001887"></ix:relationship>
  <ix:relationship fromRefs="Fact001882" toRefs="Footnote001887"></ix:relationship>
  <ix:relationship fromRefs="Fact001894" toRefs="Footnote001911"></ix:relationship>
  <ix:relationship fromRefs="Fact001895" toRefs="Footnote001911"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20220101__20221231_zUxHdBKFIT2l"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--DocumentAnnualReport_c20220101__20221231_zcywetuBecjf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_908_edei--DocumentPeriodEndDate_c20220101__20221231_zziRpooy10Z2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_90E_edei--CurrentFiscalYearEndDate_c20220101__20221231_zUqKOqYJRwY6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20220101__20221231_zei2C2ZNb6tf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentTransitionReport_c20220101__20221231_zAfMLJ5oVWC9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _________ to ___________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <span id="xdx_902_edei--EntityFileNumber_c20220101__20221231_zbvQIZs8dSS1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-40678</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20220101__20221231_zDvm87zwLhm3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">EUDA
HEALTH HOLDINGS LIMITED</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_dxL_c20220101__20221231_zs36QBqmIdce" title="::XDX::D8"><span style="-sec-ix-hidden: xdx2ixbrl0021">British
    Virgin Islands</span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n/a</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityAddressAddressLine1_c20220101__20221231_zbNkX6b5yym5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">1
Pemimpin Drive #12-07</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityAddressCityOrTown_c20220101__20221231_z6jPFGRdxTt5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">One
Pemimpin</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressCountry_c20220101__20221231_z6tb0zXmgQHj" title="Entity Address, Country"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Singapore</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20220101__20221231_zG5gRiXV0SJ" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">576151</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices and Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--CityAreaCode_c20220101__20221231_zq7Y7tZi3BA1" title="City Area Code"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">65</ix:nonNumeric></span>
<span id="xdx_90B_edei--LocalPhoneNumber_c20220101__20221231_z6F6cA78oAIa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">6268 6821</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesMember_zsvvcKd5lYJj"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember" name="dei:Security12bTitle">Ordinary
    Shares</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesMember_zPhQrx47pWE4"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember" name="dei:TradingSymbol">EUDA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_904_edei--SecurityExchangeName_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesMember_zB90sQ1BnB7g"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsMember_zlh4fqm65SI8"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember" name="dei:Security12bTitle">Redeemable
    Warrants</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsMember_z68nFbS8iLPa"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember" name="dei:TradingSymbol">EUDAW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_909_edei--SecurityExchangeName_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsMember_zhtl6PeDBMn7"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_zCvJA0PZsSSl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90B_edei--EntityVoluntaryFilers_c20220101__20221231_z7c6glFuzvS3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes &#9744; <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20220101__20221231_zrMZRrS1783g"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20220101__20221231_zBjoHQX2UT7c"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20220101__20221231_zIjZMo2WY5J8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntitySmallBusiness_c20220101__20221231_zc6iUWXdin69"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20220101__20221231_zSFBOHyJPvN5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20220101__20221231_zd326k45T2Oj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span><span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zgT0DSctMIr9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; <span id="xdx_90F_edei--EntityShellCompany_c20220101__20221231_zvdrBCd7ARFf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of voting and non-voting common stock held by non-affiliates of 8i Acquisition 2 Corp., our predecessor, as of
January 31, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<span id="xdx_904_edei--EntityPublicFloat_iI_pn5n6_c20220630_zYB2nuSGJcDb"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">84.0</ix:nonFraction></span>
million, based on the closing price on that day of $9.745. As of June 19, 2023, there were <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20230619_zVU2O5f5cXg9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-06-19" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,777,509</ix:nonFraction></span> ordinary shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt">&#160;</div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Frequently
used terms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated in this Annual Report on Form 10-K (&#8220;Annual Report&#8221; or &#8220;Form 10-K&#8221;), or the context otherwise
requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; &#8220;EUDA&#8221; or the &#8220;Company&#8221;
are to EUDA Health Holdings Limited, a British Virgin Islands exempt company and references to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;8i&#8221; means 8i Acquisition 2 Corp., a BVI business company that
changed its name to &#8220;EUDA Health Holdings Limited&#8221; after the Business Combination.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#8220;Board&#8221; means the board of directors of 8i prior to the Closing,
and the board of directors of the Company following the Closing.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>&#8220;Business
    Combination&#8221; means the transactions contemplated under the SPA relating to the Share Purchase.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Charter&#8221;
    are to the Company&#8217;s Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on November
    17, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Closing&#8221;
    means the consummation of the Business Combination.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Closing
    Date&#8221; means November 17, 2022, the date of the consummation of the Business Combination.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Code&#8221;
    means the Internal Revenue Code of 1986, as amended.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#8220;EHL&#8221; means EUDA Health Limited, a British Virgin Islands business
company.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange
    Act&#8221; means the Securities Exchange Act of 1934, as amended.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Founder
    Shares&#8221; means the outstanding Ordinary Shares held by the Initial Shareholders since November 24, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;GAAP&#8221;
    means accounting principles generally accepted in the United States of America.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Initial
    Stockholders&#8221; means our Sponsor and all of our officers and directors who hold our Ordinary Shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;IPO&#8221;
    means 8i&#8217;s initial public offering.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Nasdaq&#8221;
    means The Nasdaq Stock Market LLC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SEC&#8221;
    means the U.S. Securities and Exchange Commission.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities
    Act&#8221; means the Securities Act of 1933, as amended.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Sponsor&#8221;
    means 8i Holdings 2 Pte Ltd, a Singapore limited liability company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Units&#8221;
    means 8i units, each consisting of one ordinary share, one redeemable warrant, and one right to receive one-tenth of an ordinary
    share upon consummation of the Business Combination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act,
and Section 21E of the Exchange Act. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995 and include this statement for purposes of complying with
these safe harbor provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document contains certain forward-looking statements with respect to our financial condition, results of operations and business, plans,
objectives and strategies. These forward-looking statements can be identified by the fact that they do not relate only to historical
or current facts. Forward-looking statements often use words such as &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;anticipate,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;aim,&#8221; &#8220;goal,&#8221; &#8220;target,&#8221;
&#8220;objective,&#8221; &#8220;commit,&#8221; &#8220;advance,&#8221; &#8220;likely&#8221; or similar expressions that convey the prospective
nature of events or outcomes. There are several factors which could cause actual plans and results to differ materially from those expressed
or implied in forward-looking statements. Such factors include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are an early-stage company with a history of losses and expect to incur significant expenses for the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    significant amount of our revenues is derived from a limited number of customers. A substantial portion of our current revenue is
    generated by sales to government entities, which are subject to a number of uncertainties, challenges, and risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to effectively manage our growth, we may not be able to design, develop, manufacture, market, and launch new generations
    of our robotic systems successfully.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    operating and financial projections rely on management assumptions and analyses. If these assumptions or analyses prove to be incorrect,
    our actual operating results may be materially different from our forecasted results.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business plans require a significant amount of capital. Our future capital needs may require us to sell additional equity or debt
    securities that may dilute our stockholders or introduce covenants that may restrict our operations or ability to pay dividends.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will incur significant increased expenses and administrative burdens as a public company, which could have a material adverse effect
    on our business, prospects, financial condition and operating results. </span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to access sufficient capital needed to fund and grow our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    operate in a competitive industry that is subject to rapid technological change, and we expect competition to increase.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    financial results may vary significantly from period to period due to fluctuations in our operating costs, product demand and other
    factors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have yet to achieve positive operating cash flow and, given our projected funding needs, our ability to generate positive cash flow
    is uncertain.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    we became a public reporting company by means other than a traditional underwritten initial public offering, our stockholders may
    face additional risks and uncertainties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our common stock is likely to be highly volatile, and shareholders may lose some or all of their investment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility
    in our share price could subject us to securities class action litigation.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    management team has limited skills and experience related to managing a public company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to
    new compliance initiatives and corporate governance practices.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stock price may continue to fluctuate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other factors could cause actual results to differ from those implied by the forward-looking statements. Forward-looking statements
are not guarantees of performance and speak only as of the date hereof. The forward-looking statements are based on the current and reasonable
expectations of our management but are inherently subject to uncertainties and changes in circumstances and their potential effects and
speak only as of the date of such statements. There can be no assurance that future developments will be those that have been anticipated
or that we will achieve or realize these plans, intentions or expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing
cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based upon information available to us as of the date of this filing, and while we believe such information forms a reasonable basis
for such statements, such information may be limited or incomplete, and statements should not be read to indicate that we have conducted
an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and
investors are cautioned not to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only
risks we face. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties found
in &#8220;Item 1A. Risk Factors.&#8221; You should carefully consider these risk factors, together with the risk factors set forth in
&#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K and the other reports and documents filed by us with the U.S.
Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are not currently in compliance with the continued listing standards
of Nasdaq and may not be able to regain compliance with Nasdaq&#8217;s continued listing standards in the future.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our independent registered public accounting firm&#8217;s report contains
an explanatory paragraph that expresses substantial doubt about our ability continue as a &#8220;going concern.&#8221;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The digital health industry is relatively young, is currently in its early
growth stages and is still evolving, and if it develops towards a mature stage more slowly than we expect, if it encounters a pessimistic
outlook or if our services are not competitive, the growth of our business will be adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    short operating history and the rapidly evolving nature of the industry make it difficult to assess our success and predict the risks
    and challenges it may encounter.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will require additional funding through sale of either debt or equity securities to support its continuing operations and growth
    of business, and such funding may not be available on acceptable terms, or at all, and that may adversely impact our business, financial
    condition, results of operations and growth potential</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on our corporate clients for a significant portion of its revenue, the loss of which would have a material adverse effect on
    our business, financial condition, and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely heavily on technology services provided by third parties and its own systems for providing services to clients and members,
    and any failure or interruption in these services could expose us to litigation and negatively impact relationships with clients,
    its reputation, brand and business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    sales and implementation cycle can be long and unpredictable and requires considerable time and expenses, which may cause our results
    of operations to fluctuate.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    digital health industry faces evolving government regulations, and failure to comply with these changes may result in increased costs
    or adversely affect our results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our security measures fail to ensure protection of clients&#8217; data, services may be deemed insecure and as a result w could incur
    significant liabilities, reputational harm, and loss of sales and clients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    previously identified material weaknesses and significant deficiencies in the Company&#8217;s internal control over financial reporting,
    and if we are unable to achieve and maintain effective internal control over financial reporting, this could have a material adverse
    effect on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are not currently in compliance with the continued listing standards of Nasdaq and may not be able to regain compliance with Nasdaq&#8217;s
    continued listing standards in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    we have become a public reporting company by means other than a traditional underwritten initial public offering, our stockholders
    may face additional risks and uncertainties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are not currently in compliance with the continued listing standards of Nasdaq and may not be able to regain compliance with Nasdaq&#8217;s
    continued listing standards in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our Common Stock is likely to be highly volatile, and you may lose some or all of your investment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility
    in our share price could subject us to securities class action litigation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to stockholders, thereby making Public Warrants
    worthless.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more complete discussion of the material risk factors relevant to us, see &#8220;Item 1A. Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EUDA
HEALTH HOLDINGS LIMITED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
REPORT ON FORM 10-K </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART
    I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Mine
    Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_008">PART
    II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Disclosures
    Regarding Foreign Jurisdiction that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_016">PART
    III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Certain
    Relationships and Related Transactions and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Principal
    Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Exhibits
    and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
mission is to make high-quality, personalized healthcare affordable and accessible for all its patients. It aims to provide one stop
healthcare and wellness services through its proprietary platform, EUDA. EUDA currently has operations in Singapore and has plans to
expand across Southeast Asia. Its operations in Singapore includes provision of medical urgent care and property management services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2020, EUDA acquired 100% of the equity interests in Super Gateway Group Limited (&#8220;SGGL&#8221;), a property management service
company that services shopping malls, business office building, or residential apartments. EUDA aimed to build an Omni-channel health
care and products platform in economies of scale and cross-sell opportunities and allows our management services section to expand into
new and different verticals of management services in the medical field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headquartered
in Singapore and established in 2019, EUDA aims to be a leading next-generation Southeast Asian healthcare-technology provider, integrating
a full continuum of healthcare services with healthcare data analytics to drive high-quality and efficient care for their patients. The
proprietary platform, EUDA, is its core holistic, connected platform, through which it also offers a mobile application platform for
its users. What makes EUDA unique is the integration of Artificial Intelligence (AI) and Machine Learning (ML), which provides real-time
actionable analytics functionality that enables EUDA&#8217;s users to make quick analysis and accurate diagnosis as well as business
decisions. The platform gathers numerous data points and performs predictive analysis, where it can compare events and results over time
to identify trends across various segments and provide accurate insights, analysis, and predictions regarding healthcare. Its AI applications
supported on the EUDA platform include smart triage, smart match, smart claims supports and image recognition, as well as predictive
algorithms that can read and analyze MRIs and X-rays. EUDA&#8217;s robust unique proprietary technology platform reduces the time taken
for diagnostics yet continues to promote standardization of diagnostics, which effectively eliminates inefficiencies. Through EUDA&#8217;s
software platform, it aims to deliver data-driven, personalized quality insights to patients while they are at the doctor&#8217;s office
in order to provide them with different healthcare and treatment choices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
aims to provide a series of products and services through its network and offer an array of complementary products and services to deepen
their relationship with its members from assessing the condition, evaluating the risk level to providing personalized support services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
markets and promotes its Medical Urgent Care services to healthcare provider organizations throughout Singapore using a go-to-market
and direct sales organization composed of highly trained and technical team members that are segmented into several highly targeted and
coordinated teams. These dedicated sales teams develop content and identifies prospects that the sales development team research and
qualify to generate high-grade, actionable sales programs. EUDA&#8217;s sales and marketing department leverages on their deep experience
to deliver an urgent care solution tailor-fit to the size and specialty of each practice. Through this targeted, coordinated approach,
EUDA is able to maximize resource allocation and allow its sales teams to concentrate on execution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
utilizes both an inside and outside direct sales force to execute on the qualified marketing programs, partnering with client services
to ensure the prospect is educated on the breadth of EUDA&#8217;s capabilities and demonstrable value proposition. Medical and clinical
partners also play an important role in marketing and selling EUDA&#8217;s products to its customer base. These partners may shorten
the sales cycle and lower the customer acquisition costs. For example, through the Clinic Management System (CMS) partners, EUDA is able
to embed its technology into existing health system technology infrastructure which, as a competitive differentiator, may lead to a higher
win rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
sales and marketing department is primarily responsible for planning and developing its overall marketing strategy, conducting market
research, coordinating the sales and marketing activities to attract new customers and maintain and strengthen relationships with existing
customers, managing the efforts in relation to tender bids and negotiating the terms of EUDA&#8217;s Property Management Service and
Security Service contracts. The team will explore and establish information channels for business development and market research purposes.
Such information channels include websites or other platforms on which property developers or property owners&#8217; associations announce
tender opportunities, uncovering business opportunities by way of recommendation or frequent communication with customers and other industry
players, and organizing promotional events to showcase EUDA&#8217;s service offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
EUDA implements various incentive measures to encourage the sales teams to obtain property management service contracts of properties
developed by third-party developers through research and analysis of and communication with target customers in the real estate industry
and taking advantage of EUDA&#8217;s resources and expertise. In addition, various communication channels are adopted to explore more
opportunities to provide EUDA&#8217;s Property Management Services that are customized and tailored to the specific localities to bring
convenience to local property owners and residents. EUDA continually seeks business cooperation opportunities with third-party merchants
to enhance the width and depth of its services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from EUDA&#8217;s property management services decreased from approximately $4.6 million for the year ended December 31, 2021 to approximately
$3.8 million for the year ended December 31, 2022. Currently, we do not have any property management services provided to any medical
clinics. EUDA generates revenue primarily from services in connection with medical services fees and property management service fees.
Medical services fees are generally derived from specialty medical visits in which EUDA acts as a principal connecting physicians to
patients. Property management service fees are obtained from contractually recurring revenue from common area management and security
management services which it provides to retail and residential properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that EUDA&#8217;s platform will eventually provide a full continuum of healthcare services integrated with healthcare data analytics
to drive improved outcomes for patients. To achieve this, EUDA aims to continuously build towards a consumer-centric digital ecosystem
to allow clients and patients to gain access to quality healthcare while keeping costs affordable. EUDA incorporates AI and ML on the
platform and implements relevant solutions to a wide variety of healthcare and homecare services that it currently provides. AI-driven
advancement will be increasingly visible throughout the healthcare journey including a strong potential for interactive virtual assistants
to improve patient experience and clinician operational workflow. EUDA believes in incorporating technology into the traditional medical
services market and creating an end-to-end ecosystem that provides a comprehensive suite of healthcare and wellness services adds great
value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the wake of the COVID-19 pandemic as nations went into various degrees of lockdown, there was also a permanent and massive digital adoption
spurt and an acceleration in the telehealth and digital-health sector. According to Markets &amp; Markets, the global telehealth and
telemedicine market is expected to reach USD 191.7 billion by 2025 from an estimated USD 38.7 billion in 2020, due to the following reasons:
(1) a rising and aging population (2) the need to expand healthcare access; (3) the growing prevalence of chronic diseases and conditions:
(4) a shortage of physicians, (5) advancements in telecommunications, and (6) government support and increasing awareness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
2000 and 2017, global health spending grew by 3.9% a year, outpacing global economic growth as global GDP grew by 3.0%. The World Health
Organization has reported that as the growth of cost in healthcare per capita continues to outpace the growth in GDP per capita, the
burden of healthcare cost could ultimately grow faster than the economic power to sustain such costs. Particularly in Southeast Asia,
the rise in the cost of healthcare is expected to accelerate given the rapid demographic shift in a larger proportion of an aging population,
according to Solidiance. As the working age population ages, EUDA believes the prevalence of smoking, overweight and obesity will also
translate into a high prevalence of severe non-communicable diseases in the future, adding further pressure and costs to healthcare.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an impetus to ensure that healthcare remains more affordable and accessible and in pursuit of this, many technological innovations
have been sprouting up in various healthcare verticals. Yet, there remain gaps in the fragmented infrastructure of the healthcare industry
which has led to cost and quality inefficiencies. EUDA had taken various steps and measures to integrate technology into various aspects
of the healthcare system and aims to bridge the gap between various siloed healthcare verticals to form a comprehensive healthcare and
wellness ecosystem. Management believes that EUDA&#8217;s platform will eventually improve consumers access to an even higher-quality
and more affordable healthcare options that were previously constrained by geographic locations, physician availability, office hours
and costs. Digital-health providers that are part of their network had and will continue to undergo a rigorous screening and training
process. Additionally, EUDA is currently in partnerships with reputable specialist providers to ensure quality care for their patients,
providers on the EUDA network, including medical institutions such as clinics and hospitals, government health agencies and insurers.
They are working towards providing providers on their network with greater convenience and flexibility in their operations, training,
and support to ensure professional development and through their network of consumers, enabling them to increase income opportunities.
The network of providers can also form unique partnerships to further increase their reach of products and services through complementary
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
Challenges</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lack
of Access to Healthcare</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the outbreak of the COVID-19 pandemic, many Asia-Pacific countries experienced first-hand suffering from a lack of resilient health systems
to provide timely and quality care. The impact varied across nations and populations but there has been a disproportionate impact upon
the most vulnerable populations. While the number of doctors per 1,000 people varies widely across Asia-Pacific countries and territories,
it is generally lower than the OECD average and is unlikely to meet rising health needs. Patients have faced challenges gaining access
to affordable and timely health care especially in communities that are traditionally underserved, such as those in remote or rural areas
with few health facilities and medical staff. The shortage of skilled health professionals also has an adverse impact on the quality
of care offered in health institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Aging
population to strain healthcare resources</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Economic Research Institute for ASEAN and East Asia, the East and South-East Asia Region currently has the largest number, about
37% of the world&#8217;s population, aged 65 or above and this trend is expected to continue over the next three decades. By 2025, 10%
of Asia&#8217;s population will be people aged 65 years old and above, which is a 14% growth over 2021. This increase is driven by reduced
fertility rates and higher life expectancy. By 2025, there will be close to half a billion people aged 65 or above in the Asia-Pacific
Region.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the number of people aged 65 or above increases, there will be a demand for primary care services to screen, assess and manage chronic
illnesses and comorbidities, potentially straining healthcare resources. This demographic change also indicates that there may be fewer
medical providers to deliver patient care and this shortage will necessitate a change in the existing model for medical care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
cost has outpaced economic growth</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the World Health Organization, between 2000 and 2017, global health spending grew by 3.9% a year while the global GDP grew by only
3.0% a year. The increase in health spending was even faster in low-income countries, where it rose 7.8% a year between 2000 and 2017
while the economy grew by 6.4% a year. In middle income countries, health spending grew more than 6% a year. In high income countries,
the average annual growth was 3.5%, about twice as fast as economic growth. If this trend persists, healthcare could grow to a share
of the economy and government budgets in ways that are unsustainable, and governments are unlikely to allocate a higher proportion of
their budgets to healthcare spending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coupled
with an aging population, this would mean that a relatively smaller workforce will have to produce the economic wealth to sustain the
ever-growing demand for healthcare due to a relatively larger elder population. This will be exacerbated by the future elder population
being composed of the working population today, which sees a prevalence of smoking, overweight and obesity rates that may result in a
high occurrence of severe non-communicable diseases in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
firm Solidiance has reported that even at present rates, the cost of healthcare in Southeast Asia&#8217;s major economies (Malaysia,
Singapore, Philippines, Vietnam, Thailand, and Indonesia) is expected to outpace both GDP and population growth, leading to an estimated
total healthcare cost of more than US$ 750 billion by 2025, an added burden of US$ 320 billion higher than the total spending of US$
420 billion back in 2017. Given that public sector is heavily involved in the provision of healthcare, governments are expected to make
payments on the majority of this incremental spend. This may cause a crisis in the healthcare systems in several nations unless policy
makers are able to develop a more efficient healthcare model for the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Poor
Medical Experience</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asia-Pacific
has been burdened with a problem of an aging population, which is further accentuated by the lack of proper healthcare facilities in
developing countries such as Indonesia. One of the key healthcare industry challenges is the limited availability of efficient and quality
healthcare services. Patients and doctors are increasingly frustrated by the long wait times, in addition to the high costs associated
with traditional medical consultations. There is an increased demand for more convenience, more emphasis on wellness and preventative
services, and generally, more control over a person&#8217;s own healthcare. The COVID-19 pandemic has driven consumers to demand one-stop
solutions for not only their medical needs, but also their overall wellness and educational information on the treatment options. According
to a survey by Bain &amp; Company, 72% of the people in Asia Pacific consider wait times to be one of the primary pain points in the
healthcare system. Furthermore, the time taken for available traditional medical care services has increased the frustration of not only
the aging population but young adults as well. For example, in Indonesia, the average time taken to visit a doctor is 4 hours whereas
the average time spent in a doctor consultation is only 10 minutes. This clearly highlights a huge gap in the market which requires the
industry leaders to pivot and explore better digital-health services in order to improve the healthcare landscape in the region.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opportunities
for EUDA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Primed
for healthcare disruption</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Driven
by shifting demographics, technological innovations and limited healthcare resources, the Asia-Pacific region is primed for healthcare
disruption and digital health ecosystems. McKinsey &amp; Co. estimates that today, digital health impacts more than a billion lives,
and estimates show that digital health in Asia could collectively create up to US$ 100 billion in value by 2025, up from US$ 37 billion
in 2020. Furthermore, the rising rate of internet users in Asia-Pacific provides a solid platform for the digital healthcare landscape
to address the key challenges and burden on the healthcare system in the region. In Southeast Asia alone, the COVID-19 pandemic has also
accelerated Internet usage, with 40 million new users in 2020 alone and over 400 million users in the region. The internet penetration
rate in Southeast Asia was 69% as of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pandemic has lowered commercial barriers for health-tech as this sector sees continued funding by financial and strategic investors which
could further fuel technological innovations. The Asia-Pacific region is also expected to present an immense commercial opportunity for
the healthcare sector as regional healthcare expenditure in APAC is projected to grow by 11.5% annually to US$ 115.9 billion by 2025,
according to a report by L.E.K. Regulators have also begun to recognize the efficacy of Telemedicine, eliminating regulatory barriers
and increased policy support to establish and enforce regulation especially during the pandemic. Healthcare investment in Asia-Pacific
will also continue to outpace other regions. According to Bain &amp; Company, there was US$ 15.8 billion in healthcare private equity
buyout deal value, with a growth rate of 38% between 2013 and 2018, compared with 29% for the rest of the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accelerated
consumer adoption of Health-Tech</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bain&#160;&amp; Co. estimates that in Southeast Asia, Health-tech usage has grown by 400% in 2020 and has retained its users post-lockdown. As
telehealth played crucial roles during the various degrees of lockdown, it has accelerated consumer adoption of health-tech. Within Indonesia,
as the healthcare system remains under pressure from the pandemic with hospitals struggling with the surge of patients, the government
turned to provide remote services by telehealth firms such as Alodokter and Halodoc and included free consultations and medication delivery.
This allows for prescriptions to be issued and delivered to non-critical patients eliminating the time spent on travel and waiting for
a consultation. At the same time, telehealth has alleviated the load on healthcare systems and prioritized hospitals for patients with
more critical symptoms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telemedicine
also enables communities in rural and underserved urban areas to gain access to healthcare by overcoming distance and time barriers between
healthcare providers and patients. Remote care and diagnosis via telemedicine will reduce patients&#8217; distance travelled for specialist
care and related expense, especially critical for countries with a large, dispersed population such as Indonesia. Emerging health ecosystems
have already impacted more than a billion lives in Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Platform
to improve health and wellness of all participants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
diseases remain a significant burden on healthcare systems globally. These progressive diseases are significant causes of illness and
death and can last for extended periods of time and require long-term treatment. These could be managed through chronic disease management
and some public and private payers have begun leveraging digital technologies to nudge consumers to monitor their health and lower the
long-term cost of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
presence of a healthcare ecosystem will allow for tie-ups with an extensive network of medical partners to promote fitness and dietary
guidelines to a wider pool of the population. The utilization of big data and AI in digital health will also allow for forward-looking
data that can help avoid or mitigate non-communicable diseases. Telehealth can promote a healthy lifestyle and provide value-added services
ranging from post-surgery rehabilitation work to customizable fitness plans to combating chronic conditions, amongst others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitive
Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
believes that the following competitive strengths helped differentiate it from its competitors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unique
business model that encompasses the full spectrum of healthcare &amp; wellness services</b>: Its unique ecosystem-based business model
integrates a full continuum of healthcare services with healthcare data analytics to drive improved outcomes for patients. EUDA is an
all-encompassing healthcare management platform purpose-built to power the entire ecosystem of value-based care for both businesses and
individual consumers. EUDA operates on a unified platform to deliver better care for their patients, improving their overall journey
with EUDA. The platform allows healthcare providers and employers to give patients more personalized affordable care and improved healthcare
outcomes utilizing data and technology. EUDA offers a comprehensive suite of services for both healthcare and wellness services in order
to recognize the needs of their customers at every step of their journey.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
    services are divided into four verticals, namely, Healthcare, Lifestyle &amp; Wellness, Health Plans and Enablement. This ensures
    that the entire patient journey within the EUDA platform itself has been fully captured and EUDA is strategically aligned to provide
    end to end solutions for their patients. This begins from customer acquisition and runs all the way to prescriptions to the delivery
    of medications and ultimately provision of continuous care.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img src="form10-k_001.jpg" alt="" /><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
                                                         <p style="margin-top: 0; margin-bottom: 0"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
    healthcare solutions include services ranging from 24/7 medical urgent care to digital pharmacy solutions as well as diagnostic and
    monitoring services. Subsequently, EUDA will be able to digitally connect their patients requiring support for mental health to their
    panel of therapists and psychologists. Furthermore, in line with their commitment to cover the entire spectrum of care and wellness
    services, their wellness vertical includes services such as an e-commerce one-stop shop marketplace for the sale of health and supplement
    products including dietary snacks, home care services such as home nursing care and home consultation services, a fitness segment,
    and also a men&#8217;s and women&#8217;s health which covers a suite of targeted wellness content. Lastly, under the health plans
    vertical, EUDA will be providing monthly subscription packages that covers corporations as well as individuals for a selection of
    telehealth services such as teleconsultation, online pharmacy and health screenings. Therefore, through their spectrum of services,
    EUDA will be addressing the needs of multiple consumer segments and hence, take a holistic approach that improves health outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">    <b>Creating superior user experience through their wide array of technological capabilities</b>: EUDA&#8217;s integrated platform
    is a one-stop healthcare hub that will centralize all of its existing and future programs into a single, user-friendly application,
    providing its customers access to its services in real-time 24/7. One of its key differentiating factors arises from the proprietary
    technology platform is to enhance the speed and efficacy of care. Regardless of the nature of the malaise or injury, EUDA&#8217;s
    proprietary technology can recognize, analyze, and determine the type of treatment required instantly. The software platform will
    allow members to be able to enjoy better care coordination, receive remote consultation and enables clients to reach out to the local
    assistance centers for medical assistance as well as to receive precautionary reminders and any potential disaster warnings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">By using such integrated technology, EUDA aims to provide a premium experience to each of its members as they progress through different stages of their health care journey. The ability to deliver efficient, high-quality care is done through leveraging their proprietary AI and ML capabilities. It seamlessly guides the intake of members, facilitating assessment of inquiries, collection of relevant data and review of medical records with the sole aim of safely navigating its members to the right healthcare resources together with the right clinical expertise. This ultimately leads to better outcomes and more efficient utilization of resources. Furthermore, valuable data is collated throughout the process, that in turn feeds back into improving the performance of its machine intelligence.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In addition to the merits of EUDA&#8217;s technological capabilities, EUDA will be able to run secure and effective solutions such as the blockchain that will cover the entire healthcare process. EUDA will be utilizing blockchain&#8217;s ability to keep an incorruptible, decentralized, and transparent log of all patient data. While blockchain is transparent, it is also private, concealing the identity of any individual with complex and secure codes that can protect the sensitivity of medical data. The decentralized nature of the technology also allows patients, doctors, and healthcare providers to share the same information quickly and safely.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Therefore, EUDA believes its investment in technology ultimately will enable it to provide a better user experience at a lower cost of service, giving it an added advantage over its competitors.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">- </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Strong presence and wide network of partners to complement its Always-On approach</b>: EUDA provides 24/7 concierge-level care coordination services for its high-risk members. As a digital health company, EUDA strongly believes in advocating the presence of healthcare at any time and any place as needed by its customers. Its coordination specialists are trained to cover all emergency, primary and specialty services and provide the highest level of personalized medical concierge level services at the push of a button. Furthermore, EUDA is working to strengthen its capability through its geographical presence and wide network of relationships with medical partners.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    currently operates in Singapore and has a sizeable number of medical partners across the healthcare spectrum ranging from ambulatory
    service providers and General Practitioner (GP) clinics to hospitals and specialist consultants. This allows them to provide to their
    clients, which consists of a range of corporate clients coming from various industries, as well as households. The widest range of
    urgent care options are usually based around pricing, proximity, choice of treatment and medications. Therefore, EUDA&#8217;s relationships
    with medical partners give it a great competitive edge as it is able to provide top notch round-the-clock healthcare services based
    on the requirements expected from its clients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Led
    by a team of visionary leaders</b>: Another key differentiating factor for EUDA is the rich blended nature of the management team.
    EUDA&#8217;s management team comprises of executives with extensive experience in Healthcare, Technology, Insurance &amp; Consumer
    Experience segments. The wide array of industries captured by EUDA&#8217;s management team allows EUDA to deliver superior products
    and services to its customers as the management team possesses an in-depth understanding of the pain points prevalent in the industry.
    The combination has also enabled us to address the market gap in the healthcare industry with an innovative data driven all-in-one
    healthcare platform.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rapidly
    diversifying and growing service verticals to improve monetization channels</b>: EUDA believes that its competitive advantage is
    its wide array of service verticals that allows it to serve the needs of multiple consumer segments. The diverse nature of its offerings
    allows EUDA to expand its market reach both horizontally and vertically. The cross-selling of services further lends itself to a
    sustainable and ever-expanding business model. EUDA aspires to make the EUDA ecosystem a perpetually growing platform in terms of
    the addition of health and wellness verticals. EUDA has a wide array of additional health verticals in its roadmap and is determined
    to realize providing digital health access to specialist health and wellness verticals in the Southeast Asia region. Segments that
    are currently in development include: Digital Pharmacy, Medical Tourism, Chronic Disease Management, Mental Health, Diagnostics and
    Monitoring, Marketplace, Fitness, Women&#8217;s Health, Corporate &amp; Individual Health Plans and EUDA Society (Doctor&#8217;s
    Insurance). With the expansion of its service verticals, EUDA hopes to provide a more comprehensive platform customers and expand
    its monetization channels to increase synergies between their business segments. However, due to budgetary and other financial issues
    during the first five months of 2023, the timeline for the development of such health verticals have been pushed back to the second
    quarter of 2024 at the earliest. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EUDA&#8217;s
Growth Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
growth strategies include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drive
Greater Adoption with their Existing Clients</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    intends to drive greater adoption among existing patients by expanding the populations to which it offers services. Health plans
    may offer the option of digital health to a subset of their total membership and over time expand this service to more members. Health
    systems may start with a single hospital or region and then expand system wide. EUDA also plans to increase adoption within Singapore.
    EUDA believes in continually increasing awareness of and loyalty to its solution by adding new and complementary products and services,
    third-party connections, and other strategic alliances, so as to grow its solution towards becoming the single source for on-demand
    healthcare for its clients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clients
    have also embedded digital care more fully into their operations, where they plan to continually refine and enhance their user experience.
    Hence, they will be using targeted patient and medical provider engagement campaigns, best practices training as well as operational
    support to further drive an increase in usage across their platform. EUDA is also building robust data repositories to strengthen
    its predictive models and multi-channel marketing strategies to provide a more complete picture of its clients, enhancing its ability
    to lead targeted and purposeful campaigns, and it plans to invest heavily in marketing technologies that allow us to increase client
    touchpoints. Lastly, EUDA plans to actively engage clients in benefit design, worksite marketing and executive sponsorship strategies
    to drive awareness about its services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increase
Penetration by Adding New Clients within its Core Verticals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    had and will continue to invest in its direct sales force and channel management capabilities to sustain growth and client support.
    As its clientele stems mainly from the realm of blue-chip companies, it represents a significant opportunity for new client growth
    with large employers. EUDA further believes in forging ahead to compete with the market leaders in the digital health industry, given
    its unique positioning strategy to capitalize on the Business to Business to Consumer, or B2B2C. Growth is expected to be generated
    by word of mouth amongst corporations accompanied by enhanced brand awareness. EUDA believes the B2B2C model will bring about higher
    growth with lower cost of customer acquisition in comparison to a direct Business to Consumer, or B2C model. EUDA will also direct
    resources into new marketing technologies and campaigns to support their sales force in lead generation along with new client generation
    and implementations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Invest
in New Clinical Specialties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    currently offers its client&#8217;s access across a wide range of areas from chronic disease management, medical tourism, mental
    health to men&#8217;s and women&#8217;s health such as hair loss and contraception. It plans to also offer direct access to behavioral
    health professionals who treat conditions such as anxiety and smoking cessation. It plans to leverage on its highly scalable platform
    by expanding into new clinical specialties, such as standalone dermatology services, second opinions and chronic conditions such
    as diabetes, and by focusing on expanding its services amongst current clients such as by offering behavioral health as a commercial
    service to their clients. As EUDA expands its clinical offerings, it plans to further eliminate gaps in continuity of care in order
    to provide coordinated care along the healthcare delivery continuum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand
Across Care Settings and Use Cases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    intends to expand its solutions across additional care settings and explore ancillary opportunities that will broaden its business.
    EUDA believes its services have wide applicability across new use cases, including home care, post discharge, wellness, screening
    and chronic care. It takes a holistic approach to improve outcomes for its clients and provide wellness and prevention through Health,
    Fitness and Nutritional modules. It is also looking to provide campus clinics and workplace health services as well as medical emergency
    assistance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    is also currently extending the number, range and functionality of their benefits applications, and will hope to continue to respond
    quickly to evolving market needs with innovative solutions, including broadened health kiosk access, mobile applications, biometric
    devices and at-home testing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Invest
in Digitalization and Innovation for Digital Care Capabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    plans to expand the reach of its digital platform into new areas by investing in new technologies. For example, it is looking to
    incorporate a fitness function within EUDA, allowing individuals to connect to fitness applications on the EUDA platform. It is looking
    to partner with a local digital fitness provider that offers a suite of fitness and wellness content. The classes will allow individuals
    to reach their fitness goals anywhere and anytime, offering a series of workout sessions including full body, targeted workouts,
    stretch and recovery.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    is constantly investing in AI technology that is designed to help expand patient engagement while improving efficiencies, reducing
    the cost of care and promoting better care coordination. For example, there will be an AI deployment enabling a patient-provider
    matching tool, allowing patients to input their preference for doctors, timing and area of specialist onto the EUDA platform and
    its platform will synthesize patient&#8217;s preference to ensure best matches to boost efficiency and user experience.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
    investment in interoperability, including remote patient monitoring, advanced analytics and lab services as well as the home delivery
    of pharmaceuticals, is expected to allow EUDA to expand use cases. Its investments in interoperability with other technologies have
    also allowed it to partner with innovative companies to develop unique products and services. Its strategic partnership will allow
    its services to be accessed directly through the EUDA interfaces. EUDA believes these partnerships will differentiate their offering
    and add new capabilities to drive demand and add value for its clients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage
Existing Sales Channels and Penetrate New Medical Provider Markets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
    has developed a highly effective distribution network to target large employers and it is committing incremental sales and marketing
    resources to the small-medium enterprises to increase its penetration within this market. Additionally, EUDA intends to further penetrate
    the medical provider market, notably hospitals and group physician practices, as it believes its solution offers the medical community
    an attractive platform from which to generate substantial income by acquiring new patients and to better participate in emerging
    risk-sharing and value-based payment models. With expanded access to available health insurance, it also intends to pursue health
    insurance companies about their services, hence, insurance companies may represent an attractive new sales channel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand
into International Markets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    regulatory and reimbursement systems around the world evolve, EUDA sees a significant opportunity to expand internationally. It is
    also exploring joint international offerings with existing partners, as well as with strategic acquisitions to further boost their
    geographical footprints in Southeast Asia.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue
Focused Acquisitions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
    comprehensive platform and know-how enable it to selectively pursue strategic and complementary businesses to support its clients&#8217;
    needs. Its acquisition strategy is centered on acquiring technologies, products, capabilities, clinical specialties and distribution
    channels that are highly scalable and rapidly growing. EUDA will continue to evaluate and pursue acquisition opportunities that are
    complementary to their business, though we have no acquisitions contemplated at this time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
owns or otherwise have rights to the trademarks and service marks, used in conjunction with the marketing and sale of its products and
services. This includes trademarks, such as EUDA, Euda and euda, which are protected under applicable intellectual property laws and
are EUDA&#8217;s property and the property of its subsidiaries. Solely for convenience, EUDA&#8217;s trademarks and trade names referred
to in this Annual Report may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate, in any way,
that EUDA will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks
and trade names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
for the trademarks and domain name disclosed in this Annual Report, EUDA&#8217;s business and profitability is not materially dependent
on any trademark, patent, domain name or other intellectual property. EUDA holds no issued patent and EUDA is not aware of any infringement
(a) by EUDA of any intellectual property rights owned by any third parties; or (b) by any third party of any intellectual property rights
owned by EUDA. To the best of EUDA&#8217;s knowledge, there had not been any pending or threatened claim made against EUDA, nor have
there been any claim made by EUDA against third parties, with respect to the infringement of intellectual property rights owned by EUDA
or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
currently does not hold any patents, but retains intellectual property rights in its technology and platform (which are used in managing
and delivering consultations) by including contractual provisions in each service agreement with its customers, which provide that background
intellectual property rights either (i) owned or licensed by EUDA or (ii) developed outside of the respective services agreement, belong
to EUDA. This includes significant know-how in understanding how to leverage cloud components deployed in the current platform, other
third-party technologies, and EUDA&#8217;s own technology, to deliver a first-class digital healthcare service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EUDA
Ecosystem</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumer-centric
digital ecosystems are emerging across the world in response to these fundamental forces disrupting healthcare. Such ecosystems are designed
to seamlessly deliver the right care in the right setting at the right time by integrating three critical components: (a) a network of
health-service providers across care settings, (b) a system of intelligence that leverages behavioral, social, and health data to analyze
patients&#8217; needs and selects the appropriate provider, and (c) a technology backbone that enables data and insights to flow between
care providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to capitalize on this industry trend, EUDA is building a healthcare ecosystem that encompasses the full spectrum of healthcare
and offers a comprehensive suite of health and wellness solutions. EUDA is an all-encompassing healthcare management platform purpose-built
to power the entire ecosystem of value-based care for both businesses and individuals. EUDA offers healthcare solutions that strengthen
the delivery of holistic medical care. It operates on a unified platform to streamline comprehensive patient-centered care and disease
management, unmatched data integration, broad-spectrum collaboration, patient engagement and configurable analytics and reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
ecosystem is strategically aligned to provide comprehensive solutions for their patients. This begins when a person signs up for their
service and runs all the way to prescriptions, the delivery of medication and providing continuous care. The software will be powered
by ML and AI capabilities that will cover the full spectrum of a patient&#8217;s visit cycle from E-triage, GP consult, E-medical certificates,
and medical prescriptions. In addition to the medical aspect of healthcare, their ecosystem also encompasses the general well-being of
their customer and patients and therefore, caters to the fitness, dietary supplements and healthy snacks needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
AI and ML driven chatbot service will be supported by its extensive database that drives the e-triage process. The ML function learns
and improves the accuracy of outcomes as the database expands with more data inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
its patients are connected to the EUDA ecosystem through the EUDA mobile application. This, in turn, enables its users to connect to
certified doctors 24/7 through the convenience of video consultations via either phone or tablet. The application provides patients with
quick and easy communication with doctors who are readily available for addressing any medical issues. If medically necessary, doctors
can also quickly prescribe medication and connect patients with the pharmacy of their choice. Furthermore, the inbuilt data analytics
functionality gives user insights on improving health through health management modules and encourages program participation for targeted
lifestyle rewards and campaigns with selected partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unique
Value Proposition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
provides a unique value proposition to its users through the utilization of its core resources and competencies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Superior
    capabilities of Artificial Intelligence and Machine Learning</b>: EUDA&#8217;s technology platform leverages on at least 1,000 common
    diagnostic patterns and represents a repository of valuable healthcare information of its clients that can be analyzed and dissected
    through data analytics to ensure optimal therapeutic outcomes for its patients. ML can also be used to better understand human behavior,
    habits, and interactions to realize continuously improved outcomes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Always-On
    Approach</b>: The coordinator specialists provide 24/7 concierge-level care coordination services for their high-risk members and
    cover all emergency, primary and specialty services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expanding
    Network of medical partners</b>: EUDA&#8217;s network consists of various medical partners across the healthcare spectrum ranging
    from ambulatory service providers and GP Clinics to Hospitals and Specialist Consultants. By leveraging on their expanding network,
    EUDA is able to offer its clients the widest possible range of urgent care options based around pricing, proximity, choice of treatment
    and medications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensuring
    real-time quality of their service providers</b>: EUDA&#8217;s service network is composed of accredited medical professionals who
    are continuously trained to maintain a high standard of care. The roster of medical professionals is continuously reviewed and updated
    to ensure the highest quality of healthcare resources are made available to its clients. Each of the medical practitioners in EUDA&#8217;s
    roster has on average 15 years of experience.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
plans to establish its presence beyond Singapore, across the Southeast Asia region. Its strategy continues to be targeted at underdeveloped
health and wellness verticals to first establish its presence before dedicating more resources to capture more market share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EUDA&#8217;s
Solutions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
platform will provide a full continuum of healthcare services integrated with healthcare data analytics to drive improved outcomes for
patients. Its services can be broken down into four spectrums: Healthcare, Lifestyle &amp; Wellness, Health Plans, and Enablement all
on a single platform. The convenience of expanding existing offerings to provide services from Primary to Post-surgery care as well as
ongoing preventive healthcare for clients, regardless of the level of healthcare required, is unparalleled in the healthcare services
Southeast Asia market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 293px; width: 670px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
currently provides 2 services namely Medical Urgent Care and Property Management Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    Urgent Care</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
Medical Urgent Care service aims to deliver top-notch healthcare assistance and medical evacuation to offer individual and corporate
client&#8217;s peace of mind around the clock. The proprietary technology enables EUDA to provide the members with a seamlessly integrated
medical assistance operation, reducing any possible delays in execution of cases. Regardless of the severity of the injury, the platform
can recognize, analyze, and determine the type of treatment required instantly, mitigating any health-related risks and associated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
continues to invest in the existing EUDA platform to develop new technologies, products, modules, programs, and capabilities to meet
the broadening needs of its clients. EUDA is also looking to partner with its clients and/or other stakeholders to build new features,
modules, and programs. This includes the ongoing development of its digital tools program capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
plans to expand the reach of its digital platforms into new areas by investing in new technologies such as AI and its digitally enabled
technology with the goal of improving the patient-physician consult experience, enhancing the company&#8217;s health service offerings,
improving healthcare delivery efficiency and providing one avenue for the collection, organization and structuring of data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    Management Services (Home Care Services)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Property Management Service covers the management of properties such as condominiums and shopping malls, which are part of the retail
and residential properties we service. Categorized under Home Care Service line from 2023 onwards, this service line together with the
Security Service will eventually evolve to provide home-based medical services to households. The home care service line will be a medical
integrated property management services in homes and offices that comes with general home care and specialized care service curated based
on member&#8217;s needs. Services include but not limited to are remote monitoring, continuous care management, chronic disease management,
post-surgery care, infusion, and preventative service. EUDA aims to also integrate the Security Service with its core business of providing
users with an integrated platform offering medical services by eventually training and providing security personnel at public events
for medical support.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketplace</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internet
penetration and the proliferation of online mobile applications has marked a significant shift in the global retail landscape to e-commerce
platforms. Consumer shopping habits have been molded with increasing digitalization as they can now explore a plethora of options and
products at the simple touch of a finger. E-commerce has transformed the entire retail value chain from the selection of products to
the transaction process and finally receiving the actual product. This has also had a trickle-down effect on health and wellness products
as more and more consumers are turning to the internet as a marketplace to address and fulfil their needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to capitalize on this industry uptick, and as part of its wider ecosystem, EUDA operates a Digital Health Marketplace (DHM), a
smart online retail platform specializing in consumer health and wellness. This platform is powered by smart capabilities for members
to compare and find the most cost-efficient product. The DHM represents an online marketplace that aims to simplify clients and end-users&#8217;
access to health and wellness-based consumer products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DHM, EUDA operates in three main segments that are outside the realm of prescription medicine:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dietary
    Supplements</i>: The dietary supplements market came under the limelight as a result of the COVID-19 pandemic which drove a massive
    awareness for personal health and immunity-boosting supplements. According to Grand View Research, the global dietary supplements
    market was valued at US$ 151.9 billion in 2021 and is expected to expand at a CAGR of 8.9% between 2022 to 2030. In terms of demographics,
    working adults accounted for 46.6% of the overall revenue in 2021 as a result of significant lifestyle changes and hectic work schedules
    due to the shift to work-from-home amidst the pandemic. Southeast Asia is one of the key markets which is expected to see significant
    growth during the forecast owing to the growing middle class and the increasing expenditure on health-enhancing products. EUDA is
    well-poised to capitalize on this untapped potential with its data driven DHM and its growing presence in the Southeast Asia market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Skincare</i>:
    The demand for skincare products, especially through online outlets, saw a massive increase during the pandemic period as there was
    a rising cognizance of the various benefits of using personal care products. Moreover, within the skincare segment, the demand for
    natural and organic skincare products proved to be more lucrative. According to Mordor Intelligence, the Global Skincare Products
    Market was valued at US$ 140.92 billion in 2020 and is forecast to grow at a CAGR of 4.69% from 2021 to 2026. EUDA is strategically
    positioned to capture the robust growth due to its strategic presence in the region as well its reliable and credible network of
    partners.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Healthy
    Snacks</i>: Health consciousness has been one of the major drivers behind the exponential growth of the healthcare industry, especially
    the healthy snacks industry. The preference for a quality lifestyle and ensuring that the nutritional needs of the body are met has
    boosted the demand for healthy snacks. According to Fortune Global Insights, the global healthy snacks market was valued at USD$
    78.13 billion in 2019 and is projected to reach USD$ 108.11 billion by 2027, exhibiting a CAGR of 4.2% during the forecast period.
    Another key contributor to the growth of this market is the increasing prevalence of chronic and acute diseases which have driven
    the shift to healthier lifestyle choices. Health-conscious consumers are expected to increase as the need for healthier lifestyle
    becomes more prevalent and therefore, with EUDA&#8217;s DHM, it will augment the online retail space for the healthy snacks industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
ecosystem facilitates patients who are looking for healthier lifestyles to utilize the marketplace for their nutritional supplementation
at the click of a button. EUDA marketplace is an online e-commerce function of the EUDA application and website that provides consumers
with the tools to optimize their wellness e-commerce experience and maximize their health savings through making qualified and informed
decisions in their shopping experience. The platform will offer on-demand and subscription-based services for health and wellness products,
supplementing the service of care with technology, both at the front and back end. The AI-assisted bot will offer suggestive content
and products to boost user&#8217;s well-being. EUDA platform not only enables consumers to make informed decisions but also helps them
understand, manage and purchase products through educational content in accordance with their individual needs and benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
Marketplace will improve the lives of their patients by providing convenience, lowering prices and offering discounts and wide range
of products for the consumer health and wellness industry. They aim to leverage their expanding network of medical partners to further
promote the need for health-consciousness and using superior dietary supplements for a healthier lifestyle as they continue to steer
through the pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued,
as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed
to be material to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 30, 2022, the State Courts of the Republic of Singapore had reached a verdict that the Company&#8217;s subsidiaries, KRHSG and
Melana (Defendants) is liable to compensate Jamie Fan Wei Zhi (Plaintiff), the Company&#8217;s related party for failing to procure the
release of the Plaintiff from the guarantees to secure a credit line from United Overseas Bank before December 31, 2020. The Defendants
agree to compensate the Plaintiff the sum of $3,704 (SGD 5,000) per month as guarantor fee starting from January 1, 2021 until the Defendants
procured the release of the Plaintiff as the guarantor of the loan. The Defendants released the Jamie Fan Wei Zhi as the guarantor of
the loan on October 31, 2022. As of December 31, 2022, the Company has paid Jamie Fan Wei Zhi $74,966 (SGD 100,000), and no more balance
outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had 150 employees as of December 31, 2022, including our three named executive officers. None of our employees are covered by collective
bargaining agreements, and we have not experienced any strikes or work stoppages related to labor relations issues. We believe we have
good relations with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Purchase Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Closing Date, the Company consummated the previously announced business combination contemplated by the Share Purchase Agreement
(the &#8220;SPA&#8221;) between 8i Acquisition 2 Corp., a BVI business company (&#8220;8i&#8221;), EUDA Health Limited, a British Virgin
Islands business company (&#8220;EHL&#8221;), Watermark Developments Limited, a British Virgin Islands business company (&#8220;Watermark&#8221;
or the &#8220;Seller&#8221;), and Kwong Yeow Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022.
As contemplated by the SPA, a business combination between 8i and EUDA was effected by the purchase by 8i of all of the issued and outstanding
shares of EUDA from the Seller (the &#8220;Share Purchase&#8221;), resulting in EUDA becoming a wholly owned subsidiary of 8i. In addition,
in connection with the consummation of the Share Purchase, 8i has changed its name to &#8220;EUDA Health Holdings Limited.&#8221; The
transactions contemplated under the SPA relating to the Share Purchase are referred to herein as the &#8220;Business Combination.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the SPA, upon the consummation of the Business Combination (the &#8220;Closing&#8221;), any and all outstanding units
of 8i, composed of one ordinary share of 8i, no par value (the &#8220;8i Ordinary Shares&#8221;), one warrant (the &#8220;8i Warrants&#8221;),
with every two 8i Warrants entitling the registered holder to purchase one 8i Ordinary Share, and one right to receive one-tenth (1/10)
of one 8i Ordinary Share upon the consummation of an initial business combination (the &#8220;Rights&#8221;) (collectively, the &#8220;Units&#8221;)
were separated into their component parts and the 8i Ordinary Shares and 8i Warrants were re-designated on a one-for-one basis, and the
Rights were converted (at the rate of one-tenth (1/10) of a share for each outstanding Right), into ordinary shares of EUDA Health Holdings
Limited, no par value (the &#8220;Company Shares&#8221;). The Company&#8217;s shareholders of record (the &#8220;Shareholders&#8221;)
are entitled to one vote for each Company Share held on all matters to be voted on by Shareholders. Shareholders have no conversion,
preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the Company Shares. The
Company Shares and warrants (the &#8220;Warrants&#8221;) are listed on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbols
&#8220;EUDA&#8221; and &#8220;EUDAW,&#8221; respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Closing, the Units, 8i Ordinary Shares, 8i Warrants and Rights were listed on Nasdaq under the symbols &#8220;LAXXU,&#8221; &#8220;LAX,&#8221;
&#8220;LAXXW,&#8221; and &#8220;LAXXR,&#8221; respectively. In connection with the Business Combination, all of the Units separated into
their component parts and ceased trading on Nasdaq. No fractional Company Shares were issued upon the conversion of the Rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended
and Restated Registration Rights Agreement. </i></b>At the closing, the Company entered into an amended and restated registration rights
agreement (as amended, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with certain existing stockholders of the
Company and with the Seller with respect to their shares of the Company acquired before or pursuant to the Share Purchase, and including
the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company&#8217;s initial public offering
and any shares issuable on conversion of working capital loans from the Sponsor (as defined in the SPA) to the Company (collectively,
the &#8220;Registrable Securities&#8221;). The agreement amends and restates the registration rights agreement the Company entered into
on November 22, 2021 in connection with its initial public offering. Pursuant to the terms of the Amended and Restated Registration Rights
Agreement, no later than fourteen (14) calendar days from the Closing, the Company is to file with the SEC a registration statement on
Form S-3 (or Form S-1) covering the resale of all or such maximum portion of the Registrable Securities as permitted by the SEC. The
Amended and Restated Registration Rights Agreement does not contain liquidating damages or other cash settlement provisions resulting
from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing
of any such registration statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-up
Agreement. </i></b>In connection with the Closing, the Seller and its designees entered into lock-up agreements agreeing, subject to
certain exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any Lockup Shares
(as defined below), (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement
that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Shares or otherwise or engage in any
short sales or other arrangement with respect to the Lock-Up Shares or (iv) publicly announce any intention to effect any transaction
specified in clause (i) or (ii) until the date that is 18 months after the Closing Date (the &#8220;Lock-up Period,&#8221; which may,
upon written agreement of the Company and the Seller, be reduced for one or more holders of the Lockup Shares). The term &#8220;Lockup
Shares&#8221; mean the Purchaser Shares (as defined in the SPA) and the Earnout Shares (as defined in the SPA), if any, delivered as
earnout payment, whether or not earned prior to the end of the Lock-up Period, and including any securities convertible into, or exchangeable
for, or representing the rights to receive ordinary shares of the Company after the Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Indemnification
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
Closing the Company entered into indemnification agreements with each of its directors and executive officers. Each indemnification agreement
provides for indemnification and advancement by the Company of certain expenses and costs relating to claims, suits or proceedings arising
from service as an officer, director, employee, agent or fiduciary of the Company to the fullest extent permitted by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Seller
Release</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
Closing, the Company entered into a release (the <b><i>&#8220;Seller Release&#8221;</i></b>) whereby Seller agreed to release 8i, EUDA,
and all of their respective past and present officers, directors, managers, stockholders, members, employees, agents, predecessors, subsidiaries,
affiliates, estates, successors, assigns, partners and attorneys (each, a <b><i>&#8220;Released Party&#8221;</i></b>) to the maximum
extent permitted by applicable law, from any and all claims, obligations, rights, liabilities or commitments of any nature whatsoever
against 8i, EUDA, or any of the Released Parties, arising at or prior to the Closing, or related to any act, omission or event occurring,
or condition existing, at or prior to the Closing. The Seller does not release 8i, EUDA, or any of the Released Parties from claims arising
after the date of the Seller Release, any of the other ancillary agreements to the SPA, or any organizational or governing documents
or, of any indemnification agreements with, 8i or any of its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Where
You Can Find More Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed
pursuant to Sections 13(a) and 15(d) of the Exchange Act are filed with the SEC. Such reports and other information filed by the Company
with the SEC are available free of charge on our website at https://www.nauticusrobotics.com as soon as reasonably practicable after
they are electronically filed with or furnished to the SEC. Our SEC filings are also available to the public from the SEC&#8217;s internet
site at https://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including
risks specific to us or the robotics industry, as well as risks that affect businesses in general. The risks disclosed in this Annual
Report on Form 10-K could materially adversely affect our business, financial condition, cash flows, or results of operations and thus
our stock price. These risk factors may be important to understanding other statements in this Annual Report on Form 10-K and should
be read in conjunction with the consolidated financial statements and related notes in Part I, Item 7, &#8220;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations&#8221; and Part I, Item 8, &#8220;Financial Statements and Supplementary
Data&#8221; of this Annual Report on Form 10-K. Because of such risk factors, as well as other factors affecting the Company&#8217;s
financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance,
and investors should not use historical trends to anticipate results or trends in future periods.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
operations and financial results are subject to various risks and uncertainties, including but not limited to those described below,
which could harm our business, reputation, financial condition, and operating results.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are not currently in compliance with the continued listing standards of Nasdaq and may not be able to regain compliance with Nasdaq&#8217;s
continued listing standards in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares and warrants currently trade on The Nasdaq Capital Market under the symbols &#8220;EUDA&#8221; and &#8220;EUDAW,&#8221;
respectively. We are not currently in compliance with Nasdaq&#8217;s continued listing standards and our failure to continue to meet
these requirements may result in our securities being delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2023, the Company received a notice from Nasdaq (the &#8220;Initial Notice&#8221;) indicating that, as a result of not having
timely filed the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 with the SEC (the &#8220;Initial
Delinquent Filing&#8221;), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all
required periodic financial reports with the SEC. On May 18, 2023, the Company received an additional notice from Nasdaq indicating that,
as a result of an additional delinquency in the timely filing of the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2023 (together with the Initial Delinquency Filing, the &#8220;Delinquent Filings&#8221;), the Company remained out of compliance
with Nasdaq Listing Rule 5250(c)(1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was provided up to June 5, 2023 to or 60 days from the Initial Notice, to submit to Nasdaq a plan to regain compliance with the
Nasdaq Listing Rules. The Company submitted such plan on June 5, 2023. On June 13, 2023, the Company received a determination letter
from Nasdaq advising it that the Nasdaq Staff has accepted the Company&#8217;s plan to regain compliance with the Rules provided that
the Company must file its Delinquent Filings as required by the Rule on or before August 4, 2023. If the Company fails to file the Delinquent Filings by August 4, 2023, the Company may receive a notice that its securities will be delisted. In that case, the Company will have
the opportunity to appeal that decision to a Nasdaq Hearings Panel. If our appeal fails, the Company&#8217;s securities may be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to satisfy the continued listing requirements of Nasdaq, Nasdaq may take steps to delist our ordinary shares. In the event of
a delisting, we would take action to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance
that any such action taken by us would allow our ordinary shares to become listed again, stabilize the market price or improve the liquidity
of our ordinary shares, prevent our ordinary shares from dropping below the Nasdaq Capital Market&#8217;s minimum bid price requirement
or prevent future non-compliance with Nasdaq&#8217;s other listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delisting
from Nasdaq could also result in negative publicity. If we are delisted, we would also incur additional costs under state blue sky laws
in connection with any sales of our securities. These requirements could severely limit the liquidity of our ordinary shares and/or warrants
and the ability of our shareholders to sell our ordinary shares and/or warrants in the secondary market. If our ordinary shares and/or
warrants are delisted by Nasdaq, our ordinary shares and/or warrants may be eligible to trade on an over-the-counter quotation system,
such as the OTCQB Market, where an investor may find it more difficult to sell our securities or obtain accurate quotations as to the
market value of our ordinary shares and/or warrants. In the event our ordinary shares and/or warrants are delisted from The Nasdaq Capital
Market, we may not be able to list our ordinary shares and/or warrants on another national securities exchange or obtain quotation on
an over-the counter quotation system. Delisting could also lead to the potential loss of confidence by employees and customers, the loss
of investor interest, and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm&#8217;s report contains an explanatory paragraph that expresses substantial doubt about
our ability continue as a &#8220;going concern.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s negative working capital deficit was approximately $4.1 million, and the Company had cash
and restricted cash of approximately $0.8 million. The Company has experienced recurring losses from operations and negative cash
flows from operating activities since 2020. In addition, the Company had, and may potentially continue to have, an ongoing need to
raise additional cash from outside sources to fund its expansion plan and related operations. There is no assurance that the
Company&#8217;s capital raising efforts will be successful. Successful transition to attaining profitable operations is dependent
upon achieving a level of revenues adequate to support the Company&#8217;s cost structure. Further, the Company has incurred and
expects to continue to incur significant professional costs to remain as a publicly traded company. These factors, among others,
raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements contained
elsewhere in this Form 10-K do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
previously identified material weaknesses in the Company&#8217;s internal control over financial reporting,
and if EUDA is unable to achieve and maintain effective internal control over financial reporting, this could have a material adverse
effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company produces our consolidated financial statements in accordance with the requirements of U.S. GAAP. Effective internal controls
are necessary for EUDA to provide reliable financial reports to help mitigate the risk of fraud and to operate as a publicly traded company.
Prior to the Business Combination, EUDA was a private company with limited accounting personnel and other resources with which to address
internal controls and procedures. EUDA and our independent registered public accounting firm identified material weaknesses in the Company&#8217;s internal controls over financial reporting in connection with the audits of EUDA&#8217;s financial
statements for the years ended December 31, 2022 and 2021. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies,
in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or
interim financial statements will not be prevented or detected on a timely basis. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weaknesses that were identified related to: (i) lack of sufficient financial reporting and accounting personnel, especially those
with understanding of U.S. GAAP knowledge; (ii)
lack of proper mechanism to identify and assess the experience and qualification
of third-party specialists. As a result of these material weaknesses,
the Company&#8217;s management concluded that our internal control over financial reporting was not effective as of December 31, 2022
and 2021. EUDA is in the process of developing a plan to remediate these material weaknesses and will continue to identify additional
appropriate remediation measures. However, the material weaknesses will not be considered remediated until the remediation plan has been
fully implemented, the applicable controls are fully operational for a sufficient period of time, and the Company has concluded, through
testing, that the newly implemented&#160;and enhanced controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, EUDA cannot predict the success of such efforts or the outcome of future assessments of the remediation efforts. As a public
company, EUDA will be required to further design, document and test the Company&#8217;s internal controls over financial reporting to
comply with Sarbanes-Oxley Act Section 404. If existing material weaknesses or control deficiencies are not remediated or if material
weaknesses or control deficiencies occur in the future, EUDA may be unable to report the Company&#8217;s financial results accurately
on a timely basis or help prevent fraud, which could cause EUDA&#8217;s reported financial results to be materially misstated and result
in the loss of investor confidence or delisting and cause the market price of EUDA&#8217;s ordinary shares to decline. If we have material
weaknesses in the future, it could affect the financial results that the Company reports or create a perception that those financial
results do not fairly state EUDA&#8217;s financial position or results of operations. Either of those events could have an adverse effect
on the value of the Company&#8217;s ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
even if EUDA concludes that our internal control over financial reporting provides reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, because of its inherent
limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required
new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s results of operations or
cause EUDA to fail to meet future reporting obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
will require additional funding through sale of either debt or equity securities to support its continuing operations and growth of business,
and such funding may not be available on acceptable terms, or at all, and that may adversely impact EUDA&#8217;s business, financial
condition, results of operations and growth potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
operations have consumed substantial funds since inception. It will continue to require substantial funding to support its continuing
operations. The Company also intends to continue to make significant investments to support business growth, respond to business challenges
or opportunities, develop new applications and services, enhance existing solution and services, enhance operating infrastructure and
potentially acquire complementary businesses and technologies. EUDA may seek to use equity or debt financings to raise additional funds
to support its continuing operations and support growth initiatives. In February 2023, Alfred Lim, Executive Director of EUDA, provided
a working capital loan in the amount of $128,750 to EUDA. From January to May 2023, James Tan, the former Chief Executive officer of
8i loaned the Company with an aggregate amount of $500,700. In May 2023, EUDA initiated efforts to raise up to $4,000,000 from the sale
of ordinary shares at $1.00 per share. Between May 16 and May 20, 2023, EUDA raised an aggregate of $940,000 from the sale of 940,000
shares of restricted ordinary shares at $1.00 per share. Between May and June 2023, as a result of a number of transactions between
EUDA and each of its CEO and two current shareholders who held promissory notes or claims against EUDA, EUDA was able to settle in full
its debt obligations in the aggregate amount of $1,617,606 by issuing a total of 1,345,739 ordinary shares to these three creditors, two
of whom are related parties to EUDA (see &#8220;Item 13. Certain Relationships and Related Transactions and Director Independence&#8221;).
There are no assurances that related parties will accept shares of the Company as payment for any of their future loans to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
EUDA raises additional funds through further issuances of equity or convertible debt securities, existing shareholders could suffer significant
dilution, and any new equity securities issued could have rights, preferences and privileges superior or similar to those of holders
of ordinary shares. EUDA could also face additional restrictive covenants relating to capital-raising activities and other financial
and operational matters if EUDA were to secure additional funds from such financing methods, which may make it more difficult for it
to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, EUDA may not be able
to obtain additional financing on commercially reasonable terms, if at all, especially during times of economic uncertainty, while failure
to obtain sufficient funding in a timely manner could result in a delay and indefinite postponement of its plans. If EUDA is unable to
obtain adequate financing or financing on terms satisfactory to the Company, it could have a material adverse effect on EUDA&#8217;s
business, financial condition and results of operations. Any restructuring of EUDA&#8217;s current debt could also affect the financial
condition of the Company. Failure to properly manage the Company&#8217;s debt-to-equity ratio could create a disproportionately large
interest payment obligation, thereby adversely affecting the Company&#8217;s profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Company&#8217;s management team has limited skills related to experience managing a public company. Loss of any senior management or
other key employees could adversely affect its business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the departure of the Company&#8217;s Chief Technology Officer in May 2023, the Company&#8217;s management team was comprised of Dr.
Kelvin Chen, the Chief Executive officer, Steven John Sobak, the Chief Financial Officer, and a Chief Technology Officer. The Company&#8217;s
management team have limited experience managing a publicly traded company, interacting with public company investors, and complying
with the increasingly complex laws, rules and regulations that govern public companies. As a public company, the Company is subject to
significant obligations relating to reporting, procedures and internal controls, and its management team may not successfully or efficiently
manage such obligations. These obligations and scrutiny has required, and will continue to require, significant attention from the Company&#8217;s
management and could divert their attention away from the day-to-day management of its business, which could adversely affect its business,
financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
future success depends on the Company&#8217;s ability to continue attracting, developing, motivating and retaining highly qualified and
skilled employees. EUDA&#8217;s success also depends, to a significant extent, on the continued services of the individual members of
the management team and the Board, who have substantial experience in the industries and in the different jurisdictions in which they
operate. Between January and May 2023, four former independent directors left EUDA&#8217;s Board. Although highly qualified director
nominees were subsequently identified and appointed to fill the vacancies, there is no guarantee that EUDA can continue to retain its
current directors. As competition for qualified individuals in the industry could intensify, EUDA may incur significant time and costs
to attract and replace key personnel, including Board members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, EUDA&#8217;s loss of any senior management or other key employees on EUDA&#8217;s inability to recruit and develop mid-level
managers could materially and adversely affect the Company&#8217;s ability to execute its business plan and find adequate replacements.
All of EUDA&#8217;s employees are at-will employees, meaning that they may terminate their employment relationship at any time, and their
knowledge of EUDA&#8217;s business and industry would be extremely difficult to replace. If EUDA fails to retain talented senior management
and other key personnel, or if the Company does not succeed in attracting well-qualified employees or retaining and motivating existing
employees, its business, financial condition and results of operations may be materially adversely affected. There can be no assurance
that any management team member will remain with EUDA. Any loss of the services of key members of the management team could have a material
adverse effect on EUDA&#8217;s business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
one or more of EUDA&#8217;s key personnel are unable to discharge their duties properly, or in the best interest of EUDA, that may impact
EUDA&#8217;s business, operations and financial performance adversely.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed, EUDA&#8217;s Board voted in favor to remove two former directors from the Board because the Board believed that
the conduct of these two former directors were disruptive to the Company&#8217;s operations. Similarly, if for any reason, one or more
of EUDA&#8217;s employees are unable to discharge their duties properly or in the best interest of the Company, that may have an adverse
impact on EUDA&#8217;s reputation, brand and attractiveness to bring in talent. EUDA may as result incur some costs or losses and there
is potential that the Company will lose revenue or future revenue potential. Although it is EUDA&#8217;s endeavor to ensure that all
of the Company&#8217;s employees work to their full potential and in a harmonious manner within the Company&#8217;s organization, there
are always risks associated with one or more employees not discharging their duties properly and going unnoticed for a period of time,
impacting EUDA adversely. Such acts by certain employees may cause employees to lose trust in each other, give rise to conflicts between
employees, and failure to meet their responsibilities. Consequently, EUDA&#8217;s business may lose revenue and miss out on potential
opportunities. Moreover, in other scenarios, it could result in lawsuits, defamation, or similar negative outcomes. Such cases may require
sanctions from the senior management of EUDA leading up to and including termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
has incurred, and may incur, significantly increased costs and has continued to devote substantial management time as a result of operating
as a public company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, EUDA has incurred significant costs related to legal, accounting, listing, hiring of external consultants and advisors,
and other expenses. EUDA expects that management and other personnel will need to divert attention from operational and other business
matters to devote substantial time to these public company requirements. EUDA may also need to hire additional accounting and financial
staff with appropriate public company experience and technical accounting knowledge and establish an internal audit function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
as a public company has also made it more expensive to obtain director and officer liability insurance and the Company may be required
to accept reduced coverage or incur substantially higher costs to obtain coverage. This could also make it more difficult for EUDA to
attract and retain qualified people to serve on its board of directors, its board committees or as executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
may qualify as a foreign private issuer, and as a foreign private issuer, EUDA will be subject to reduced reporting requirements applicable
to foreign private issuers. It cannot be certain if the reduced reporting requirements will make EUDA&#8217;s ordinary shares less attractive
to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">If
the Board determines that EUDA qualifies for the &#8220;foreign private issuer&#8221; status defined in Rule 3b-4(c) of the Exchange
Act, EUDA will start reporting under the Exchange Act as a foreign private issuer as soon as its second fiscal quarter ends on June 30,
2023. As a foreign private issuer, EUDA will be exempt from the rules under the Exchange Act, prescribing the furnishing and content
of proxy statements, and its officers, directors and principal shareholders will be exempt from the reporting and short-swing profit
recovery provisions contained in Section 16 of the Exchange Act. In addition, EUDA will not be required under the Exchange Act to file
quarterly periodic reports and financial statements with the SEC as frequently or as promptly as U.S. domestic issuers, and will not
be required to disclose in its periodic reports all of the information that U.S. domestic issuers are required to disclose. EUDA will
also be permitted to follow corporate governance practices in accordance with the laws of the British Virgin Islands in lieu of most
of the corporate governance rules set forth by Nasdaq. As a result, EUDA&#8217;s corporate governance practices may differ in some respects
from those required to be followed by U.S. companies listed on a national securities exchange. For instance, EUDA&#8217;s Amended and
Restated Memorandum and Articles of Association do not require EUDA to have a majority of the board consisting of independent directors
nor require EUDA to hold an annual shareholders&#8217; meeting during each fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0.2pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company cannot predict if investors will find its ordinary shares less attractive because the Company would switch to a foreign private
issuer status. If some investors find the Company&#8217;s ordinary shares less attractive as a result, there may be a less active trading
market for the ordinary shares and its market price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
an emerging growth company, EUDA is subject to reduced reporting requirements applicable to emerging growth companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
is an emerging growth company, as defined in the JOBS Act. For as long as EUDA continues to be an emerging growth company, it may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging
growth companies,&#8221; including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure
obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved. The Company will remain an emerging growth
company until the earlier of: (1) December 31, 2027 (the last day of the fiscal year following the fifth anniversary of the consummation
of the Company&#8217;s initial public offering), (2) the last day of the fiscal year in which we have total annual gross revenue of at
least $1.235 billion, (3) the last day of the fiscal year in which we are deemed to be a large accelerated filer, as defined in the Securities
Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or (4) the date on which we have issued more than $1.0 billion in
non-convertible debt during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those
standards apply to private companies. The Company has elected to avail itself of this exemption from new or revised accounting standards
and, therefore, the Company will not be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after the Company no longer qualifies as an emerging growth company, it may still qualify as a &#8220;smaller reporting company,&#8221;
which would allow it to take advantage of many of the same exemptions from disclosure requirements including exemption from compliance
with the auditor attestation requirements of Section 404 and reduced disclosure obligations regarding executive compensation in this
proxy statement and the Company&#8217;s periodic reports and proxy statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company cannot predict if investors will find its ordinary shares less attractive because the Company may rely on these exemptions. If
some investors find the Company&#8217;s ordinary shares less attractive as a result, there may be a less active trading market for the
ordinary shares and its market price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
of the Company&#8217;s public float, the impact of the actions taken by a few shareholders on the price of its ordinary shares may be
amplified by the Company&#8217;s public float, and such price volatility may make it difficult for prospective investors to assess the
value of the Company&#8217;s ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ordinary shares may be subject to extreme volatility that is seemingly unrelated to the underlying performance of its
business. Recently, companies with comparable public floats and public offering sizes have experienced instances of extreme stock price
run-ups followed by rapid price declines, and such stock price volatility was seemingly unrelated to the respective company&#8217;s underlying
performance. Although the specific cause of such volatility is unclear, the Company&#8217;s public float may amplify the impact of the
actions taken by a few shareholders on the price of its ordinary shares, which may cause its share price to deviate, potentially significantly,
from a price that better reflects the underlying performance of its business. Should the Company&#8217;s ordinary shares experience run-ups
and declines that are seemingly unrelated to the Company&#8217;s actual or expected operating performance and financial condition or
prospects, prospective investors may have difficulty assessing the rapidly changing value of the Company&#8217;s ordinary shares. In
addition, investors in the Company&#8217;s ordinary shares may experience losses, which may be material, if the price of the Company&#8217;s
ordinary shares declines after this offering or if such investors purchase ordinary shares prior to any price decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Business-Related Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
and Operational</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
could incur significant upfront costs in client acquisitions and relationships, and if the Company is unable to maintain and grow these
client relationships over time, EUDA is likely to fail to recover these costs or major part of it, which could have a material adverse
effect on the Company&#8217;s business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
derives most of its revenue from additional services required from clients and subscription access fees. The costly initial upfront investment
of the Company&#8217;s business model and the recognition of associated revenue on a ratable basis renders the Company substantially
dependent on achieving economies of scale. Additionally, EUDA devotes significant resources to establish relationships with the Company&#8217;s
clients and implement solution and related services. Accordingly, EUDA&#8217;s results of operations will substantially depend on the
Company&#8217;s ability to deliver a successful experience for both clients and members and continue maintaining and growing its relationship
with the Company. EUDA&#8217;s client acquisition costs could also increase faster than revenue as the business continues to grow and
expand, and EUDA may be unable to reduce total operating costs through economies of scale such that the Company is unable to achieve
desirable profitability. If EUDA fails to achieve appropriate economies of scale or fails to manage or anticipate the evolution and in
future periods, demand, of the subscription access fee model, the Company&#8217;s business, financial condition and results of operations
could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
digital health industry is relatively young, is currently in its early growth stages and is still evolving, and if it develops towards
a mature stage more slowly than EUDA expects, if it encounters a pessimistic outlook or if EUDA&#8217;s services are not competitive,
the growth of EUDA&#8217;s business will be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
digital health industry is relatively young even though it is rapidly evolving, and it is uncertain whether it will achieve and maintain
high levels of demand, consumer acceptance and market adoption. EUDA&#8217;s success will substantially depend on the willingness of
its clients&#8217; members or patients to adopt, and the frequency and extent of their utilization of, EUDA&#8217;s services and solutions,
as well as on EUDA&#8217;s ability to demonstrate the value of digital health to employers, health plans, government agencies and other
purchasers of healthcare for beneficiaries. If EUDA&#8217;s clients, or its members or patients do not acknowledge the benefits of EUDA&#8217;s
services or platform, or if EUDA&#8217;s services are not competitive, then the market may not develop at all, or EUDA may develop slower
than it expects. Similarly, individual and healthcare industry concerns or negative publicity regarding patient confidentiality and privacy
in the context of digital health could restrict market acceptance of the Company&#8217;s healthcare services. An occurrence of any of
these events could have a material adverse effect on its business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
short operating history and the rapidly evolving nature of the industry make it difficult to assess the Company&#8217;s success and predict
the risks and challenges it may encounter.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
EUDA&#8217;s business operations began only in 2019, its short operating history and the evolving nature of the digital health industry
make it difficult to evaluate and assess the success of EUDA&#8217;s business to date, EUDA&#8217;s future prospects, and the risks and
challenges that EUDA may encounter. These risks and challenges include EUDA&#8217;s ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    new consumers to use EUDA&#8217;s products and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">position
    EUDA&#8217;s platform as a comprehensive healthcare and wellness provider;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retain
    consumers purchasing healthcare products and services through EUDA&#8217;s platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    new and existing consumers to adopt new offerings on EUDA&#8217;s platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    the number of consumers that subscribe to its offerings or the number of subscription programs that EUDA manages;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain industry players for inclusion in its platform, such as pharmacies, physicians, digital health providers, and others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
    with existing and new laws and regulations applicable to the Company&#8217;s business and in its industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipate
    and respond to macroeconomic changes, changes in medication pricing and industry pricing benchmarks and changes in the markets in
    which they operate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">react
    to challenges from existing and new competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    and enhance the value of its reputation and brand;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    manage its growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire,
    integrate and retain talented employees at all levels of its organization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    and improve the infrastructure underlying its platform, including its mobile apps and website, data protection and cybersecurity;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    update its platform, including expanding the Company&#8217;s platform and offerings into different healthcare products and services;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and update the Company&#8217;s mobile apps, features, offerings and services to benefit consumers and members and enhance their experience.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure to address the risks and difficulties that EUDA faces, including those associated with the challenges listed above and elsewhere
in this &#8220;Risk Factors&#8221; section, could adversely affect EUDA&#8217;s business, financial condition, and results of operations.
Further, EUDA&#8217;s limited historical financial data and the evolving nature of the digital health industry in the Southeast Asian
region could limit the accuracy of any predictions about its future revenue and expenses as it would be if EUDA had a longer operating
history, operated a more predictable business or operated in a less regulated industry. If EUDA&#8217;s assumptions regarding these risks
and uncertainties, which it uses to plan and operate its business, are incorrect or change, or if EUDA does not address these risks effectively
and efficiently, EUDA&#8217;s results of operations could differ materially from its expectations and EUDA&#8217;s business, financial
condition and results of operations would be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
relies on its corporate clients for a significant portion of its revenue, the loss of which would have a material adverse effect on EUDA&#8217;s
business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
has historically relied on its corporate clients and members based in Singapore for a substantial portion of its total revenue. The Company
has a high concentration risk on its corporate clients, which represent a significant portion of its revenue, and could render them unable
to grow its business quickly enough to drive organic growth from individual clients. It is also dependent on its Singapore members as
drivers for growth in that market and has forecasted them to contribute a significant portion of future revenues in the next 5 years.
It also relies on its reputation and recommendations from key clients for the promotion of the Company&#8217;s solution to potential
new clients. The loss of any of key clients or members, failure to retain some of them or failure to renew or increase subscriptions
could have a significant impact on revenue, growth rate, reputation, and ability to obtain new clients. In addition, clients could cancel
or fail to renew their contracts in the event of a merger or acquisition of companies, thereby reducing the number of EUDA&#8217;s existing
and potential clients, members and patient populations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
majority of EUDA&#8217;s business serves a large population of employees working in the construction industry and similar labor-intensive
industries. Any resurgence of SARS, COVID, or a highly communicable pandemic condition, and the actions taken by health authorities and
policy makers to contain its impacts on public, can affect these industries and in turn would have a material effect on the continuity
our business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
there is a decrease in the number of individuals covered under the Company&#8217;s platform or health, or if the number of applications
or services to which they subscribe decreases, EUDA&#8217;s revenue will be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
currently relies mainly on organic growth driven by an increase in corporate clients. The Company&#8217;s fees are directly proportional
to the number of individuals to whom corporate clients provide benefits and the number of applications or services subscribed to by its
corporate clients under most of its contracts with them. There are many factors that may lead to a decrease in the number of individuals
covered by EUDA&#8217;s corporate clients and the number of applications or services subscribed to by the Company&#8217;s corporate clients,
including, but not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of corporate clients to adopt or maintain effective business practices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the nature or operations of corporate clients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
    regulations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    competition or other changes in the benefits marketplace.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
EUDA is unable to retain the active customers while attracting new customers, it would result in a loss of future revenue and have an
adverse material effect on the Company&#8217;s business, financial position, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
digital healthcare industry faces significant risks and challenges from rapid technological changes.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
digital healthcare market faces rapid technological change, changing consumer requirements, short product lifecycles and evolving industry
standards. EUDA&#8217;s success will depend on its ability to enhance its solutions with the latest technologies and to develop or to
acquire and market new services to access new consumer populations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that EUDA will possess the resources, either financial or personnel, for the research, design, development and deployment
of new applications, technological requirements, or services, or that they will be able to utilize these resources successfully and avoid
technological or market obsolescence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there can be no assurance that technological advances by one or more of EUDA&#8217;s current or future competitors will not result in
the Company&#8217;s present or future software-based products and services to become uncompetitive or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
industry that EUDA operates in is highly competitive and rapidly evolving, and if it is not able to compete effectively, its business,
financial condition and results of operations may be adversely impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
operates in a highly competitive and rapidly evolving industry, and we expect that competition will increase as a result of consolidation
in both the information technology and healthcare industries and also from new entrants in the markets in which we operate. The Company&#8217;s
future growth and success will depend on its ability to successfully compete with other companies that provide similar services and other
healthcare organizations that seek to build and operate competing services and newer companies that provide similar services at substantially
lower prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
competes on the basis of various factors, including breadth and depth of services, reputation, reliability, quality, innovation, security,
team, technology, platform robustness, price, industry expertise, and experience. If the Company is unable to maintain or improve its
technology, management, healthcare, or regulatory expertise or attract and retain a sufficient number of qualified sales and marketing
leadership and support personnel, the Company will be at a competitive disadvantage. Some competitors, in particular larger technology
or technology-enabled consultative service providers, have greater name recognition, longer operating histories, and significantly greater
resources than the Company does.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
current or potential competitors may have greater resources financially and logistically than EUDA does, which may allow them to be less
sensitive to changes in client preferences and more aggressive in pricing strategies, any of which could put the Company at a competitive
disadvantage. As a result, competitors may be more adapt in responding to new or changing opportunities, technologies, standards, or
trends and may have the ability to initiate or withstand substantial price competition. In addition, potential corporate clients frequently
have requested competitive bids from the Company and competitors in terms of price and services offered and, if the Company does not
accurately assess potential corporate clients&#8217; needs and budgets when submitting proposals, EUDA may appear less attractive than
those competitors, and the Company may not be successful in attracting new business. If EUDA&#8217;s prospective or current corporate
clients fail to perceive the value of EUDA&#8217;s products and services, corporate clients could view competitors&#8217; products to
be more attractive. Increases in competition in the Company&#8217;s industry could reduce EUDA&#8217;s market share and result in price
declines for certain services, which could negatively impact EUDA&#8217;s business, profitability, and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is foreign exchange (FX) risk in EUDA&#8217;s business as we operate in multiple countries and exchange rates fluctuate, and that may
cause FX-related losses or translation losses for the Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
EUDA operates in multiple countries, EUDA&#8217;s business could also face foreign exchange risks. To date, the Company&#8217;s revenue
has been denominated in currencies such as Singapore dollars, and Malaysian ringgit, while EUDA also has intention to expand its operations
in other parts of the Asian region. As its international contracts are denominated in the respective local currencies, EUDA&#8217;s operating
results might be impacted from fluctuations in the value of reporting currency when translated. As the Company further expands internationally,
its exposure to foreign currency exchange risk may increase as well. However, EUDA plans to move towards creating its own payment ecosystem
through the introduction of its own digital currency in the future and that will help the Company in having a more standardized system
and help reduce FX risks. The Company also has a certain level of natural hedge in the countries in which it operates as its revenues
and major costs in individual markets are both denominated in the same currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
growth depends on the success of the Company&#8217;s strategic relationships with third parties and partners.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
anticipates that it will continue to depend on relationships with third parties, including partner organizations and technology and content
providers to grow the Company&#8217;s business. Identifying partners, and negotiating and documenting relationships with them, requires
significant time and resources. The Company&#8217;s competitors may be more effective in incentivizing such potential partners to favor
their products or services over EUDA&#8217;s. In addition, acquisitions of EUDA&#8217;s existing and potential partners by competitors
could result in a decrease in the number of EUDA&#8217;s current and potential clients, as partners may no longer facilitate the adoption
of EUDA&#8217;s applications and services to potential clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
EUDA is unsuccessful in establishing or maintaining relationships with third parties, the Company&#8217;s ability to compete in the marketplace
or to grow the Company&#8217;s revenue could be impaired and the results of operations may suffer. Even if the Company is successful,
it cannot assure investors that these relationships will result in increased client use of its applications or increased revenue. While
EUDA expects that these relationships will continue, it cannot guarantee that they will. Any material changes in government regulations,
or the loss of these affiliations, could impair the Company&#8217;s ability to provide services to members and clients and could have
a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
business and growth strategy depends on its ability to maintain and expand a network of qualified providers and partners.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
success is substantially dependent upon the Company&#8217;s continued ability to maintain a network of skilled and qualified digital
health providers. EUDA, through its wholly owned subsidiaries, provides medical services including multi-care specialty care services
and holistic care services. EUDA is also dependent on third-party entities and a related party, which they do not own or control, to
provide healthcare services to consumers. The significant competition in the digital health market for qualified digital health providers
may hinder the Company&#8217;s ability to recruit or retain physicians and other healthcare professionals and service providers, which
would negatively impact the growth of the Company&#8217;s digital health offerings and would have a material adverse effect on the Company&#8217;s
business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any particular market, providers could demand higher payments or take other actions that could result in higher medical costs, less attractive
services for EUDA&#8217;s clients or difficulty meeting regulatory or accreditation requirements. EUDA&#8217;s ability to develop and
maintain satisfactory relationships with third-party providers also may be negatively impacted by other factors not associated with the
Company, such as changes in medical reimbursement levels and other pressures on healthcare providers and consolidation activity among
hospitals, physician groups and healthcare providers. The failure to maintain or to secure new cost-effective provider contracts may
result in a loss of or an inability to grow the Company&#8217;s membership base, higher costs, healthcare provider network disruptions,
less attractive service for clients and/or difficulty in meeting regulatory or accreditation requirements, any of which could have a
material adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
relies heavily on technology services provided by third parties and its own systems for providing services to clients and members, and
any failure or interruption in these services could expose the Company to litigation and negatively impact relationships with clients,
its reputation, brand and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
relies heavily on significant IT infrastructure and systems and the ongoing maintenance of the regional and local Internet infrastructure
to provide the necessary data speed, capacity and security to offer viable services. If EUDA&#8217;s relevant service providers&#8217;
infrastructure or systems were to fail for any reason, this may cause EUDA&#8217;s portals to experience significant downtime or impaired
performance, which could have an impact on the Company&#8217;s reputation. EUDA&#8217;s platform may also be exposed to damage or interruption
from system failures, cyber threats (including malware, ransomware, phishing and denial of service (DoS) attacks), telecommunication
provider or third-party supplier failures, inadequate system maintenance, damage to the physical infrastructure associated with the network,
disasters from natural or human causes, or other unforeseen events which may cause unplanned disruption to EUDA&#8217;s systems. These
technology failures may affect EUDA&#8217;s ability to deliver consistent, quality services, meet contractual and service level obligations,
attract new customers, or lead to data integrity issues or data loss. While EUDA has backup plans in place, such as switching to text
messages and call services when platforms sense a weak internet connection, significant disruptions to the platform or services could
have a material impact on the Company&#8217;s reputation and brand and may result in a loss of users of products and services, which
could have a material adverse effect on the Company&#8217;s business, result of operations, financial performance and financial condition.
Any vulnerabilities or conditions that could potentially interrupt access or flow of information, or violate patient confidentiality
or the Personal Data Protection Act in Singapore could have a material adverse effect on the Company&#8217;s business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
currently does not hold any issued patents. EUDA&#8217;s financial and operational success depends highly on the Company&#8217;s ability
to protect the Company&#8217;s intellectual property and intellectual property rights and failure to do so will adversely impact the
Company&#8217;s business and financial performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
success depends largely on the Company&#8217;s ability to protect the Company&#8217;s proprietary software, confidential information
and know-how, technology, and other intellectual property and intellectual property rights. While EUDA generally relies on copyright,
trademark and trade secret laws, confidentiality and invention assignment agreements with employees and third parties, and license and
other agreements with consultants, vendors, and clients, there can be no assurance that EUDA will enter into such agreements or that
the Company or its counterparties have not breached or will not breach their agreements. EUDA also may not have adequate remedies for
any breach or assurances that its trade secrets will not otherwise become known or independently developed by competitors. Additionally,
EUDA monitors the use of open-source software to avoid use-cases that would require the Company to disclose its proprietary source code
or violate applicable open-source licenses, but if engaged in such uses inadvertently, the Company may be required to take remedial action
or release certain of proprietary source code, which could materially and adversely affect the Company&#8217;s business, financial condition,
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a third party could, without authorization, copy or otherwise obtain and use EUDA&#8217;s products or technology, or develop
similar technology in spite of the agreements and protections put in place. EUDA could also face difficulties enforcing agreement terms
in the various jurisdictions that address non-competition, which might not be enforceable in certain cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
currently does not hold any issued patents. As EUDA begins to pursue patents, the Company might not be able to obtain meaningful and
adequate patent protection for its technology. Moreover, if any patents are issued in the future, they might not provide any meaningful
competitive advantages or might be successfully challenged by third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
may also rely on unpatented proprietary technology and competitors may independently develop the same or similar technology or obtain
access to EUDA&#8217;s own unpatented technology. While EUDA enters into confidentiality agreements with employees, partners and other
relevant parties to protect its trade secrets and other proprietary information, EUDA cannot assure that these agreements will provide
meaningful protection in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets or other proprietary
information. In addition, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive,
and time-consuming, and the outcome is unpredictable. If any of EUDA&#8217;s trade secrets were to be lawfully obtained or independently
developed by a competitor or other third party, EUDA would have no right to prevent them from using that technology or information to
compete. Further, the theft or unauthorized use or publication of EUDA&#8217;s trade secrets and other confidential business information
could reduce the differentiation of the Company&#8217;s services and harm the Company&#8217;s business, the value of investment in development
or business acquisitions could be reduced, and third parties might make claims against the Company related to losses of its confidential
or proprietary information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
may also rely on trademarks, service marks, trade names, and brand names to distinguish the Company&#8217;s services from the services
of competitors. While EUDA has registered or applied to register many of these trademarks, it cannot assure that its trademark applications
will be approved. Third parties may also challenge the Company&#8217;s applications, or otherwise challenge use of its trademarks. In
the event that EUDA&#8217;s trademarks are successfully opposed or challenged, the Company could be forced to rebrand the Company&#8217;s
services, which could result in loss of existing brand value and require EUDA to expend additional resources for advertising and marketing
purposes. Further, EUDA cannot assure that its competitors will not infringe on its trademarks or that the Company will have adequate
resources to enforce its own trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
operations are dependent on its relationships with professional entities, which it may or may not own, to provide physician, healthcare,
and consultation services, and its business would be adversely affected if those relationships were disrupted or discontinued.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
uses contract physicians for the clinical and professional services provided to the Company&#8217;s clients and members through its platform.
While EUDA expects that these relationships will continue, EUDA cannot guarantee that they will. Any material change in the relationships
with the Company&#8217;s existing physicians and healthcare professionals, whether resulting from a dispute among the entities, a change
in government regulation, or the loss of these affiliations, could impair EUDA&#8217;s ability to provide services to clients and members
and could have a material adverse effect on its business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
mitigate the dependence on external professionals, EUDA does own some clinics and directly employ some professionals, and plans to continue
that strategy in the future. Currently, EUDA directly employs about 10% of physicians and primary care specialists that provide digital
health services on the Company&#8217;s platform and is actively seeking to hire and expand its direct employment of primary care specialists
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
EUDA is not able to develop new competitive and market relevant services that are adopted by clients, or if EUDA fails to innovate in
providing high quality support services required by its clients, EUDA&#8217;s growth prospects, revenues and operating results could
be materially and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
longer-term operating results and revenue growth will depend in part on its ability to successfully develop and sell new services that
existing and potentially new clients want and are willing to purchase. EUDA needs to continuously invest significant resources in research
and development in order to enhance existing services and introduce new high-quality services to clients and prospective clients. If
EUDA is unable to predict or adapt to changes in user preferences or industry or regulatory changes, or if the Company is unable to add
on or modify its services on a timely basis in response to those changes, clients may not renew their agreements with EUDA, and EUDA&#8217;s
services may be perceived as less competitive or somewhat obsolete. If EUDA&#8217;s innovations are not responsive to the needs of clients,
are not appropriately timed with market opportunity, or are not effectively brought to market, it could have a material adverse impact
on operating results. EUDA&#8217;s success also depends on successfully providing high-quality support services to resolve any issues
related to EUDA&#8217;s services, as they are important for the successful marketing and sale of services and for the renewal of existing
clients. If EUDA does not help clients quickly resolve issues and provide effective ongoing support, the Company&#8217;s ability to sell
additional services to existing clients would suffer and EUDA&#8217;s reputation with existing or potential clients would be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
EUDA fails to maintain brand awareness economically, business might suffer and it could adversely impact the Company&#8217;s operational
and financial performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
awareness of EUDA&#8217;s brand in an economical manner is critical for the promotion of existing services and is an important element
in attracting new clients and in attracting and retaining qualified employees. EUDA&#8217;s future growth is also expected to be driven
by word of mouth accompanied by enhanced brand awareness. As EUDA seeks to differentiate itself from competitors, the success of brand
awareness initiatives is crucial, which will depend largely on the effectiveness of marketing efforts and on the ability to provide reliable
and useful services at competitive prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
clients might not associate the different brands EUDA owns under the broader umbrella of the EUDA brand. For example, customers might
not associate a EUDA service as being under the EUDA brand or related to it, which may result in losing integration benefits to its competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
third parties&#8217; use of trademarks or similar branding could materially harm EUDA&#8217;s business or result in litigation and other
costs. If EUDA fails to successfully maintain the Company&#8217;s brand or lower customer acquisition costs to maintain the Company&#8217;s
brand, EUDA may fail to attract enough new clients or retain existing clients to the extent necessary to realize a sufficient return
on brand-building efforts, and EUDA&#8217;s business and ability to attract and retain qualified employees could suffer, and thus adversely
impact the Company&#8217;s operational and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
marketing efforts depend significantly on EUDA&#8217;s ability to receive positive references from existing clients.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
marketing efforts depend significantly on EUDA&#8217;s ability to call upon current clients and members to provide positive references
to new and potential clients. The loss or dissatisfaction of any client, especially long-term clients, could substantially harm EUDA&#8217;s
brand and reputation, inhibit widespread adoption of the Company&#8217;s solutions and services and impair the Company&#8217;s ability
to attract new clients and members and retain existing clients and members. Any of these consequences could lower EUDA&#8217;s annual
net dollar retention rate and/or cause loss of future and potential revenue and thereby have a material adverse effect on EUDA&#8217;s
business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
relies on third-party vendors to perform certain services provided on EUDA&#8217;s platform and failure to provide these services adequately
could have an adverse effect on EUDA&#8217;s business, results of operations and growth prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
relies in part on third-party vendors to perform certain services provided on its platform, including payment, hosting and video streaming,
and delivery of certain products and services to clients. There is no guarantee that these third-party vendors will perform their obligations
in a timely and cost-effective manner, in compliance with applicable regulations, or in a manner that is in EUDA&#8217;s and its clients&#8217;
best interests, and thus could have an adverse effect on EUDA&#8217;s reputation and ability to retain and attract clients. There is
also no guarantee that these third-party vendors will be able to continue to provide these services, goods, technology, or intellectual
property rights cost efficiently in a manner consistent with EUDA&#8217;s business practices. If EUDA fails to replace these services,
goods, technologies, or intellectual property rights in a timely manner or cost-efficiently, EUDA&#8217;s operating results and financial
condition could be harmed. If EUDA&#8217;s third-party vendors do not perform their services at a level acceptable to the Company&#8217;s
clients, or if the Company is unable to leverage its services to a larger group of clients, it could have an adverse effect on EUDA&#8217;s
business, results of operations, and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
proprietary software and platform may not operate properly or in accordance with clients&#8217; expectations, which could damage EUDA&#8217;s
reputation, give rise to legal claims against the Company or divert resources from other purposes, any of which could harm EUDA&#8217;s
business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
proprietary application platform provides clients, members and providers with the ability to, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">register
    for EUDA&#8217;s services;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete,
    view and edit medical history;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">request
    a visit (either scheduled or on demand);</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    a visit with a healthcare professional (via video or phone);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    electronic claims for EUDA&#8217;s services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">register
    for mental wellness related options and services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">utilize
    lifestyle related services; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">register
    for nutrition, exercises and other similar services and options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the different services and solutions that EUDA provides, development and updating of the proprietary software is resource intensive and
complex and may involve unforeseen difficulties. EUDA may encounter technical obstacles during the development and updating stages and
may encounter additional problems even as it is in service. If EUDA&#8217;s services do not function reliably or fail to achieve clients&#8217;
and members&#8217; expectations in terms of performance, clients could assert liability claims against the Company or attempt to cancel
their contracts, which could damage EUDA&#8217;s reputation and impair the Company&#8217;s ability to attract or maintain clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA&#8217;s
sales and implementation cycle can be long and unpredictable and requires considerable time and expenses, which may cause EUDA&#8217;s
results of operations to fluctuate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sales cycle for EUDA&#8217;s solutions, from initial contact with a potential lead to contract execution and implementation, varies widely
from client to client. Some of EUDA&#8217;s clients undertake a significant and prolonged evaluation process to determine whether EUDA&#8217;s
services and solutions meet their unique healthcare needs, which frequently involves evaluation of not only EUDA&#8217;s solutions but
also an evaluation of those of EUDA&#8217;s competitors, which is a process that has in the past resulted in extended sales cycles. EUDA&#8217;s
sales efforts involve educating clients about the use, technical capabilities and potential benefits of EUDA&#8217;s solution. Moreover,
EUDA&#8217;s large enterprise clients often begin to deploy EUDA&#8217;s solution on a limited basis, but nevertheless demand extensive
configuration, integration services and pricing concessions, which increases EUDA&#8217;s upfront investment in the sales effort with
no guarantee that these clients will deploy EUDA&#8217;s solution widely enough across their organization to justify the substantial
upfront investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that in the future EUDA may experience even longer sales cycles, more complex client needs, higher upfront sales costs and
less predictability in completing some sales as EUDA continues to grow its direct sales force, expand into new territories and market
additional applications and services. If EUDA&#8217;s sales cycle lengthens or if substantial upfront sales and implementation investments
do not result in sufficient sales to justify investments, it could have a material adverse effect on EUDA&#8217;s business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
EUDA cannot implement the Company&#8217;s solution for clients or resolve any technical issues in a timely manner, the Company may lose
clients and the Company&#8217;s reputation may be harmed, and which may adversely impact the Company&#8217;s operational and financial
performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
clients utilize a variety of data formats, applications and infrastructure and the Company&#8217;s solution must support clients&#8217;
data formats and integrate with complex enterprise applications and infrastructures. EUDA could incur additional expenses to ensure the
Company&#8217;s platform is compatible to support clients&#8217; or members&#8217; data or integrate with its existing applications and
infrastructure. Additionally, EUDA does not control clients&#8217; implementation schedules and could face a delay in implementation
if clients do not allocate the necessary resources to meet its implementation responsibilities or if it faces unanticipated implementation
difficulties. If the client implementation process is not executed successfully or if execution is delayed, EUDA could incur significant
costs, clients could become dissatisfied and decide not to continue utilization of the Company&#8217;s solution or not to implement the
Company&#8217;s solution beyond an initial period prior to their term commitment. Moreover, competitors with more efficient operating
models with lower implementation costs could potentially jeopardize client relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
clients and members depend on support services to resolve technical issues relating to the Company&#8217;s solution and services, and
may be unable to respond quickly enough to accommodate short-term increases in member demand for support services, particularly as the
Company increases the size of the Company&#8217;s client and membership bases. EUDA also may be unable to modify the format of the Company&#8217;s
support services to compete with changes in support services provided by competitors. It is difficult to predict member demand for technical
support services, and if member demand increases significantly, EUDA may be unable to provide satisfactory support services to members.
Further, if EUDA is unable to address member needs in a timely fashion or further develop and enhance the Company&#8217;s solution, or
if a client or member is not satisfied with the quality of work performed by EUDA or with the technical support services rendered, EUDA
could incur additional costs to address the situation or be required to issue credits or refunds for amounts related to unused services,
the Company&#8217;s profitability may be impaired and clients&#8217; dissatisfaction with the Company&#8217;s solution could damage the
Company&#8217;s ability to expand the number of applications and services purchased by such clients. These clients may not renew their
contracts, or may seek to terminate their relationship or renew on less favorable terms. Moreover, negative publicity related to client
relationships, regardless of its accuracy, may further damage EUDA&#8217;s business by affecting the Company&#8217;s reputation or ability
to compete for new business with current and prospective clients. If any of these were to occur, EUDA&#8217;s revenue may decline, and
the Company&#8217;s business, financial condition and results of operations could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and business to clients based in different countries or EUDA&#8217;s international operations may expose the Company to risks inherent
in international sales that, if realized, could adversely affect its business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the longer term, EUDA may require significant resources and management attention for international expansion, which will subject EUDA
to differing regulatory, economic and political risks. EUDA&#8217;s international expansion efforts may not be successful in creating
demand for EUDA&#8217;s products and services outside of the Southeast Asian region, or in effectively selling the Company&#8217;s solutions
in the international markets EUDA may enter, due to the Company&#8217;s limited experience with these international operations. In addition,
EUDA will face risks in doing business internationally that could adversely affect EUDA&#8217;s business, including, but not limited
to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    need to localize and adapt EUDA&#8217;s solutions for each specific countries the Company seeks to expand into, including translation
    into foreign languages and associated expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different
    data privacy laws of the various jurisdictions in which EUDA may operate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing foreign operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contrasting
    pricing environments, longer payment cycles and collections issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
    to new and multiple sources of competition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laws
    and business practices favoring local competitors and trade partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexity
    of various governmental laws and regulations, including employment, healthcare, tax, privacy and data protection laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    financial accounting and reporting burdens and complexities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on fund transfers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    exchange risks from fluctuations in value of currencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    tax consequences; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unstable
    economic and political conditions of the economies in which EUDA may operate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
relies on third-party platforms such as the Apple App Store and Google Play App Store to distribute its platform and offerings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
apps are accessed and operated through third-party platforms or marketplaces, including the Apple App Store and Google Play App Store.
As such, EUDA depends on continued relationships with these providers and any other emerging platform providers that are widely adopted
by consumers for the expansion and prospects of EUDA&#8217;s business and apps. EUDA is subject to the standard terms and conditions
that these providers have for all application developers that govern the content, promotion, distribution and operation of apps on their
platforms or marketplaces, which the providers can change unilaterally on little or no notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
business would be harmed if these changes were to: prevent or limit EUDA&#8217;s access to the platforms; cause a decline in popularity
among users; modify algorithms or communication channels available to developers; change respective terms of service or other policies;
increase applicable fees; or require EUDA to modify or update its apps and technology to ensure compatibility and access for the platform&#8217;s
users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
alternative providers increase in popularity, EUDA could be adversely impacted if the Company fails to create compatible versions of
its apps in a timely manner, or if the Company fails to establish a relationship with such alternative providers. If EUDA&#8217;s providers
do not perform their obligations in accordance with platform agreements, EUDA could be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, some of these platforms or marketplaces have been unavailable for short periods of time. The occurrence of such an event, or
users encountering issues that impact their ability to download or access apps and other information, could have a material adverse effect
on EUDA&#8217;s brand and reputation, as well as EUDA&#8217;s business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
(Compliance/Security)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EUDA
could incur significant costs as a result of any claim or lawsuit of infringement of another party&#8217;s intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been significant litigation in different parts of the world involving patents and other intellectual property rights in recent years.
Companies that are in the internet and technology industries are increasingly bringing and becoming subject to lawsuits alleging infringement
of proprietary rights, particularly patent rights, and EUDA&#8217;s competitors and other third parties may hold patents or have pending
patent applications that could be related to EUDA&#8217;s business. As the Company applies for its own patents in the future, EUDA&#8217;s
expects that it may receive notices in the future that claim EUDA or its clients, who are using EUDA&#8217;s` solution, have misappropriated
or misused other parties&#8217; intellectual property rights, particularly as competition grows and the functionality of applications
amongst competitors overlap. If EUDA is sued or served a legal notice by a third party that claims that EUDA&#8217;s technology infringes
its rights, the litigation, whether or not successful, could be extremely costly to defend, divert EUDA&#8217;s management&#8217;s time,
attention and resources, damage EUDA&#8217;s reputation and brand and substantially harm EUDA&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has invested significant time and resources to create its own proprietary software platform. Development of the current software
and solutions has been undertaken by employees in Vietnam, Indonesia and Singapore, with whom the Company has non-disclosure agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
software integrates open-source software code and database systems, and leverages on application programming interface (API) connectors
to deliver an integrated user experience. The software includes multiple critical trade secrets of the business as well as representing
a significant volume of code to be understood if it is to be replicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of key content resources have been developed to help scale the effective communication of its proposition to the market. Copyright
exists in content or written materials that EUDA has created and owns. The copyright also exists in the software codebase created, especially
important for those aspects of the software exposed to users such as the application interface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some instances, EUDA has agreed to indemnify clients against certain third-party claims, which may include claims that EUDA&#8217;s
software solution infringes the intellectual property rights of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA&#8217;s
business could be adversely affected by any significant disputes between the Company and the Company&#8217;s clients as to the applicability
or scope of the Company&#8217;s indemnification obligations to them. The results of any intellectual property litigation to which EUDA
may become a party, or for which EUDA is required to provide indemnification, may require the Company to do one or more of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cease
    offering or using technologies that incorporate the challenged intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    substantial payments for legal fees, settlement payments or other costs or damages;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    a license, which may not be available on reasonable terms, to sell or use the relevant technology; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redesign
    technology to avoid infringement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
EUDA is required to make substantial payments or undertake any of the other actions noted above as a result of any intellectual property
infringement claims or lawsuits against the Company or any obligation to indemnify the Company&#8217;s clients for such claims, such
payments or costs could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breach
of the Company&#8217;s intellectual property may also require the Company to commence legal actions, which could be costly and time consuming.
Failure to defend the Company&#8217;s position or intellectual property could reduce the Company&#8217;s market position and have similar
adverse effects on the Company&#8217;s business, financial conditions, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company fails to develop or license technology for any allegedly infringing aspect of the Company&#8217;s business in the future,
the Company would be forced to limit its services and may be unable to compete effectively. Any of these events could materially harm
the Company&#8217;s business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the Company&#8217;s arrangements and agreements with the Company&#8217;s partners or its customers are found to violate laws and regulations
relevant to the digital health industry, the Company&#8217;s business, financial condition and its ability to operate in those jurisdictions
could be adversely impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
EUDA&#8217;s businesses operate internationally, the Company must adhere to the various laws and regulation of the respective jurisdictions,
which includes laws governing remote healthcare, the practice of medicine and healthcare delivery in general which are subject to change
and interpretation. Failure to adhere to these regulations could put the Company at risk of statutory actions and cessation of operations
and fines, litigation and compensation claims from patients and customers which could have material adverse effect on the Company&#8217;s
business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
digital health services EUDA offers are subject to laws, rules and policies governing the practice of medicine and relevant medical council
oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to provide and promote the Company&#8217;s digital health offerings in each of the jurisdictions that the Company
operates in is dependent upon the individual jurisdiction&#8217;s treatment of digital health, under such jurisdiction&#8217;s laws,
rules and policies governing the practice of medicine, which are subject to changing political, regulatory, and other influences. Some
medical boards relevant to the jurisdictions that the Company operates in may have established rules or interpreted existing rules in
a manner that limits or restricts the Company&#8217;s ability to conduct or optimize its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s digital health offerings offer patients and users the ability to see a board-certified medical professional for advice,
diagnosis, and treatment of routine health conditions on a remote basis. The nature of such services and the provision of medical care
and treatment by board-certified medical professionals could subject the Company and certain of the Company&#8217;s affiliated physicians
and healthcare professionals to complaints, inquiries, and compliance orders by national and other relevant medical boards in the future.
Such complaints, inquiries or compliance orders may result in disciplinary actions taken by these medical boards against the licensed
physicians who provide services through the Company&#8217;s digital health offerings, which could include suspension, restriction or
revocation of the physician&#8217;s medical license, probation, required continuing medical education courses, monetary fines, administrative
actions, and other conditions. Regardless of outcome, these complaints, inquiries or compliance orders could have an adverse impact on
the Company&#8217;s digital health offerings and its platform generally due to defense actions related and settlement costs, diversion
of management resources, negative publicity, reputational harm and other factors. Any loss of specific licensure, such as medical staff
or clinic, as well as loss of license or accreditation required for provision of professional building or residential management or security
services could also have a material adverse effect on the Company&#8217;s business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the uncertain regulatory environment, certain government authorities or relevant boards may determine that the Company is in violation
of their laws and regulations, or such laws and regulations may evolve over time. In the event that the Company must remedy such violations,
the Company may be required to modify its offerings in such jurisdictions in a manner that undermines its offerings or business, the
Company may become subject to fines or other penalties or, if the Company determines that the requirements to operate in compliance in
such jurisdictions are overly burdensome, the Company may elect to terminate its operations in such jurisdictions. In each case, the
Company&#8217;s revenue may decline, and the Company&#8217;s business, financial condition and results of operations could be materially
adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
digital health industry faces evolving government regulations, and failure to comply with these changes may result in increased costs
or adversely affect the Company&#8217;s results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
uncertainty of the regulatory climate of the Company&#8217;s industry may subject the Company&#8217;s operations to direct and indirect
adoption, expansion or reinterpretation of various laws and regulations. The Company may be required to change its practices at undeterminable
future laws and regulation and possibly incur significant initial monetary and annual expense to adhere to the new regulatory changes.
These additional monetary expenditures may increase future overhead, which could have a material adverse effect on the Company&#8217;s
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified what the Company believes are the areas of government regulation that, if changed, would be costly to the Company.
These include rules governing the practice of medicine by physicians; licensure standards for doctors and behavioral health professionals;
laws limiting the corporate practice of medicine; cybersecurity and privacy laws; laws and rules relating to the distinction between
independent contractors and employees; and tax and other laws encouraging employer-sponsored health insurance. There could be laws and
regulations applicable to the Company&#8217;s business that it has not identified or that, if changed, may be costly to the Company,
and it cannot predict all the ways in which implementation of such laws and regulations may affect it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the introduction of new services may require EUDA to comply with additional, yet undetermined, laws and regulations. This may require
EUDA to obtain additional appropriate medical board licenses or certificates, increase the Company&#8217;s security measures and expend
additional resources to monitor developments in applicable rules and ensure compliance. The failure to adequately comply with these future
laws and regulations may delay or possibly prevent some of EUDA&#8217;s products or services from being offered to clients and members,
which could have a material adverse effect on the Company&#8217;s business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inaccurate
or incomplete information and data provided to EUDA&#8217;s clients through the Company&#8217;s platform could adversely impact the Company&#8217;s
business reputation, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare and digital health industries are highly data-driven, and EUDA aggregates, processes, and analyzes healthcare-related data
and information for use by the Company&#8217;s clients. As the healthcare industry faces the issue of data fragmentation, inconsistency,
and incompletion, the overall quality of data received is often poor while the degree or amount of data which is knowingly or unknowingly
absent or omitted can be material. EUDA could also encounter data issues and errors during data integrity checks. If the analytical data
that the Company provides to its clients and members are based on incorrect or incomplete data or if it makes mistakes in the capture,
input, or analysis of these data, EUDA&#8217;s reputation may suffer and its ability to attract and retain clients may be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, EUDA assists clients with the management and submission of data to governmental entities. These processes and submissions are
governed by complex data processing and validation policies and regulations, and may expose EUDA to liabilities regarding storage, handling,
submission, delivery, or display of health information or other data that was wrongful or erroneous if the Company fails to adhere to
the policies and regulations. Although EUDA maintains insurance coverage, this coverage may prove to be inadequate or could cease to
be available to the Company on acceptable terms, if at all. EUDA could incur substantial costs and diversion of management time, attention,
and resources even if such claims are unsuccessful. A claim brought against EUDA that is uninsured or under-insured could harm EUDA&#8217;s
business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
EUDA&#8217;s security measures fail to ensure protection of clients&#8217; data, services may be deemed insecure and as a result the
Company could incur significant liabilities, reputational harm, and loss of sales and clients.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
provided on EUDA&#8217;s platforms are highly dependent on artificial intelligence and blockchain technology, devices such as the wearable
technologies offered by EUDA or its partners, which involve the storage and transmission of clients&#8217; proprietary information, sensitive
or confidential data, including valuable intellectual property and personal information of employees, clients and others, as well as
protected health information, or PHI, of clients&#8217; patients. Due to the extreme sensitivity of the information EUDA stores and transmits,
the security features of the Company&#8217;s computers and systems, network, and communications systems infrastructure are critical to
the success of the Company&#8217;s business. A breach or failure in the Company&#8217;s security measures could occur from a variety
of circumstances and events, including third-party action, employee negligence or error, malfeasance, computer viruses, cyber-attacks
or ransom related attacks by computer hackers, failures during the process of upgrading or replacing software and databases, power outages,
hardware failures, telecommunication failures, user errors, or catastrophic events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
cyber threats continue to evolve with the proliferation of new technologies and the increased sophistication and activities of perpetrators
of cyber-attacks, EUDA may be required to expend additional resources to continue to enhance information security measures or to investigate
and remediate any information security vulnerabilities. If EUDA&#8217;s security measures fail or are breached, it could result in unauthorized
persons accessing sensitive client or patient data (including PHI) and a loss of or damage to the Company&#8217;s data, resulting in
an inability to access data sources, process data, or provide services to the Company&#8217;s clients. The occurrence of such failures
or breaches of EUDA&#8217;s security measures, or any inability to effectively resolve such failures or breaches in a timely manner,
could severely damage the Company&#8217;s reputation, adversely affect client or investor confidence in the Company, and reduce the demand
for its services from existing and potential clients. In addition, EUDA could face litigation, damages for contractual breaches, monetary
penalties, or regulatory actions for violation of applicable laws or regulations and incur significant costs for remedial measures to
prevent future occurrences and mitigate past violations. While EUDA has outsourced security measures to a third-party agency as preventive
measures to protect the integrity of the Company&#8217;s clients&#8217; and members&#8217; information, this solution might not be comprehensive
enough to ensure the safety of such data. Although EUDA maintains adequate insurance coverage covering certain security and privacy damages
and claim expenses, EUDA may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance
coverage would not address the reputational damage that could result from a security lapse or a breach related incident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
may experience cyber-security and other breaches that may remain undetected for an extended period as cyber-attack techniques constantly
evolve. EUDA also may not be able to comprehensively anticipate such cyber security threats as they may not be recognized until the breach
occurs. As such, EUDA may be unable to implement adequate preventive measures and the Company&#8217;s actions would be limited to being
reactive in nature. EUDA also cannot ensure the complete integrity or security of such data in the Company&#8217;s systems in the event
that the Company&#8217;s clients authorize or enable third party access to the information stored on the Company&#8217;s platforms and
systems. If an actual or perceived breach of EUDA&#8217;s security occurs, or if EUDA is unable to effectively resolve such breaches
in a timely manner, the market perception of the effectiveness of the Company&#8217;s security measures could be harmed and it could
lose sales and clients, which could have a material adverse effect on the Company&#8217;s business, operations, and financial results.
EUDA could also be subjected to litigation from clients and providers in the event of such security breaches and that could result in
substantial costs and a diversion of management&#8217;s attention and resources, which could have a material adverse effect on the Company&#8217;s
business, financial condition, or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
EUDA uses best efforts to maintain insurance coverage the Company deems adequate to address cyber-security, EUDA may find such coverage
lacking or unavailable in certain instances which could have material adverse effect on the Company&#8217;s business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
2. Properties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located in 1 Pemimpin Drive #12-07, One Pemimpin Singapore 576151, where we lease and occupy approximately
1,679 square feet of office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
subsidiary Kent Ridge Health Pte Ltd leases and occupies approximately 1,679 square feet of combined office space at 1 Pemimpin Drive
#12-06, One Pemimpin Singapore 576151 for general business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our subsidiary Melana International Pte. Ltd. leases and occupies approximately 3,714 square feet of combined office space
at 60 Kaki Bukit Place #03-01 Singapore, 415979 for general business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our properties are suitable for the purposes for which they are being used and fit our needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_006"></span>Item 3. Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company is party to certain
legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible
losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 30, 2022, the State
Courts of the Republic of Singapore had reached a verdict that the Company&#8217;s subsidiaries, Healthcare Singapore Pte Ltd. and Melana
International Pte. Ltd. (Defendants) are liable to compensate Jamie Fan Wei Zhi (Plaintiff), the Company&#8217;s related party for failing
to procure the release of the Plaintiff from the guarantees to secure a credit line from United Overseas Bank before December 31, 2020.
The Defendants agreed to compensate the Plaintiff the sum of $3,704 (SGD 5,000) per month as guarantor fee starting from January 1, 2021
until the Defendants procured the release of the Plaintiff as the guarantor of the loan. The Defendants released the Jamie Fan Wei Zhi
as the guarantor of the loan on October 31, 2022. As of December 31, 2022, the Company has paid Jamie Fan Wei Zhi $74,966 (SGD 100,500),
and no more balance outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>Item 4. Mine Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_008"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_009"></span>Item 5. Market for Registrant&#8217;s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are quoted
on The Nasdaq Stock Market LLC under the symbol &#8220;EUDA.&#8221; Our redeemable warrants are quoted on The Nasdaq Stock Market LLC
under the symbol &#8220;EUDAW.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Shareholders</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
there are approximately 28 shareholders of record of our ordinary shares based upon our transfer agent&#8217;s report. Because many of
our ordinary shares are held by brokers and other nominees on behalf of shareholders, including in trust, we are unable to estimate the
total number of shareholders represented by these record holders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our ordinary shares. To date we have utilized all available cash to finance our operations. Payment of cash dividends
in the future will be at the discretion of our Board and will depend upon our earnings levels, capital requirements, any restrictive loan
covenants and other factors the Board considers relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2022,
there were 8,625,000 Public Warrants outstanding and 292,250 Private Warrants outstanding. Refer to Note 16 to the consolidated
financial statements included in this annual report for additional information relating to outstanding warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Recent Sales of Unregistered Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We made no sales of our equity
securities during the fourth quarter of the fiscal year covered by the report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We made no purchases of our equity
securities during the fourth quarter of the fiscal year covered by the report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>Item 6. [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion and analysis of the Company&#8217;s
financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related
notes included elsewhere in the Report. This discussion contains forward-looking statements that involve risks and uncertainties. Actual
results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result
of various factors. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our mission is to make high-quality,
personalized healthcare affordable and accessible for all our patients. Our aim is to provide a one stop healthcare and wellness services
through our propriety platform. We currently have operations in Singapore and expect to expand across Southeast Asia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2020, we acquired 100%
of the equity interests in Super Gateway Group Limited (&#8220;SGGL&#8221;), which engaged in the property and security management of
commercial units (shopping malls, business office buildings, industrial buildings), and residential apartments. We aimed to build an Omni-channel
health care and products platform in economies of scale and cross-sell opportunities which would allow our management services section
to expand into new and different verticals of management services in the medical field.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Headquartered in Singapore and
established in 2019, we aim to be a leading next-generation Southeast Asian healthcare-technology provider, integrating a full continuum
of healthcare services with healthcare data analytics to drive high-quality and efficient care for their patients. The proprietary platform,
is its core holistic, connected platform, through which it also offers a mobile application platform for its users. What makes us unique
is the integration of Artificial Intelligence (AI) and Machine Learning (ML), which provides real-time actionable analytics functionality
that enables our users to make quick analysis and accurate diagnosis as well as business decisions. The platform gathers numerous data
points and performs predictive analysis, where it can compare events and results over time to identify trends across various segments
and provide accurate insights, analysis, and predictions regarding healthcare. Its AI applications supported on our platform include smart
triage, smart match, smart claims supports and image recognition, as well as predictive algorithms that can read and analyze MRIs and
X-rays. our robust unique proprietary technology platform reduces the time taken for diagnostics yet continues to promote standardization
of diagnostics, which effectively eliminates inefficiencies. Through our software platform, it aims to deliver data-driven, personalized
quality insights to patients while they are at the doctor&#8217;s office in order to provide them with different healthcare and treatment
choices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We aim to provide a series of
products and services through its network and offer an array of complementary products and services to deepen their relationship with
its members from assessing the condition, evaluating the risk level to providing personalized support services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We market and promote our Medical
Urgent Care services to healthcare provider organizations throughout Singapore using a go-to-market and direct sales organization composed
of highly trained and technical team members that are segmented into several highly targeted and coordinated teams. These dedicated sales
teams develop content and identifies prospects that the sales development team research and qualify to generate high-grade, actionable
sales programs. Our sales and marketing department leverages on their deep experience to deliver an urgent care solution tailor-fit to
the size and specialty of each practice. Through this targeted, coordinated approach, We are able to maximize resource allocation and
allow its sales teams to concentrate on execution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We utilize both an inside and
outside direct sales force to execute on the qualified marketing programs, partnering with client services to ensure the prospect is educated
on the breadth of our capabilities and demonstrable value proposition. Medical and clinical partners also play an important role in marketing
and selling our products to its customer base. These partners may shorten the sales cycle and lower the customer acquisition costs. For
example, through the Clinic Management System (CMS) partners, we are able to embed its technology into existing health system technology
infrastructure which, as a competitive differentiator, may lead to a higher win rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our sales and marketing department
is primarily responsible for planning and developing its overall marketing strategy, conducting market research, coordinating the sales
and marketing activities to attract new customers and maintain and strengthen relationships with existing customers, managing the efforts
in relation to tender bids and negotiating the terms of our Property Management Service and Security Service contracts. The team will
explore and establish information channels for business development and market research purposes. Such information channels include websites
or other platforms on which property developers or property owners&#8217; associations announce tender opportunities, uncovering business
opportunities by way of recommendation or frequent communication with customers and other industry players, and organizing promotional
events to showcase our service offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore, we implement various
incentive measures to encourage the sales teams to obtain property management service contracts of properties developed by third-party
developers through research and analysis of and communication with target customers in the real estate industry and taking advantage of
our resources and expertise. In addition, various communication channels are adopted to explore more opportunities to provide our Property
Management Services that are customized and tailored to the specific localities to bring convenience to local property owners and residents.
We continually seek business cooperation opportunities with third-party merchants to enhance the width and depth of its services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that our platform will
eventually provide a full continuum of healthcare services integrated with healthcare data analytics to drive improved outcomes for patients.
To achieve this, we aim to continuously build towards a consumer-centric digital ecosystem to allow clients and patients to gain access
to quality healthcare while keeping costs affordable. We incorporate AI and ML on the platform and implements relevant solutions to a
wide variety of healthcare and homecare services that it currently provides. AI-driven advancement will be increasingly visible throughout
the healthcare journey including a strong potential for interactive virtual assistants to improve patient experience and clinician operational
workflow. We believe in incorporating technology into the traditional medical services market and creating an end-to-end ecosystem that
provides a comprehensive suite of healthcare and wellness services adds great value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 17, 2022, we consummated
the business combination contemplated by the &#8220;SPA&#8221; between us, Euda Health Limited (&#8220;EHL&#8221;), Watermark Developments
Limited, a British Virgin Islands business company (&#8220;Watermark&#8221; or the &#8220;Seller&#8221;) and the sole owner of EUDA, and
Kwong Yeow Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business
combination between us and EUDA was effected by the purchase by us of all of the issued and outstanding shares of EUDA from the Seller
(the &#8220;Share Purchase&#8221;), resulting in EUDA becoming a wholly owned subsidiary of us. In addition, in connection with the consummation
of the Share Purchase, we have changed our name to &#8220;EUDA Health Holdings Limited.&#8221; The transactions contemplated under the
SPA relating to the Share Purchase are referred to in this annual report as the &#8220;Business Combination.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Closing
of the Business Combination, we issued convertible notes in an aggregate principal amount of $3,402,225 (the &#8220;Convertible Notes&#8221;)
in a private placement to certain advisors. Indeterminate or fixed number of ordinary shares (the &#8220;Convertible Note Shares&#8221;)
could be issuable upon the conversion of the Convertible Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Key Factors that Affect Operating Results</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Strong Presence and wide Network of Partners to
Complement our &#8220;Always-On&#8221; Approach</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We provide 24/7 concierge-level
care coordination services for our high-risk members. As a digital health company, we strongly believe in advocating the presence of healthcare
at any time and any place needed by our customers. Our coordination specialists are trained to cover all emergency, primary and specialty
services and provide the highest level of personalized medical concierge level services at the push of a button. Furthermore, we strengthen
this capability through our geographical presence and wide network of relationships with medical partners. We have a sizeable number of
medical partners across the healthcare spectrum, ranging from ambulatory service providers and General Practitioner (GP) clinics to hospitals
and specialist consultants. The widest range urgent care options are usually based around pricing, proximity, choice of treatment and
medications. Therefore, our relationships with medical partners gives a great competitive edge as we are able to provide top notch round-the-clock
healthcare services based on the requirements expected from our clients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Retention of Key Management Team Members</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Another key differentiating factor
for us is the rich blended nature of our management team. Our management team comprises executives with extensive experience in Healthcare,
Technology, Insurance &amp; Consumer Experience segments. The wide array of industries captured by our management team allows us to deliver
superior products and services to Our customers as the management team possesses an in-depth understanding of the pain points prevalent
in the industry. The combination has also enabled us to address the market gap in the healthcare industry with an innovative data driven
all-in-one healthcare platform. However, the loss of any of our key executive team member, such as the loss of our Chief Technology Officer
in May 2023, might affect our quality of services clients are currently receiving and might lead to our clients to seek medical service
from other medical providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Key Personnel Discharge of their Duties</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If for any reason, one or more
of our employees are unable to discharge their duties properly or in the best interest of us in the property management sector, that may
have an adverse impact on our reputation and our brand and our attractiveness to retain our shopping malls, business office buildings,
or residential apartments clients. We may as result potentially lose future revenue from our existing clients to retain our property management
services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investment in Digitalization and Innovation for
Digital Care Capabilities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are constantly investing in
AI technology that is designed to help expand patient engagement while improving efficiencies, reducing the cost of care and promoting
better care coordination. For example, there is an AI deployment enabling a patient-provider matching tool, allowing patients to input
our preference for doctors, timing and area of specialist onto our platform, and our platform will synthesize patient&#8217;s preference
to ensure best matches to boost efficiency and user experience. Continued investment in interoperability, including remote patient monitoring,
advanced analytics and lab services as well as the home delivery of pharmaceuticals, is expected to allow us to expand its use cases.
Our investments in interoperability with other technologies have also allowed them to partner with innovative companies to develop unique
products and services. Our strategic partnerships allow our services to be accessed directly through our interfaces. We believe these
partnerships will differentiate our offerings and add new capabilities to drive demand and add value for our clients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Our Ability to Leverage Existing Sales Channels
and Penetrate New Markets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have developed a highly effective
distribution network to target large employers and is committing incremental sales and marketing resources to the small-medium enterprises
to increase our penetration within this market. Additionally, we intend to further penetrate the medical provider market, notably hospitals
and group physician practices, as we believe our solution offers the medical community an attractive platform from which to generate substantial
income by acquiring new patients and to better participate in emerging risk-sharing and value-based payment models. With expanded access
to available health insurance, we also intend to pursue health insurance companies about our services, hence, which will represent an
attractive new sales channel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of Years Ended December 31, 2022 and
2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Year Ended December 31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage Change</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-indent: 0pt">Revenues</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 10%; text-align: right">9,840,709</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 10%; text-align: right">10,544,550</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 10%; text-align: right">(703,841</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">(6.7</td>
    <td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt">Cost of revenues</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">6,486,513</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">6,300,197</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">186,316</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">3.0</td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,543,196</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,244,353</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(890,157</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21.0</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Selling expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,902,865</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,258,442</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">644,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">51.2</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">General and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">12,352,877</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,084,873</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">8,268,004</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">202.4</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Impairment loss on long-lived assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,139,016</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,139,016</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">100.0</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Research and development expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">17,209</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">129,265</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(112,056</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(86.7</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Loss from operations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(12,057,771</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,228,227</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(10,829,544</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">881.7</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Other (loss) income, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(12,874,053</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,176,764</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(15,050,817</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(691.4</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Provision for income taxes</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">17,422</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">48,141</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(30,719</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(63.8</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Net (loss) income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(24,949,246</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">900,396</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(25,849,642</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,870.9</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Less: Net (loss) income attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(65,124</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">35,567</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(100,691</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(283.1</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">Net (loss) income attribute to EUDA</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,884,122</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">864,829</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(25,748,951</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(2,977.3</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our revenues are derived from
medical services, product sales, and property management services. Total revenues decreased by approximately $0.7 million, or 6.7%, to
approximately $9.8 million for the year ended December 31, 2022 as compared to approximately $10.5 million for the year ended December
31, 2021. The decrease of the total revenue was mainly attributable to the decrease of our property management services by approximately
$0.8 million, or 17.4%, to $3.8 million for the year ended December 31, 2022 as compared to approximately $4.6 million for the year ended
December 31, 2021, and also attributable to the decrease of our product sales by approximately $0.2 million, or 95.7%, to approximately
$11,000 for the year ended December 31, 2022 as compared to approximately $0.3 million for the year ended December 31, 2021, offset by
the increase of medical services by approximately $0.3 million, or 5.9%, to approximately $6.1 million for the year ended December 31,
2022 as compared to approximately $5.7 million for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our revenues from our revenue
categories are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2021</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change (%)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt">Revenues</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; text-indent: 0pt">Medical services &#8211; specialty care</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">6,001,439</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">5,010,837</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">990,602</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">19.8</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Medical services &#8211; general practice</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">63,794</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,712</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(648,918</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(91.0</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Medical services &#8211; general practice (related parties)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(4,505</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(97.1</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Medical services &#8211; subtotal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,065,368</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5,728,189</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">337,179</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.9</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Product sales</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">11,046</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">257,841</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(246,795</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(95.7</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Property management services</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">3,764,295</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,558,520</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(794,225</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(17.4</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">Total revenues</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">9,840,709</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">10,544,550</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(703,841</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(6.7</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Medical services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenues from medical services
increased by approximately $0.3 million, or 5.9%, to approximately $6.1 million for the year ended December 31, 2022 from approximately
$5.7 million for the year ended December 31, 2021. Revenue growth is mainly due to the increased number of employees/patients from our
corporate clients. Approximately 860 and 800 corporate clients had utilized our specialty healthcare services in each of the year ended
December 31, 2022 and 2021, respectively. The average usage of our specialty care services per corporate client were approximately $7,000 during
the year ended December 31, 2022, as compared to approximately $6,300 during the year ended December 31, 2021. Such increase was mainly
due to more employees/patients from corporate clients utilizing our specialty care services during the year ended December 31, 2022 as
compared to the same period in 2021. Approximately 5,200 and 4,000 employees/patients from our corporate clients had utilized our healthcare
services during the year ended December 31, 2022 and 2021, respectively. The average usage of our specialty care services per employee/patient
were approximately $1,200 during the year ended December 31, 2022, as compared to approximately $1,300 during the year ended December
31, 2021. The average usage of our specialty care services per employee/patient decreased by approximately $100 from the year ended December
31, 2021 to the same period in 2022 mainly due to the employees/patients from our corporate clients required lesser degree of specialty
care services in 2022 as compared to the same period in 2021. Our general practice medical services were insignificant to our operations
during the year ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenues from product sales decreased
by approximately $0.2 million or 95.7%, to approximately $11,000 for the year ended December 31, 2022 from approximately $0.3 million
for the year ended December 31, 2021. Our product sales have decreased for the year ended December 31, 2022 as compared to the same period
in 2021 due to the decreased demand of our facial recognition and temperature measurement monitor system as the COVID-19 pandemic has
been eased.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Property management services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenues from property management
services decreased by approximately $0.8 million, or 17.4%, to approximately $3.8 million for the year ended December 31, 2022 from approximately
$4.6 million for the year ended December 31, 2021. Property management services revenue decreased mainly due to the decrease of property
management units that we managed without our security guard services and the decrease of property management units that we managed with
our security guard services. The number of properties managed without security guard service decreased from 39 units for the year ended
December 31, 2021 to 37 units for the year ended December 31, 2022. The number of properties managed with security guard services decreased
from 13 units for the year ended December 31, 2021 to 12 units for the year ended December 31, 2022. Currently, we do not have any property
management services provided to any medical clinics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our percentage of property management
services revenue from each property type are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">For the Year Ended</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">For the Year Ended</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left; text-indent: 0pt">Residential Apartments</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">60</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">59</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Commercial Units</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">40</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">41</td>
    <td style="text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, we provided more
property management services in the residential apartments than in the commercial units during the year ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cost of Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Total cost of revenues increased
by approximately $0.2 million, or 3.0%, to approximately $6.5 million for the year ended December 31, 2022 as compared to approximately
$6.3 million for the year ended December 31, 2021. The increase in cost of revenues was mainly due to the increased of medical services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cost of revenues from our
revenue categories are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">
    <p style="margin-top: 0; margin-bottom: 0">For the Year</p>
    <p style="margin-top: 0; margin-bottom: 0">Ended</p></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">
    <p style="margin-top: 0; margin-bottom: 0">For the Year</p>
    <p style="margin-top: 0; margin-bottom: 0">Ended</p></td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b> </span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b> </span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change (%)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt">Cost of revenues</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; text-indent: 0pt">Medical services &#8211; specialty care</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">2,995,778</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">46,849</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">2,948,929</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">6,294.5</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Medical services &#8211; specialty care (related party)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,858,203</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(79.1</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Medical services &#8211; general practice</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">45,549</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">427,908</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(382,359</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(89.4</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Medical services&#8211; subtotal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,532,826</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,824,459</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">708,367</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">25.1</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Product sales</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">59,391</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">167,202</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(107,811</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(64.5</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Property management services</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">2,894,296</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">3,308,536</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(414,240</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(12.5</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">Total cost of revenues</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">6,486,513</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">6,300,197</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">186,316</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">3.0</td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cost of revenues from medical
services increased by approximately $0.7 million or 25.1% to approximately $3.5 million for the year ended December 31, 2022 from approximately
$2.8 million for the year ended December 31, 2021. The increase in cost of revenues from our medical services is in line with our increase
of revenues from medical services which was due to increased usage of our specialty services per customer. The increase in cost of revenues
from medical services &#8211; specialty care of approximately $2.9 million or 6,294.5% was mainly because beginning in April 2022, we
directly utilized the third party clinic service providers and no longer utilized our related party vendor, Cadence Health Pte. Ltd. (&#8220;Cadence&#8221;),
during the year ended December 31, 2022 as compared to the same period in 2021. Same reason was applied to the decrease in cost of revenues
from medical services &#8211; specialty care (related party) of approximately $1.9 million or 79.1%. Historically, EUDA&#8217;s specialty
care medical services provided by the third party clinic service providers were insignificant up until March 2022 and majority of the
cost of revenue from EUDA&#8217;s specialty care medical services for the year ended December 31, 2021 and for the three months ended
March 31, 2022 were provided by our related party vendor, Cadence. Our general practice medical services were insignificant to our operations
during the year ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cost of revenues from product
sales decreased by approximately $108,000, or 64.5%, to approximately $59,000 for the year ended December 31, 2022 from approximately
$167,000 for the year ended December 31, 2021. The decrease in cost of revenues from product sales is in line with our decrease of revenues
from product sales which was due to lower demand of our facial recognition and temperature measurement monitor system as the COVID-19
pandemic has eased.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cost of revenues from property
management services decreased by approximately $0.4 million, or 12.5%, to approximately $2.9 million for the year ended December 31, 2022
from approximately $3.3 million for the year ended December 31, 2021. The decrease in cost of revenues from property management services
is in line with our decrease of revenues from property management services which was mainly due to the decreased number of property management
units that we managed and the decreased number of property management employees offset by the increase of salary and benefits of the property
management employees per individual employee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our gross profit from our major
revenue categories is summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended <br />
December 31, 2022</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended <br />
December 31, 2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change (%)</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Medical services</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; text-indent: 0pt">Gross profit</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">2,532,542</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">2,903,730</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">(371,188</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">(12.8</td>
    <td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gross profit percentage</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">41.8</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">50.7</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(8.9</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Product sales</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(48,345</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">90,639</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(138,984</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(153.3</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gross profit percentage</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(437.7</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">35.2</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(472.9</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Property management services</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">869,999</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,249,984</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(379,985</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(30.4</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gross profit percentage</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23.1</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">27.4</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(4.3</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt">Total</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">3,354,196</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">4,244,353</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(890,157</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21.0</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gross profit percentage</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">34.1</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">40.3</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6.2</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our gross profit decreased by approximately $0.9 million, or 21.0%, to approximately $3.4 million for the year ended
December 31, 2022 from approximately $4.2 million for the year ended December 31, 2021. The decrease in gross profit is primarily due
to decrease of gross profit from medical service as a result of the increase of medical service cost over the increase of revenue. The
decrease in gross profit also due to the decrease of our revenues from our property management services against the increase of staff
salary</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the year ended December 31,
2022 and 2021, Our overall gross profit percentage was 34.1% and 40.3%, respectively. The decrease in gross profit percentage of 6.2%
was primarily due to the combination of the decrease of our medical services gross profit percentage of 8.9%, the decrease of our product
sales gross profit percentage of 472.9%, and the decrease of our property management services gross profit percentage of 4.3%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Gross profit percentage for medical
services was 41.8% and 50.7% for the year ended December 31, 2022 and 2021, respectively. The decrease of gross profit percentage of 8.9%
was mainly because beginning in April 2022, we directly utilized the third party clinic service providers and less service discounts provided
by our major medical service providers during the year ended December 31, 2022 as compared to the same period in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Gross (loss) profit
percentage for product sales was (437.7)% and 35.2% for the year ended December 31, 2022 and 2021, respectively. The decrease of
gross profit percentage of 472.9% was primarily caused by lower customer demand of our facial recognition and temperature
measurement monitor products as COVID-19 pandemic has eased which resulted in write-off of non-saleable items and reduce our
inventory level to $0 as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Gross profit percentage for
property management services was 23.1% and 27.4% for the year ended December 31, 2022 and 2021, respectively. The decrease of gross
profit percentage of 4.3% was primarily attributable to increase of salary and benefits of the property management employees per
employee. Although we had reduced the number of employees in the property management operations due to the decrease of property that
we managed, we increased the salary of property management employees on performance and inflation adjustment to retain more
qualified employees and did not pass on the cost of such adjustments to our customers, which significantly lowered our gross profit
percentage for property management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Total operating expenses
increased by approximately $9.9 million, or 181.6%, to approximately $15.4 million for the year ended December 31, 2022 from
approximately $5.5 million for the year ended December 31, 2021. The increase was mainly attributable to the increase of general and
administrative expenses and earnout share payment of approximately $8.3 million, increase of selling expenses of approximately $0.6
million and increase of impairment loss on long-lived assets of approximately $1.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An increase of approximately $8.3
million in general and administrative expenses, and earnout share payment was mainly attributable to an approximately $1.4 million increases in professional fees,
including but not limited to, attorney, auditors and consulting expenses incurred in relation to the Business Combination in 2022 which
was not allowed to be capitalized according to U.S. GAAP. The increase was also attributable to an approximately $2.8 million increase
in provision for bad debt, which was resulted from write-off of the uncollectible balance of receivable from divestment from BPT, an unrelated
third party and the balance from loan to PT total Prima Indonesia as we determined these balances will not be recovered in the future.
In addition, we incurred approximately $5.2 million of earnout payment upon assessing
the fair value of the Earnout Share. The increase was offset by the decrease of salary expenses of approximately $1.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An increase of approximately $0.6
million in selling expenses was mainly attributable to the approximately $0.6 million increase in advertising, marketing and entertainment
expenses, which was directly attributed to the increase of corporate clients and medical services revenues as more advertisement posting
to attract potential corporate clients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An increase of approximately $1.1
million in impairment loss on long-lived assets as we fully impaired the remaining balance of goodwill and intangible assets recognized
through acquisition of Super Gateway Group Limited in January 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Approximately $0.1 million decrease
in research and development expenses for the year ended December 31, 2022 as compared to the same period in 2021 was due to less research
and development expenses required as our existing platform becomes more mature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Other(expenses) income, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our other income, net is summarized
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times NewRoman, Times, Serif; font-size: 10pt"><b>For the Year<br /> Ended<br /> December 31,</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Year<br />
 Ended<br />
 December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Change (%)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Other (Expense) Income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; text-indent: 0pt">Interest expense, net</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">(120,082</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">(127,126</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">7,044</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">(5.5</td>
    <td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Gain on disposal of a subsidiary</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">30,055</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">30,055</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">100.0</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Change in prepaid forward purchase liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(12,911,503</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(12,911,503</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">100.0</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Other income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">127,477</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">386,828</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(259,351</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(67.0</td>
    <td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Investment income</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,917,062</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(1,917,062</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(100.0</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">Total Other (Expense) Income, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(12,874,053</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,176,764</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(15,050,817</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(691.4</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Total other expense, net
were amounted to approximately $12.9 million for the year ended December 31, 2022 while total other income, net were amounted to
approximately $2.2 million for the year ended December 31, 2021. The changes were mainly due to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Change in prepaid forward purchase liabilities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We incurred a loss from
change in prepaid forward purchase liabilities amounted approximately $12.9 million for the year ended December 31, 2022 as we
entered into two equity prepaid forward transactions in November 2022, which required for fair value accounting.
Due to our stock price has significantly dropped after the Business Combination in November 2022, the fair value of the prepaid forward purchase liabilities also decreased significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investment income </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had investment income of approximately
$1.9 million from the Affordable Home Program investment in Indonesia during the year ended December 31, 2021 while no investment income
was recognized during the same period in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Interest expense, net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The interest expense, net decreased
was due to less outstanding loans with similar interest rate during the year ended December 31, 2022 as compared to the same period in
2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other income</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The decrease of other income was
because we did not obtain government grant for the year ended December 31, 2022, while there was government grant of approximately $0.3 million
received by us during the same period in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Provision for income taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our provision for income taxes
decreased by approximately $31,000 for the year ended December 31, 2022 as  compared to the year ended December 31, 2021. Our provision
for income taxes amounted to approximately $17,000 and $48,000 for the year ended December 31, 2022 and 2021, respectively. The decrease
in provision for income taxes is mainly due to decrease of deferred tax as we wrote off our deferred tax liability as a result of impairment of our intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net (loss) income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We incurred a net loss was
approximately $24.9 million for the year ended December 31, 2022, while we had a net income of approximately $0.9 million for the
year ended December 31, 2021. Changes from net income for the year ended 2021 to net loss for the same period in 2022 was predominately due to the reasons as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing liquidity, we monitor and analyze cash
on-hand and operating and capital expenditure commitments. Our liquidity needs are to meet working capital requirements, operating expenses
and capital expenditure obligations. Debt financing in the form of short-term borrowings from banks, private lenders, third parties and
related parties and cash generated from operations have been utilized to finance working capital requirements. As of December 31, 2022,
our working deficit was approximately $4.1 million, and we had cash and restricted cash of approximately $0.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The global outbreak of COVID-19 caused
volatile economic activity around the world, and the degrees of any economic recovery in various jurisdictions have not been linear. We
have experienced recurring losses from operations and negative cash flows from operating activities since 2020. The digital health industry
is relatively immature and rapidly evolving, and it is uncertain whether it will achieve and maintain high levels of demand, consumer
acceptance and market adoption. Our success will substantially depend on the willingness of our clients&#8217; members or patients to
adopt, and the frequency and extent of their utilization of, our services and solutions, as well as on our ability to demonstrate the
value of digital health to employers, health plans, government agencies and other purchasers of healthcare for beneficiaries. If our clients,
members or patients do not acknowledge the benefits of our services or platform, or if our services are not competitive, then the market
may not develop at all, or we may develop slower than we expect. Similarly, individual and healthcare industry concerns or negative publicity
regarding patient confidentiality and privacy in the context of digital health could restrict market acceptance of our healthcare services.
An occurrence of any of these events could have a material adverse effect on our business, financial condition, or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal year 2022, we missed our previously
projected revenue target mainly due to the relative immaturity of the digital health industry and the ongoing effects of the COVID-19
pandemic. A potential economic recession and uncertainty in financial markets
have resulted in changes in market conditions and produced market volatility. The impact of inflation and rising interest rates may affect
the financial performance of the customers we serve and influence customer demand. Despite these uncertainties, we continue to seek growth
in terms of new and additional corporate clients. We currently rely mainly on organic growth driven by an increase in corporate clients.
If we are unable to retain the active customers while attracting new customers, it could result in a loss of future revenue and will deteriorate
our liquidity and operating cash flow. As a result, we have an ongoing need to raise additional cash from outside sources to fund our
expansion plan and related operations. Successful transition to attaining profitable operations is dependent upon achieving a level of
revenues adequate to support our cost structure. In connection with our assessment of going concern considerations in accordance with
Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties
about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management has determined that these conditions raise substantial
doubt about our ability to continue as a going concern within one year after the date that our consolidated financial statements are issued.
The management&#8217;s plan in addressing this uncertainty is through the following sources:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other available sources of financing from Singapore banks and other financial institutions or private lenders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support and credit guarantee commitments from our related parties; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity financing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In light of the disparity between the exercise price
of the warrants and our current trading price, it is very unlikely that any potential proceeds from the exercise of our warrants will
be realized in the near future. We are in active discussions with underwriters regarding a potential financing transaction through the
issuance of convertible notes and our goal is for such transactions to be completed in the fourth quarter of 2023 to improve our liquidity
and capital resource needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2023, Mr. Alfred Lim, our independent
director, loaned us an amount of $128,750 for working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Between January to May 2023, Mr. Meng Dong (James)
Tan, one of our shareholders who currently owns approximately 28% of our ordinary shares, loaned us in an aggregate amount to approximately
$ 0.5 million for working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Between May 16 and May 22,
2023, we issued and sold to eight accredited investors an aggregate of 940,000 ordinary shares (the &#8220;Placement Shares&#8221;) at
$1.00 per share for an aggregate purchase price of $940,000 in a private placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Should we need to seek additional capital prior to
the potential convertible notes financing transaction, we may continue to go to our related parties for additional financial support.
If the trading price of our ordinary shares experiences a further decline following or as a result of this offering, it will negatively
impact our ability to raise additional capital on favorable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal
course of business and, as such, the financial statements do not include any adjustments relating to the recoverability and classification
of recorded amounts or amounts and classification of liabilities that might be necessary should we be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following summarizes the
key components of cash flows for the years ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left; text-indent: 0pt">Net cash (used in) provided by operating activities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(1,526,828</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">443,920</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Net cash used in investing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(268,206</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(356,183</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Net cash provided by (used in) financing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,488,947</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(168,373</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Effect of exchange rate change on cash and restricted cash</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(99,424</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">19,865</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">Net change in cash and restricted cash</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">594,489</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(60,771</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities was
approximately $1.5 million for the year ended December 31, 2022 and was primarily attributable to (i) approximately $24.9 million in
net loss as discussed above, (ii) approximately $0.2 million increase in accounts receivable due to less collections, and (iii)
approximately $2.4 million decrease in accounts payable &#8211; related party as we are making more timely payments while we are no
longer using the medical services from the related party beginning in April 2022, offset by (i) approximately $1.6 million decrease in other receivables mainly
resulted from the collection of our investment income, (ii) approximately $1.3 million increase in accounts payable mainly due to the increase usage of medical
services and related medical products from third party service providers, (iii) approximately $1.0 million increase in other payables
and accrued liabilities mainly resulted from accrued professional fees, (iv) approximately $12.9 million in change in fair value of
prepaid forward purchase liabilities, (v) approximately $2.9 million in provision for doubtful accounts due to write-off of the
balance of receivable from divestment from BPT, an unrelated third party and the balance from loan to PT total Prima Indonesia,
(vi) approximately $5.2 million in earn out payment upon assessing the fair value of the Earnout Share and (vii) approximately $1.1
million in impairment loss on goodwill and intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by operating activities was approximately
$0.4 million for the year ended December 31, 2021 and was primarily attributable to (i) a net income of approximately $0.9 million (ii)
approximately $0.3 million in non-cash items such as depreciation and amortization expense, (iii) approximately $44,000 in provision for
doubtful accounts, and (iv) approximately $56,000 decrease in other receivables, (v) approximately $1.4 million increase in accounts payable
and accounts payable &#8211; related party, and (vi) approximately $0.1 million increase in taxes payable, offset by (i) approximately
$28,000 in deferred tax benefit, (ii) approximately $1.9 million of investment income from the Affordable Home Program investment in Indonesia,
(iii) approximately $0.3 million increase in accounts receivable, (iv) approximately $18,000 increase in prepaid expenses and other current
assets, and (v) approximately $62,000 decrease in operating lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Investing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was approximately
$0.3 million for the year ended December 31, 2022 and was attributable to approximately $0.2 million loan to a third party, approximately
$3,000 in cash released upon disposal of a subsidiary, and approximately $18,000 purchases of equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was approximately
$0.4 million for the year ended December 31, 2021 and was attributable to approximately $2,000 of equipment purchases, and approximately
$0.4 million in loan to third party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financing activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities was
approximately $2.5 million for the year ended December 31, 2022 and was primarily attributable to (i) approximately $1.4 million
borrowings from related parties, (ii) $0.5 million issuance of ordinary shares, (iii) approximately $0.6 million receipt of
subscribed shares deposit, and (iv) approximately $1.3 million proceeds from Reverse Recapitalization, offset by (i) approximately
$1.3 million payments of merger costs, and (ii) approximately $0.1 million repayments to short-term loans &#8211; bank and private
lender.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities was approximately
$0.2 million for the year ended December 31, 2021 and was primarily attributable to approximately $67,000 repayments to short-term loans
&#8211; bank and private lender, approximately $0.3 million repayments to short-term loans &#8211; third parties, and approximately $7,000
payment of finance lease liabilities, offset by approximately $36,000 repayments from other receivable &#8211; related parties, approximately
$88,000 proceeds from short-term loans &#8211; bank and private lender, and approximately $94,000 borrowings from other payables &#8211;
related parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the normal course of business, we are subject to
loss contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among
others, government investigations and tax matters. In accordance with ASC No. 450-20, &#8220;Loss Contingencies&#8221;, we will record
accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our contractual obligations
as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Payments due by period</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Contractual obligations</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Less than 1 year</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">1 &#8211; 3</p>
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">years</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">3 &#8211; 5</p>
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">years</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">More than</p>
    <p style="text-align: center; margin-top: 0; margin-bottom: 0">5 years</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: 0pt">Short-term loans - bank and private lender</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">204,240</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">204,240</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">&#8212;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Other payable &#8211; related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,571,945</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,571,945</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Promissory note</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">170,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">170,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Operating lease obligations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">79,959</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">79,959</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Convertible notes &#8211; third parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,619,625</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,619,625</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Convertible notes- related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">782,600</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">782,600</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Finance lease obligations</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">22,201</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">7,186</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">15,015</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: 0pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">5,450,570</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">5,435,555</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">15,015</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capital Expenditures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021, we
purchased approximately $18,000 and $2,000, respectively, of equipment mainly for use in medical services. We did not purchase any material
equipment for operational use. We do not have any other material commitments to capital expenditures as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, we have no off-balance
sheet arrangements including arrangements that would affect liquidity, capital resources, market risk support and credit risk support
or other benefits.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company</b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected to use such extended transition
period which means that when a standard is issued or revised and we have different application dates for public or private companies,
we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of our consolidated financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial statements and accompanying notes have been
prepared in accordance with U.S. GAAP. The preparation of these financial statements and accompanying notes requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under
the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. We have identified certain accounting policies that are significant to the preparation of financial
statements. These accounting policies are important for an understanding of our financial condition and results of operation. Critical
accounting policies are those that are most important to the portrayal of our financial conditions and results of operations and require
management&#8217;s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters
that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of
our significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly
from management&#8217;s current judgments. Our significant accounting policies are more fully described in Note 3 to the consolidated
financial statements, but we believe that the following critical accounting policies involve the most significant estimates and judgments
used in the preparation of our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts
    receivable, net</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
    of long-lived assets and Goodwill</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prepaid
    forward purchase liabilities</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
    taxes</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
    Recognition</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates and Assumptions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in our consolidated financial statements
include estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of prepaid forward purchase and warrant, valuation allowance of deferred tax assets, and other provisions
and contingencies. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Accounts receivable, net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with our customers. Our management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Currently, our policy is to provide 100% allowance on balance over 2 years past due, 40% allowance
on balance between 1 &#8211; 2 years past due, 10% allowance on balance between 10 &#8211; 12 months past due, and 1% on balance between
7 &#8211; 9 months past due. Our management also periodically evaluates individual customer&#8217;s financial condition, credit history,
and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged
off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Our management
continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Impairment of long-lived assets and
Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 360-10, Long-lived
assets, including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances
(such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying
value of an asset may not be recoverable. We assess the recoverability of the assets based on the undiscounted future cash flows the
assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result
from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the
asset. If an impairment is identified, We would reduce the carrying amount of the asset to its estimated fair value based on a
discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021,
approximately $0.2 million and nil impairment on intangible assets was recognized, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of income and comprehensive income. Impairment losses on goodwill are
not reversed. For the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing a qualitative
assessment on the two reporting units and determine that it is more likely than not that the fair value of each reporting unit is less
than its carrying amount. Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $971,229 was recognized
for the year ended December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended
December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Prepaid forward purchase
liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Forward Purchase Agreement,
we recognized prepaid forward purchase liabilities in accordance with ASC 480-10-25-8 by using carry and reverse carry arbitrage model
to determine the fair value of the prepaid forward purchase liabilities as we have the obligation to pay cash to settle the maturity consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">In accordance with ASC 480,&#160;<i>Distinguishing
Liabilities from Equity</i>, we have determined that the prepaid forward contract is a financial instrument other than a share that represent
or are indexed to obligations to repurchase the issuer&#8217;s equity shares by transferring assets, referred to herein as the &#8220;prepaid
forward purchase liability&#8221; on <span style="background-color: white">the </span> consolidated balance sheets. We initially measure the prepaid forward purchase liability at fair
value and measured subsequently at fair value with changes in fair value recognized in earnings. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the closing of the Business Combination, the fair value of the prepaid forward purchase liability was determined to be $7,409,550.
Subsequently, the change of fair value of the prepaid forward purchase liability was amounted to a loss of $12,911,503 for the year end
December 31, 2022. As of December 31, 2022, the prepaid forward purchase liabilities amounted to $20,321,053.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, Distinguishing Liabilities
from Equity (&#8220;ASC&#160;480&#8221;) and ASC&#160;815, Derivatives and Hedging (&#8220;ASC&#160;815&#8221;). The assessment considers
whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to
ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the
warrants are indexed to our ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of
professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants
are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of equity at the time of issuance. We determined that upon further review of the warrant agreements, we concluded that the warrants qualify
for equity accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the business combination, all of 8i&#8217;s public and private warrants remain outstanding were replaced by our public
and private warrants. We treated such warrants replacement as a warrant modification and no incremental fair value was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes in accordance with U.S.
GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable
or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax is calculated using the balance sheet
liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in
the consolidated financial statements and the corresponding tax basis. In principle, deferred tax liabilities are recognized for all taxable
temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable income will be utilized with
prior net operating loss carried forwards using tax rates that are expected to apply to the period when the asset is realized, or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than
not that some portion or all of the deferred tax assets will not be utilized. Current income taxes are provided for in accordance with
the laws of the relevant tax authorities. Our assumptions on valuation allowance includes our subsidiaries historical operating result
and likelihood of whether we expect we can realize such deferred tax assets in the near future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit
only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized
on examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 3 of the notes to the consolidated financial
statements for a discussion of recently issued accounting standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Quantitative and Qualitative Disclosures about
Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Interest Rate Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to interest rate risk while we have
short-term bank, private lender, and third-party loans outstanding. Although interest rates for short-term loans are typically fixed for
the terms of the loans, the terms are typically twelve months and interest rates are subject to change upon renewal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Credit risk is controlled by the application of credit
approvals, limits and monitoring procedures. Credit risk is managed through in-house research and analysis of the economy and the underlying
obligors and transaction structures. We identify credit risk collectively based on industry, geography and customer type. In measuring
the credit risk of our sales to our customers, we mainly reflect the &#8220;probability of default&#8221; by the customer on our contractual
obligations and consider the current financial position of the customer and the current and likely future exposures to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Liquidity Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to liquidity risk, which is risk that
will be unable to provide sufficient capital resources and liquidity to meet commitments and business needs. Liquidity risk is controlled
by the application of financial position analysis and monitoring procedures. When necessary, we will turn to other financial institutions
and related parties to obtain short-term funding to cover any liquidity shortage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Exchange Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While our reporting currency is the U.S. dollar, the
majorities of our consolidated revenues and consolidated costs and expenses are denominated in SGD, VND and MYR. Majorities of assets
are denominated in SGD, VND and MYR. As a result, we are exposed to foreign exchange risk as revenues and results of operations may be
affected by fluctuations in the exchange rate between the U.S. dollar, SGD, VND and MYR. If the SGD, VND and MYR depreciates against the
U.S. dollar, the value of our SGD, VND and MYR revenues, earnings and assets as expressed in U.S. dollar financial statements will decline.
We have not entered into any hedging transactions in an effort to reduce exposure to foreign exchange risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>Item 7A. Quantitative and Qualitative Disclosure About Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not required for smaller reporting companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>Item 8. Financial Statements and Supplementary Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our financial statements are contained in pages F-1 through F-44, which
appear at the end of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>Item
9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 1, 2022, Friedman LLP (&#8220;Friedman&#8221;), our then independent registered public accounting firm, combined with Marcum
LLP and continued to operate as an independent registered public accounting firm. On November 22, 2022, approved by the Company&#8217;s
board of directors, we engaged Marcum Asia CPAs LLP (&#8220;Marcum Asia&#8221;) to serve as our independent registered public accounting
firm. The services previously provided by Friedman are now provided by Marcum Asia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to applicable rules, the Company makes the following additional disclosures:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
During the period from December 31, 2021 through November 22, 2022 there were no disagreements with Friedman on any matter of
accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which if not resolved to Friedman&#8217;s
satisfaction would have caused it to make reference thereto in connection with its reports on the financial statements for such year.
During the period from December 31, 2021 through November 22, 2022 other than the material weaknesses in the Company&#8217;s internal
control over financial reporting, there were no events of the type described in Item 304(a)(1)(v) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
During the period from December 31, 2021 through November 22, 2022 the Company did not consult with Marcum Asia with respect to any
matter whatsoever including without limitation with respect to any of (i) the application of accounting principles to a specified transaction,
either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company&#8217;s financial statements; or (iii)
any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or an event of the type
described in Item 304(a)(1)(v) of Regulation S-K.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_025"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of disclosure controls and procedures</i>. Our Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this Annual Report on Form 10-K. Our disclosure controls and procedures are designed to ensure that information we are required
to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time
periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our
chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
Annual Report on Internal Control over Financial Reporting</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting at the Company. The Company&#8217;s
internal control over financial reporting is a process designed under the supervision of the Chief Executive Officer and Chief Financial
Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external reporting purposes in accordance with generally accepted accounting principles, and includes those policies and procedures
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
the assets of the Company;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with
authorizations of management and directors of the Company; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
assets that could have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Executive Officer and the Chief Financial Officer conducted an evaluation of the effectiveness of our internal control over financial
reporting as of December 31, 2022, based on the framework and criteria established in Internal Control &#8211; Integrated Framework,
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the previously disclosed material weakness in our internal control over financial reporting discussed below, our Chief Executive Officer
and Chief Financial Officer concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective. In light
of this fact, our Chief Executive Officer and Chief Financial Officer have performed additional analyses, reconciliations, and other
post-closing procedures and have concluded that, notwithstanding the material weakness in our internal control over financial reporting,
the consolidated financial statements for the periods covered by and included in this Annual Report on Form 10-K fairly present, in all
material respects, our financial position, results of operations and cash flows for the periods presented in conformity with GAAP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Previously
identified material weakness. </i>Prior to the Business Combination, EUDA was a private company with limited accounting personnel and
other resources with which to address internal controls and procedures. EUDA and our independent registered public accounting firm identified
material weaknesses and significant deficiencies in the Company&#8217;s internal controls over financial reporting in connection with
the audits of EUDA&#8217;s financial statements for the years ended December 31, 2021. A &#8220;material weakness&#8221; is
a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility
that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A &#8220;significant
deficiency&#8221; is a deficiency or a combination of deficiencies in internal control over financial reporting that is less severe than
a material weakness, yet important enough to merit attention by those responsible for oversight of the Company&#8217;s financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weaknesses that were identified related to: (i) lack of sufficient financial reporting and accounting personnel, especially
those with understanding of U.S. GAAP knowledge; (ii) lack of proper mechanism to identify and assess the experience and qualification
of third-party specialists. As a result of these material weaknesses, the Company&#8217;s
management concluded that our internal control over financial reporting was not effective as of December 31, 2022 and 2021. EUDA is
in the process of developing a plan to remediate these material weaknesses and will continue to identify additional appropriate
remediation measures. However, the material weaknesses will not be considered remediated until the remediation plan has been fully
implemented, the applicable controls are fully operational for a sufficient period of time, and the Company has concluded, through
testing, that the newly implemented and enhanced controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Remediation Plan.</i> Management and our Audit
Committee are currently reviewing and determining a plan to remediate the material weakness described above and to enhance our overall
control environment. We will not consider the material weakness remediated until our enhanced control is operational for a sufficient
period of time and tested, enabling management to conclude that the enhanced controls are operating effectively. Our remediation plan
includes (1) hiring of additional finance and accounting staff with qualifications and work experiences in U.S. GAAP and SEC reporting
requirements to formalize and strengthen the key internal control over financial reporting; (2) allocating sufficient resources to prepare
and review financial statements and related disclosures in accordance with U.S.GAAP and SEC reporting requirements, (3) hiring of qualified
consultant to assess Sarbanes-Oxley Act compliance readiness, to assess where we can improve our overall internal control over financial
reporting function, and to assist us in implementing improvements where necessary; and (4) setting up an effective internal mechanism
to perform background check, identify and assess the qualification of the engaged third-party specialists; and (5) consulting with experienced
valuation specialist on a timely basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, EUDA cannot predict the success of such efforts or the outcome of future assessments of the remediation efforts. As a public
company, EUDA is required to further design, document and test the Company&#8217;s internal controls over financial reporting to comply
with Sarbanes-Oxley Act Section 404. If existing material weaknesses or control deficiencies are not remediated or if material weaknesses
or control deficiencies occur in the future, EUDA may be unable to report the Company&#8217;s financial results accurately on a timely
basis or help prevent fraud, which could cause EUDA&#8217;s reported financial results to be materially misstated and result in the loss
of investor confidence or delisting and cause the market price of EUDA&#8217;s ordinary shares to decline. If we have material weaknesses
in the future, it could affect the financial results that the Company reports or create a perception that those financial results do
not fairly state EUDA&#8217;s financial position or results of operations. Either of those events could have an adverse effect on the
value of the Company&#8217;s ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inherent
limitation on the effectiveness of internal control.</i> The effectiveness of any system of internal control over financial reporting,
including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating
the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure
controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter
how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. In addition,
the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required
to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Moreover, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal
controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with
effective internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_014"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>Item 9C. Disclosures Regarding Foreign Jurisdiction that Prevent Inspections</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in; background-color: white"><b><span id="a_016"></span>PART
III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_017"></span>Item 10. Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s current directors
and executive officers are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: 0pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: 0pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 54%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Lim</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Lew</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajay Kumar Rajpal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kong-Yew Wong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Below is a summary of the business experience of each
of the directors and executive officers of the Company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Wei Wen Kelvin Chen</i></b>.
Dr. Wei Wen Kelvin Chen brings over 20 years of expertise as a software executive, operation&#8217;s leader and strategy professional
within the healthcare sector. Since 2019, he has served as the Chief Executive Officer and founder as well as the Executive Director at
EUDA. Previously, from 2012 to 2017, Dr. Chen worked at Healthway Medical Group (Healthway), the largest listed healthcare company in
Singapore with more than 100 medical clinics. While at Healthway, he started off as the Group Marketing Manager (from 2012 to 2014), was
promoted to the Head of the Adult Specialist and CMO department (from 2014 to 2015), General Manager of the Specialist Division (2015)
and eventually served as the Vice President (from 2015 to 2017), where he was responsible for the enterprise&#8217;s operations and growth,
contributing to its exceptional revenue growth in 2015. Dr, Chen was instrumental in restructuring exercise and strategizing the Healthcare
and Corporate Sales division to achieve the annual targets set by the board of Healthway, While at Healthway, Dr. Chen saw the gaps within
the traditional healthcare infrastructure and an opportunity for technological innovation to propel digitalization across the entire health
ecosystem, spurring him to establish Kent Ridge Health. Dr. Chen started his career with the Singapore Police Force (SPF) as a police
officer, where the experience of managing operations formed the foundations of his management skills. He served as SPF&#8217;s IT consultant
on emerging technologies, managing information systems and operations. In this role, he was instrumental in facilitating the overhaul
of SPF&#8217;s transition from outdated organization-wide technologies to cutting edge, cost-effective business solutions that dramatically
improved efficiency, decreased expenses, and optimized data integrity and safety. Dr. Chen holds a Doctorate in Business Administration
from the University of South Australia and a Bachelor of Science, with honors, in Computer Science from the University of Greenwich.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Steven John Sobak</i></b>.
Mr. Steven John Sobak has been serving as EUDA&#8217;s Chief Financial Officer since March 2022 and has over 45 years in healthcare administrative
experience covering most aspects of hospital management in both the public and private sectors, in general acute and various specialty
facilities. Within Singapore and Malaysia, he has served as Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer
at various hospitals ranging from 100 to over 1,500 beds. Over the years he has worked in the US, Saudi Arabia, Singapore, Malaysia and
with consulting assignments in China and India. Since 2014, Mr. Sobak has been an Independent Healthcare Consultant for new, greenfield
and brownfield projects as well as other potential ventures in Singapore, where he offered healthcare related consulting and advisory
services of both. He provided guidance and feasibility study preparations for projects in China to gather required information, guidance
and direction for managing the planning, construction and pre-opening requirements. From June 2010 to July 2016, he served as the Chief
Operating Officer (June 2010 to January 2016) and Senior Director of National Neuroscience Institute (January 2016 to July 2016). Prior
to that, Mr. Sobak was the Chief Executive Officer of Singapore Cord Blood Bank from January 2009 through June 2015. Concurrently, he
was the Senior Instructor at Business Continuity Management Institute. From October 1969 through January 2014, he held various positions
at Singapore Management University - Singhealth, Healthcura Consulting Pvt Ltd, KK Women&#8217;s and Children&#8217;s Hospital, United
Engineers Group (Medical Hall Ltd), Southern Hospital Group, Tan Tock Seng Hospital Pte Ltd and Hospital Corporation of America/International
Inc. At various times in his career, he had direct operational responsibility for many departments such as Finance, Purchasing, Corporate
Communications, Quality Service Management (QSM), Legal, Facilities and Maintenance Operations, Bio-Medical Services, IT, and more. He
introduced the concept of Pre-Admission Patient Financial Counseling in 1989, which was subsequently adopted by all hospitals in Singapore.
He has supervised and been responsible for various Divisions within the Executive, Allied Health, Outpatient, Operational Support, etc.
He has also authored / co-authored and published two books on healthcare related topics. Mr. Sobak holds a Master&#8217;s Degree in Finance
and a Bachelor&#8217;s Degree in Management, both from Wayne State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Alfred Lim. </i></b>Mr.
Alfred Lim has over 44 years of experience in international trade business, covering the Asia Pacific region. He started his career
in 1978 with May &amp; Baker Ltd/Rhone Poulenc Singapore Pte Ltd, one of Europe&#8217;s top chemicals and pharmaceutical companies,
before moving on to Neste Chemicals Trading Singapore Pte Ltd in 1990, where he was the Managing Director responsible for sales and
marketing to companies in United States, Europe, and Asia. Between 1994 to 2002, he was the managing director of Borealis Singapore
Pte Ltd, managing the company&#8217;s Asia Pacific offices and distributors. Under Mr. Lim&#8217;s remit, Borealis Singapore was
awarded the International Trade Award from Ministry of Finance, Approved International Trader status from Ministry of Trade &amp;
Industry and Singapore 1,000 Ranking for Highest Returns on Shareholders&#8217; Funds for year 1998/1999. In 2002, Mr Lim co-founded
Akashi Sdn Bhd, a Malaysian distributor for chemicals which was later sold to East Asiatic Chemicals/Brenntag. From 2006 to 2018,
Mr. Lim acted as a senior consultant to An Duong Group, setting up a distributor network in Vietnam for international bathroom
product brands. Since 2018, he has been a consultant to Roca Group, the world&#8217;s largest sanitary ware manufacturer for
Vietnam. Alfred received his Bachelor of Science (Honors) degree in Chemistry from the University of Singapore in 1976, Graduate
diploma in Marketing from Singapore Institute of Management in 1986.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Eric Lew</i></b>. Mr. Eric
Lew has over 25 years of business experience. Mr. Lew started his career as an auditor with KPMG LLP for nearly 3 years before joining
Wong Fong Industries Ltd where he served for 16 years as the Executive Director and remains as a board member. He served as the Executive
Chairman of Y Ventures Group Ltd from March 2019 to July 2022, where his role was to drive the e-commerce group&#8217;s strategic direction
and growth and to provide mentorship to management. Mr. Lew has served on the board of Eggriculture Foods Ltd since January 2023. He also
serves on Executive Committee Board of WMRAS (Waste Management and Recycle Association of Singapore), the Board of Directors of Northlight
School, and the NTU Nanyang Business School Alumni Board. In 2016, Mr. Lew was nominated for the Straits Times&#8217; Singaporean of the
Year for his contribution to small and medium-sized entities (SMEs) and innovation in Singapore. Mr. Lew has a Bachelor&#8217;s Degree
in Accountancy with a Minor in Banking and Finance from the Nanyang Technological University of Singapore.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Ajay Kumar Rajpal</i></b>.
Mr. Ajay Kumar Rajpal is a Chartered Accountant and member of the Institute of Chartered Accountants in England &amp; Wales (ICAEW). During
his career, he has gained broad-ranging commercial experience developed in the US, Europe, Middle East and Far East, with a particular
focus on M&amp;A, financial management and insolvency/restructuring. Post qualification, Mr. Rajpal held a number of finance-related roles
which involved working for periods in the US, Europe, Middle East and Far East. Since 2011, Mr. Rajpal has run his own consultancy business,
NAS Corporate Services Ltd, providing companies with various corporate services, such as assistance with their pre-IPO funding, the IPO
process and post IPO management. Mr. Rajpal has project managed the initial public offering process and assisted with the associated funding
of two businesses on AIM, namely New Trend Lifestyle Group Plc, which provides Feng Shui products and services across Asia, and Zibao
Metals Recycling Group Plc, a Hong Kong and China based metals recycling company. He currently is a director of Grand Vision Media Holdings
Plc, RC365 Holding Plc and Essentially Group Plc, all of which are listed on the London Stock Exchange. Mr. Rajpal was previously an independent
director of Moxian, Inc., a US company with a China based internet business listed on Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Kong-Yew Wong</i></b>. Dr.
Kong-Yew Wong has been serving as the Group CEO at D&#8217;Mace Pty Ltd (Australian) since September 2021, responsible for the company&#8217;s
corporate governance, strategic directions and performance. He has also served as the lead consultant in several initiatives with ASEAN
and UNWTO. Dr. Wong has also been serving as the Executive Director of E-Plus Ltd. in Australia since November 2020. He is also an international
keynote speaker with appearances at major international conference in Asia, and features in newspapers and TV news (with personal interview
at Astro Awani, Berita, TV2 etc). From April 2017 to September 2020, Dr. Wong served as the CEO at DYBIOTECH Bhd., a privately-held company
in Malaysia that promotes beauty tourism to Malaysia. Dr. Wong received his Bachelor of Business Administration degree in Economics from
Western Michigan University in December 1996. He received his Master of Economics from Universiti Putra Malaysia in December 2000. Dr.
Wong received his Ph.D. degree in Economics from Strathclyde University in December 2004.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Nasdaq
requires that a majority of our board must be composed of &#8220;independent directors.&#8221; Currently, Eric Lew, Ajay Rajpal, and Kong-Yew
Wong would each be considered an &#8220;independent director&#8221; under the Nasdaq listing rules, which is defined generally as a person
other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion
of the company&#8217;s board of directors would interfere with the director&#8217;s exercise of independent judgment in carrying out the
responsibilities of a director. Our independent directors will have regularly scheduled meetings at which only independent directors are
present.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Audit Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Nasdaq listing standards and applicable SEC rules, we are required to have three members of the audit committee all of whom must be
independent. Our audit committee of the board of directors consists of Ajay Kumar Rajpal, Eric Lew, and Kong-Yew Wong, each of whom is
an independent director under Nasdaq&#8217;s listing standards. Ajay Kumar Rajpal is the Chairperson of the audit committee. The audit
committee&#8217;s duties, which are specified in our Audit Committee Charter, include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with management major risk assessment and risk management policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring the independence of the independent auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all related-party transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inquiring and discussing with management our compliance with applicable laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing or replacing the independent auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving reimbursement of expenses incurred by our management team in identifying potential target businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Financial Experts on Audit
Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The audit
committee will at all times be composed exclusively of &#8220;independent directors&#8221; who are &#8220;financially literate&#8221;
as defined under Nasdaq listing standards. Nasdaq listing standards define &#8220;financially literate&#8221; as being able to read and
understand fundamental financial statements, including a company&#8217;s balance sheet, income statement and cash flow statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
we must certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in
finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in
the individual&#8217;s financial sophistication. The board of directors has determined that Ajay Kumar Rajpal qualified as an &#8220;audit
committee financial expert,&#8221; as defined under rules and regulations of the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Nominating Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our nominating
committee of the board of directors consists of Kong-Yew Wong, Eric Lew, and Ajay Kumar Rajpal, each of whom is an independent director
under Nasdaq&#8217;s listing standards. Kong-Yew Wong is the Chairperson of the nominating committee. The nominating committee is responsible
for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons
identified by its members, management, shareholders, investment bankers and others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Guidelines for Selecting
Director Nominees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The guidelines
for selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have demonstrated notable or significant achievements in business, education or public service;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The nominating
committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism
in evaluating a person&#8217;s candidacy for membership on the board of directors. The nominating committee may require certain skills
or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider
the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The board of directors will also
consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to
stand for election at the next annual meeting of shareholders (or, if applicable, a special meeting of shareholders). Our shareholders
that wish to nominate a director for election to the Board should follow the procedures set forth in our memorandum and articles of association,
as amended. The nominating committee does not distinguish among nominees recommended by shareholders and other persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Compensation Committee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our compensation
committee of the board of directors consists of Eric Lew, Ajay Kumar Rajpal, and Kong-Yew Wong, each of whom is an independent director
under Nasdaq&#8217;s listing standards. Eric Lew is the Chairperson of the compensation committee. The compensation committee&#8217;s
duties, which are specified in our Compensation Committee Charter, include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer&#8217;s based on such evaluation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the compensation of all of our other executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our executive compensation policies and plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing and administering our incentive compensation equity-based remuneration plans;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting management in complying with our proxy statement and annual report disclosure requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if required, producing a report on executive compensation to be included in our annual proxy statement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Notwithstanding
the foregoing, as indicated above, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any
of our existing shareholders, including our directors or any of their respective affiliates, prior to, or for any services they render
in order to effectuate, the consummation of a business combination. Accordingly, it is likely that prior to the consummation of an initial
business combination, the compensation committee will only be responsible for the review and recommendation of any compensation arrangements
to be entered into in connection with such initial business combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We have
adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the business
and ethical principles that govern all aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_018"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This section describes the executive
compensation for EUDA&#8217;s executive officers since the Company was formed on January 21, 2021 (the &#8220;Formation Date&#8221;).
This discussion may contain forward-looking statements that are based on EUDA&#8217;s current plans, considerations, expectations and
determinations regarding future compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From the Formation Date until
the Closing of the Business Combination, Mr. Meng Dong (James) Tan served as Chief Executive Officer and Mr. Guan Hong (William) Yap served
as Chief Financial Officer of the Company. Mr. Tan and Mr. Yap were the Company&#8217;s only executive officers, principal or otherwise,
prior to the Closing of the Business Combination. Prior to the Closing of the Business Combination, no executive officers received any
cash compensation for services rendered to the Company. No compensation of any kind, including finders, consulting or other similar fees,
were paid to any shareholders, including directors, or any of their respective affiliates, prior to, or for any services rendered in order
to effectuate, the Business Combination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Closing of the Business Combination, the former directors and executive officers of 8i resigned, and certain independent directors
and EUDA&#8217;s executive officers were appointed. Except for Mr. Alfred Lim, all independent directors appointed at the Closing have
either resigned or been removed from the board. EUDA&#8217;s current compensation structure is designed to align executives&#8217; compensation
with the Company&#8217;s business objectives and the creation of shareholder value, while helping EUDA to continue to attract, motivate
and retain individuals who contribute to the long-term success of the Company. Compensation for executive officers consists, at this
time, only of base salary. The annual salary of each of EUDA&#8217;s executive officers for the year of 2022 is set forth in the summary
compensation table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Non-equity</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>incentive plan compensation ($)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Position</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock-based awards ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option-<br /> based awards ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Annual incentive plans</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Long term incentive plans</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All other compensation ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total compensation ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%; text-align: left; text-indent: 0pt">Kelvin Chen</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">2022</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 6%; text-align: right">390,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;0</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 6%; text-align: right">390,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: 0pt">Chief Executive Officer</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Steven John Sobak</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">110,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">110,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: 0pt">Chief Financial Officer</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">Daniel Tan(1)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2022</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">137,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">137,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: 0pt">Former Chief Technology Officer</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Mr. Tan left the Company on May 12, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Material Terms of Employment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Chen receives an annual salary
of $390,000 for his service as Chief Executive Officer with no set term of employment. Mr. Sobak receives an annual salary of $110,000
for his service as Chief Financial Officer. Mr. Sobak&#8217;s term of employment is set to expire on February 29, 2024, unless further
renewed or extended. Mr. Tan receives an annual salary of $143,000 for his service as Chief Technology Officer with no set term of employment.
Mr. Tan left the Company on May 12, 2023. Following any termination of service, (i) Dr. Chen may not be employed in Singapore in a known
directly competing business providing health platforms and healthcare policies to corporations for a period of six months and (ii) Mr.
Sobak and Mr. Tan may not be employed in Singapore in a known directly competing business providing health platforms and healthcare policies
to corporations for a period of one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not pay, and
historically has not ever paid, directors for service to its board of directors or its board committees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_019"></span>Item 12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The following
table sets forth information regarding the beneficial ownership of ordinary shares of EUDA Health Holdings Limited as of June 19, 2023,
by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person who is known to be the beneficial owner of more than 5% of the outstanding ordinary shares of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of the Company&#8217;s directors and named executive officers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all directors and executive officers of the Company as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if he, she, or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently
exercisable or exercisable within 60 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The beneficial
ownership percentages set forth in the following table are based on 24,777,509 ordinary shares of EUDA Health Holdings Limited outstanding
as of June 19, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
otherwise indicated, the Company believes that all persons named in the table below have sole voting and investment power with respect
to the voting securities beneficially owned by them. Unless otherwise indicated, the address of each individual below is 1 Pemimpin Drive
#12-07, One Pemimpin Singapore 576151.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Beneficial Owner</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Ordinary Shares</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>of EUDA Health</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Holdings Limited</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Beneficially</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Owned</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">% of</p>
    <p style="margin-top: 0; margin-bottom: 0">Ownership</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Five Percent Holders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Watermark Developments Limited<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">9,660,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">38.99</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meng Dong (James) Tan<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,648,650</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">26.83</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">Directors and Executive Officers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,651,772</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6.67</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5,742</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Daniel Tan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Alfred Lim</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Eric Lew</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Ajay Kumar Rajpal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Kong-Yew Wong</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt">All Directors and Executive Officers of the Company as a Group (7 persons)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,657,514</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7.2</td>
    <td style="text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents beneficial ownership of less than 1%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,660,000 ordinary shares were issued to Watermark Developments Limited at closing of the Business Combination, of which at closing of the Business Combination (a) approximately 25.6% are beneficially owned by Fan Pingli through Wilke Services Limited, at Suite 9, Ansuya Estate, Revolution Avenue Victoria, Mahe, Seychelles, (b) approximately 11.1% are beneficially owned by Kelvin Chen, through Interglobe Venture Inc, at Ground Floor, Coastal Building, Wickhams Cay II, PO Box 3169, Road Town, Tortola, British Virgin Islands, (c) approximately 10.9% are beneficially owned by Hartanto through Mount Locke Limited, at Suite 9, Ansuya Estate, Revolution Avenue Victoria, Mahe, Seychelles, (d) approximately 10.9% are beneficially owned by Koh Yong Pau through Pine Alliance Limited, at Vistra Corporate Services Centre, Wickhams Cay II Road Town, Tortola VG 1110 British Virgin Islands, (e) approximately 10.9% are beneficially owned by Kng Pong Sai through Scotgold Holdings Limited, at Vistra Corporate Services Centre, Wickhams Cay II Road Town, Tortola VG 1110 British Virgin Islands, and (f) approximately 10.9% are beneficially owned by Janic Pacific Limited, at Vistra Corporate Services Centre, Wickhams Cay II Road Town, Tortola VG 1110 British Virgin Islands. The remaining shareholders of Watermark Developments Limited each own less than 5% of Watermark Developments Limited. The address of Watermark Developments Limited is c/o Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 2,223,850 shares held by 8i Holdings 2 Pte. Ltd of which Mr. Tan is the sole shareholder and director and therefore has the sole voting and dispositive power over these shares; and (ii) 146,125 shares underlying warrants acquired by Mr. Tan in a private placement that closed concurrently with the Company&#8217;s initial public offering. The address for 8i Holdings 2 Pte. Ltd is c/o 6 Eu Tong Sen Street #08-13 Singapore 059817. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kelvin Chen beneficially owns 100,000 ordinary shares of Watermark, which owns 9,660,000 Company Ordinary Shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak beneficially owns 535 ordinary shares of Watermark, which owns 9,660,000 Company Ordinary Shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_020"></span>Item 13. Certain Relationships and Related Transactions and Director
Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">For
the fiscal year ended December 31, 2022 and through the date of this Annual Report, EUDA (including any of its subsidiaries) has entered into the following related party
transactions (with each transaction involving the aggregate amount in excess of $120,000) with our executive officer, director,
nominee to become a director or a holder of more than 5% of our ordinary shares, including any of their immediate family members and
affiliates, and entities owned or controlled by such persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Settlement Agreement with Kelvin Chen, our CEO</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On May
26, 2023, EUDA issued to Dr. Kelvin Chen, EUDA&#8217;s CEO, 850,306 restricted ordinary shares at $1.00 per share pursuant to a settlement
agreement between Dr. Chen and EUDA, dated May 16, 2023 (the &#8220;Chen Settlement Agreement&#8221;) in full satisfaction of Dr. Chen&#8217;s
claim for unpaid loans in the aggregate principal amount of $850,306 (or approximately S$1,136,264.06) of Kent Ridge Healthcare Singapore
Pte Ltd. (&#8220;KRHSG&#8221;), a wholly-owned subsidiary of EUDA. In order to comply with Nasdaq&#8217;s shareholder approval requirement
for issuance of stock to an executive officer of a company pursuant to Nasdaq Listing Rule 5635(c), EUDA, KRHSG and Dr. Chen amended the
Chen Settlement Agreement by entering into a Supplemental Agreement (the &#8220;Supplemental Agreement&#8221;) on June 6, 2023, so that
the shares issued to Dr. Chen would be issued at a per share price not less than the closing bid price of $1.47 per share on May 15, 2023,
the day prior to the execution of the Chen Settlement Agreement. Pursuant to the Supplemental Agreement, Dr. Chen has agreed to release
and discharge KRHSG of all claims in return for 578,439 ordinary shares at $1.47 per share, and to forfeit and surrender 271,867 ordinary
shares of the 850,306 ordinary shares issued to him on May 16, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Agreements with James Tan, former Chief Executive
Officer and significant shareholder</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 12, 2022, March 28,
2022 and August 16, 2022, the Company issued promissory notes to Mr. Tan in the amount of $300,000, $500,000 and $200,000, respectively,
evidencing loans from Mr. Tan to the Company for working capital purposes. On November 17, 2022 at the Closing of the Business Combination,
$300,000 was repaid to Mr. Tan and a new convertible promissory note was issued in the aggregate principal amount of $700,000 (the &#8220;Tan
2022 Note&#8221;). The Tan 2022 Note was interest free and was due on the one-year anniversary of the Closing of the Business Combination.
Pursuant to the Tan 2022 Note, on November 17, 2023, the maturity date, James Tan would have the right to convert the unpaid principal
amount of the Tan 2022 Note into ordinary shares of the Company based on the five day volume weighted average price of the Company&#8217;s
ordinary shares immediately preceding the maturity date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to a loan agreement dated January 9, 2023, James Tan loaned the Company an additional $145,450 (the &#8220;Initial Tan Loan&#8221;) at
8% interest per annum and was to be repaid by March 31, 2023. The Initial Tan Loan was not timely repaid by March 31, 2023, and was replaced
as disclosed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to a second loan agreement with the Company dated April 24, 2023, James Tan loaned the Company an additional $332,750 (the &#8220;Tan
Second Loan&#8221;) at 8% interest per annum, which matures on the earlier of June 30, 2023 or within seven days of the Company receiving
the proceeds from the sales of securities in the private placement (the &#8220;Private Placement&#8221;). Pursuant to the terms of the
Tan Second Loan, the Company agreed to issue to James Tan a new promissory note in the principal amount of $145,450 dated April 24, 2023
(the &#8220;Tan First Loan&#8221;) to replace the Initial Tan Loan. The Tan First Loan contained the same payment terms as the Tan Second
Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On May
15, 2023, James Tan entered into a third loan agreement with the Company pursuant to which James Tan agreed to loan the Company an additional
$22,500 (the &#8220;Tan Third Loan&#8221;), provided that the Company issued a new promissory note to James Tan in the principal amount
of $700,000 (the &#8220;Tan 2023 Note&#8221;) to replace the Tan 2022 Note. The Tan Third Loan would bear interest at 8% per annum, and
would be repaid upon the earlier of June 30, 2023 or within seven days of the Company receiving the proceeds from the sales of securities
in the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On May
15, 2023, the Company issued to James Tan the Tan 2023 Note to replace the Tan 2022 Note. The Tan 2023 Note was an interest-free convertible
promissory note in the aggregate principal amount of $700,000. On May 15, 2023, James Tan elected to convert the entire unpaid principal
in the amount of $700,000 of the Tan 2023 Note into ordinary shares of the Company at $1.00 per share in accordance with the terms of
the Tan 2023 Note. On May 16, 2023, the Company issued to James Tan 700,000 ordinary shares in full satisfaction of the Tan 2023 Note.
Pursuant to the terms of the Tan 2023 Note, the Company has agreed to register the 700,000 ordinary shares for resale. We refer to these
700,000 restricted ordinary shares as the &#8220;Converted Shares.&#8221; As of the date of this report, the Tan 2023 Note has been converted
in full into the Converted Shares and is no longer outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 16, 2023, the Company issued
to James Tan an aggregate of 478,200 restricted ordinary shares pursuant to a Settlement Agreement between the Company and James Tan dated
May 16, 2023 in full settlement of all obligations of the Company under the Tan First Loan and the Tan Second Loan. As of the date of
this report, the Tan Third Loan remains outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">All of
the above related party transactions were approved by the Company&#8217;s Board of Directors and ratified by its audit committee pursuant
to the Related Party Transactions Policy described below and the audit committee charter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Cadence Health Pte.
Ltd. (&#8220;Cadence&#8221;)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Cadence
had the same shareholders as EUDA prior to the Business Combination and until April 2022, was a related party clinic service vendor of
EUDA. As of December 31, 2022, EUDA had an aggregate receivable amount of $266,653 with Cadence which has since been repaid. For the
year ended December 31, 2022, EUDA incurred and owed to Cadence an aggregate medical service fee of $496,383. Beginning in April 2022,
EUDA directly utilized third party clinic service providers and no longer used Cadence. See Note 15 of the notes to the consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Indemnification Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the Closing of the Business
Combination, the Company entered into indemnification agreements with each of its directors and executive officers. Each indemnification
agreement provides for indemnification and advancement by the Company of certain expenses and costs relating to claims, suits or proceedings
arising from service as an officer, director, employee, agent or fiduciary of the Company to the fullest extent permitted by applicable
law. We believe that these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forgiveness of debt by a related party</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 31, 2022, the Company and Wilke entered into
a deed of release of debt (&#8220;Deed&#8221;), pursuant to the Deed, upon the closing of the Business Combination, Wilke agrees to release
and discharge the Company from the Obligation to repay to Wilke of $2,763,018. As Wilke&#8217;s shareholder also is a shareholder of the
Company under common control, such debt forgiveness were treated as an addition to the Company&#8217;s capital during the year ended December
31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Amended and Restated Registration Rights Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the closing
of the Business Combination, the Company entered into an amended and restated registration rights agreement with certain existing shareholders
of the Company and with the Seller with respect to their ordinary shares of the Company acquired before or pursuant to the Share Purchase,
and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company&#8217;s initial public
offering and any shares issuable on conversion of working capital loans from the Sponsor to the Company . The Company further amended
the amended and restated registration rights agreement (as amended, the &#8220;Amended and Restated Registration Rights Agreement&#8221;)
to include certain noteholders with respect to the ordinary shares of the Company issuable upon conversion of the Convertible Notes made
in connection with the closing of the Business Combination. Those securities are referred to herein collectively as the &#8220;Registrable
Securities.&#8221; Pursuant to the terms of the Amended and Restated Registration Rights Agreement, following the Closing, the Company
is to file with the SEC a registration statement on Form S-3 (or Form S-1) covering the resale of all or such maximum portion of the Registrable
Securities as permitted by the SEC. The Amended and Restated Registration Rights Agreement does not contain liquidating damages or other
cash settlement provisions resulting from delays in registering the Registrable Securities. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Related Party Transactions Policy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately following the Closing
of the Business Combination, the Company&#8217;s board of directors adopted a written Related Party Transactions Policy that sets forth
our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related party transactions.&#8221;
For purposes of our policy only, a &#8220;related party transaction&#8221; is a transaction, arrangement or relationship (or any series
of similar transactions, arrangements or relationships) in which (i) we (including any of our subsidiaries, if any) we are or will be
a participant, (ii) the aggregate amount involved exceeds or may be expected to exceed $100,000, and (iii) a related party has or will
have a direct or indirect material interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to certain limitations,
transactions involving compensation for services provided to us as an employee or director will not be considered related party transactions
under this policy. A related party is any executive officer, director, nominee to become a director or a holder of more than 5% of any
class of our voting securities (including our ordinary shares), including any of their immediate family members and affiliates, including
entities owned or controlled by such persons. A related party is also someone who has a position or relationship with any firm, corporation
or other entity that engages in the transaction if (i) such person is employed or is a general partner or principal or in a similar position
with significant decision making influence, or (ii) the direct or indirect ownership by such person and all other foregoing persons, in
the aggregate, is 10% or greater in another person which is party to the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the policy, any related
party, or any director, officer or employee of ours who knows of the transaction, must report the information regarding the proposed related
party transaction to our audit committee for review. To identify related party transactions in advance, we will rely on information supplied
by our executive officers, directors and certain significant shareholders. In considering related party transactions, our audit committee
will take into account the relevant available facts and circumstances, which may include, but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction was undertaken in the ordinary course of business of the Company; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction was initiated by the Company, a subsidiary, a controlled company of the Company, or the related party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the transaction with the related party is proposed to be, or was, entered into on terms no less favorable to the Company than terms that could have been reached with an unrelated third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approximate dollar value of the transaction involved, particularly as it relates to the related party; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other information regarding the transaction or the related party that would be material to the Company&#8217;s shareholders in light of the circumstances of the particular transaction.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All related party transactions
may be consummated or continued only if approved or ratified by our audit committee. No director or member of our audit committee may
participate in the review, approval or ratification of a transaction with respect to which he or she is a related party, except that such
member may be counted for purposes of a quorum and shall provide such information with respect to the transaction as may be reasonably
requested by other members of our audit committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Code of Business Conduct and Ethics</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have also adopted a Code of Business Conduct and
Ethics, a copy of which is posted on our website at https://euda.com/.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_021"></span>Item 14. Principal Accountant Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Public Accounting Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The
following table presents fees approved by the Audit Committees and billed for professional services rendered for the years ended December
31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left; text-indent: 0pt">Audit Fees (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">755,000</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">Audit-Related Fees (2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">88,973</p></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Tax Fees (3)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">All Other Fees (4)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-indent: 0pt">Total</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">755,000</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">688,973</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees. Audit fees consist of fees for the audit of our annual financial statements and the reviews of our interim financial statements. Audit fees for each period also include related services that are normally provided in connection with registration statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees. Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our financial statements and are not reported under &#8220;Audit Fees.&#8221; These services include attest services that are not required by statute or regulation and consultation concerning financial accounting and reporting standards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees. Tax fees consist of fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Fees. All other fees represent amounts billed in each of the years presented for services not classifiable under the other categories listed in the table above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Pre-Approval of Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
our audit committee had not yet been formed when the work commenced in 2021, the audit committee was not able to pre-approve all of the
foregoing services, although all such services were approved by our board of directors. All services subsequent to the formation of the
audit committee have been approved by the audit committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_022"></span>Item 15. Exhibits and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">(a) <i>The following documents are filed as part of this report:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All financial statements:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eu_001">Report of Independent Registered Public Accounting Firm</a> (Marcum Asia CPAs LLP, PCAOB ID 5395)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (Friedman LLP, PCAOB ID 711)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Consolidated
    Balance Sheets as of December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Consolidated
    Statements of Operations and Comprehensive Income (Loss) for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Consolidated
    Statements of Changes in Shareholders&#8217; Equity (Deficit) for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
    to F-44</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial statement schedules</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Not
Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    required by Item 601 of Regulation S-K:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-indent: 0pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Schedule/ Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>File</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Number</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Filing Date</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex2-1.htm" style="-sec-extract: exhibit">Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated April 11, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex2-2.htm" style="-sec-extract: exhibit">Amendment No. 1 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated May 30, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex2-3.htm" style="-sec-extract: exhibit">Amendment No. 2 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated June 10, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex2-4.htm" style="-sec-extract: exhibit">Amendment No. 3 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated September 7, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Memorandum and Articles of Association of EUDA Health Holdings Limited</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex4-1.htm" style="-sec-extract: exhibit">Specimen Warrant Certificate</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex4-2.htm" style="-sec-extract: exhibit">Form of Warrant Agreement between American Stock Transfer &amp; Trust Company, LLC and 8i Acquisition 2 Corp.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex4-3.htm" style="-sec-extract: exhibit">Specimen Ordinary Share Certificate of EUDA Health Holdings Limited</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-5.htm">Description of Registered Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex10-1.htm" style="-sec-extract: exhibit">Form of Amended and Restated Registration Rights Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex10-2.htm" style="-sec-extract: exhibit">Form of First Amendment to Amended and Restated Registration Rights Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex10-3.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex10-4.htm" style="-sec-extract: exhibit">Form of Lock-up Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222036478/ex10-5.htm" style="-sec-extract: exhibit">Form of Seller Release</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-268994</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223019182/ex10-1.htm" style="-sec-extract: exhibit">Settlement Agreement with Mr. Meng Dong (James) Tan, dated May 16, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223019182/ex10-2.htm" style="-sec-extract: exhibit">Settlement Agreement with 8i Holdings 2 Pte Ltd., dated May 16, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223019182/ex10-3.htm" style="-sec-extract: exhibit">Settlement Agreement with Shine Link Limited, dated May 16, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223019182/ex10-4.htm" style="-sec-extract: exhibit">Settlement Agreement with Menora Capital Pte Ltd, dated May 16, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223019182/ex10-5.htm" style="-sec-extract: exhibit">Settlement Agreement with Kelvin Chen, dated May 16, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 26, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223020785/ex10-1.htm" style="-sec-extract: exhibit">Supplemental Agreement with Kelvin Chen, dated June 6, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 9, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222031193/ex10-1.htm" style="-sec-extract: exhibit">Prepaid Forward Purchase Agreement dated November 9, 2022</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223020785/ex10-2.htm" style="-sec-extract: exhibit">Amendment to Prepaid Forward Agreement dated June 8, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 9, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222031708/ex10-1.htm" style="-sec-extract: exhibit">Prepaid Forward Purchase Agreement dated November 13, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 14, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315223020785/ex10-3.htm" style="-sec-extract: exhibit">Amendment to Prepaid Forward Agreement dated June 8, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40678</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 9, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1847846/000149315222033558/ex16-1.htm" style="-sec-extract: exhibit">Letter from UHY LLP to the SEC, dated November 23, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">001-40678</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">16.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">November 23, 2022</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List of Subsidiaries</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">23.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><a href="ex23-1.htm">Consent of Friedman LLP</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">23.2*</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><a href="ex23-2.htm">Consent of Friedman LLP under &#8220;Change in Registrant&#8217;s Certifying Accountant&#8221;</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within
    the Inline XBRL document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3pt">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3pt">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_023"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Wei Wen Kelvin Chen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer and Executive Director <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Power of Attorney</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Wei Wen Kelvin Chen and Steven John Sobak, jointly and
severally, his or her attorneys-in-fact, each with the power of substitution, for him in any and all capacities, to sign any amendments
to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes,
may do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Wei Wen Kelvin Chen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (principal executive officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Steven John Sobak</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (principal financial officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ajay Kumar Rajpal</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajay Kumar Rajpal</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alfred Lim</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alfred Lim</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Lew</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Lew </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kong-Yew Wong</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kong-Yew Wong </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>EUDA HEALTH HOLDINGS LTD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#eu_001">Report of Independent Registered Public Accounting Firm</a> (Marcum Asia CPAs LLP, PCAOB ID: <span id="xdx_905_edei--AuditorFirmId_c20220101__20221231_zmjX3Cpo7r7e"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">5395</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (Friedman LLP PCAOB ID: 711)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Consolidated
    Balance Sheets as of December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Consolidated
    Statements of Operations and Comprehensive Income (Loss) for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Consolidated
    Statements of Changes in Shareholders&#8217; Equity (Deficit) for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
    to F-44</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="report_002.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="eu_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
Health Holdings Limited</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of EUDA Health Holdings Limited (the &#8220;Company&#8221;) as of December 31,
2022, the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity (deficit) and cash
flows for the year ended December 31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 2, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise
additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our audit of the financial statements as of and for the year ended December 31, 2022, we also audited the adjustments to the
2021 financial statements to retrospectively apply the change in accounting related to the reverse recapitalization described in Note
4. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any
procedures to the 2021 financial statements, other than with respect to the retrospective adjustments and, accordingly, we do not express
an opinion or any other form of assurance on the 2021 financial statements as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_903_edei--AuditorName_c20220101__20221231_z4aa2K5wRTc8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Marcum Asia CPAs LLP</ix:nonNumeric></span><span style="font-variant: small-caps"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022 (such date takes into account the acquisition of certain assets of Friedman LLP
by Marcum Asia CPAs LLP effective September 1, 2022)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--AuditorLocation_c20220101__20221231_zZAgdW1q2mGd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">New
York, NY</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
28, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW YORK OFFICE &#9679; 7 Penn Plaza &#9679; Suite 830 &#9679; New York, New York &#9679; 10001</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone 646.442.4845 &#9679; Fax 646.349.5200
&#9679; www.marcumasia.com</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 72; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="report_001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b><span id="f_001"></span>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Shareholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
Health Limited</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited, before the effects of the adjustments to retrospectively apply the change in accounting related to the reverse recapitalization
described in Note 4, the accompanying consolidated balance sheet of EUDA Health Limited (the &#8220;Company&#8221;) as of December 31,
2021, and the related consolidated statement of income and comprehensive income, changes in shareholders&#8217; equity, and cash flows
for the year ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our
opinion, except for the effects of the adjustments to retrospectively apply the change in accounting related to the reverse recapitalization
described in Note 4, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2021, and the results of its operation and its cash flow for the year ended December 31, 2021, in conformity with
accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were not engaged to audit, review or apply any procedures to the adjustments to retrospectively apply the change in accounting related
to the reverse recapitalization as described in Note 4, accordingly, we do not express an opinion or any other form of assurance about
whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by other auditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audit provides a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Friedman LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
served as the Company&#8217;s auditor in 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
3, 2022, except for Note 3 which is dated July 25, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="f_002"></span>CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_z99MOfjtpbNh" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20221231_zpMyMlayzHD9" style="text-align: center">December 31,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zxzlacsWAnH5" style="text-align: center">December 31,</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zaOvB5N22QRd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">CURRENT ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pp0p0_maACzeQh_zUGfo7KBcfO4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-indent: 0pt">Cash</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,024</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,996</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RestrictedCashCurrent_i01I_pp0p0_maACzeQh_z8Yj8z5fZif9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Restricted cash</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">641,461</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0063">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i01I_pp0p0_maACzeQh_zQzBGbIW8z5h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Accounts receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,851,503</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,802,316</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherReceivablesNetCurrent_i01I_pp0p0_maACzeQh_zYTTthPeXNC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,467</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,991,226</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueFromRelatedPartiesCurrent_i01I_pp0p0_maACzeQh_zgCLbDsoD0Sh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Due from related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">267,863</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">297,621</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pp0p0_maACzeQh_zNONORHJf1zh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">222,633</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,495</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ForwardPurchaseReceivables_i01I_pp0p0_maACzeQh_zdNbobRQv2P7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Forward purchase receivables</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="EUDA:ForwardPurchaseReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,892,527</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i01TI_pp0p0_mtACzeQh_maAzJ0S_zp2KCRH98mx9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Total Current Assets</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,026,478</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,352,654</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzJ0S_zdkxVdCELov3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">PROPERTY AND EQUIPMENT, NET</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,628</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,927</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsNoncurrentAbstract_i01B_z5EkYvFgNv0k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">OTHER ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherReceivablesNonCurrent_i02I_maANzLJZ_zcccMMBAhugl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Other receivables - non-current</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:OtherReceivablesNonCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,830,603</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseNoncurrent_i02I_maANzLJZ_zdalSxINDmfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Prepaid expenses - non-current</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,061</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maANzLJZ_zNFs5cToLLod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Intangible assets, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,962</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Goodwill_i02I_maANzLJZ_zItKMeb1W7jb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">Goodwill</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">992,686</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzLJZ_zwXy5doSGCcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Operating lease right-of-use asset</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,528</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,862</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseRightOfUseAsset_i02I_maANzLJZ_z2nOimuaZvxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Finance lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,345</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,372</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--LoanToThirdParty_i02I_maANzLJZ_z2QmVIgcsBc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Loan to third party</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="EUDA:LoanToThirdParty" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">371,962</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssets_i02TI_mtANzLJZ_maAzJ0S_zF8roir6LRic" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Other Assets</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">570,934</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,589,447</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i01TI_pp0p0_mtAzJ0S_ztOenThOpIH8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Total Assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,629,040</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,999,028</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zLWwPStSPay6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maLzDa5_zlTZ7sJ98mFa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Short term loans - bank and private lender</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,240</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,427</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ShortTermLoansThirdParties_i02I_maLzDa5_z8hkoo9oePD7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Short term loans - third parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:ShortTermLoansThirdParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,302</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PromissoryNote_i02I_maLzDa5_zKPszOaWq9jl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Promissory note</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:PromissoryNote" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0129">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLzDa5_z8luHpz6gtni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Convertible notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,619,625</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ConvertibleNotesRelatedParties_i02I_maLzDa5_zsii6trnSzG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Convertible notes - related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:ConvertibleNotesRelatedParties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,600</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLzDa5_zoRGRoZCvICe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,635,483</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,716</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccountsPayableRelatedParty_i02I_maLzDa5_zdPoqDVxhmFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Accounts payable - related party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0140">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:AccountsPayableRelatedParty" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,459,411</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherPayablesAndAccruedLiabilities_i02I_maLzDa5_zKEl3VFtZeCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Other payables and accrued liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:OtherPayablesAndAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592,815</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:OtherPayablesAndAccruedLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,597</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OtherPayablesRelatedParties_i02I_maLzDa5_zYt0eYL4Ofvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Other payables - related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:OtherPayablesRelatedParties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,521,945</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:OtherPayablesRelatedParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,272,311</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maLzDa5_zUjn91EqzfHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Operating lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,959</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,478</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_maLzDa5_zcWwVIMl1RQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Finance lease liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,186</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,447</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrepaidForwardPurchaseLiabilities_iI_maLzDa5_zjB9lKNCT33a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Prepaid forward purchase liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--TaxesPayableCurrent_iI_maLzDa5_zBf2JvB30Gb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Taxes payable</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,150</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,343</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i01TI_pp0p0_mtLzDa5_maLzqMb_zUQEtSaLKUmc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Total Current Liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,121,056</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,316,032</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zsremtqf6oo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">OTHER LIABILITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i02I_maLNz4t6_za6JFz8FelXb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">Deferred tax liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,294</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNz4t6_zYC56TjUKwcf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Operating lease liability - non-current</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,384</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLNz4t6_zjde0GEsKlya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Finance lease liabilities - non-current</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,015</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,268</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNz4t6_maLzqMb_zrxzVBtH6ZZ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Total Other Liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,015</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,946</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtLzqMb_maLASEzwHZ_zB3703iVUCs7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Total Liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,136,071</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,398,978</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzwHZ_zQRqioSytiX8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">COMMITMENTS AND CONTINGENCIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0182">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0183">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">SHAREHOLDERS&#8217; (DEFICIT) EQUITY</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzb0w_zTz253eRQQ1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">Ordinary shares, <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20221231_zoNOOOk87du2" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_do_c20211231_z806nNMo9x3e" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span>
    </span>par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorizedUnlimited_c20220101__20221231_zVSAeKCa80B5" title="Common stock, shares authorized, unlimited"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorizedUnlimited_c20210101__20211231_zIDQGqfU3sHa" title="Common stock, shares authorized, unlimited"><span style="-sec-ix-hidden: xdx2ixbrl0195"><span style="-sec-ix-hidden: xdx2ixbrl0197">unlimited</span></span></span></span>
    shares authorized, <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z0uX7k5Fetob" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,191,770</ix:nonFraction></span> shares and
    <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zugVbU3yeFyg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,333,333</ix:nonFraction></span> shares outstanding as
    of December 31, 2022 and 2021, respectively<span id="xdx_F4B_zkfWzcRentob">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,308,969</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">334,863</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzb0w_zbfeSIu9D3Ra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt">Retained earnings (accumulated deficit)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">24,703,789</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">180,333</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzb0w_z9cjPcr518Kh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Accumulated other comprehensive (loss) income</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">125,689</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,036</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_i02TI_mtSEzb0w_maSEIPAzvuH_zUUw8S4GT1K5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Total Euda Health Holdings Limited Shareholders&#8217; (Deficit) Equity</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,520,509</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,232</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--MinorityInterest_i02I_maSEIPAzvuH_zV1opBfNnFL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Noncontrolling interests</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,478</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,818</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pp0p0_mtSEIPAzvuH_maLASEzwHZ_zWUKWJXZhvmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Total Shareholders&#8217; (Deficit) Equity</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,507,031</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,050</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzwHZ_zLzdZwynkylj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Total Liabilities and Shareholders&#8217; (Deficit) Equity</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,629,040</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,999,028</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F03_zY2QfvGwEl0i" style="width: 18pt; text-align: right">*</td>
<td id="xdx_F1A_z7MDXErfZBVl" style="text-align: justify"><ix:footnote id="Footnote000220" xml:lang="en-US">Giving retroactive effect to reverse recapitalization effected on November 17, 2022</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><i>The accompanying notes
are an integral part of the financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>EUDA HEALTH HOLDINGS LTD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; background-color: white"><b><span id="f_003"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zWPt55mXozEk" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zm3B3AWRszU6" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231_zuekHWuL9lXh" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">REVENUES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesMember_zzq2faEt4vSd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; text-indent: 0pt; padding-left: 10pt">Medical services</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,065,233</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,723,549</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesRelatedPartiesMember_zXaTzsuaatPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Medical services - related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,640</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zcHDgNHXQpgk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Product sales</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,046</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,841</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesMember_zaajGAMvdHR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Property management services</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,764,295</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,520</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maGPzasB_zmBFyS1Habui" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 20pt">Total Revenues</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,840,709</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,544,550</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfRevenueAbstract_iB_zCLyHqkYWUOg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">COST OF REVENUES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesMember_zxIjcmXwYWLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Medical services</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,041,327</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,757</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesRelatedPartiesMember_zASHOZVghy8c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Medical services - related party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,499</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,349,702</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zpvltAdK5tF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Product sales</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,391</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,202</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesMember_zoTVA0kWKAa6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Property management services</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,894,296</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,308,536</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfRevenue_i01_msGPzasB_zEHI5iwL4Zkf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 20pt">Total Cost of Revenues</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,486,513</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,300,197</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GrossProfit_iT_mtGPzasB_maOILz7ih_zfqGvSohtrC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">GROSS PROFIT</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,354,196</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,244,353</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zAtQmokA4Yo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">OPERATING EXPENSES:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SellingAndMarketingExpense_i01_maOEziMd_zAabYhbjQ3Ab" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt; padding-left: 10pt">Selling</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,902,865</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,258,442</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEziMd_zivs2V3Ft7Gj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,153,248</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,084,873</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EarnoutSharePayment_i01_maOEziMd_zRvFJIy1brD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Earnout share payment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="EUDA:EarnoutSharePayment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,199,629</ix:nonFraction></p></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></p></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetImpairmentCharges_i01_maOEziMd_z9FrnlLTxoEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Impairment loss on long-lived assets and goodwill</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,139,016</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEziMd_zTDPGl7tETQ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Research and development</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,209</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,265</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_i01T_mtOEziMd_msOILz7ih_zSRwiuztSKjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 20pt">Total Operating Expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,411,967</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,472,580</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtOILz7ih_maILFCOzQeK_zieFxDcqLb5f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">LOSS FROM OPERATIONS</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,057,771</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,228,227</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zO2rcVhfDSB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">OTHER INCOME (EXPENSE)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpenseOther_i01N_di_msNIEzHuH_zENSyUmYS1ui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Interest expense, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,082</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,126</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_i01_maNIEzHuH_zUqIGCnS0eej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Gain on disposal of subsidiary</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,055</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_i01N_di_msNIEzHuH_zLVvqUaCUmT8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Change in fair value of prepaid forward purchase liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,503</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzHuH_zUdADBBAbeei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Other income, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,477</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,828</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentIncomeNet_i01_maNIEzHuH_zkpHEjS1bJXg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Investment income</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,917,062</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzHuH_maILFCOzQeK_zd3ZqaePOXi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 20pt">Total Other Income (Expense), net</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,874,053</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,176,764</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzQeK_maPLzLSI_zE1uWCH4FB31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">(LOSS) INCOME BEFORE INCOME TAXES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,931,824</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">948,537</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_msPLzLSI_zvJh71Vi9706" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">PROVISION FOR INCOME TAXES</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,422</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,141</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_iT_mtPLzLSI_maNILz5Ct_zhWt9LwVgXac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">NET (LOSS) INCOME</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILz5Ct_zWMe9ZfzMfGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Less: Net (income) loss attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,124</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,567</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILz5Ct_zjeBpy0Gm3wh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">NET (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMITED</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,884,122</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,829</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_iT_maCINOTzNiK_zCoFXUmVTvyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">NET (LOSS) INCOME</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_maCINOTzNiK_zfA0eITCvbbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">FOREIGN CURRENCY TRANSLATION ADJUSTMENT</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">131,941</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,009</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_iT_mtCINOTzNiK_maCINOTzW03_zoCdL4oMtE0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt">TOTAL COMPREHENSIVE (LOSS) INCOME</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,081,187</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">917,405</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_msCINOTzW03_zaK51MQwu0i8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt">Less: Comprehensive (loss) income attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,340</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,584</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzW03_z6HIe5zMKrb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt">COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMIT</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,015,847</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">881,821</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareBasicOtherDisclosuresAbstract_iB_zIGLxOuDVNBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES*</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_zrBUsb85MG12" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,029,656</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,253,333</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasicAbstract_iB_z1fOJ47v87ki" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 0pt">(LOSS) EARNINGS PER SHARE</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EarningsPerShareBasic_i01_pid_zVYpjPao9Iwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.07</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><i>The accompanying notes
are an integral part of the financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center">EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75pt; text-align: center"><span id="f_004"></span>CONSOLIDATED STATEMENTS OF CHANGE IN SHAREHOLDERS&#8217;
EQUITY (DEFICIT)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zUwxSvsUBzmg" summary="xdx: Statement - Consolidated Statements of Change in Shareholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares*</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zY0rTFfqVYd2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zRh0GUjZ2yH6" style="border-bottom: Black 1.5pt solid; text-align: center">deficit)</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zfk22kkkLMSc" style="border-bottom: Black 1.5pt solid; text-align: center">income (loss)</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zq5LVupJhIi1" style="border-bottom: Black 1.5pt solid; text-align: center">interest</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B9_zEiXTVRR3Fp3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Retained</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">earnings</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">other</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Ordinary shares</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">(Accumulated</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">comprehensive</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Noncontrolling</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares*</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">deficit)</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">income (loss)</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">interest</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zV9YS7eBICpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">BALANCE, December 31, 2020</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzXdDcbZRpcf" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,253,333</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,863</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,496</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,956</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,234</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">317,355</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zZlr5P2D3rz4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,829</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,567</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zGtwdPi6qnEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,992</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,009</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z5oNMfSPqZw3" style="vertical-align: bottom; background-color: White">
    <td>BALANCE, December 31, 2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKld8SkNLPQ" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,253,333</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,863</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,333</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,036</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,818</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,050</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProfitLoss_zCzZyhWMAHLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,884,122</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,124</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--ProfitLoss_zCB8yl88SQE4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net income (loss)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,884,122</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,124</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
<tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueCapitalContributions_zubZmb3UKgI1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Capital contributions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesCapitalContributions_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcYFs8ka3J6" title="Capital contributions, shares" style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodSharesCapitalContributions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueCapitalContributions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueCapitalContributions" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_zgKfWyWTfmYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Forgiveness of debt by a related party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,763,018</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,763,018</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueEarnoutSharesPayament_zJcVhQy3oJOi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Earnout shares payment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,199,629</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,199,629</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z0GbwevyJFZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issuance of ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z37fwx5sls32" title="Issuance of ordinary shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,626,667</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_zyYlLiXoGvfb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of ordinary shares upon the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIqp7qd5Mzaa" title="Issuance of ordinary shares upon the reverse recapitalization , shares" style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,191,770</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,911,459</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,911,459</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zYdU6yC4Oy99" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">131,725</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">216</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">131,941</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zVgUICPYmRy7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">BALANCE, December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIiEiUHMaoD4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,191,770</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,308,969</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,703,789</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">125,689</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,478</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,507,031</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><i>The accompanying notes
are an integral part of the financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="f_005"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zX3B4KhCKCs8" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zi9kTmyjk5tl" style="text-align: center">December 31,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20210101__20211231_ziM3YY7brZ6c" style="text-align: center">December 31,</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Years Ended</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zbF119I72eTc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_i01_maNCPBUzt3i_zLZykHYwNm87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net (loss) income</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zhtWTSZ9qGW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Depreciation_i02_maNCPBUzt3i_zpsj25UsDy61" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Depreciation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,347</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,523</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzt3i_zYGSHvx1DvK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of intangible assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,907</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,825</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzt3i_zjOAFJrygKVg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of operating right-of-use asset</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,056</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,602</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i02_maNCPBUzt3i_zsR2DeOEDCd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of finance right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,948</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,153</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzt3i_zk30fr4MEdpf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Provision for doubtful accounts</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,872,789</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,804</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefit_i02_maNCPBUzt3i_za2PijYjy888" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Deferred taxes benefits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,228</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,680</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--InvestmentIncomeNet_i02N_di_msNCPBUzt3i_zUbAR0feT4Uj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Investment income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,917,062</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_i02N_di_msNCPBUzt3i_zLogB7ELamQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on disposal of subsidiary</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,055</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EarnoutPayment_i02_maNCPBUzt3i_zvH8tKhNwnde" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Earnout payment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:EarnoutPayment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,199,629</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GoodwillImpairmentLoss_i02_maNCPBUzt3i_zngnyPGaxNt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Impairment loss on goodwill</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,229</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_i02_maNCPBUzt3i_zewwqCbPW9Ne" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Impairment loss on intangible assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,787</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities_i02_maNCPBUzt3i_zDfThA0yyIti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of prepaid forward purchase liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,503</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zGfWkuNc6Und" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in operating assets and liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzt3i_zg3vN4l7C205" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,824</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,950</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInNotesReceivableCurrent_i03N_di_msNCPBUzt3i_zNqiedg9Fk2e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Interest receivable from loan to third party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesReceivableCurrent" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,071</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherReceivables_i03N_di_msNCPBUzt3i_zEKXk5FIidyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,582,724</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,692</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzt3i_zLDaqbBOqkrk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,749</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,010</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzt3i_zLNNfW092s06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,268,701</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,560</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInAccountsPayableRelatedParty_i03_maNCPBUzt3i_zZIj6ZHpl1z" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payables - related party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:IncreaseDecreaseInAccountsPayableRelatedParty" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,396,931</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:IncreaseDecreaseInAccountsPayableRelatedParty" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,022,714</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzt3i_zI3RlSXpRK07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other payables and accrued liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,437</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i03_maNCPBUzt3i_zmSR4z6cLxyb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Taxes payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">114,133</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,188</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzt3i_zeUGXVBfDra5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Operating lease liability</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">105,719</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,124</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzt3i_maCCERCzm24_zgYhdnDTep7h" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Net cash (used in) provided by operating activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,526,828</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,920</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zg8NkWSjv0S4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzXEg_zaslo2xqosai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Purchases of equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,137</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,957</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquireNotesReceivable_i01N_di_msNCPBUzXEg_z911LtF0IVm8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loan to third party</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,664</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireBusinessesGross_i01N_di_msNCPBUzXEg_z8qugEylhow3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash acquired through business combination</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,226</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquireInterestInSubsidiariesAndAffiliates_i01N_di_msNCPBUzXEg_zpopWJZhAzza" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Cash released upon disposal of a subsidiary</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,405</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzXEg_maCCERCzm24_zK0e1EPfBqoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Net cash used in investing activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">268,206</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">356,183</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zTd61StCwd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzuxu_zQN2Zbm5MSq" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromContributedCapital_i01_maNCPBUzuxu_zKus7JrhnKS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Capital contributions</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProceedsFromReverseRecapitalization_i01_maNCPBUzuxu_zgO0kM8G8ZJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:ProceedsFromReverseRecapitalization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,961</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfMergerRelatedCostsFinancingActivities_i01N_di_msNCPBUzuxu_zjmx04yYekLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payments of merger costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,305,580</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--RepaymentsFromOtherReceivableRelatedParties_i01_maNCPBUzuxu_ztDLgVwPzJ5f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Repayments from other receivable - related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:RepaymentsFromOtherReceivableRelatedParties" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,670</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:RepaymentsFromOtherReceivableRelatedParties" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,189</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromShortTermDebt_i01_maNCPBUzuxu_ztV8PMB0ptBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from short-term loans - bank and private lender</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,548</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,812</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RepaymentsOfShortTermDebt_i01N_di_msNCPBUzuxu_zq89x0a2pjzg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Repayments to short-term loans - bank and private lender</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,895</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,801</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--RepaymentsToShorttermLoansThirdParties_i01N_di_msNCPBUzuxu_zSVbpgKc91ma" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repayments to short-term loans - third parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:RepaymentsToShorttermLoansThirdParties" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,553</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzuxu_zMyczsE4WY79" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Borrowings from other payables - related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,347,745</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,666</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzuxu_zHHO0kt0JCA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Payment of finance lease liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,502</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,686</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzuxu_maCCERCzm24_zjB0MawrNME1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Net cash provided by (used in) financing activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,488,947</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">168,373</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzm24_z99nDv0hSq01" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">EFFECT OF EXCHANGE RATE CHANGES</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,424</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,865</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzm24_zJsthgYf0Lkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NET CHANGE IN CASH AND RESTRICTED CASH</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,489</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,771</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zylO4iY4nUa2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">CASH AND RESTRICTED CASH, beginning of the year</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,996</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,767</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zHRXRkdjzMXb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">CASH AND RESTRICTED CASH, end of the year</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">784,485</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,996</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zF6oVWom3ewe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxesPaidNet_i01_zAHW4FOdUwzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Cash paid for income tax</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,339</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,185</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPaidNet_i01_z4F0NEemKnB4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Cash paid for interest</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,588</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,835</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zJ7rTaCnqsW9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability_i01_z0ZOjmOTm9G5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Initial recognition of operating right of use asset and lease liability</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,350</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,834</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary_i01_z1eDcKAXpTF6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Initial recognition of payables to former subsidiary upon disposal of subsidiary</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,158</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ConversionOfDebtIntoPromissoryNote_i01_zrMIvoRXbX21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Conversion of debt into a promissory note</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:ConversionOfDebtIntoPromissoryNote" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ConversionOfDebtsIntoConvertibleNotes_i01_zAFpleUt4sj1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Conversion of debts into convertible notes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:ConversionOfDebtsIntoConvertibleNotes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,500</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ForgivenessOfDebtByRelatedParty_i01_zM6PDHwtGUwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Forgiveness of debt by a related party</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:ForgivenessOfDebtByRelatedParty" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,763,018</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfOrdinarySharesUponReverseRecapitalization_i01_zaebyqObHOI" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Issuance of ordinary shares upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:IssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,911,459</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_pp0p0_z6FGmS2HdzY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%">Cash</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 14%"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,024</ix:nonFraction></td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 14%"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,996</ix:nonFraction></td>
    <td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RestrictedCashCurrent_i01E_pp0p0_zsER3UQXd2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Restricted cash</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">641,461</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_pp0p0_z3PCjcWmbNnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total cash and restricted cash</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">784,485</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,996</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><i>The accompanying notes
are an integral part of the financial statements.</i></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>EUDA HEALTH
HOLDINGS LIMITED AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="f_006"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(In U.S. dollars, unless stated otherwise)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zKQMxfp0Fkph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1&#8211; <span id="xdx_828_zNqFg2jPDEB">Nature of business and organization</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EUDA Health Holdings Limited, which until November
17, 2022 was known as 8i Acquisition 2 Corp. (the &#8220;Company&#8221;, &#8220;EUDA&#8221; or &#8220;8i&#8221;) is a company incorporated
on January 21, 2021, under the laws of the British Virgin Islands for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a &#8220;Initial
Business Combination&#8221;). The Company is an &#8220;emerging growth company&#8221;, as defined in Section 2(a) of the Securities Act
of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;). The Company&#8217;s efforts to identify a prospective target business were not limited to a particular industry or geographic
location (excluding China). The Articles of Association prohibited the Company from undertaking the Initial Business Combination with
any entity that conducts a majority of its business or is headquartered in China (including Hong Kong and Macau).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022 (the &#8220;Closing Date&#8221;),
EUDA Health Holdings Limited, a British Virgin Islands business company (formerly known as 8i Acquisition 2 Corp.) (the &#8220;Company&#8221;),
consummated the business combination contemplated by the Share Purchase Agreement (the &#8220;SPA&#8221;) between 8i Acquisition 2 Corp.,
a BVI business company (&#8220;8i&#8221;), EUDA Health Limited, a British Virgin Islands business company (&#8220;EHL&#8221;), Watermark
Developments Limited, a British Virgin Islands business company (&#8220;Watermark&#8221; or the &#8220;Seller&#8221;), and Kwong Yeow
Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination
between 8i and EHL was effected by the purchase by 8i of all of the issued and outstanding shares of EHL from the Seller (the &#8220;Share
Purchase&#8221;), resulting in EHL becoming a wholly owned subsidiary of 8i. In addition, in connection with the consummation of the Share
Purchase, 8i has changed its name to &#8220;EUDA Health Holdings Limited.&#8221; <span style="background-color: white">See Note 4 - Reverse
Recapitalization for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, through its subsidiaries, operates its
business in two segments, 1) engaged in the healthcare specialty group (other than general practice) business offering range of specialty
care services to patients, and engaged in the medical facility general practice clinic that provides holistic care for various illnesses,
and 2) engaged in the property management service that services shopping malls, business office building, or residential apartments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Reorganization under EUDA Health Limited (&#8220;EHL&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2021, EHL completed a reverse recapitalization
(&#8220;Reorganization&#8221;) under common control of its then existing shareholders, who collectively owned all of the equity interests
of Kent Ridge Health Private Limited (&#8220;KRHPL&#8221;), a holding company incorporated under the laws of the Singapore prior to the
Reorganization, through the following transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2021, EHL acquired <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zr02GQ456Lkf" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests in Kent Ridge Healthcare Singapore Private Limited (&#8220;KRHSG&#8221;) through KRHPL for consideration of SG$<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z4LfnmqH9Cjc" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2021, EHL acquired <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zfvys17pJ3hd" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-07-24_custom_EUDAPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests in EUDA Private Limited (&#8220;EUDA PL&#8221;) through KRHPL for consideration of SG$<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_z9Xmt3BimM8a" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2021, Kent Ridge Health Limited (&#8220;KRHL&#8221;), EHL&#8217;s wholly owned subsidiary, acquired <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zOhCDKBHIvx8" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-08-01_custom_SuperGatewayGroupLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests in Super Gateway Group Limited (&#8220;SGGL&#8221;) through KRHPL for consideration of SG$<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210801__20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zvLfN0Bs7tSf" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-08-012021-08-01_custom_SuperGatewayGroupLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 3, 2021, EHL acquired <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTNwSVY0eqh9" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests in Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;) through KRHPL for no consideration.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before and after the Reorganization, the Company,
together with its subsidiaries (as indicated above), is effectively controlled by the same shareholders, and therefore the Reorganization
is considered as a recapitalization of entities under common control in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
805-50-25. The consolidation of the Company and its subsidiaries have been accounted for at historical cost and prepared on the basis
as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated
financial statements in accordance with ASC 805-50-45-5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Reorganization under KRHPL</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;KRHSG Agreement&#8221;) with the sole shareholder of KRHSG who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the KRHSG Agreement, KRHPL will acquire <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z62K6jKh6Zfi" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests
in KRHSG (&#8220;Reorganization of KRHSG&#8221;) for a total consideration of SG$<span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zoT5ljnFNSrf" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span> (&#8220;Total Consideration&#8221;). The transaction
was completed and effective on January 3, 2020. Since KRHSG and KRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of KRHSG are prepared on the basis as
if the restructuring of KRHSG became effective as of the beginning of the first period presented in the accompanying consolidated financial
statements of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;EUDA PL Agreement&#8221;) with the sole shareholder of EUDA PL who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the EUDA PL Agreement, KRHPL will acquire <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zmZCeMevBZ25" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-07-24_custom_EUDAPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests
in EUDA PL (&#8220;Reorganization of EUDA PL&#8221;) for a total consideration of SG$<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zKznHPSUl4Jh" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span> (&#8220;Total Consideration&#8221;). The transaction
was completed and effective on January 3, 2020. Since EUDA PL and LRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of EUDA PL are prepared on the basis
as if the restructuring of EUDA PL became effective as of the beginning of the first period presented in the accompanying consolidated
financial statements of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;SEMA Agreement&#8221;) with the sole shareholder of SEMA who is effectively controlled
by the same shareholders of KRHPL on December 31, 2019. Pursuant to the SEMA PL Agreement, KRHPL will acquire <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_z3QxUw59Vmq2" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interests
in SEMA (&#8220;Reorganization of SEMA&#8221;) for no consideration. SEMA is a holding company and has no operations prior to December
31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock"><p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zzrsYIVYtU3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
reflect the activities of EUDA and each of the following entities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zO0MFroHEgr2" style="display: none">Schedule of consolidated financial statement</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_ztt8seKfNKj7" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember" name="EUDA:NameOfCompany">EUDA Health Limited (&#8220;EHL&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company
Incorporated on <span id="xdx_905_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_z0ync8rYeFLe" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">June 8, 2021</ix:nonNumeric></span> <br />
A holding Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_zgcbYWPo4abj" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_EUDAHealthLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EUDA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zUwAwOFjT3ae" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember" name="EUDA:NameOfCompany">Kent Ridge Healthcare Singapore Pte. Ltd. (&#8220;KRHSG&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_901_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zDe7wPuvozp7" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">November 9, 2017</ix:nonNumeric></span> <br />
Multi-care specialty group offering range of specialty care services to patients.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zyMEq0S7QwXf" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zd99RF1PNEQe" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember" name="EUDA:NameOfCompany">EUDA Private Limited (&#8220;EUDA PL&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_90A_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zqbIwHB4wP9" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">April 13, 2018</ix:nonNumeric></span> <br />
A digital health company that provides a platform to serve the healthcare industry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zZRNTkRCwAO3" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_EUDAPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zClTqn3LSgL9" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" name="EUDA:NameOfCompany">Zukitek Vietnam Private Limited Liability Company (&#8220;ZKTV PL&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Vietnam company <br />
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zIbJX9cpEhxi" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">May 2, 2019</ix:nonNumeric></span> <br />
A Research and Development Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zeq5sYBziRI9" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EUDA PL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zX4UnAQNcqWi" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" name="EUDA:NameOfCompany">Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zA4bi8mmhEid" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">March 18, 2019</ix:nonNumeric></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTC1BKBCjE3c" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_fKDEp_zHby8OhBz5Ug" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember" id="Fact000679" name="EUDA:NameOfCompany">The Good Clinic Private Limited (&#8220;TGC&#8221;)</ix:nonNumeric></span>(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_90D_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zP7pQMx9TP38" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">April 8, 2020</ix:nonNumeric></span> <br />
Medical facility general practice clinic that provides holistic care for various illnesses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zGVp5NzdxIwb" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_TheGoodClinicPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by SEMA</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zjbB0SBuz2hc" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember" name="EUDA:NameOfCompany">EUDA Doctor Private Limited</ix:nonNumeric></span><br />
(&#8220;ED PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_z21LqjYwPzZ6" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">December 1, 2021</ix:nonNumeric></span> <br />
A platform solution for doctors and physicians to find, connect, and collaborate with trusted peers, specialists, and other professionals </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zVVm4RT5bkb1" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_EUDADoctorPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zLagWTm6o119" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember" name="EUDA:NameOfCompany">Kent Ridge Hill Private Limited</ix:nonNumeric></span><br />
(&#8220;KR Hill PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zmeybEREw8Fl" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">December 1, 2021</ix:nonNumeric></span> <br />
A B2B2C pharmaceutical and OTC drugs e-commerce platform to promote its drug products </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zhNEsidOtjBd" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_KentRidgeHillPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zKjP4pd0gpGd" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember" name="EUDA:NameOfCompany">Kent Ridge Health Limited</ix:nonNumeric></span> (&#8220;KRHL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br />
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zei81uu1GRzc" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">June 8, 2021</ix:nonNumeric></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_z5AP4aBUTiKj" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_KentRidgeHealthLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_za1FjQC2ABA6" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember" name="EUDA:NameOfCompany">Zukitech Private Limited (&#8220;Zukitech&#8221;)</ix:nonNumeric></span> <br />
(&#8220;ZKT PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zXGpcJ4eg2Nf" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">June 13, 2019</ix:nonNumeric></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zyQCIXcWfqib" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_ZukitechPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_z4WLm1MsH2U1" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember" name="EUDA:NameOfCompany">Super Gateway Group Limited</ix:nonNumeric></span><br />
(&#8220;SGGL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br />
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zeV5hsW0wkk3" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">April 18, 2008</ix:nonNumeric></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zao2DCaqPzEl" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SuperGatewayGroupLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zMOecuW4Fqi1" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember" name="EUDA:NameOfCompany">Universal Gateway International Pte. Ltd. (&#8220;UGI&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_900_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zKlwvd3khwCi" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">September 30, 2000</ix:nonNumeric></span> <br />
Registered capital of RMB <span id="xdx_90F_ecustom--RegisteredCapital_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_za0HkDmqDWNg" title="Registered capital"><ix:nonFraction name="EUDA:RegisteredCapital" contextRef="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zROkB5aEsc1" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">98.3</ix:nonFraction></span>% owned by SGGL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zsewKPcKPdcb" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember" name="EUDA:NameOfCompany">Melana International Pte. Ltd</ix:nonNumeric></span>.<br />
(&#8220;Melana&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_90B_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zlTxMQFCZW6h" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">September 9, 2000</ix:nonNumeric></span> <br />
Property management service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_ziXPMehyxJyc" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zDCItDPyBzsh" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember" name="EUDA:NameOfCompany">Tri-Global Security Pte. Ltd.</ix:nonNumeric></span><br />
(&#8220;Tri-Global&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zzvYqTMqIBo" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">August 10, 2000</ix:nonNumeric></span> <br />
Property security service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zk6fh7HFQ2qi" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zOOPNxBp4PV1" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember" name="EUDA:NameOfCompany">UG Digitech Private Limited (&#8220;UGD&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zNkhSBnW2Tu9" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">August 16, 2001</ix:nonNumeric></span> <br />
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_z1qwKbytOAu3" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_UGDigitechPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4aUNoMPGah" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember" name="EUDA:NameOfCompany">Nosweat Fitness Company Private Limited (&#8220;NFC&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679; <br />
&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_za8fPS5Rl4Nh" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">July 6, 2021</ix:nonNumeric></span> <br />
A virtual personal training platform for fitness enthusiasts </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4oTRX8nSFNe" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zipiYmzHA6ma" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember" name="EUDA:NameOfCompany">True Cover Private Limited (&#8220;TCPL&#8221;)</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zakOLADYtd2i" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">December 1, 2021</ix:nonNumeric></span> <br />
A B2B e-claims healthcare insurance platform </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_z5tDhmcTVXL9" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_TrueCoverPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_fKDIp_zFEmzLZg0sp3" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember" id="Fact000753" name="EUDA:NameOfCompany">KR Digital Pte. Ltd. (&#8220;KR Digital&#8221;)</ix:nonNumeric></span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br />
&#9679;<br />
&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br />
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zpXuE3yx6uOb" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">December 29, 2021</ix:nonNumeric></span> <br />
Development of software and applications </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zX8VmugoK8Se" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_KRDigitalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_fKDIp_zdUNGwzuWvB1" title="Name of company"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember" id="Fact000759" name="EUDA:NameOfCompany">Zukihealth Sdn. Bhd. (&#8220;Zukihealth&#8221;)</ix:nonNumeric></span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br />
&#9679; <br />
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Malaysian company <br />
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zD1qRMBHP42c" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember" format="ixt:datemonthdayyearen" name="EUDA:DateOfIncorporation">February 15, 2018</ix:nonNumeric></span> <br />
Distribution of health care supplement products</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zUKWwA5SnhD9" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_ZukihealthSdnBhdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned by KR Digital</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_z6JKmcmddXa8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zDswtzrNKI4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000764" xml:lang="en-US">On March 1, 2022, SEMA, the Company&#8217;s wholly owned subsidiary, sold <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ <span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-03-012022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span> (see Note 5).</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zy1YdGXNhCJ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zqN3c8c5vTv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000769" xml:lang="en-US">On April 19, 2022, the Company acquired <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-19_custom_KRDigitalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% equity interest of KR Digital Pte Ltd, (&#8220;KR Digital&#8221;), a Singapore Company, from Mr. Kelvin Chen, the Company&#8217;s Chief Executive Office (&#8220;CEO&#8221;) and shareholder for total consideration of SG$<span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-04-192022-04-19_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1</ix:nonFraction></span>. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-15_custom_KRDigitalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% equity interest of Zukihealth Sdn Bhd, (&#8220;Zukihealth&#8221;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#8217;s CEO and shareholder for total consideration of SG$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-04-152022-04-15_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1</ix:nonFraction></span>. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zTQLonPtSSH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zDcc1z2Lds37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; <span id="xdx_82F_zKuph1zEvmn3">Going concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the Company&#8217;s going concern,
the Company monitors and analyzes its cash on-hand and its operating and capital expenditure commitments. The Company&#8217;s
liquidity needs are to meet its working capital requirements, operating expenses and capital expenditure obligations. Debt financing
in the form of short-term borrowings from bank, private lender, third parties and related parties and cash generated from operations
have been utilized to finance the working capital requirements of the Company. As of December 31, 2022, the Company&#8217;s negative
working capital deficit was approximately $<span id="xdx_908_ecustom--WorkingCapital_iI_pn5n6_c20221231_zBHHUd4E5RPh" title="Working capital"><ix:nonFraction name="EUDA:WorkingCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction></span>
million, and the Company had cash and restricted cash of approximately $<span><span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20221231_zrvGci6Apb7h" title="Cash and restricted cash"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span></span>
million. The Company has experienced recurring losses from operations and negative cash flows from operating activities since 2020.
In addition, the Company had, and may potentially continue to have, an ongoing need to raise additional cash from outside sources to
fund its expansion plan and related operations. Successful transition to attaining profitable operations is dependent upon achieving
a level of revenues adequate to support the Company&#8217;s cost structure. In connection with the Company&#8217;s assessment of
going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update
(&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going
Concern,&#8221; management has determined that these conditions raise substantial doubt about the Company&#8217;s ability to
continue as a going concern within one year after the date that these consolidated financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is unable to generate sufficient funds
to finance the working capital requirements of the Company within the normal operating cycle of a twelve-month period from the date of
these financial statements are issued, the Company may have to consider supplementing its available sources of funds through the following
sources:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other available sources of financing from Singapore banks and other financial institutions or private lender;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support and credit guarantee commitments from the Company&#8217;s related parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity financing. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company can make no assurances that required financings
will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one or all of these events
does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material
adverse effect on the Company and would materially adversely affect its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements have been prepared
assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the
outcome of this uncertainty.</p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zPF0MauuHu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; <span id="xdx_829_zm7DM01RW2zd">Summary of significant accounting
policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSsB6kvupef4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zwCniqxuvEQk">Basis of presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for information pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z3DChkLqzxSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zF6ALmZSU2v3">Principles of consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the
financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been
eliminated upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A subsidiary is an entity in which the Company, directly
or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint
or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_ziE8lyISxu0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86F_zqhn5KtRmAdi">Use of estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated
financial statements include lease classification and liabilities, right-of-use assets, determinations of the useful lives and valuation
of long-lived assets, estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of deferred tax assets, other provisions and contingencies, estimated fair value of earn-out shares, prepaid forward purchase liability
and private warrants. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zHTqyqU43xT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_zRgjT4PnAlrb">Foreign currency translation and transaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements
of operations and comprehensive income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is United States
Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed in US$. The Company&#8217;s subsidiaries in
Singapore, Vietnam, and Malaysia conduct its businesses and maintain its books and records in the local currency, Singapore Dollars (&#8220;SGD&#8221;),
Vietnamese Dong (&#8220;VND&#8221;), and Malaysian Ringgit (&#8220;MYR&#8221;), as its functional currency, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, for consolidation purposes, assets and
liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation
of Financial Statement&#8221;</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average
rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are
recorded as a separate component of accumulated other comprehensive income (loss) within the statements of shareholders&#8217; equity
(deficit). Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of
cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been
made at the following exchange rates for the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zOSriTLcuXej">Schedule
of foreign currency exchange rates</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br />
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br />
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Period-end SGD: US$1 exchange rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2022-12-31_currency_SGD" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.34</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2021-12-31_currency_SGD" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.35</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2022-12-31_currency_VND" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">23,635.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2021-12-31_currency_VND" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">22,855.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end MYR: US$1 exchange rate<span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2022-12-31_currency_MYR" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.40</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateRemeasurement1" contextRef="AsOf2022-12-31_currency_MYR" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.40</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average SGD: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_currency_SGD" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.38</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_currency_SGD" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.34</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-average VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_currency_VND" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">23,409.44</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_currency_VND" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">22,935.24</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average MYR: US$1 exchange rate<span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_currency_MYR" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.39</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_currency_MYR" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.39</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right">*</td><td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify"><ix:footnote id="Footnote000820" xml:lang="en-US">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AE_zKpYTNGnrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:NonControllingInterestPolicyTextBlock"><p id="xdx_84A_ecustom--NonControllingInterestPolicyTextBlock_zYE5SHVmHsF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zGnl4f1z7Jvi">Non-controlling interests</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the Company&#8217;s non-wholly
owned subsidiaries, a non-controlling interest is recognized to reflect portion of equity that is not attributable, directly or indirectly,
to the Company. The cumulative results of operations attributable to non-controlling interests are also recorded as non-controlling interests
in the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive income (loss). Cash flows
related to transactions with non-controlling interests are presented under financing activities in the consolidated statements of cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq5C34a2q0Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zVLy6WJnWLAc">Segment reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s chief operating decision-maker
is identified as the chief executive officer who reviews financial information presented on a consolidated basis, accompanied by disaggregated
information about revenues by different revenues streams for purposes of allocating resources and evaluating financial performance. Based
on qualitative and quantitative criteria established by Accounting Standards Codification (&#8220;ASC&#8221;) 280, &#8220;Segment Reporting&#8221;,
the Company considers itself to be operating within two operating and reportable segments as set forth in Note 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zotmo0AGUb46" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z5C95HgCqS8b">Cash and restricted cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash represent cash on hand and demand deposits
placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities less
than three months. Restricted cash represents cash held in bank account from 8i which was restricted due to the incomplete
procedures of changing signers as of December 31, 2022. As of the date of the issuance of these financial statements, such
restriction has been lifted and the remaining cash held in bank account has transfer to the Company&#8217;s operating bank account.
Therefore, such restricted cash should be classified as current asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJz3RXlAubL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zPOqmiGawfKf">Accounts receivable, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with its customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial condition, credit
history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.
As of December 31, 2022 and 2021, the Company provided allowance for doubtful accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zlpZMgdcDzik" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,438</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zGHVaJ0GDus1" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,799</ix:nonFraction></span>, respectively. For the
years ended December 31, 2022 and 2021, the Company did not write off any allowance for doubtful account against the account receivable
balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_z4vpRxO1nkdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_865_zsymQJuC8us1">Other receivables</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables primarily include receivables
from investment from the Company&#8217;s Affordable Home project in Indonesia and employee advance, and refundable deposits from
third party service providers. Management regularly reviews the aging of receivables and changes in payment trends and records
allowances when management believes collection of amounts due are at risk. Accounts considered uncollectable are written off against
allowances after exhaustive efforts at collection are made. $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zEjhEcO3zEY8" title="Other receivables allowance for doubtful account"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,209,825</ix:nonFraction></span>
allowance for doubtful account related to other receivable was recorded and written off for the year ended December 31, 2022. <span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_dxL_c20211231_zsJbaTAAdVvd" title="Other receivables allowance for doubtful account::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">Nil</span></span>
allowance for doubtful account related to other receivable was recorded for the year ended December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:PrepaidExpensesAndOtherAssetsPolicyTextBlock"><p id="xdx_84E_ecustom--PrepaidExpensesAndOtherAssetsPolicyTextBlock_zMunaeL9wrni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zykHIuOSgNul">Prepaid expenses and other current assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
primarily include prepaid expenses paid to services providers, and other deposits. Management regularly reviews the aging of such
balances and changes in payment and realization trends and records allowances when management believes collection or realization of
amounts due are at risk. Accounts considered uncollectable are written off against allowances after exhaustive efforts at collection
are made. As of December 31, 2022 and 2021, <span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20221231_zUw43t5ro5Aj" title="Allowance"><span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20211231_zrGIS7vVUmQd" title="Allowance"><ix:nonFraction name="EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
allowance for doubtful account related to prepaid expenses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zXARoPszRa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zaRi3G7tDwil">Property and equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value.
The estimated useful lives are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:PropertyPlantAndEquipmentsTextBlock"><p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z0h1r7koBEI2">Schedule
of property and equipment useful lives</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected useful lives</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MedicalEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> </span>years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Shorter of the lease term or 5 years</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zLzJMkKXwnGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost and related accumulated depreciation of assets
sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations
and comprehensive income (loss). Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals
and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of
depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows
that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the
carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. </span>For the years ended
December 31, 2022 and 2021, there was <span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20220101__20221231_z6WGodJ7oX5h" title="Impairment of property and equipment"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20210101__20211231_zFIoeZHOdOic" title="Impairment of property and equipment"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2022-01-01to2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment of property and equipment recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_846_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4QpciiqLaml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zYQ9S0iEeFT8">Intangible assets, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Purchased intangible assets
are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue
to be amortized over the Company&#8217;s best estimate of its useful life as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B5_ztDHNIRRQgA">Schedule
of intangible assets net</span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Categories</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">6</ix:nonNumeric></span> years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zehZDb2Ho9u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company amortized the
intangible assets using the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up in accordance
with ASC Topic 350 &#8220;<i>Intangibles - Goodwill and Other</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Separately identifiable intangible
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting
from the use of the asset and its eventual disposition. Measurement of any impairment loss for identifiable intangible assets is based
on the amount by which the carrying amount of the assets exceeds the fair value of the assets. $<span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zjvw1S4emLo" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,787</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20210101__20211231_zFcl6YU05hN" title="Impairment of intangible assets::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0868">nil</span></span> impairment of intangibles
assets was recorded for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zjKgluIGYFj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline"><span id="xdx_86F_zCo9PuvNtMii">Goodwill</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of operations and comprehensive income (loss). Impairment losses on goodwill
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the carrying value of intangible
assets not subject to amortization, including goodwill, to determine whether impairment may exist annually or more frequently if events
and circumstances indicate that it is more likely than not that an impairment has occurred. Management has determined that the Company
has two reporting units within the entity at which goodwill is monitored for internal management purposes. The Company adopted ASU 2017-04
in 2022, which primary goal is to simplify the goodwill impairment test and provide cost savings for all entities. This is accomplished
by removing the requirement to determine the fair value of individual assets and liabilities in order to calculate a reporting unit&#8217;s
&#8220;implied&#8221; goodwill under current GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in ASU 2017-04 eliminate Step 2 of
the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value
of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting
unit&#8217;s carrying amount exceeds its fair value. If fair value exceeds the carrying amount, no impairment should be recorded. Any
loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Impairment losses on goodwill cannot
be reversed once recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When measuring a goodwill impairment loss, an entity
should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit. The ASU contains
an illustration of the simultaneous equations method to demonstrate this, which reflects a deferred tax benefit from reducing the carrying
amount of tax-deductible goodwill relative to the tax basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An entity may still perform the optional qualitative
assessment for a reporting unit to determine if it is more likely than not that goodwill is impaired. However, this ASU eliminates the
requirement to perform a qualitative assessment for any reporting unit with zero or negative carrying amount. Therefore, the same one-step
impairment assessment will apply to all reporting units. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing qualitative assessment on the two
reporting units and determine that it is more likely than not that the fair value of each reporting unit is less than its carrying amount.
Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zxdgRoAYe1c3" title="Impairment loss on goodwill"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,229</ix:nonFraction></span> was recognized for the year ended
December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended December 31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zyAO3IcI2ZW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zzN6hD19dQzg">Impairment for long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 360-10, Long-lived assets,
including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a
significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets
are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use
of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment
is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows
approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, $<span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20220101__20221231_zbzqUjYEcIoc" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and <span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_dxL_c20210101__20211231_ziwZdHFyfgN4" title="Impairment of long-lived assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0878">nil</span></span> impairment of long-lived assets was recognized, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:WarrantsPolicyTextBlock"><p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zoHy4sXBp72b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zCKIbY0JNRSj">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s
own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside
of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For issued or
modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of
equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that
its warrants qualify for equity accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
completion of the business combination, all of 8i&#8217;s public and private warrants remain outstanding were replaced by the Company&#8217;s
public and private warrants. The Company treated such warrants replacement as a warrant modification and no  incremental fair value
was recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock"><p id="xdx_84D_ecustom--ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_zAbr4mxqpXwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_z0xs9mPGPiI1">Forward Purchase Receivables and Prepaid Forward
Purchase Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The
Company recorded Forward Purchase Receivables on its consolidated balance sheets of $<span id="xdx_90C_ecustom--ForwardPurchaseReceivables_iI_c20221231_zufvipqGptB7" title="Forward purchase receivables"><ix:nonFraction name="EUDA:ForwardPurchaseReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,892,527</ix:nonFraction></span>
as of December 31, 2022 to account for the Prepayment Amount of the Forward Purchase Agreement, as discussed in Note 11. The
Prepayment Amount will be held in a deposit account until the Valuation Date (the second anniversary of the closing of the Business
Combination, subject to certain acceleration provisions). At the Maturity Date, the Sellers are entitled to received $2.50 per
Recycled Shares (&#8220;Maturity Consideration&#8221;) in cash or in shares. As of December 31, 2022, no shares were sold after
Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In
connection with the Forward Purchase Agreement, the Company recognized a liability in accordance with ASC 480-10-25-8 as the Company
has the obligation to pay cash to settle the maturity consideration, referred to herein as the &#8220;prepaid forward purchase
liability&#8221; on its consolidated balance sheets of $<span id="xdx_909_ecustom--PrepaidForwardPurchaseLiability_iI_c20221231_zgkSaEqRPUdh" title="Purchase liability"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></span>
as of December 31, 2022. Refer to Note 11 for further detail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zHa2YQMTAD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zQWedSe4xpl2">Revenue recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the revenue accounting requirements
of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;Accounting Standards
Codification (&#8220;ASC&#8221;) 606&#8221;). The core principle underlying the revenue recognition of this ASU allows the Company to
recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and
determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers
to a customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To achieve that core principle, the Company applies
five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for a contract with a customer
when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial
substance and collectability is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue recognition policies for each type of revenue
stream are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates on a unified technology
health care platform which provide a full continuum of healthcare services integrated with healthcare data analytics to drive
improved outcomes for patients. The Company operates the medical services on a business-to-business (B2B) platform, and serves the
corporate customers involved in various industries. The Company is primarily generating revenue on a per healthcare visit basis for
specialty medical visits for specialist treatment such as cardiology, dermatology and etc, at the time which the single performance obligation was satisfied. Such fees are paid by the corporate
customers on behalf of their employees. <span style="background-color: white">The Company generally bills their corporate customers
for the healthcare visit services on a weekly basis, or in arrears depending on the service, with payment terms generally between 30
to 90 days. There are not significant differences between the timing of revenue recognition and billing. Consequently, the Company
has determined that the Company&#8217;s contracts do not include a financing component. </span>Revenue is recognized in an amount
that reflects the consideration that is expected in exchange for the service at a point in time at the time of the visit. In
addition, the Company&#8217;s contracts do not generally contain refund provisions for fees earned related to services
performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for medical service revenue on
a gross basis as the Company is acting as a principal in these transactions and is responsible for fulfilling the promise to provide the
specified services, which the Company has control of the services and has the ability to direct the service providers to be performed
to obtain substantially all the benefits. In making this determination, the Company also assesses whether it is primarily obligated in
these transactions, is subject to inventory risk, has latitude in establishing prices, or has met several but not all of these indicators
in accordance with ASC 606-10-55-36 through 40.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the medical services revenue
when the control of the specified services is transferred to its customer, which at a point in time at the time after completion of the
visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also operates on a general practice clinic
and generating such revenue on a per healthcare visit basis. Revenues are recognized when the visits are completed at a point in time
at the time of the visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company purchases, sells, and installs facial
recognition and temperature measurement monitor system to corporate customer, where the product and the installation are interrelated
and are not capable of being distinct since the customer cannot benefit from the product or installation either on its own. The Company
recognized the products revenue when control of the product is passed to the customer, which is the point in time that the customers are
able to direct the use of and obtain substantially all of the economic benefit of the goods after the installation by the Company&#8217;s
technician. The transfer of control typically occurs at a point in time based on consideration of when the customer has an obligation
to pay for the goods, and physical possession of, legal title to, and the risks and rewards of ownership of the goods has been transferred,
and the customer has accepted the goods. Revenue is recognized net of estimates of variable consideration, including product returns,
customer discounts and allowance. Historically, the Company has not experienced any significant returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied over a period of
time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides property management services
in shopping malls, business office building, or residential apartments to all tenants and property owners. Property management services
include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional
services and also include security property management services provided to all tenants and property owners. Each of the two services
is within separate agreements. The Company identified common area property management services as a single performance obligation as the
kinds of service in the contract are not capable of being distinct and identified the security management services as another single performance
obligation as there is only one service that is to provide security services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the common area property management
revenue and security property management revenue on a straight-line basis over the terms of the common area property management agreement
and security property management agreement, generally over one year period because its customer simultaneously receives and consumes the
benefits provided by the Company throughout the performance obligations period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to apply the practical expedient
to expense costs as incurred for incremental costs to obtain a contract when the amortization period would have been one year or less.
As of December 31, 2022 and 2021, the Company did not have any contract assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized advance payments from its customer
prior to revenue recognition as contract liability until the revenue recognition performance obligation are met. As of December 31, 2022
and 2021, the Company did not have any contract liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zwogmTEuY6ql">Schedule
of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,001,439</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,010,837</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; general practice</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,794</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,712</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practice (related parties)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,640</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,065,368</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,728,189</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,046</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,841</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management service &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceCommonAreaManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,335</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceCommonAreaManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,508,663</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management service &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceSecurityManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,960</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceSecurityManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,857</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management service</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,764,295</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,520</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,840,709</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,544,550</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zwNQtZ3F5UWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cost of revenues</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical supplies
purchased and medical service was provided by Cadence Health Pte. Ltd., a related party, prior to March 2022. Medical supplies purchased
and medical service provided by the third party service providers were insignificant prior to March 2022. Beginning in April 2022, cost
of revenues mainly consists of medical supplies purchased and medical service are provided by third party service providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical product
or equipment purchased for resale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of labor expenses
incurred attributable to property management service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of cost of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfCostOfRevenueTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zIQd8Hn75Yi9">Schedule
of cost of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,995,778</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,849</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; specialty care (related party)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,499</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,349,702</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practices</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,549</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,908</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,532,826</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,824,459</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,391</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_ProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,202</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management services &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesCommonAreaManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,210,703</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesCommonAreaManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,461,981</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management services &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesSecurityManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,593</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesSecurityManagementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">846,555</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management services</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_custom_ProductMangementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,894,296</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31_custom_ProductMangementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,308,536</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cost of revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,486,513</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,300,197</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_z0IzxNUwrZ11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zjMJr2QoqkRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zr5XE1q82T8i">Advertising costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising is mainly through online and offline promotion
activities. Advertising costs amounted to $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zszyCFvLJSLj" title="Advertising cost"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,795</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_c20210101__20211231_zsS5Uxd9nK9j" title="Advertising cost"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,361</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7X9jQrXD66f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zpOYfJHLeqJh">Research and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses include salaries
and other compensation-related expenses to the Company&#8217;s research and product development personnel, and related expenses for the
Company&#8217;s research and product development team. Research and development expenses amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zspS1u46hib6" title="Research and Development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,209</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zxLEZpIcrsY9" title="Research and Development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,265</ix:nonFraction></span> for the years
ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:DefinedContributionPlanPolicyTextBlock"><p id="xdx_84D_ecustom--DefinedContributionPlanPolicyTextBlock_zz7xjkCOkr5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_862_zCUiQA3XaXMi">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full-time employees of the Company are entitled
to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages
of the employees&#8217; respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and
make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_z0ATFRFJrw8f" title="Employee expenses"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,591</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231_zXCCuwdZ0eO9" title="Employee expenses"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">574,535</ix:nonFraction></span>
for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The related contribution plans include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Singapore subsidiaries</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Central Provident Fund (&#8220;CPF&#8221;) &#8211;
<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--CentralProvidentFundMember_zUu8bYl0NPrk" title="Employee plan description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CentralProvidentFundMember" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription">17.00% based on employee&#8217;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase</ix:nonNumeric></span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Skill Development Levy (&#8220;SDL&#8221;) &#8211;
<span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zJvENAmvNVCg" title="Employee plan description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription">up to 0.25% based on employee&#8217;s monthly salary capped $<span id="xdx_906_eus-gaap--SalariesAndWages_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zlsgb4ysvVoj" title="Monthly salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.3</ix:nonFraction></span> (SGD <span id="xdx_90C_eus-gaap--SalariesAndWages_pn4n6_uSGD_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zO9j3tWmsHil" title="Monthly salary"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="SGD">11.25</ix:nonFraction></span>)</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vietnam subsidiary</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Social Insurance Fund (&#8220;SIF&#8221;) &#8211;
<span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zWfExI0ZcJOl" title="Employee plan description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SocialInsuranceFundMember" name="us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription">20% based on employee&#8217;s monthly salary</ix:nonNumeric></span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Trade Union Fee &#8211; <span id="xdx_907_ecustom--TradeUnionFeePercentage_iI_pid_dp_c20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zL0wDN9ABgB" title="Trade union fee"><ix:nonFraction name="EUDA:TradeUnionFeePercentage" contextRef="AsOf2022-12-31_custom_SocialInsuranceFundMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.00</ix:nonFraction>%</span> of SIF</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:GoodsAndServicesTaxesPolicyTextBlock"><p id="xdx_84F_ecustom--GoodsAndServicesTaxesPolicyTextBlock_ztdAswiUWax5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zk8Bn1NLCiC6">Goods and services taxes (&#8220;GST&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue represents the invoiced value of service,
net GST. The GST are based on gross sales price. GST rate is generally 7% in Singapore. Entities that are GST general taxpayers are allowed
to offset qualified input GST paid to suppliers against their output GST liabilities. Net GST balance between input GST and output GST
is recorded in tax payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zkrVaXBFCHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_z96DWJzY5po1">Income taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance
with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are
non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Deferred tax
is calculated using the balance sheet liability method in respect of temporary differences arising from differences between the carrying
amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis. In principle, deferred tax
liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable
that taxable income will be utilized with prior net operating loss carried forwards using tax rates that are expected to apply to the
period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when
it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion or all of the deferred tax assets will not be utilized. Current income taxes
are provided for in accordance with the laws of the relevant tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit
only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is <span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zk2Ix9U7GPQk" title="Income tax likelihood description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">greater than 50% likely of being realized
on examination</ix:nonNumeric></span>. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. No penalties and
interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021. <span style="background-color: white">As
of December 31, 2022, the tax returns of the Company&#8217;s Singapore entities for the calendar year from 2019 through 2022 remain open
for statutory examination by Singapore tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognize interest and penalties related to unrecognized tax
benefits, if any, on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties
are included on the related tax liability line in the consolidated balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts much of its business activities
in Singapore and is subject to tax in its jurisdiction. As a result of its business activities, the Company&#8217;s subsidiaries file
separate tax returns that are subject to examination by the foreign tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zLbU2af5srSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zJZj3giURid">Comprehensive income (loss)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive income (loss) consists of two components,
net income and other comprehensive income. Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under
GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net income. Other comprehensive income (loss) consists
of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zMCDFPoIvl4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zzedsnCQU4vf">(Loss) earnings per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes (loss) earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is
measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect
on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e.,
those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates basic and diluted (loss)/earnings
per share as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zRuz5Eat8IOc" style="display: none">Schedule
of basic and diluted earnings per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Years Ended<br />
December 31</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net (loss) income</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,949,246</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less: Net (income) loss attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,124</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,567</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Net (loss)/income attributable to common shareholders, basic</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,884,122</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,829</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average number of shares outstanding, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,029,656</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,253,333</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">(Loss)/Earnings per share, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.07</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.09</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zuN25CFHeBDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of December
31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants are convertible into <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zOB5W99vo8ma" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,725</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zk0BBegFiS8l" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,458,625</ix:nonFraction></span>
of the Company&#8217;s ordinary shares, respectively, were not included in the computation of dilutive loss per share because the inclusion
of such convertible notes and warrants would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzVOHzfqt77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zbaSlXmfzUo">Fair value measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received
for an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Valuation
techniques maximize the use of observable inputs and minimize the use of unobservable inputs. When determining the fair value measurements
for assets and liabilities, we consider the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability. The following summarizes the three levels of inputs required to
measure fair value, of which the first two are considered observable and the third is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Unadjusted quoted prices in active markets
for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Unobservable inputs that are supported by
little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value for certain assets and liabilities
such as cash and restricted cash, accounts receivable, net, other receivables, prepaid expenses and other current assets, loan to third-party,
short-term loans, promissory note, convertible notes, accounts payable, other payables and accrued liabilities, and tax payables have
been determined to approximate carrying amounts due to the short maturities of these instruments. The Company believes that its long-term
loan to third party approximates the fair value based on current yields for debt instruments with similar terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"><p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zkN130Ffe2af" style="display: none">Schedule
of fair value hierarchy of financial liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value at</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Fair Value Measurement at</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Prepaid forward purchase liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" title="Prepaid forward purchase liabilities" style="width: 18%; text-align: right"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" title="Prepaid forward purchase liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" title="Prepaid forward purchase liabilities" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" title="Prepaid forward purchase liabilities" style="width: 10%; text-align: right"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zNGpWR5NLY12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zBcQXMqTTOY2" style="display: none">Schedule of reconciliation of financial
liability measured at fair value on a recurring basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilitiesBalance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,409,550</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Change in fair value of prepaid forward purchase liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,503</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilitiesBalance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zoLBIGo0IqXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z6axbXx4rODj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_861_zbRXPdj5KhW6">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company accounts for leases in accordance with ASC 842. </span>The Company entered into two agreements as a lessee to lease office equipment
for general and administrative operations. If any of the following criteria are met, the Company classifies the lease as a finance lease:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease term is for 75% or more of the remaining economic life of the underlying asset, unless the commencement date falls within the last 25% of the economic life of the underlying asset;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The present value of the sum of the lease payments equals or exceeds 90% of the fair value of the underlying asset; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Leases that do not meet any
of the above criteria are accounted for as operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company combines lease
and non-lease components in its contracts under Topic 842, when permissible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Finance
and operating lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. Since the implicit rate for the Company&#8217;s leases is not readily determinable,
the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present
value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized
basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its finance or operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company
has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term
of twelve months or less. Its leases generally do not provide a residual guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
finance or operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease
term for operating lease. Meanwhile, the Company recognizes the finance leases ROU assets and interest on an amortized cost basis. The
amortization of finance ROU assets is recognized on an accretion basis as amortization expense, while the lease liability is increased
to reflect interest on the liability and decreased to reflect the lease payments made during the period. Interest expense on the lease
liability is determined each period during the lease term as the amount that results in a constant periodic interest rate of the </span>office
equipment <span style="background-color: white">on the remaining balance of the liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset
may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from
the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows. For the years ended December 31, 2022 and 2021, </span>the Company did not recognize impairment loss on its finance
and operating lease ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:RelatedPartyPolicyTextBlock"><p id="xdx_842_ecustom--RelatedPartyPolicyTextBlock_zW3ikgaDVMkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zkWRq3C9mr3e">Related parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject
to common control or common significant influence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"><p id="xdx_844_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zMhejxndWpM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zNRPmrsYJrIc">Recent accounting pronouncements not yet adopted</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging
growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the
adoption of these accounting standards until they would apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, which
is an update to ASU Updated No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive accounting
model on revenue recognition for contracts with customers. The amendments in this update require that an entity (acquirer) recognize and
measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective
for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted,
including adoption in an interim period. The Company has adopted this standard on January 1, 2023, and the adoption did not have a material
impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the FASB issued ASU 2019-05, which is
an update to ASU Update No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured
at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial
Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting
for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized
cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The
amendments in this Update address those stakeholders&#8217; concerns by providing an option to irrevocably elect the fair value option
for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase
comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets.
Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13
while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which
to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies
applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after
December 15, 2022. In March 2022, the FASB issued ASU No. 2022-02, which is to (1) eliminate the accounting guidance for TDRs by creditors
in Subtopic 310-40, Receivables&#8212;Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan
refinancings and restructurings by creditors when a borrower is experiencing financial difficulty, and (2) disclose current-period gross
write offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, Financial
Instruments&#8212;Credit Losses&#8212;Measured at Amortized Cost. ASU 2019-05 is effective for the Company for annual and interim reporting
periods beginning January 1, 2023 as the Company is qualified as an emerging growth company. The Company has adopted this standard on
January 1, 2023, and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfmIHjiMvRu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zaJ77kGpf1n8">Recently adopted accounting pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, &#8220;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. The amendments in this Update simplify the accounting for income
taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments
in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years
beginning after December 15, 2022. Early adoption of the amendments is permitted, including adoption in any interim period for (1) public
business entities for periods for which financial statements have not yet been issued and (2) all other entities for periods for which
financial statements have not yet been made available for issuance. An entity that elects to early adopt the amendments in an interim
period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity
that elects early adoption must adopt all the amendments in the same period. The Company has adopted this standard on January 1, 2022,
and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the Financial Accounting Standards
Board issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities
and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for
convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer
conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment.
The Company early adopted this ASU on January 1, 2022, and the adoption did not have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-08, &#8220;Codification
Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs&#8221;. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021.
Early adoption was permitted, including adoption in an interim period. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10, &#8220;Codification
Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve the codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed.
The amendments also clarify guidance so that an entity can apply the guidance more consistently. ASU 2020-10 is effective for the Company
for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or
interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively.
An entity should apply the amendments at the beginning of the period that includes the adoption date. The adoption of this standard on
January 1, 2022 did not have a material impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive income (loss) and statements of cash flows.</p>
<!-- Field: Split-Segment; Name: 003 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ReverseRecapitalizationTextBlock"><p id="xdx_802_ecustom--ReverseRecapitalizationTextBlock_zbr9crjZOD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; <span id="xdx_827_zm4Ug66kEmEa">Reverse Recapitalization</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022, the Company consummated the
Business Combination contemplated by the SPA between 8i, EHL, Watermark, and Kwong Yeow Liew, dated April 11, 2022 and amended May 30,
2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination between 8i and EHL was effected by the
purchase by 8i of all of the issued and outstanding shares of EHL from Watermark, resulting in EHL becoming a wholly owned subsidiary
of 8i.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Upon the consummation
of the Business Combination, the following events contemplated by the SPA occurred, based on EUDA&#8217;s capitalization as of November
17, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20221117_zl1rg65nScSj" title="Ordinary shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221117_zlMHyCCRhM2a" title="Ordinary shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding shares of EHL were converted into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20221116__20221117_zGzbKo7wh5Sk" title="Converted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></span> shares of the Company&#8217;s <span id="xdx_90A_eus-gaap--CommonStockNoParValue_iI_do_c20221117_z6xJXm9DpvYl" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-11-17" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span> par value ordinary shares after giving effect to the exchange ratio of <span id="xdx_906_ecustom--ExchangeRatioPerShare_uUSDPShares_c20221116__20221117_zcPGHtg6aWJf" title="Exchange ratio"><ix:nonFraction name="EUDA:ExchangeRatioPerShare" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.33</ix:nonFraction></span> (&#8220;Exchange Ratio&#8221;); and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the entitlement of <span id="xdx_901_eus-gaap--ExcessStockSharesIssued_iI_c20221117_zQsXMCyjvlM8" title="Earnout shares"><ix:nonFraction name="us-gaap:ExcessStockSharesIssued" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> shares (&#8220;Earnout Shares&#8221;) of the Company&#8217;s no par value ordinary shares  issued to the Seller subject to the following four triggering events:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zLL1ZnV9BSq1" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Fifteen Dollars ($<span id="xdx_90C_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zTRb6G0BGPIl" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-17_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span>) after the Closing Date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zPTwYDZFtCOk" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17_custom_SecondAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Twenty Dollars ($<span id="xdx_903_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_z8t70shXeXW2" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-17_custom_SecondAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z5Yylc7ZgxFa" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zf0MctxrLzN1" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,100,000</ix:nonFraction></span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zHd7pW60YWxe" title="Net income"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,600,000</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zteS9tPEwaW2" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z1mvoCyzIofg" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,100,000</ix:nonFraction></span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z2EiWSDrhp" title="Net income"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,100,000</ix:nonFraction></span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In connection
with the closing the Business Combination:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90D_eus-gaap--CommonStockNoParValue_iI_do_c20221117_zB6icRiCHLBk" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-11-17" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span> par value public ordinary shares of <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20221117_zlx85hd0PEuk" title="Public ordinary shares"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,591,545</ix:nonFraction></span>, net of the redemption of <span id="xdx_90E_eus-gaap--TemporaryEquitySharesIssued_iI_c20221117_ztrqDzstJkka" title="Redemption shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,033,455</ix:nonFraction></span> shares of Company&#8217;s no par value ordinary shares, remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90D_ecustom--PrivateOrdinarySharesNoParValue_iI_do_c20221117_z9ok4XwrjGW2" title="Private ordinary shares, par value"><ix:nonFraction name="EUDA:PrivateOrdinarySharesNoParValue" contextRef="AsOf2022-11-17" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span> par value private ordinary shares of <span id="xdx_900_ecustom--PrivateOrdinarySharesOutstanding_iI_c20221117_z0Cn5NB7sB52" title="Private ordinary shares, outstanding"><ix:nonFraction name="EUDA:PrivateOrdinarySharesOutstanding" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">292,250</ix:nonFraction></span> remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90F_ecustom--FounderSharesNoParValue_iI_do_c20221117_zpC1DFH1mZ1a" title="Founder shares, par value"><ix:nonFraction name="EUDA:FounderSharesNoParValue" contextRef="AsOf2022-11-17" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span> par value founder shares of <span id="xdx_90F_ecustom--FounderSharesOutstanding_iI_do_c20221117_zdc0DNfpavY9" title="Founder shares, outstanding"><ix:nonFraction name="EUDA:FounderSharesOutstanding" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,156,250</ix:nonFraction></span> remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s rights, consisting of <span id="xdx_90D_ecustom--PublicRightsShares_iI_do_c20221117_zMv0Vnha75J2" title="Public rights shares"><ix:nonFraction name="EUDA:PublicRightsShares" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> public rights and <span id="xdx_906_ecustom--PrivateRightsShares_iI_do_c20221117_zK6X1bDKNf34" title="Private rights shares"><ix:nonFraction name="EUDA:PrivateRightsShares" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">292,250</ix:nonFraction></span> private rights, automatically converted into an aggregate of <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_do_c20221116__20221117_z5sJxeneivNa" title="Converted shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">891,725</ix:nonFraction></span> of the Company&#8217;s no par value ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--BusinessAcquisitionAxis__custom--BusinessCombinationMember_z96J0QkqAHk3" title="Ordinary shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-11-17_custom_BusinessCombinationMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of the Company&#8217;s no par value ordinary shares were issued to a service provider in connection with the business combination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zerllM4TxsJe" title="Ordinary shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-11-17_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span> shares of the Company&#8217;s no par value ordinary shares were issued to a service provider in connection with the closing of transactions contemplated pursuant to certain share purchase agreement. Such issuance of the ordinary share serves the purpose of securing the repayment of $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20221116__20221117_zT4OZU8qZZ4a" title="Repayments of convertible promissory note"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> convertible promissory note to the service provider;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_zBeeqGaFG5A7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued and outstanding immediately following the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B7_zVgBvJgIzF69" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of shares issued and outstanding reverse recapitalization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zb0lTmQofba6" style="border-bottom: Black 1.5pt solid; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_z2g0qVWdUx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,073,500</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RedemptionOfOrdinaryShares_z69JroSkZSC6" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:RedemptionOfOrdinaryShares" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">6,033,455</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ConversionOfStockSharesConverted1_zVcyOG4GNiY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">891,725</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zAq1VTpujEE7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued to service providers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_zMYXv5SiTefh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of EHL ordinary shares into 8i ordinary shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_z7rRd8Ocj1e9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares outstanding</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,191,770</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_z29Zb4pG6xHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EHL
was determined to be the accounting acquirer given EHL effectively controlled the combined entity after the SPAC Transaction. The transaction
is not a business combination because 8i was not a business. The transaction is accounted for as a reverse recapitalization, which is
equivalent to the issuance of shares by EHL for the net monetary assets of 8i, accompanied by a recapitalization. EHL is determined as
the accounting acquirer and the historical financial statements of EHL became the Company&#8217;s historical financial statements, with
retrospective adjustments to give effect of the reverse recapitalization. The net assets of 8i were recognized as of the closing date
at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Merger are those of EHL and EHL&#8217;s
operations are the only ongoing operations of EHL. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In connection
with the Reverse Recapitalization, the Company raised approximately $<span id="xdx_908_ecustom--ProceedsFromReverseRecapitalization_pn5n6_c20221116__20221118_zG1meDfBrGfl" title="Proceeds from the Reverse Recapitalization"><ix:nonFraction name="EUDA:ProceedsFromReverseRecapitalization" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million of proceeds, presented as cash flows from financing activities,
which included the contribution of approximately $<span id="xdx_90E_ecustom--FundsHeldInTrustAccount_pn5n6_c20221116__20221118_zsSJCLygQ6L6" title="Funds held in trust account"><ix:nonFraction name="EUDA:FundsHeldInTrustAccount" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">87.1</ix:nonFraction></span> million of funds held in 8i&#8217;s trust account, approximately $<span id="xdx_90D_ecustom--FundsHeldInOperatingCashAccount_pn5n6_c20221116__20221118_zNkgJLfaW1bj" title="Funds held in operating cash account"><ix:nonFraction name="EUDA:FundsHeldInOperatingCashAccount" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of
cash held in 8i&#8217;s operating cash account, net of approximately $<span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20221116__20221118_zsBAqBTbunOf" title="Amount paid to redeem public shares"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">60.8</ix:nonFraction></span> million paid to redeem <span id="xdx_90E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20221116__20221118_zK1FPIE4gAa2" title="Redeem public shares"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,033,455</ix:nonFraction></span> public shares of 8i&#8217;s
ordinary shares, approximately $<span id="xdx_909_eus-gaap--PaymentsOfFinancingCosts_pn5n6_c20221116__20221118_zKWDNB4YQfL4" title="Payments of transaction costs"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million in transaction costs incurred by 8i, approximately $<span id="xdx_909_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_pn5n6_c20221116__20221118_zGrn3atMY60j" title="Payments of forward purchase agreements"><ix:nonFraction name="us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">21.9</ix:nonFraction></span> million prepayment of two forward
purchase agreements, and repayments of a promissory note in the amount of $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_pn4n6_c20221116__20221118_zgOIUP1sDwA" title="Repayments of promissory note related party"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million issued to 8i&#8217;s related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfFinancialStatementsOfReverseRecapitalization"><p id="xdx_893_ecustom--ScheduleOfFinancialStatementsOfReverseRecapitalization_zsrzfqySb78h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table reconcile the elements of the Reverse Recapitalization to the consolidated statements of cash flows and the changes in shareholders&#8217;
equity (deficit):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zs643UtKtaB4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of financial statements of reverse recapitalization</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221116__20221118_zOxJtSiMfxCd" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November 18, 2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FundsHeldInTrustAccount_zehMN4o63yAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in 8i&#8217;s trust account</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:FundsHeldInTrustAccount" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,074,185</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FundsHeldInOperatingCashAccount_zt01GCUOfkn2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Funds held in 8i&#8217;s operating cash account</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:FundsHeldInOperatingCashAccount" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,499</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_iN_di_zzzzDCZVY0F5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: amount paid to redeem public shares of 8i&#8217;s ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,839,550</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_iN_di_zpx87L2Bo0d3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payments of transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,965,646</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_iN_di_zA7C4IHEYhW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: payments of forward purchase agreements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,892,527</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_zSoD2cgzRQia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: repayments of promissory note &#8211; related party of 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromReverseRecapitalizations_ztFWhTtAiet" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:ProceedsFromReverseRecapitalizations" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,324,961</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromUnpaidDeferredUnderwritingFee_iN_di_zWqlMe7o9Z7i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unpaid deferred underwriting fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:ProceedsFromUnpaidDeferredUnderwritingFee" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,113,125</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromUnpaidTransactionCostsIncurred_iN_di_zgIdS356acO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unpaid transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:ProceedsFromUnpaidTransactionCostsIncurred" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,600</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsForMergerRelatedCosts_iN_di_z2I5Gil7nk79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForMergerRelatedCosts" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,305,580</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--NoncashNetAssetsAssumedValue_zX0HEBOPqic6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Add: non-cash net assets assumed from 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="EUDA:NoncashNetAssetsAssumedValue" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,387,803</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfOrdinarySharesUponTheReverseRecapitalization_zXq9Lb4MbIEj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net contributions from issuance of ordinary shares upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:IssuanceOfOrdinarySharesUponTheReverseRecapitalization" contextRef="From2022-11-162022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,911,459</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_ziutALg4KB1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares and corresponding capital amounts and all
per share data related to EHL&#8217;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the <span style="background-color: white">Exchange Ratio</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:DispositionOfSubsidiariesTextBlock"><p id="xdx_800_ecustom--DispositionOfSubsidiariesTextBlock_zKMBLSoqlxdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_82F_zOiVGXeRmOC1">Disposition of Subsidiary</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline">Disposition of TGC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 1, 2022, SEMA, the Company&#8217;s wholly
owned subsidiary, sold <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zojCpiWNxB9a" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-02_custom_SEMAAgreementMember_custom_TheGoodClinicPrivateLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity interest in TGC to an unrelated individual for a total consideration of SG$ <span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220227__20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_zU32cBat6QA8" title="Consideration received"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-02-272022-03-02_custom_SEMAAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1.0</ix:nonFraction></span> (&#8220;TGC
transaction&#8221;). TGC is not a significant subsidiary and the disposition of all of the equity interests in TGC did not constitute
a strategic shift that would have a major effect on the Company&#8217;s operations and financial results. As a result, the results of
operations for TGC were not reported as discontinued operations under the guidance of ASC 205 &#8220;<i>Presentation of Financial Statements.</i>&#8221;
For the year ended December 31, 2022, the Company recognized a gain of $<span id="xdx_900_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_z1eew5RitL97" title="Gain loss on disposal of deficit interest"><ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="From2022-01-012022-12-31_custom_SEMAAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,055</ix:nonFraction></span> on the disposal of all of the deficit interests in TGC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsAndNontradeReceivableTextBlock"><p id="xdx_802_eus-gaap--AccountsAndNontradeReceivableTextBlock_zmGbnm6GsoY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 6 &#8211; <span style="background-color: white"><span id="xdx_826_zu9ssnZ29rO6">Accounts
receivable, net</span></span></b></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zMhK0HSTMdbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BC_zHzDNUZ44Kuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of accounts receivable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zcMItTl2T9xl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br />
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_z3ijY3QGHvng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br />
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCztie_z3ep6qxzal53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts receivable<span id="xdx_F43_zWaGns4rARcb">*</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2022-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,048,941</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2021-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,883,115</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCztie_zRK6tXjbUUog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,438</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,799</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCztie_zkvPItfGhR1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,851,503</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,802,316</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zs9ul92a2oP" style="width: 35pt; text-align: right">*</td><td id="xdx_F18_zJxNpVRPZkM1" style="text-align: justify"><ix:footnote id="Footnote001173" xml:lang="en-US">As of December 31, 2022 and 2021, accounts receivable of up to approximately $<span id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"><span id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></ix:nonFraction></span></span> million (SGD
<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"><span id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="SGD"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="SGD">0.8</ix:nonFraction></ix:nonFraction></span></span> million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A5_zPN22OAMO2o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><p id="xdx_891_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_ztLygfgLjhBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from account receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zMTDzXo5MK5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of movements of allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20220101__20221231_zcovL1rvmRAg" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,799</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20210101__20211231_zcvGX2FYAFPf" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,898</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Addition</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20220101__20221231_z8XAct8nYU8j" title="Addition" style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,156</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20210101__20211231_z5DdUW9hgWq7" title="Addition" style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,804</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20220101__20221231_za86uPhprpbf" title="Exchange rate effect" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20210101__20211231_znwo3yjlZrM3" title="Exchange rate effect" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">903</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20220101__20221231_zpF4Zltoi4Oc" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,438</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20210101__20211231_zVJIDX9L3fo1" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,799</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zYIOiCa78Gkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FinancingReceivablesTextBlock"><p id="xdx_806_eus-gaap--FinancingReceivablesTextBlock_z5HnZ5pwRvYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><b>Note
7 </b></span><b>&#8211; <span style="background-color: white"><span id="xdx_828_zhvb8czeQFGl">Other receivables</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="background-color: white"><span>&#160;</span></span></b></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" continuedAt="ConU001205-01" escape="true" name="us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_gL3SOCLFFRCTT-SYHD_zLU1wdUknP36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8B4_zm2o4zebu17c" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zDKDXeHiu4z4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z99WFoJqh6Fg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DivestmentReceivable_iI_zJLBvk7YMAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4E_zsEu6CSI4vDd" style="width: 60%; text-align: left">Receivable from divestment (1)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:DivestmentReceivable" contextRef="AsOf2021-12-31" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,818,776</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--EmployeeAdavance_iI_zcID7PtGmN9l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:EmployeeAdavance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,695</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:EmployeeAdavance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,803</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesGrossCurrent_iI_zbuKkhWbI621" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesGrossCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesGrossCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherReceivables_iTI_zrj7Lt6AQ06c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,467</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,821,829</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherReceivablesNetNonCurrent_iI_zUGyuvchwHX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables &#8211; non-current</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="EUDA:OtherReceivablesNetNonCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,830,603</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_zY5ijrVtuv4a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Other receivables &#8211; current</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,467</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,991,226</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zGquBdtFUhBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"><p id="xdx_89E_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zIhFE6hXSJTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from other receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8B6_zqZDXVequpWg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2021</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20220101__20221231_zxKXdlcdjFL" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20210101__20211231_zmCGZGwzcF25" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20220101__20221231_ze2dQp5ImR9c" title="Addition" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="EUDA:AllowanceForDoubtfulOtherReceivableRecoveries" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,209,825</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20210101__20211231_z3xmEJVhb1Xh" title="Addition" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Write-off</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20220101__20221231_zf6OO450jHxj" title="Write-off" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="EUDA:AllowanceForDoubtfulOtherReceivableWriteOffs" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,209,825</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20210101__20211231_zaud4Oz7a86f" title="Write-off" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20220101__20221231_zw6SVgzdNWad" title="Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20210101__20211231_zzbirWUHir8g" title="Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zJe59GrryAxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<div id="xdx_C01_gL3SOCLFFRCTT-SYHD_z0qD234omzY7"><ix:continuation continuedAt="ConU001205-02" id="ConU001205-01"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zd6Pvz8IPeDk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zmtH88VrDzji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><ix:footnote id="Footnote001242" xml:lang="en-US">The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#8217;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2018-01-18" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
    million (SGD <span id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2018-01-18" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,580,000</ix:nonFraction></span>)
    in BPT&#8217;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#8220;Agreement&#8221;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#8217;s
    investment amounted to $<span id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" title="Investment owned face amount"><ix:nonFraction name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,913,096</ix:nonFraction></span>
    (SGD <span id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" title="Investment owned face amount"><ix:nonFraction name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,580,000</ix:nonFraction></span>),
    and compensated UGI with the additional amount of $<span id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:InvestmentOwnedAdditionalAmountAtMarketValues" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,905,681</ix:nonFraction></span>(SGD <span id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:InvestmentOwnedAdditionalAmountAtMarketValues" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,570,000</ix:nonFraction></span>).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $<span id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:InstallmentReceived" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span>
    million (SGD <span id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:InstallmentReceived" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,200,000</ix:nonFraction></span>)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $<span id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:InvestmentOwnedBalancePrincipalAmount" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span>
    million (SGD <span id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:InvestmentOwnedBalancePrincipalAmount" contextRef="AsOf2022-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,950,000</ix:nonFraction></span>)
    in eight equal quarterly installments with annual <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonNumeric contextRef="From2022-05-012022-05-31" name="us-gaap:DebtInstrumentInterestRateTerms">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</ix:nonNumeric></span> As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $<span id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:OtherReceivableInstallmentAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
    million (SGD <span id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"><ix:nonFraction name="EUDA:OtherReceivableInstallmentAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">987,500</ix:nonFraction></span>).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.</ix:footnote></span></td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C05_gL3SOCLFFRCTT-SYHD_zbdyBPC29sF7"><ix:continuation id="ConU001205-02">&#160;</ix:continuation></span></p>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyMk2kn5E6Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 8 &#8211; <span id="xdx_825_zf6b8YFI3Hs8">Property
and equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z5mSdoucpmWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zHVhLfbGLoI5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of property and equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zpTMbdGlLwJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_ztk0nqQP2YN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zG25ePGsgDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office equipment</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,387</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,051</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zd23T65SSPy2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,724</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,917</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zll8szp4GZf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvement</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,217</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,704</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzHdg_zvTRCTRytXkk" style="vertical-align: bottom; background-color: White">
    <td>Subtotal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,328</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,672</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzHdg_zHrtvnki6eN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,700</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,745</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzHdg_zUAXZg8rAIVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,628</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,927</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_z1WWtsDoBedj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2022 and 2021 amounted to $<span id="xdx_904_eus-gaap--Depreciation_c20220101__20221231_zFYeemxvYkSi" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,347</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--Depreciation_c20210101__20211231_zpPXFA3mEZFi" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,523</ix:nonFraction></span>, respectively.</p>
<!-- Field: Split-Segment; Name: 004 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGHgwodzg8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; <span id="xdx_822_z4rXifXJO9Y7">Intangible assets, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrWdLnkeBuS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Intangible assets
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zheLd0sPrDVe" style="display: none">Schedule
of intangible assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zcyIRETse008" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_zzE61IlI6fNe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedCustomerRelationshipsGross_iI_maFLIANzay9_zRwiwhzpsrZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Customer relationships</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedCustomerRelationshipsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,102</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedCustomerRelationshipsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">646,246</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzay9_zhbXYS2amUw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,584</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,284</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Impairment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zTEvWZD4UnYd" title="Less: Impairment"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,787</ix:nonFraction></span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_904_ecustom--ExchangeRateEffect_c20220101__20221231_z2NPAqwNwf1b" title="Exchange rate effect"><ix:nonFraction name="EUDA:ExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,731</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzay9_zFsJe5o6sdB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,962</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zvCsgAwYDaag" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for the years ended December
31, 2022 and 2021 amounted to $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zWme17rtLEp6" title="Amortization expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,907</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_z0uKtxehJye5" title="Amortization expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,825</ix:nonFraction></span>, respectively. The management performed quantitative assessment and determined to
fully impair the carrying value of intangible assets due to the Company&#8217;s limited business development and uncertain surrounding
economic environment. For the year ended December 31, 2022, The Company recorded $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zxhS0JQC4AGj" title="Impairment loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,787</ix:nonFraction></span> impairment loss related to intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:GoodwillDisclosureTextBlock"><p id="xdx_807_eus-gaap--GoodwillDisclosureTextBlock_zy8t5lF1Tp49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; <span id="xdx_822_zoKzAW3jSGDl">Goodwill</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfGoodwillTextBlock_zTmbmb4e5ynd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The
changes in the carrying amount of goodwill from Melana reporting unit and Tri-Global reporting unit are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zaVXBpQzDt7b" style="display: none">Schedule
of goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--BusinessAcquisitionAxis_custom--MelanaInternationalPteLimitedMember_zYD13vnzyCac" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Melana</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--BusinessAcquisitionAxis_custom--TriGlobalSecurityPteLimitedMember_zBUWt9d98jUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tri-Global</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zvGbVsnACRs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--Goodwill_iS_z4FHyz86k8F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Balance as of December 31, 2020</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,286</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,344</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,630</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_zspcihJYudB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2021-01-012021-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,621</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2021-01-012021-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,323</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,944</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--Goodwill_iS_zbBKMWrIpF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,665</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,021</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">992,686</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--Goodwill_iS_zbqKn29MhMlf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,665</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,021</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">992,686</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_z74a0yqnTzp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,427</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,030</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,457</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_iN_di_znOKDbByjexd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Impairment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">517,238</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,991</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,229</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--Goodwill_iE_zF56Pdc9x6Ca" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220101__20221231_eus-gaap--Goodwill_iE_zSB1sptjUfLg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AA_zZG1P5u3sWu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021,
the Company record $<span id="xdx_90D_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_z4iOefuPl8Ih" title="Impairment loss" class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,229</ix:nonFraction></span>
and <span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zwAbYirFwWy3" title="Impairment loss::XDX::-" class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><span style="-sec-ix-hidden: xdx2ixbrl1357">nil</span></span> impairment loss on good will, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ForwardPurchaseAgreementsDisclosureTextBlock"><p id="xdx_805_ecustom--ForwardPurchaseAgreementsDisclosureTextBlock_zcvGACHMS2T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; <span id="xdx_82E_zJCLxrxZRVS6">Forward Purchase Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
November 9, 2022 and November 13, 2022, 8i, EHL, and certain institutional investors, HB Strategies LLC (the &#8220;Seller 1&#8221;) and
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (&#8220;Seller 2&#8221;) entered into an agreement (the &#8220;Prepaid
Forward Agreement 1&#8221; and &#8220;Prepaid Forward Agreement 2&#8221;), respectively, for an equity prepaid forward transaction (the
&#8220;Prepaid Forward Transaction 1&#8221; and &#8220;Prepaid Forward Transaction 2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the terms of the Prepaid Forward Agreements, Seller 1 and Seller 2 may (i) purchase through a broker in the open market, from holders
of Shares other than 8i Acquisition or affiliates thereof, 8i Acquisition&#8217;s ordinary shares, no par value, (the &#8220;Shares&#8221;),
or (ii) reverse Seller 1&#8217;s and Seller 2&#8217;s prior exercise of redemption rights as to Shares in connection with the Business
Combination (all such purchased or reversed Shares, the &#8220;Recycled Shares 1&#8221; and &#8220;Recycled Shares 2&#8221;, respectively).
While Seller 1 and Seller 2 has no obligation to purchase any Shares under the Prepaid Forward Agreement 1 and Prepaid Forward Agreement
2, the aggregate total Recycled Shares 1 and Recycled Shares 2 that may be purchased or reversed under the Prepaid Forward Agreement 1
and Prepaid Forward Agreement 2 shall be no more than <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember_zdunTvhqRqti" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-11-082022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></span> shares and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember_zDtb2O9UQyHi" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-11-082022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,125,000</ix:nonFraction></span> shares, respectively. Seller 1 and Seller 2 have
agreed to hold the Recycled Shares 1 and Recycled Shares 2, for the benefit of (a) 8i Acquisition until the closing of the Business Combination
(the &#8220;Closing&#8221;) and (b) the Company after the Closing (each a &#8220;Counterparty&#8221;). Seller 1 and Seller 2 also may
not beneficially own greater than <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zHPSmS187ile" title="Beneficially ownership percentage"><span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zB6YSivLA8I5" title="Beneficially ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember_custom_InstitutionalInvestorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember_custom_InstitutionalInvestorsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></ix:nonFraction></span></span>% of issued and outstanding Shares following the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
key terms of the forward contracts are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Sellers can terminate the Transaction no later than
the later of: (a) Third Local Business Day following the Optional Early Termination (&#8220;OET&#8221;); (b) the first Payment Date after
the OET Date which shall specify the quantity by which the Number of Shares is to be reduced (such quantity, the &#8220;Terminated Shares&#8221;)
Seller shall terminate the Transaction in respect of any Shares sold on or prior to the Maturity Date. The Counterparty is entitled to
an amount from the Seller equal to the number of terminated shares multiplied by the Reset Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">-Seller 1 and Seller 2 are entitled to receive the
Maturity Consideration, an amount equal to the product of: (1) Number of Recycled Shares specified in the Pricing Date Notice, less(b)
the number of Terminated Shares multiplied by (2) USD <span id="xdx_907_eus-gaap--ForwardContractIndexedToEquitySettlementShareFairValuePerShare_iI_c20221109__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ForwardContractsMember_zZbPNqu29Yzc" title="Forward contract, fair value per share"><ix:nonFraction name="us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare" contextRef="AsOf2022-11-09_us-gaap_ForwardContractsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span> (the &#8220;Maturity Consideration&#8221;), in cash. The Company can also pay
the Seller 1 and Seller 2 shares based on the Company&#8217;s average volume weighted average share price (&#8220;VWAP&#8221;) of the
Shares over 30 Scheduled Trading Days ending on the Maturity Date. Such settlement consideration or OET is considered to be an embedded
feature (or instrument) with in the Prepaid Forward Transaction 1 and 2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- <span style="background-color: white">The </span>Prepaid
Forward Transaction 1 and 2 required <span style="background-color: white">physical settlement by repurchase of remaining of the recycled
shares in exchange for cash and if either the amount to be paid or the settlement date varies based on specified conditions, the earlier
of a) first anniversary of the closing of the transactions between Counterparty and EUDA on November 18, 2022 or b) the date specified
by Seller in a written notice to be delivered at Seller&#8217;s discretion (not earlier than the day such notice is effective) after the
occurrence of a VWAP Trigger Event, those instruments shall be measured subsequently at the amount of cash that would be paid under the
conditions specified in the contract if settlement occurred at the reporting date, recognizing the resulting change in that amount from
the previous reporting date as interest cost, which we recorded as change in fair value of prepaid forward purchase liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In accordance
with ASC 480, <i>Distinguishing Liabilities from Equity</i>, the Company has determined that the prepaid forward contract is a financial
instrument other than a share that represent or are indexed to obligations to repurchase the issuer&#8217;s equity shares by transferring
assets, referred to herein as the &#8220;prepaid forward purchase liability&#8221; on its consolidated balance sheets. The Company initially
measure the prepaid forward purchase liability at fair value and measured subsequently at fair value with changes in fair value recognized
in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of the closing
of the Business Combination, the fair value of the prepaid forward purchase liability was $<span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221109_zaMJj0MtG3f1" title="Prepaid forward purchase liability"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-11-09" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,409,550</ix:nonFraction></span> and was recorded on the Company&#8217;s
consolidated balance sheets. Subsequently, the change of fair value of the prepaid forward purchase liability was amounted to a loss of
$<span id="xdx_902_ecustom--ChangeOfFairValueOfPrepaidForwardPurchaseLiability_c20220101__20221231_zk8mdFAp9Kb" title="Change of fair value of prepaid forward purchase liability"><ix:nonFraction name="EUDA:ChangeOfFairValueOfPrepaidForwardPurchaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,503</ix:nonFraction></span> for the year end December 31, 2022. As of December 31, 2022, the prepaid forward purchase liabilities amounted to $<span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zHmPZ78KJ7M5" title="Prepaid forward purchase liability"><ix:nonFraction name="EUDA:PrepaidForwardPurchaseLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,321,053</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:LoanToThirdPartyTextBlock"><p id="xdx_806_ecustom--LoanToThirdPartyTextBlock_zL285YpqCUo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 &#8211; <span id="xdx_827_ziKYrlXoDPGe">Loan to third party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 20, 2020, the Company&#8217;s
subsidiary, UGI has entered into a loan agreement with PT total Prima Indonesia (&#8220;PT&#8221;), an unrelated third party. Upon
execution of the loan agreement and supplemental agreement, PT may borrow up to approximately $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zz9LM4qIYGt4" title="Loan borrow up amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million (SGD <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_uSGD_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zpjNTXaMDrtf" title="Loan borrow up amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,000,000</ix:nonFraction></span>)
from UGI for a period of three years with <span id="xdx_90D_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20201119__20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_znZMGL4TKZl4" title="Loan interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2020-11-192020-11-20_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.00</ix:nonFraction></span>%
annual interest rate. The loan shall be due and payable, including all disbursed loan amount and accrued interest, on the maturity
date. As of December 31, 2022 and 2021, the Company had provided a total of $<span id="xdx_90F_ecustom--LoanAccumulativelyDisbursed_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zbhSDnXagvBl" title="Loan accumulatively disbursed"><ix:nonFraction name="EUDA:LoanAccumulativelyDisbursed" contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">608,683</ix:nonFraction></span>
(SGD <span id="xdx_905_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zxWWGcujFD3g" title="Loan accumulatively disbursed"><ix:nonFraction name="EUDA:LoanAccumulativelyDisbursed" contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">816,000</ix:nonFraction></span>)
and $<span id="xdx_906_ecustom--LoanAccumulativelyDisbursed_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zgLDgzDCTmG1" title="Loan accumulatively disbursed"><ix:nonFraction name="EUDA:LoanAccumulativelyDisbursed" contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,959</ix:nonFraction></span>
(SGD <span id="xdx_903_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zE7WpbPZsArh" title="Loan accumulatively disbursed"><ix:nonFraction name="EUDA:LoanAccumulativelyDisbursed" contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">476,000</ix:nonFraction></span>)
of loan to PT, respectively, and had $<span id="xdx_908_eus-gaap--InterestReceivable_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zTko21MGX8G6" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,766</ix:nonFraction></span>
(SGD <span id="xdx_903_eus-gaap--InterestReceivable_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zroAxy2XF2Y1" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">84,144</ix:nonFraction></span>)
and $<span id="xdx_901_eus-gaap--InterestReceivable_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zptswBR8l66e" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,003</ix:nonFraction></span>
(SGD <span id="xdx_901_eus-gaap--InterestReceivable_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zhGiqvBn7qoa" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">25,627</ix:nonFraction></span>)
of interest receivable balance, respectively. However, the Company determined its unlikely to recover such loan to third party upon
expiration of the loan contract due to PT was no longer in business, therefore, the company had recorded a fully allowance against
and wrote off the remaining balance of loan to third party as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021, the
Company has recognized <span id="xdx_907_eus-gaap--InterestIncomeRelatedParty_dxL_c20220101__20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zrjP4Ex1NwK1" title="Interest income from loan to third party::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1401">nil</span></span> and $<span id="xdx_906_eus-gaap--InterestIncomeRelatedParty_c20210101__20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_z2QUkc6cqAY3" title="Interest income from loan to third party"><ix:nonFraction name="us-gaap:InterestIncomeRelatedParty" contextRef="From2021-01-012021-12-31_custom_PTTotalPrimaIndonesiaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,071</ix:nonFraction></span> of interest income from loan to third party, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ShortTermDebtTextBlock"><p id="xdx_800_eus-gaap--ShortTermDebtTextBlock_zh08Du6kRIEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 13 &#8211; <span id="xdx_82C_zrCFg2wk8roj">Credit facilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_BankAndPrivateLenderMember" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zmF1bzcg9U3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loans &#8211; bank and private lender</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on short-term bank loans consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zq36MWtvWq1i" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Bank/Private<br />
 lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br />
Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center">*<span id="xdx_908_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zNb9oHGId5b3" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001409" name="us-gaap:ShortTermDebtLender">United Overseas Bank Limited</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zcPdpLsyMHwe" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001411" name="us-gaap:ShortTermDebtTerms">90 days from disbursement</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zCfVBhT5mU4h" title="Interest Rate"><ix:nonFraction name="EUDA:ShortTermDebtInterestRate" contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.25</ix:nonFraction></span>% plus prime rate of <span id="xdx_90E_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_fKg_____zfTw109SRvOj" title="Interest Rate"><ix:nonFraction name="EUDA:ShortTermDebtInterestRate" contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember_us-gaap_PrimeRateMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></span>%</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zxA309aHY1W" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001417" name="us-gaap:DebtInstrumentCollateral">Collateral: Accounts receivable</ix:nonNumeric> </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zU1uJrnqARda" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">185,592</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zpWzgzbbh6j3" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" id="Fact001421" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">184,491</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z4BHA2B8rqh5" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:ShortTermDebtLender">FS Capital Ptd. Ltd.</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zI7qFSDU1774" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:ShortTermDebtTerms">Fully repaid in February, 2022</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zNuDnn3QNN28" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zvCfKLrWXRyj" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:DebtInstrumentCollateral">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder, and Kent Ridge Health Private Limited</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zQ5MFLMoFAd" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zpYyfAyUGRL8" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,936</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zMXeUYuTfen1" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:ShortTermDebtLender">Funding Societies Pte. Ltd</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zfXoQB7pA524" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:ShortTermDebtTerms">Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zSQFIVgvja5" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zUwHlHqO7fMh" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" name="us-gaap:DebtInstrumentCollateral">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zBtuoQvS27d" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,648</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zhYCBo1e7Gg7" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1445">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zLUz0RfsiKDd" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-12-31_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,240</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z9IcxqQF0pI4" title="Short term loans - bank and private lender"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,427</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_z6mo09h38t7d" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F11_zGbdAhWmd92k" style="text-align: justify"><ix:footnote id="Footnote001450" xml:lang="en-US">On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">593,208</ix:nonFraction></span>
                                                                                                       (SGD <span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="SGD">800,000</ix:nonFraction></span>)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#8217;s account receivable (see Note 6). The loan bears an average annual interest rate of <span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2019-08-202019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.50</ix:nonFraction></span>%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A1_zW3FpakUMLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ThirdPartiesMember" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zY63Gd0UPNQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loan &#8211; third party</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zDPEKbNdLZR1" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br /> Guarantee</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2022</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2021</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zWUelSEUsRz8" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" name="us-gaap:ShortTermDebtLender">Koh Wee Sing</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_fKg_____zohy9rpeA1yd" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" id="Fact001462" name="us-gaap:ShortTermDebtTerms">Due on demand beginning in July 2022</ix:nonNumeric></span>*</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zdeDx9uPfRl2" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.0</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_ztbcHFYM3FFb" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" name="us-gaap:DebtInstrumentCollateral">None</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zxzEPGi05kJ4" title="Short term loans - third parties"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z5xGRUTk034g" title="Short term loans - third parties"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,302</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_z1EDzRQXpF0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense pertaining to the above loans for
the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90E_eus-gaap--InterestExpense_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zkRqwaLlo5Lf" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,845</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zvwZUt2myhBh" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-12-31_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,071</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Weighted average interest rate to the above loans
for the years ended December 31, 2022 and 2021 are <span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zjnwdHR3Vu6j" title="Weighted average interest rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRate" contextRef="AsOf2022-12-31_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.0</ix:nonFraction></span>% and <span id="xdx_90B_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z1TcG7S1XL62" title="Weighted average interest rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRate" contextRef="AsOf2021-12-31_custom_ThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.3</ix:nonFraction></span>%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F02_zkILJEdptxJ7" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F14_zHLspWhHk04" style="text-align: justify"><ix:footnote id="Footnote001479" xml:lang="en-US">On December 16, 2022, the Company has signed a loan agreement
                                                                                                       (&#8220;Agreement&#8221;) with Kent Ridge Health Pte Ltd (&#8220;KRHPL&#8221;), a related party. Pursuant to the Agreement, KRHPL
                                                                                                       agreed to fully remit the loan payment to Koh Wee Sing on behalf of the Company. As a result, such short-term loan- third party was
                                                                                                       transfer to other payable, related parties under KRHPL&#8217;s balance as of December 31, 2022.</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_PromissoryNoteMember" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zS0Hd9Z016Yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Promissory note</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on promissory note consist of
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zcPLWGqMCYe7" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br /> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zf3uHzslHwm4" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" name="us-gaap:ShortTermDebtLender">Kaufaman &amp; Canoles, P. C. (&#8220;KC&#8221;)</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_fKg_____zw9ZL6sd9fx" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001485" name="us-gaap:DebtInstrumentMaturityDate">February 15, 2023</ix:nonNumeric></span>*</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zU5yjNtaf0Vi" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zeFtooQHWzd" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" name="us-gaap:DebtInstrumentCollateral">None</ix:nonNumeric></span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zYLH44Kwk1Oj" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zIzXFkXVtur3" title="Convertible promissory note"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zpEKxG4NhYhc" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F17_zPRb9fRRhpn6" style="text-align: justify"><ix:footnote id="Footnote001494" xml:lang="en-US">This promissory note has a default interest of <span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2023-02-142023-02-15_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#8220;the Agreement&#8221;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31_custom_SettlementAgreementMember_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> within two days of the dates that the Company&#8217;s US counsel,
Loeb &amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> within two business days after the date the first amendment to the registration
statement is filed with the SEC.</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A1_zDvC8uBoAIGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ConvertibleNotesThirdPartiesMember" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z6Kq57Fc2mRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; third parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on convertible notes consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zIx7neI1HJM5" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br /> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zlNna5WB78N5" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:ShortTermDebtLender">Maxim Group LLC (&#8220;Maxim&#8221;)</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zfoXWsI7F5v8" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zjkttMFlHCPh" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztXGFtXMJN8f" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:DebtInstrumentCollateral">Automatically be converted into the Company&#8217;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztsqhZq0sHA4" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,113,125</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zf5U7gDmOlBi" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zSsHM3l6l3yl" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:ShortTermDebtLender">Menora Capital Pte Ltd (&#8220;Menora&#8221;)</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zIZinwYcTpof" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zk2TFLc8rWAf" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTru3X9M6YHk" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:DebtInstrumentCollateral">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zus0fLgGYue3" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,500</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z1YSxfG1CkVk" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zopxcbfv9hXh" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:ShortTermDebtLender">Loeb &amp; Loeb LLP (&#8220;Loeb&#8221;)</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zroUwCDFpdXb" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTyfqJNfkBX" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zu8WjfcyB14j" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:DebtInstrumentCollateral">(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zHTqs3US7m5b" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zvZ8ZSyjqAda" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zpagZK7g6tVe" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:ShortTermDebtLender">Shine Link Limited (&#8220;Shine Link&#8221;)</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z9U1S8dyCFGj" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zilIXU8l8SIc" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zVslrOjeWenf" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" name="us-gaap:DebtInstrumentCollateral">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zQgMBnixlro5" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zFxmkamWZZld" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z7rF8dRBeDOg" title="Convertible notes"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_ConvertibleNotesThirdPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,619,625</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zhuRXnCbNOUk" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 101; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br /> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br />
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___znbO2pVoMxG3" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001556" name="us-gaap:ShortTermDebtLender">8i Holdings 2 Ptd Ltd (&#8220;8i Holding&#8221;)</ix:nonNumeric></span> (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPmBWhZaYdel" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" format="ixt:datemonthdayyearen" id="Fact001558" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVGdVWy5ZHr5" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001560" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPN6yhISMwJa" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001562" name="us-gaap:DebtInstrumentCollateral">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</ix:nonNumeric></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVz4gtl0mjkl" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,600</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___ziXyfpdsC1lj" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zjxf3Va2gX8k" title="Bank/Private lender Name"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001568" name="us-gaap:ShortTermDebtLender">Meng Dong (James) Tan</ix:nonNumeric></span> (2)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z4ACxPfpB3rk" title="Maturities"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" format="ixt:datemonthdayyearen" id="Fact001570" name="us-gaap:DebtInstrumentMaturityDate">November 17, 2023</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z8dHohPUY0Ll" title="Interest Rate"><ix:nonFraction name="us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime" contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zBDEoEI6pFpb" title="Collateral/Guarantee"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001574" name="us-gaap:DebtInstrumentCollateral">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z0dyAvH33lId" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember" id="Fact001576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z36i6145qhS4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zC1o1ov4Asgj" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_custom_ConvertibleNotesRelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,600</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zDEMXZWVheW4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1582">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F06_z5wkCNalLiU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zCH2TRI7EMM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001583" xml:lang="en-US">Mr. Meng Dong (James) Tan, the Company&#8217;s related party who had more than <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zXTuoVGxiL12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z3Xa8GI0PEof" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001586" xml:lang="en-US">Mr. Meng Dong (James) Tan, the Company&#8217;s related party has more than <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% ownership of the Company.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zOzsMuA8L2Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined that the embedded conversion
feature from the convertible notes, related parties and third parties qualifies for the scope exception due to the embedded conversion
feature indexed to the Company&#8217;s stock in accordance with ASC 815-40-15 and meet the equity requirement in accordance with ASC815-40-25.</p>
<!-- Field: Split-Segment; Name: 005 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z9MDkjJEGRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 &#8211; <span id="xdx_828_z9cl25epj90f">Other payables and accrued liabilities</span></b></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBuhOgPURNs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zftKXCe0kcd4" style="display: none">Schedule of other
payables and accrued liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zSgZCR3P792e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zIpxn6JlxMck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zpQPLdKmIVU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F47_z8HVuhmkRhoa" style="width: 60%; text-align: left">Accrued expenses (i)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">671,743</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,029</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maAPAOAzzja_zI4xHyEQc5We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued payroll</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">730,037</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,591</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAOAzzja_zafAiA1CKgLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F49_zN5hy8VB081c" style="text-align: left">Accrued interests (ii)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" id="Fact001600" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">157,032</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31" id="Fact001601" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,448</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zLoJEYDz1RH9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,003</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,529</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzzja_z6d9ObFAejjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other payables and accrued liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,592,815</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">488,597</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zU2DIwdDueu">(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued expenses</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_z4IbBhnBkeRa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001608" xml:lang="en-US">The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0B_z6utxZKjB9Nj">(ii)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued interests</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zV7yk6cQZZJg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001609" xml:lang="en-US">The balance of accrued interests represented the balance of interest payable from short-term loan &#8211; bank, private lender, and third parties (See Note 13).</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zKZSEqLD8882" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 102; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zP6LmKYQgF4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 15 &#8211; <span id="xdx_828_zHj4nySH6Z16">Related
party balances and transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party balances</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfRelatedPartyBalancesTableTextBlock_zPZ1uaGCMUMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zfRWSr5yCTk6" style="display: none">Schedule of related
party balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other receivables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_ztoJKWrxBA42" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br />
December 31,<br />
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zyTjiRvJ4dfh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br />
December 31,<br />
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHillCapitalPteLtdMember_z0mfXxXciPC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">KR Hill Capital Pte Ltd</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Related party advance, due on demand</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_KRHillCapitalPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_KRHillCapitalPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeMedicalPtdLtdMember_zAq8s75D8qZd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Medical Ptd Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_KentRidgeMedicalPtdLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_KentRidgeMedicalPtdLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zHO23HkMDnR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">UG Digital Sdn Bhd</td>
    <td>&#160;</td>
    <td style="text-align: center">UGD, subsidiary of the Company owned 40% of this company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_UGDigitalSdnBhdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,673</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanicLimitedMember_zC0mw7zyTSR8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Janic Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_JanicLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">724</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_JanicLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">720</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZukihealthSDNMember_ziAJ7HyPFp21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Zukihealth SDN</td>
    <td>&#160;</td>
    <td style="text-align: center">Kelvin Chen, Chief Executive Office (&#8220;CEO&#8221;) and shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_ZukihealthSDNMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,173</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JenniferGohMember_ziC0ykyOqEp5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jennifer Goh</td>
    <td>&#160;</td>
    <td style="text-align: center">President, operation manager, and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_JenniferGohMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,527</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FrescoInvestmentPteLtdMember_zq7QNokGLm3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fresco Investment Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Fan Know Hin, an immediate family member of a shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31_custom_FrescoInvestmentPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z7fbUupTuyb1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Cadence Health Pte Ltd<span id="xdx_F44_zQSR0Ta8OmEk">*</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember" id="Fact001636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">266,653</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1637">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueFromOtherRelatedParties_iI_zuvDNg31UKsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,863</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,621</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_zIA3J1Gf4zx7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other receivables -  related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,863</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromOtherRelatedParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,621</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zP8tNp0ijJTb" style="width: 15pt; text-align: right">*</td><td id="xdx_F15_zgC4CpQgx3s8" style="text-align: justify"><ix:footnote id="Footnote001644" xml:lang="en-US">As of date of <span style="background-color: white">the issuance of these financial statements</span>,
this receivable has been repaid by the related party.</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Convertible notes &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Please see Note 13 for details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 103; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Account payable &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zBrRVkpdoTJ6" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, <br />
2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zDQz9HW8SBy2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,<br />
 2021</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z0mCq6DLSO6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1646">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,459,411</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zvpsHUzGFawi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Account
payable, related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1649">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,459,411</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other payables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zip7jWxR6Se2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br />
 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zhtnBhies9n5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br />
 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CheeYinMehMember_zz7vcouE5aP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Chee Yin Meh</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholder of Scotgold Holding Ltd which is the shareholder of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Operating expense paid on behalf of the Company</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_CheeYinMehMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,739</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CheeYinMehMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,512</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamieFanWeiZhiMember_z9QK4EFAzbzj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jamie Fan Wei Zhi</td>
    <td>&#160;</td>
    <td style="text-align: center">An immediate family member of a shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company, and Guarantor fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_JamieFanWeiZhiMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,783</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinChenMember_zBpY8n1QudJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kelvin Chen</td>
    <td>&#160;</td>
    <td style="text-align: center">CEO and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_KelvinChenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">589,681</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_KelvinChenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,776</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeHealthPteLtdMember_zLHx7qXv6Q8d" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_KentRidgeHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,508</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_KentRidgeHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,129</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zfpOR0lwSdz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kent Ridge Pacific Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,303</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,483</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WatermarkDevelopmentsLtdMember_zfv4OeX9Bfjc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Watermark Developments Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_WatermarkDevelopmentsLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,945</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilkeServicesLtdMember_zNA9ZSroyVse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F48_zmQu2DhV61qj" style="vertical-align: top; text-align: left">Wilke Services Ltd (&#8220;Wilke&#8221;) (1)</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Investment payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_WilkeServicesLtdMember" id="Fact001671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,746,628</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MountLockeLimitedMember_zKIL5ddMHgag" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Mount Locke Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_MountLockeLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,753</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zX7SUmfS20E6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">UG Digital Sdn Bhd</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">UGD, subsidiary of the Company owned 40% of this company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Operating expense paid on behalf of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_UGDigitalSdnBhdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,016</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_zIe3sA7HREPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,521,945</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,272,311</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_ztc2s4OuxTI" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other payables &#8211; related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,521,945</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,272,311</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zxZa2MGh7q3l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zm2d6c2NZKWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001684" xml:lang="en-US">Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). </ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zpFPxEoFU2E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zToPN3CoiZAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zCapYiqAPdR9" style="display: none">Schedule of related
party transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name of Related Party</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Relationship</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Nature</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zurTmBRiKc72" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br />
 2022</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zpcv2OHuWiq5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br />
 2021</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zl5RS8mBhFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-bottom: 1.5pt; width: 20%; text-align: left">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 20%; text-align: center">Sales of swab test, and other medical related product</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,640</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromRelatedParties_zwIhRiOq4kfb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Revenue from related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromRelatedParties" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,640</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_ze3CZo48Hep9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br />
 2022</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zNusAPiH0Pig" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br />
 2021</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zNFfncj0E74i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Cadence Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Medical service fee provided for the third party medical service revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:PurchaseFromRelatedParties" contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,499</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:PurchaseFromRelatedParties" contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,349,702</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zY3fPo9wn83k" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    from related parties</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Medical service fee provided for the third party medical service revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:PurchaseFromRelatedParties" contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">491,499</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="EUDA:PurchaseFromRelatedParties" contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,349,702</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Rental expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3fkoprXpF84" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br />
 2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOyZQ4ETTLLk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br />
 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_ztsBbbMgSJ85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent Ridge Pacific Pte Ltd</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of this entity also are the shareholders of the Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office rental</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,954</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,589</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zgzY3mePmvcj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt">Rental Expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Office rental</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,954</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A3_zQj6Och3N0Za" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfznblAnfTG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16 &#8211; <span id="xdx_82E_ziuigU50LnRe">Shareholders&#8217; equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Capital Contribution</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 20, 2022, the Company received capital
of $<span id="xdx_908_eus-gaap--Capital_iI_c20220920__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztVJWgixa4m3" title="Capital contributions"><ix:nonFraction name="us-gaap:Capital" contextRef="AsOf2022-09-20_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> from an investor for the issuance in 8i acquisition&#8217;s ordinary shares. Such deposit is refundable if the business combination
will not be completed by November 30, 2022. Initially, the Company recognized the subscribed shares deposit liability in accordance with
ASC 480, &#8220;Distinguishing Liabilities from Equity&#8221; on inception. On November 17, 2022, Upon the closing of the Business Combination
with 8i acquisition, the Company issued <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuIjvMLiguE" title="Common stock, shares authorized, unlimited"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-11-17_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> ordinary shares to this investor and transferred such the subscribed shares deposit liability
into equity as capital contribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Forgiveness of debt by a related party</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2022, the Company and Wilke entered into
a deed of release of debt (&#8220;Deed&#8221;), pursuant to the Deed, upon the closing of the Business Combination, Wilke agrees to release
and discharge the Company from the Obligation to repay to Wilke of $<span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220330__20220331_zJzlKLPZyKt1" title="Forgiveness of debt by a related party"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2022-03-302022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,763,018</ix:nonFraction></span>. As Wilke&#8217;s is a shareholder of the
Company, such debt forgiveness were treated as an addition to the Company&#8217;s capital during the year ended December
31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Ordinary shares</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue unlimited ordinary
shares of <span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_do_c20221231_zaCuw9jMoO18" title="Ordinary shares, no par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></span> par value. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each ordinary share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">-<i>Issuance of ordinary shares to EHL</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220724__20220725_zGWtm18XmmZ7" title="Stock issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-242022-07-25" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,626,667</ix:nonFraction></span> ordinary
shares (<span id="xdx_909_ecustom--OrdinaryShareBeforeReverseRecapitalization_iI_c20220725_zlZ74xAunDWi" title="Ordinary share before reverse recapitalization"><ix:nonFraction name="EUDA:OrdinaryShareBeforeReverseRecapitalization" contextRef="AsOf2022-07-25" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> ordinary share before reverse recapitalization) for total consideration of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220724__20220725_zby4WkGXyx61" title="Total consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-242022-07-25" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> to the shareholder of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares and corresponding capital amounts and all
per share data related to EHL&#8217;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the <span style="background-color: white">Exchange Ratio</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>-Issuance of ordinary shares upon the reverse recapitalization
(See Note 4)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022, upon the consummation of the
Business Combination, the Company issued an aggregate total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EightIHoldingsTwoPtdLtdMember_zErY58aPpDSk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17_custom_EightIHoldingsTwoPtdLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,191,770</ix:nonFraction></span> ordinary shares to 8i and various service provider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_z80GmA1oLSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued upon the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zf6K3XnLVwLg">Schedule
of reverse recapitalization</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zgcRg6Xenr1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_zzG2plFquwuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 15%; text-align: right"><ix:nonFraction name="EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,073,500</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RedemptionOfOrdinaryShares_zxMwMp166mZf" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="EUDA:RedemptionOfOrdinaryShares" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">6,033,455</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ConversionOfStockSharesConverted1_zHBwDEqARuZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">891,725</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zcAJmygmIXLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued to service providers</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_zLFaxoKqb1O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,191,770</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zzq2uO8DNXl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Warrants</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with the reverse
recapitalization, the Company has assumed <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zDVV5lWDMxkl" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,917,250</ix:nonFraction></span> Warrants outstanding, which consisted of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zFgO5YE9Cw4c" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PublicWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> Public Warrants and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zOFl2bZJ3ty7" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PrivateWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">292,250</ix:nonFraction></span> Private
Warrants. Both of the Public Warrants and private warrant met the criteria for equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Warrants became exercisable
on the later of (a) the completion of the reverse recapitalization or (b) 12 months from the closing of the initial public offering (&#8220;IPO&#8221;).
The warrants will expire five years after the completion of a reverse recapitalization or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company had <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z9YrzymsPfo1" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PublicWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,625,000</ix:nonFraction></span> Public Warrants outstanding and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zFQZvRHccI8k" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_PrivateWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">292,250</ix:nonFraction></span> Private Warrants outstanding. Each whole Public Warrant and Private
Warrant entitles the registered holder to purchase one-half share of the Company&#8217;s ordinary share at a price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zs3TtM99Kn47" title="Warrant to purchase ordinary share, price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span> per share,
subject to the following conditions discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company may redeem the Public Warrants and Private Warrants in whole and not in part, at a price of $<span id="xdx_909_ecustom--WarrantsRedemptionPrice_c20220101__20221231_zaneHSRPkiYh" title="Warrants redemption price"><ix:nonFraction name="EUDA:WarrantsRedemptionPrice" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per warrant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; at any time while
the warrants are exercisable and prior to their expiration,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; upon not less than
30 days&#8217; prior written notice of redemption to each warrant holder,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; if, and only if,
the reported last sale price of the ordinary shares equals or exceeds $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20221231_zLYx9bInE134" title="Sale price of the ordinary shares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.50</ix:nonFraction></span> per share (as adjusted for share splits, share dividends,
reorganizations and recapitalizations), for any 20 trading days within a 30 trading days period ending on the third trading business day
prior to the notice of redemption to warrant holders, and,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; if, there is a current
registration statement in effect with respect to the Ordinary Shares underlying the Warrants for each day in the 30-day trading period
and continuing each day thereafter until the Redemption Date or the cashless exercise of the Warrants is exempt from the registration
requirements under the Securities Act of 1933, as amended (the &#8220;Act&#8221;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If the Company calls the
warrants for redemption as described above, management will have the option to require all holders that wish to exercise the warrants
to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of ordinary shares issuable
upon exercise of the warrants may be adjusted for splits, dividends, recapitalizations and other similar events. Additionally, in no event
will the Company be required to net cash settle the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The only difference between
Public Warrants and Private Warrants is that the Private Warrants will not be transferable, assignable or salable until after the completion
of reverse recapitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGUjZC76KfO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The summary of warrants activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zzr0MdKF5Uth" style="display: none">Schedule
of warrant activities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants <br /> Outstanding</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares Issuable</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average <br /> Remaining <br /> Contractual <br /> Life</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k4YsaJj09j" title="Warrants Outstanding, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zle586Mp5ZOd" title="Ordinary Shares Issuable, Beginning balance" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuI9vnNPvPp8" title="Weighted Average Exercise Price, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 32%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2tEcJVkBChj" title="Warrants Outstanding, Granted" style="width: 14%; text-align: right"><ix:nonFraction name="EUDA:ClassOfWarrantOrRightOutstandingGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,917,250</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk9jia2wAIug" title="Ordinary Shares Issuable, Granted" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,458,625</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ8n0xDs4CJ7" title="Weighted Average Exercise Granted" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Uz0dEn5Ahi" title="Average Remaining Contractual Life,Granted" style="width: 14%; text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="EUDA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted">5.00</ix:nonNumeric></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPEAZegbYagh" title="Warrants Outstanding, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqRvcI0CV19" title="Ordinary Shares Issuable, Forfeited" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKd6a5gxKJl" title="Warrants Outstanding, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1771">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuBRpBJPYxg" title="Ordinary Shares Issuable, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1773">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022 </span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqz7I5Ro0ma" title="Warrants Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,917,250</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZGV5NIKUml" title="Ordinary Shares Issuable, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,458,625</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfmvdnmBM0c" title="Weighted Average Exercise Price, Ending balance" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfgfRXJMsei" title="Average Remaining Contractual Life," style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.88</ix:nonNumeric></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_znjZf6mtcpC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Earnout shares</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the Business Combination, <span style="background-color: white">Watermark
is entitled to the <span id="xdx_908_ecustom--EarnoutShares_iI_c20221117_z3yaAlSoENGj" title="Earnout shares"><ix:nonFraction name="EUDA:EarnoutShares" contextRef="AsOf2022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span>
Earnout Shares of the Company&#8217;s no par value ordinary shares subject to the following four
triggering events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_z7I2xD4C2gA2" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Fifteen Dollars ($<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zioO45nyzk6j" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-17_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span>) after the Closing Date (&#8220;Triggering Event 1&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zG1xgo4MJ34l" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-162022-11-17_custom_SecondAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Twenty Dollars ($<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zHrCNVw6hgmk" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-17_custom_SecondAnniversaryMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span>) (&#8220;Triggering Event 2&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyKq1vRCQwW5" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuzuCeqW4FM4" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,100,000</ix:nonFraction></span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zwikntQiRO4b" title="Net income"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,600,000</ix:nonFraction></span> (&#8220;Triggering Event 3&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyVK9Ao8Npl5" title="Number of additional shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zIMlKNFPLAge" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,100,000</ix:nonFraction></span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zqFqjSmVDPxb" title="Net income"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,100,000</ix:nonFraction></span> (&#8220;Triggering Event 4&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Earnout
Shares are accounted for as equity classified equity instruments, were included as merger consideration as part of the Reverse Recapitalization
and recorded in capital</span>. The fair value of the Earnout Shares was estimated using a model based on multiple stock price paths developed
through the use of a Monte Carlo simulation that incorporates into the valuation the possibility that the market condition targets may
not be satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_zkrxSCwyG2u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Earnout Shares for Triggering
Event 1 and 2 was estimated using the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zsrpRMLIlhei" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of earnout shares
for triggering event</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Closing date</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221116__20221117_zcGCE22cZ9rk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">November 17, 2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharePriceAsOfClosingDate_zRAWZuTdtPpa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Share price of the Company as of closing date</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:SharePriceAsOfClosingDate" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.21</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AverageDailyReturnRate_dp_uPure_z7DBL6zpBT7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Average daily return rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="EUDA:AverageDailyReturnRate" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.02</ix:nonFraction></p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--DailyVolatilityForTriggeringEvent1_dp_zZ2VBZUgxvL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daily volatility for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:DailyVolatilityForTriggeringEvent1" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.74</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--DailyVolatilityForTriggeringEvent2_dp_zpbCH6ark1Zk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Daily volatility for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="EUDA:DailyVolatilityForTriggeringEvent2" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.30</ix:nonFraction></p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--RiskFreeRateForTriggeringEventOne_dp_zVi2jU7hK501" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:RiskFreeRateForTriggeringEventOne" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.75</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--RiskFreeRateForTriggeringEventTwo_dp_zaUYULj3ClW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:RiskFreeRateForTriggeringEventTwo" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.49</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--GrantPriceForTriggingEventOne_zaQcxUq3EBe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant Price for Trigging Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:GrantPriceForTriggingEventOne" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.0</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--GrantPriceForTriggingEventTwo_z3lSuOMSi7I1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Grant Price for Trigging Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:GrantPriceForTriggingEventTwo" contextRef="From2022-11-162022-11-17" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.0</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zQAB6u2oxEU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Company determined the fair value
of the Earnout Shares for Triggering Event 1 and 2 is amounted to $<span id="xdx_90E_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventOneMember_zyywS5HPlvZg" title="Fair value of earnout shares"><ix:nonFraction name="EUDA:FairValueOfEarnoutShares" contextRef="From2022-01-012022-12-31_custom_TriggeringEventOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,926,610</ix:nonFraction></span> and $<span id="xdx_903_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventTwoMember_zmL8IJ55UEmg" title="Fair value of earnout shares"><ix:nonFraction name="EUDA:FairValueOfEarnoutShares" contextRef="From2022-01-012022-12-31_custom_TriggeringEventTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,273,019</ix:nonFraction></span>, respectively, and recorded the same amount in consolidated statements of change in shareholders&#8217; equity (deficit) and
consolidated statements of operations and comprehensive income (loss) as earnout share payment for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Company determined that the probabilities
of achieving the revenue and net income thresholds are nil for Triggering Event 3 and 4 and estimated the fair value of the Earnout Shares
of nil.</p>
<!-- Field: Split-Segment; Name: 005 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zrpXafO6iun3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 17 &#8211;<span id="xdx_829_z5alBoi1aj22"> Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>British Virgin Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KRHL and SGGL are incorporated in the British Virgin
Islands and are not subject to tax on income or capital gains under current British Virgin Islands law. In addition, upon payments of
dividends by these entities to their shareholders, no British Virgin Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Vietnam</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary operating in Vietnam
is subject to the Vietnam Income Tax at a standard income tax rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_znefJsdO9JN" title="Foreign income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31_country_VN" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Malaysia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary operating in Malaysia
is governed by the income tax laws of Malaysia and the income tax provision in respect of operations in Malaysia is calculated at the
applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof.
Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zLuDvpwO3Yak" title="Foreign income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31_country_MY" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% enterprise income
tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Singapore</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiaries incorporated in Singapore
and is subject to Singapore Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance
with relevant Singapore tax laws. <span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_z4KtS2eEjV12" title="Income tax description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_country_SG" name="us-gaap:IncomeTaxExaminationDescription">The applicable tax rate is <span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_zsKL6vaATBQ5" title="Foreign income tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31_country_SG" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% in Singapore, with 75% of the first $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z17NV6d87dW4" title="Taxable income"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,255</ix:nonFraction></span> (SGD <span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z6EBZQcRybQb" title="Taxable income"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,000</ix:nonFraction></span>) taxable income
and 50% of the next $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zg9APfydA9V4" title="Taxable income"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,842</ix:nonFraction></span> (SGD <span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zyjXZunjUH2g" title="Taxable income"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">190,000</ix:nonFraction></span>) taxable income are exempted from income tax.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zXpPe41qzvhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and foreign components of loss before
income taxes were comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_ziFSmCvuVuV3" style="display: none">Schedule
of components of loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zjH9PVeyKvkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_zKAtD8HE96P4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zty8c8T8eeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Singapore</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,400,034</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">930,312</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zGyACxvHKX16" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,531,790</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,225</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zPMlSqriWVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total loss (income) before income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,931,824</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">948,537</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zuXGiTrb4pr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJEm2njnqpLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z8zw5yCpj5M2" style="display: none">Schedule
of provision for income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zTFi7qbIvTRg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_z0BLIXxcd0F4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_zSdIKhIucPrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Current</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,650</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,821</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_z3jXFocNLYm2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deferred</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,228</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,680</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_z4lm9TXIxmI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Provision for income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,422</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,141</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zzL73rSJesra" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zVCS992fOng2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles Singapore statutory
rates to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zXLp5P8Uow19" style="display: none">Schedule
of effective income tax rate</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zz6LSmlqgw5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zTpHYWL3WU07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_z0uGVyCX6sAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Singapore statutory income tax rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.0</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.0</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zzJ1jJekuC2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax rate difference outside Singapore <span id="xdx_F46_zNQo6BcZgG44">(1)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-01to2022-12-31" id="Fact001872" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">13.3</ix:nonFraction></td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-01-012021-12-31" id="Fact001873" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxExemptIncome_pid_dp_zXhXG4014Vxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxable income below exemption threshold</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.4</ix:nonFraction></td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_z8YJ0GXrWI66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.9</ix:nonFraction></td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29.8</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_zY13CpOijIs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others <span id="xdx_F44_zoi5p425LcQg">(2)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2022-01-01to2022-12-31" id="Fact001881" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.9</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2021-01-012021-12-31" id="Fact001882" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">39.4</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zzQWY82pIy2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.1</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zLE8wzDmLyza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zCFPCErDySXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001886" xml:lang="en-US">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zvUE81Un7MEd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zxFItljtEDT" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001887" xml:lang="en-US">Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zSka9sprHmQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUkfkUCI7RE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant components
of the aggregate deferred tax assets and liabilities of the Company as of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zcM8q1Pzzg4" style="display: none">Schedule
of deferred tax assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zdo2j9fZOWhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0XqsOKD6XUj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred Tax Assets/Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzYwk_zbqU7KgOgUqg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,309</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,715</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTANzYwk_zDROOYfiD1Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allowance for doubtful account<span id="xdx_F4E_zYFMyP1TGDhg">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2022-12-31" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,564</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="AsOf2021-12-31" id="Fact001895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,736</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilityNet_iI_maDTANzYwk_z5ZAY0uJdmu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="EUDA:DeferredTaxAssetsLeaseLiabilityNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">823</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1898">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYwk_zk1qx9VNeCJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">783,696</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">826,451</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYwk_zqEefreGb4e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1903">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzaoX_zYICzYnBxxwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,294</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzaoX_z5NtqG7k2ot8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1909">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,294</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F06_zH7RhItHCiA2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1A_z3zULlLWpA9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001911" xml:lang="en-US">The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $<span id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,755</ix:nonFraction></span> as of December 31, 2022.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A1_zNhoceS2p6ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, the Company had
net operating losses carry forward (including temporary taxable difference of bad debt expense) of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zS4fiEcjSZze" title="Operating losses carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span> million and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zC153U1F2Kc3" title="Operating losses carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span>
million, respectively, from the Company&#8217;s Singapore subsidiaries. The net operating losses from the Singapore subsidiaries can be
carried forward indefinitely. Due to the limited operating history of certain Singapore subsidiaries, the Company is uncertain when these
net operating losses can be utilized. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses
(including temporary taxable difference of bad debt expense) of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zWUOmpGWmkRa" title="Deferred tax assets, operating losses carry forward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_SingaporeSubsidiariesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20211231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zc33zuHgyiKj" title="Deferred tax assets, operating losses carry forward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31_custom_SingaporeSubsidiariesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million related to Singapore subsidiaries
as of December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, the Company had
net operating losses carry forward of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_zPvacqmpq7ik" title="Operating losses carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_VN" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zeBSl8AgbJW4" title="Operating losses carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_country_VN" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,000</ix:nonFraction></span>, respectively, from the Company&#8217;s Vietnam subsidiary. <span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_zhFLnRHG3UGg" title="Operating losses carry forward description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_country_VN" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.</ix:nonNumeric></span> Due to
the Vietnam subsidiary have been operating at losses and the Company believes it is more likely than not that its Vietnam operations will
be unable to fully utilize its deferred tax assets related to the net operating losses in the foreseeable future. As a result, the Company
provided a 100% allowance on deferred tax assets on net operating losses of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_z602ld7w8qj2" title="Deferred tax assets, operating losses carry forward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_VN" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zMjWK0J359u3" title="Deferred tax assets, operating losses carry forward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31_country_VN" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> related to its Vietnam subsidiary
as of December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, the Company had net operating
losses carry forward of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zCMRe980OpB1" title="Operating losses carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000</ix:nonFraction></span> from the Company&#8217;s Malaysia subsidiary. The net operating losses from the Malaysia
subsidiary can be carried forward for seven years. Due to the Malaysia subsidiary have been operating at losses and the Company believes
it is more likely than not that its Malaysia operations will be unable to fully utilize its deferred tax assets related to the net operating
losses in the foreseeable future. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses of
approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zWUhV0tS1ski" title="Deferred tax assets, operating losses carry forward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> related to its Malaysia subsidiary as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Uncertain tax positions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates each uncertain tax position
(including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated
with the tax positions. As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions.
The Company did not incur interest and penalties tax for the year ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfTaxesPayableTableTextBlock"><p id="xdx_895_ecustom--ScheduleOfTaxesPayableTableTextBlock_zxbuH9pHz6Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Taxes payable consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z9nWMz0MpKS5" style="display: none">Schedule
of taxes payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zDcGYLGYVkoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zXvZQgoUd4K9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedGSTTaxesPayableCurrent_iI_maTPCzp1w_zSuZfuCNFxE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">GST taxes payable</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:AccruedGSTTaxesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,695</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="EUDA:AccruedGSTTaxesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,095</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedIncomeTaxesCurrent_iI_maTPCzp1w_z0eWsO3lfjj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income taxes payable</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,455</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,248</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_iTI_mtTPCzp1w_zmg2voh1nZe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Totals</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,150</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,343</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zunOrIXdAOZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zPIH40SFxH9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 18 &#8211; <span id="xdx_823_zXna5lN7Lt73">Concentrations  risks</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Major customers</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021, no
customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zTovobfOfiA1" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zaNsgn5U49Dd" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% or more of the Company&#8217;s total revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, no customer accounted
for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zh7Wpr17vVWf" title="Concentration risk percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zI9iyFYtFh8h" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% or more of the total balance of accounts receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Major vendors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2022, no vendor accounted
for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoVendorMember_zpOiyZK5geXh" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% or more of the Company&#8217;s total purchases. For the year ended December 31, 2021, one vendor which is the Company&#8217;s
related party accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zeNLcYsJ6y5a" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">37.3</ix:nonFraction></span>% of the Company&#8217;s total purchases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, two vendors accounted for
<span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zGVonptqQ3Xc" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.9</ix:nonFraction></span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zz3FjCjNnZ87" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.1</ix:nonFraction></span>% of the Company&#8217;s total balance of accounts payable, respectively. As of December 31, 2021, one vendor which is the
Company&#8217;s related party accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zpODy6RlWja5" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87.2</ix:nonFraction></span>% of the total balance of accounts payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to significant concentrations of credit risk consist primarily of cash. The Singapore Deposit Insurance Corporation
Limited (SDIC) insures deposits in a Deposit Insurance (DI) Scheme member bank or finance company up to approximately $<span id="xdx_907_eus-gaap--Deposits_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zjAJyOOSPUBl" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,000</ix:nonFraction></span>
(SGD <span id="xdx_907_eus-gaap--Deposits_iI_uSGD_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zFDaVftMjKAl" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">75,000</ix:nonFraction></span>)
per account. As of December 31, 2022 and 2021, the Company had cash balance of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zSAjXjlWusZj" title="Cash balance"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,710</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zqEfCScdMxK1" title="Cash balance"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,746</ix:nonFraction></span>
was maintained at DI Scheme banks in Singapore, of $<span id="xdx_90B_eus-gaap--BankOverdrafts_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuhytM0ddrp6" title="Bank balance"><ix:nonFraction name="us-gaap:BankOverdrafts" contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--BankOverdrafts_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zaA9mkzk3ohj" title="Bank balance"><ix:nonFraction name="us-gaap:BankOverdrafts" contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,606</ix:nonFraction></span>
was subject to credit risk, respectively. The Federal Deposit Insurance Corporation (FDIC) standard insurance amount is up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zNoSNL8CGM58" title="Cash FDIC"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
per depositor per insured bank. As of December 31, 2022 and 2021, the Company had  restricted cash balance of $<span id="xdx_90B_eus-gaap--RestrictedCash_iI_c20221231_ziJm2MEsyNM2" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">641,461</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231_zXwqTCDm5kgk" title="Restricted cash::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1984">0</span></span> was
maintained at banks in the United States, of $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuvKPIz6x74d" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">391,461</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_ztL1dnl9lkhg" title="Restricted cash::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1988">0</span></span>
was subject to credit risk, respectively. While management believes that these financial institutions are of high credit quality, it
also continually monitors their credit worthiness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is also exposed to risk from accounts
receivable and other receivables. These assets are subjected to credit evaluations. An allowance has been made for estimated unrecoverable
amounts which have been determined by reference to past default experience and the current economic environment.</p>
<!-- Field: Split-Segment; Name: 006 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_z36yamL3BM55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 19 &#8211; <span id="xdx_82E_zn5DNKDgyIBf">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022 and
2021, the Company has leased three offices, and one office, respectively, which were classified as operating leases. In addition, the
Company had two office equipment leases which were classified as finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company occupies various
offices under operating lease agreements with a term shorter than twelve months which it elected not to recognize lease assets and lease
liabilities under ASC 842. Instead, the Company recognized the lease payments in profit or loss on a straight-line basis over the lease
term and variable lease payments in the period in which the obligation for those payments is incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&#8217;s lease
agreements do not contain any material residual value guarantees or material restrictive covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognized lease
expense on a straight-line basis over the lease term for operating lease. Meanwhile, the Company recognized the finance leases ROU assets
and interest on an amortized cost basis. The amortization of finance ROU assets is recognized on an accretion basis as amortization expense,
while the lease liability is increased to reflect interest on the liability and decreased to reflect the lease payments made during the
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The ROU assets and lease
liabilities are determined based on the present value of the future minimum rental payments of the lease as of the adoption date, using
an effective interest rate of <span id="xdx_90C_eus-gaap--OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate_iI_pid_dp_uPure_c20221231_z7pOJ4NUxHkf" title="Effective interest rate"><ix:nonFraction name="us-gaap:OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></span>%, which is determined using an incremental borrowing rate with similar term in Singapore.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the weighted average remaining lease terms of the Company&#8217;s operating lease and finance leases are <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKQihOLmG2li" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.69</ix:nonNumeric></span> years and <span id="xdx_907_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zPHpfCn6dn6e" title="Finance lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">2.01</ix:nonNumeric></span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_zEuaX77mg0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Operating and finance lease
expenses consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zva4W5Cc3jEe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of operating and finance lease expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; text-align: left">Lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 31%; text-align: left">General and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z02GJdR0Isi6" title="Lease expenses" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,390</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--OperatingLeaseExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8YRaCVWT2G1" title="Lease expenses" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,810</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease expenses &#8211; short-term</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OperatingLeaseExpenseShortTerm_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ3haufxx6Qg" title="Lease expenses - short-term" style="text-align: right"><ix:nonFraction name="EUDA:OperatingLeaseExpenseShortTerm" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,055</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseExpenseShortTerm_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsGM83lzv0Je" title="Lease expenses - short-term" style="text-align: right"><ix:nonFraction name="EUDA:OperatingLeaseExpenseShortTerm" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,589</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Finance lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of leased asset</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3O1dqy7VBD" title="Amortization of leased asset" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,948</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znDHIxe4Tzjl" title="Amortization of leased asset" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,153</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense -Interest expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zf2DKu4lGdQg" title="Interest on lease liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2022-01-012022-12-31_us-gaap_InterestExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,276</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseInterestExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zHzFNIMwu5vk" title="Interest on lease liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2021-01-012021-12-31_us-gaap_InterestExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,639</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--LeaseCost_c20220101__20221231_zXuIrMiSvqCe" title="Total lease expenses" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,669</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--LeaseCost_c20210101__20211231_z2u05tGTexK8" title="Total lease expenses" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,191</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zsHhe4ynVdql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z4bF3JJAwasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Weighted-average remaining
term and discount rate related to leases were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;<span id="xdx_8B7_z33Jp2miFTYa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of weighted average remaining term and discount rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining term</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zrKJVK0Me2f7" title="Operating lease, weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.69</ix:nonNumeric></span> year</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zzCZShx2g3Sb" title="Operating lease, weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.25</ix:nonNumeric></span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKWt37oTrso2" title="Finance leases, weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">2.01</ix:nonNumeric></span> years</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zHvVzkkI36U7" title="Finance leases, weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">3.00</ix:nonNumeric></span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Operating lease</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zdJsEKHuuDU" title="Operating lease, weighted-average discount rate" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z4c645fgDIx4" title="Operating lease, weighted-average discount rate" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zZokI2Cnpue8" title="Finance leases, weighted-average discount rate" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zfAld1JBxjki" title="Finance leases, weighted-average discount rate" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.25</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zG9d63cfbRE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="EUDA:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_z73KmCspbejd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table sets
forth the Company&#8217;s minimum lease payments in future periods as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zSmAwDeYnclg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of future minimum lease payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Operating lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Finance lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Twelve months ending December 31, 2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_z5TkiMa5Sj6k" title="Operating lease payments, 2023" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,522</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_zBj0F5oLzmwe" title="Finance lease payments, 2023" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,151</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_c20221231_z5CMRkqW6N71" title="Total 2023" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligationDueInNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,673</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Twelve months ending December 31, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zGcD4UX1NxMj" title="Operating lease payments, 2024" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_z4BdzkewRGyj" title="Finance lease payments, 2024" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,614</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ContractualObligationDueInSecondYear_iI_c20221231_zPK2RPFfFAGf" title="Total 2024" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligationDueInSecondYear" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,614</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20221231_zqWjAHy6kPmh" title="Total Operating lease payments" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,522</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20221231_zBpcpcCZWHTi" title="Total Finance lease payments" style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,765</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_c20221231_zY66KBstjHkk" title="Total lease payments" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,287</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: discount</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pid_di_c20221231_zHNYt3BVcdDi" title="Total Operating lease payments, discount" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,563</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20221231_zbL4SNROjyw4" title="Total Finance lease payments, discount" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,564</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractualObligationDiscount_iNI_di_c20221231_zpQcmUJrGt7d" title="Total lease payments" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="EUDA:ContractualObligationDiscount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,127</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Present value of lease liabilities</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20221231_zDKjpPsmED13" title="Present value of lease liabilities, operating lease payments" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,959</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_c20221231_zLCdbSOaIrge" title="Present value of lease liabilities, finance lease payments" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,201</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98B_ecustom--ContractualObligationLeaseLiability_iI_c20221231_zAbONJPGacC5" title="Total lease payments" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="EUDA:ContractualObligationLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,160</ix:nonFraction></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_z2O3vH1oe0Fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company minimum short term lease payments to be due within one year amounted to $<span id="xdx_90F_eus-gaap--ShortTermLeasePayments_c20220101__20221231_zShqFY5C3tnb" title="Short term lease payments"><ix:nonFraction name="us-gaap:ShortTermLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,075</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z97gDaYoTsq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 20 &#8211; <span id="xdx_820_zdvDPpG9pSve">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is party to certain
legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible
losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
March 30, 2022, the State Courts of the Republic of Singapore had reached a verdict that </span>the Company&#8217;s subsidiaries, KRHSG
and Melana (Defendants) is liable to compensate Jamie Fan Wei Zhi (Plaintiff), the Company&#8217;s related party for failing to procure
the release of the Plaintiff from the guarantees to secure a credit line from United Overseas Bank before December 31, 2020. The Defendants
agree to compensate the Plaintiff the sum of $<span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_c20220101__20221231_zFDZre1WF5E2" title="Compensate amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,704</ix:nonFraction></span> (SGD <span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_uSGD_c20220101__20221231_z5ccxlYxcuN4" title="Compensate amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,000</ix:nonFraction></span>) per month as guarantor fee starting from January 1, 2021 until the Defendants
procured the release of the Plaintiff as the guarantor of the loan. The Defendants released the Jamie Fan Wei Zhi as the guarantor of
the loan on October 31, 2022. As of December 31, 2022, the Company has paid Jamie Fan Wei Zhi $<span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_z0gJyQsSiHCd" title="Legal payment"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,966</ix:nonFraction></span> (SGD <span id="xdx_909_eus-gaap--LossContingencyDamagesPaidValue_uSGD_c20220101__20221231_zg0kSTSngrTl" title="Legal payment"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,000</ix:nonFraction></span>), and <span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_do_c20221231_zPzPd6PPcPw6" title="Contingent liability balance outstanding"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> more balance
outstanding.</p>
<!-- Field: Split-Segment; Name: 007 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zwpZ64DM5STf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 21 &#8211; <span id="xdx_828_z8TB7ces3og4">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company presents segment
information after elimination of inter-company transactions. In general, revenue, cost of revenue and operating expenses are directly
attributable, or are allocated, to each segment. The Company allocates costs and expenses that are not directly attributable to a specific
segment, such as those that support infrastructure across different segments, to different segments mainly on the basis of usage, revenue
or headcount, depending on the nature of the relevant costs and expenses. The Company does not allocate assets to its segments as the
Chief Operating Decision Maker (&#8220;CODM&#8221;) does not evaluate the performance of segments using asset information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company evaluates performance
and determines resource allocations based on a number of factors with the primary measurements being revenues and income/loss from operations
of the Company&#8217;s two reportable segments: 1) Medical Services and 2) Property Management Services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" continuedAt="ConU002088-01" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MLIH_zjoOcL57Ylw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following tables present
the summary of each segment&#8217;s revenue, loss from operations, income (loss) before income taxes and net income (loss) which is considered
as a segment operating performance measure, for the years ended December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B0_z4eZA4e9mIg4">Schedule
of segment reporting information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z8ah55WnuA9h" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zrSGorQLJfp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_zKJkRiVaJPA6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zl3ryZVn9in2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,076,414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,764,295</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,840,709</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zaMLuK1Pn4W6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,463,593</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,991,371</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,454,964</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zLLEelNKyzpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,613,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,800,755</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,414,370</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zSBZ9LCdrvli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,651,826</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,779,966</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,431,792</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zyBIyrSXf8Tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"><p id="xdx_89E_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zbi74RH6UiDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
of the Company&#8217;s segment net loss before income taxes to the consolidated statement of operation and comprehensive income (loss)&#8217;s
net loss before income taxes for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zpfkpXgIvIX8" style="display: none">Schedule
of consolidated statement of operation and comprehensive income (loss)
net loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zXS513TrVwDk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_zOMhaUDoz60a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Segment loss before income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,414,370</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_iN_di_zknj3pCpykoj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of prepaid forward purchase liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,503</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--EarnoutSharePayment_iN_di_zPE6c6oJ1S65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Earnout share payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="EUDA:EarnoutSharePayment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,199,629</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--OtherCorporateExpenses_iN_di_zm0mIqCHIh78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other corporate expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="EUDA:OtherCorporateExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zCETa8iJRSp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Consolidated net loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,931,824</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zquxMWINXwS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_C0F_gL3SOSRIBSTB-MLIH_zhbSOpfrzthh"><ix:continuation continuedAt="ConU002088-02" id="ConU002088-01"><table cellpadding="0" cellspacing="0" id="xdx_300_134_zFFbIL40VGB7" summary="xdx: Disclosure - Schedule of segment reporting information (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zVxPERp1WWMl" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zTNi99oY9Fs5" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_z8ikQOnygo5k">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zGz5sfcm7hve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,986,030</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,558,520</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,544,550</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zD7lB9iowtJ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,186,885</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,342</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,228,227</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zFo1MeNfyLA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) before income taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,239,438</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,187,975</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">948,537</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zntSrFKSsDmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,241,091</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,141,487</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,396</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C0E_gL3SOSRIBSTB-MLIH_zGOTHpjMkVNl"><ix:continuation id="ConU002088-02">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The accounting principles
for the Company&#8217;s revenue by segment are set out in Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company&#8217;s total assets were composed of $<span id="xdx_905_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zbmKTNq76yB1" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,176,405</ix:nonFraction></span> for medical services, $<span id="xdx_90E_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zq0FYx5BA2m3" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,068</ix:nonFraction></span> for property management services and $<span id="xdx_909_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z633Pm9fTjOf" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,117,567</ix:nonFraction></span>
for corporate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2021,
the Company&#8217;s total assets were composed of $<span id="xdx_90D_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z37c18cR0cu5" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31_custom_MedicalServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,478,872</ix:nonFraction></span> for medical services and $<span id="xdx_904_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zbLh0WQ3Q2me" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31_custom_PropertyManagementServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,412,439</ix:nonFraction></span> for property management services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As substantially all of the
Company&#8217;s long-lived assets are located in Singapore and all of the Company&#8217;s revenue is derived from Singapore, no geographical
information is presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zuzOVkCGMsug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 22 &#8211; <span id="xdx_82E_zcNpE211EV0i">Subsequent events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated all events and transactions
that occurred after December 31, 2022 up through the date the Company issued these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 9, 2023, James
Tan, who is the former Chief Executive officer of 8i loaned the Company for an amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwvKSPWUo7Lj" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,450</ix:nonFraction></span> (the &#8220;Initial Tan Loan&#8221;)
at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrdc6AGExaIh" title="Interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-01-092023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% interest per annum and was to be repaid by March 31, 2023. The Initial Tan Loan was not timely repaid by March 31, 2023 and was
replaced as disclosed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On February 2, 2023, the
Company entered into a loan agreement (&#8220;Agreement&#8221;) with Alfred Lim, the independent director of the Company, pursuant to
which Alfred Lim granted a loan amounted to $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zsPcwkQXuOWk" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,750</ix:nonFraction></span> to the Company at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230202__20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zXOxAWbA5bNd" title="Interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-02-022023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% interest per annum. The loan was due on March 31, 2023. On March 31, 2023 the Company further extended the maturity date of such
loan to December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 24, 2023, James
Tan loaned the Company an additional $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zbCIDayRCKQf" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,750</ix:nonFraction></span> (the &#8220;Tan Second Loan&#8221;) at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230424__20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zcwEjE8Ctpq7" title="Interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-04-242023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% interest per annum, which matures on the earlier
of June 30, 2023 or within seven days of the Company receiving the proceeds from the sales of securities in the private placement (the
&#8220;Private Placement&#8221;). Pursuant to the terms of the Tan Second Loan, the Company agreed to issue to James Tan a new promissory
note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanFirstLoanMember_zkRq0lx9ib71" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanFirstLoanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,450</ix:nonFraction></span> dated April 24, 2023 (the &#8220;Tan First Loan&#8221;) to replace the Initial Tan Loan. The
Tan First Loan contained the same payment terms as the Tan Second Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 15, 2023, James Tan
entered into a third loan agreement with the Company pursuant to which James Tan agreed to loan the Company an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zUldxfZ1Ilk9" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,500</ix:nonFraction></span> (the
&#8220;Tan Third Loan&#8221;), provided that the Company issued a new promissory note to James Tan in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zKGxivdVcAv1" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span>
(the &#8220;Tan 2023 Note&#8221;) to replace the James Tan&#8217;s convertible note balance as of December 31, 2023 (see note 13) (the
&#8220;Tan 2022 Note&#8221;). The Tan Third Loan would bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zeiqIaFVcq56" title="Interest rate percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum, and would be repaid upon the earlier of June 30,
2023 or within seven days of the Company receiving the proceeds from the sales of securities in the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 15, 2023, the Company
issued to James Tan the Tan 2023 Note to replace the Tan 2022 Note. The Tan 2023 Note was an interest-free convertible promissory note
in the aggregate principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zzWinkIh26gb" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span>. On May 15, 2023, James Tan elected to convert the entire unpaid principal in the amount
of $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zv70B64MBabh" title="Conversion of unpaid principal amount"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span> of the Tan 2023 Note into ordinary shares of the Company at $<span id="xdx_900_eus-gaap--CommonStockNoParValue_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z6dwX8c71ju3" title="Ordinary shares per share"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in accordance with the terms of the Tan 2023 Note.
On May 16, 2023, the Company issued to James Tan <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z17zh96cLhL9" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> ordinary shares in full satisfaction of the Tan 2023 Note. Pursuant to the terms
of the Tan 2023 Note, the Company has agreed to register the <span id="xdx_901_ecustom--OrdinarySharesAvailableForResale_iI_pid_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zPKW5sl73qPb" title="Ordinary shares available for resale"><ix:nonFraction name="EUDA:OrdinarySharesAvailableForResale" contextRef="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> ordinary shares for resale. The Company refers to these <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zWkLcYVdQoxc" title="Restricted ordinary shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> restricted
ordinary shares as the &#8220;Converted Shares.&#8221; <span id="xdx_90D_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zpMWkwmqoqCc" title="Conversion of ordinary shares, description"><ix:nonNumeric contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember" name="us-gaap:ConversionOfStockTypeOfStockConverted">This conversion is likely resulted in modification of the convertible notes as
the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher than $1.00 and reduced
the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreement (&#8220;Settlement Agreement&#8221;) with James Tan, pursuant to which the Company
agreed to issue to James Tan an aggregate of <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--JamesTanMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5Xn83LZdkS7" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_JamesTanMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">478,200</ix:nonFraction></span> restricted ordinary shares of the Company in full satisfaction of all obligations
of the Company under the Tan First Loan and the Tan Second Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreements (&#8220;Settlement Agreements 2&#8221;) with two third parties, Shine Link, and
Menora, and a related party, 8i Holding, pursuant to which the Company agreed to issue to Shine Link, Menora, and 8i Holding <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ShineLinkMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zQgSLj6Z6cJ2" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_ShineLinkMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></span>, <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MenoraMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zHLX7osHK2J" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_MenoraMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,000</ix:nonFraction></span>,
and <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EightiHoldingMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zjQ3w0HKv452" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_EightiHoldingMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,600</ix:nonFraction></span> restricted ordinary shares of the Company, respectively, in full satisfaction of all obligations of the Company under the convertible
notes balance set forth in Note 13 from Shine Link, Menora, and 8i Holding. <span id="xdx_90E_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5UCitQn2lq8" title="Conversion of ordinary shares, description"><ix:nonNumeric contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" name="us-gaap:ConversionOfStockTypeOfStockConverted">These conversions are likely resulted in modification of the
convertible notes as the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher
than $1.00 and reduced the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreement (&#8220;Chen Settlement Agreement&#8221;) with </span>Kelvin Chen<span style="background-color: white">,
the CEO of the Company, pursuant to which the Company agreed to issue to Kelvin Chen an aggregate of <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_zZl44HNO4skh" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,306</ix:nonFraction></span> restricted ordinary shares
of the Company in full satisfaction of Kelvin Chen&#8217;s claim for an aggregate amount of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_z2aaH48OMdw2" title="Ordinary shares aggregate amount"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850,306</ix:nonFraction></span> provided to KRHSG from time to time
since inception. Upon issuance of the restricted ordinary shares, the balance own to Kelvin Chen reduced to nil. In order to comply with
Nasdaq&#8217;s shareholder approval requirement for issuance of stock to an executive officer of a company pursuant to Nasdaq Listing
Rule 5635(c), the Company and Dr. Chen amended the Chen Settlement Agreement by entering into a Supplemental Agreement (the &#8220;Supplemental
Agreement&#8221;) on June 6, 2023, so that the shares issued to Dr. Chen would be issued at a per share price not less than the closing
bid price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--RangeAxis__srt--MaximumMember_zwKXWZNOpfxb" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> per share on May 15, 2023, the day prior to the execution of the Chen Settlement Agreement. Pursuant to the Supplemental
Agreement, Dr. Chen has agreed to release and discharge KRHSG of all claims in return for <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zhGY4wswNL5f" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">578,439</ix:nonFraction></span> ordinary shares at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zGMENy2YPEll" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> per share,
the closing bid price of EUDA ordinary shares on May 15, 2023. Dr. Chen has agreed to forfeit and surrender <span id="xdx_902_ecustom--OrdinarySharesForfeited_iI_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zxsJuOxCsBAk" title="Ordinary shares forfeited"><ix:nonFraction name="EUDA:OrdinarySharesForfeited" contextRef="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,867</ix:nonFraction></span> ordinary shares of
the <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zFkCGPb20iF3" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,306</ix:nonFraction></span> ordinary shares issued to him on May 16, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Between
May 16 and May 22, 2023, the Company issued and sold to eight accredited investors an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPv0cxwTk9r3" title="Investors sale of stock and issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">940,000</ix:nonFraction></span> ordinary shares (the &#8220;Placement
Shares&#8221;) at $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zouuncvZXAnf" title="Investors sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for an aggregate to purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq5hcj1QIaB3" title="Investors sale of stock aggregate purchase price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,000</ix:nonFraction></span> in a private placement in reliance upon the exemption
from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506
promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 8, 2023, the Company
and the Seller 1 and Seller 2 (together, the &#8220; Sellers&#8221;) entered into amendments to the Prepaid Forward Agreements (together,
the &#8220;Amendments&#8221;), to amend the definition of &#8220;Maturity Consideration,&#8221; such that, Maturity Consideration shall
consist of <span id="xdx_90A_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zERqaZKpCb72" title="Ordinary shares to be issued"><span id="xdx_908_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zt5U0FtuUMcj" title="Ordinary shares to be issued"><ix:nonFraction name="EUDA:OrdinarySharesToBeIssued" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="EUDA:OrdinarySharesToBeIssued" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></ix:nonFraction></span></span> ordinary shares of the Company to be issued to the Sellers by the Company. Pursuant to the Prepaid Forward Agreements,
the maturity date of the Prepaid Forward Transaction 1 and 2 (together, the &#8220;Prepaid Forward Transactions&#8221;) (the &#8220;Maturity
Date&#8221;) may be accelerated by the Sellers after any occurrence wherein during any 30 consecutive trading-day period, the dollar volume-weighted
average price of Company&#8217;s ordinary shares for 20 trading days is less than $<span id="xdx_908_eus-gaap--SharePrice_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zXUEz4uhktu3" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share. Pursuant to the Amendments, the parties
agreed that the Prepaid Forward Transactions shall be accelerated as of the date of the Amendments, and accordingly, the <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zKT4Dq40Cy5j" title="Ordinary shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zzSp6mQhPTc8" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></ix:nonFraction></span></span> ordinary
shares (or <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkLrsvQOtkB9" title="Ordinary shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,600,000</ix:nonFraction></span> ordinary shares in the aggregate), became immediately due and payable to the Sellers upon execution of the Amendments.
The Amendments provide the Sellers with registration rights for the ordinary shares issuable as Maturity Consideration, and also prohibit
the Sellers from selling such ordinary shares on any exchange business day in an amount greater than <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zkt7DP8QMf0h" title="Debt instrument trading percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of the daily trading volume of
the Company&#8217;s ordinary shares on such day. In addition, as of June 8, 2023 (the &#8220;Maturity Date&#8221;), the Sellers became
entitled to retain (a) the remaining prepayment amount paid from the Company&#8217;s trust account to the Sellers upon consummation of
the Company&#8217;s business combination, and (b) the remaining ordinary shares held by each Seller that were subject to the Prepaid Forward
Transactions. Pursuant to the Amendments, no other fees, consideration or other amounts are due to the Seller or the Company upon the
Maturity Date.</p>

</ix:nonNumeric><p id="xdx_817_zXxgIN2qg0ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 114; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>ex4-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE COMPANY&rsquo;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized capital stock of the Company consists of an unlimited number of shares of a single class, each with no par value. No preferred
shares are issued or outstanding or authorized by the Company&rsquo;s Charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Pursuant
to the Company&rsquo;s Charter. at least seven days&rsquo; notice must be given for each general meeting of shareholders (although the
Company will provide whatever minimum number of days are required under Federal securities laws). Shareholders may vote at meetings in
person or by proxy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our board of directors serve two year terms. There is no cumulative voting with respect to the election of directors, with
the result that the holders of more than 50% of the shares eligible to vote for the election of directors can elect all of the directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the ordinary shares being registered hereby are issuable upon the conversion of certain convertible promissory notes issued in connection
with the Business Combination. Each of the convertible notes has a maturity date of one year from the date of issuance. The outstanding
unpaid principal amount of certain of those convertible promissory notes is convertible at maturity at a conversion price based on the
five-day volume weighted average trading price of our ordinary shares immediately prior to the time of conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the SPA, upon the consummation of the Business Combination (the &ldquo;Closing&rdquo;), any and all outstanding units
of 8i, composed of one ordinary share of 8i, no par value (the &ldquo;8i Ordinary Shares&rdquo;), one warrant (the &ldquo;8i Warrants&rdquo;),
with every two 8i Warrants entitling the registered holder to purchase one 8i Ordinary Share, and one right to receive one-tenth (1/10)
of one 8i Ordinary Share upon the consummation of an initial business combination (the &ldquo;Rights&rdquo;) (collectively, the &ldquo;Units&rdquo;)
were separated into their component parts and the 8i Ordinary Shares and 8i Warrants were re-designated on a one-for-one basis, and the
Rights were converted (at the rate of one-tenth (1/10) of a share for each outstanding Right), into ordinary shares of EUDA Health Holdings
Limited, no par value. Our ordinary shares and warrants are listed on the Nasdaq Stock Market LLC, or Nasdaq, under the symbols &ldquo;EUDA&rdquo;
and &ldquo;EUDAW,&rdquo; respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
warrants entitle the registered holder to purchase one ordinary share at a price of $11.50 per share, subject to adjustment as discussed
below, at any time commencing on the later of the completion of our initial business combination and 12 months from the date the registration
statement was filed in connection with our initial public offering was declared effective by the SEC. Pursuant to the warrant agreement,
a warrant holder may exercise its warrants only for a whole number of shares. This means that only an even number of warrants may be
exercised at any given time by a warrant holder. However, except as set forth below, no warrants will be exercisable for cash unless
we have an effective and current registration statement covering the ordinary shares issuable upon exercise of the warrants and a current
prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares
issuable upon exercise of the warrants is not effective within 60 days from the consummation of our initial business combination, warrant
holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain
an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption from registration provided by Section
3(a)(9) of the Securities Act provided that such exemption is available. If an exemption from registration is not available, holders
will not be able to exercise their warrants on a cashless basis. The warrants will expire five years after the completion of our initial
business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may call the warrants for redemption, in whole and not in part, at a price of $0.01 per warrant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    any time while the warrants are exercisable,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    not less than 30 days&rsquo; prior written notice of redemption to each warrant holder,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share, for any 20 trading days within
    a 30 trading day period ending on the third business day prior to the notice of redemption to warrant holders (the &ldquo;Force-Call
    Provision&rdquo;), and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at
    the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date
    of redemption.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and
after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&rsquo;s
warrant upon surrender of such warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
redemption criteria for our warrants have been established at a price which is intended to provide warrant holders a reasonable premium
to the initial exercise price and provide a sufficient differential between the then-prevailing share price and the warrant exercise
price so that if the share price declines as a result of our redemption call, the redemption will not cause the share price to drop below
the exercise price of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we call the warrants for redemption as described above, our management will have the option to require all holders that wish to exercise
warrants to do so on a &ldquo;cashless basis.&rdquo; In such event, each holder would pay the exercise price by surrendering the whole
warrants for that number of ordinary shares equal to the quotient obtained by dividing (x) the product of the number of ordinary shares
underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &ldquo;fair market value&rdquo;
(defined below) by (y) the fair market value. The &ldquo;fair market value&rdquo; shall mean the average reported last sale price of
the ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent
to the holders of warrants. Whether we will exercise our option to require all holders to exercise their warrants on a &ldquo;cashless
basis&rdquo; will depend on a variety of factors including the price of our ordinary shares at the time the warrants are called for redemption,
our cash needs at such time and concerns regarding dilutive share issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if (x) we issue additional ordinary shares or equity-linked securities for capital raising purposes in connection with the
closing of our initial business combination at an issue price or effective issue price of less than $9.50 per ordinary share (with such
issue price or effective issue price to be determined in good faith by our board of directors), (y) the aggregate gross proceeds from
such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business
combination, and (z) the Market Price is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent)
to be equal to 115% of the Market Price, and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest
cent) to be equal to 165% of the Market Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants will be issued in registered form under a warrant agreement between American Stock Transfer &amp; Trust Company, LLC, as warrant
agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure
any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of a majority
of the then outstanding warrants in order to make any change that adversely affects the interests of the registered holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price and number of ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including
in the event of a share capitalizations, extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of ordinary shares at a price below their respective exercise prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant
agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full
payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant
holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their warrants and
receive ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be entitled to one vote
for each share held of record on all matters to be voted on by shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described above, no warrants will be exercisable and we will not be obligated to issue ordinary shares unless at the time a holder
seeks to exercise such warrant, a prospectus relating to the ordinary shares issuable upon exercise of the warrants is current and the
ordinary shares have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder
of the warrants. Under the terms of the warrant agreement, we have agreed to use our best efforts to meet these conditions and to maintain
a current prospectus relating to the ordinary shares issuable upon exercise of the warrants until the expiration of the warrants. However,
we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the ordinary shares issuable
upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant
exercise. If the prospectus relating to the ordinary shares issuable upon the exercise of the warrants is not current or if the ordinary
shares is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be
required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited
and the warrants may expire worthless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
holders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrant holder (and his, her
or its affiliates) would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder
(and his, her or its affiliates) would beneficially own in excess of 9.8% of the ordinary shares issued and outstanding. Notwithstanding
the foregoing, any person who acquires a warrant with the purpose or effect of changing or influencing the control of our company, or
in connection with or as a participant in any transaction having such purpose or effect, immediately upon such acquisition will be deemed
to be the beneficial owner of the underlying ordinary shares and not be able to take advantage of this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive
a fractional interest in a share (as a result of a subsequent share capitalizations payable in ordinary shares, or by a split up of the
ordinary shares or other similar event), we will, upon exercise, round up or down to the nearest whole number the number of ordinary
shares to be issued to the warrant holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representative of the underwriters has agreed that it will not be permitted to exercise any warrants underlying the purchase option to
be issued to it and/or its designees after the five year anniversary of the effective date of the registration statement of which this
prospectus forms a part. Furthermore, because the private warrants will be issued in a private transaction, the holders and their transferees
will be allowed to exercise the private warrants for cash even if a registration statement covering the ordinary shares issuable upon
exercise of such warrants is not effective and receive unregistered ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preemptive
or Other Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shareholders of the Company have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions
applicable to the ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Register
of Members</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the British Virgin Islands Business Companies Act, 2004 (the &ldquo;Companies Act&rdquo;), the entry of the name of a person in the Company&rsquo;s
register of members as a holder of the shares is prima facie evidence that the person a legal owner of the shares. The register of members
will be maintained by the Company&rsquo;s transfer agent, American Stock Transfer &amp; Trust Company, LLC, which will enter the name
of Cede &amp; Co in the register of members as nominee for each of the respective public shareholders. If (a) information that is required
to be entered in the register of members is omitted from the register or is inaccurately entered in the register, or (b) there is unreasonable
delay in entering information in the register, a shareholder of the Company, or any person who is aggrieved by the omission, inaccuracy
or delay, may apply to the British Virgin Islands courts for an order that the register be rectified, and the court may either refuse
the application or order the rectification of the register, and may direct the company to pay all costs of the application and any damages
the applicant may have sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We have never
declared or paid any cash dividends on our capital stock. We do not intend to pay cash dividends to our shareholders in the foreseeable
future. Investors should not purchase our ordinary shares with the expectation of receiving cash dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition,
operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our stockholders or their permitted transferees, are entitled to rights with respect to the registration of certain shares of Ordinary
Shares held by them under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). These rights are provided under
the terms of a registration rights agreement between us and such stockholders (the &ldquo;Registration Rights Agreement&rdquo;) and include
demand registration rights and piggyback registration rights. The Registration Rights Agreement also provides that we will pay certain
expenses of these holders relating to such registrations and indemnify them against certain liabilities which may arise under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing
of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Ordinary Share is listed on The Nasdaq Global Market under the symbol &ldquo;EUDA&rdquo;. Our Warrant is listed on The Nasdaq Global
Market under the symbol &ldquo;EUDAW&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent for the Common Stock is American Stock Transfer &amp; Trust Company, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
of EUDA Health Holdings Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
Doctor Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
Health Limited, A British Virgin Islands company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EUDA
Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent
Ridge Health Limited, A British Virgin Islands company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent
Ridge Healthcare Singapore Pte. Ltd., A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent
Ridge Hill Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR
Digital Pte. Ltd., A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melana
International Pte. Ltd., A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nosweat
Fitness Company Private Lim, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
Emergency Medical Assistance Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Super
Gateway Group Limited, A British Virgin Islands company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tri-Global
Security Pte. Ltd., A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">True
Cover Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UG
Digital Sdn. Bhd., A Malaysian company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UG
Digitech Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universal
Gateway International Pte. Ltd., A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zukihealth
Sdn. Bhd., A Malaysian company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zukitech
Private Limited, A Singapore company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zukitek
Vietnam Private Limited Liability Company, A Vietnam company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><IMG SRC="ex23-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Annual Report on Form 10-K of our report dated June 3, 2022, except for Note 3 which is dated July 25,
2022, with respect to our audit of the consolidated financial statements of EUDA Health Limited as of December 31, 2021 and for the year
ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Friedman LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">June
<FONT STYLE="background-color: white">28</FONT>, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex23-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><IMG SRC="ex23-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
28, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir or Madam:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have read the Annual Report on Form 10-K dated June 28, 2023 of EUDA Health Holdings Limited (&ldquo;Registrant&rdquo;) and are in
agreement with the statements contained under the section of Change in Registrant&rsquo;s Certifying Accountant as it pertains to our
firm; we are not in a position to agree or disagree with other statements of Registrant contained therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Friedman LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Kelvin Chen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.I
have reviewed this Annual Report on Form 10-K of EUDA Health Holdings Limited;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 28, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wei Wen Kelvin Chen</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Steven John Sobak, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.I
have reviewed this Annual Report on Form 10-K of EUDA Health Holdings Limited;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 28, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Steven John Sobak</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO 18 U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of EUDA Health Holdings Ltd (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December
31, 2022 (the &ldquo;Report&rdquo;), Kelvin Chen, Chief Executive Officer of the Company, certifies, to the best of his knowledge, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 28, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 3%">By:
</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wei Wen Kelvin Chen</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wei Wen Kelvin Chen</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO 18 U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of EUDA Health Holdings Limited (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December
31, 2022 (the &ldquo;Report&rdquo;), Steven John Sobak, Chief Financial Officer of the Company, certifies, to the best of his knowledge,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 28, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Steven John Sobak</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven John Sobak</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial Officer)</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: 84# 2(  A$! Q$!_\0
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M>\OK33X1->W4%M$3M#S2!%SZ9/>A)O1 VEJRQ15>SOK/4(3-97<%S$&VEX9
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MW^:A;[N<8P1ZFO8P2FZ$E3WN>'CW36(BZOPV.]_X4M'_ -!UO_ 7_P"SK?\
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M,\!4]E&4)=$I?)H\@\::FVM^*]1O4)>!)/*C;L%7@?G@G\:]M\"_\B1I'_7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUJGA^]D1!'?VUQ+"EZ@4=TRK%22,,,].QH [G2+ZZO[ 2WNG2V%RKLDD#N'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23-1_002.jpg
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ HD# 2(  A$! Q$!_\0
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MXO&/AZ><0Q:M;NY4L-I)4@#/!Q@G SC.:TH=2LKB:**&YCDDEA$Z*IR6C/\
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MU=%9FC:J^IQW23VQMKNTF,$\.\.%;:&!!'4%64_C6G0 4444 %%%% !1110
M4444 %%%% !16'=>)K2TUJ2PE9$2&'SIY78@(.V..:F'B+3?+EF>[B$*.J C
M)8DKG&W&<_TK3V4[7L9^TAM<UJ*S9]?TNW@AF:]BVSJ7B(.=P'?V'N:@M_$^
ME26]L\UW%!+/$DAB9N4W*& )[=?QH]G.U[#]I"]KFS166WB+2%M5N#?1^4S%
M 0"3D=1C&:?-KVE6[1K+?PJ945T^;.58D!OID'FE[.?9ASQ[FC16,_B*WAOI
MX)U\J*!W5YF;Y0%C1R3[?/\ I5ZRU2RU$RBTN4E,1PX7J/\ ZWO0Z<DKM IQ
M;LF6Z*SAK^D^=-%]O@#P@F3+8 QUYZ''M2)X@TF2U:Y6^B\I7"%B2,,1D#!Y
MY[>M'LY]F'/'N:5%9UMKVEWD\<-O>Q/)("449YQU'U]NM:-2XN.Z*4D]F%%%
M%(85F:UI<FI0P/;S+#>6LHF@D9=R[@",,,C((.#6G56^U*QTR$37]W!:Q$[0
M\T@0$^F332;=D)M+5G-WWAG5-<6>75KFR\[[.;>VC@C;9&&*EV8L<MG:!C'&
M.],UOP5)JEY)=QW,:2+/!/$C!@I*1LA#%2#T8D$="!6O_P )?X;_ .@]IO\
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MX$TS[F)BQ$J8W,26.5')]>G%:/\ PE_AO_H/:;_X$I_C1_PE_AO_ *#VF_\
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M "#VD/YE]Z_S.6/P[O8[UKT:DEU.)YBGVC>N8G2-0"RG)<>4!G^(9SR:N/\
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MXC=79D4@_>*YR!ZXP:22_LXHWD>YB"H"6(<' '7^8_.CVD^[^]AR1[+[BO\
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M-:E% &7J'A_3M3NDNKB.59U3RS)!.\1=,YVML(W+['(IRZ#IJKM6V 'V@7.
MQQY@X!Z_ITK2HH YF^\%:=?ZU'>2!UA$,ZND<KHS/*T9+;E((&$((Z'-67\&
MZ"]VMQ]AV[2A,*2NL3%!A"T8.UB,#!(/0>E;M% &/-X7T:?[7YEBA^UW"74P
MW$;I4QM;KP>!G'7OUI8/#6EVUX]S%#*I=F?RA._E!FZL(\[03D\@9Y/K6O10
M!C2^%=)EALXA#-"+. 6\+07$D3"(  (65@67@<$FF2>$-#EO4NFLR'5TD"+*
MZQ[T^Z^P';N XSC-;E% $<,*P1[%+D9)R[ECS[FI*** "BBB@ HHHH ****
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F^=XE51L:-2N0V<X]P<5IVD'V:V2'*G;T*KM'Y5-10 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V 5X# 2(  A$! Q$!_\0
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MNU/3X-7N+7RY)9-S2.1@/C  /'6ND_X5;KW_ $-,GYR?_%5R6EG7QXRU0^'
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8\'G=U&/>BB@#UFBBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L A # 2(  A$! Q$!_\0
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M?\+!_P"H9_Y,?_8UQ7?\:*KG9S\S.U_X6#_U#/\ R8_^QH_X6"?^@7_Y,?\
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M"_\ R8_^QH_X6#_U#/\ R8_^QKBJ.U'.PYF=K_PL'_J&?^3'_P!C4D'C^%I
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M84444 %%%% !1110 4444 8^M_\ +#_@7]*\#NO^/N;_ *Z-_.O?-;_Y8?\
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M_P#+=OYUI+X44]D9U3V]E<W:NUO \BQC+E1PHSC)].HJ#MBMWP\A>QULF)I
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M_(/C_'^9JYWJGIG_ "#X_P ?YFKG>L);L]./PH6BBBD4%%%% !1110 4444
M%%%% $$\"7$9C<9!_,'U%<SJ7A6*_<"YLX[@ 85\[2!Z9R#764M5&;B1*"EN
M<#_PK_3O^@4/_ AO_BJ7_A7^G?\ 0*'_ ($-_P#%5WF*,57M69^PB<%_PK_3
MO^@4/_ AO_BJ7_A -/\ ^@7_ .3#?_%5WE%+VC#V$3@_^%?Z=_T"A_X$-_\
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MKB5YY%Y.2-FU3Q@@9_$=G87,CIJJW=]:V,0DN[J&",MM#RR!%)],GOP:P?\
MA&=1N85&H>)M3DD5CM:TV6PP<<$*#D\=2?ZYM0>$M"@EEE_LV&629MSM< S%
MCSSER>>3GUH"[?08WBW2&GFM[:>2^GC0R&.RA>8L,=BH*]P.N,GG%1#7M:N6
MA>R\,W'V>0@&2\N$@9#N(.4^9L#KZGL.F>@BAC@B2*)%2-  JJ,  = !V%34
M!9]6<P;'Q;=QJ9]9L;!U8\6=H90XXP29#P>O 'Y]GR>#;&Z$HU.[U'4E=_,"
M75TVQ&YY54V@=?3CMBNDHHN'*C*LM TK3_*>UTVTADC7:DBQ#>.,?>ZGCOGF
MM6BEI#22"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !245ROC7Q+_PCVD@
MV[;;ZY!6W)3<%QC<Q[< \=>2.",T)7)E)15V:FJ^(M)T10-0OHXF;&$Y9SG/
M.U03C@\XQ6;_ ,+!\,'_ )B?_DO+_P#$UQ'AKP'<:Z@U+5KB:&&9BZ@<RS Y
M^<DYP"2#D@YYZ<$V=0'P]TF7[&UE=W<T3&*9HVDRK+P=V649)S]WC@].*JR,
M7.=KZ)>9U_\ PL+PO_T$_P#R7E_^)H_X6%X7_P"@G_Y+R_\ Q-<+_:?P\_Z
M.H_]_#_\=H_M/X>?] '4?^_A_P#CM%B?:/NCNO\ A8/A?_H)_P#DO+_\31_P
ML'PO_P!!/_R7E_\ B:X7^T_AY_T =1_[^'_X[1_:?P\_Z .H_P#?P_\ QVCE
M0_:ONCNO^%A>%_\ H)_^2\O_ ,31_P +!\+_ /03_P#)>7_XFN%_M/X>?] '
M4?\ OX?_ ([1_:GP\_Z .H?]_#_\=HY1>T?='2:CKO@'5?--XUO(\A&^7[)(
MLAQC'SA0W8#KTXK/CU'PM9L6TKQ/J=@H4B&!5DD@C)'78Z'(R2<$]3V[9?\
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MG_0 U#_OX?\ X[1_:GP\_P"@#J'_ '\/_P =I6*4[;-'<_\ "P?"_P#T$_\
MR7E_^)H_X6%X7_Z"?_DO+_\ $UPO]I_#S_H ZC_W\/\ \=H_M/X>?] '4?\
MOX?_ ([2Y0]H^Z.Z_P"%@^%_^@G_ .2\O_Q-'_"P?"__ $$__)>7_P")KA?[
M3^'G_0!U'_OX?_CM']I_#S_H ZC_ -_#_P#':.5#]I+NCNO^%A>%_P#H)_\
MDO+_ /$T?\+"\,?]!3_R7E_^)KA?[3^'G_0!U'_OX?\ X[1_:?P\_P"@#J/_
M '\/_P =HL+VC[H[J/Q[X;EE2-=34,Y"@M%(HY]25P![FNABFCGB66)U>-P"
MK*<@@]"#WK@#X&\,^([(7F@W<D"?<RA+J&!YW*_S9P>F1V/UP_#U]J/@CQ.-
M)U-O+LYW D!.4YX6522,#.,GT!R,C@LGL6IR3][;N>Q44=J*DW"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>NF'_O\ Q?\ Q5'_  K_ ,3_ /0+/_?^+_XJO=,48I\[,_81/"_^%?\ B?\
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M_P#T"_\ R/%_\51_P@'BC_H%_P#DQ%_\57NE%'.P]A$\+_X5_P")_P#H%_\
MDQ%_\51_P@'BC_H%_P#DQ%_\57NE%'.P]A$\+_X0#Q1_T"S_ -_XO_BJ/^$
M\4?] O\ \CQ?_%5[IBC%'.P]A$\+_P"%?^)_^@7_ .1XO_BJ/^$ \4?] O\
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M?0O-^]LEQ_N^:^W],5F>,O"OQ$U7Q+-=^'?%$.GZ<ZH$MVE<%2!@G 0CD^]
M&!Y/QZ(_X^=/_*W_ ,*T_%7B+QIX4^$,6H:C=11^(5N@DTB1QNNTNV!@#;]W
M;VK,_P"$$^,/_0]0?]_I/_C=+\2-+UVP^!(MM>O5O]1@NT>>X5BP*F0[>2!T
M#** /0OAUK%]K_@+2M5U*7S;RXC9I7"A,D.PZ  = *X;4?'GB&W^/-OX7CO$
M&DO+&K1>2I)!BW'YL9ZFND^#-[!=?"[2%BE5GMQ)%(H/*,'8X/X$'\:\SNIH
M]1_:D@>SD$ZI.BLR<C*0?,,^V"/PH N^)?'?C^7XJW_A7PW>PC$FVWB>&+
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MI7_7G#_Z *U*EEQV0M%%%!04444 %%%% !1110 4444 %%%% !1110 4444
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M  DNA_\ 0:T[_P "D_QH_P"$ET/_ *#.G?\ @4G^-'_"-Z)_T!M._P# 5/\
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MI_A1H'O^0?\ "2Z'_P!!K3O_  *3_&C_ (270_\ H-:=_P"!2?XT?\(WH?\
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MB?\ 0&T[_P !4_PH_P"$;T/_ * VG?\ @,G^%&@>_P"0?\)+H?\ T&M._P#
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M7944!9]V>>:KI_C36XDCU&))UC)9"S0 KZ\K@X]N^!Z5>BG^(4$211,D<:*
MJ*ML H'0 #IQ7:T4Q<G6[..^V_$?_GJ?_);_  H^V_$?_GJ?_);_  KL:*0[
M/NSC?M_Q'_YZ_I;4OVWXC_\ /4_^2W^%=C10%GW9Q$^J?$.WB,DDLFU>3LB@
M<_D 376>#/%Q\2P317*1Q7T/S,L9PKJ3P5!)/'0]>HYYP+=<=X!18_B#JZ*
M%6.8 #L/-6DUH";C):[GJM%%%0=0F.*X_P 8^,O^$<\NUM81+?RX<!P=BIG&
M3C&2<$  ^Y[ ]C7D'B'=<?%98Y69TCEA"*Q)"C8K8'H,DG\3515V959.,="6
M'4_B+-$)%D< ]GC@4_D0#4GV_P"(_P#SU_2VKL:7O56,K/NSCOM_Q'_YZ_I;
M4GV[XC_\]3_Y+?X5V5'X4!9]V<;]N^(W_/7]+:HKF3X@W=M-:SN'AF0QNO\
MHXRI&",CVS7;T46#E?=GGVEV?C?1;9K?3T$$+N9&7= <L0 3EL]@*O?;?B/_
M ,]?_2;_  KLZ*+"4;:79QWVWXC_ //4_P#DM_A1]O\ B/\ \]?TMJ[&BBP[
M/NSC?MWQ'_YZG_R6_P *0W_Q' SYO_CMO_A79_K10'*^[.7\->-=5AUN/2-?
MCW//*$65EV-&2, ;57# G: >,9)R1T]+KQGXAJ/[1LV ^8PD9_&O91TJ9(TI
M-ZI]!U%%%2;">]<'XI\?-IEZ-.TB.*ZNT;$S,"RJ?[@"D$MZ\\=.3G'=GI^%
M>,^!W:_\2WE[<D27#1M(7( ^9F&3@=.IZ>M5%&-635DNIK?\)QXS/_,"3_P#
MF_\ BJ/^$X\:?] %/_ .;_XJNNHJK(SM+NSD?^$Y\:?] &/_ , YO_BJ/^$X
M\9_] %/_  #F_P#BJZZBBR#WNYR/_"<>-/\ H I_X!S?_%4?\)QXS_Z *?\
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M?9VM9)5()DC8YP<C (.2",8R>W%96K^%%A\/:]!I*RO-?V*VL5MN4(FR/RT
M)Q@8ZY)H'H7H_%=L;J6QFLKNWOEECC2WE10TGF!BC*02,8C<G)R-AR/6-/&%
MM+=06D%A>S7<DDT30H$S$T3*'#$L!P'5@0<$'CDXJ67PS;WDBWEQ-<&_#Q2I
M<?*K1F,,%  &W'[R3(YSO/MA\'AJUM]4M]12:;SXFGD;IB5I=N\MQZ(H&,8
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MP!(Z'BMSBN3?P:TGAK3=&>[B/V*#RH[D0E98W  66-@V488/&2#GGBNK4%5
M)+>Y[T"%_P _6C^5'Z44".%T7_DKR_\ 767_ -%-7KG>O(]%_P"2O+_UUE_]
M%-7KGI2D.EL_4=1114FYY/\ $/\ Y'S3/^N,/_HUZ[2N+^(?_(^:9_UQA_\
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M%CIA\]PY12. SN0  3CTZ].:ZP_"S0Q_R]:C_P!_$_\ B*V="\'Z-HDB7%M
:[W2!E$\KEFQGT^Z#CC( .,^IHN*SD[,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W ^L# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4455O+Z&QB,D[8!. !R2?04";L6J*RDUN 2HLT
M,\ ?[KRIA3^-:@.0#182DF+11104%%%% !1110 4444 %%&:3- "T4QY @)8
M@ #)).*K)J=G*^Q+B-F[ 'K185T7**:&]J=0,**** "BBB@ HHHH *#12$\4
M +FC-,+CGVIHF1NA!QUP>E%A71+FBF+(&^[R/6G9H 6BDS2T#"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YWQ1H%UK8L7M+F*":SG\Y3-&75N.A (IA
M\.WEQJECJ5W=0">WMYH&6"(JC;QP0"3C%=+10!PU_P"$+B'0;>*&<SS6-C-
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MV?R00TL\+-U.<KM8%6&>#G\*ZC3;1['3K>UDG>=X8U0ROU? QDU:HH ****
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M=@N7LT9JCYU[_P ^J?\ ?5'G7O\ SZI_WU18+E[-&:H^=>_\^J?]]4>=>_\
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MQ39&"(SDX &:XBZ\>[;AUM[3?&IQN+8S51@Y;&%:O"DO>.YR*,BN _X3^?\
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M_P!_:/\ A=5[_P! =/\ O[1]6J=@]M$]EHKQK_A=-[_T!D_[^TG_  NJ\/\
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M!_6KE-=%==K#(X.*=P#T-.!I#D+_ $IJ-N&2"*B^HR2BDS1FJN(6D-(6 '-
MYHN H%+113 **** "BBB@ HHHH *0D4M(>U #2P'4\52.JV4<K))=P*1V,@K
M*U^>>YO;32;>0Q&X):1QU"#KBK$/A;2(HU0V:.1_$W)/UJK+J<SJ3E*T$7O[
M8T[_ )_K?_OX*/[8T[_G^M_^_@JJ/#6CG_F'PTO_  C.C?\ 0/A_*CW0O6[(
ML_VQIW_/];_]_!1_;&G?\_UO_P!_!5;_ (1G1_\ H'0_E1_PC.C_ /0.A_*C
MW0O6[(L_VOIW_/\ 6_\ W\%+_:^G_P#/[;_]_!57_A&='_Z!T/Y4?\(SH_\
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M!5S_ (1G1O\ H'P_E7ERY;GV%-U>56L6?[7T_P#Y_;?_ +^"C^V-._Y_K?\
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MDG&33:>A D1CV8&N&*3>IV.]M";[$_FRQ[AF)=QJ$Q2! Y1@IZ'%:1OXVEN
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M><7^Z*R_Y>%_8L6.?6CFEHK4@8Y8#(&33ATI::&.>E3;4!]%(#2YJP"BBB@
MI#2TUC28"@TM,C4KG+9I]" ****8!3=OO3J* $P:#FEHH B7>6.X<=J?3J;0
M(YR__P"1UTS_ *XR5T0ZBN=OO^1UTW_KB]=$*N70YZ7Q3]1PI:04M0=(444G
M:@!<TF1TS2-TK,O5,^I06Y=A'M9B%.,TR9.QI,P YJ@-5B<GRHI9%!QN5>,U
M46PB.K/"7FV"$,!YAZY(ITFF:=:*J--)$I)P#*13LC*4IO8OVU['<EU 960_
M,K#D5:R/6LK^Q[1$DD1I<L,EO,-5(K4#15NA+,)1&&!\PGFC0%*2W.AHJ"U=
MGMXF8Y)4$FK%2;+5"44M% Q**6B@!**6B@!**6B@!*3M3J;VH$4;V_6T98U0
MR3R9V(O4_P#UJPM0TW4-2N3.T"9,81-DO"G.<T:O?"/5I%B8;FB2,OGF/+<D
M?@<U;TR6ZT^R2V:SFE*'&_>#GWK5*QPRFIRY7T(M2>\N+6*RE86QERK.ASP!
M629]]C/G_CR"^6H,>)0V?O8ZXJ[]K::&:.Y@G#&X8P,G)!W>O;'>KG]A737I
MNC-$'9-K-MY(^G3-4FDM3.<93=XEGP])(UFT3RF7RFVK(>K"MJJEE9QV-N(H
MP2,Y)/4FKE8L[Z2:C9A1112- I#UI:0]: .;'_(]R?\ 7HO_ *$:Z6N:'_(]
MR?\ 7HO_ *$:Z6JD<U#>7J,E_P!6WT-4=&_X\!_O'^=7I/\ 5M]#5'1O^0>/
M]X_SI=#?J:/:DI:*DH2BEHIV 2BEHHL E1RR"*-G8\*,FI:CD02*58<&@3,[
MS87,89_F<[F.VD>X@87#9&> .*FA@>55E,AW*2%XZ=J5K,+&X,IVL<OQ5W1)
M&LUN)TP1ATV_=[U&LT2('1OFB/.!U%2XC+(WGG,?W>*/* ">7+N25_FX_P ^
ME %]"&4$=#3J11A0 *=4%B44M%*P"44M%%@$I#TIU(W2F(S=$_X\V_WS6D:S
M=%_X\V_WS6D:<MQ1V.$\#_\ (T^*_P#K\'\J[OO7">!_^1I\5_\ 7X/Y5WG>
MKJ_$*&P4E+1698E%+10 E%+0: &FJ>IZ@FFV+74B.ZJRJ%3J2S!1^IJU,2L+
MD=0":\Q>/4+NT6[>=S#'<0L[.Y_>,9%X Z8%5&-]29.QVLFOW$2;Y-(NT7')
M<J,?K3K/76O781V,X 7=G*GM[&N<\6W-R=4>(1F2.*%613T3)(:3'\1'I69I
M\C65]"=/?[1&LRB.Z"[?-R0&C([\%F]L5JH)QN1S:G>:;K(U"ZN+9K6:WF@Q
MN23'(/?BM,-DXKSW7$N!XFO;B.4K$J0QR(&()SNY&*ZOPQ-+/H-I)*Y=]N"Q
MZD=JSE&RN4I:V-BBEHJ"Q**6B@!*6BB@!*X7PA_R/7BS_KM'_P"@BNZ/0UPO
MA#_D>O%G_7:/_P!!%:0^&1+W1W7>J&K_ /(.E^E7^]4-7_Y!TOTK"?PLTC\2
M+-M_QZQ?[B_RJ:H;;_CUB_W%_E4U..R)>X44M%4 E%+118!**6BBP#&.T$U#
M;W<5PSJA.5.#5@U#L2)_DC^^?F(J&G<9)N ') 'O2YSTJHS!2851I3G)&>!3
MT<3-@AD9.JYHY@L!NXEN1 3\YZ<59[5"JH[>88\,.!FIA328F%%+15 )12T4
M %%%% %+5/\ D'3?[M/L_P#CSB_W13-5_P"0=-_NU)9_\></^Z*Q7\1^A;^
ML4HI*45J0(:8QVD&I#3",]:3 4&EXIBN#D>AQ3A33 =12<4G>BX"D@<TT#+9
MS2,I8C!Z4^A +10**8!1110 4444 %%%% !3:4TAH YR^_Y'73?^N,E=$*YV
M_P#^1VTS_KC)71CJ*J6R.:C\4_444M)2U)TA24M!H 2LR;_D.6__ %R;^8K3
M/2LJ]D^SZG!.ZMY?ELI(4G!XIHSF/R1K<F/^>"_S-9$_FLY_M)6W"-]N!\HY
M&,>]74U"$:L\I\SRS" #Y;=<GBII[O3;K;YR,^TY&8VJ]C"4>=:.PS3WNV@E
M$P/D[/W9(P3Q1'_R+2_]<A4SZG:>4R*7'RX'[LU0BNHSHBVP$IE,>-OED'-(
MI::7N;5C_P >D/\ N"K-06JE+:)&^\% -3U#-X[!11104%%%% !1110 4444
M %4-5O#8V$EPJ[F4<#UJ\:S-:BDETR18D+N"#M'?FFMS.I\+.>BT:_O+:>5[
M@1-,6;88^0#]>>:LV&HW<GV>WE!CDCE"-QC<N#V_"J$U_-<M<W$4-QY88[CG
M&W*8&>?6K1:>ZM9M4B1XQ'Y;Q[QG?@$'O[UOZGF1;O[J-O2 &CN"1G%Q)CC_
M &C6K7.>';X2>;;R,/M#.TI4=,$YKHQS6,MST:+3B&*6BBI-@HHHH *0]:6D
M/6@#FQ_R/<G_ %Z+_P"A&NEKFA_R/<G_ %Z+_P"A&NEJI'-0WEZC)/\ 5M]#
M5'1O^0>/]X_SJ])_JV^AJCHW_(/'^\?YTNAOU-&BBBI104444P"BBD)Q0 M-
M:ESFD- %!"Y2)%8J&=LD?6I"K[I8MQ?Y. U*;-,@B1Q@Y !]:5;15<OYTF3Q
MUJA#4-PJ*OV93@8R6%,1'C2!77:?,SC/UJ?[/Q_K9/SH^S .C%W)4YY-*X%@
M4M("*,TABT4@.:6@ HHHH *1NE+2-TH S=$_X\V_WS6D:S=%_P"/-O\ ?-:1
MIRW)CL<)X'_Y&GQ7_P!?@_E7>=ZX/P/_ ,C3XK_Z_!_*N\[U=7XA0V"BBBLR
MPHHHH *#10: (KC_ (]I,_W3_*O.;.1VT:>)G8QK-;;5/13YJ]*[;7]1.F:1
M-<+'O;& "<#GCFN/BT>_@M)8/[1THB0Q-DRG@HP;TYSBM(:(SD;'C A5M<1_
MO#G$@&63Z?G63X8 35[>-HF?J5,B?<ZYQV&?I1X@O+VXGMH[A;1XPK$26\V=
MI]#GFJ6F3W%KJMLUM' 69B"TLQ"H-IY/K6R7N6(ZFIK7&IZG_O6_7ZM70>$_
M^1=M/I6!>Z?J5U+<737>E1BX*<^<V/DSTX]ZU/"<\L*3:3*89#9A<2PME6W<
MX^M92?NEKXCIZ*2EK(T"BBB@ HHHH 0]#7"^$/\ D>O%G_7:/_T$5W1Z&N%\
M(?\ (]>+/^NT?_H(K2'PR)>Z.Z[U0U?_ )!TOTJ_WJAJ_P#R#I?I6$_A9I'X
MD6;;_CUB_P!Q?Y5-4-M_QZQ?[B_RJ:B/PH3W%HHHJQ!1110 4444 )WJ+(,Q
M^?( ^[Z5*:K3%E28A1@*2,=<XXJ6"(%D9;AVBC:1'_B'K1#*6NF>:,QEAM4'
MN*M0!5@0#'0=*BO,>4I[AQC\^:SLD5<F0XD;+Y/]WTJ45$H/FGA<8X/>I1TK
M5/0EBT444P"BBB@ HHHH I:K_P @Z;_=J2S_ ./.'_=%1ZI_R#I_]VGVG_'G
M#_NBL5_$?H6_@+-+245L0'4TAH)Q2J.YI (% [4N >U+118!-H]*:Z;EVY(^
ME/HH: 8@VKMSG%.I.AI30 M%%%, HHHH **** "BBB@!#24II* .<O\ _D==
M-_ZXR5T0/-<[?_\ (ZZ;_P!<7KH@.:J6R.:C\4_4<*6D'6ANE2=(9'K1D5R.
MO>(KS2/%6GV^8O[+>)FNF8?,GHV?2J-CXTN!J&H+?(CPM,$L(HE^9EQG))H
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MHR3_ %;?0U1T;_D'C_>/\ZO2?ZMOH:HZ-_R#Q_O'^=+H;]31HHHJ44%%%%,
MI":6D- '%W/BJZL/&=W:71A72DA'EOCYA+Z$^]1:5XPNX=#DO-:CB\S[4R;8
M_EVQYXX/4UT-]X:TO49)7N[42^:Z.V3W0Y4U#<^$M)NF=I+=\NQ9]K$;L]0?
M:@#&U7QK'!##>1A[>PCO8X))G7/F@XX4?0XS5Z;QG:QW/V8PN+@*-\8/*N5+
M '_OG]:T3X;TPVRVK6H,(E$NT\@L,#G\A26_AVQM95DA612$",-YPX (&[UZ
MG\Z ,F#QH6L8YI]+F$IMWN9$0A@D:D@G/_ 3Q20>+4M;"\O+IA+;B\>.,Y"D
M1Y X'<C-3R>#+-M12;S)%M$MVA$*L?XF+'\.>E6KKPEH]T"&MBNYF+!&(# D
M$@CN,J#^% $<GBVUCLYKTP2?8T<1),>!(Y.,8[<]ZJ2ZOK6L)9W'A](1"LQC
MO%FZC!YP>_UK3'AC3/)E@$+K#)@^4'.U6!SN Z YYS6I:6JVENL2,[ ?Q.<D
M_4T 3KTYZTM HH **** "D;I2TC=* ,W1?\ CS;_ 'S6F:S-%_X\V_WS6F:<
MMR8['!^!_P#D:?%?_7X/Y5WG>N#\#_\ (T^*_P#K\'\J[SO5U?B%#8***0UF
M6&:7(]:Y_P 5ZI<Z5IT$MJ0KR7$<9/E[SAFP<"L^;Q(VEZJT5[,TL36\7DKY
M>UVD9F]^.E '7Y'J*"0!DFN:B\5QW:N+.SN)I(XS),G"^7CH#G%06GC)9;>W
M:ZTZ>&22W:Y?:594C!P3G(H ZB:&*XB:*5%=&&"K $&J(T33.?\ 0+?YNOR=
M:RG\7P+(D)L+K[1,4\F+"EG#YP>N.U0KXOMS=*V)BKH52W"+N\P.$(W9P>M
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MH]%M9K/38H)RQD7@DG-2:;<+>:?;W*)L22,,%]/:KM9M]"DK!1112*"BBB@
MHHHH 0]#7"^$/^1Z\6?]=H__ $$5W1Z&N%\(?\CUXL_Z[1_^@BM(?#(E[H[K
MO5#5_P#D'2_2K_>J&K_\@Z7Z5A/X6:1^)%FV_P"/6+_<7^535#;?\>L7^XO\
MJFHC\*$]Q:***L04444 %%%% %"_VG8, N3\I)Z56 EB,+N8VVK@!.IXJUJ$
M)DC#*VUE]1U%4\?:'MUZ&,_*1_NUR5+)F\%="B0SS0M"R<9V[OXJ591!E92I
M!<G(Z9]*;]G^QS1R%O,;D!1V&1G%+':&>1Y5?:2Y.,<&L]=NI6FXW;*T$Q7R
MU0GD?W:OV!4PD@8.XY^M9Y_<130KW8G=[\5I6<1BAP6W$G<36M+XKD3V+0Z4
M4#I1748A1110 AIFYM^W;D>M.)YQZTX# I6 HZF?^)=/Q_#4EF?]#B_W13-4
M_P"0=/\ [M/L_P#CRA_W162_B/T+?P%C<.YH!5QQ1P1SBD50O &!6I \44"B
M@ HHHI@(:1LX..M.I#0(2,Y7GK3JA\PB;;MX]:DW>QH =12 @TM PHHHH **
M** "BBB@ --IQIM '.7_ /R.NF?]<9*Z(=17.W__ ".NF?\ 7&2NB'45<NAS
M4OBGZCA2T@H/2H.DI:LEQ)I%XEKN^T&%A'MZ[L<8KDXK^WL/#T7V*WG6^*B.
M9DC.5;N2<>OI7:F1 Q!<9'49IDEQ!&0))8U); RW>@#@X=3\2W=F+@2O%)'#
M$0GD9WEF()//I3)==U:*]>QN+R2,HLQB(@R9BK#;GGH<XKMKW5;:QDMXW;<\
MTRPA01D$]S[4YOL/VQ+O,9N/+*(P;DKUP/R!H Y"+7==\V.UG!AO'G&_,)*Q
MH8U//I\Q;IZ5:AU75?\ A$9KA8I&O(YA&TA4\KO 9E'4C'TKH]/U2VU&T@GC
M8)YQ8*CG#':Q4\?A5C[5;@2$SQXC;:YW=#Z'T- '$2_:EU]+BWWW:,ENGG21
MG!'F-GZ$>M0F^UYK2U6=&NGGA2=@\. D@.-O7C.?P_&NTU#6+;3FM1-TN'V*
MP/ ^IJUY\0=%,J9D^X"P^;Z4"L<3+JNK#1GN4NI/M2RDS6[0LI4 _=3'?^=-
M\;1WE]#I1MTEMR$:5I&!)/',1'8MTSVKK;_5[6QMS*S"11*D3!&Y5F.!GTJ)
M?$.FO>6]O%<Q2+.'Q*K@KE>H)]:!D'A*\:\T"!GLWLRI*+;OG=&HZ \=:WZQ
M?^$ET\>(QH9=_MA7>!LXQ]:VJ "BBB@ H/2BB@#DKT0Q>+IGU2)GMGMU%J2A
M9=V?F'^]6#:3:UI=K(MF)0D\LY5&BSY7S<'\J[;7-;L_#VG-J%^TBVX=5)12
MY!)P.!VJ.7Q'IT&JV6FO*QN;Q#)"%4D;1W8]OQH YR?4M<MITA\R4S+'&85\
MK/VAFQNR?X>XJO-?Z\; M,KW!N8I&:)X.(RK+M'7W;ZX]J[O[7;^5Y@GCV=-
MV\8S3O/B\T1>8OF,,A<\X]: ,/P_>7-W<7+7DSK<!W4VOED+&H8A2#WR,'\:
MXZT@?^Q=-^PVLOV^W24W64;!3=]UL]2>"/I7I9O;78[_ &F+;'PYWC"_6G-<
M0J0C3(&(R 7 )% '!OK&NVRS1PQ--^[B92B%4@0D*P8=0P&3QFDO==URUL+<
M#?-/OWH\:$K(F<8/')'OBN]%Q"0A\Y,/]P[A\WT]:CFOK2WBDDFN(D2)=SEG
M "#W]* .)N-;UU&N8<-(IN%\RX12$BC(R .,Y_ _6NNT66[ETJ%[YXWG(Y:,
M$ CMU[U3G\5Z5!K%GIGFL\UTN^)HQN4CZUO4 +1110 4AZTM(>M '-C_ )'N
M3_KT7_T(UTM<T/\ D>Y/^O1?_0C72U4CFH;R]1DG^K;Z&J.C?\@\?[Q_G5Z3
M_5M]#5'1O^0>/]X_SI=#?J:-)2T5**$QDUY[KTEU)J6JO"S?:(KNTCB .,+]
M[)Z_+DFO0ZJ_8;<:@]X(QYSHL;-Z@'(_G3 X-=3U2PUW4DE=81/.%,P0R1Q
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MW>EC+MDNN".E(!XSW'-+GVI1THI@4M4(_LZ?_=IUJZBTA!/513=4_P"0=/\
M[M.M #9P^H45BOXC+?P%H4AZ4M&>U;$ .E+31Q3J "BBB@!#2,>PZTI.!2 9
MYH 3&/PIW44M1+(/,*4")0,44@.:6@84444 %%%% !1110 &FTXTV@#G+_\
MY'73/^N,E=$.HKG;_P#Y'73/^N,E=$.HJY=#FI?%/U'"@]*!2U!TG*^)O#ES
MJUY');2K'$Z;+@$D%L$%,?\  @*S5\*:HL6Z5K>YN)H6CE+N0L<A/$B\'G'%
M=Y10!P=SX(NIM&FLUO!'</>+.;I6.\J /UXJLGA_4;W4KZV:VMX,+;J;A&(V
M;<GY..<]_K7HE% '!3>%=<=;&!+F%(X)5D+HQ# ^:S'Z\$?C4DGA747TVRMQ
MY*26K_O&CE(-R-K*2QQP<D'&#]:[:618XF=CA5&2:RQKD#C*07#+U#",X--(
MES2W,^?PV9K/1[7AXK.822+*Q8D=<9[UCVW@S44> 7-UYJ"-% 64KY14YXX.
M>?I73MKT"?-)#.B]V:,X%:J$,H8'-#5@C-2V.'_X1;6I]3>YN9[<JQ0LH8[6
MVR%LA<<'&!4D'@^988(I([4+ MPJ\D[B_P!UNG45VPIU(HS-)T[['8VBW*I)
M=Q0B-I<<G'O6G110 4444 %%%% &)XDT=M:T^.U!4IYZ/(K?Q*,Y'ZUSMMX.
MU2VDBG^V02W,$K+$[ _+"%PB^YYYKO:* .!L?!VHF],VHO!(C2-(8PY(!,>T
M$<#OSBHKOPUKRV]H3/"Z685LQL=[ !\CISU'<=*]#IM 'EFC:%?7L2>7DRQ^
M5)+)EHTE 0+L(P3E>O<$BMIO!,K.WSJ_,&QI)"6 0N6&<<_?KKWOK6)BIE0,
M#RHZBGQ7=O,=L<J,WH#S^5&HN9'%?\(;>_VB9'N-UH9)"L*RE/*4R;E(X.3C
M''%//@JZ^R"/S(2SK<"8DGY]^W;GZ;3^==SQ2T#,S3=.6&QLQ<6T*SP1A 5&
M=N/0XK3Q2T4 %%%% !2'K2TAZT <V/\ D>Y/^O1?_0C72US0_P"1[D_Z]%_]
M"-=+52.:AO+U&2?ZMOH:HZ-_R#Q_O'^=7I/]6WT-4=&_Y!X_WC_.ET-^IHT4
M45**"BBBF 4444 %07,IAA9P 2.U3U'+&LBE6&0:!,I1G<;5BH!+-P*<9'2]
MEV(&^5<G=C%0QGRFMU=&4*Q&3T[U8C$<EY,>&&P#/6J8B.:9WDB!0 ;QSN]Z
M?* ;E\\_NC1<PQQ^4X11AQSZ<BF22JUV=@,@\O!VG(IH&36$K26X#  KQQ5H
M5#;1+#$%5=N>2*GJ'N-!1110,**** "D;I2TC=* ,W1?^/-O]\UI&LW1/^/-
MO]\UI&G+<F.QPG@?_D:?%?\ U^#^5=WWKA/ _P#R-/BO_K\'\J[SO5U?B%#8
M:X##! (]ZRX?#NEPC"6<>T$%5QPI&>1^9K6HK,LRQH>F)$\:V4>QBA9<==N"
MOY%1^5(FA:;'-%-':1H\8PI7C'.?ZDUJT4 9EUHNFWC2M<6<4AE9'<L,[F7[
MI_"H;CPUH]T2TUC$Y9BQ./O$]:V:* ,IM"TMX]ILH2NXN!CN0 ?Y"L:_\$V<
MKQM9B*# (8-'NR<$*P]& )YKK3TJ.:>*WC,DTB1QCJSG H R[;P]800X>(2R
M-&(Y6;_EI@8R??BIVT73B"#:1$'9GC^Y]W\J#K>E!<_VG:8Q_P ]EJ&S\2:5
M?WDUM;WB-)#@OG@8]B>M.S%=$D.A:;""$M4"^8)0N. P)((^A)IR:-81W$<Z
M6R++$[.K@="W+?G5G[9;8_X^8O\ OL4^.XAE;$<J,?16!HL%RA-HMG)<2W21
M*MRX8"0\X)&#Q56P\+:?::78V$D2S):9*%AU)).3^)K?HI#,G_A'-+W _9(P
M1(9>/[QZU*ND6 E$@M8]PE$P;'\> N?R _*M&B@"M:6D%E;1V]M&L<,8PBKT
M%6,4M% "'H:X7PA_R/7BS_KM'_Z"*[H]#7"^$/\ D>O%G_7:/_T$5I#X9$O=
M'==ZH:O_ ,@Z7Z5?[U0U?_D'2_2L)_"S2/Q(LVW_ !ZQ?[B_RJ:H;;_CUB_W
M%_E4U$?A0GN+1115B U6NK."\MV@N(UDB?[RD=:LT4 8S>&=*>.-&M5/EYVM
MWQZ>]1ZEX;L;ZT6V2-88C<1W$@1?O;"./TK=HH QSX:T@I&GV&+$?W>/?/\
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M5-33U!I>.M  32!1WI:* %HI ><4M PHHHH **** "BBB@ --IQIM '.7_\
MR.NF?]<9*Z(=17.W_P#R.NF?]<9*Z(=15RZ'-2^*?J.%+2"EJ#I"BBB@ H/2
MBFGI0!!>A6LI0S;5VG+>@]:Y_3Y-3&FH8F01H"$'EDEE&,&K?B SR?9+6( B
M:3:P8X!'I4GG:I!'_P >UHL:@]9#A1^56MCEGK(R+^]OYK?RIU*V\I"2LT)
M53U.:ZN$#RUP<C'!]:RI'U*>$A[6T>-QR-Y((_*H]"G>"SECNI%40RM&#NX
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M%%J#LLJ@.,%?]JM <C%6G<S:L.'2BD%+5B"BBFL<?6@"-Y DH7NW3VJ0$>M
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M%%% !1110 4C=*6D;I0!FZ+_ ,>;?[YK2-9NB?\ 'FW^^:TC3EN3'8X3P/\
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M28VMZK<6%Q86UK%&\UY*8P9&(5?E)[?3]:I6/BN*X9EN%%LT((GC)+,&!P
M.H/M6AJVCMJ,EG/%<M!/:2&2-@,@Y!'(_&N>U?P7BT#6;2RS97S?GVLPW;B0
M?6@"_/XTL88S<Y>2UP!\D3^8&SCE<9 ^M6]4\1P6,$RQY-RD7FI'(A4./8]Z
MR;#PE)/8O]KE:"8KLB"\[5!RI8]SZU//X*BNK]KJXOIG8[L<<@L,=?3VH =J
MWBB;3X]/*0PYN;9KAC*^!A4W$#W[4_1O%<5_=2P3JT$GF;(E9#\WRY )Z;L
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MB7Q3,ETWGSK)OV^4@!RI=<,AZ#Y<U),OB:TEE-K-=W#K<O%&)<%3'Y:D,?\
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MTGU.EQ2X'I3 P/0\?SIXK,W%Q1113 **** "D/6EI#UH YL?\CW)_P!>B_\
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MPU>I?\-0W4.DJESO!W-L5SEE3/ -;8IB+M11[5)6;W.^G&T4@HHHI&@4444
M%(>M+2'K0!S8_P"1[D_Z]%_]"-=+7-#_ )'N3_KT7_T(UTM5(YJ&\O49)_JV
M^AJCHW_(/'^\?YU>D_U;?0U1T;_D'C_>/\Z70WZFC1114HH****8!2$9I:*
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M'2@0HZ4444#"BBB@!"0*4=*:RY.:=0!2U7_D'3_[M.M1FRB_W13=4_Y!T_\
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M(S$=\@/3 Q[5:M_$5A/*L*O()FF\CRC&0P; /(QQ@'K2-#8HI!R*6@ HHHH
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M **** "D;I2TC=* ,W1?^/-O]\UIFLS1/^/-O]\UI&G+<F.QPG@?_D:?%?\
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M "%58?!^G6MU]HB:7<<F3<00XSD9R.Q%9U_XT>POEM4\FZ81OO*$_+(L8?\
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MO&03DY]>E:5 "T4E% !ZUPOA#_D>O%G_ %VC_P#017=5POA'_D>O%G_7>/\
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MJ,/^JNH&PP]CZBLC_A%/%8X3QE/M[9A%:.TG<A7CH=UFC-<*/"GBW_H<IO\
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M** &D4GXT_%)B@5A.*.*=BC%&@QM%.HH ;13J* &T4ZBBP#:*=118!M%.HH
M;13J* &T4ZBBP#:*=118!M%.HH ;13J* &T4ZBBP#:*=10 VBG44 -HIU&*
M&\T=^E+BC% A*=1BB@848HHH 2BEHH 3%&*7%%(!**6BBP"44M%%@$HI:*+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>report_002.jpg
<TEXT>
begin 644 report_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O 2P# 2(  A$! Q$!_\0
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M"%BRQ_* N(0?)4_>*QAG)D+D_$/_  4<_;2\+_L _L2_M&?M9^)X;>[/PD\
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M=.4Z=]EDNTOKO3[:[^UJ_D!_X/5O^46?P"_[/^^%O_K.O[5- '[>_%W_ (+
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M(YU30/A:?&^IBYA5X[74Y=*@W1R31L0#TKX#?\' _P#P27_:?^-_@/\ 9O\
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M]N7[,_BKX*?LL1ZIXI^%>LV$"77AC5[OP58Z1\ _@3KMU>".YMI$U:RL]?\
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M4+3P18P7^L>&_ GAJS^'7A]]/U/7(X-=NH+G7]4US0] LX+2(_H5_P %_O\
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M#I?C'XN^7:1--83ZOX)^ /P_\-ZU;7-YD6>H:SJFG7,=HD-T\WUG_P &IO\
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M)XE\ WDLUQ&888(?'6C>'IKN5^(K4W4@.]$#_=*C:H&<XZG &3U)(4 9)Y.
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M:WESX,^$?P>T[Q/'IGBJ*W\6ZY?:A>W^@Z!JVOZII,]D=&M?ZB=,_P"#6/\
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A*5HX?BO"U9TL?F\5>-.#QV6>RP]:-."=2K%U9M.T3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>report_001.jpg
<TEXT>
begin 644 report_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !+ 8\# 2(  A$! Q$!_\0
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M)_(5=KBDK29UQV0E07DC0V<\B8W)&S#/J!4]5M1_Y!MU_P!<7_D:%N#V.1\
M>*-1\0W%ZFH/&PA1638FWJ3_ (5VXKS'X2?\?>I?]<X_YFO3JWQ<(PK.,488
M63E238M5=1E>WTVYFCQOCB9USZ@9%6JI:O\ \@6^_P"N#_\ H)K&*O)&TM(L
MYCP!XDU#Q#'>'4'C;RBNW8FWK79UYQ\)/]5J/U3^5>CUOBXJ%9QBK(RPTG*D
MFQ:I:O<26>DW=Q#@211,ZDC(R!5RL[Q#_P B]J'_ %[O_*L(ZR1K/2+/-K/Q
MQXKU -]C2.?9C=LM\XJR?%'C902UF<#_ *=:?\+;VVM%U'[3<10[BFW>X7/7
MUKT!M;TQ1DZA:X_ZZBNZM*,)N*IH\^C%S@I2J-'&>&OB#<76JK8:U%'$TA"H
MZJ5(;T(]ZW-?\0RZ;>"&/"QK@,VT$[B"0.>V!7!>(;FWU3X@1/IV'4S1+N4?
M>8$9/^?2O3=3T1-0F6='6.8 J2R;@1TZ>N">:BK&G"49-6NMC6A.<U*-[V>Y
M/I=S-<6A:Z""9'*/LZ'T/Y$5?JK8V26-HL"%F Y+,<ECZFK5<;M?0[%>VIY1
M\45#>)K)3T-N ?\ OHUT8^%^AD#YKO\ [^__ %JP_B39W-QXFL7@MY9%$*@L
MB$@?,:].7[H^E=U2M*%*FH.VAQTZ49U9\R.7T_X=Z1INH07D#7)EA;>NZ3(S
M^5=2*6BN.=24W>3N=4(1A\*/.?BY_JM+_P!Z3^0J#2?AE::EI-K>/?2HT\8<
MJ$&!FK?Q6MI[F+31;P22[6DSL4G' KK?#*-'X:TY)%*N(%!!&".*[?;2IX:/
M([.[.3V49UY<R/'-1T--#\1_8=0WK:B0#S5&"T9_B%>R:!I5CI&F1PZ: 8&^
M;S,Y+Y[DUC^/?#7]N:3Y\ 'VJU!9?5U[K6?\-]6O#:G2KZVN$\D%H9'0@;?[
MN:=:HZ]!2OJMT%&"HU7&V^QW3_ZMOH:\4\"_\CS9?[\G_H)KVI_N-]#7CO@J
MQNH?&EG)):SH@>3+-&0/NGO4X-I4ZE^P\4G[2GZGLE>3?$Q _B^V5NC0(#CW
M8UZS7E?Q*M;J7Q/!);V\L@6W7YD0D AC48%VK?(K&J](Z'_A5^AD#+W?_?W_
M .M5K3/A_I&DZC#>VS7'G0G<NZ3(_E7"_P#"5^,?[]U_X"C_  H/BOQC_P ]
M+K_P%'^%=#H8AJSJ+[S!5J"UY']Q[%7EGCK_ )*%8_2'_P!"KT30I[BXT*RF
MO-WVAX5:3<N#NQSQ7G/Q%M[P^+8[BUMYG*1(59$+ $$FL,%I6:?9F^*=Z2:\
MCU7-9/BC58-)T"ZFF<*60H@/\3$8 KS3_A*O&3' >ZR>/^/8?X5)%X=\4^*Y
MU;4GD6->CSG 7Z*.]5'!\C4JDE9$O%<ZM"+N;7PFLV2WO[M@=KLL8^HY/\ZO
M?%3_ )%J'_KX'\C73Z-I-MHFFQ65HN$3DGNQ[DUSGQ.@FN/#L2P1/(PG!PBD
MGH:F%55,4I]+E2IN&'<>MC(\4Z0+OX?:7?(/WMG"N<=T( /]*Q_$/B9];\.Z
M1I\!W2D?OE'4LORJ/ZUZ+IM@M]X,M[&Y0@2VHC96'3BO.O!GAVZ;Q=$+FWD6
M&T9G9G0@,5X&/QKHH5(-2<MXMM&%:$KI1^TDF:/C[3_[+\'Z)9XYB)#?[VWG
M]:]!T/\ Y &G_P#7M'_Z"*Y+XJ6\]SIEB((9)2)6)"*3CBNNT52FA6"L"K"W
M0$'J/E%<M67-0C?>[.BG&U:2\D8GQ"U?^S/#,L:'][=GR5^AZG\J\Z\,>,&\
M,0SI!:13/,06=V(.!VK?\7I>^(O&EOIRP3BSA=8PQ0[>>6;->@1Z'IL<:HMC
M;X4 #,8K:,Z=&BHS5[ZF4H3JU7*+M;0\@\3>+V\3I )K..&2$DAT;)P>U>F^
M"-8.L>&;>21@9HOW4GU'3],5?NM TZXM)H?L=NOF(5R(P",BN#\ +?Z)XEN-
M-NH9Q!("N[8=N]>AS[BB<Z=:BXP5N74(1G2JIR=[G=^)/^1<U#_K@W\JY7X3
M_P#(#O?^O@?^@BNK\0JTGA^_1%+,8& 4#)/%<S\++>:VT:\6>&2(FXR ZD$_
M**Q@U]6DO-&LT_K$?1F1X_\ ##Z==?VYINY$W!I0G'EM_>'L:P?%7B,>([33
M)) %N88W291TSQ@CZU[3-!'<0O%,@>-QM96'!%>,^+/"%SHNJ$6L,D]K-EHO
M+4G8,_=-=6#KQJ-1J;K9G/BJ,H)N&SW/7M(_Y UG_P!<$_D*NU3TD%=(M P(
M(A0$'MP*N5YDOB9Z,=D)5;4/^0;=?]<7_D:LU7U $Z?<@#),38'X&E'=!+8\
MY^$G_'UJ7_7./^9KT[->$:3<:]HK2-IT5U TH <B#.0.G45I_P#"4>,?^>EW
M_P" P_PKU,1A'5J.<9(\ZAB53@HM,]DS5/6/^0+??]<'_P#037"^#-<\17_B
M)(-4>X-L8V)#P[1GMSBN[U52VCWBJ"28'  ZGY37!.DZ511;N=D:BJ0<DC@_
MA)_J=1^J?RKT?->%:3=^(-%5QIT5U"),;\09SCZBM'_A*?&'_/2[_P# <?X5
MWXC"2JU'-26OF<=#$JG!1:9[)FL[Q#_R+VH?]>[_ ,JXCP=KOB.^\1PP:F]P
M;4HQ8/#M&0..<5W&NJSZ#?JBEF,#@ #)/%<$Z3I5%%LZXU%5@VD>3^#_  E'
MXI%UYERT/D;<87.<Y_PKI?\ A4EOG_D)2?\ ?L4OPKM9[8:E]H@EBR8\;T*Y
MZ^M>A5T8C$U(U&HO0Y\/AJ<J:<EJ<QX>\"6&@77VE9)+BX PK28POT%=.**6
MN.<Y3=Y.YV0A&"M%6"BBBI+$Q12T4 %%%% "$9HI:* $H I:* $HI:* $HQ2
MT4 )BC%+10 E&*6B@!,44M% "4=:6B@!*,4M% "44M% "8HI:* $HQS2T4 )
M1C%+10 E&,TM% "44M% "44M% "8HQ2T4 )12T4 )BC%+10 E%+10 @%+110
M 4444 %%%% %/5=3ATC3I;RX#%(QPJC+,3T '<DT_3[Z+4K**Z@/R2+G!Z@]
MP?<5@>(Y=0N]:LK+3;2*Y6VQ=S++)L7/(09P>^3CVIOAB2[T_5;W3M1@2W:Y
M8WD$<;[U /#C./7G'O0!IW^O&VOOL=I8W%[.JAI/*QMC!Z9/J?2I]*U>/5$E
M AE@GA;;+#*N&0]OJ#ZUC6^J6F@:]J<&J3K;F\E%Q!(^=KKM QGID$'BM72-
M:M=::XDL5=H(F""<KA9#WV^H'K0!!<^(V6[G@L-.N;[[.=LKQ8"JW]T$]35_
M3M2BU*S%Q$&3DJZ.,,C#J"/45A:9KFG:(;S3]3N4M;B*>24^;P)$9BP8'OP:
MU;.\36])GFM(WCCF#K$[C;OXP'QUP?>@"F_BEW:1['2KR[M8R0;B,#:V.I4?
MQ5K6>HV^H6"7ELV^%U+ XP1CJ".Q%<YHGB72])T*&RU"X2UN["(13P,#N##C
MY1WSVQZUI>'(I7T:65X6A^U32S1QN,%58DC([>M &CI^H1ZCIL-[$&$<R;P#
MUQ46C:M#K>DP:A;*RQ3 E0W7@D?TKGM#\1Z;I?AB&TO[I;>ZLX_)F@?.\,.,
M8[Y[5I^#-/FTKPCI]K<KME2,EE/;))Q^M %G0]?MM>@D>W#HT;%6CD&&QV/T
M/8U-'J0FTV2[@ADDV%P(U'S,58C _*N<LM.GBT33=8T]'-[;1;7B!QY\6XDH
M1Z]P?6M?PI,+GP_%.JLJRR2N XP0"['D4 5?^$MG^T>1_8&I>;L\S;M7.W.,
M]:V1?JFF?;;F-[=5C,CI)U0 9(-52/\ BJP<<?83_P"ABJ/BYKRYMK?3=.A2
M::ZDW2([;5\I<%LGMG@?C0!J:/J\.M6 N8%=!N*M&XPRD>H_7\:BO?$%II^K
MV]A<[D:X7*R$?(#G !/;)Z5B:5)J6G>*9&U.U@M8-34*BPR^8/.0=>@QE?Y5
MH7UC#J7B">UN4W126&#['?U!]10!J/J$::G%8E3YDL;2 ]L @'^=9VL^)'T9
MY2^E7LT$0!:>-05YK*TJ6]C\86^GZEODN+6TEVW&W"S1EEVG/][L:U_%H)\+
MWP&2=@Z?[PH L:7JLVH&02Z;=6>P#!G &[Z8JE)XFD>6?[#I5W>00.8VECQ@
ML#A@H/7%;B_ZM?H*XPWFC6EQ?+%K-WH\RRL\L$A&-Q/+!6!X/7B@#K[2Z2]M
M8[B(,$D&0&7!'L1ZU-65X:N[N^T.">^'[UBV&V[=ZY.UL=LC!J[J%[%IUA/>
M7!(B@0NV!DX'I0!3_P"$BLO^$@_LC<?M&S.[^'=UV9_O8YQZ59U34$TK3)[V
M2-Y%A7<4099O85P_V+7SI9O/[(MO.-Q_:/F_:/WF>H&W']WY<5U&KW::AX2>
MZ@R4FC1UR.<%@: +2Z[:R:&VJQ[F@5"[+C#+CJ".Q'I3M3U>/2]):_>*21!M
MPB#+$L0 !^=<YXKM9=&M=0N[1'DLK]"MU$O/ER' $@'OT/YU?\5NL/@_S)#A
M4:!F/H ZY- $T'B@?:8XK[3;VQ65MB2SJ-A8]!D=,UNUR>L:_IVO6JZ;I,ZW
MMU-(F%C!(0!@2Q/0 8KK!0 CNL:,[D*J@DD] *SM#UR#7;1YX(Y8MCE"DJX;
MU!QZ$<BJ/C&6]DTZ/3M+17N[Y_+ 8X C'+DGMQQ^-9UD=7T_Q1!<7]G!:V5W
M$MJPBE\S]XN2A/ QQQ^5 &WJVO\ ]F7L%I'8W-W/,C2!80#A00"3GZT[3->B
MU"X>VEMY[.[5=_DW"[69?[P]167K6I6FD^,=.N+^=((3:2J'?IG<O%-AO(?$
M/BZPO-+(FM;&*59K@ @%GQA1GKTR?PH W[;44N;Z[M=C)+;%<AOX@1D,/;K^
M5);:I#=ZE=V<.6>UV^8P^Z&;G;GUQ_.LCQ)*VB7MOKZ!VAB0P74:#)=#RI ]
M0W\ZO>';)[32U>X0+=W3&XN,?WVY/Y<#\* $T+Q!'K=M>SK"8%M+J2V;<V<[
M.K547Q8TL7VJVTF\GL2?EN(P#N7^\!UQ6?\ #_:=+UP;=X.JW.5'?D<53CU'
M1]/TV0:;KMUIQAR!9R@,8V[)M()Z^AH [::^@M[%KR5PL"IO+'TK&'BMHPD]
MWI-[;63$#[0ZCY0>A9>H'O46J1:AJO@F!YH +S;%/-".^U@S ?ETIFH>+=(U
M#1I8K.Y%Q<72-#';HIWEB,8*]O?- &UK&K1:/ICWLJ/(BD +'R6).!C\ZST\
M5;)XDO\ 3+VRBD<()IE&P,>@)!XS53Q5;20^!TMF8F1/(0LO)R&49%,U2REB
MUNP35KV:YTN5QM5@!BX!RN[ ^[C/XB@#>U755TN"-O(EN)I7V10Q#+.>O\A4
M&GZV]U>?9;K3[FSE*[T\P95@.O([^U0>*'T^.UMY=3>X@C28%+F'(\EL<$D=
M >E9^G:H6\1VMG8:P^I6\D;O.K(#Y0 ^4[P!U/&#0!UM%)2T %%%% !1110
M4444 -VC).!D]31L7<&(&X=#CFG44 12V\4Z[9HDD7T=013U144*BA5'0 8
MIU% $4MM#,0988Y"O0LH.*D"A1@  >@I:* (7M8)) \D,;..C,@)'XU+BEHH
M A>U@>3S&AB:3^\4!/YU+2T4 -"A0 H  ["E"A1A0 /04M% ";1G.!GIFDVC
M.<#([TZB@!I56QD XY&1THVC.<#/K3J* &[!G.!NQC..:5E### $>AI:* $J
M*2U@F</+#$[#HS(":FHH 0#%(RAU*L 0>H(IU% "8XQVI-B[=NT;?3'%.HH
M:5# A@"#V-#(K+M8 KZ$<4ZB@"-(8XSE(T4_[*@4^EHH :5!(.!D=\4I4-C(
M!QSR*6B@!CQ))CS$5L=-PS0L:H,(H4>@&*?10 UE### $>A%+BEHH BB@B@#
M"*-(PQW-M4#)[D^](UI \GF-!$TG]XH,_G4U% "8J-;6!)3(L,8D/5P@S^=2
MT4 -95888 CT(H9%;A@&'N*=10 UD5U*LH93U!&0:9%;PP B&*.//78H%2T4
4 )2T44 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>euda-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSOSbP9z5Z8iekhvWBwbdlaPyIis9qBCiP2vg12IcYM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:EUDA="http://euda.com/20221231" elementFormDefault="qualified" targetNamespace="http://euda.com/20221231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://euda.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementsOfOperationsAndComprehensiveIncomeLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" id="StatementsOfChangeInShareholdersEquityDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Change in Shareholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/NatureOfBusinessAndOrganization" id="NatureOfBusinessAndOrganization">
          <link:definition>00000007 - Disclosure - Nature of business and organization</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/GoingConcern" id="GoingConcern">
          <link:definition>00000008 - Disclosure - Going concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - Summary of significant accounting policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ReverseRecapitalization" id="ReverseRecapitalization">
          <link:definition>00000010 - Disclosure - Reverse Recapitalization</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/DispositionOfSubsidiary" id="DispositionOfSubsidiary">
          <link:definition>00000011 - Disclosure - Disposition of Subsidiary</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/AccountsReceivableNet" id="AccountsReceivableNet">
          <link:definition>00000012 - Disclosure - Accounts receivable, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/OtherReceivables" id="OtherReceivables">
          <link:definition>00000013 - Disclosure - Other receivables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>00000014 - Disclosure - Property and equipment, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
          <link:definition>00000015 - Disclosure - Intangible assets, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/Goodwill" id="Goodwill">
          <link:definition>00000016 - Disclosure - Goodwill</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ForwardPurchaseAgreements" id="ForwardPurchaseAgreements">
          <link:definition>00000017 - Disclosure - Forward Purchase Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/LoanToThirdParty" id="LoanToThirdParty">
          <link:definition>00000018 - Disclosure - Loan to third party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/CreditFacilities" id="CreditFacilities">
          <link:definition>00000019 - Disclosure - Credit facilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilities" id="OtherPayablesAndAccruedLiabilities">
          <link:definition>00000020 - Disclosure - Other payables and accrued liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactions" id="RelatedPartyBalancesAndTransactions">
          <link:definition>00000021 - Disclosure - Related party balances and transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>00000022 - Disclosure - Shareholders&#8217; equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000023 - Disclosure - Income taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ConcentrationsRisks" id="ConcentrationsRisks">
          <link:definition>00000024 - Disclosure - Concentrations risks</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/Leases" id="Leases">
          <link:definition>00000025 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000026 - Disclosure - Commitments and contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>00000027 - Disclosure - Segment information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000028 - Disclosure - Subsequent events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000029 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationTables" id="NatureOfBusinessAndOrganizationTables">
          <link:definition>00000030 - Disclosure - Nature of business and organization (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000031 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ReverseRecapitalizationTables" id="ReverseRecapitalizationTables">
          <link:definition>00000032 - Disclosure - Reverse Recapitalization (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/AccountsReceivableNetTables" id="AccountsReceivableNetTables">
          <link:definition>00000033 - Disclosure - Accounts receivable, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/OtherReceivablesTables" id="OtherReceivablesTables">
          <link:definition>00000034 - Disclosure - Other receivables (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>00000035 - Disclosure - Property and equipment, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
          <link:definition>00000036 - Disclosure - Intangible assets, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/GoodwillTables" id="GoodwillTables">
          <link:definition>00000037 - Disclosure - Goodwill (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/CreditFacilitiesTables" id="CreditFacilitiesTables">
          <link:definition>00000038 - Disclosure - Credit facilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" id="OtherPayablesAndAccruedLiabilitiesTables">
          <link:definition>00000039 - Disclosure - Other payables and accrued liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
          <link:definition>00000040 - Disclosure - Related party balances and transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
          <link:definition>00000041 - Disclosure - Shareholders&#8217; equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000042 - Disclosure - Income taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000043 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>00000044 - Disclosure - Segment information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" id="ScheduleOfConsolidatedFinancialStatementDetails">
          <link:definition>00000045 - Disclosure - Schedule of consolidated financial statement (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" id="NatureOfBusinessAndOrganizationDetailsNarrative">
          <link:definition>00000046 - Disclosure - Nature of business and organization (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>00000047 - Disclosure - Going concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" id="ScheduleOfForeignCurrencyExchangeRatesDetails">
          <link:definition>00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" id="ScheduleOfPropertyAndEquipmentUsefulLivesDetails">
          <link:definition>00000049 - Disclosure - Schedule of property and equipment useful lives (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" id="ScheduleOfIntangibleAssetsNetDetails">
          <link:definition>00000050 - Disclosure - Schedule of intangible assets net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfRevenueDetails" id="ScheduleOfRevenueDetails">
          <link:definition>00000051 - Disclosure - Schedule of revenue (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfCostOfRevenueDetails" id="ScheduleOfCostOfRevenueDetails">
          <link:definition>00000052 - Disclosure - Schedule of cost of revenue (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" id="ScheduleOfBasicAndDilutedEarningsPerShareDetails">
          <link:definition>00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" id="ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails">
          <link:definition>00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" id="ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails">
          <link:definition>00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" id="ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails">
          <link:definition>00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" id="ReverseRecapitalizationDetailsNarrative">
          <link:definition>00000059 - Disclosure - Reverse Recapitalization (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" id="DispositionOfSubsidiaryDetailsNarrative">
          <link:definition>00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetails" id="ScheduleOfAccountsReceivableDetails">
          <link:definition>00000061 - Disclosure - Schedule of accounts receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" id="ScheduleOfAccountsReceivableDetailsPharanthetical">
          <link:definition>00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" id="ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails">
          <link:definition>00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetails" id="ScheduleOfOtherReceivablesDetails">
          <link:definition>00000064 - Disclosure - Schedule of other receivables (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" id="ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails">
          <link:definition>00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" id="ScheduleOfOtherReceivablesDetailsParanthetical">
          <link:definition>00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000067 - Disclosure - Schedule of property and equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
          <link:definition>00000068 - Disclosure - Property and equipment, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000069 - Disclosure - Schedule of intangible assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
          <link:definition>00000070 - Disclosure - Schedule of goodwill (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
          <link:definition>00000071 - Disclosure - Intangible assets, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/GoodwillDetailsNarrative" id="GoodwillDetailsNarrative">
          <link:definition>00000072 - Disclosure - Goodwill (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" id="ForwardPurchaseAgreementsDetailsNarrative">
          <link:definition>00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/LoanToThirdPartyDetailsNarrative" id="LoanToThirdPartyDetailsNarrative">
          <link:definition>00000074 - Disclosure - Loan to third party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetails" id="ScheduleOfShort-termLoansDetails">
          <link:definition>00000075 - Disclosure - Schedule of short-term loans (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" id="ScheduleOfShort-termLoansDetailsParanthetical">
          <link:definition>00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/CreditFacilitiesDetailsNarrative" id="CreditFacilitiesDetailsNarrative">
          <link:definition>00000077 - Disclosure - Credit facilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" id="ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails">
          <link:definition>00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" id="ScheduleOfRelatedPartyBalancesDetails">
          <link:definition>00000079 - Disclosure - Schedule of related party balances (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" id="ScheduleOfRelatedPartyTransactionsDetails">
          <link:definition>00000080 - Disclosure - Schedule of related party transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" id="ScheduleOfReverseRecapitalizationDetails">
          <link:definition>00000081 - Disclosure - Schedule of reverse recapitalization (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" id="ScheduleOfWarrantActivitiesDetails">
          <link:definition>00000082 - Disclosure - Schedule of warrant activities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" id="ScheduleOfEarnoutSharesForTriggeringEventDetails">
          <link:definition>00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>00000084 - Disclosure - Shareholders&#8217; equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" id="ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails">
          <link:definition>00000085 - Disclosure - Schedule of components of loss before income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>00000086 - Disclosure - Schedule of provision for income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
          <link:definition>00000087 - Disclosure - Schedule of effective income tax rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical">
          <link:definition>00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfTaxesPayableDetails" id="ScheduleOfTaxesPayableDetails">
          <link:definition>00000090 - Disclosure - Schedule of taxes payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000091 - Disclosure - Income taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ConcentrationsRisksDetailsNarrative" id="ConcentrationsRisksDetailsNarrative">
          <link:definition>00000092 - Disclosure - Concentrations risks (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" id="ScheduleOfOperatingAndFinanceLeaseExpensesDetails">
          <link:definition>00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" id="ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails">
          <link:definition>00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" id="ScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:definition>00000095 - Disclosure - Schedule of future minimum lease payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000096 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000097 - Disclosure - Commitments and contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" id="ScheduleOfSegmentReportingInformationDetails">
          <link:definition>00000098 - Disclosure - Schedule of segment reporting information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" id="ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails">
          <link:definition>00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>00000100 - Disclosure - Segment information (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://euda.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000101 - Disclosure - Subsequent events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="euda-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="euda-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="euda-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="euda-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="EUDA_OrdinarySharesMember" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RedeemableWarrantsMember" name="RedeemableWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesMember" name="MedicalServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesRelatedPartiesMember" name="MedicalServicesRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProductSalesMember" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServicesMember" name="PropertyManagementServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" name="KentRidgeHealthcareSingaporePrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EUDAPrivateLimitedMember" name="EUDAPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SuperGatewayGroupLimitedMember" name="SuperGatewayGroupLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" name="SingaporeEmergencyMedicalAssistancePrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EUDAHealthLimitedMember" name="EUDAHealthLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeHealthcareSingaporePteLtdMember" name="KentRidgeHealthcareSingaporePteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" name="ZukitekVietnamPrivateLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TheGoodClinicPrivateLimitedMember" name="TheGoodClinicPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EUDADoctorPrivateLimitedMember" name="EUDADoctorPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeHillPrivateLimitedMember" name="KentRidgeHillPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeHealthLimitedMember" name="KentRidgeHealthLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ZukitechPrivateLimitedMember" name="ZukitechPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_UniversalGatewayInternationalPteLtdMember" name="UniversalGatewayInternationalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MelanaInternationalPteLtdMember" name="MelanaInternationalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TriGlobalSecurityPteLtdMember" name="TriGlobalSecurityPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_UGDigitechPrivateLimitedMember" name="UGDigitechPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NosweatFitnessCompanyPrivateLimitedMember" name="NosweatFitnessCompanyPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TrueCoverPrivateLimitedMember" name="TrueCoverPrivateLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KRDigitalPteLtdMember" name="KRDigitalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ZukihealthSdnBhdMember" name="ZukihealthSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_CentralProvidentFundMember" name="CentralProvidentFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SkillDevelopmentLevyMember" name="SkillDevelopmentLevyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SocialInsuranceFundMember" name="SocialInsuranceFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesSpecialtyCareMember" name="MedicalServicesSpecialtyCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesGeneralPracticeMember" name="MedicalServicesGeneralPracticeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" name="MedicalServicesGeneralPracticeRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesSubTotalMember" name="MedicalServicesSubTotalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServiceCommonAreaManagementMember" name="PropertyManagementServiceCommonAreaManagementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServiceSecurityManagementMember" name="PropertyManagementServiceSecurityManagementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServiceMember" name="PropertyManagementServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" name="MedicalServicesSpecialtyCareRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesGeneralPracticesMember" name="MedicalServicesGeneralPracticesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServicesCommonAreaManagementMember" name="PropertyManagementServicesCommonAreaManagementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyManagementServicesSecurityManagementMember" name="PropertyManagementServicesSecurityManagementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProductMangementServicesMember" name="ProductMangementServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FirstAnniversaryMember" name="FirstAnniversaryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SecondAnniversaryMember" name="SecondAnniversaryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_BusinessCombinationMember" name="BusinessCombinationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SEMAAgreementMember" name="SEMAAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_UnitedOverseasBankLimitedMember" name="UnitedOverseasBankLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MelanaInternationalPteLimitedMember" name="MelanaInternationalPteLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TriGlobalSecurityPteLimitedMember" name="TriGlobalSecurityPteLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidForwardAgreementOneMember" name="PrepaidForwardAgreementOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidForwardAgreementTwoMember" name="PrepaidForwardAgreementTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_InstitutionalInvestorsMember" name="InstitutionalInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PTTotalPrimaIndonesiaMember" name="PTTotalPrimaIndonesiaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_BankAndPrivateLenderMember" name="BankAndPrivateLenderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ThirdPartiesMember" name="ThirdPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConvertibleNotesThirdPartiesMember" name="ConvertibleNotesThirdPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FSCapitalPtdLtdMember" name="FSCapitalPtdLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FundingSocietiesPteLtdMember" name="FundingSocietiesPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KohWeeSingMember" name="KohWeeSingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KaufamanAndCanolesPcKcMember" name="KaufamanAndCanolesPcKcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MaximGroupLlcMember" name="MaximGroupLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MenoraCapitalPteLtdMember" name="MenoraCapitalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_LoebAndLoebLlpMember" name="LoebAndLoebLlpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ShineLinkLimitedMember" name="ShineLinkLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EightIHoldingsTwoPtdLtdMember" name="EightIHoldingsTwoPtdLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConvertibleNotesRelatedPartiesMember" name="ConvertibleNotesRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MengDongJamesTanMember" name="MengDongJamesTanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KRHillCapitalPteLtdMember" name="KRHillCapitalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeMedicalPtdLtdMember" name="KentRidgeMedicalPtdLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_UGDigitalSdnBhdMember" name="UGDigitalSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_JanicLimitedMember" name="JanicLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ZukihealthSDNMember" name="ZukihealthSDNMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_JenniferGohMember" name="JenniferGohMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FrescoInvestmentPteLtdMember" name="FrescoInvestmentPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_CadenceHealthPteLtdMember" name="CadenceHealthPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_CheeYinMehMember" name="CheeYinMehMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_JamieFanWeiZhiMember" name="JamieFanWeiZhiMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KelvinChenMember" name="KelvinChenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgeHealthPteLtdMember" name="KentRidgeHealthPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_KentRidgePacificPteLtdMember" name="KentRidgePacificPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WatermarkDevelopmentsLtdMember" name="WatermarkDevelopmentsLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WilkeServicesLtdMember" name="WilkeServicesLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MountLockeLimitedMember" name="MountLockeLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PublicWarrantMember" name="PublicWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrivateWarrantMember" name="PrivateWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TriggeringEventOneMember" name="TriggeringEventOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TriggeringEventTwoMember" name="TriggeringEventTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SeventyFivePercentageMember" name="SeventyFivePercentageMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FiftyPercentageMember" name="FiftyPercentageMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SingaporeSubsidiariesMember" name="SingaporeSubsidiariesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NoCustomerMember" name="NoCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NoVendorMember" name="NoVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OneVendorMember" name="OneVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_VendorOneMember" name="VendorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_VendorTwoMember" name="VendorTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConsolidatedMember" name="ConsolidatedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AlfredLimMember" name="AlfredLimMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TanSecondLoanMember" name="TanSecondLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TanFirstLoanMember" name="TanFirstLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TanThirdLoanMember" name="TanThirdLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TanTwoThousandTwentyThreeNoteMember" name="TanTwoThousandTwentyThreeNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_JamesTanMember" name="JamesTanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ShineLinkMember" name="ShineLinkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MenoraMember" name="MenoraMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EightiHoldingMember" name="EightiHoldingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ChenSettlementAgreementMember" name="ChenSettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SellerOneMember" name="SellerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SellerTwoMember" name="SellerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ForwardPurchaseReceivables" name="ForwardPurchaseReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherReceivablesNonCurrent" name="OtherReceivablesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_LoanToThirdParty" name="LoanToThirdParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ShortTermLoansThirdParties" name="ShortTermLoansThirdParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PromissoryNote" name="PromissoryNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConvertibleNotesRelatedParties" name="ConvertibleNotesRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AccountsPayableRelatedParty" name="AccountsPayableRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherPayablesAndAccruedLiabilities" name="OtherPayablesAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherPayablesRelatedParties" name="OtherPayablesRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidForwardPurchaseLiabilities" name="PrepaidForwardPurchaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EarnoutSharePayment" name="EarnoutSharePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" name="IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodValueCapitalContributions" name="StockIssuedDuringPeriodValueCapitalContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodSharesCapitalContributions" name="StockIssuedDuringPeriodSharesCapitalContributions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" name="StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" name="StockIssuedDuringPeriodValueEarnoutSharesPayament" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" name="StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" name="StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EarnoutPayment" name="EarnoutPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" name="ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" name="IncreaseDecreaseInAccountsPayableRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProceedsFromReverseRecapitalization" name="ProceedsFromReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RepaymentsFromOtherReceivableRelatedParties" name="RepaymentsFromOtherReceivableRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RepaymentsToShorttermLoansThirdParties" name="RepaymentsToShorttermLoansThirdParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" name="InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" name="InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConversionOfDebtIntoPromissoryNote" name="ConversionOfDebtIntoPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ConversionOfDebtsIntoConvertibleNotes" name="ConversionOfDebtsIntoConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ForgivenessOfDebtByRelatedParty" name="ForgivenessOfDebtByRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" name="IssuanceOfOrdinarySharesUponReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DisclosureReverseRecapitalizationAbstract" name="DisclosureReverseRecapitalizationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ReverseRecapitalizationTextBlock" name="ReverseRecapitalizationTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DisclosureDispositionOfSubsidiaryAbstract" name="DisclosureDispositionOfSubsidiaryAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DispositionOfSubsidiariesTextBlock" name="DispositionOfSubsidiariesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DisclosureForwardPurchaseAgreementsAbstract" name="DisclosureForwardPurchaseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" name="ForwardPurchaseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DisclosureLoanToThirdPartyAbstract" name="DisclosureLoanToThirdPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_LoanToThirdPartyTextBlock" name="LoanToThirdPartyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NonControllingInterestPolicyTextBlock" name="NonControllingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" name="PrepaidExpensesAndOtherAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" name="ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DefinedContributionPlanPolicyTextBlock" name="DefinedContributionPlanPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_GoodsAndServicesTaxesPolicyTextBlock" name="GoodsAndServicesTaxesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RelatedPartyPolicyTextBlock" name="RelatedPartyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PropertyPlantAndEquipmentsTextBlock" name="PropertyPlantAndEquipmentsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" name="ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfCostOfRevenueTableTextBlock" name="ScheduleOfCostOfRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" name="ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" name="ScheduleOfFinancialStatementsOfReverseRecapitalization" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" name="ScheduleOfRelatedPartyBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" name="ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" name="ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfTaxesPayableTableTextBlock" name="ScheduleOfTaxesPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" name="ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" name="ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NameOfCompany" name="NameOfCompany" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DateOfIncorporation" name="DateOfIncorporation" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RegisteredCapital" name="RegisteredCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" name="PrepaidForwardPurchaseLiabilitiesBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" name="AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrepaidForwardPurchaseLiability" name="PrepaidForwardPurchaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_TradeUnionFeePercentage" name="TradeUnionFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" name="OrdinarySharesOutstandingPriorToReverseRecapitalization" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RedemptionOfOrdinaryShares" name="RedemptionOfOrdinaryShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FundsHeldInTrustAccount" name="FundsHeldInTrustAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FundsHeldInOperatingCashAccount" name="FundsHeldInOperatingCashAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProceedsFromReverseRecapitalizations" name="ProceedsFromReverseRecapitalizations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" name="ProceedsFromUnpaidDeferredUnderwritingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ProceedsFromUnpaidTransactionCostsIncurred" name="ProceedsFromUnpaidTransactionCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_NoncashNetAssetsAssumedValue" name="NoncashNetAssetsAssumedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" name="IssuanceOfOrdinarySharesUponTheReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ExchangeRatioPerShare" name="ExchangeRatioPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrivateOrdinarySharesNoParValue" name="PrivateOrdinarySharesNoParValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrivateOrdinarySharesOutstanding" name="PrivateOrdinarySharesOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FounderSharesNoParValue" name="FounderSharesNoParValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FounderSharesOutstanding" name="FounderSharesOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PublicRightsShares" name="PublicRightsShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PrivateRightsShares" name="PrivateRightsShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" name="AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DivestmentReceivable" name="DivestmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EmployeeAdavance" name="EmployeeAdavance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherReceivablesNetNonCurrent" name="OtherReceivablesNetNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" name="AllowanceForDoubtfulOtherReceivableRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" name="AllowanceForDoubtfulOtherReceivableWriteOffs" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" name="InvestmentOwnedAdditionalAmountAtMarketValues" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_InstallmentReceived" name="InstallmentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherReceivableInstallmentAmount" name="OtherReceivableInstallmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ExchangeRateEffect" name="ExchangeRateEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" name="ChangeOfFairValueOfPrepaidForwardPurchaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_LoanAccumulativelyDisbursed" name="LoanAccumulativelyDisbursed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ShortTermDebtInterestRate" name="ShortTermDebtInterestRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_PurchaseFromRelatedParties" name="PurchaseFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ClassOfWarrantOrRightOutstandingGranted" name="ClassOfWarrantOrRightOutstandingGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ClassOfWarrantOrRightOutstandingForfeited" name="ClassOfWarrantOrRightOutstandingForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ClassOfWarrantOrRightOutstandingExercised" name="ClassOfWarrantOrRightOutstandingExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_SharePriceAsOfClosingDate" name="SharePriceAsOfClosingDate" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AverageDailyReturnRate" name="AverageDailyReturnRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DailyVolatilityForTriggeringEvent1" name="DailyVolatilityForTriggeringEvent1" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DailyVolatilityForTriggeringEvent2" name="DailyVolatilityForTriggeringEvent2" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RiskFreeRateForTriggeringEventOne" name="RiskFreeRateForTriggeringEventOne" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_RiskFreeRateForTriggeringEventTwo" name="RiskFreeRateForTriggeringEventTwo" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_GrantPriceForTriggingEventOne" name="GrantPriceForTriggingEventOne" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_GrantPriceForTriggingEventTwo" name="GrantPriceForTriggingEventTwo" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OrdinaryShareBeforeReverseRecapitalization" name="OrdinaryShareBeforeReverseRecapitalization" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WarrantsRedemptionPrice" name="WarrantsRedemptionPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_EarnoutShares" name="EarnoutShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_FairValueOfEarnoutShares" name="FairValueOfEarnoutShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DeferredTaxAssetsLeaseLiabilityNet" name="DeferredTaxAssetsLeaseLiabilityNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AccruedGSTTaxesPayableCurrent" name="AccruedGSTTaxesPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OperatingLeaseExpenseShortTerm" name="OperatingLeaseExpenseShortTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ContractualObligationDiscount" name="ContractualObligationDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_ContractualObligationLeaseLiability" name="ContractualObligationLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherCorporateExpenses" name="OtherCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OrdinarySharesAvailableForResale" name="OrdinarySharesAvailableForResale" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OrdinarySharesForfeited" name="OrdinarySharesForfeited" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OrdinarySharesToBeIssued" name="OrdinarySharesToBeIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesSpecialtyCaresMember" name="MedicalServicesSpecialtyCaresMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember" name="MedicalServicesSpecialtyCaresRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_DeemedDividendOnWarrantReplacement" name="DeemedDividendOnWarrantReplacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement" name="StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_AverageMonthlyNegativeReturnRate" name="AverageMonthlyNegativeReturnRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_MonthlyStandardDerivation" name="MonthlyStandardDerivation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_OtherReceivablesRelatedParties" name="OtherReceivablesRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="EUDA_WatermarkCapitalPLMember" name="WatermarkCapitalPLMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>euda-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://euda.com/role/Cover" xlink:href="euda-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheets" xlink:href="euda-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheetsParenthetical" xlink:href="euda-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="euda-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:href="euda-20221231.xsd#StatementsOfChangeInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfCashFlows" xlink:href="euda-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcern" xlink:href="euda-20221231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalization" xlink:href="euda-20221231.xsd#ReverseRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiary" xlink:href="euda-20221231.xsd#DispositionOfSubsidiary" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNet" xlink:href="euda-20221231.xsd#AccountsReceivableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivables" xlink:href="euda-20221231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNet" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNet" xlink:href="euda-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Goodwill" xlink:href="euda-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreements" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdParty" xlink:href="euda-20221231.xsd#LoanToThirdParty" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilities" xlink:href="euda-20221231.xsd#CreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquity" xlink:href="euda-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxes" xlink:href="euda-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisks" xlink:href="euda-20221231.xsd#ConcentrationsRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Leases" xlink:href="euda-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingencies" xlink:href="euda-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformation" xlink:href="euda-20221231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEvents" xlink:href="euda-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationTables" xlink:href="euda-20221231.xsd#ReverseRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNetTables" xlink:href="euda-20221231.xsd#AccountsReceivableNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivablesTables" xlink:href="euda-20221231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetTables" xlink:href="euda-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillTables" xlink:href="euda-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesTables" xlink:href="euda-20221231.xsd#CreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityTables" xlink:href="euda-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesTables" xlink:href="euda-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesTables" xlink:href="euda-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationTables" xlink:href="euda-20221231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcernDetailsNarrative" xlink:href="euda-20221231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:href="euda-20221231.xsd#ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfCostOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="euda-20221231.xsd#ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:href="euda-20221231.xsd#ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="euda-20221231.xsd#ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:href="euda-20221231.xsd#ReverseRecapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:href="euda-20221231.xsd#DispositionOfSubsidiaryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:href="euda-20221231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="euda-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillDetailsNarrative" xlink:href="euda-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:href="euda-20221231.xsd#LoanToThirdPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:href="euda-20221231.xsd#CreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfWarrantActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:href="euda-20221231.xsd#ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:href="euda-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:href="euda-20221231.xsd#ScheduleOfTaxesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:href="euda-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:href="euda-20221231.xsd#ConcentrationsRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="euda-20221231.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesDetailsNarrative" xlink:href="euda-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="euda-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSegmentReportingInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:href="euda-20221231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:href="euda-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivables" xlink:label="loc_EUDAForwardPurchaseReceivables" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_EUDAForwardPurchaseReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesNonCurrent" xlink:label="loc_EUDAOtherReceivablesNonCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_EUDAOtherReceivablesNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanToThirdParty" xlink:label="loc_EUDALoanToThirdParty" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_EUDALoanToThirdParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermLoansThirdParties" xlink:label="loc_EUDAShortTermLoansThirdParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAShortTermLoansThirdParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNote" xlink:label="loc_EUDAPromissoryNote" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedParties" xlink:label="loc_EUDAConvertibleNotesRelatedParties" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAConvertibleNotesRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccountsPayableRelatedParty" xlink:label="loc_EUDAAccountsPayableRelatedParty" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAAccountsPayableRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesAndAccruedLiabilities" xlink:label="loc_EUDAOtherPayablesAndAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAOtherPayablesAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesRelatedParties" xlink:label="loc_EUDAOtherPayablesRelatedParties" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAOtherPayablesRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutSharePayment" xlink:label="loc_EUDAEarnoutSharePayment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_EUDAEarnoutSharePayment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Change in Shareholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutPayment" xlink:label="loc_EUDAEarnoutPayment" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EUDAEarnoutPayment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:label="loc_EUDAChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EUDAChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInNotesReceivableCurrent" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInNotesReceivableCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="loc_EUDAIncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_EUDAIncreaseDecreaseInAccountsPayableRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapPaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalization" xlink:label="loc_EUDAProceedsFromReverseRecapitalization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_EUDAProceedsFromReverseRecapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsFromOtherReceivableRelatedParties" xlink:label="loc_EUDARepaymentsFromOtherReceivableRelatedParties" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_EUDARepaymentsFromOtherReceivableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsToShorttermLoansThirdParties" xlink:label="loc_EUDARepaymentsToShorttermLoansThirdParties" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_EUDARepaymentsToShorttermLoansThirdParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:title="00000007 - Disclosure - Nature of business and organization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcern" xlink:title="00000008 - Disclosure - Going concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of significant accounting policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalization" xlink:title="00000010 - Disclosure - Reverse Recapitalization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiary" xlink:title="00000011 - Disclosure - Disposition of Subsidiary" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNet" xlink:title="00000012 - Disclosure - Accounts receivable, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivables" xlink:title="00000013 - Disclosure - Other receivables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - Property and equipment, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - Intangible assets, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/Goodwill" xlink:title="00000016 - Disclosure - Goodwill" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreements" xlink:title="00000017 - Disclosure - Forward Purchase Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdParty" xlink:title="00000018 - Disclosure - Loan to third party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilities" xlink:title="00000019 - Disclosure - Credit facilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000020 - Disclosure - Other payables and accrued liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related party balances and transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquity" xlink:title="00000022 - Disclosure - Shareholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisks" xlink:title="00000024 - Disclosure - Concentrations risks" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/Leases" xlink:title="00000025 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingencies" xlink:title="00000026 - Disclosure - Commitments and contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformation" xlink:title="00000027 - Disclosure - Segment information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEvents" xlink:title="00000028 - Disclosure - Subsequent events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of significant accounting policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:title="00000030 - Disclosure - Nature of business and organization (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of significant accounting policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationTables" xlink:title="00000032 - Disclosure - Reverse Recapitalization (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNetTables" xlink:title="00000033 - Disclosure - Accounts receivable, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivablesTables" xlink:title="00000034 - Disclosure - Other receivables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:title="00000035 - Disclosure - Property and equipment, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetTables" xlink:title="00000036 - Disclosure - Intangible assets, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillTables" xlink:title="00000037 - Disclosure - Goodwill (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesTables" xlink:title="00000038 - Disclosure - Credit facilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - Other payables and accrued liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - Related party balances and transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityTables" xlink:title="00000041 - Disclosure - Shareholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - Income taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesTables" xlink:title="00000043 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationTables" xlink:title="00000044 - Disclosure - Segment information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:title="00000045 - Disclosure - Schedule of consolidated financial statement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:title="00000046 - Disclosure - Nature of business and organization (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcernDetailsNarrative" xlink:title="00000047 - Disclosure - Going concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:title="00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:title="00000049 - Disclosure - Schedule of property and equipment useful lives (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000050 - Disclosure - Schedule of intangible assets net (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRevenueDetails" xlink:title="00000051 - Disclosure - Schedule of revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:title="00000052 - Disclosure - Schedule of cost of revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:title="00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:title="00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:title="00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:title="00000059 - Disclosure - Reverse Recapitalization (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:title="00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000061 - Disclosure - Schedule of accounts receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:title="00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:title="00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="00000064 - Disclosure - Schedule of other receivables (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:title="00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:title="00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000067 - Disclosure - Schedule of property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000068 - Disclosure - Property and equipment, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000069 - Disclosure - Schedule of intangible assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedCustomerRelationshipsGross" xlink:label="loc_us-gaapFiniteLivedCustomerRelationshipsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedCustomerRelationshipsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:title="00000070 - Disclosure - Schedule of goodwill (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000071 - Disclosure - Intangible assets, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillDetailsNarrative" xlink:title="00000072 - Disclosure - Goodwill (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:title="00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:title="00000074 - Disclosure - Loan to third party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:title="00000075 - Disclosure - Schedule of short-term loans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:title="00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:title="00000077 - Disclosure - Credit facilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:title="00000079 - Disclosure - Schedule of related party balances (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000080 - Disclosure - Schedule of related party transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:title="00000081 - Disclosure - Schedule of reverse recapitalization (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:title="00000082 - Disclosure - Schedule of warrant activities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:title="00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000084 - Disclosure - Shareholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:title="00000085 - Disclosure - Schedule of components of loss before income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000086 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000087 - Disclosure - Schedule of effective income tax rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DeferredTaxAssetsLeaseLiabilityNet" xlink:label="loc_EUDADeferredTaxAssetsLeaseLiabilityNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_EUDADeferredTaxAssetsLeaseLiabilityNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:title="00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:title="00000090 - Disclosure - Schedule of taxes payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccruedGSTTaxesPayableCurrent" xlink:label="loc_EUDAAccruedGSTTaxesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTaxesPayableCurrent" xlink:to="loc_EUDAAccruedGSTTaxesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTaxesPayableCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000091 - Disclosure - Income taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:title="00000092 - Disclosure - Concentrations risks (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:title="00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:title="00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000095 - Disclosure - Schedule of future minimum lease payments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesDetailsNarrative" xlink:title="00000096 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000097 - Disclosure - Commitments and contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="00000098 - Disclosure - Schedule of segment reporting information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:title="00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:title="00000100 - Disclosure - Segment information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000101 - Disclosure - Subsequent events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>euda-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://euda.com/role/Cover" xlink:href="euda-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheets" xlink:href="euda-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheetsParenthetical" xlink:href="euda-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="euda-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:href="euda-20221231.xsd#StatementsOfChangeInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfCashFlows" xlink:href="euda-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcern" xlink:href="euda-20221231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalization" xlink:href="euda-20221231.xsd#ReverseRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiary" xlink:href="euda-20221231.xsd#DispositionOfSubsidiary" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNet" xlink:href="euda-20221231.xsd#AccountsReceivableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivables" xlink:href="euda-20221231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNet" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNet" xlink:href="euda-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Goodwill" xlink:href="euda-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreements" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdParty" xlink:href="euda-20221231.xsd#LoanToThirdParty" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilities" xlink:href="euda-20221231.xsd#CreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquity" xlink:href="euda-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxes" xlink:href="euda-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisks" xlink:href="euda-20221231.xsd#ConcentrationsRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Leases" xlink:href="euda-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingencies" xlink:href="euda-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformation" xlink:href="euda-20221231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEvents" xlink:href="euda-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationTables" xlink:href="euda-20221231.xsd#ReverseRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNetTables" xlink:href="euda-20221231.xsd#AccountsReceivableNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivablesTables" xlink:href="euda-20221231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetTables" xlink:href="euda-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillTables" xlink:href="euda-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesTables" xlink:href="euda-20221231.xsd#CreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityTables" xlink:href="euda-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesTables" xlink:href="euda-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesTables" xlink:href="euda-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationTables" xlink:href="euda-20221231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcernDetailsNarrative" xlink:href="euda-20221231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:href="euda-20221231.xsd#ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfCostOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="euda-20221231.xsd#ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:href="euda-20221231.xsd#ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="euda-20221231.xsd#ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:href="euda-20221231.xsd#ReverseRecapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:href="euda-20221231.xsd#DispositionOfSubsidiaryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:href="euda-20221231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="euda-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillDetailsNarrative" xlink:href="euda-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:href="euda-20221231.xsd#LoanToThirdPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:href="euda-20221231.xsd#CreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfWarrantActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:href="euda-20221231.xsd#ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:href="euda-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:href="euda-20221231.xsd#ScheduleOfTaxesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:href="euda-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:href="euda-20221231.xsd#ConcentrationsRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="euda-20221231.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesDetailsNarrative" xlink:href="euda-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="euda-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSegmentReportingInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:href="euda-20221231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:href="euda-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesMember" xlink:label="loc_EUDAOrdinarySharesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_EUDAOrdinarySharesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedeemableWarrantsMember" xlink:label="loc_EUDARedeemableWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_EUDARedeemableWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="61" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesRelatedPartiesMember" xlink:label="loc_EUDAMedicalServicesRelatedPartiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesRelatedPartiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_110" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="loc_us-gaapCostOfRevenueAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenueAbstract_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostOfRevenueAbstract_110" xlink:to="loc_us-gaapCostOfRevenue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapSellingAndMarketingExpense_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutSharePayment" xlink:label="loc_EUDAEarnoutSharePayment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_EUDAEarnoutSharePayment_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapAssetImpairmentCharges_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapOperatingExpenses_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapInterestExpenseOther_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapInvestmentIncomeNet_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_110" xlink:to="loc_us-gaapNonoperatingIncomeExpense_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract_110" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract_110" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_110" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract_110" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract_110" xlink:to="loc_us-gaapEarningsPerShareBasic_110" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Change in Shareholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueCapitalContributions" xlink:label="loc_EUDAStockIssuedDuringPeriodValueCapitalContributions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueCapitalContributions_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesCapitalContributions" xlink:label="loc_EUDAStockIssuedDuringPeriodSharesCapitalContributions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodSharesCapitalContributions_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:label="loc_EUDAStockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:label="loc_EUDAStockIssuedDuringPeriodValueEarnoutSharesPayament_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueEarnoutSharesPayament_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:label="loc_EUDAStockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:title="00000007 - Disclosure - Nature of business and organization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcern" xlink:title="00000008 - Disclosure - Going concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of significant accounting policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalization" xlink:title="00000010 - Disclosure - Reverse Recapitalization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiary" xlink:title="00000011 - Disclosure - Disposition of Subsidiary" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNet" xlink:title="00000012 - Disclosure - Accounts receivable, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivables" xlink:title="00000013 - Disclosure - Other receivables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - Property and equipment, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - Intangible assets, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/Goodwill" xlink:title="00000016 - Disclosure - Goodwill" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreements" xlink:title="00000017 - Disclosure - Forward Purchase Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdParty" xlink:title="00000018 - Disclosure - Loan to third party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilities" xlink:title="00000019 - Disclosure - Credit facilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000020 - Disclosure - Other payables and accrued liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related party balances and transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquity" xlink:title="00000022 - Disclosure - Shareholders&#8217; equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisks" xlink:title="00000024 - Disclosure - Concentrations risks" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/Leases" xlink:title="00000025 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingencies" xlink:title="00000026 - Disclosure - Commitments and contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformation" xlink:title="00000027 - Disclosure - Segment information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEvents" xlink:title="00000028 - Disclosure - Subsequent events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of significant accounting policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:title="00000030 - Disclosure - Nature of business and organization (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of significant accounting policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationTables" xlink:title="00000032 - Disclosure - Reverse Recapitalization (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNetTables" xlink:title="00000033 - Disclosure - Accounts receivable, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivablesTables" xlink:title="00000034 - Disclosure - Other receivables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:title="00000035 - Disclosure - Property and equipment, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetTables" xlink:title="00000036 - Disclosure - Intangible assets, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillTables" xlink:title="00000037 - Disclosure - Goodwill (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesTables" xlink:title="00000038 - Disclosure - Credit facilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesThirdPartiesMember" xlink:label="loc_EUDAConvertibleNotesThirdPartiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesThirdPartiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaapScheduleOfShortTermDebtTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTextBlock_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - Other payables and accrued liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - Related party balances and transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityTables" xlink:title="00000041 - Disclosure - Shareholders&#8217; equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - Income taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesTables" xlink:title="00000043 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationTables" xlink:title="00000044 - Disclosure - Segment information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:title="00000045 - Disclosure - Schedule of consolidated financial statement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAHealthLimitedMember" xlink:label="loc_EUDAEUDAHealthLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAHealthLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePteLtdMember" xlink:label="loc_EUDAKentRidgeHealthcareSingaporePteLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthcareSingaporePteLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAPrivateLimitedMember" xlink:label="loc_EUDAEUDAPrivateLimitedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAPrivateLimitedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:label="loc_EUDAZukitekVietnamPrivateLimitedLiabilityCompanyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukitekVietnamPrivateLimitedLiabilityCompanyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:label="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TheGoodClinicPrivateLimitedMember" xlink:label="loc_EUDATheGoodClinicPrivateLimitedMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATheGoodClinicPrivateLimitedMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDADoctorPrivateLimitedMember" xlink:label="loc_EUDAEUDADoctorPrivateLimitedMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDADoctorPrivateLimitedMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHillPrivateLimitedMember" xlink:label="loc_EUDAKentRidgeHillPrivateLimitedMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHillPrivateLimitedMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthLimitedMember" xlink:label="loc_EUDAKentRidgeHealthLimitedMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthLimitedMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitechPrivateLimitedMember" xlink:label="loc_EUDAZukitechPrivateLimitedMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukitechPrivateLimitedMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SuperGatewayGroupLimitedMember" xlink:label="loc_EUDASuperGatewayGroupLimitedMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASuperGatewayGroupLimitedMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UniversalGatewayInternationalPteLtdMember" xlink:label="loc_EUDAUniversalGatewayInternationalPteLtdMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAUniversalGatewayInternationalPteLtdMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLtdMember" xlink:label="loc_EUDAMelanaInternationalPteLtdMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAMelanaInternationalPteLtdMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLtdMember" xlink:label="loc_EUDATriGlobalSecurityPteLtdMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATriGlobalSecurityPteLtdMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitechPrivateLimitedMember" xlink:label="loc_EUDAUGDigitechPrivateLimitedMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAUGDigitechPrivateLimitedMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NosweatFitnessCompanyPrivateLimitedMember" xlink:label="loc_EUDANosweatFitnessCompanyPrivateLimitedMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDANosweatFitnessCompanyPrivateLimitedMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TrueCoverPrivateLimitedMember" xlink:label="loc_EUDATrueCoverPrivateLimitedMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATrueCoverPrivateLimitedMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRDigitalPteLtdMember" xlink:label="loc_EUDAKRDigitalPteLtdMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKRDigitalPteLtdMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSdnBhdMember" xlink:label="loc_EUDAZukihealthSdnBhdMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukihealthSdnBhdMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_410" xlink:type="arc" order="412" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NameOfCompany" xlink:label="loc_EUDANameOfCompany_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDANameOfCompany_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DateOfIncorporation" xlink:label="loc_EUDADateOfIncorporation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDADateOfIncorporation_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RegisteredCapital" xlink:label="loc_EUDARegisteredCapital_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDARegisteredCapital_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_450" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:title="00000046 - Disclosure - Nature of business and organization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" xlink:label="loc_EUDAKentRidgeHealthcareSingaporePrivateLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthcareSingaporePrivateLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAPrivateLimitedMember" xlink:label="loc_EUDAEUDAPrivateLimitedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAPrivateLimitedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SuperGatewayGroupLimitedMember" xlink:label="loc_EUDASuperGatewayGroupLimitedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASuperGatewayGroupLimitedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:label="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcernDetailsNarrative" xlink:title="00000047 - Disclosure - Going concern (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:title="00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD" xlink:label="loc_currencySGD_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencySGD_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_VND" xlink:label="loc_currencyVND_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyVND_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MYR" xlink:label="loc_currencyMYR_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyMYR_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateRemeasurement1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateRemeasurement1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:title="00000049 - Disclosure - Schedule of property and equipment useful lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalEquipmentMember" xlink:label="loc_EUDAMedicalEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_EUDAMedicalEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000050 - Disclosure - Schedule of intangible assets net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRevenueDetails" xlink:title="00000051 - Disclosure - Schedule of revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticeRelatedPartiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticeRelatedPartiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSubTotalMember" xlink:label="loc_EUDAMedicalServicesSubTotalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSubTotalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceCommonAreaManagementMember" xlink:label="loc_EUDAPropertyManagementServiceCommonAreaManagementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceCommonAreaManagementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceSecurityManagementMember" xlink:label="loc_EUDAPropertyManagementServiceSecurityManagementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceSecurityManagementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceMember" xlink:label="loc_EUDAPropertyManagementServiceMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:title="00000052 - Disclosure - Schedule of cost of revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticesMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSubTotalMember" xlink:label="loc_EUDAMedicalServicesSubTotalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSubTotalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesCommonAreaManagementMember" xlink:label="loc_EUDAPropertyManagementServicesCommonAreaManagementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesCommonAreaManagementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesSecurityManagementMember" xlink:label="loc_EUDAPropertyManagementServicesSecurityManagementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesSecurityManagementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductMangementServicesMember" xlink:label="loc_EUDAProductMangementServicesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductMangementServicesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:title="00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CentralProvidentFundMember" xlink:label="loc_EUDACentralProvidentFundMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDACentralProvidentFundMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SkillDevelopmentLevyMember" xlink:label="loc_EUDASkillDevelopmentLevyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDASkillDevelopmentLevyMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SocialInsuranceFundMember" xlink:label="loc_EUDASocialInsuranceFundMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDASocialInsuranceFundMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:label="loc_EUDAAllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAAllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivables" xlink:label="loc_EUDAForwardPurchaseReceivables_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAForwardPurchaseReceivables_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiability" xlink:label="loc_EUDAPrepaidForwardPurchaseLiability_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiability_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdvertisingExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSalariesAndWages_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TradeUnionFeePercentage" xlink:label="loc_EUDATradeUnionFeePercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDATradeUnionFeePercentage_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:title="00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:title="00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:title="00000059 - Disclosure - Reverse Recapitalization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FirstAnniversaryMember" xlink:label="loc_EUDAFirstAnniversaryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFirstAnniversaryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SecondAnniversaryMember" xlink:label="loc_EUDASecondAnniversaryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASecondAnniversaryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BusinessCombinationMember" xlink:label="loc_EUDABusinessCombinationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDABusinessCombinationMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SharePurchaseAgreementMember" xlink:label="loc_EUDASharePurchaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASharePurchaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ExchangeRatioPerShare" xlink:label="loc_EUDAExchangeRatioPerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAExchangeRatioPerShare_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesNoParValue" xlink:label="loc_EUDAPrivateOrdinarySharesNoParValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateOrdinarySharesNoParValue_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesOutstanding" xlink:label="loc_EUDAPrivateOrdinarySharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateOrdinarySharesOutstanding_120" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesNoParValue" xlink:label="loc_EUDAFounderSharesNoParValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFounderSharesNoParValue_120" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesOutstanding" xlink:label="loc_EUDAFounderSharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFounderSharesOutstanding_120" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicRightsShares" xlink:label="loc_EUDAPublicRightsShares_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPublicRightsShares_120" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateRightsShares" xlink:label="loc_EUDAPrivateRightsShares_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateRightsShares_120" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_120" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_120" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalization" xlink:label="loc_EUDAProceedsFromReverseRecapitalization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAProceedsFromReverseRecapitalization_120" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInTrustAccount" xlink:label="loc_EUDAFundsHeldInTrustAccount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFundsHeldInTrustAccount_120" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInOperatingCashAccount" xlink:label="loc_EUDAFundsHeldInOperatingCashAccount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFundsHeldInOperatingCashAccount_120" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_120" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_120" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_120" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities_120" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_120" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:title="00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SEMAAgreementMember" xlink:label="loc_EUDASEMAAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASEMAAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TheGoodClinicPrivateLimitedMember" xlink:label="loc_EUDATheGoodClinicPrivateLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATheGoodClinicPrivateLimitedMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000061 - Disclosure - Schedule of accounts receivable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:title="00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:title="00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="00000064 - Disclosure - Schedule of other receivables (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:title="00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:title="00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000067 - Disclosure - Schedule of property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalEquipmentMember" xlink:label="loc_EUDAMedicalEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_EUDAMedicalEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000068 - Disclosure - Property and equipment, net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000069 - Disclosure - Schedule of intangible assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:title="00000070 - Disclosure - Schedule of goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLimitedMember" xlink:label="loc_EUDAMelanaInternationalPteLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDAMelanaInternationalPteLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLimitedMember" xlink:label="loc_EUDATriGlobalSecurityPteLimitedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDATriGlobalSecurityPteLimitedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapGoodwillTranslationAndPurchaseAccountingAdjustments_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwillTranslationAndPurchaseAccountingAdjustments_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_160" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000071 - Disclosure - Intangible assets, net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillDetailsNarrative" xlink:title="00000072 - Disclosure - Goodwill (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:title="00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementOneMember" xlink:label="loc_EUDAPrepaidForwardAgreementOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAPrepaidForwardAgreementOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementTwoMember" xlink:label="loc_EUDAPrepaidForwardAgreementTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAPrepaidForwardAgreementTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InstitutionalInvestorsMember" xlink:label="loc_EUDAInstitutionalInvestorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAInstitutionalInvestorsMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaapForwardContractsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapForwardContractsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:label="loc_us-gaapForwardContractIndexedToEquitySettlementShareFairValuePerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForwardContractIndexedToEquitySettlementShareFairValuePerShare_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:label="loc_EUDAChangeOfFairValueOfPrepaidForwardPurchaseLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAChangeOfFairValueOfPrepaidForwardPurchaseLiability_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:title="00000074 - Disclosure - Loan to third party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PTTotalPrimaIndonesiaMember" xlink:label="loc_EUDAPTTotalPrimaIndonesiaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_EUDAPTTotalPrimaIndonesiaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanAccumulativelyDisbursed" xlink:label="loc_EUDALoanAccumulativelyDisbursed_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDALoanAccumulativelyDisbursed_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestReceivable_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="loc_us-gaapInterestIncomeRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeRelatedParty_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:title="00000075 - Disclosure - Schedule of short-term loans (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FSCapitalPtdLtdMember" xlink:label="loc_EUDAFSCapitalPtdLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAFSCapitalPtdLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundingSocietiesPteLtdMember" xlink:label="loc_EUDAFundingSocietiesPteLtdMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAFundingSocietiesPteLtdMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KohWeeSingMember" xlink:label="loc_EUDAKohWeeSingMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKohWeeSingMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KaufamanAndCanolesPcKcMember" xlink:label="loc_EUDAKaufamanAndCanolesPcKcMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKaufamanAndCanolesPcKcMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MaximGroupLlcMember" xlink:label="loc_EUDAMaximGroupLlcMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMaximGroupLlcMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraCapitalPteLtdMember" xlink:label="loc_EUDAMenoraCapitalPteLtdMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMenoraCapitalPteLtdMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoebAndLoebLlpMember" xlink:label="loc_EUDALoebAndLoebLlpMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDALoebAndLoebLlpMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkLimitedMember" xlink:label="loc_EUDAShineLinkLimitedMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAShineLinkLimitedMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MengDongJamesTanMember" xlink:label="loc_EUDAMengDongJamesTanMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMengDongJamesTanMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesThirdPartiesMember" xlink:label="loc_EUDAConvertibleNotesThirdPartiesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesThirdPartiesMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedPartiesMember" xlink:label="loc_EUDAConvertibleNotesRelatedPartiesMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesRelatedPartiesMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLender" xlink:label="loc_us-gaapShortTermDebtLender_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtLender_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTerms" xlink:label="loc_us-gaapShortTermDebtTerms_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtTerms_410" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermDebtInterestRate" xlink:label="loc_EUDAShortTermDebtInterestRate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_EUDAShortTermDebtInterestRate_410" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateral" xlink:label="loc_us-gaapDebtInstrumentCollateral_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentCollateral_410" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable_410" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime_410" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_410" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_410" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_410" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_410" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:title="00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KaufamanAndCanolesPcKcMember" xlink:label="loc_EUDAKaufamanAndCanolesPcKcMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKaufamanAndCanolesPcKcMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MengDongJamesTanMember" xlink:label="loc_EUDAMengDongJamesTanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMengDongJamesTanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SettlementAgreementMember" xlink:label="loc_EUDASettlementAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASettlementAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:title="00000077 - Disclosure - Credit facilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRate_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:title="00000079 - Disclosure - Schedule of related party balances (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRHillCapitalPteLtdMember" xlink:label="loc_EUDAKRHillCapitalPteLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKRHillCapitalPteLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeMedicalPtdLtdMember" xlink:label="loc_EUDAKentRidgeMedicalPtdLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgeMedicalPtdLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitalSdnBhdMember" xlink:label="loc_EUDAUGDigitalSdnBhdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAUGDigitalSdnBhdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JanicLimitedMember" xlink:label="loc_EUDAJanicLimitedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJanicLimitedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSDNMember" xlink:label="loc_EUDAZukihealthSDNMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAZukihealthSDNMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JenniferGohMember" xlink:label="loc_EUDAJenniferGohMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJenniferGohMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FrescoInvestmentPteLtdMember" xlink:label="loc_EUDAFrescoInvestmentPteLtdMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAFrescoInvestmentPteLtdMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CadenceHealthPteLtdMember" xlink:label="loc_EUDACadenceHealthPteLtdMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACadenceHealthPteLtdMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CheeYinMehMember" xlink:label="loc_EUDACheeYinMehMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACheeYinMehMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamieFanWeiZhiMember" xlink:label="loc_EUDAJamieFanWeiZhiMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJamieFanWeiZhiMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KelvinChenMember" xlink:label="loc_EUDAKelvinChenMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKelvinChenMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthPteLtdMember" xlink:label="loc_EUDAKentRidgeHealthPteLtdMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgeHealthPteLtdMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgePacificPteLtdMember" xlink:label="loc_EUDAKentRidgePacificPteLtdMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgePacificPteLtdMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WatermarkDevelopmentsLtdMember" xlink:label="loc_EUDAWatermarkDevelopmentsLtdMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAWatermarkDevelopmentsLtdMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WilkeServicesLtdMember" xlink:label="loc_EUDAWilkeServicesLtdMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAWilkeServicesLtdMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MountLockeLimitedMember" xlink:label="loc_EUDAMountLockeLimitedMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAMountLockeLimitedMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties" xlink:label="loc_us-gaapDueFromOtherRelatedParties_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOtherRelatedParties_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrentAndNoncurrent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrentAndNoncurrent_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent_350" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000080 - Disclosure - Schedule of related party transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CadenceHealthPteLtdMember" xlink:label="loc_EUDACadenceHealthPteLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACadenceHealthPteLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgePacificPteLtdMember" xlink:label="loc_EUDAKentRidgePacificPteLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgePacificPteLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PurchaseFromRelatedParties" xlink:label="loc_EUDAPurchaseFromRelatedParties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_EUDAPurchaseFromRelatedParties_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:title="00000081 - Disclosure - Schedule of reverse recapitalization (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:title="00000082 - Disclosure - Schedule of warrant activities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingGranted" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingGranted_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:label="loc_EUDAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingForfeited" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingForfeited_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingForfeited_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingExercised" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingExercised_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:title="00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000084 - Disclosure - Shareholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicWarrantMember" xlink:label="loc_EUDAPublicWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_EUDAPublicWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateWarrantMember" xlink:label="loc_EUDAPrivateWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_EUDAPrivateWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FirstAnniversaryMember" xlink:label="loc_EUDAFirstAnniversaryMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFirstAnniversaryMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SecondAnniversaryMember" xlink:label="loc_EUDASecondAnniversaryMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASecondAnniversaryMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventOneMember" xlink:label="loc_EUDATriggeringEventOneMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_EUDATriggeringEventOneMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventTwoMember" xlink:label="loc_EUDATriggeringEventTwoMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_EUDATriggeringEventTwoMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="loc_us-gaapCapital_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCapital_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinaryShareBeforeReverseRecapitalization" xlink:label="loc_EUDAOrdinaryShareBeforeReverseRecapitalization_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAOrdinaryShareBeforeReverseRecapitalization_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WarrantsRedemptionPrice" xlink:label="loc_EUDAWarrantsRedemptionPrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAWarrantsRedemptionPrice_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutShares" xlink:label="loc_EUDAEarnoutShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAEarnoutShares_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNetIncomeLoss_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FairValueOfEarnoutShares" xlink:label="loc_EUDAFairValueOfEarnoutShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAFairValueOfEarnoutShares_200" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:title="00000085 - Disclosure - Schedule of components of loss before income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000086 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000087 - Disclosure - Schedule of effective income tax rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:title="00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:title="00000090 - Disclosure - Schedule of taxes payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000091 - Disclosure - Income taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_VN" xlink:label="loc_countryVN_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryVN_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="loc_countrySG_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countrySG_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SeventyFivePercentageMember" xlink:label="loc_EUDASeventyFivePercentageMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASeventyFivePercentageMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FiftyPercentageMember" xlink:label="loc_EUDAFiftyPercentageMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFiftyPercentageMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeSubsidiariesMember" xlink:label="loc_EUDASingaporeSubsidiariesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_EUDASingaporeSubsidiariesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:title="00000092 - Disclosure - Concentrations risks (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoCustomerMember" xlink:label="loc_EUDANoCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDANoCustomerMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoVendorMember" xlink:label="loc_EUDANoVendorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDANoVendorMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OneVendorMember" xlink:label="loc_EUDAOneVendorMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAOneVendorMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorOneMember" xlink:label="loc_EUDAVendorOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAVendorOneMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorTwoMember" xlink:label="loc_EUDAVendorTwoMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAVendorTwoMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaapCreditRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:to="loc_us-gaapCreditRiskMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapDeposits_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts" xlink:label="loc_us-gaapBankOverdrafts_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapBankOverdrafts_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRestrictedCash_140" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:title="00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OperatingLeaseExpenseShortTerm" xlink:label="loc_EUDAOperatingLeaseExpenseShortTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAOperatingLeaseExpenseShortTerm_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:title="00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000095 - Disclosure - Schedule of future minimum lease payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesDetailsNarrative" xlink:title="00000096 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000097 - Disclosure - Commitments and contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="00000098 - Disclosure - Schedule of segment reporting information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAMedicalServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAPropertyManagementServicesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConsolidatedMember" xlink:label="loc_EUDAConsolidatedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAConsolidatedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:title="00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:title="00000100 - Disclosure - Segment information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAMedicalServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAPropertyManagementServicesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000101 - Disclosure - Subsequent events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AlfredLimMember" xlink:label="loc_EUDAAlfredLimMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAAlfredLimMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamesTanMember" xlink:label="loc_EUDAJamesTanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAJamesTanMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkMember" xlink:label="loc_EUDAShineLinkMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAShineLinkMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraMember" xlink:label="loc_EUDAMenoraMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAMenoraMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightiHoldingMember" xlink:label="loc_EUDAEightiHoldingMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAEightiHoldingMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KelvinChenMember" xlink:label="loc_EUDAKelvinChenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAKelvinChenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerOneMember" xlink:label="loc_EUDASellerOneMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDASellerOneMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerTwoMember" xlink:label="loc_EUDASellerTwoMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDASellerTwoMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanSecondLoanMember" xlink:label="loc_EUDATanSecondLoanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanSecondLoanMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanFirstLoanMember" xlink:label="loc_EUDATanFirstLoanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanFirstLoanMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanThirdLoanMember" xlink:label="loc_EUDATanThirdLoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanThirdLoanMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanTwoThousandTwentyThreeNoteMember" xlink:label="loc_EUDATanTwoThousandTwentyThreeNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanTwoThousandTwentyThreeNoteMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SettlementAgreementMember" xlink:label="loc_EUDASettlementAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASettlementAgreementMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChenSettlementAgreementMember" xlink:label="loc_EUDAChenSettlementAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAChenSettlementAgreementMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="193" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_290" xlink:type="arc" order="292" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesAvailableForResale" xlink:label="loc_EUDAOrdinarySharesAvailableForResale_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesAvailableForResale_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="loc_us-gaapConversionOfStockTypeOfStockConverted_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockTypeOfStockConverted_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesForfeited" xlink:label="loc_EUDAOrdinarySharesForfeited_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesForfeited_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesToBeIssued" xlink:label="loc_EUDAOrdinarySharesToBeIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesToBeIssued_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_310" xlink:type="arc" order="16" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>euda-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesMember" xlink:label="EUDA_OrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesMember" xlink:to="EUDA_OrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedeemableWarrantsMember" xlink:label="EUDA_RedeemableWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RedeemableWarrantsMember" xlink:to="EUDA_RedeemableWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RedeemableWarrantsMember_lbl" xml:lang="en-US">Redeemable Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="EUDA_MedicalServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesMember" xlink:to="EUDA_MedicalServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesMember_lbl" xml:lang="en-US">Medical Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesRelatedPartiesMember" xlink:label="EUDA_MedicalServicesRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesRelatedPartiesMember" xlink:to="EUDA_MedicalServicesRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesRelatedPartiesMember_lbl" xml:lang="en-US">Medical Services Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="EUDA_ProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProductSalesMember" xlink:to="EUDA_ProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProductSalesMember_lbl" xml:lang="en-US">Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="EUDA_PropertyManagementServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesMember" xlink:to="EUDA_PropertyManagementServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServicesMember_lbl" xml:lang="en-US">Property Management Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" xlink:label="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" xlink:to="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember_lbl" xml:lang="en-US">Kent Ridge Healthcare Singapore Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAPrivateLimitedMember" xlink:label="EUDA_EUDAPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDAPrivateLimitedMember" xlink:to="EUDA_EUDAPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EUDAPrivateLimitedMember_lbl" xml:lang="en-US">EUDA Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SuperGatewayGroupLimitedMember" xlink:label="EUDA_SuperGatewayGroupLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SuperGatewayGroupLimitedMember" xlink:to="EUDA_SuperGatewayGroupLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SuperGatewayGroupLimitedMember_lbl" xml:lang="en-US">Super Gateway Group Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:label="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:to="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember_lbl" xml:lang="en-US">Singapore Emergency Medical Assistance Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAHealthLimitedMember" xlink:label="EUDA_EUDAHealthLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDAHealthLimitedMember" xlink:to="EUDA_EUDAHealthLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EUDAHealthLimitedMember_lbl" xml:lang="en-US">EUDA Health Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePteLtdMember" xlink:label="EUDA_KentRidgeHealthcareSingaporePteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthcareSingaporePteLtdMember" xlink:to="EUDA_KentRidgeHealthcareSingaporePteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeHealthcareSingaporePteLtdMember_lbl" xml:lang="en-US">Kent Ridge Healthcare SingaporePte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:label="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:to="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember_lbl" xml:lang="en-US">Zukitek Vietnam Private Limited Liability Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TheGoodClinicPrivateLimitedMember" xlink:label="EUDA_TheGoodClinicPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TheGoodClinicPrivateLimitedMember" xlink:to="EUDA_TheGoodClinicPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TheGoodClinicPrivateLimitedMember_lbl" xml:lang="en-US">The Good Clinic Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDADoctorPrivateLimitedMember" xlink:label="EUDA_EUDADoctorPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDADoctorPrivateLimitedMember" xlink:to="EUDA_EUDADoctorPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EUDADoctorPrivateLimitedMember_lbl" xml:lang="en-US">EUDA Doctor Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHillPrivateLimitedMember" xlink:label="EUDA_KentRidgeHillPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHillPrivateLimitedMember" xlink:to="EUDA_KentRidgeHillPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeHillPrivateLimitedMember_lbl" xml:lang="en-US">Kent Ridge Hill Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthLimitedMember" xlink:label="EUDA_KentRidgeHealthLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthLimitedMember" xlink:to="EUDA_KentRidgeHealthLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeHealthLimitedMember_lbl" xml:lang="en-US">Kent Ridge Health Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitechPrivateLimitedMember" xlink:label="EUDA_ZukitechPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukitechPrivateLimitedMember" xlink:to="EUDA_ZukitechPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ZukitechPrivateLimitedMember_lbl" xml:lang="en-US">Zukitech Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UniversalGatewayInternationalPteLtdMember" xlink:label="EUDA_UniversalGatewayInternationalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UniversalGatewayInternationalPteLtdMember" xlink:to="EUDA_UniversalGatewayInternationalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_UniversalGatewayInternationalPteLtdMember_lbl" xml:lang="en-US">Universal Gateway International Pvt Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLtdMember" xlink:label="EUDA_MelanaInternationalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MelanaInternationalPteLtdMember" xlink:to="EUDA_MelanaInternationalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MelanaInternationalPteLtdMember_lbl" xml:lang="en-US">Melana International Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLtdMember" xlink:label="EUDA_TriGlobalSecurityPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriGlobalSecurityPteLtdMember" xlink:to="EUDA_TriGlobalSecurityPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TriGlobalSecurityPteLtdMember_lbl" xml:lang="en-US">Tri Global Security Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitechPrivateLimitedMember" xlink:label="EUDA_UGDigitechPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UGDigitechPrivateLimitedMember" xlink:to="EUDA_UGDigitechPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_UGDigitechPrivateLimitedMember_lbl" xml:lang="en-US">UG Digitech Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NosweatFitnessCompanyPrivateLimitedMember" xlink:label="EUDA_NosweatFitnessCompanyPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NosweatFitnessCompanyPrivateLimitedMember" xlink:to="EUDA_NosweatFitnessCompanyPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NosweatFitnessCompanyPrivateLimitedMember_lbl" xml:lang="en-US">Nosweat Fitness Company Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TrueCoverPrivateLimitedMember" xlink:label="EUDA_TrueCoverPrivateLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TrueCoverPrivateLimitedMember" xlink:to="EUDA_TrueCoverPrivateLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TrueCoverPrivateLimitedMember_lbl" xml:lang="en-US">True Cover Private Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRDigitalPteLtdMember" xlink:label="EUDA_KRDigitalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KRDigitalPteLtdMember" xlink:to="EUDA_KRDigitalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KRDigitalPteLtdMember_lbl" xml:lang="en-US">KR Digital Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSdnBhdMember" xlink:label="EUDA_ZukihealthSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukihealthSdnBhdMember" xlink:to="EUDA_ZukihealthSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ZukihealthSdnBhdMember_lbl" xml:lang="en-US">Zukihealth Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD" xlink:label="currency_SGD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_SGD" xlink:to="currency_SGD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_SGD_lbl" xml:lang="en-US">Singapore, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_VND" xlink:label="currency_VND" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_VND" xlink:to="currency_VND_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_VND_lbl" xml:lang="en-US">Viet Nam, Dong</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MYR" xlink:label="currency_MYR" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_MYR" xlink:to="currency_MYR_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_MYR_lbl" xml:lang="en-US">Malaysia, Ringgits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CentralProvidentFundMember" xlink:label="EUDA_CentralProvidentFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CentralProvidentFundMember" xlink:to="EUDA_CentralProvidentFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_CentralProvidentFundMember_lbl" xml:lang="en-US">Central Provident Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SkillDevelopmentLevyMember" xlink:label="EUDA_SkillDevelopmentLevyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SkillDevelopmentLevyMember" xlink:to="EUDA_SkillDevelopmentLevyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SkillDevelopmentLevyMember_lbl" xml:lang="en-US">Skill Development Levy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SocialInsuranceFundMember" xlink:label="EUDA_SocialInsuranceFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SocialInsuranceFundMember" xlink:to="EUDA_SocialInsuranceFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SocialInsuranceFundMember_lbl" xml:lang="en-US">Social Insurance Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalEquipmentMember" xlink:label="EUDA_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalEquipmentMember" xlink:to="EUDA_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareMember" xlink:label="EUDA_MedicalServicesSpecialtyCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCareMember" xlink:to="EUDA_MedicalServicesSpecialtyCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesSpecialtyCareMember_lbl" xml:lang="en-US">Medical Services Specialty Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeMember" xlink:label="EUDA_MedicalServicesGeneralPracticeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticeMember" xlink:to="EUDA_MedicalServicesGeneralPracticeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesGeneralPracticeMember_lbl" xml:lang="en-US">Medical Services General Practice [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" xlink:label="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" xlink:to="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember_lbl" xml:lang="en-US">Medical Services General Practice Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSubTotalMember" xlink:label="EUDA_MedicalServicesSubTotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSubTotalMember" xlink:to="EUDA_MedicalServicesSubTotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesSubTotalMember_lbl" xml:lang="en-US">Medical Services Sub Total [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceCommonAreaManagementMember" xlink:label="EUDA_PropertyManagementServiceCommonAreaManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceCommonAreaManagementMember" xlink:to="EUDA_PropertyManagementServiceCommonAreaManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServiceCommonAreaManagementMember_lbl" xml:lang="en-US">Property Management Service Common Area Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceSecurityManagementMember" xlink:label="EUDA_PropertyManagementServiceSecurityManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceSecurityManagementMember" xlink:to="EUDA_PropertyManagementServiceSecurityManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServiceSecurityManagementMember_lbl" xml:lang="en-US">Property Management Service Security Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceMember" xlink:label="EUDA_PropertyManagementServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceMember" xlink:to="EUDA_PropertyManagementServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServiceMember_lbl" xml:lang="en-US">Property Management Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" xlink:label="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" xlink:to="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember_lbl" xml:lang="en-US">Medical Services Specialty Care Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticesMember" xlink:label="EUDA_MedicalServicesGeneralPracticesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticesMember" xlink:to="EUDA_MedicalServicesGeneralPracticesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MedicalServicesGeneralPracticesMember_lbl" xml:lang="en-US">Medical Services General Practices [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesCommonAreaManagementMember" xlink:label="EUDA_PropertyManagementServicesCommonAreaManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesCommonAreaManagementMember" xlink:to="EUDA_PropertyManagementServicesCommonAreaManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServicesCommonAreaManagementMember_lbl" xml:lang="en-US">Property Management Services Common Area Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesSecurityManagementMember" xlink:label="EUDA_PropertyManagementServicesSecurityManagementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesSecurityManagementMember" xlink:to="EUDA_PropertyManagementServicesSecurityManagementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyManagementServicesSecurityManagementMember_lbl" xml:lang="en-US">Property Management Services Security Management [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductMangementServicesMember" xlink:label="EUDA_ProductMangementServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProductMangementServicesMember" xlink:to="EUDA_ProductMangementServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProductMangementServicesMember_lbl" xml:lang="en-US">Product Mangement Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FirstAnniversaryMember" xlink:label="EUDA_FirstAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FirstAnniversaryMember" xlink:to="EUDA_FirstAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SecondAnniversaryMember" xlink:label="EUDA_SecondAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SecondAnniversaryMember" xlink:to="EUDA_SecondAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SecondAnniversaryMember_lbl" xml:lang="en-US">Second Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BusinessCombinationMember" xlink:label="EUDA_BusinessCombinationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_BusinessCombinationMember" xlink:to="EUDA_BusinessCombinationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_BusinessCombinationMember_lbl" xml:lang="en-US">Business Combination [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SharePurchaseAgreementMember" xlink:label="EUDA_SharePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SharePurchaseAgreementMember" xlink:to="EUDA_SharePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SharePurchaseAgreementMember_lbl" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SEMAAgreementMember" xlink:label="EUDA_SEMAAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SEMAAgreementMember" xlink:to="EUDA_SEMAAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SEMAAgreementMember_lbl" xml:lang="en-US">SEMA Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="EUDA_UnitedOverseasBankLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UnitedOverseasBankLimitedMember" xlink:to="EUDA_UnitedOverseasBankLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_UnitedOverseasBankLimitedMember_lbl" xml:lang="en-US">United Overseas Bank Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLimitedMember" xlink:label="EUDA_MelanaInternationalPteLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MelanaInternationalPteLimitedMember" xlink:to="EUDA_MelanaInternationalPteLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MelanaInternationalPteLimitedMember_lbl" xml:lang="en-US">Melana International Pte Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLimitedMember" xlink:label="EUDA_TriGlobalSecurityPteLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriGlobalSecurityPteLimitedMember" xlink:to="EUDA_TriGlobalSecurityPteLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TriGlobalSecurityPteLimitedMember_lbl" xml:lang="en-US">TriGlobal Security Pte Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementOneMember" xlink:label="EUDA_PrepaidForwardAgreementOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardAgreementOneMember" xlink:to="EUDA_PrepaidForwardAgreementOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidForwardAgreementOneMember_lbl" xml:lang="en-US">Prepaid Forward Agreement 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementTwoMember" xlink:label="EUDA_PrepaidForwardAgreementTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardAgreementTwoMember" xlink:to="EUDA_PrepaidForwardAgreementTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidForwardAgreementTwoMember_lbl" xml:lang="en-US">Prepaid Forward Agreement 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InstitutionalInvestorsMember" xlink:label="EUDA_InstitutionalInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InstitutionalInvestorsMember" xlink:to="EUDA_InstitutionalInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_InstitutionalInvestorsMember_lbl" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember" xlink:label="us-gaap_ForwardContractsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractsMember" xlink:to="us-gaap_ForwardContractsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractsMember_lbl" xml:lang="en-US">Forward Contracts [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PTTotalPrimaIndonesiaMember" xlink:label="EUDA_PTTotalPrimaIndonesiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PTTotalPrimaIndonesiaMember" xlink:to="EUDA_PTTotalPrimaIndonesiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PTTotalPrimaIndonesiaMember_lbl" xml:lang="en-US">PT Total Prima Indonesia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="EUDA_BankAndPrivateLenderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_BankAndPrivateLenderMember" xlink:to="EUDA_BankAndPrivateLenderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_BankAndPrivateLenderMember_lbl" xml:lang="en-US">Bank and Private Lender [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="EUDA_ThirdPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ThirdPartiesMember" xlink:to="EUDA_ThirdPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ThirdPartiesMember_lbl" xml:lang="en-US">Third Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="EUDA_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PromissoryNoteMember" xlink:to="EUDA_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesThirdPartiesMember" xlink:label="EUDA_ConvertibleNotesThirdPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesThirdPartiesMember" xlink:to="EUDA_ConvertibleNotesThirdPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConvertibleNotesThirdPartiesMember_lbl" xml:lang="en-US">Convertible Notes Third Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FSCapitalPtdLtdMember" xlink:label="EUDA_FSCapitalPtdLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FSCapitalPtdLtdMember" xlink:to="EUDA_FSCapitalPtdLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FSCapitalPtdLtdMember_lbl" xml:lang="en-US">FS Capital Ptd Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundingSocietiesPteLtdMember" xlink:label="EUDA_FundingSocietiesPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundingSocietiesPteLtdMember" xlink:to="EUDA_FundingSocietiesPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FundingSocietiesPteLtdMember_lbl" xml:lang="en-US">Funding Societies Pte. Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KohWeeSingMember" xlink:label="EUDA_KohWeeSingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KohWeeSingMember" xlink:to="EUDA_KohWeeSingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KohWeeSingMember_lbl" xml:lang="en-US">Koh Wee Sing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KaufamanAndCanolesPcKcMember" xlink:label="EUDA_KaufamanAndCanolesPcKcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KaufamanAndCanolesPcKcMember" xlink:to="EUDA_KaufamanAndCanolesPcKcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KaufamanAndCanolesPcKcMember_lbl" xml:lang="en-US">Kaufaman &amp; Canoles, P.C. (KC) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MaximGroupLlcMember" xlink:label="EUDA_MaximGroupLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MaximGroupLlcMember" xlink:to="EUDA_MaximGroupLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MaximGroupLlcMember_lbl" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraCapitalPteLtdMember" xlink:label="EUDA_MenoraCapitalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MenoraCapitalPteLtdMember" xlink:to="EUDA_MenoraCapitalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MenoraCapitalPteLtdMember_lbl" xml:lang="en-US">Menora Capital Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoebAndLoebLlpMember" xlink:label="EUDA_LoebAndLoebLlpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoebAndLoebLlpMember" xlink:to="EUDA_LoebAndLoebLlpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_LoebAndLoebLlpMember_lbl" xml:lang="en-US">Loeb and Loeb LLP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkLimitedMember" xlink:label="EUDA_ShineLinkLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShineLinkLimitedMember" xlink:to="EUDA_ShineLinkLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ShineLinkLimitedMember_lbl" xml:lang="en-US">Shine Link Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="EUDA_EightIHoldingsTwoPtdLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EightIHoldingsTwoPtdLtdMember" xlink:to="EUDA_EightIHoldingsTwoPtdLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EightIHoldingsTwoPtdLtdMember_lbl" xml:lang="en-US">8i Holdings Two Ptd Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedPartiesMember" xlink:label="EUDA_ConvertibleNotesRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesRelatedPartiesMember" xlink:to="EUDA_ConvertibleNotesRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConvertibleNotesRelatedPartiesMember_lbl" xml:lang="en-US">Convertible Notes Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MengDongJamesTanMember" xlink:label="EUDA_MengDongJamesTanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MengDongJamesTanMember" xlink:to="EUDA_MengDongJamesTanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MengDongJamesTanMember_lbl" xml:lang="en-US">Meng Dong James Tan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SettlementAgreementMember" xlink:label="EUDA_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SettlementAgreementMember" xlink:to="EUDA_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRHillCapitalPteLtdMember" xlink:label="EUDA_KRHillCapitalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KRHillCapitalPteLtdMember" xlink:to="EUDA_KRHillCapitalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KRHillCapitalPteLtdMember_lbl" xml:lang="en-US">KR Hill Capital Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeMedicalPtdLtdMember" xlink:label="EUDA_KentRidgeMedicalPtdLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeMedicalPtdLtdMember" xlink:to="EUDA_KentRidgeMedicalPtdLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeMedicalPtdLtdMember_lbl" xml:lang="en-US">Kent Ridge Medical Ptd Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitalSdnBhdMember" xlink:label="EUDA_UGDigitalSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UGDigitalSdnBhdMember" xlink:to="EUDA_UGDigitalSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_UGDigitalSdnBhdMember_lbl" xml:lang="en-US">UG Digital Sdn. Bhd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JanicLimitedMember" xlink:label="EUDA_JanicLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JanicLimitedMember" xlink:to="EUDA_JanicLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_JanicLimitedMember_lbl" xml:lang="en-US">Janic Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSDNMember" xlink:label="EUDA_ZukihealthSDNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukihealthSDNMember" xlink:to="EUDA_ZukihealthSDNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ZukihealthSDNMember_lbl" xml:lang="en-US">Zukihealth SDN [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JenniferGohMember" xlink:label="EUDA_JenniferGohMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JenniferGohMember" xlink:to="EUDA_JenniferGohMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_JenniferGohMember_lbl" xml:lang="en-US">Jennifer Goh [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FrescoInvestmentPteLtdMember" xlink:label="EUDA_FrescoInvestmentPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FrescoInvestmentPteLtdMember" xlink:to="EUDA_FrescoInvestmentPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FrescoInvestmentPteLtdMember_lbl" xml:lang="en-US">Fresco Investment Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CadenceHealthPteLtdMember" xlink:label="EUDA_CadenceHealthPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CadenceHealthPteLtdMember" xlink:to="EUDA_CadenceHealthPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_CadenceHealthPteLtdMember_lbl" xml:lang="en-US">Cadence Health Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CheeYinMehMember" xlink:label="EUDA_CheeYinMehMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CheeYinMehMember" xlink:to="EUDA_CheeYinMehMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_CheeYinMehMember_lbl" xml:lang="en-US">Chee Yin Meh [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamieFanWeiZhiMember" xlink:label="EUDA_JamieFanWeiZhiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JamieFanWeiZhiMember" xlink:to="EUDA_JamieFanWeiZhiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_JamieFanWeiZhiMember_lbl" xml:lang="en-US">Jamie Fan Wei Zhi [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KelvinChenMember" xlink:label="EUDA_KelvinChenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KelvinChenMember" xlink:to="EUDA_KelvinChenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KelvinChenMember_lbl" xml:lang="en-US">Kelvin Chen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthPteLtdMember" xlink:label="EUDA_KentRidgeHealthPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthPteLtdMember" xlink:to="EUDA_KentRidgeHealthPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgeHealthPteLtdMember_lbl" xml:lang="en-US">Kent Ridge Health Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgePacificPteLtdMember" xlink:label="EUDA_KentRidgePacificPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgePacificPteLtdMember" xlink:to="EUDA_KentRidgePacificPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_KentRidgePacificPteLtdMember_lbl" xml:lang="en-US">Kent Ridge Pacific Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WatermarkDevelopmentsLtdMember" xlink:label="EUDA_WatermarkDevelopmentsLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WatermarkDevelopmentsLtdMember" xlink:to="EUDA_WatermarkDevelopmentsLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_WatermarkDevelopmentsLtdMember_lbl" xml:lang="en-US">Watermark Developments Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WilkeServicesLtdMember" xlink:label="EUDA_WilkeServicesLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WilkeServicesLtdMember" xlink:to="EUDA_WilkeServicesLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_WilkeServicesLtdMember_lbl" xml:lang="en-US">Wilke Services Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MountLockeLimitedMember" xlink:label="EUDA_MountLockeLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MountLockeLimitedMember" xlink:to="EUDA_MountLockeLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MountLockeLimitedMember_lbl" xml:lang="en-US">Mount Locke Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicWarrantMember" xlink:label="EUDA_PublicWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PublicWarrantMember" xlink:to="EUDA_PublicWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PublicWarrantMember_lbl" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateWarrantMember" xlink:label="EUDA_PrivateWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateWarrantMember" xlink:to="EUDA_PrivateWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrivateWarrantMember_lbl" xml:lang="en-US">Private Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventOneMember" xlink:label="EUDA_TriggeringEventOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriggeringEventOneMember" xlink:to="EUDA_TriggeringEventOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TriggeringEventOneMember_lbl" xml:lang="en-US">Triggering Event One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventTwoMember" xlink:label="EUDA_TriggeringEventTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriggeringEventTwoMember" xlink:to="EUDA_TriggeringEventTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TriggeringEventTwoMember_lbl" xml:lang="en-US">Triggering Event Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_VN" xlink:label="country_VN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_VN" xlink:to="country_VN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_VN_lbl" xml:lang="en-US">VIET NAM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="country_MY" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MY" xlink:to="country_MY_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MY_lbl" xml:lang="en-US">MALAYSIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="country_SG" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_SG_lbl" xml:lang="en-US">SINGAPORE</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SeventyFivePercentageMember" xlink:label="EUDA_SeventyFivePercentageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SeventyFivePercentageMember" xlink:to="EUDA_SeventyFivePercentageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SeventyFivePercentageMember_lbl" xml:lang="en-US">75% [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FiftyPercentageMember" xlink:label="EUDA_FiftyPercentageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FiftyPercentageMember" xlink:to="EUDA_FiftyPercentageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FiftyPercentageMember_lbl" xml:lang="en-US">50% [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeSubsidiariesMember" xlink:label="EUDA_SingaporeSubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SingaporeSubsidiariesMember" xlink:to="EUDA_SingaporeSubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SingaporeSubsidiariesMember_lbl" xml:lang="en-US">Singapore Subsidiaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoCustomerMember" xlink:label="EUDA_NoCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoCustomerMember" xlink:to="EUDA_NoCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NoCustomerMember_lbl" xml:lang="en-US">No Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoVendorMember" xlink:label="EUDA_NoVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoVendorMember" xlink:to="EUDA_NoVendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NoVendorMember_lbl" xml:lang="en-US">No Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OneVendorMember" xlink:label="EUDA_OneVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OneVendorMember" xlink:to="EUDA_OneVendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorOneMember" xlink:label="EUDA_VendorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_VendorOneMember" xlink:to="EUDA_VendorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_VendorOneMember_lbl" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorTwoMember" xlink:label="EUDA_VendorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_VendorTwoMember" xlink:to="EUDA_VendorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis_lbl" xml:lang="en-US">Servicing Assets and Servicing Liabilities Risk [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember" xlink:label="us-gaap_CreditRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditRiskMember" xlink:to="us-gaap_CreditRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditRiskMember_lbl" xml:lang="en-US">Credit Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConsolidatedMember" xlink:label="EUDA_ConsolidatedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConsolidatedMember" xlink:to="EUDA_ConsolidatedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConsolidatedMember_lbl" xml:lang="en-US">Consolidated [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="us-gaap_CorporateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl" xml:lang="en-US">Corporate Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AlfredLimMember" xlink:label="EUDA_AlfredLimMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AlfredLimMember" xlink:to="EUDA_AlfredLimMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AlfredLimMember_lbl" xml:lang="en-US">Alfred Lim [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanSecondLoanMember" xlink:label="EUDA_TanSecondLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanSecondLoanMember" xlink:to="EUDA_TanSecondLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TanSecondLoanMember_lbl" xml:lang="en-US">Tan Second Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanFirstLoanMember" xlink:label="EUDA_TanFirstLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanFirstLoanMember" xlink:to="EUDA_TanFirstLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TanFirstLoanMember_lbl" xml:lang="en-US">Tan First Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanThirdLoanMember" xlink:label="EUDA_TanThirdLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanThirdLoanMember" xlink:to="EUDA_TanThirdLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TanThirdLoanMember_lbl" xml:lang="en-US">Tan Third Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanTwoThousandTwentyThreeNoteMember" xlink:label="EUDA_TanTwoThousandTwentyThreeNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanTwoThousandTwentyThreeNoteMember" xlink:to="EUDA_TanTwoThousandTwentyThreeNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TanTwoThousandTwentyThreeNoteMember_lbl" xml:lang="en-US">Tan 2023 Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamesTanMember" xlink:label="EUDA_JamesTanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JamesTanMember" xlink:to="EUDA_JamesTanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_JamesTanMember_lbl" xml:lang="en-US">James Tan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkMember" xlink:label="EUDA_ShineLinkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShineLinkMember" xlink:to="EUDA_ShineLinkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ShineLinkMember_lbl" xml:lang="en-US">Shine Link [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraMember" xlink:label="EUDA_MenoraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MenoraMember" xlink:to="EUDA_MenoraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_MenoraMember_lbl" xml:lang="en-US">Menora [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightiHoldingMember" xlink:label="EUDA_EightiHoldingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EightiHoldingMember" xlink:to="EUDA_EightiHoldingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EightiHoldingMember_lbl" xml:lang="en-US">8i Holding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChenSettlementAgreementMember" xlink:label="EUDA_ChenSettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChenSettlementAgreementMember" xlink:to="EUDA_ChenSettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ChenSettlementAgreementMember_lbl" xml:lang="en-US">Chen Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerOneMember" xlink:label="EUDA_SellerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SellerOneMember" xlink:to="EUDA_SellerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SellerOneMember_lbl" xml:lang="en-US">Seller One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerTwoMember" xlink:label="EUDA_SellerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SellerTwoMember" xlink:to="EUDA_SellerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SellerTwoMember_lbl" xml:lang="en-US">Seller Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivables" xlink:label="EUDA_ForwardPurchaseReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseReceivables" xlink:to="EUDA_ForwardPurchaseReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ForwardPurchaseReceivables_lbl" xml:lang="en-US">Forward purchase receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesNonCurrent" xlink:label="EUDA_OtherReceivablesNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivablesNonCurrent" xlink:to="EUDA_OtherReceivablesNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherReceivablesNonCurrent_lbl" xml:lang="en-US">Other receivables - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanToThirdParty" xlink:label="EUDA_LoanToThirdParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanToThirdParty" xlink:to="EUDA_LoanToThirdParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_LoanToThirdParty_lbl" xml:lang="en-US">Loan to third party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short term loans - bank and private lender</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermLoansThirdParties" xlink:label="EUDA_ShortTermLoansThirdParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShortTermLoansThirdParties" xlink:to="EUDA_ShortTermLoansThirdParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ShortTermLoansThirdParties_lbl" xml:lang="en-US">Short term loans - third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNote" xlink:label="EUDA_PromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PromissoryNote" xlink:to="EUDA_PromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PromissoryNote_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedParties" xlink:label="EUDA_ConvertibleNotesRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesRelatedParties" xlink:to="EUDA_ConvertibleNotesRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConvertibleNotesRelatedParties_lbl" xml:lang="en-US">Convertible notes - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccountsPayableRelatedParty" xlink:label="EUDA_AccountsPayableRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AccountsPayableRelatedParty" xlink:to="EUDA_AccountsPayableRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AccountsPayableRelatedParty_lbl" xml:lang="en-US">Accounts payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesAndAccruedLiabilities" xlink:label="EUDA_OtherPayablesAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherPayablesAndAccruedLiabilities" xlink:to="EUDA_OtherPayablesAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherPayablesAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesRelatedParties" xlink:label="EUDA_OtherPayablesRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherPayablesRelatedParties" xlink:to="EUDA_OtherPayablesRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherPayablesRelatedParties_lbl" xml:lang="en-US">Other payables - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="EUDA_PrepaidForwardPurchaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilities" xlink:to="EUDA_PrepaidForwardPurchaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidForwardPurchaseLiabilities_lbl" xml:lang="en-US">Prepaid forward purchase liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liabilities - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value, unlimited shares authorized, 20,191,770 shares and 9,333,333 shares outstanding as of December 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Euda Health Holdings Limited Shareholders&#8217; (Deficit) Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Shareholders&#8217; (Deficit) Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&#8217; (Deficit) Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xml:lang="en-US">Common stock, shares authorized, unlimited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US">COST OF REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Total Cost of Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutSharePayment" xlink:label="EUDA_EarnoutSharePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutSharePayment" xlink:to="EUDA_EarnoutSharePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EarnoutSharePayment_lbl" xml:lang="en-US">Earnout share payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment loss on long-lived assets and goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_lbl" xml:lang="en-US">Gain on disposal of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:to="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_lbl" xml:lang="en-US">Change in fair value of prepaid forward purchase liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">(LOSS) INCOME BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET (LOSS) INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: Net (income) loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMITED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">FOREIGN CURRENCY TRANSLATION ADJUSTMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL COMPREHENSIVE (LOSS) INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: Comprehensive (loss) income attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES*</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">(LOSS) EARNINGS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueCapitalContributions" xlink:label="EUDA_StockIssuedDuringPeriodValueCapitalContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueCapitalContributions" xlink:to="EUDA_StockIssuedDuringPeriodValueCapitalContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodValueCapitalContributions_lbl" xml:lang="en-US">Capital contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesCapitalContributions" xlink:label="EUDA_StockIssuedDuringPeriodSharesCapitalContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodSharesCapitalContributions" xlink:to="EUDA_StockIssuedDuringPeriodSharesCapitalContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodSharesCapitalContributions_lbl" xml:lang="en-US">Capital contributions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:label="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:to="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_lbl" xml:lang="en-US">Forgiveness of debt by a related party</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:label="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:to="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament_lbl" xml:lang="en-US">Earnout shares payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_lbl" xml:lang="en-US">Issuance of ordinary shares upon the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:label="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:to="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_lbl" xml:lang="en-US">Issuance of ordinary shares upon the reverse recapitalization , shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNet_2_lbl" xml:lang="en-US">Investment income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_2_lbl" xml:lang="en-US">Gain on disposal of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutPayment" xlink:label="EUDA_EarnoutPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutPayment" xlink:to="EUDA_EarnoutPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EarnoutPayment_lbl" xml:lang="en-US">Earnout payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment loss on goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment loss on intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:label="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:to="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities_lbl" xml:lang="en-US">Change in fair value of prepaid forward purchase liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_lbl" xml:lang="en-US">Interest receivable from loan to third party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:to="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty_lbl" xml:lang="en-US">Accounts payables - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xml:lang="en-US">Loan to third party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Cash acquired through business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_lbl" xml:lang="en-US">Cash released upon disposal of a subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Capital contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalization" xlink:label="EUDA_ProceedsFromReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromReverseRecapitalization" xlink:to="EUDA_ProceedsFromReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProceedsFromReverseRecapitalization_lbl" xml:lang="en-US">Proceeds from the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_lbl" xml:lang="en-US">Payments of merger costs</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsFromOtherReceivableRelatedParties" xlink:label="EUDA_RepaymentsFromOtherReceivableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RepaymentsFromOtherReceivableRelatedParties" xlink:to="EUDA_RepaymentsFromOtherReceivableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RepaymentsFromOtherReceivableRelatedParties_lbl" xml:lang="en-US">Repayments from other receivable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term loans - bank and private lender</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayments to short-term loans - bank and private lender</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsToShorttermLoansThirdParties" xlink:label="EUDA_RepaymentsToShorttermLoansThirdParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RepaymentsToShorttermLoansThirdParties" xlink:to="EUDA_RepaymentsToShorttermLoansThirdParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_RepaymentsToShorttermLoansThirdParties_lbl" xml:lang="en-US">Repayments to short-term loans - third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings from other payables - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND RESTRICTED CASH, beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND RESTRICTED CASH, end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" xlink:label="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" xlink:to="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability_lbl" xml:lang="en-US">Initial recognition of operating right of use asset and lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" xlink:label="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" xlink:to="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary_lbl" xml:lang="en-US">Initial recognition of payables to former subsidiary upon disposal of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConversionOfDebtIntoPromissoryNote" xlink:label="EUDA_ConversionOfDebtIntoPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConversionOfDebtIntoPromissoryNote" xlink:to="EUDA_ConversionOfDebtIntoPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConversionOfDebtIntoPromissoryNote_lbl" xml:lang="en-US">Conversion of debt into a promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConversionOfDebtsIntoConvertibleNotes" xlink:label="EUDA_ConversionOfDebtsIntoConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConversionOfDebtsIntoConvertibleNotes" xlink:to="EUDA_ConversionOfDebtsIntoConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ConversionOfDebtsIntoConvertibleNotes_lbl" xml:lang="en-US">Conversion of debts into convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForgivenessOfDebtByRelatedParty" xlink:label="EUDA_ForgivenessOfDebtByRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForgivenessOfDebtByRelatedParty" xlink:to="EUDA_ForgivenessOfDebtByRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ForgivenessOfDebtByRelatedParty_lbl" xml:lang="en-US">Forgiveness of debt by a related party</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_lbl" xml:lang="en-US">Issuance of ordinary shares upon the Reverse Recapitalization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashCurrent_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Nature of business and organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of significant accounting policies</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="EUDA_DisclosureReverseRecapitalizationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureReverseRecapitalizationAbstract" xlink:to="EUDA_DisclosureReverseRecapitalizationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DisclosureReverseRecapitalizationAbstract_lbl" xml:lang="en-US">Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ReverseRecapitalizationTextBlock" xlink:label="EUDA_ReverseRecapitalizationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ReverseRecapitalizationTextBlock" xlink:to="EUDA_ReverseRecapitalizationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ReverseRecapitalizationTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureDispositionOfSubsidiaryAbstract" xlink:label="EUDA_DisclosureDispositionOfSubsidiaryAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureDispositionOfSubsidiaryAbstract" xlink:to="EUDA_DisclosureDispositionOfSubsidiaryAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DisclosureDispositionOfSubsidiaryAbstract_lbl" xml:lang="en-US">Disposition Of Subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DispositionOfSubsidiariesTextBlock" xlink:label="EUDA_DispositionOfSubsidiariesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DispositionOfSubsidiariesTextBlock" xlink:to="EUDA_DispositionOfSubsidiariesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DispositionOfSubsidiariesTextBlock_lbl" xml:lang="en-US">Disposition of Subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="us-gaap_CreditLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossAbstract" xlink:to="us-gaap_CreditLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossAbstract_lbl" xml:lang="en-US">Credit Loss [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock" xlink:label="us-gaap_FinancingReceivablesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesTextBlock" xlink:to="us-gaap_FinancingReceivablesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancingReceivablesTextBlock_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureForwardPurchaseAgreementsAbstract" xlink:label="EUDA_DisclosureForwardPurchaseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureForwardPurchaseAgreementsAbstract" xlink:to="EUDA_DisclosureForwardPurchaseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DisclosureForwardPurchaseAgreementsAbstract_lbl" xml:lang="en-US">Forward Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" xlink:label="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" xlink:to="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">Forward Purchase Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLoanToThirdPartyAbstract" xlink:label="EUDA_DisclosureLoanToThirdPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureLoanToThirdPartyAbstract" xlink:to="EUDA_DisclosureLoanToThirdPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DisclosureLoanToThirdPartyAbstract_lbl" xml:lang="en-US">Loan To Third Party</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanToThirdPartyTextBlock" xlink:label="EUDA_LoanToThirdPartyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanToThirdPartyTextBlock" xlink:to="EUDA_LoanToThirdPartyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_LoanToThirdPartyTextBlock_lbl" xml:lang="en-US">Loan to third party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">Credit facilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related party balances and transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Concentrations risks</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="EUDA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureLeasesAbstract" xlink:to="EUDA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation and transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NonControllingInterestPolicyTextBlock" xlink:label="EUDA_NonControllingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NonControllingInterestPolicyTextBlock" xlink:to="EUDA_NonControllingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NonControllingInterestPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:label="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:to="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment for long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WarrantsPolicyTextBlock" xlink:label="EUDA_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WarrantsPolicyTextBlock" xlink:to="EUDA_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" xlink:label="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" xlink:to="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Forward Purchase Receivables and Prepaid Forward Purchase Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DefinedContributionPlanPolicyTextBlock" xlink:label="EUDA_DefinedContributionPlanPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DefinedContributionPlanPolicyTextBlock" xlink:to="EUDA_DefinedContributionPlanPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US">Defined contribution plan</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GoodsAndServicesTaxesPolicyTextBlock" xlink:label="EUDA_GoodsAndServicesTaxesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GoodsAndServicesTaxesPolicyTextBlock" xlink:to="EUDA_GoodsAndServicesTaxesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_GoodsAndServicesTaxesPolicyTextBlock_lbl" xml:lang="en-US">Goods and services taxes (&#8220;GST&#8221;)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">(Loss) earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RelatedPartyPolicyTextBlock" xlink:label="EUDA_RelatedPartyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RelatedPartyPolicyTextBlock" xlink:to="EUDA_RelatedPartyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RelatedPartyPolicyTextBlock_lbl" xml:lang="en-US">Related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements not yet adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of consolidated financial statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:label="us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:to="us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_lbl" xml:lang="en-US">Schedule of foreign currency exchange rates</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyPlantAndEquipmentsTextBlock" xlink:label="EUDA_PropertyPlantAndEquipmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyPlantAndEquipmentsTextBlock" xlink:to="EUDA_PropertyPlantAndEquipmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PropertyPlantAndEquipmentsTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:label="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock" xlink:label="us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock" xlink:to="us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock_lbl" xml:lang="en-US">Schedule of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfCostOfRevenueTableTextBlock" xlink:label="EUDA_ScheduleOfCostOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfCostOfRevenueTableTextBlock" xlink:to="EUDA_ScheduleOfCostOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfCostOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of cost of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value hierarchy of financial liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of financial liability measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" xlink:to="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_lbl" xml:lang="en-US">Schedule of shares issued and outstanding reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" xlink:label="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" xlink:to="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization_lbl" xml:lang="en-US">Schedule of financial statements of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of movements of allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of other receivables allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Schedule of goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of short-term loans</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" xlink:label="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" xlink:to="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock_lbl" xml:lang="en-US">Schedule of related party balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related party transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" xlink:to="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_lbl" xml:lang="en-US">Schedule of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" xlink:label="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" xlink:to="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_lbl" xml:lang="en-US">Schedule of earnout shares for triggering event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfTaxesPayableTableTextBlock" xlink:label="EUDA_ScheduleOfTaxesPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfTaxesPayableTableTextBlock" xlink:to="EUDA_ScheduleOfTaxesPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfTaxesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" xlink:label="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" xlink:to="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of operating and finance lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining term and discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:label="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:to="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment reporting information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NameOfCompany" xlink:label="EUDA_NameOfCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NameOfCompany" xlink:to="EUDA_NameOfCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NameOfCompany_lbl" xml:lang="en-US">Name of company</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DateOfIncorporation" xlink:label="EUDA_DateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DateOfIncorporation" xlink:to="EUDA_DateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RegisteredCapital" xlink:label="EUDA_RegisteredCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RegisteredCapital" xlink:to="EUDA_RegisteredCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RegisteredCapital_lbl" xml:lang="en-US">Registered capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WorkingCapital" xlink:label="EUDA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WorkingCapital" xlink:to="EUDA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:to="us-gaap_ForeignCurrencyExchangeRateRemeasurement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateRemeasurement1_lbl" xml:lang="en-US">Period-end : US$1 exchange rate*</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Period-average : US$1 exchange rate*</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Electronic equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Leasehold equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Customer relationships</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Total cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net (loss)/income attributable to common shareholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">(Loss)/Earnings per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:label="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:to="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:to="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_2_lbl" xml:lang="en-US">Change in fair value of prepaid forward purchase liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:to="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Other receivables allowance for doubtful account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Other receivables allowance for doubtful account</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:label="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:to="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_lbl" xml:lang="en-US">Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiability" xlink:label="EUDA_PrepaidForwardPurchaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiability" xlink:to="EUDA_PrepaidForwardPurchaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidForwardPurchaseLiability_lbl" xml:lang="en-US">Purchase liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription_lbl" xml:lang="en-US">Employee plan description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Monthly salary</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TradeUnionFeePercentage" xlink:label="EUDA_TradeUnionFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TradeUnionFeePercentage" xlink:to="EUDA_TradeUnionFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_TradeUnionFeePercentage_lbl" xml:lang="en-US">Trade union fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Income tax likelihood description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureReverseRecapitalizationAbstract" xlink:to="EUDA_DisclosureReverseRecapitalizationAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_DisclosureReverseRecapitalizationAbstract_2_lbl" xml:lang="en-US">Schedule Of Shares Issued And Outstanding Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:label="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:to="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization_lbl" xml:lang="en-US">8i ordinary shares outstanding prior to Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedemptionOfOrdinaryShares" xlink:label="EUDA_RedemptionOfOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RedemptionOfOrdinaryShares" xlink:to="EUDA_RedemptionOfOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RedemptionOfOrdinaryShares_lbl" xml:lang="en-US">Less: redemption of 8i ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of 8i rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued to service providers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of EHL ordinary shares into 8i ordinary shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_2_lbl" xml:lang="en-US">Total shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureReverseRecapitalizationAbstract" xlink:to="EUDA_DisclosureReverseRecapitalizationAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="EUDA_DisclosureReverseRecapitalizationAbstract_3_lbl" xml:lang="en-US">Schedule Of Financial Statements Of Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInTrustAccount" xlink:label="EUDA_FundsHeldInTrustAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInTrustAccount" xlink:to="EUDA_FundsHeldInTrustAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FundsHeldInTrustAccount_lbl" xml:lang="en-US">Funds held in 8i&#8217;s trust account</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInOperatingCashAccount" xlink:label="EUDA_FundsHeldInOperatingCashAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInOperatingCashAccount" xlink:to="EUDA_FundsHeldInOperatingCashAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FundsHeldInOperatingCashAccount_lbl" xml:lang="en-US">Funds held in 8i&#8217;s operating cash account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Less: amount paid to redeem public shares of 8i&#8217;s ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Less: payments of transaction costs incurred by 8i</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:to="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_lbl" xml:lang="en-US">Less: payments of forward purchase agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Less: repayments of promissory note &#8211; related party of 8i</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalizations" xlink:label="EUDA_ProceedsFromReverseRecapitalizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromReverseRecapitalizations" xlink:to="EUDA_ProceedsFromReverseRecapitalizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ProceedsFromReverseRecapitalizations_lbl" xml:lang="en-US">Proceeds from the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" xlink:label="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" xlink:to="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_lbl" xml:lang="en-US">Less: unpaid deferred underwriting fee</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromUnpaidTransactionCostsIncurred" xlink:label="EUDA_ProceedsFromUnpaidTransactionCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidTransactionCostsIncurred" xlink:to="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_lbl" xml:lang="en-US">Less: unpaid transaction costs incurred by 8i</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xml:lang="en-US">Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoncashNetAssetsAssumedValue" xlink:label="EUDA_NoncashNetAssetsAssumedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoncashNetAssetsAssumedValue" xlink:to="EUDA_NoncashNetAssetsAssumedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_NoncashNetAssetsAssumedValue_lbl" xml:lang="en-US">Add: non-cash net assets assumed from 8i</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" xlink:label="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" xlink:to="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization_lbl" xml:lang="en-US">Net contributions from issuance of ordinary shares upon the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Ordinary shares, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Ordinary shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ExchangeRatioPerShare" xlink:label="EUDA_ExchangeRatioPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ExchangeRatioPerShare" xlink:to="EUDA_ExchangeRatioPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ExchangeRatioPerShare_lbl" xml:lang="en-US">Exchange ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Earnout shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of additional shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Public ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Redemption shares</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesNoParValue" xlink:label="EUDA_PrivateOrdinarySharesNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateOrdinarySharesNoParValue" xlink:to="EUDA_PrivateOrdinarySharesNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrivateOrdinarySharesNoParValue_lbl" xml:lang="en-US">Private ordinary shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesOutstanding" xlink:label="EUDA_PrivateOrdinarySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateOrdinarySharesOutstanding" xlink:to="EUDA_PrivateOrdinarySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrivateOrdinarySharesOutstanding_lbl" xml:lang="en-US">Private ordinary shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesNoParValue" xlink:label="EUDA_FounderSharesNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FounderSharesNoParValue" xlink:to="EUDA_FounderSharesNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FounderSharesNoParValue_lbl" xml:lang="en-US">Founder shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesOutstanding" xlink:label="EUDA_FounderSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FounderSharesOutstanding" xlink:to="EUDA_FounderSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FounderSharesOutstanding_lbl" xml:lang="en-US">Founder shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicRightsShares" xlink:label="EUDA_PublicRightsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PublicRightsShares" xlink:to="EUDA_PublicRightsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PublicRightsShares_lbl" xml:lang="en-US">Public rights shares</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateRightsShares" xlink:label="EUDA_PrivateRightsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateRightsShares" xlink:to="EUDA_PrivateRightsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrivateRightsShares_lbl" xml:lang="en-US">Private rights shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Converted shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of convertible promissory note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInTrustAccount" xlink:to="EUDA_FundsHeldInTrustAccount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_FundsHeldInTrustAccount_2_lbl" xml:lang="en-US">Funds held in trust account</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInOperatingCashAccount" xlink:to="EUDA_FundsHeldInOperatingCashAccount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_FundsHeldInOperatingCashAccount_2_lbl" xml:lang="en-US">Funds held in operating cash account</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_2_lbl" xml:lang="en-US">Amount paid to redeem public shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Redeem public shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:to="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_2_lbl" xml:lang="en-US">Payments of forward purchase agreements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of promissory note related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Ownership interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xml:lang="en-US">Consideration received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3_lbl" xml:lang="en-US">Gain loss on disposal of deficit interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Total accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_3_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:label="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:to="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_lbl" xml:lang="en-US">Exchange rate effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DivestmentReceivable" xlink:label="EUDA_DivestmentReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DivestmentReceivable" xlink:to="EUDA_DivestmentReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DivestmentReceivable_lbl" xml:lang="en-US">Receivable from divestment (1)</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EmployeeAdavance" xlink:label="EUDA_EmployeeAdavance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EmployeeAdavance" xlink:to="EUDA_EmployeeAdavance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EmployeeAdavance_lbl" xml:lang="en-US">Employee advance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="us-gaap_OtherReceivablesGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Total other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesNetNonCurrent" xlink:label="EUDA_OtherReceivablesNetNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivablesNetNonCurrent" xlink:to="EUDA_OtherReceivablesNetNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherReceivablesNetNonCurrent_lbl" xml:lang="en-US">Other receivables &#8211; non-current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Other receivables &#8211; current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_lbl" xml:lang="en-US">Write-off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Investment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:to="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl" xml:lang="en-US">Investment owned face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" xlink:label="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" xlink:to="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues_lbl" xml:lang="en-US">Additional amount</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InstallmentReceived" xlink:label="EUDA_InstallmentReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InstallmentReceived" xlink:to="EUDA_InstallmentReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_InstallmentReceived_lbl" xml:lang="en-US">Installment received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl" xml:lang="en-US">Remaining balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Debt intrument interest rate, description</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivableInstallmentAmount" xlink:label="EUDA_OtherReceivableInstallmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivableInstallmentAmount" xlink:to="EUDA_OtherReceivableInstallmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherReceivableInstallmentAmount_lbl" xml:lang="en-US">Other installment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedCustomerRelationshipsGross" xlink:label="us-gaap_FiniteLivedCustomerRelationshipsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedCustomerRelationshipsGross" xlink:to="us-gaap_FiniteLivedCustomerRelationshipsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedCustomerRelationshipsGross_lbl" xml:lang="en-US">Customer relationships</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3_lbl" xml:lang="en-US">Less: Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ExchangeRateEffect" xlink:label="EUDA_ExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ExchangeRateEffect" xlink:to="EUDA_ExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ExchangeRateEffect_lbl" xml:lang="en-US">Exchange rate effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_3_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xml:lang="en-US">Beneficially ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl" xml:lang="en-US">Forward contract, fair value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilities" xlink:to="EUDA_PrepaidForwardPurchaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_PrepaidForwardPurchaseLiabilities_2_lbl" xml:lang="en-US">Prepaid forward purchase liability</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:label="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:to="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability_lbl" xml:lang="en-US">Change of fair value of prepaid forward purchase liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Loan borrow up amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Loan interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanAccumulativelyDisbursed" xlink:label="EUDA_LoanAccumulativelyDisbursed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanAccumulativelyDisbursed" xlink:to="EUDA_LoanAccumulativelyDisbursed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_LoanAccumulativelyDisbursed_lbl" xml:lang="en-US">Loan accumulatively disbursed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="us-gaap_InterestIncomeRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeRelatedParty" xlink:to="us-gaap_InterestIncomeRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeRelatedParty_lbl" xml:lang="en-US">Interest income from loan to third party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLender" xlink:label="us-gaap_ShortTermDebtLender" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLender" xlink:to="us-gaap_ShortTermDebtLender_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLender_lbl" xml:lang="en-US">Bank/Private lender Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTerms" xlink:label="us-gaap_ShortTermDebtTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTerms" xlink:to="us-gaap_ShortTermDebtTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTerms_lbl" xml:lang="en-US">Maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermDebtInterestRate" xlink:label="EUDA_ShortTermDebtInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShortTermDebtInterestRate" xlink:to="EUDA_ShortTermDebtInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ShortTermDebtInterestRate_lbl" xml:lang="en-US">Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateral" xlink:label="us-gaap_DebtInstrumentCollateral" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateral" xlink:to="us-gaap_DebtInstrumentCollateral_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCollateral_lbl" xml:lang="en-US">Collateral/Guarantee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_lbl" xml:lang="en-US">Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Short term loans - third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible promissory note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses (i)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interests (ii)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties" xlink:label="us-gaap_DueFromOtherRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedParties" xlink:to="us-gaap_DueFromOtherRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedParties_lbl" xml:lang="en-US">Other receivables - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Account payable, related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other payables &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US">Revenue from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PurchaseFromRelatedParties" xlink:label="EUDA_PurchaseFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PurchaseFromRelatedParties" xlink:to="EUDA_PurchaseFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PurchaseFromRelatedParties_lbl" xml:lang="en-US">Purchase from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rental Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Total shares issued upon the Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Ordinary Shares Issuable, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingGranted" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingGranted" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingGranted_lbl" xml:lang="en-US">Warrants Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Ordinary Shares Issuable, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:label="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:to="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_lbl" xml:lang="en-US">Average Remaining Contractual Life,Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingForfeited" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingForfeited" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingForfeited_lbl" xml:lang="en-US">Warrants Outstanding, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Ordinary Shares Issuable, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingExercised" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingExercised" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingExercised_lbl" xml:lang="en-US">Warrants Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Ordinary Shares Issuable, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Ordinary Shares Issuable, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Average Remaining Contractual Life,</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SharePriceAsOfClosingDate" xlink:label="EUDA_SharePriceAsOfClosingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SharePriceAsOfClosingDate" xlink:to="EUDA_SharePriceAsOfClosingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_SharePriceAsOfClosingDate_lbl" xml:lang="en-US">Share price of the Company as of closing date</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AverageDailyReturnRate" xlink:label="EUDA_AverageDailyReturnRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AverageDailyReturnRate" xlink:to="EUDA_AverageDailyReturnRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AverageDailyReturnRate_lbl" xml:lang="en-US">Average daily return rate</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DailyVolatilityForTriggeringEvent1" xlink:label="EUDA_DailyVolatilityForTriggeringEvent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DailyVolatilityForTriggeringEvent1" xlink:to="EUDA_DailyVolatilityForTriggeringEvent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DailyVolatilityForTriggeringEvent1_lbl" xml:lang="en-US">Daily volatility for Triggering Event 1</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DailyVolatilityForTriggeringEvent2" xlink:label="EUDA_DailyVolatilityForTriggeringEvent2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DailyVolatilityForTriggeringEvent2" xlink:to="EUDA_DailyVolatilityForTriggeringEvent2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DailyVolatilityForTriggeringEvent2_lbl" xml:lang="en-US">Daily volatility for Triggering Event 2</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RiskFreeRateForTriggeringEventOne" xlink:label="EUDA_RiskFreeRateForTriggeringEventOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RiskFreeRateForTriggeringEventOne" xlink:to="EUDA_RiskFreeRateForTriggeringEventOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RiskFreeRateForTriggeringEventOne_lbl" xml:lang="en-US">Risk-free rate for Triggering Event 1</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RiskFreeRateForTriggeringEventTwo" xlink:label="EUDA_RiskFreeRateForTriggeringEventTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RiskFreeRateForTriggeringEventTwo" xlink:to="EUDA_RiskFreeRateForTriggeringEventTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RiskFreeRateForTriggeringEventTwo_lbl" xml:lang="en-US">Risk-free rate for Triggering Event 2</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GrantPriceForTriggingEventOne" xlink:label="EUDA_GrantPriceForTriggingEventOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GrantPriceForTriggingEventOne" xlink:to="EUDA_GrantPriceForTriggingEventOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_GrantPriceForTriggingEventOne_lbl" xml:lang="en-US">Grant Price for Trigging Event 1</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GrantPriceForTriggingEventTwo" xlink:label="EUDA_GrantPriceForTriggingEventTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GrantPriceForTriggingEventTwo" xlink:to="EUDA_GrantPriceForTriggingEventTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_GrantPriceForTriggingEventTwo_lbl" xml:lang="en-US">Grant Price for Trigging Event 2</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="us-gaap_Capital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Capital" xlink:to="us-gaap_Capital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Capital_lbl" xml:lang="en-US">Capital contributions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares authorized, unlimited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Forgiveness of debt by a related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockNoParValue_2_lbl" xml:lang="en-US">Ordinary shares, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinaryShareBeforeReverseRecapitalization" xlink:label="EUDA_OrdinaryShareBeforeReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinaryShareBeforeReverseRecapitalization" xlink:to="EUDA_OrdinaryShareBeforeReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinaryShareBeforeReverseRecapitalization_lbl" xml:lang="en-US">Ordinary share before reverse recapitalization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant to purchase ordinary share, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WarrantsRedemptionPrice" xlink:label="EUDA_WarrantsRedemptionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WarrantsRedemptionPrice" xlink:to="EUDA_WarrantsRedemptionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_WarrantsRedemptionPrice_lbl" xml:lang="en-US">Warrants redemption price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale price of the ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutShares" xlink:label="EUDA_EarnoutShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutShares" xlink:to="EUDA_EarnoutShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_EarnoutShares_lbl" xml:lang="en-US">Earnout shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Number of additional shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FairValueOfEarnoutShares" xlink:label="EUDA_FairValueOfEarnoutShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FairValueOfEarnoutShares" xlink:to="EUDA_FairValueOfEarnoutShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_FairValueOfEarnoutShares_lbl" xml:lang="en-US">Fair value of earnout shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Singapore</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Total loss (income) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Singapore statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Tax rate difference outside Singapore</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Taxable income below exemption threshold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful account</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DeferredTaxAssetsLeaseLiabilityNet" xlink:label="EUDA_DeferredTaxAssetsLeaseLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DeferredTaxAssetsLeaseLiabilityNet" xlink:to="EUDA_DeferredTaxAssetsLeaseLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_DeferredTaxAssetsLeaseLiabilityNet_lbl" xml:lang="en-US">Net lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Customer relationships</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liabilities, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance on all deferred tax assets increased</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccruedGSTTaxesPayableCurrent" xlink:label="EUDA_AccruedGSTTaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AccruedGSTTaxesPayableCurrent" xlink:to="EUDA_AccruedGSTTaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AccruedGSTTaxesPayableCurrent_lbl" xml:lang="en-US">GST taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TaxesPayableCurrent_2_lbl" xml:lang="en-US">Totals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xml:lang="en-US">Foreign income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating losses carry forward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Deferred tax assets, operating losses carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating losses carry forward description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts" xlink:label="us-gaap_BankOverdrafts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankOverdrafts" xlink:to="us-gaap_BankOverdrafts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankOverdrafts_lbl" xml:lang="en-US">Bank balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OperatingLeaseExpenseShortTerm" xlink:label="EUDA_OperatingLeaseExpenseShortTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OperatingLeaseExpenseShortTerm" xlink:to="EUDA_OperatingLeaseExpenseShortTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OperatingLeaseExpenseShortTerm_lbl" xml:lang="en-US">Lease expenses - short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_2_lbl" xml:lang="en-US">Amortization of leased asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureLeasesAbstract" xlink:to="EUDA_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Term And Discount Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease, weighted-average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance leases, weighted-average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance leases, weighted-average discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DisclosureLeasesAbstract" xlink:to="EUDA_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="EUDA_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating lease payments, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance lease payments, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Total 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating lease payments, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance lease payments, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">Total 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total Operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total Finance lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Total Operating lease payments, discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Total Finance lease payments, discount</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ContractualObligationDiscount" xlink:label="EUDA_ContractualObligationDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationDiscount" xlink:to="EUDA_ContractualObligationDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_ContractualObligationDiscount_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities, operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities, finance lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ContractualObligationLeaseLiability" xlink:label="EUDA_ContractualObligationLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationLeaseLiability" xlink:to="EUDA_ContractualObligationLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="EUDA_ContractualObligationLeaseLiability_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" xlink:label="us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" xlink:to="us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate_lbl" xml:lang="en-US">Effective interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Finance lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US">Short term lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Compensate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Legal payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Contingent liability balance outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xml:lang="en-US">Income (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Segment loss before income tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutSharePayment" xlink:to="EUDA_EarnoutSharePayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_EarnoutSharePayment_2_lbl" xml:lang="en-US">Earnout share payment</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherCorporateExpenses" xlink:label="EUDA_OtherCorporateExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherCorporateExpenses" xlink:to="EUDA_OtherCorporateExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="EUDA_OtherCorporateExpenses_lbl" xml:lang="en-US">Other corporate expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of unpaid principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_3_lbl" xml:lang="en-US">Ordinary shares per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesAvailableForResale" xlink:label="EUDA_OrdinarySharesAvailableForResale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesAvailableForResale" xlink:to="EUDA_OrdinarySharesAvailableForResale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinarySharesAvailableForResale_lbl" xml:lang="en-US">Ordinary shares available for resale</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_3_lbl" xml:lang="en-US">Restricted ordinary shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockTypeOfStockConverted" xlink:to="us-gaap_ConversionOfStockTypeOfStockConverted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted_lbl" xml:lang="en-US">Conversion of ordinary shares, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Ordinary shares aggregate amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesForfeited" xlink:label="EUDA_OrdinarySharesForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesForfeited" xlink:to="EUDA_OrdinarySharesForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinarySharesForfeited_lbl" xml:lang="en-US">Ordinary shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Investors sale of stock and issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Investors sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Investors sale of stock aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesToBeIssued" xlink:label="EUDA_OrdinarySharesToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesToBeIssued" xlink:to="EUDA_OrdinarySharesToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OrdinarySharesToBeIssued_lbl" xml:lang="en-US">Ordinary shares to be issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_3_lbl" xml:lang="en-US">Ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument trading percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RedeemableWarrantsMember" xlink:to="EUDA_RedeemableWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RedeemableWarrantsMember_doc" xml:lang="en-US">Redeemable Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesMember" xlink:to="EUDA_OrdinarySharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinarySharesMember_doc" xml:lang="en-US">Ordinary Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseReceivables" xlink:to="EUDA_ForwardPurchaseReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ForwardPurchaseReceivables_doc" xml:lang="en-US">Forward purchase receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SeventyFivePercentageMember" xlink:to="EUDA_SeventyFivePercentageMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SeventyFivePercentageMember_doc" xml:lang="en-US">75% [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FiftyPercentageMember" xlink:to="EUDA_FiftyPercentageMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FiftyPercentageMember_doc" xml:lang="en-US">50% [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesMember" xlink:to="EUDA_MedicalServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesMember_doc" xml:lang="en-US">Medical Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesMember" xlink:to="EUDA_PropertyManagementServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServicesMember_doc" xml:lang="en-US">Property Management Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDAPrivateLimitedMember" xlink:to="EUDA_EUDAPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EUDAPrivateLimitedMember_doc" xml:lang="en-US">EUDA Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivablesNonCurrent" xlink:to="EUDA_OtherReceivablesNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherReceivablesNonCurrent_doc" xml:lang="en-US">Other receivables non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SuperGatewayGroupLimitedMember" xlink:to="EUDA_SuperGatewayGroupLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SuperGatewayGroupLimitedMember_doc" xml:lang="en-US">Super Gateway Group Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:to="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember_doc" xml:lang="en-US">Singapore Emergency Medical Assistance Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDAHealthLimitedMember" xlink:to="EUDA_EUDAHealthLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EUDAHealthLimitedMember_doc" xml:lang="en-US">EUDA Health Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" xlink:to="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember_doc" xml:lang="en-US">Kent Ridge Healthcare Singapore Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OperatingLeaseExpenseShortTerm" xlink:to="EUDA_OperatingLeaseExpenseShortTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OperatingLeaseExpenseShortTerm_doc" xml:lang="en-US">Operating lease expense short term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ReverseRecapitalizationTextBlock" xlink:to="EUDA_ReverseRecapitalizationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ReverseRecapitalizationTextBlock_doc" xml:lang="en-US">Reverse Recapitalization [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NonControllingInterestPolicyTextBlock" xlink:to="EUDA_NonControllingInterestPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NonControllingInterestPolicyTextBlock_doc" xml:lang="en-US">Non Controlling Interest [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShortTermLoansThirdParties" xlink:to="EUDA_ShortTermLoansThirdParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ShortTermLoansThirdParties_doc" xml:lang="en-US">Short term loans third parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanToThirdParty" xlink:to="EUDA_LoanToThirdParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_LoanToThirdParty_doc" xml:lang="en-US">Loan to third party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PromissoryNote" xlink:to="EUDA_PromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PromissoryNote_doc" xml:lang="en-US">Promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesRelatedParties" xlink:to="EUDA_ConvertibleNotesRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConvertibleNotesRelatedParties_doc" xml:lang="en-US">Convertible notes related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ExchangeRateEffect" xlink:to="EUDA_ExchangeRateEffect_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ExchangeRateEffect_doc" xml:lang="en-US">The amount of exchange rate effect.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DeferredTaxAssetsLeaseLiabilityNet" xlink:to="EUDA_DeferredTaxAssetsLeaseLiabilityNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DeferredTaxAssetsLeaseLiabilityNet_doc" xml:lang="en-US">Deferred tax assets lease liability net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NameOfCompany" xlink:to="EUDA_NameOfCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NameOfCompany_doc" xml:lang="en-US">Name of Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilities" xlink:to="EUDA_PrepaidForwardPurchaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidForwardPurchaseLiabilities_doc" xml:lang="en-US">Prepaid forward purchase liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AccountsPayableRelatedParty" xlink:to="EUDA_AccountsPayableRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AccountsPayableRelatedParty_doc" xml:lang="en-US">Accounts payable related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ExchangeRatioPerShare" xlink:to="EUDA_ExchangeRatioPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ExchangeRatioPerShare_doc" xml:lang="en-US">Exchange ratio per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherPayablesAndAccruedLiabilities" xlink:to="EUDA_OtherPayablesAndAccruedLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherPayablesAndAccruedLiabilities_doc" xml:lang="en-US">Other payables and accrued liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherPayablesRelatedParties" xlink:to="EUDA_OtherPayablesRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherPayablesRelatedParties_doc" xml:lang="en-US">Other payables related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FirstAnniversaryMember" xlink:to="EUDA_FirstAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FirstAnniversaryMember_doc" xml:lang="en-US">First Anniversary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SecondAnniversaryMember" xlink:to="EUDA_SecondAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SecondAnniversaryMember_doc" xml:lang="en-US">Second Anniversary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationDiscount" xlink:to="EUDA_ContractualObligationDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ContractualObligationDiscount_doc" xml:lang="en-US">Contractual obligation discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationLeaseLiability" xlink:to="EUDA_ContractualObligationLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ContractualObligationLeaseLiability_doc" xml:lang="en-US">Contractual obligation lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" xlink:to="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_doc" xml:lang="en-US">Entire disclosure of forward purchase agreements disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardAgreementOneMember" xlink:to="EUDA_PrepaidForwardAgreementOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidForwardAgreementOneMember_doc" xml:lang="en-US">Prepaid Forward Agreement 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardAgreementTwoMember" xlink:to="EUDA_PrepaidForwardAgreementTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidForwardAgreementTwoMember_doc" xml:lang="en-US">Prepaid Forward Agreement 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" xlink:to="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of Operating And Finance Lease Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:to="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_doc" xml:lang="en-US">Schedule Of Future Minimum Lease Payments [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PublicWarrantMember" xlink:to="EUDA_PublicWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PublicWarrantMember_doc" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KRDigitalPteLtdMember" xlink:to="EUDA_KRDigitalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KRDigitalPteLtdMember_doc" xml:lang="en-US">KR Digital Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukihealthSdnBhdMember" xlink:to="EUDA_ZukihealthSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ZukihealthSdnBhdMember_doc" xml:lang="en-US">Zukihealth Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" xlink:to="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Forward Purchase Receivables and Prepaid Forward Purchase Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesAvailableForResale" xlink:to="EUDA_OrdinarySharesAvailableForResale_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinarySharesAvailableForResale_doc" xml:lang="en-US">Ordinary shares available for resale.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JamesTanMember" xlink:to="EUDA_JamesTanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_JamesTanMember_doc" xml:lang="en-US">James Tan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WorkingCapital" xlink:to="EUDA_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SharePurchaseAgreementMember" xlink:to="EUDA_SharePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SharePurchaseAgreementMember_doc" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCareMember" xlink:to="EUDA_MedicalServicesSpecialtyCareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesSpecialtyCareMember_doc" xml:lang="en-US">Medical Services Specialty Care [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticeMember" xlink:to="EUDA_MedicalServicesGeneralPracticeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesGeneralPracticeMember_doc" xml:lang="en-US">Medical Services General Practice [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SettlementAgreementMember" xlink:to="EUDA_SettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SettlementAgreementMember_doc" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" xlink:to="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember_doc" xml:lang="en-US">Medical Services General Practice Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShineLinkMember" xlink:to="EUDA_ShineLinkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ShineLinkMember_doc" xml:lang="en-US">Shine Link [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MenoraMember" xlink:to="EUDA_MenoraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MenoraMember_doc" xml:lang="en-US">Menora [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:to="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability_doc" xml:lang="en-US">Change of fair value of prepaid forward purchase liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiability" xlink:to="EUDA_PrepaidForwardPurchaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidForwardPurchaseLiability_doc" xml:lang="en-US">The amount of prepaid forward purchase liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EightiHoldingMember" xlink:to="EUDA_EightiHoldingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EightiHoldingMember_doc" xml:lang="en-US">8i Holding [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PTTotalPrimaIndonesiaMember" xlink:to="EUDA_PTTotalPrimaIndonesiaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PTTotalPrimaIndonesiaMember_doc" xml:lang="en-US">PT Total Prima Indonesia [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KelvinChenMember" xlink:to="EUDA_KelvinChenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KelvinChenMember_doc" xml:lang="en-US">Kelvin Chen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChenSettlementAgreementMember" xlink:to="EUDA_ChenSettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ChenSettlementAgreementMember_doc" xml:lang="en-US">Chen Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanAccumulativelyDisbursed" xlink:to="EUDA_LoanAccumulativelyDisbursed_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_LoanAccumulativelyDisbursed_doc" xml:lang="en-US">Loan accumulatively disbursed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanToThirdPartyTextBlock" xlink:to="EUDA_LoanToThirdPartyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_LoanToThirdPartyTextBlock_doc" xml:lang="en-US">Loan to third party [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:to="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization_doc" xml:lang="en-US">Ordinary shares outstanding prior to reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RedemptionOfOrdinaryShares" xlink:to="EUDA_RedemptionOfOrdinaryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RedemptionOfOrdinaryShares_doc" xml:lang="en-US">Redemption of ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UnitedOverseasBankLimitedMember" xlink:to="EUDA_UnitedOverseasBankLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_UnitedOverseasBankLimitedMember_doc" xml:lang="en-US">United Overseas Bank Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_BankAndPrivateLenderMember" xlink:to="EUDA_BankAndPrivateLenderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_BankAndPrivateLenderMember_doc" xml:lang="en-US">Bank and Private Lender [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesForfeited" xlink:to="EUDA_OrdinarySharesForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinarySharesForfeited_doc" xml:lang="en-US">Ordinary shares forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceCommonAreaManagementMember" xlink:to="EUDA_PropertyManagementServiceCommonAreaManagementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServiceCommonAreaManagementMember_doc" xml:lang="en-US">Property Management Service Common Area Management [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceSecurityManagementMember" xlink:to="EUDA_PropertyManagementServiceSecurityManagementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServiceSecurityManagementMember_doc" xml:lang="en-US">Property Management Service Security Management [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServiceMember" xlink:to="EUDA_PropertyManagementServiceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServiceMember_doc" xml:lang="en-US">Property Management Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCaresMember" xlink:label="EUDA_MedicalServicesSpecialtyCaresMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCaresMember" xlink:to="EUDA_MedicalServicesSpecialtyCaresMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesSpecialtyCaresMember_doc" xml:lang="en-US">Medical Services Specialty Cares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember" xlink:label="EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember" xlink:to="EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesSpecialtyCaresRelatedPartyMember_doc" xml:lang="en-US">Medical Services Specialty Cares Related Party [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesGeneralPracticesMember" xlink:to="EUDA_MedicalServicesGeneralPracticesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesGeneralPracticesMember_doc" xml:lang="en-US">Medical Services General Practices [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SellerOneMember" xlink:to="EUDA_SellerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SellerOneMember_doc" xml:lang="en-US">Seller One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SellerTwoMember" xlink:to="EUDA_SellerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SellerTwoMember_doc" xml:lang="en-US">Seller Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesCommonAreaManagementMember" xlink:to="EUDA_PropertyManagementServicesCommonAreaManagementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServicesCommonAreaManagementMember_doc" xml:lang="en-US">Property Management Services Common Area Management [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyManagementServicesSecurityManagementMember" xlink:to="EUDA_PropertyManagementServicesSecurityManagementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyManagementServicesSecurityManagementMember_doc" xml:lang="en-US">Property Management Services Security Management [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProductMangementServicesMember" xlink:to="EUDA_ProductMangementServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProductMangementServicesMember_doc" xml:lang="en-US">Product Mangement Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfCostOfRevenueTableTextBlock" xlink:to="EUDA_ScheduleOfCostOfRevenueTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfCostOfRevenueTableTextBlock_doc" xml:lang="en-US">Schedule of cost of revenue [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" xlink:to="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization_doc" xml:lang="en-US">Schedule of financial statements of reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DefinedContributionPlanPolicyTextBlock" xlink:to="EUDA_DefinedContributionPlanPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DefinedContributionPlanPolicyTextBlock_doc" xml:lang="en-US">Defined contribution plan [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInTrustAccount" xlink:to="EUDA_FundsHeldInTrustAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FundsHeldInTrustAccount_doc" xml:lang="en-US">Funds held in trust account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundsHeldInOperatingCashAccount" xlink:to="EUDA_FundsHeldInOperatingCashAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FundsHeldInOperatingCashAccount_doc" xml:lang="en-US">Funds held in operating cash account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CentralProvidentFundMember" xlink:to="EUDA_CentralProvidentFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_CentralProvidentFundMember_doc" xml:lang="en-US">Central Provident Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SkillDevelopmentLevyMember" xlink:to="EUDA_SkillDevelopmentLevyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SkillDevelopmentLevyMember_doc" xml:lang="en-US">Skill Development Levy [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinarySharesToBeIssued" xlink:to="EUDA_OrdinarySharesToBeIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinarySharesToBeIssued_doc" xml:lang="en-US">Ordinary shares to be issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SocialInsuranceFundMember" xlink:to="EUDA_SocialInsuranceFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SocialInsuranceFundMember_doc" xml:lang="en-US">Social Insurance Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TradeUnionFeePercentage" xlink:to="EUDA_TradeUnionFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TradeUnionFeePercentage_doc" xml:lang="en-US">Trade union fee percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" xlink:to="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_doc" xml:lang="en-US">Proceeds from unpaid deferred underwriting fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GoodsAndServicesTaxesPolicyTextBlock" xlink:to="EUDA_GoodsAndServicesTaxesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_GoodsAndServicesTaxesPolicyTextBlock_doc" xml:lang="en-US">Good and services taxes [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoncashNetAssetsAssumedValue" xlink:to="EUDA_NoncashNetAssetsAssumedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NoncashNetAssetsAssumedValue_doc" xml:lang="en-US">Noncash net assets assumed value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" xlink:to="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization_doc" xml:lang="en-US">Issuance of ordinary shares upon the reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForgivenessOfDebtByRelatedParty" xlink:to="EUDA_ForgivenessOfDebtByRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ForgivenessOfDebtByRelatedParty_doc" xml:lang="en-US">Forgiveness of debt by related party.</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DeemedDividendOnWarrantReplacement" xlink:label="EUDA_DeemedDividendOnWarrantReplacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DeemedDividendOnWarrantReplacement" xlink:to="EUDA_DeemedDividendOnWarrantReplacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DeemedDividendOnWarrantReplacement_doc" xml:lang="en-US">Deemed dividend on warrant replacement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RelatedPartyPolicyTextBlock" xlink:to="EUDA_RelatedPartyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RelatedPartyPolicyTextBlock_doc" xml:lang="en-US">Related party [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_doc" xml:lang="en-US">New accounting pronouncements not yet adopted policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DispositionOfSubsidiariesTextBlock" xlink:to="EUDA_DispositionOfSubsidiariesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DispositionOfSubsidiariesTextBlock_doc" xml:lang="en-US">Disposition of subsidiaries [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:to="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament_doc" xml:lang="en-US">Stock issued during period value earnout shares payment.</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement" xlink:label="EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement" xlink:to="EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodValueDeemedDividendOnWarrantReplacement_doc" xml:lang="en-US">Stock issued during period value deemed dividend on warrant replacement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:to="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty_doc" xml:lang="en-US">Stock issued during period value forgiveness of debt by related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_doc" xml:lang="en-US">Stock issued during period value issuance of ordinary shares upon reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SEMAAgreementMember" xlink:to="EUDA_SEMAAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SEMAAgreementMember_doc" xml:lang="en-US">SEMA Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:to="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization_doc" xml:lang="en-US">Stock issued during period shares issuance of ordinary shares upon the Reverse Recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodValueCapitalContributions" xlink:to="EUDA_StockIssuedDuringPeriodValueCapitalContributions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodValueCapitalContributions_doc" xml:lang="en-US">Stock issued during period value capital contributions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_StockIssuedDuringPeriodSharesCapitalContributions" xlink:to="EUDA_StockIssuedDuringPeriodSharesCapitalContributions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_StockIssuedDuringPeriodSharesCapitalContributions_doc" xml:lang="en-US">Stock issued during period shares capital contributions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:to="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_doc" xml:lang="en-US">Allowance for doubtful accounts receivable exchange rate effect.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesThirdPartiesMember" xlink:to="EUDA_ConvertibleNotesThirdPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConvertibleNotesThirdPartiesMember_doc" xml:lang="en-US">Convertible Notes Third Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OrdinaryShareBeforeReverseRecapitalization" xlink:to="EUDA_OrdinaryShareBeforeReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OrdinaryShareBeforeReverseRecapitalization_doc" xml:lang="en-US">Ordinary shares before reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FSCapitalPtdLtdMember" xlink:to="EUDA_FSCapitalPtdLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FSCapitalPtdLtdMember_doc" xml:lang="en-US">FS Capital Ptd Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FundingSocietiesPteLtdMember" xlink:to="EUDA_FundingSocietiesPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FundingSocietiesPteLtdMember_doc" xml:lang="en-US">Funding Societies Pte. Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KohWeeSingMember" xlink:to="EUDA_KohWeeSingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KohWeeSingMember_doc" xml:lang="en-US">Koh Wee Sing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ThirdPartiesMember" xlink:to="EUDA_ThirdPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ThirdPartiesMember_doc" xml:lang="en-US">Third Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PromissoryNoteMember" xlink:to="EUDA_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KaufamanAndCanolesPcKcMember" xlink:to="EUDA_KaufamanAndCanolesPcKcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KaufamanAndCanolesPcKcMember_doc" xml:lang="en-US">Kaufaman &amp; Canoles, P.C. (KC) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MaximGroupLlcMember" xlink:to="EUDA_MaximGroupLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MaximGroupLlcMember_doc" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DivestmentReceivable" xlink:to="EUDA_DivestmentReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DivestmentReceivable_doc" xml:lang="en-US">Divestment receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EmployeeAdavance" xlink:to="EUDA_EmployeeAdavance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EmployeeAdavance_doc" xml:lang="en-US">Empolyee advance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivablesNetNonCurrent" xlink:to="EUDA_OtherReceivablesNetNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherReceivablesNetNonCurrent_doc" xml:lang="en-US">Other receivable net non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MenoraCapitalPteLtdMember" xlink:to="EUDA_MenoraCapitalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MenoraCapitalPteLtdMember_doc" xml:lang="en-US">Menora Capital Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateWarrantMember" xlink:to="EUDA_PrivateWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrivateWarrantMember_doc" xml:lang="en-US">Private Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_doc" xml:lang="en-US">Allowance for doubtful other receivable recoveries.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoebAndLoebLlpMember" xlink:to="EUDA_LoebAndLoebLlpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_LoebAndLoebLlpMember_doc" xml:lang="en-US">Loeb and Loeb LLP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_doc" xml:lang="en-US">Allowance for doubtful other receivable write offs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShineLinkLimitedMember" xlink:to="EUDA_ShineLinkLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ShineLinkLimitedMember_doc" xml:lang="en-US">Shine Link Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InstallmentReceived" xlink:to="EUDA_InstallmentReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_InstallmentReceived_doc" xml:lang="en-US">Installment received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WarrantsRedemptionPrice" xlink:to="EUDA_WarrantsRedemptionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WarrantsRedemptionPrice_doc" xml:lang="en-US">Warrant redemption price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EightIHoldingsTwoPtdLtdMember" xlink:to="EUDA_EightIHoldingsTwoPtdLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EightIHoldingsTwoPtdLtdMember_doc" xml:lang="en-US">8i Holdings Two Ptd Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivableInstallmentAmount" xlink:to="EUDA_OtherReceivableInstallmentAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherReceivableInstallmentAmount_doc" xml:lang="en-US">Other receivable installment amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MengDongJamesTanMember" xlink:to="EUDA_MengDongJamesTanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MengDongJamesTanMember_doc" xml:lang="en-US">Meng Dong James Tan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutPayment" xlink:to="EUDA_EarnoutPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EarnoutPayment_doc" xml:lang="en-US">Earnout payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:to="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities_doc" xml:lang="en-US">Change in fair value of prepaid forward purchase liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_BusinessCombinationMember" xlink:to="EUDA_BusinessCombinationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_BusinessCombinationMember_doc" xml:lang="en-US">Business Combination [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:to="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_doc" xml:lang="en-US">Share based compensation arrangement by share award equity instruments other than options outstanding weighted average remaining contractual terms granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingGranted" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingGranted_doc" xml:lang="en-US">Class of warrant outstanding granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingForfeited" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingForfeited_doc" xml:lang="en-US">Class of warrant outstanding forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ClassOfWarrantOrRightOutstandingExercised" xlink:to="EUDA_ClassOfWarrantOrRightOutstandingExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ClassOfWarrantOrRightOutstandingExercised_doc" xml:lang="en-US">Class of warrant outstanding exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromReverseRecapitalization" xlink:to="EUDA_ProceedsFromReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProceedsFromReverseRecapitalization_doc" xml:lang="en-US">Proceeds from reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RepaymentsToShorttermLoansThirdParties" xlink:to="EUDA_RepaymentsToShorttermLoansThirdParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RepaymentsToShorttermLoansThirdParties_doc" xml:lang="en-US">Repayments to short term loans third parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConversionOfDebtIntoPromissoryNote" xlink:to="EUDA_ConversionOfDebtIntoPromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConversionOfDebtIntoPromissoryNote_doc" xml:lang="en-US">Conversion of debt into promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConversionOfDebtsIntoConvertibleNotes" xlink:to="EUDA_ConversionOfDebtsIntoConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConversionOfDebtsIntoConvertibleNotes_doc" xml:lang="en-US">Conversion of debts into convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" xlink:to="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability_doc" xml:lang="en-US">Initial recognition of operating right of use asset and lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" xlink:to="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary_doc" xml:lang="en-US">Initial recognition of payables to former subsidiary upon disposal of subsidiary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_doc" xml:lang="en-US">Issuance of ordinary shares upon reverse recapitalization.</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AverageMonthlyNegativeReturnRate" xlink:label="EUDA_AverageMonthlyNegativeReturnRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AverageMonthlyNegativeReturnRate" xlink:to="EUDA_AverageMonthlyNegativeReturnRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AverageMonthlyNegativeReturnRate_doc" xml:lang="en-US">Average monthly negative return rate.</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MonthlyStandardDerivation" xlink:label="EUDA_MonthlyStandardDerivation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MonthlyStandardDerivation" xlink:to="EUDA_MonthlyStandardDerivation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MonthlyStandardDerivation_doc" xml:lang="en-US">Monthly standard derivation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:to="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_IncreaseDecreaseInAccountsPayableRelatedParty_doc" xml:lang="en-US">Accounts payables - related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RepaymentsFromOtherReceivableRelatedParties" xlink:to="EUDA_RepaymentsFromOtherReceivableRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RepaymentsFromOtherReceivableRelatedParties_doc" xml:lang="en-US">Repayments from other receivable related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KRHillCapitalPteLtdMember" xlink:to="EUDA_KRHillCapitalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KRHillCapitalPteLtdMember_doc" xml:lang="en-US">KR Hill Capital Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeMedicalPtdLtdMember" xlink:to="EUDA_KentRidgeMedicalPtdLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeMedicalPtdLtdMember_doc" xml:lang="en-US">Kent Ridge Medical Ptd Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JanicLimitedMember" xlink:to="EUDA_JanicLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_JanicLimitedMember_doc" xml:lang="en-US">Janic Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukihealthSDNMember" xlink:to="EUDA_ZukihealthSDNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ZukihealthSDNMember_doc" xml:lang="en-US">Zukihealth SDN [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FrescoInvestmentPteLtdMember" xlink:to="EUDA_FrescoInvestmentPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FrescoInvestmentPteLtdMember_doc" xml:lang="en-US">Fresco Investment Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CheeYinMehMember" xlink:to="EUDA_CheeYinMehMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_CheeYinMehMember_doc" xml:lang="en-US">Chee Yin Meh [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JamieFanWeiZhiMember" xlink:to="EUDA_JamieFanWeiZhiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_JamieFanWeiZhiMember_doc" xml:lang="en-US">Jamie Fan Wei Zhi [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthPteLtdMember" xlink:to="EUDA_KentRidgeHealthPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeHealthPteLtdMember_doc" xml:lang="en-US">Kent Ridge Health Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WatermarkDevelopmentsLtdMember" xlink:to="EUDA_WatermarkDevelopmentsLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WatermarkDevelopmentsLtdMember_doc" xml:lang="en-US">Watermark Developments Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesRelatedParties" xlink:label="EUDA_OtherReceivablesRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherReceivablesRelatedParties" xlink:to="EUDA_OtherReceivablesRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherReceivablesRelatedParties_doc" xml:lang="en-US">Other receivables related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InstitutionalInvestorsMember" xlink:to="EUDA_InstitutionalInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_InstitutionalInvestorsMember_doc" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MelanaInternationalPteLimitedMember" xlink:to="EUDA_MelanaInternationalPteLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MelanaInternationalPteLimitedMember_doc" xml:lang="en-US">Melana International Pte Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriGlobalSecurityPteLimitedMember" xlink:to="EUDA_TriGlobalSecurityPteLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TriGlobalSecurityPteLimitedMember_doc" xml:lang="en-US">TriGlobal Security Pte Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AlfredLimMember" xlink:to="EUDA_AlfredLimMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AlfredLimMember_doc" xml:lang="en-US">Alfred Lim [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfTaxesPayableTableTextBlock" xlink:to="EUDA_ScheduleOfTaxesPayableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfTaxesPayableTableTextBlock_doc" xml:lang="en-US">Schedule of taxes payable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanSecondLoanMember" xlink:to="EUDA_TanSecondLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TanSecondLoanMember_doc" xml:lang="en-US">Tan Second Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AccruedGSTTaxesPayableCurrent" xlink:to="EUDA_AccruedGSTTaxesPayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AccruedGSTTaxesPayableCurrent_doc" xml:lang="en-US">GST taxes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:to="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_doc" xml:lang="en-US">Prepaid expenses and other assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoCustomerMember" xlink:to="EUDA_NoCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NoCustomerMember_doc" xml:lang="en-US">No Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanFirstLoanMember" xlink:to="EUDA_TanFirstLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TanFirstLoanMember_doc" xml:lang="en-US">Tan First Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" xlink:to="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock_doc" xml:lang="en-US">Schedule of Related party balances [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NoVendorMember" xlink:to="EUDA_NoVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NoVendorMember_doc" xml:lang="en-US">No Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OneVendorMember" xlink:to="EUDA_OneVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OneVendorMember_doc" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanThirdLoanMember" xlink:to="EUDA_TanThirdLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TanThirdLoanMember_doc" xml:lang="en-US">Tan Third Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthcareSingaporePteLtdMember" xlink:to="EUDA_KentRidgeHealthcareSingaporePteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeHealthcareSingaporePteLtdMember_doc" xml:lang="en-US">Kent Ridge Healthcare SingaporePte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_VendorOneMember" xlink:to="EUDA_VendorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_VendorOneMember_doc" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_VendorTwoMember" xlink:to="EUDA_VendorTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_VendorTwoMember_doc" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TanTwoThousandTwentyThreeNoteMember" xlink:to="EUDA_TanTwoThousandTwentyThreeNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TanTwoThousandTwentyThreeNoteMember_doc" xml:lang="en-US">Tan 2023 Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:to="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_doc" xml:lang="en-US">Allowance for doubtful accounts prepaid and other current assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DateOfIncorporation" xlink:to="EUDA_DateOfIncorporation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DateOfIncorporation_doc" xml:lang="en-US">Date of incorporation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:to="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember_doc" xml:lang="en-US">Zukitek Vietnam Private Limited Liability Company [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TheGoodClinicPrivateLimitedMember" xlink:to="EUDA_TheGoodClinicPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TheGoodClinicPrivateLimitedMember_doc" xml:lang="en-US">The Good Clinic Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalEquipmentMember" xlink:to="EUDA_MedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalEquipmentMember_doc" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UGDigitalSdnBhdMember" xlink:to="EUDA_UGDigitalSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_UGDigitalSdnBhdMember_doc" xml:lang="en-US">UG Digital Sdn. Bhd. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_JenniferGohMember" xlink:to="EUDA_JenniferGohMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_JenniferGohMember_doc" xml:lang="en-US">Jennifer Goh [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_CadenceHealthPteLtdMember" xlink:to="EUDA_CadenceHealthPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_CadenceHealthPteLtdMember_doc" xml:lang="en-US">Cadence Health Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EUDADoctorPrivateLimitedMember" xlink:to="EUDA_EUDADoctorPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EUDADoctorPrivateLimitedMember_doc" xml:lang="en-US">EUDA Doctor Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateOrdinarySharesNoParValue" xlink:to="EUDA_PrivateOrdinarySharesNoParValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrivateOrdinarySharesNoParValue_doc" xml:lang="en-US">Private ordinary shares no par value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHillPrivateLimitedMember" xlink:to="EUDA_KentRidgeHillPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeHillPrivateLimitedMember_doc" xml:lang="en-US">Kent Ridge Hill Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesRelatedPartiesMember" xlink:to="EUDA_MedicalServicesRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesRelatedPartiesMember_doc" xml:lang="en-US">Medical Services Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateOrdinarySharesOutstanding" xlink:to="EUDA_PrivateOrdinarySharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrivateOrdinarySharesOutstanding_doc" xml:lang="en-US">Private ordinary shares outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProductSalesMember" xlink:to="EUDA_ProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProductSalesMember_doc" xml:lang="en-US">Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgeHealthLimitedMember" xlink:to="EUDA_KentRidgeHealthLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgeHealthLimitedMember_doc" xml:lang="en-US">Kent Ridge Health Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FounderSharesNoParValue" xlink:to="EUDA_FounderSharesNoParValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FounderSharesNoParValue_doc" xml:lang="en-US">Carrying amount of the par value of founder shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ZukitechPrivateLimitedMember" xlink:to="EUDA_ZukitechPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ZukitechPrivateLimitedMember_doc" xml:lang="en-US">Zukitech Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FounderSharesOutstanding" xlink:to="EUDA_FounderSharesOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FounderSharesOutstanding_doc" xml:lang="en-US">Founder shares outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PublicRightsShares" xlink:to="EUDA_PublicRightsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PublicRightsShares_doc" xml:lang="en-US">Public rights shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WatermarkCapitalPLMember" xlink:label="EUDA_WatermarkCapitalPLMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WatermarkCapitalPLMember" xlink:to="EUDA_WatermarkCapitalPLMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WatermarkCapitalPLMember_doc" xml:lang="en-US">Watermark Capital PL [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrivateRightsShares" xlink:to="EUDA_PrivateRightsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrivateRightsShares_doc" xml:lang="en-US">Private rights shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WilkeServicesLtdMember" xlink:to="EUDA_WilkeServicesLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WilkeServicesLtdMember_doc" xml:lang="en-US">Wilke Services Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MountLockeLimitedMember" xlink:to="EUDA_MountLockeLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MountLockeLimitedMember_doc" xml:lang="en-US">Mount Locke Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UniversalGatewayInternationalPteLtdMember" xlink:to="EUDA_UniversalGatewayInternationalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_UniversalGatewayInternationalPteLtdMember_doc" xml:lang="en-US">Universal Gateway International Pvt Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RegisteredCapital" xlink:to="EUDA_RegisteredCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RegisteredCapital_doc" xml:lang="en-US">Registeration capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PurchaseFromRelatedParties" xlink:to="EUDA_PurchaseFromRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PurchaseFromRelatedParties_doc" xml:lang="en-US">Proceeds from purchases of related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MelanaInternationalPteLtdMember" xlink:to="EUDA_MelanaInternationalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MelanaInternationalPteLtdMember_doc" xml:lang="en-US">Melana International Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriGlobalSecurityPteLtdMember" xlink:to="EUDA_TriGlobalSecurityPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TriGlobalSecurityPteLtdMember_doc" xml:lang="en-US">Tri Global Security Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_UGDigitechPrivateLimitedMember" xlink:to="EUDA_UGDigitechPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_UGDigitechPrivateLimitedMember_doc" xml:lang="en-US">UG Digitech Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_WarrantsPolicyTextBlock" xlink:to="EUDA_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_WarrantsPolicyTextBlock_doc" xml:lang="en-US">The accounting policy of warants text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_NosweatFitnessCompanyPrivateLimitedMember" xlink:to="EUDA_NosweatFitnessCompanyPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_NosweatFitnessCompanyPrivateLimitedMember_doc" xml:lang="en-US">Nosweat Fitness Company Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TrueCoverPrivateLimitedMember" xlink:to="EUDA_TrueCoverPrivateLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TrueCoverPrivateLimitedMember_doc" xml:lang="en-US">True Cover Private Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:to="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_doc" xml:lang="en-US">Increase decrease In fair value of prepaid forward purchase liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ShortTermDebtInterestRate" xlink:to="EUDA_ShortTermDebtInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ShortTermDebtInterestRate_doc" xml:lang="en-US">Short term debt interest rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" xlink:to="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_InvestmentOwnedAdditionalAmountAtMarketValues_doc" xml:lang="en-US">Investment owned additional amount at market values.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PropertyPlantAndEquipmentsTextBlock" xlink:to="EUDA_PropertyPlantAndEquipmentsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PropertyPlantAndEquipmentsTextBlock_doc" xml:lang="en-US">Property plant and equipments [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConsolidatedMember" xlink:to="EUDA_ConsolidatedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConsolidatedMember_doc" xml:lang="en-US">Consolidated [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:to="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_doc" xml:lang="en-US">Prepaid forward purchase liabilities balance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSubTotalMember" xlink:to="EUDA_MedicalServicesSubTotalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesSubTotalMember_doc" xml:lang="en-US">Medical Services Sub Total [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromReverseRecapitalizations" xlink:to="EUDA_ProceedsFromReverseRecapitalizations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProceedsFromReverseRecapitalizations_doc" xml:lang="en-US">Proceeds from reverse recapitalizations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of finite lived intangible assets useful lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ConvertibleNotesRelatedPartiesMember" xlink:to="EUDA_ConvertibleNotesRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ConvertibleNotesRelatedPartiesMember_doc" xml:lang="en-US">Convertible Notes Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_KentRidgePacificPteLtdMember" xlink:to="EUDA_KentRidgePacificPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_KentRidgePacificPteLtdMember_doc" xml:lang="en-US">Kent Ridge Pacific Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" xlink:to="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_doc" xml:lang="en-US">Schedule of Earnout Shares for triggering event [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" xlink:to="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_doc" xml:lang="en-US">Schedule of ordinary shares issued of reverse recapitalization [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutShares" xlink:to="EUDA_EarnoutShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EarnoutShares_doc" xml:lang="en-US">Earnout shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_FairValueOfEarnoutShares" xlink:to="EUDA_FairValueOfEarnoutShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_FairValueOfEarnoutShares_doc" xml:lang="en-US">Fair value of earnout shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriggeringEventOneMember" xlink:to="EUDA_TriggeringEventOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TriggeringEventOneMember_doc" xml:lang="en-US">Triggering Event One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_TriggeringEventTwoMember" xlink:to="EUDA_TriggeringEventTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_TriggeringEventTwoMember_doc" xml:lang="en-US">Triggering Event Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RiskFreeRateForTriggeringEventOne" xlink:to="EUDA_RiskFreeRateForTriggeringEventOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RiskFreeRateForTriggeringEventOne_doc" xml:lang="en-US">Risk free rate for triggering event one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RiskFreeRateForTriggeringEventTwo" xlink:to="EUDA_RiskFreeRateForTriggeringEventTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_RiskFreeRateForTriggeringEventTwo_doc" xml:lang="en-US">Risk free rate for triggering event two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GrantPriceForTriggingEventOne" xlink:to="EUDA_GrantPriceForTriggingEventOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_GrantPriceForTriggingEventOne_doc" xml:lang="en-US">Grant price for trigging event one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_GrantPriceForTriggingEventTwo" xlink:to="EUDA_GrantPriceForTriggingEventTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_GrantPriceForTriggingEventTwo_doc" xml:lang="en-US">Grant price for trigging event two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SharePriceAsOfClosingDate" xlink:to="EUDA_SharePriceAsOfClosingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SharePriceAsOfClosingDate_doc" xml:lang="en-US">Share price as of closing date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidTransactionCostsIncurred" xlink:to="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_doc" xml:lang="en-US">Proceeds from unpaid transaction costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" xlink:to="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_doc" xml:lang="en-US">Schedule of ordinary shares issued and outstanding of reverse recapitalization [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_SingaporeSubsidiariesMember" xlink:to="EUDA_SingaporeSubsidiariesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_SingaporeSubsidiariesMember_doc" xml:lang="en-US">Singapore Subsidiaries [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DailyVolatilityForTriggeringEvent1" xlink:to="EUDA_DailyVolatilityForTriggeringEvent1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DailyVolatilityForTriggeringEvent1_doc" xml:lang="en-US">Daily volatility for triggering event 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_DailyVolatilityForTriggeringEvent2" xlink:to="EUDA_DailyVolatilityForTriggeringEvent2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_DailyVolatilityForTriggeringEvent2_doc" xml:lang="en-US">Daily volatility for triggering event 2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AverageDailyReturnRate" xlink:to="EUDA_AverageDailyReturnRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_AverageDailyReturnRate_doc" xml:lang="en-US">Average daily return rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutSharePayment" xlink:to="EUDA_EarnoutSharePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_EarnoutSharePayment_doc" xml:lang="en-US">Earnout share payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" xlink:to="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_MedicalServicesSpecialtyCareRelatedPartyMember_doc" xml:lang="en-US">Medical Services Specialty Care Related Party [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherCorporateExpenses" xlink:to="EUDA_OtherCorporateExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="EUDA_OtherCorporateExpenses_doc" xml:lang="en-US">Other corporate expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_2_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_2_lbl" xml:lang="en-US">Interest Expense, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:to="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_4_lbl" xml:lang="en-US">IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivableCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Notes Receivable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_2_lbl" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_2_lbl" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_2_lbl" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2_lbl" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_RepaymentsToShorttermLoansThirdParties" xlink:to="EUDA_RepaymentsToShorttermLoansThirdParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_RepaymentsToShorttermLoansThirdParties_3_lbl" xml:lang="en-US">RepaymentsToShorttermLoansThirdParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForgivenessOfDebtByRelatedParty" xlink:to="EUDA_ForgivenessOfDebtByRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ForgivenessOfDebtByRelatedParty_3_lbl" xml:lang="en-US">ForgivenessOfDebtByRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:to="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization_3_lbl" xml:lang="en-US">IssuanceOfOrdinarySharesUponReverseRecapitalization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ReverseRecapitalizationTextBlock" xlink:to="EUDA_ReverseRecapitalizationTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ReverseRecapitalizationTextBlock_3_lbl" xml:lang="en-US">ReverseRecapitalizationTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:to="us-gaap_AccountsAndNontradeReceivableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndNontradeReceivableTextBlock_2_lbl" xml:lang="en-US">Accounts and Nontrade Receivable [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivablesTextBlock" xlink:to="us-gaap_FinancingReceivablesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivablesTextBlock_2_lbl" xml:lang="en-US">Financing Receivables [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillDisclosureTextBlock_2_lbl" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" xlink:to="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ForwardPurchaseAgreementsDisclosureTextBlock_3_lbl" xml:lang="en-US">ForwardPurchaseAgreementsDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_LoanToThirdPartyTextBlock" xlink:to="EUDA_LoanToThirdPartyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_LoanToThirdPartyTextBlock_3_lbl" xml:lang="en-US">LoanToThirdPartyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:to="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock_3_lbl" xml:lang="en-US">PrepaidExpensesAndOtherAssetsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:to="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_PrepaidForwardPurchaseLiabilitiesBalance_4_lbl" xml:lang="en-US">PrepaidForwardPurchaseLiabilitiesBalance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_4_lbl" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromReverseRecapitalizations" xlink:to="EUDA_ProceedsFromReverseRecapitalizations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProceedsFromReverseRecapitalizations_3_lbl" xml:lang="en-US">ProceedsFromReverseRecapitalizations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" xlink:to="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProceedsFromUnpaidDeferredUnderwritingFee_3_lbl" xml:lang="en-US">ProceedsFromUnpaidDeferredUnderwritingFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ProceedsFromUnpaidTransactionCostsIncurred" xlink:to="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ProceedsFromUnpaidTransactionCostsIncurred_3_lbl" xml:lang="en-US">ProceedsFromUnpaidTransactionCostsIncurred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_2_lbl" xml:lang="en-US">Payments for Merger Related Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableRecoveries_3_lbl" xml:lang="en-US">AllowanceForDoubtfulOtherReceivableRecoveries</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" xlink:to="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs_3_lbl" xml:lang="en-US">AllowanceForDoubtfulOtherReceivableWriteOffs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedCustomerRelationshipsGross" xlink:to="us-gaap_FiniteLivedCustomerRelationshipsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedCustomerRelationshipsGross_2_lbl" xml:lang="en-US">Finite-Lived Customer Relationships, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ExchangeRateEffect" xlink:to="EUDA_ExchangeRateEffect_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ExchangeRateEffect_3_lbl" xml:lang="en-US">ExchangeRateEffect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime_2_lbl" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, over Time</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Due to Related Parties, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Capital" xlink:to="us-gaap_Capital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Capital_2_lbl" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_2_lbl" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_EarnoutShares" xlink:to="EUDA_EarnoutShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_EarnoutShares_3_lbl" xml:lang="en-US">EarnoutShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationDiscount" xlink:to="EUDA_ContractualObligationDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ContractualObligationDiscount_3_lbl" xml:lang="en-US">Contractual obligation discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_ContractualObligationLeaseLiability" xlink:to="EUDA_ContractualObligationLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_ContractualObligationLeaseLiability_3_lbl" xml:lang="en-US">Contractual obligation lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EUDA_OtherCorporateExpenses" xlink:to="EUDA_OtherCorporateExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="EUDA_OtherCorporateExpenses_3_lbl" xml:lang="en-US">OtherCorporateExpenses</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>euda-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://euda.com/role/Cover" xlink:href="euda-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheets" xlink:href="euda-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/BalanceSheetsParenthetical" xlink:href="euda-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="euda-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:href="euda-20221231.xsd#StatementsOfChangeInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/StatementsOfCashFlows" xlink:href="euda-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcern" xlink:href="euda-20221231.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalization" xlink:href="euda-20221231.xsd#ReverseRecapitalization" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiary" xlink:href="euda-20221231.xsd#DispositionOfSubsidiary" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNet" xlink:href="euda-20221231.xsd#AccountsReceivableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivables" xlink:href="euda-20221231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNet" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNet" xlink:href="euda-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Goodwill" xlink:href="euda-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreements" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdParty" xlink:href="euda-20221231.xsd#LoanToThirdParty" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilities" xlink:href="euda-20221231.xsd#CreditFacilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquity" xlink:href="euda-20221231.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxes" xlink:href="euda-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisks" xlink:href="euda-20221231.xsd#ConcentrationsRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/Leases" xlink:href="euda-20221231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingencies" xlink:href="euda-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformation" xlink:href="euda-20221231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEvents" xlink:href="euda-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationTables" xlink:href="euda-20221231.xsd#ReverseRecapitalizationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/AccountsReceivableNetTables" xlink:href="euda-20221231.xsd#AccountsReceivableNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherReceivablesTables" xlink:href="euda-20221231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetTables" xlink:href="euda-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillTables" xlink:href="euda-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesTables" xlink:href="euda-20221231.xsd#CreditFacilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="euda-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="euda-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityTables" xlink:href="euda-20221231.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesTables" xlink:href="euda-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesTables" xlink:href="euda-20221231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationTables" xlink:href="euda-20221231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedFinancialStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:href="euda-20221231.xsd#NatureOfBusinessAndOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoingConcernDetailsNarrative" xlink:href="euda-20221231.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:href="euda-20221231.xsd#ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:href="euda-20221231.xsd#ScheduleOfCostOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="euda-20221231.xsd#ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:href="euda-20221231.xsd#ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="euda-20221231.xsd#ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="euda-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:href="euda-20221231.xsd#ReverseRecapitalizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:href="euda-20221231.xsd#DispositionOfSubsidiaryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:href="euda-20221231.xsd#ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfOtherReceivablesDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="euda-20221231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="euda-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="euda-20221231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:href="euda-20221231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="euda-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/GoodwillDetailsNarrative" xlink:href="euda-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:href="euda-20221231.xsd#ForwardPurchaseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:href="euda-20221231.xsd#LoanToThirdPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:href="euda-20221231.xsd#ScheduleOfShort-termLoansDetailsParanthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:href="euda-20221231.xsd#CreditFacilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="euda-20221231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:href="euda-20221231.xsd#ScheduleOfReverseRecapitalizationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfWarrantActivitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:href="euda-20221231.xsd#ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:href="euda-20221231.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:href="euda-20221231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:href="euda-20221231.xsd#ScheduleOfTaxesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:href="euda-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:href="euda-20221231.xsd#ConcentrationsRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:href="euda-20221231.xsd#ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:href="euda-20221231.xsd#ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="euda-20221231.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/LeasesDetailsNarrative" xlink:href="euda-20221231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="euda-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:href="euda-20221231.xsd#ScheduleOfSegmentReportingInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:href="euda-20221231.xsd#ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:href="euda-20221231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:href="euda-20221231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesMember" xlink:label="loc_EUDAOrdinarySharesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_EUDAOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedeemableWarrantsMember" xlink:label="loc_EUDARedeemableWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_EUDARedeemableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivables" xlink:label="loc_EUDAForwardPurchaseReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_EUDAForwardPurchaseReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesNonCurrent" xlink:label="loc_EUDAOtherReceivablesNonCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_EUDAOtherReceivablesNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanToThirdParty" xlink:label="loc_EUDALoanToThirdParty" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_EUDALoanToThirdParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermLoansThirdParties" xlink:label="loc_EUDAShortTermLoansThirdParties" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAShortTermLoansThirdParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNote" xlink:label="loc_EUDAPromissoryNote" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedParties" xlink:label="loc_EUDAConvertibleNotesRelatedParties" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAConvertibleNotesRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccountsPayableRelatedParty" xlink:label="loc_EUDAAccountsPayableRelatedParty" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAAccountsPayableRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesAndAccruedLiabilities" xlink:label="loc_EUDAOtherPayablesAndAccruedLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAOtherPayablesAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherPayablesRelatedParties" xlink:label="loc_EUDAOtherPayablesRelatedParties" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_EUDAOtherPayablesRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaapCommonStockSharesAuthorizedUnlimited" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorizedUnlimited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesRelatedPartiesMember" xlink:label="loc_EUDAMedicalServicesRelatedPartiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="loc_us-gaapCostOfRevenueAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutSharePayment" xlink:label="loc_EUDAEarnoutSharePayment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_EUDAEarnoutSharePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Change in Shareholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueCapitalContributions" xlink:label="loc_EUDAStockIssuedDuringPeriodValueCapitalContributions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueCapitalContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesCapitalContributions" xlink:label="loc_EUDAStockIssuedDuringPeriodSharesCapitalContributions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodSharesCapitalContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:label="loc_EUDAStockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:label="loc_EUDAStockIssuedDuringPeriodValueEarnoutSharesPayament" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueEarnoutSharesPayament" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:label="loc_EUDAStockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAStockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutPayment" xlink:label="loc_EUDAEarnoutPayment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_EUDAEarnoutPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:label="loc_EUDAChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_EUDAChangeInFairValueOfPrepaidForwardPurhcaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInNotesReceivableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInNotesReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInAccountsPayableRelatedParty" xlink:label="loc_EUDAIncreaseDecreaseInAccountsPayableRelatedParty" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_EUDAIncreaseDecreaseInAccountsPayableRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaapPaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalization" xlink:label="loc_EUDAProceedsFromReverseRecapitalization" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_EUDAProceedsFromReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:label="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsFromOtherReceivableRelatedParties" xlink:label="loc_EUDARepaymentsFromOtherReceivableRelatedParties" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_EUDARepaymentsFromOtherReceivableRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RepaymentsToShorttermLoansThirdParties" xlink:label="loc_EUDARepaymentsToShorttermLoansThirdParties" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_EUDARepaymentsToShorttermLoansThirdParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" xlink:label="loc_EUDAInitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAInitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" xlink:label="loc_EUDAInitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAInitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConversionOfDebtIntoPromissoryNote" xlink:label="loc_EUDAConversionOfDebtIntoPromissoryNote" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAConversionOfDebtIntoPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConversionOfDebtsIntoConvertibleNotes" xlink:label="loc_EUDAConversionOfDebtsIntoConvertibleNotes" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAConversionOfDebtsIntoConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForgivenessOfDebtByRelatedParty" xlink:label="loc_EUDAForgivenessOfDebtByRelatedParty" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAForgivenessOfDebtByRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="loc_EUDAIssuanceOfOrdinarySharesUponReverseRecapitalization" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_EUDAIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganization" xlink:title="00000007 - Disclosure - Nature of business and organization">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcern" xlink:title="00000008 - Disclosure - Going concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of significant accounting policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalization" xlink:title="00000010 - Disclosure - Reverse Recapitalization">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="loc_EUDADisclosureReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ReverseRecapitalizationTextBlock" xlink:label="loc_EUDAReverseRecapitalizationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAReverseRecapitalizationTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiary" xlink:title="00000011 - Disclosure - Disposition of Subsidiary">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureDispositionOfSubsidiaryAbstract" xlink:label="loc_EUDADisclosureDispositionOfSubsidiaryAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DispositionOfSubsidiariesTextBlock" xlink:label="loc_EUDADispositionOfSubsidiariesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureDispositionOfSubsidiaryAbstract" xlink:to="loc_EUDADispositionOfSubsidiariesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNet" xlink:title="00000012 - Disclosure - Accounts receivable, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndNontradeReceivableTextBlock" xlink:label="loc_us-gaapAccountsAndNontradeReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAccountsAndNontradeReceivableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivables" xlink:title="00000013 - Disclosure - Other receivables">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesTextBlock" xlink:label="loc_us-gaapFinancingReceivablesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapFinancingReceivablesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - Property and equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - Intangible assets, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/Goodwill" xlink:title="00000016 - Disclosure - Goodwill">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreements" xlink:title="00000017 - Disclosure - Forward Purchase Agreements">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureForwardPurchaseAgreementsAbstract" xlink:label="loc_EUDADisclosureForwardPurchaseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseAgreementsDisclosureTextBlock" xlink:label="loc_EUDAForwardPurchaseAgreementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureForwardPurchaseAgreementsAbstract" xlink:to="loc_EUDAForwardPurchaseAgreementsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdParty" xlink:title="00000018 - Disclosure - Loan to third party">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLoanToThirdPartyAbstract" xlink:label="loc_EUDADisclosureLoanToThirdPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanToThirdPartyTextBlock" xlink:label="loc_EUDALoanToThirdPartyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLoanToThirdPartyAbstract" xlink:to="loc_EUDALoanToThirdPartyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilities" xlink:title="00000019 - Disclosure - Credit facilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000020 - Disclosure - Other payables and accrued liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related party balances and transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquity" xlink:title="00000022 - Disclosure - Shareholders&#8217; equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisks" xlink:title="00000024 - Disclosure - Concentrations risks">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/Leases" xlink:title="00000025 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingencies" xlink:title="00000026 - Disclosure - Commitments and contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformation" xlink:title="00000027 - Disclosure - Segment information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEvents" xlink:title="00000028 - Disclosure - Subsequent events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - Summary of significant accounting policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NonControllingInterestPolicyTextBlock" xlink:label="loc_EUDANonControllingInterestPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDANonControllingInterestPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:label="loc_EUDAPrepaidExpensesAndOtherAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAPrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WarrantsPolicyTextBlock" xlink:label="loc_EUDAWarrantsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" xlink:label="loc_EUDAForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DefinedContributionPlanPolicyTextBlock" xlink:label="loc_EUDADefinedContributionPlanPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDADefinedContributionPlanPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GoodsAndServicesTaxesPolicyTextBlock" xlink:label="loc_EUDAGoodsAndServicesTaxesPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAGoodsAndServicesTaxesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RelatedPartyPolicyTextBlock" xlink:label="loc_EUDARelatedPartyPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDARelatedPartyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="loc_EUDANewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDANewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationTables" xlink:title="00000030 - Disclosure - Nature of business and organization (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000031 - Disclosure - Summary of significant accounting policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:label="loc_us-gaapScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyPlantAndEquipmentsTextBlock" xlink:label="loc_EUDAPropertyPlantAndEquipmentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAPropertyPlantAndEquipmentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:label="loc_EUDAScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock" xlink:label="loc_us-gaapScheduleOfPrincipalTransactionsRevenueTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPrincipalTransactionsRevenueTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfCostOfRevenueTableTextBlock" xlink:label="loc_EUDAScheduleOfCostOfRevenueTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAScheduleOfCostOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationTables" xlink:title="00000032 - Disclosure - Reverse Recapitalization (Tables)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="loc_EUDADisclosureReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" xlink:label="loc_EUDAScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization" xlink:label="loc_EUDAScheduleOfFinancialStatementsOfReverseRecapitalization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAScheduleOfFinancialStatementsOfReverseRecapitalization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/AccountsReceivableNetTables" xlink:title="00000033 - Disclosure - Accounts receivable, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherReceivablesTables" xlink:title="00000034 - Disclosure - Other receivables (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:label="loc_us-gaapAllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetTables" xlink:title="00000035 - Disclosure - Property and equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetTables" xlink:title="00000036 - Disclosure - Intangible assets, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillTables" xlink:title="00000037 - Disclosure - Goodwill (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesTables" xlink:title="00000038 - Disclosure - Credit facilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesThirdPartiesMember" xlink:label="loc_EUDAConvertibleNotesThirdPartiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaapScheduleOfShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - Other payables and accrued liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - Related party balances and transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock" xlink:label="loc_EUDAScheduleOfRelatedPartyBalancesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_EUDAScheduleOfRelatedPartyBalancesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityTables" xlink:title="00000041 - Disclosure - Shareholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" xlink:label="loc_EUDAScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" xlink:label="loc_EUDAScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAScheduleOfEarnoutSharesForTriggeringEventTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - Income taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfTaxesPayableTableTextBlock" xlink:label="loc_EUDAScheduleOfTaxesPayableTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_EUDAScheduleOfTaxesPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesTables" xlink:title="00000043 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" xlink:label="loc_EUDAScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_EUDAScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:label="loc_EUDAScheduleOfFutureMinimumLeasePaymentsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_EUDAScheduleOfFutureMinimumLeasePaymentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationTables" xlink:title="00000044 - Disclosure - Segment information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails" xlink:title="00000045 - Disclosure - Schedule of consolidated financial statement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAHealthLimitedMember" xlink:label="loc_EUDAEUDAHealthLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAHealthLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePteLtdMember" xlink:label="loc_EUDAKentRidgeHealthcareSingaporePteLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthcareSingaporePteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAPrivateLimitedMember" xlink:label="loc_EUDAEUDAPrivateLimitedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:label="loc_EUDAZukitekVietnamPrivateLimitedLiabilityCompanyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukitekVietnamPrivateLimitedLiabilityCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:label="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TheGoodClinicPrivateLimitedMember" xlink:label="loc_EUDATheGoodClinicPrivateLimitedMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATheGoodClinicPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDADoctorPrivateLimitedMember" xlink:label="loc_EUDAEUDADoctorPrivateLimitedMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDADoctorPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHillPrivateLimitedMember" xlink:label="loc_EUDAKentRidgeHillPrivateLimitedMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHillPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthLimitedMember" xlink:label="loc_EUDAKentRidgeHealthLimitedMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukitechPrivateLimitedMember" xlink:label="loc_EUDAZukitechPrivateLimitedMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukitechPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SuperGatewayGroupLimitedMember" xlink:label="loc_EUDASuperGatewayGroupLimitedMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASuperGatewayGroupLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UniversalGatewayInternationalPteLtdMember" xlink:label="loc_EUDAUniversalGatewayInternationalPteLtdMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAUniversalGatewayInternationalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLtdMember" xlink:label="loc_EUDAMelanaInternationalPteLtdMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAMelanaInternationalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLtdMember" xlink:label="loc_EUDATriGlobalSecurityPteLtdMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATriGlobalSecurityPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitechPrivateLimitedMember" xlink:label="loc_EUDAUGDigitechPrivateLimitedMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAUGDigitechPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NosweatFitnessCompanyPrivateLimitedMember" xlink:label="loc_EUDANosweatFitnessCompanyPrivateLimitedMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDANosweatFitnessCompanyPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TrueCoverPrivateLimitedMember" xlink:label="loc_EUDATrueCoverPrivateLimitedMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATrueCoverPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRDigitalPteLtdMember" xlink:label="loc_EUDAKRDigitalPteLtdMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKRDigitalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSdnBhdMember" xlink:label="loc_EUDAZukihealthSdnBhdMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAZukihealthSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NameOfCompany" xlink:label="loc_EUDANameOfCompany" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDANameOfCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DateOfIncorporation" xlink:label="loc_EUDADateOfIncorporation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDADateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RegisteredCapital" xlink:label="loc_EUDARegisteredCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDARegisteredCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative" xlink:title="00000046 - Disclosure - Nature of business and organization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember" xlink:label="loc_EUDAKentRidgeHealthcareSingaporePrivateLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAKentRidgeHealthcareSingaporePrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EUDAPrivateLimitedMember" xlink:label="loc_EUDAEUDAPrivateLimitedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEUDAPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SuperGatewayGroupLimitedMember" xlink:label="loc_EUDASuperGatewayGroupLimitedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASuperGatewayGroupLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:label="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDASingaporeEmergencyMedicalAssistancePrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/GoingConcernDetailsNarrative" xlink:title="00000047 - Disclosure - Going concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WorkingCapital" xlink:label="loc_EUDAWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_EUDAWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails" xlink:title="00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_SGD" xlink:label="loc_currencySGD" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencySGD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_VND" xlink:label="loc_currencyVND" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyVND" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_MYR" xlink:label="loc_currencyMYR" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyMYR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateRemeasurement1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateRemeasurement1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateRemeasurement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails" xlink:title="00000049 - Disclosure - Schedule of property and equipment useful lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalEquipmentMember" xlink:label="loc_EUDAMedicalEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_EUDAMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000050 - Disclosure - Schedule of intangible assets net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRevenueDetails" xlink:title="00000051 - Disclosure - Schedule of revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticeRelatedPartiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticeRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSubTotalMember" xlink:label="loc_EUDAMedicalServicesSubTotalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSubTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceCommonAreaManagementMember" xlink:label="loc_EUDAPropertyManagementServiceCommonAreaManagementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceCommonAreaManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceSecurityManagementMember" xlink:label="loc_EUDAPropertyManagementServiceSecurityManagementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceSecurityManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServiceMember" xlink:label="loc_EUDAPropertyManagementServiceMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfCostOfRevenueDetails" xlink:title="00000052 - Disclosure - Schedule of cost of revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSpecialtyCareRelatedPartyMember" xlink:label="loc_EUDAMedicalServicesSpecialtyCareRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSpecialtyCareRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesGeneralPracticesMember" xlink:label="loc_EUDAMedicalServicesGeneralPracticesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesGeneralPracticesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesSubTotalMember" xlink:label="loc_EUDAMedicalServicesSubTotalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAMedicalServicesSubTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductSalesMember" xlink:label="loc_EUDAProductSalesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesCommonAreaManagementMember" xlink:label="loc_EUDAPropertyManagementServicesCommonAreaManagementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesCommonAreaManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesSecurityManagementMember" xlink:label="loc_EUDAPropertyManagementServicesSecurityManagementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAPropertyManagementServicesSecurityManagementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProductMangementServicesMember" xlink:label="loc_EUDAProductMangementServicesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_EUDAProductMangementServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails" xlink:title="00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilitiesBalance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilitiesBalance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilitiesBalance" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilitiesBalance_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilitiesBalance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CentralProvidentFundMember" xlink:label="loc_EUDACentralProvidentFundMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDACentralProvidentFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SkillDevelopmentLevyMember" xlink:label="loc_EUDASkillDevelopmentLevyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDASkillDevelopmentLevyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SocialInsuranceFundMember" xlink:label="loc_EUDASocialInsuranceFundMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_EUDASocialInsuranceFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:label="loc_EUDAAllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAAllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ForwardPurchaseReceivables" xlink:label="loc_EUDAForwardPurchaseReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAForwardPurchaseReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiability" xlink:label="loc_EUDAPrepaidForwardPurchaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription" xlink:label="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeStockOwnershipPlanESOPPlanDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TradeUnionFeePercentage" xlink:label="loc_EUDATradeUnionFeePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDATradeUnionFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails" xlink:title="00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="loc_EUDADisclosureReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:label="loc_EUDAOrdinarySharesOutstandingPriorToReverseRecapitalization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAOrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedemptionOfOrdinaryShares" xlink:label="loc_EUDARedemptionOfOrdinaryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDARedemptionOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:label="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAStockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails" xlink:title="00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="loc_EUDADisclosureReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInTrustAccount" xlink:label="loc_EUDAFundsHeldInTrustAccount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAFundsHeldInTrustAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInOperatingCashAccount" xlink:label="loc_EUDAFundsHeldInOperatingCashAccount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAFundsHeldInOperatingCashAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalizations" xlink:label="loc_EUDAProceedsFromReverseRecapitalizations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAProceedsFromReverseRecapitalizations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromUnpaidDeferredUnderwritingFee" xlink:label="loc_EUDAProceedsFromUnpaidDeferredUnderwritingFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAProceedsFromUnpaidDeferredUnderwritingFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromUnpaidTransactionCostsIncurred" xlink:label="loc_EUDAProceedsFromUnpaidTransactionCostsIncurred" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAProceedsFromUnpaidTransactionCostsIncurred" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="loc_us-gaapPaymentsForMergerRelatedCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapPaymentsForMergerRelatedCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoncashNetAssetsAssumedValue" xlink:label="loc_EUDANoncashNetAssetsAssumedValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDANoncashNetAssetsAssumedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization" xlink:label="loc_EUDAIssuanceOfOrdinarySharesUponTheReverseRecapitalization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_EUDAIssuanceOfOrdinarySharesUponTheReverseRecapitalization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ReverseRecapitalizationDetailsNarrative" xlink:title="00000059 - Disclosure - Reverse Recapitalization (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureReverseRecapitalizationAbstract" xlink:label="loc_EUDADisclosureReverseRecapitalizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureReverseRecapitalizationAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FirstAnniversaryMember" xlink:label="loc_EUDAFirstAnniversaryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFirstAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SecondAnniversaryMember" xlink:label="loc_EUDASecondAnniversaryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASecondAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BusinessCombinationMember" xlink:label="loc_EUDABusinessCombinationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDABusinessCombinationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SharePurchaseAgreementMember" xlink:label="loc_EUDASharePurchaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASharePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ExchangeRatioPerShare" xlink:label="loc_EUDAExchangeRatioPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAExchangeRatioPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaapExcessStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapExcessStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesNoParValue" xlink:label="loc_EUDAPrivateOrdinarySharesNoParValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateOrdinarySharesNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateOrdinarySharesOutstanding" xlink:label="loc_EUDAPrivateOrdinarySharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateOrdinarySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesNoParValue" xlink:label="loc_EUDAFounderSharesNoParValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFounderSharesNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FounderSharesOutstanding" xlink:label="loc_EUDAFounderSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFounderSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicRightsShares" xlink:label="loc_EUDAPublicRightsShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPublicRightsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateRightsShares" xlink:label="loc_EUDAPrivateRightsShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAPrivateRightsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ProceedsFromReverseRecapitalization" xlink:label="loc_EUDAProceedsFromReverseRecapitalization" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAProceedsFromReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInTrustAccount" xlink:label="loc_EUDAFundsHeldInTrustAccount" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFundsHeldInTrustAccount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundsHeldInOperatingCashAccount" xlink:label="loc_EUDAFundsHeldInOperatingCashAccount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_EUDAFundsHeldInOperatingCashAccount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative" xlink:title="00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureDispositionOfSubsidiaryAbstract" xlink:label="loc_EUDADisclosureDispositionOfSubsidiaryAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureDispositionOfSubsidiaryAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SEMAAgreementMember" xlink:label="loc_EUDASEMAAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASEMAAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TheGoodClinicPrivateLimitedMember" xlink:label="loc_EUDATheGoodClinicPrivateLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDATheGoodClinicPrivateLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000061 - Disclosure - Schedule of accounts receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical" xlink:title="00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails" xlink:title="00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract" xlink:label="loc_us-gaapCreditLossAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:label="loc_EUDAAllowanceForDoubtfulAccountsReceivableExchangeRateEffect" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_EUDAAllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditLossAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="00000064 - Disclosure - Schedule of other receivables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DivestmentReceivable" xlink:label="loc_EUDADivestmentReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDADivestmentReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EmployeeAdavance" xlink:label="loc_EUDAEmployeeAdavance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAEmployeeAdavance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaapOtherReceivablesGrossCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapOtherReceivablesGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivablesNetNonCurrent" xlink:label="loc_EUDAOtherReceivablesNetNonCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAOtherReceivablesNetNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails" xlink:title="00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulOtherReceivableRecoveries" xlink:label="loc_EUDAAllowanceForDoubtfulOtherReceivableRecoveries" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAAllowanceForDoubtfulOtherReceivableRecoveries" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs" xlink:label="loc_EUDAAllowanceForDoubtfulOtherReceivableWriteOffs" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAAllowanceForDoubtfulOtherReceivableWriteOffs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical" xlink:title="00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaapInvestmentOwnedUnderlyingFaceAmountAtMarketValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapInvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InvestmentOwnedAdditionalAmountAtMarketValues" xlink:label="loc_EUDAInvestmentOwnedAdditionalAmountAtMarketValues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAInvestmentOwnedAdditionalAmountAtMarketValues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InstallmentReceived" xlink:label="loc_EUDAInstallmentReceived" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAInstallmentReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:label="loc_us-gaapInvestmentOwnedBalancePrincipalAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapInvestmentOwnedBalancePrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherReceivableInstallmentAmount" xlink:label="loc_EUDAOtherReceivableInstallmentAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_EUDAOtherReceivableInstallmentAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000067 - Disclosure - Schedule of property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalEquipmentMember" xlink:label="loc_EUDAMedicalEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_EUDAMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000068 - Disclosure - Property and equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000069 - Disclosure - Schedule of intangible assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedCustomerRelationshipsGross" xlink:label="loc_us-gaapFiniteLivedCustomerRelationshipsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedCustomerRelationshipsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ExchangeRateEffect" xlink:label="loc_EUDAExchangeRateEffect" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_EUDAExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfGoodwillDetails" xlink:title="00000070 - Disclosure - Schedule of goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MelanaInternationalPteLimitedMember" xlink:label="loc_EUDAMelanaInternationalPteLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDAMelanaInternationalPteLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriGlobalSecurityPteLimitedMember" xlink:label="loc_EUDATriGlobalSecurityPteLimitedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_EUDATriGlobalSecurityPteLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapGoodwillTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwillTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000071 - Disclosure - Intangible assets, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/GoodwillDetailsNarrative" xlink:title="00000072 - Disclosure - Goodwill (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative" xlink:title="00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureForwardPurchaseAgreementsAbstract" xlink:label="loc_EUDADisclosureForwardPurchaseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureForwardPurchaseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementOneMember" xlink:label="loc_EUDAPrepaidForwardAgreementOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAPrepaidForwardAgreementOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardAgreementTwoMember" xlink:label="loc_EUDAPrepaidForwardAgreementTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAPrepaidForwardAgreementTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_InstitutionalInvestorsMember" xlink:label="loc_EUDAInstitutionalInvestorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAInstitutionalInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractsMember" xlink:label="loc_us-gaapForwardContractsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapForwardContractsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:label="loc_us-gaapForwardContractIndexedToEquitySettlementShareFairValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAPrepaidForwardPurchaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:label="loc_EUDAChangeOfFairValueOfPrepaidForwardPurchaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAChangeOfFairValueOfPrepaidForwardPurchaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/LoanToThirdPartyDetailsNarrative" xlink:title="00000074 - Disclosure - Loan to third party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLoanToThirdPartyAbstract" xlink:label="loc_EUDADisclosureLoanToThirdPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLoanToThirdPartyAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PTTotalPrimaIndonesiaMember" xlink:label="loc_EUDAPTTotalPrimaIndonesiaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_EUDAPTTotalPrimaIndonesiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoanAccumulativelyDisbursed" xlink:label="loc_EUDALoanAccumulativelyDisbursed" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDALoanAccumulativelyDisbursed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeRelatedParty" xlink:label="loc_us-gaapInterestIncomeRelatedParty" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetails" xlink:title="00000075 - Disclosure - Schedule of short-term loans (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FSCapitalPtdLtdMember" xlink:label="loc_EUDAFSCapitalPtdLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAFSCapitalPtdLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FundingSocietiesPteLtdMember" xlink:label="loc_EUDAFundingSocietiesPteLtdMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAFundingSocietiesPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KohWeeSingMember" xlink:label="loc_EUDAKohWeeSingMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKohWeeSingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KaufamanAndCanolesPcKcMember" xlink:label="loc_EUDAKaufamanAndCanolesPcKcMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKaufamanAndCanolesPcKcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MaximGroupLlcMember" xlink:label="loc_EUDAMaximGroupLlcMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMaximGroupLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraCapitalPteLtdMember" xlink:label="loc_EUDAMenoraCapitalPteLtdMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMenoraCapitalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_LoebAndLoebLlpMember" xlink:label="loc_EUDALoebAndLoebLlpMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDALoebAndLoebLlpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkLimitedMember" xlink:label="loc_EUDAShineLinkLimitedMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAShineLinkLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MengDongJamesTanMember" xlink:label="loc_EUDAMengDongJamesTanMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMengDongJamesTanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesThirdPartiesMember" xlink:label="loc_EUDAConvertibleNotesThirdPartiesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConvertibleNotesRelatedPartiesMember" xlink:label="loc_EUDAConvertibleNotesRelatedPartiesMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAConvertibleNotesRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVariableRateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLender" xlink:label="loc_us-gaapShortTermDebtLender" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtLender" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTerms" xlink:label="loc_us-gaapShortTermDebtTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShortTermDebtInterestRate" xlink:label="loc_EUDAShortTermDebtInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_EUDAShortTermDebtInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateral" xlink:label="loc_us-gaapDebtInstrumentCollateral" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentCollateral" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical" xlink:title="00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UnitedOverseasBankLimitedMember" xlink:label="loc_EUDAUnitedOverseasBankLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAUnitedOverseasBankLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KaufamanAndCanolesPcKcMember" xlink:label="loc_EUDAKaufamanAndCanolesPcKcMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAKaufamanAndCanolesPcKcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MengDongJamesTanMember" xlink:label="loc_EUDAMengDongJamesTanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_EUDAMengDongJamesTanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_BankAndPrivateLenderMember" xlink:label="loc_EUDABankAndPrivateLenderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDABankAndPrivateLenderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PromissoryNoteMember" xlink:label="loc_EUDAPromissoryNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SettlementAgreementMember" xlink:label="loc_EUDASettlementAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/CreditFacilitiesDetailsNarrative" xlink:title="00000077 - Disclosure - Credit facilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ThirdPartiesMember" xlink:label="loc_EUDAThirdPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_EUDAThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaapShortTermDebtWeightedAverageInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtWeightedAverageInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails" xlink:title="00000079 - Disclosure - Schedule of related party balances (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KRHillCapitalPteLtdMember" xlink:label="loc_EUDAKRHillCapitalPteLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKRHillCapitalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeMedicalPtdLtdMember" xlink:label="loc_EUDAKentRidgeMedicalPtdLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgeMedicalPtdLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_UGDigitalSdnBhdMember" xlink:label="loc_EUDAUGDigitalSdnBhdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAUGDigitalSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JanicLimitedMember" xlink:label="loc_EUDAJanicLimitedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJanicLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ZukihealthSDNMember" xlink:label="loc_EUDAZukihealthSDNMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAZukihealthSDNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JenniferGohMember" xlink:label="loc_EUDAJenniferGohMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJenniferGohMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FrescoInvestmentPteLtdMember" xlink:label="loc_EUDAFrescoInvestmentPteLtdMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAFrescoInvestmentPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CadenceHealthPteLtdMember" xlink:label="loc_EUDACadenceHealthPteLtdMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACadenceHealthPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CheeYinMehMember" xlink:label="loc_EUDACheeYinMehMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACheeYinMehMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamieFanWeiZhiMember" xlink:label="loc_EUDAJamieFanWeiZhiMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAJamieFanWeiZhiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KelvinChenMember" xlink:label="loc_EUDAKelvinChenMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKelvinChenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgeHealthPteLtdMember" xlink:label="loc_EUDAKentRidgeHealthPteLtdMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgeHealthPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgePacificPteLtdMember" xlink:label="loc_EUDAKentRidgePacificPteLtdMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgePacificPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WatermarkDevelopmentsLtdMember" xlink:label="loc_EUDAWatermarkDevelopmentsLtdMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAWatermarkDevelopmentsLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WilkeServicesLtdMember" xlink:label="loc_EUDAWilkeServicesLtdMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAWilkeServicesLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MountLockeLimitedMember" xlink:label="loc_EUDAMountLockeLimitedMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAMountLockeLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties" xlink:label="loc_us-gaapDueFromOtherRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOtherRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000080 - Disclosure - Schedule of related party transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_CadenceHealthPteLtdMember" xlink:label="loc_EUDACadenceHealthPteLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDACadenceHealthPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KentRidgePacificPteLtdMember" xlink:label="loc_EUDAKentRidgePacificPteLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAKentRidgePacificPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PurchaseFromRelatedParties" xlink:label="loc_EUDAPurchaseFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_EUDAPurchaseFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfReverseRecapitalizationDetails" xlink:title="00000081 - Disclosure - Schedule of reverse recapitalization (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:label="loc_EUDAOrdinarySharesOutstandingPriorToReverseRecapitalization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAOrdinarySharesOutstandingPriorToReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RedemptionOfOrdinaryShares" xlink:label="loc_EUDARedemptionOfOrdinaryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDARedemptionOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWarrantActivitiesDetails" xlink:title="00000082 - Disclosure - Schedule of warrant activities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingGranted" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:label="loc_EUDAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingForfeited" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ClassOfWarrantOrRightOutstandingExercised" xlink:label="loc_EUDAClassOfWarrantOrRightOutstandingExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAClassOfWarrantOrRightOutstandingExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails" xlink:title="00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SharePriceAsOfClosingDate" xlink:label="loc_EUDASharePriceAsOfClosingDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDASharePriceAsOfClosingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AverageDailyReturnRate" xlink:label="loc_EUDAAverageDailyReturnRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAAverageDailyReturnRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DailyVolatilityForTriggeringEvent1" xlink:label="loc_EUDADailyVolatilityForTriggeringEvent1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDADailyVolatilityForTriggeringEvent1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DailyVolatilityForTriggeringEvent2" xlink:label="loc_EUDADailyVolatilityForTriggeringEvent2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDADailyVolatilityForTriggeringEvent2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RiskFreeRateForTriggeringEventOne" xlink:label="loc_EUDARiskFreeRateForTriggeringEventOne" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDARiskFreeRateForTriggeringEventOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_RiskFreeRateForTriggeringEventTwo" xlink:label="loc_EUDARiskFreeRateForTriggeringEventTwo" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDARiskFreeRateForTriggeringEventTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GrantPriceForTriggingEventOne" xlink:label="loc_EUDAGrantPriceForTriggingEventOne" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAGrantPriceForTriggingEventOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_GrantPriceForTriggingEventTwo" xlink:label="loc_EUDAGrantPriceForTriggingEventTwo" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_EUDAGrantPriceForTriggingEventTwo" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000084 - Disclosure - Shareholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightIHoldingsTwoPtdLtdMember" xlink:label="loc_EUDAEightIHoldingsTwoPtdLtdMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_EUDAEightIHoldingsTwoPtdLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PublicWarrantMember" xlink:label="loc_EUDAPublicWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_EUDAPublicWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PrivateWarrantMember" xlink:label="loc_EUDAPrivateWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_EUDAPrivateWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FirstAnniversaryMember" xlink:label="loc_EUDAFirstAnniversaryMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFirstAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SecondAnniversaryMember" xlink:label="loc_EUDASecondAnniversaryMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASecondAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventOneMember" xlink:label="loc_EUDATriggeringEventOneMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_EUDATriggeringEventOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TriggeringEventTwoMember" xlink:label="loc_EUDATriggeringEventTwoMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_EUDATriggeringEventTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Capital" xlink:label="loc_us-gaapCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinaryShareBeforeReverseRecapitalization" xlink:label="loc_EUDAOrdinaryShareBeforeReverseRecapitalization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAOrdinaryShareBeforeReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_WarrantsRedemptionPrice" xlink:label="loc_EUDAWarrantsRedemptionPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAWarrantsRedemptionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutShares" xlink:label="loc_EUDAEarnoutShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAEarnoutShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FairValueOfEarnoutShares" xlink:label="loc_EUDAFairValueOfEarnoutShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_EUDAFairValueOfEarnoutShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails" xlink:title="00000085 - Disclosure - Schedule of components of loss before income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000086 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000087 - Disclosure - Schedule of effective income tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DeferredTaxAssetsLeaseLiabilityNet" xlink:label="loc_EUDADeferredTaxAssetsLeaseLiabilityNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_EUDADeferredTaxAssetsLeaseLiabilityNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical" xlink:title="00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfTaxesPayableDetails" xlink:title="00000090 - Disclosure - Schedule of taxes payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AccruedGSTTaxesPayableCurrent" xlink:label="loc_EUDAAccruedGSTTaxesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_EUDAAccruedGSTTaxesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000091 - Disclosure - Income taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_VN" xlink:label="loc_countryVN" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryVN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="loc_countrySG" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countrySG" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SeventyFivePercentageMember" xlink:label="loc_EUDASeventyFivePercentageMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDASeventyFivePercentageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_FiftyPercentageMember" xlink:label="loc_EUDAFiftyPercentageMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_EUDAFiftyPercentageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SingaporeSubsidiariesMember" xlink:label="loc_EUDASingaporeSubsidiariesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_EUDASingaporeSubsidiariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ConcentrationsRisksDetailsNarrative" xlink:title="00000092 - Disclosure - Concentrations risks (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoCustomerMember" xlink:label="loc_EUDANoCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDANoCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_NoVendorMember" xlink:label="loc_EUDANoVendorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDANoVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OneVendorMember" xlink:label="loc_EUDAOneVendorMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAOneVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorOneMember" xlink:label="loc_EUDAVendorOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAVendorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_VendorTwoMember" xlink:label="loc_EUDAVendorTwoMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_EUDAVendorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:label="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:label="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis" xlink:to="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditRiskMember" xlink:label="loc_us-gaapCreditRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain" xlink:to="loc_us-gaapCreditRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankOverdrafts" xlink:label="loc_us-gaapBankOverdrafts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapBankOverdrafts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails" xlink:title="00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OperatingLeaseExpenseShortTerm" xlink:label="loc_EUDAOperatingLeaseExpenseShortTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_EUDAOperatingLeaseExpenseShortTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails" xlink:title="00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000095 - Disclosure - Schedule of future minimum lease payments (Details)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapContractualObligationDueInNextTwelveMonths" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapContractualObligationDueInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaapContractualObligationDueInSecondYear" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapContractualObligationDueInSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ContractualObligationDiscount" xlink:label="loc_EUDAContractualObligationDiscount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_EUDAContractualObligationDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ContractualObligationLeaseLiability" xlink:label="loc_EUDAContractualObligationLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_EUDAContractualObligationLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/LeasesDetailsNarrative" xlink:title="00000096 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_DisclosureLeasesAbstract" xlink:label="loc_EUDADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" xlink:label="loc_us-gaapOperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeasePayments" xlink:label="loc_us-gaapShortTermLeasePayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EUDADisclosureLeasesAbstract" xlink:to="loc_us-gaapShortTermLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000097 - Disclosure - Commitments and contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="00000098 - Disclosure - Schedule of segment reporting information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAMedicalServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAPropertyManagementServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ConsolidatedMember" xlink:label="loc_EUDAConsolidatedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAConsolidatedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails" xlink:title="00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:label="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_EUDAIncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EarnoutSharePayment" xlink:label="loc_EUDAEarnoutSharePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_EUDAEarnoutSharePayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OtherCorporateExpenses" xlink:label="loc_EUDAOtherCorporateExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_EUDAOtherCorporateExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SegmentInformationDetailsNarrative" xlink:title="00000100 - Disclosure - Segment information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MedicalServicesMember" xlink:label="loc_EUDAMedicalServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAMedicalServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_PropertyManagementServicesMember" xlink:label="loc_EUDAPropertyManagementServicesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_EUDAPropertyManagementServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://euda.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000101 - Disclosure - Subsequent events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_AlfredLimMember" xlink:label="loc_EUDAAlfredLimMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAAlfredLimMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_JamesTanMember" xlink:label="loc_EUDAJamesTanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAJamesTanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ShineLinkMember" xlink:label="loc_EUDAShineLinkMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAShineLinkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_MenoraMember" xlink:label="loc_EUDAMenoraMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAMenoraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_EightiHoldingMember" xlink:label="loc_EUDAEightiHoldingMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAEightiHoldingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_KelvinChenMember" xlink:label="loc_EUDAKelvinChenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDAKelvinChenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerOneMember" xlink:label="loc_EUDASellerOneMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDASellerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SellerTwoMember" xlink:label="loc_EUDASellerTwoMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_EUDASellerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanSecondLoanMember" xlink:label="loc_EUDATanSecondLoanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanSecondLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanFirstLoanMember" xlink:label="loc_EUDATanFirstLoanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanFirstLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanThirdLoanMember" xlink:label="loc_EUDATanThirdLoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanThirdLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_TanTwoThousandTwentyThreeNoteMember" xlink:label="loc_EUDATanTwoThousandTwentyThreeNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_EUDATanTwoThousandTwentyThreeNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_SettlementAgreementMember" xlink:label="loc_EUDASettlementAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDASettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_ChenSettlementAgreementMember" xlink:label="loc_EUDAChenSettlementAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_EUDAChenSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesAvailableForResale" xlink:label="loc_EUDAOrdinarySharesAvailableForResale" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesAvailableForResale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="loc_us-gaapConversionOfStockTypeOfStockConverted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConversionOfStockTypeOfStockConverted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesForfeited" xlink:label="loc_EUDAOrdinarySharesForfeited" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="euda-20221231.xsd#EUDA_OrdinarySharesToBeIssued" xlink:label="loc_EUDAOrdinarySharesToBeIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_EUDAOrdinarySharesToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922818240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 19, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EUDA
HEALTH HOLDINGS LIMITED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001847846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1
Pemimpin Drive #12-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">One
Pemimpin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">576151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6268 6821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,777,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum Asia CPAs LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New
York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=EUDA_OrdinarySharesMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
    Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EUDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=EUDA_RedeemableWarrantsMember', window );">Redeemable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable
    Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EUDAW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=EUDA_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=EUDA_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=EUDA_RedeemableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=EUDA_RedeemableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922572336">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 143,024<span></span>
</td>
<td class="nump">$ 189,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">641,461<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,851,503<span></span>
</td>
<td class="nump">1,802,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">1,991,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">267,863<span></span>
</td>
<td class="nump">297,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,633<span></span>
</td>
<td class="nump">71,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ForwardPurchaseReceivables', window );">Forward purchase receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,892,527<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,026,478<span></span>
</td>
<td class="nump">4,352,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,628<span></span>
</td>
<td class="nump">56,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherReceivablesNonCurrent', window );">Other receivables - non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,830,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">478,061<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">992,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,528<span></span>
</td>
<td class="nump">79,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,345<span></span>
</td>
<td class="nump">24,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_LoanToThirdParty', window );">Loan to third party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">371,962<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total Other Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">570,934<span></span>
</td>
<td class="nump">3,589,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,629,040<span></span>
</td>
<td class="nump">7,999,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204,240<span></span>
</td>
<td class="nump">205,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ShortTermLoansThirdParties', window );">Short term loans - third parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">148,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PromissoryNote', window );">Promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,619,625<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ConvertibleNotesRelatedParties', window );">Convertible notes - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">782,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,635,483<span></span>
</td>
<td class="nump">359,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AccountsPayableRelatedParty', window );">Accounts payable - related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,459,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherPayablesAndAccruedLiabilities', window );">Other payables and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,592,815<span></span>
</td>
<td class="nump">488,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherPayablesRelatedParties', window );">Other payables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,521,945<span></span>
</td>
<td class="nump">3,272,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79,959<span></span>
</td>
<td class="nump">63,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,186<span></span>
</td>
<td class="nump">11,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,321,053<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">186,150<span></span>
</td>
<td class="nump">307,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,121,056<span></span>
</td>
<td class="nump">7,316,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>OTHER LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities - non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,015<span></span>
</td>
<td class="nump">17,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Other Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,015<span></span>
</td>
<td class="nump">82,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,136,071<span></span>
</td>
<td class="nump">7,398,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; (DEFICIT) EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value, unlimited shares authorized, 20,191,770 shares and 9,333,333 shares outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,308,969<span></span>
</td>
<td class="nump">334,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,703,789)<span></span>
</td>
<td class="nump">180,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(125,689)<span></span>
</td>
<td class="nump">6,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Euda Health Holdings Limited Shareholders&#8217; (Deficit) Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,520,509)<span></span>
</td>
<td class="nump">521,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,478<span></span>
</td>
<td class="nump">78,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Shareholders&#8217; (Deficit) Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,507,031)<span></span>
</td>
<td class="nump">600,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; (Deficit) Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,629,040<span></span>
</td>
<td class="nump">$ 7,999,028<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to reverse recapitalization effected on November 17, 2022</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AccountsPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payable related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AccountsPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ConvertibleNotesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ConvertibleNotesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ForwardPurchaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward purchase receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ForwardPurchaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_LoanToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan to third party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_LoanToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherPayablesAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherPayablesAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherPayablesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherPayablesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherReceivablesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivables non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherReceivablesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ShortTermLoansThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term loans third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ShortTermLoansThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668924490848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock, shares authorized, unlimited</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,191,770<span></span>
</td>
<td class="nump">9,333,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921802160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 9,840,709<span></span>
</td>
<td class="nump">$ 10,544,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>COST OF REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total Cost of Revenues</a></td>
<td class="nump">6,486,513<span></span>
</td>
<td class="nump">6,300,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">3,354,196<span></span>
</td>
<td class="nump">4,244,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling</a></td>
<td class="nump">1,902,865<span></span>
</td>
<td class="nump">1,258,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,153,248<span></span>
</td>
<td class="nump">4,084,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_EarnoutSharePayment', window );">Earnout share payment</a></td>
<td class="nump">5,199,629<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss on long-lived assets and goodwill</a></td>
<td class="nump">1,139,016<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,209<span></span>
</td>
<td class="nump">129,265<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">15,411,967<span></span>
</td>
<td class="nump">5,472,580<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(12,057,771)<span></span>
</td>
<td class="num">(1,228,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense, net</a></td>
<td class="num">(120,082)<span></span>
</td>
<td class="num">(127,126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on disposal of subsidiary</a></td>
<td class="nump">30,055<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities', window );">Change in fair value of prepaid forward purchase liabilities</a></td>
<td class="num">(12,911,503)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">127,477<span></span>
</td>
<td class="nump">386,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,917,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
<td class="num">(12,874,053)<span></span>
</td>
<td class="nump">2,176,764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(LOSS) INCOME BEFORE INCOME TAXES</a></td>
<td class="num">(24,931,824)<span></span>
</td>
<td class="nump">948,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="nump">17,422<span></span>
</td>
<td class="nump">48,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET (LOSS) INCOME</a></td>
<td class="num">(24,949,246)<span></span>
</td>
<td class="nump">900,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net (income) loss attributable to noncontrolling interest</a></td>
<td class="num">(65,124)<span></span>
</td>
<td class="nump">35,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMITED</a></td>
<td class="num">(24,884,122)<span></span>
</td>
<td class="nump">864,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">FOREIGN CURRENCY TRANSLATION ADJUSTMENT</a></td>
<td class="num">(131,941)<span></span>
</td>
<td class="nump">17,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL COMPREHENSIVE (LOSS) INCOME</a></td>
<td class="num">(25,081,187)<span></span>
</td>
<td class="nump">917,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive (loss) income attributable to noncontrolling interest</a></td>
<td class="num">(65,340)<span></span>
</td>
<td class="nump">35,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMIT</a></td>
<td class="num">$ (25,015,847)<span></span>
</td>
<td class="nump">$ 881,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES*</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted</a></td>
<td class="nump">12,029,656<span></span>
</td>
<td class="nump">9,253,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>(LOSS) EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted</a></td>
<td class="num">$ (2.07)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesMember', window );">Medical Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 6,065,233<span></span>
</td>
<td class="nump">$ 5,723,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>COST OF REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total Cost of Revenues</a></td>
<td class="nump">3,041,327<span></span>
</td>
<td class="nump">474,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesRelatedPartiesMember', window );">Medical Services Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>COST OF REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total Cost of Revenues</a></td>
<td class="nump">491,499<span></span>
</td>
<td class="nump">2,349,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember', window );">Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">11,046<span></span>
</td>
<td class="nump">257,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>COST OF REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total Cost of Revenues</a></td>
<td class="nump">59,391<span></span>
</td>
<td class="nump">167,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesMember', window );">Property Management Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">3,764,295<span></span>
</td>
<td class="nump">4,558,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>COST OF REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total Cost of Revenues</a></td>
<td class="nump">$ 2,894,296<span></span>
</td>
<td class="nump">$ 3,308,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_EarnoutSharePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout share payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_EarnoutSharePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In fair value of prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923720400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Change in Shareholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value</a></td>
<td class="nump">$ 334,863<span></span>
</td>
<td class="nump">$ 334,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares</a></td>
<td class="nump">9,253,333<span></span>
</td>
<td class="nump">9,253,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions', window );">Capital contributions</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodSharesCapitalContributions', window );">Capital contributions, shares</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="nump">$ 2,763,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament', window );">Earnout shares payment</a></td>
<td class="nump">5,199,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="nump">4,626,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="nump">$ 11,911,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization', window );">Issuance of ordinary shares upon the reverse recapitalization , shares</a></td>
<td class="nump">6,191,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value</a></td>
<td class="nump">$ 21,308,969<span></span>
</td>
<td class="nump">$ 334,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares</a></td>
<td class="nump">20,191,770<span></span>
</td>
<td class="nump">9,253,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value</a></td>
<td class="nump">$ 180,333<span></span>
</td>
<td class="num">$ (684,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(24,884,122)<span></span>
</td>
<td class="nump">864,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions', window );">Capital contributions</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament', window );">Earnout shares payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value</a></td>
<td class="num">(24,703,789)<span></span>
</td>
<td class="nump">180,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value</a></td>
<td class="nump">6,036<span></span>
</td>
<td class="num">(10,956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(131,725)<span></span>
</td>
<td class="nump">16,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions', window );">Capital contributions</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament', window );">Earnout shares payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value</a></td>
<td class="num">(125,689)<span></span>
</td>
<td class="nump">6,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value</a></td>
<td class="nump">78,818<span></span>
</td>
<td class="nump">43,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(65,124)<span></span>
</td>
<td class="nump">35,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(216)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions', window );">Capital contributions</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament', window );">Earnout shares payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value</a></td>
<td class="nump">13,478<span></span>
</td>
<td class="nump">78,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value</a></td>
<td class="nump">600,050<span></span>
</td>
<td class="num">(317,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(24,949,246)<span></span>
</td>
<td class="nump">900,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(131,941)<span></span>
</td>
<td class="nump">17,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions', window );">Capital contributions</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="nump">2,763,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament', window );">Earnout shares payment</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="nump">11,911,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value</a></td>
<td class="num">$ (3,507,031)<span></span>
</td>
<td class="nump">$ 600,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodSharesCapitalContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares capital contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodSharesCapitalContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of ordinary shares upon the Reverse Recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodValueCapitalContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value capital contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodValueCapitalContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value earnout shares payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value forgiveness of debt by related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of ordinary shares upon reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922389408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (24,949,246)<span></span>
</td>
<td class="nump">$ 900,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">23,347<span></span>
</td>
<td class="nump">34,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">115,907<span></span>
</td>
<td class="nump">162,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use asset</a></td>
<td class="nump">109,056<span></span>
</td>
<td class="nump">58,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance right-of-use assets</a></td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">2,872,789<span></span>
</td>
<td class="nump">43,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes benefits</a></td>
<td class="num">(48,228)<span></span>
</td>
<td class="num">(27,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,917,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on disposal of subsidiary</a></td>
<td class="num">(30,055)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_EarnoutPayment', window );">Earnout payment</a></td>
<td class="nump">5,199,629<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss on goodwill</a></td>
<td class="nump">971,229<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">167,787<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities', window );">Change in fair value of prepaid forward purchase liabilities</a></td>
<td class="nump">12,911,503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(174,824)<span></span>
</td>
<td class="num">(263,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent', window );">Interest receivable from loan to third party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(19,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,582,724<span></span>
</td>
<td class="nump">55,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(22,749)<span></span>
</td>
<td class="num">(18,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,268,701<span></span>
</td>
<td class="nump">353,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IncreaseDecreaseInAccountsPayableRelatedParty', window );">Accounts payables - related party</a></td>
<td class="num">(2,396,931)<span></span>
</td>
<td class="nump">1,022,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other payables and accrued liabilities</a></td>
<td class="nump">1,084,437<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Taxes payable</a></td>
<td class="num">(114,133)<span></span>
</td>
<td class="nump">107,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(105,719)<span></span>
</td>
<td class="num">(62,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(1,526,828)<span></span>
</td>
<td class="nump">443,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(18,137)<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Loan to third party</a></td>
<td class="num">(246,664)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash acquired through business combination</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(354,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Cash released upon disposal of a subsidiary</a></td>
<td class="num">(3,405)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(268,206)<span></span>
</td>
<td class="num">(356,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Capital contributions</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ProceedsFromReverseRecapitalization', window );">Proceeds from the Reverse Recapitalization</a></td>
<td class="nump">1,324,961<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payments of merger costs</a></td>
<td class="num">(1,305,580)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RepaymentsFromOtherReceivableRelatedParties', window );">Repayments from other receivable - related parties</a></td>
<td class="nump">30,670<span></span>
</td>
<td class="nump">36,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loans - bank and private lender</a></td>
<td class="nump">72,548<span></span>
</td>
<td class="nump">87,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments to short-term loans - bank and private lender</a></td>
<td class="num">(74,895)<span></span>
</td>
<td class="num">(66,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RepaymentsToShorttermLoansThirdParties', window );">Repayments to short-term loans - third parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(312,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings from other payables - related parties</a></td>
<td class="nump">1,347,745<span></span>
</td>
<td class="nump">93,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liabilities</a></td>
<td class="num">(6,502)<span></span>
</td>
<td class="num">(6,686)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">2,488,947<span></span>
</td>
<td class="num">(168,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES</a></td>
<td class="num">(99,424)<span></span>
</td>
<td class="nump">19,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH AND RESTRICTED CASH</a></td>
<td class="nump">594,489<span></span>
</td>
<td class="num">(60,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND RESTRICTED CASH, beginning of the year</a></td>
<td class="nump">189,996<span></span>
</td>
<td class="nump">250,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND RESTRICTED CASH, end of the year</a></td>
<td class="nump">784,485<span></span>
</td>
<td class="nump">189,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income tax</a></td>
<td class="nump">156,339<span></span>
</td>
<td class="nump">30,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">19,588<span></span>
</td>
<td class="nump">110,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability', window );">Initial recognition of operating right of use asset and lease liability</a></td>
<td class="nump">105,350<span></span>
</td>
<td class="nump">125,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary', window );">Initial recognition of payables to former subsidiary upon disposal of subsidiary</a></td>
<td class="nump">319,158<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ConversionOfDebtIntoPromissoryNote', window );">Conversion of debt into a promissory note</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ConversionOfDebtsIntoConvertibleNotes', window );">Conversion of debts into convertible notes</a></td>
<td class="nump">206,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ForgivenessOfDebtByRelatedParty', window );">Forgiveness of debt by a related party</a></td>
<td class="nump">2,763,018<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="nump">11,911,459<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">143,024<span></span>
</td>
<td class="nump">189,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">641,461<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash</a></td>
<td class="nump">$ 784,485<span></span>
</td>
<td class="nump">$ 189,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ConversionOfDebtIntoPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of debt into promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ConversionOfDebtIntoPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ConversionOfDebtsIntoConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of debts into convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ConversionOfDebtsIntoConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_EarnoutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_EarnoutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ForgivenessOfDebtByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of debt by related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ForgivenessOfDebtByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IncreaseDecreaseInAccountsPayableRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts payables - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IncreaseDecreaseInAccountsPayableRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of operating right of use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of payables to former subsidiary upon disposal of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares upon reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RepaymentsFromOtherReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments from other receivable related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RepaymentsFromOtherReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RepaymentsToShorttermLoansThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments to short term loans third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RepaymentsToShorttermLoansThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668924622992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of business and organization</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zKQMxfp0Fkph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1&#8211; <span id="xdx_828_zNqFg2jPDEB">Nature of business and organization</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EUDA Health Holdings Limited, which until November
17, 2022 was known as 8i Acquisition 2 Corp. (the &#8220;Company&#8221;, &#8220;EUDA&#8221; or &#8220;8i&#8221;) is a company incorporated
on January 21, 2021, under the laws of the British Virgin Islands for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a &#8220;Initial
Business Combination&#8221;). The Company is an &#8220;emerging growth company&#8221;, as defined in Section 2(a) of the Securities Act
of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;). The Company&#8217;s efforts to identify a prospective target business were not limited to a particular industry or geographic
location (excluding China). The Articles of Association prohibited the Company from undertaking the Initial Business Combination with
any entity that conducts a majority of its business or is headquartered in China (including Hong Kong and Macau).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022 (the &#8220;Closing Date&#8221;),
EUDA Health Holdings Limited, a British Virgin Islands business company (formerly known as 8i Acquisition 2 Corp.) (the &#8220;Company&#8221;),
consummated the business combination contemplated by the Share Purchase Agreement (the &#8220;SPA&#8221;) between 8i Acquisition 2 Corp.,
a BVI business company (&#8220;8i&#8221;), EUDA Health Limited, a British Virgin Islands business company (&#8220;EHL&#8221;), Watermark
Developments Limited, a British Virgin Islands business company (&#8220;Watermark&#8221; or the &#8220;Seller&#8221;), and Kwong Yeow
Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination
between 8i and EHL was effected by the purchase by 8i of all of the issued and outstanding shares of EHL from the Seller (the &#8220;Share
Purchase&#8221;), resulting in EHL becoming a wholly owned subsidiary of 8i. In addition, in connection with the consummation of the Share
Purchase, 8i has changed its name to &#8220;EUDA Health Holdings Limited.&#8221; <span style="background-color: white">See Note 4 - Reverse
Recapitalization for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, through its subsidiaries, operates its
business in two segments, 1) engaged in the healthcare specialty group (other than general practice) business offering range of specialty
care services to patients, and engaged in the medical facility general practice clinic that provides holistic care for various illnesses,
and 2) engaged in the property management service that services shopping malls, business office building, or residential apartments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Reorganization under EUDA Health Limited (&#8220;EHL&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2021, EHL completed a reverse recapitalization
(&#8220;Reorganization&#8221;) under common control of its then existing shareholders, who collectively owned all of the equity interests
of Kent Ridge Health Private Limited (&#8220;KRHPL&#8221;), a holding company incorporated under the laws of the Singapore prior to the
Reorganization, through the following transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2021, EHL acquired <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zr02GQ456Lkf" title="Ownership percentage">100</span>% of the equity interests in Kent Ridge Healthcare Singapore Private Limited (&#8220;KRHSG&#8221;) through KRHPL for consideration of SG$<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z4LfnmqH9Cjc" title="Consideration">1.0</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2021, EHL acquired <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zfvys17pJ3hd" title="Ownership percentage">100</span>% of the equity interests in EUDA Private Limited (&#8220;EUDA PL&#8221;) through KRHPL for consideration of SG$<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_z9Xmt3BimM8a" title="Consideration">1.0</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2021, Kent Ridge Health Limited (&#8220;KRHL&#8221;), EHL&#8217;s wholly owned subsidiary, acquired <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zOhCDKBHIvx8" title="Ownership percentage">100</span>% of the equity interests in Super Gateway Group Limited (&#8220;SGGL&#8221;) through KRHPL for consideration of SG$<span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210801__20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zvLfN0Bs7tSf" title="Consideration">1.0</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 3, 2021, EHL acquired <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTNwSVY0eqh9" title="Ownership percentage">100</span>% of the equity interests in Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;) through KRHPL for no consideration.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before and after the Reorganization, the Company,
together with its subsidiaries (as indicated above), is effectively controlled by the same shareholders, and therefore the Reorganization
is considered as a recapitalization of entities under common control in accordance with Accounting Standards Codification (&#8220;ASC&#8221;)
805-50-25. The consolidation of the Company and its subsidiaries have been accounted for at historical cost and prepared on the basis
as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated
financial statements in accordance with ASC 805-50-45-5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Reorganization under KRHPL</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;KRHSG Agreement&#8221;) with the sole shareholder of KRHSG who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the KRHSG Agreement, KRHPL will acquire <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z62K6jKh6Zfi" title="Ownership percentage">100</span>% of the equity interests
in KRHSG (&#8220;Reorganization of KRHSG&#8221;) for a total consideration of SG$<span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zoT5ljnFNSrf" title="Consideration">1.0</span> (&#8220;Total Consideration&#8221;). The transaction
was completed and effective on January 3, 2020. Since KRHSG and KRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of KRHSG are prepared on the basis as
if the restructuring of KRHSG became effective as of the beginning of the first period presented in the accompanying consolidated financial
statements of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;EUDA PL Agreement&#8221;) with the sole shareholder of EUDA PL who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the EUDA PL Agreement, KRHPL will acquire <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zmZCeMevBZ25" title="Ownership percentage">100</span>% of the equity interests
in EUDA PL (&#8220;Reorganization of EUDA PL&#8221;) for a total consideration of SG$<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zKznHPSUl4Jh" title="Consideration">1.0</span> (&#8220;Total Consideration&#8221;). The transaction
was completed and effective on January 3, 2020. Since EUDA PL and LRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of EUDA PL are prepared on the basis
as if the restructuring of EUDA PL became effective as of the beginning of the first period presented in the accompanying consolidated
financial statements of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#8220;SEMA Agreement&#8221;) with the sole shareholder of SEMA who is effectively controlled
by the same shareholders of KRHPL on December 31, 2019. Pursuant to the SEMA PL Agreement, KRHPL will acquire <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_z3QxUw59Vmq2" title="Ownership percentage">100</span>% of the equity interests
in SEMA (&#8220;Reorganization of SEMA&#8221;) for no consideration. SEMA is a holding company and has no operations prior to December
31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zzrsYIVYtU3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
reflect the activities of EUDA and each of the following entities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zO0MFroHEgr2" style="display: none">Schedule of consolidated financial statement</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_ztt8seKfNKj7" title="Name of company">EUDA Health Limited (&#8220;EHL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company
Incorporated on <span id="xdx_905_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_z0ync8rYeFLe" title="Date of incorporation">June 8, 2021</span> <br/>
A holding Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_zgcbYWPo4abj" title="Ownership percentage">100</span>% owned by EUDA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zUwAwOFjT3ae" title="Name of company">Kent Ridge Healthcare Singapore Pte. Ltd. (&#8220;KRHSG&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_901_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zDe7wPuvozp7" title="Date of incorporation">November 9, 2017</span> <br/>
Multi-care specialty group offering range of specialty care services to patients.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zyMEq0S7QwXf" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zd99RF1PNEQe" title="Name of company">EUDA Private Limited (&#8220;EUDA PL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90A_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zqbIwHB4wP9" title="Date of incorporation">April 13, 2018</span> <br/>
A digital health company that provides a platform to serve the healthcare industry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zZRNTkRCwAO3" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zClTqn3LSgL9" title="Name of company">Zukitek Vietnam Private Limited Liability Company (&#8220;ZKTV PL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Vietnam company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zIbJX9cpEhxi" title="Date of incorporation">May 2, 2019</span> <br/>
A Research and Development Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zeq5sYBziRI9" title="Ownership percentage">100</span>% owned by EUDA PL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zX4UnAQNcqWi" title="Name of company">Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zA4bi8mmhEid" title="Date of incorporation">March 18, 2019</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTC1BKBCjE3c" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_fKDEp_zHby8OhBz5Ug" title="Name of company">The Good Clinic Private Limited (&#8220;TGC&#8221;)</span>(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90D_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zP7pQMx9TP38" title="Date of incorporation">April 8, 2020</span> <br/>
Medical facility general practice clinic that provides holistic care for various illnesses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zGVp5NzdxIwb" title="Ownership percentage">100</span>% owned by SEMA</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zjbB0SBuz2hc" title="Name of company">EUDA Doctor Private Limited</span><br/>
(&#8220;ED PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_z21LqjYwPzZ6" title="Date of incorporation">December 1, 2021</span> <br/>
A platform solution for doctors and physicians to find, connect, and collaborate with trusted peers, specialists, and other professionals </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zVVm4RT5bkb1" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zLagWTm6o119" title="Name of company">Kent Ridge Hill Private Limited</span><br/>
(&#8220;KR Hill PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zmeybEREw8Fl" title="Date of incorporation">December 1, 2021</span> <br/>
A B2B2C pharmaceutical and OTC drugs e-commerce platform to promote its drug products </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zhNEsidOtjBd" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zKjP4pd0gpGd" title="Name of company">Kent Ridge Health Limited</span> (&#8220;KRHL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br/>
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zei81uu1GRzc" title="Date of incorporation">June 8, 2021</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_z5AP4aBUTiKj" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_za1FjQC2ABA6" title="Name of company">Zukitech Private Limited (&#8220;Zukitech&#8221;)</span> <br/>
(&#8220;ZKT PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zXGpcJ4eg2Nf" title="Date of incorporation">June 13, 2019</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zyQCIXcWfqib" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_z4WLm1MsH2U1" title="Name of company">Super Gateway Group Limited</span><br/>
(&#8220;SGGL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zeV5hsW0wkk3" title="Date of incorporation">April 18, 2008</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zao2DCaqPzEl" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zMOecuW4Fqi1" title="Name of company">Universal Gateway International Pte. Ltd. (&#8220;UGI&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_900_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zKlwvd3khwCi" title="Date of incorporation">September 30, 2000</span> <br/>
Registered capital of RMB <span id="xdx_90F_ecustom--RegisteredCapital_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_za0HkDmqDWNg" title="Registered capital">5,000,000</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zROkB5aEsc1" title="Ownership percentage">98.3</span>% owned by SGGL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zsewKPcKPdcb" title="Name of company">Melana International Pte. Ltd</span>.<br/>
(&#8220;Melana&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90B_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zlTxMQFCZW6h" title="Date of incorporation">September 9, 2000</span> <br/>
Property management service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_ziXPMehyxJyc" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zDCItDPyBzsh" title="Name of company">Tri-Global Security Pte. Ltd.</span><br/>
(&#8220;Tri-Global&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zzvYqTMqIBo" title="Date of incorporation">August 10, 2000</span> <br/>
Property security service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zk6fh7HFQ2qi" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zOOPNxBp4PV1" title="Name of company">UG Digitech Private Limited (&#8220;UGD&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zNkhSBnW2Tu9" title="Date of incorporation">August 16, 2001</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_z1qwKbytOAu3" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4aUNoMPGah" title="Name of company">Nosweat Fitness Company Private Limited (&#8220;NFC&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679; <br/>
&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_za8fPS5Rl4Nh" title="Date of incorporation">July 6, 2021</span> <br/>
A virtual personal training platform for fitness enthusiasts </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4oTRX8nSFNe" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zipiYmzHA6ma" title="Name of company">True Cover Private Limited (&#8220;TCPL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zakOLADYtd2i" title="Date of incorporation">December 1, 2021</span> <br/>
A B2B e-claims healthcare insurance platform </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_z5tDhmcTVXL9" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_fKDIp_zFEmzLZg0sp3" title="Name of company">KR Digital Pte. Ltd. (&#8220;KR Digital&#8221;)</span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zpXuE3yx6uOb" title="Date of incorporation">December 29, 2021</span> <br/>
Development of software and applications </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zX8VmugoK8Se" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_fKDIp_zdUNGwzuWvB1" title="Name of company">Zukihealth Sdn. Bhd. (&#8220;Zukihealth&#8221;)</span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Malaysian company <br/>
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zD1qRMBHP42c" title="Date of incorporation">February 15, 2018</span> <br/>
Distribution of health care supplement products</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zUKWwA5SnhD9" title="Ownership percentage">100</span>% owned by KR Digital</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_z6JKmcmddXa8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zDswtzrNKI4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2022, SEMA, the Company&#8217;s wholly owned subsidiary, sold <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage">100</span>% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ <span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration">1.0</span> (see Note 5).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zy1YdGXNhCJ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zqN3c8c5vTv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 19, 2022, the Company acquired <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage">100</span>% equity interest of KR Digital Pte Ltd, (&#8220;KR Digital&#8221;), a Singapore Company, from Mr. Kelvin Chen, the Company&#8217;s Chief Executive Office (&#8220;CEO&#8221;) and shareholder for total consideration of SG$<span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration">1</span>. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage">100</span>% equity interest of Zukihealth Sdn Bhd, (&#8220;Zukihealth&#8221;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#8217;s CEO and shareholder for total consideration of SG$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration">1</span>. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.</span></td></tr>
  </table>
<p id="xdx_8A8_zTQLonPtSSH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929372352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going concern</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zDcc1z2Lds37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; <span id="xdx_82F_zKuph1zEvmn3">Going concern</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the Company&#8217;s going concern,
the Company monitors and analyzes its cash on-hand and its operating and capital expenditure commitments. The Company&#8217;s
liquidity needs are to meet its working capital requirements, operating expenses and capital expenditure obligations. Debt financing
in the form of short-term borrowings from bank, private lender, third parties and related parties and cash generated from operations
have been utilized to finance the working capital requirements of the Company. As of December 31, 2022, the Company&#8217;s negative
working capital deficit was approximately $<span id="xdx_908_ecustom--WorkingCapital_iI_pn5n6_c20221231_zBHHUd4E5RPh" title="Working capital">4.1</span>
million, and the Company had cash and restricted cash of approximately $<span><span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20221231_zrvGci6Apb7h" title="Cash and restricted cash">0.8</span></span>
million. The Company has experienced recurring losses from operations and negative cash flows from operating activities since 2020.
In addition, the Company had, and may potentially continue to have, an ongoing need to raise additional cash from outside sources to
fund its expansion plan and related operations. Successful transition to attaining profitable operations is dependent upon achieving
a level of revenues adequate to support the Company&#8217;s cost structure. In connection with the Company&#8217;s assessment of
going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update
(&#8220;ASU&#8221;) 2014-15, &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going
Concern,&#8221; management has determined that these conditions raise substantial doubt about the Company&#8217;s ability to
continue as a going concern within one year after the date that these consolidated financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the Company is unable to generate sufficient funds
to finance the working capital requirements of the Company within the normal operating cycle of a twelve-month period from the date of
these financial statements are issued, the Company may have to consider supplementing its available sources of funds through the following
sources:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other available sources of financing from Singapore banks and other financial institutions or private lender;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support and credit guarantee commitments from the Company&#8217;s related parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity financing. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company can make no assurances that required financings
will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one or all of these events
does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material
adverse effect on the Company and would materially adversely affect its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements have been prepared
assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the
outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923880736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zPF0MauuHu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; <span id="xdx_829_zm7DM01RW2zd">Summary of significant accounting
policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSsB6kvupef4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zwCniqxuvEQk">Basis of presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for information pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z3DChkLqzxSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zF6ALmZSU2v3">Principles of consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the
financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been
eliminated upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A subsidiary is an entity in which the Company, directly
or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint
or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--UseOfEstimates_ziE8lyISxu0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86F_zqhn5KtRmAdi">Use of estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated
financial statements include lease classification and liabilities, right-of-use assets, determinations of the useful lives and valuation
of long-lived assets, estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of deferred tax assets, other provisions and contingencies, estimated fair value of earn-out shares, prepaid forward purchase liability
and private warrants. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zHTqyqU43xT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_zRgjT4PnAlrb">Foreign currency translation and transaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements
of operations and comprehensive income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is United States
Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed in US$. The Company&#8217;s subsidiaries in
Singapore, Vietnam, and Malaysia conduct its businesses and maintain its books and records in the local currency, Singapore Dollars (&#8220;SGD&#8221;),
Vietnamese Dong (&#8220;VND&#8221;), and Malaysian Ringgit (&#8220;MYR&#8221;), as its functional currency, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, for consolidation purposes, assets and
liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation
of Financial Statement&#8221;</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average
rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are
recorded as a separate component of accumulated other comprehensive income (loss) within the statements of shareholders&#8217; equity
(deficit). Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of
cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been
made at the following exchange rates for the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zOSriTLcuXej">Schedule
of foreign currency exchange rates</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Period-end SGD: US$1 exchange rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.34</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.35</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,635.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,855.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end MYR: US$1 exchange rate<span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average SGD: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.38</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.34</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-average VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,409.44</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,935.24</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average MYR: US$1 exchange rate<span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right">*</td><td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</td>
</tr></table>

<p id="xdx_8AE_zKpYTNGnrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_ecustom--NonControllingInterestPolicyTextBlock_zYE5SHVmHsF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zGnl4f1z7Jvi">Non-controlling interests</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the Company&#8217;s non-wholly
owned subsidiaries, a non-controlling interest is recognized to reflect portion of equity that is not attributable, directly or indirectly,
to the Company. The cumulative results of operations attributable to non-controlling interests are also recorded as non-controlling interests
in the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive income (loss). Cash flows
related to transactions with non-controlling interests are presented under financing activities in the consolidated statements of cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq5C34a2q0Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zVLy6WJnWLAc">Segment reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s chief operating decision-maker
is identified as the chief executive officer who reviews financial information presented on a consolidated basis, accompanied by disaggregated
information about revenues by different revenues streams for purposes of allocating resources and evaluating financial performance. Based
on qualitative and quantitative criteria established by Accounting Standards Codification (&#8220;ASC&#8221;) 280, &#8220;Segment Reporting&#8221;,
the Company considers itself to be operating within two operating and reportable segments as set forth in Note 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zotmo0AGUb46" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z5C95HgCqS8b">Cash and restricted cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash represent cash on hand and demand deposits
placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities less
than three months. Restricted cash represents cash held in bank account from 8i which was restricted due to the incomplete
procedures of changing signers as of December 31, 2022. As of the date of the issuance of these financial statements, such
restriction has been lifted and the remaining cash held in bank account has transfer to the Company&#8217;s operating bank account.
Therefore, such restricted cash should be classified as current asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJz3RXlAubL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zPOqmiGawfKf">Accounts receivable, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with its customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial condition, credit
history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.
As of December 31, 2022 and 2021, the Company provided allowance for doubtful accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zlpZMgdcDzik" title="Allowance for doubtful accounts">197,438</span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zGHVaJ0GDus1" title="Allowance for doubtful accounts">80,799</span>, respectively. For the
years ended December 31, 2022 and 2021, the Company did not write off any allowance for doubtful account against the account receivable
balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_z4vpRxO1nkdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_865_zsymQJuC8us1">Other receivables</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables primarily include receivables
from investment from the Company&#8217;s Affordable Home project in Indonesia and employee advance, and refundable deposits from
third party service providers. Management regularly reviews the aging of receivables and changes in payment trends and records
allowances when management believes collection of amounts due are at risk. Accounts considered uncollectable are written off against
allowances after exhaustive efforts at collection are made. $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zEjhEcO3zEY8" title="Other receivables allowance for doubtful account">2,209,825</span>
allowance for doubtful account related to other receivable was recorded and written off for the year ended December 31, 2022. <span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_dxL_c20211231_zsJbaTAAdVvd" title="Other receivables allowance for doubtful account::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">Nil</span></span>
allowance for doubtful account related to other receivable was recorded for the year ended December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_ecustom--PrepaidExpensesAndOtherAssetsPolicyTextBlock_zMunaeL9wrni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zykHIuOSgNul">Prepaid expenses and other current assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
primarily include prepaid expenses paid to services providers, and other deposits. Management regularly reviews the aging of such
balances and changes in payment and realization trends and records allowances when management believes collection or realization of
amounts due are at risk. Accounts considered uncollectable are written off against allowances after exhaustive efforts at collection
are made. As of December 31, 2022 and 2021, <span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20221231_zUw43t5ro5Aj" title="Allowance"><span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20211231_zrGIS7vVUmQd" title="Allowance">no</span></span>
allowance for doubtful account related to prepaid expenses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zXARoPszRa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zaRi3G7tDwil">Property and equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value.
The estimated useful lives are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z0h1r7koBEI2">Schedule
of property and equipment useful lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected useful lives</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment">3</span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment">3 </span>years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment">Shorter of the lease term or 5 years</span></span></td></tr>
  </table>
<p id="xdx_8AE_zLzJMkKXwnGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost and related accumulated depreciation of assets
sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations
and comprehensive income (loss). Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals
and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of
depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows
that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the
carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. </span>For the years ended
December 31, 2022 and 2021, there was <span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20220101__20221231_z6WGodJ7oX5h" title="Impairment of property and equipment"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20210101__20211231_zFIoeZHOdOic" title="Impairment of property and equipment">no</span></span> impairment of property and equipment recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_846_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4QpciiqLaml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zYQ9S0iEeFT8">Intangible assets, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Purchased intangible assets
are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue
to be amortized over the Company&#8217;s best estimate of its useful life as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B5_ztDHNIRRQgA">Schedule
of intangible assets net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Categories</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships">6</span> years</span></td></tr>
  </table>
<p id="xdx_8A5_zehZDb2Ho9u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company amortized the
intangible assets using the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up in accordance
with ASC Topic 350 &#8220;<i>Intangibles - Goodwill and Other</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Separately identifiable intangible
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting
from the use of the asset and its eventual disposition. Measurement of any impairment loss for identifiable intangible assets is based
on the amount by which the carrying amount of the assets exceeds the fair value of the assets. $<span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zjvw1S4emLo" title="Impairment of intangible assets">167,787</span> and <span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20210101__20211231_zFcl6YU05hN" title="Impairment of intangible assets::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0868">nil</span></span> impairment of intangibles
assets was recorded for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zjKgluIGYFj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline"><span id="xdx_86F_zCo9PuvNtMii">Goodwill</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of operations and comprehensive income (loss). Impairment losses on goodwill
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the carrying value of intangible
assets not subject to amortization, including goodwill, to determine whether impairment may exist annually or more frequently if events
and circumstances indicate that it is more likely than not that an impairment has occurred. Management has determined that the Company
has two reporting units within the entity at which goodwill is monitored for internal management purposes. The Company adopted ASU 2017-04
in 2022, which primary goal is to simplify the goodwill impairment test and provide cost savings for all entities. This is accomplished
by removing the requirement to determine the fair value of individual assets and liabilities in order to calculate a reporting unit&#8217;s
&#8220;implied&#8221; goodwill under current GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in ASU 2017-04 eliminate Step 2 of
the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value
of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting
unit&#8217;s carrying amount exceeds its fair value. If fair value exceeds the carrying amount, no impairment should be recorded. Any
loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Impairment losses on goodwill cannot
be reversed once recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When measuring a goodwill impairment loss, an entity
should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit. The ASU contains
an illustration of the simultaneous equations method to demonstrate this, which reflects a deferred tax benefit from reducing the carrying
amount of tax-deductible goodwill relative to the tax basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An entity may still perform the optional qualitative
assessment for a reporting unit to determine if it is more likely than not that goodwill is impaired. However, this ASU eliminates the
requirement to perform a qualitative assessment for any reporting unit with zero or negative carrying amount. Therefore, the same one-step
impairment assessment will apply to all reporting units. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing qualitative assessment on the two
reporting units and determine that it is more likely than not that the fair value of each reporting unit is less than its carrying amount.
Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zxdgRoAYe1c3" title="Impairment loss on goodwill">971,229</span> was recognized for the year ended
December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended December 31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zyAO3IcI2ZW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zzN6hD19dQzg">Impairment for long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 360-10, Long-lived assets,
including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a
significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets
are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use
of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment
is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows
approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, $<span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20220101__20221231_zbzqUjYEcIoc" title="Impairment of long-lived assets">0.2</span> million and <span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_dxL_c20210101__20211231_ziwZdHFyfgN4" title="Impairment of long-lived assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0878">nil</span></span> impairment of long-lived assets was recognized, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zoHy4sXBp72b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zCKIbY0JNRSj">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s
own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside
of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For issued or
modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of
equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that
its warrants qualify for equity accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
completion of the business combination, all of 8i&#8217;s public and private warrants remain outstanding were replaced by the Company&#8217;s
public and private warrants. The Company treated such warrants replacement as a warrant modification and no  incremental fair value
was recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_ecustom--ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_zAbr4mxqpXwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_z0xs9mPGPiI1">Forward Purchase Receivables and Prepaid Forward
Purchase Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The
Company recorded Forward Purchase Receivables on its consolidated balance sheets of $<span id="xdx_90C_ecustom--ForwardPurchaseReceivables_iI_c20221231_zufvipqGptB7" title="Forward purchase receivables">21,892,527</span>
as of December 31, 2022 to account for the Prepayment Amount of the Forward Purchase Agreement, as discussed in Note 11. The
Prepayment Amount will be held in a deposit account until the Valuation Date (the second anniversary of the closing of the Business
Combination, subject to certain acceleration provisions). At the Maturity Date, the Sellers are entitled to received $2.50 per
Recycled Shares (&#8220;Maturity Consideration&#8221;) in cash or in shares. As of December 31, 2022, no shares were sold after
Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In
connection with the Forward Purchase Agreement, the Company recognized a liability in accordance with ASC 480-10-25-8 as the Company
has the obligation to pay cash to settle the maturity consideration, referred to herein as the &#8220;prepaid forward purchase
liability&#8221; on its consolidated balance sheets of $<span id="xdx_909_ecustom--PrepaidForwardPurchaseLiability_iI_c20221231_zgkSaEqRPUdh" title="Purchase liability">20,321,053</span>
as of December 31, 2022. Refer to Note 11 for further detail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zHa2YQMTAD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zQWedSe4xpl2">Revenue recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the revenue accounting requirements
of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;Accounting Standards
Codification (&#8220;ASC&#8221;) 606&#8221;). The core principle underlying the revenue recognition of this ASU allows the Company to
recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and
determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers
to a customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To achieve that core principle, the Company applies
five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for a contract with a customer
when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial
substance and collectability is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue recognition policies for each type of revenue
stream are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates on a unified technology
health care platform which provide a full continuum of healthcare services integrated with healthcare data analytics to drive
improved outcomes for patients. The Company operates the medical services on a business-to-business (B2B) platform, and serves the
corporate customers involved in various industries. The Company is primarily generating revenue on a per healthcare visit basis for
specialty medical visits for specialist treatment such as cardiology, dermatology and etc, at the time which the single performance obligation was satisfied. Such fees are paid by the corporate
customers on behalf of their employees. <span style="background-color: white">The Company generally bills their corporate customers
for the healthcare visit services on a weekly basis, or in arrears depending on the service, with payment terms generally between 30
to 90 days. There are not significant differences between the timing of revenue recognition and billing. Consequently, the Company
has determined that the Company&#8217;s contracts do not include a financing component. </span>Revenue is recognized in an amount
that reflects the consideration that is expected in exchange for the service at a point in time at the time of the visit. In
addition, the Company&#8217;s contracts do not generally contain refund provisions for fees earned related to services
performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for medical service revenue on
a gross basis as the Company is acting as a principal in these transactions and is responsible for fulfilling the promise to provide the
specified services, which the Company has control of the services and has the ability to direct the service providers to be performed
to obtain substantially all the benefits. In making this determination, the Company also assesses whether it is primarily obligated in
these transactions, is subject to inventory risk, has latitude in establishing prices, or has met several but not all of these indicators
in accordance with ASC 606-10-55-36 through 40.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the medical services revenue
when the control of the specified services is transferred to its customer, which at a point in time at the time after completion of the
visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also operates on a general practice clinic
and generating such revenue on a per healthcare visit basis. Revenues are recognized when the visits are completed at a point in time
at the time of the visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company purchases, sells, and installs facial
recognition and temperature measurement monitor system to corporate customer, where the product and the installation are interrelated
and are not capable of being distinct since the customer cannot benefit from the product or installation either on its own. The Company
recognized the products revenue when control of the product is passed to the customer, which is the point in time that the customers are
able to direct the use of and obtain substantially all of the economic benefit of the goods after the installation by the Company&#8217;s
technician. The transfer of control typically occurs at a point in time based on consideration of when the customer has an obligation
to pay for the goods, and physical possession of, legal title to, and the risks and rewards of ownership of the goods has been transferred,
and the customer has accepted the goods. Revenue is recognized net of estimates of variable consideration, including product returns,
customer discounts and allowance. Historically, the Company has not experienced any significant returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied over a period of
time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides property management services
in shopping malls, business office building, or residential apartments to all tenants and property owners. Property management services
include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional
services and also include security property management services provided to all tenants and property owners. Each of the two services
is within separate agreements. The Company identified common area property management services as a single performance obligation as the
kinds of service in the contract are not capable of being distinct and identified the security management services as another single performance
obligation as there is only one service that is to provide security services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the common area property management
revenue and security property management revenue on a straight-line basis over the terms of the common area property management agreement
and security property management agreement, generally over one year period because its customer simultaneously receives and consumes the
benefits provided by the Company throughout the performance obligations period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to apply the practical expedient
to expense costs as incurred for incremental costs to obtain a contract when the amortization period would have been one year or less.
As of December 31, 2022 and 2021, the Company did not have any contract assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized advance payments from its customer
prior to revenue recognition as contract liability until the revenue recognition performance obligation are met. As of December 31, 2022
and 2021, the Company did not have any contract liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zwogmTEuY6ql">Schedule
of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">6,001,439</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">5,010,837</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; general practice</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">63,794</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,712</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practice (related parties)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,065,368</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,728,189</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,046</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">257,841</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management service &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,919,335</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,508,663</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management service &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">844,960</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,049,857</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management service</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,764,295</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,558,520</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,840,709</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,544,550</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AF_zwNQtZ3F5UWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cost of revenues</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical supplies
purchased and medical service was provided by Cadence Health Pte. Ltd., a related party, prior to March 2022. Medical supplies purchased
and medical service provided by the third party service providers were insignificant prior to March 2022. Beginning in April 2022, cost
of revenues mainly consists of medical supplies purchased and medical service are provided by third party service providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical product
or equipment purchased for resale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of labor expenses
incurred attributable to property management service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of cost of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zIQd8Hn75Yi9">Schedule
of cost of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">2,995,778</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">46,849</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; specialty care (related party)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practices</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">45,549</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">427,908</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,532,826</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,824,459</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">59,391</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">167,202</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management services &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,210,703</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,461,981</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management services &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">683,593</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">846,555</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management services</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,894,296</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,308,536</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cost of revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,486,513</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,300,197</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A2_z0IzxNUwrZ11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zjMJr2QoqkRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zr5XE1q82T8i">Advertising costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising is mainly through online and offline promotion
activities. Advertising costs amounted to $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zszyCFvLJSLj" title="Advertising cost">21,795</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_c20210101__20211231_zsS5Uxd9nK9j" title="Advertising cost">270,361</span> for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7X9jQrXD66f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zpOYfJHLeqJh">Research and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses include salaries
and other compensation-related expenses to the Company&#8217;s research and product development personnel, and related expenses for the
Company&#8217;s research and product development team. Research and development expenses amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zspS1u46hib6" title="Research and Development cost">17,209</span> and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zxLEZpIcrsY9" title="Research and Development cost">129,265</span> for the years
ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_ecustom--DefinedContributionPlanPolicyTextBlock_zz7xjkCOkr5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_862_zCUiQA3XaXMi">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full-time employees of the Company are entitled
to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages
of the employees&#8217; respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and
make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_z0ATFRFJrw8f" title="Employee expenses">505,591</span> and $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231_zXCCuwdZ0eO9" title="Employee expenses">574,535</span>
for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The related contribution plans include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Singapore subsidiaries</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Central Provident Fund (&#8220;CPF&#8221;) &#8211;
<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--CentralProvidentFundMember_zUu8bYl0NPrk" title="Employee plan description">17.00% based on employee&#8217;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase</span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Skill Development Levy (&#8220;SDL&#8221;) &#8211;
<span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zJvENAmvNVCg" title="Employee plan description">up to 0.25% based on employee&#8217;s monthly salary capped $<span id="xdx_906_eus-gaap--SalariesAndWages_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zlsgb4ysvVoj" title="Monthly salary">8.3</span> (SGD <span id="xdx_90C_eus-gaap--SalariesAndWages_pn4n6_uSGD_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zO9j3tWmsHil" title="Monthly salary">11.25</span>)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vietnam subsidiary</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Social Insurance Fund (&#8220;SIF&#8221;) &#8211;
<span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zWfExI0ZcJOl" title="Employee plan description">20% based on employee&#8217;s monthly salary</span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Trade Union Fee &#8211; <span id="xdx_907_ecustom--TradeUnionFeePercentage_iI_pid_dp_c20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zL0wDN9ABgB" title="Trade union fee">2.00%</span> of SIF</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84F_ecustom--GoodsAndServicesTaxesPolicyTextBlock_ztdAswiUWax5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zk8Bn1NLCiC6">Goods and services taxes (&#8220;GST&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue represents the invoiced value of service,
net GST. The GST are based on gross sales price. GST rate is generally 7% in Singapore. Entities that are GST general taxpayers are allowed
to offset qualified input GST paid to suppliers against their output GST liabilities. Net GST balance between input GST and output GST
is recorded in tax payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zkrVaXBFCHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_z96DWJzY5po1">Income taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance
with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are
non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Deferred tax
is calculated using the balance sheet liability method in respect of temporary differences arising from differences between the carrying
amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis. In principle, deferred tax
liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable
that taxable income will be utilized with prior net operating loss carried forwards using tax rates that are expected to apply to the
period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when
it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion or all of the deferred tax assets will not be utilized. Current income taxes
are provided for in accordance with the laws of the relevant tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit
only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is <span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zk2Ix9U7GPQk" title="Income tax likelihood description">greater than 50% likely of being realized
on examination</span>. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. No penalties and
interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021. <span style="background-color: white">As
of December 31, 2022, the tax returns of the Company&#8217;s Singapore entities for the calendar year from 2019 through 2022 remain open
for statutory examination by Singapore tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognize interest and penalties related to unrecognized tax
benefits, if any, on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties
are included on the related tax liability line in the consolidated balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts much of its business activities
in Singapore and is subject to tax in its jurisdiction. As a result of its business activities, the Company&#8217;s subsidiaries file
separate tax returns that are subject to examination by the foreign tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zLbU2af5srSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zJZj3giURid">Comprehensive income (loss)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive income (loss) consists of two components,
net income and other comprehensive income. Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under
GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net income. Other comprehensive income (loss) consists
of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zMCDFPoIvl4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zzedsnCQU4vf">(Loss) earnings per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes (loss) earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is
measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect
on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e.,
those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates basic and diluted (loss)/earnings
per share as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zRuz5Eat8IOc" style="display: none">Schedule
of basic and diluted earnings per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Years Ended<br/>
December 31</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net (loss) income</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(24,949,246</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">900,396</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less: Net (income) loss attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(65,124</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">35,567</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Net (loss)/income attributable to common shareholders, basic</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,884,122</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">864,829</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average number of shares outstanding, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">12,029,656</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">9,253,333</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">(Loss)/Earnings per share, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(2.07</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">0.09</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zuN25CFHeBDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of December
31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants are convertible into <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zOB5W99vo8ma" title="Antidilutive shares">1,411,725</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zk0BBegFiS8l" title="Antidilutive shares">4,458,625</span>
of the Company&#8217;s ordinary shares, respectively, were not included in the computation of dilutive loss per share because the inclusion
of such convertible notes and warrants would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzVOHzfqt77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zbaSlXmfzUo">Fair value measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received
for an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Valuation
techniques maximize the use of observable inputs and minimize the use of unobservable inputs. When determining the fair value measurements
for assets and liabilities, we consider the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability. The following summarizes the three levels of inputs required to
measure fair value, of which the first two are considered observable and the third is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Unadjusted quoted prices in active markets
for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Unobservable inputs that are supported by
little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value for certain assets and liabilities
such as cash and restricted cash, accounts receivable, net, other receivables, prepaid expenses and other current assets, loan to third-party,
short-term loans, promissory note, convertible notes, accounts payable, other payables and accrued liabilities, and tax payables have
been determined to approximate carrying amounts due to the short maturities of these instruments. The Company believes that its long-term
loan to third party approximates the fair value based on current yields for debt instruments with similar terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zkN130Ffe2af" style="display: none">Schedule
of fair value hierarchy of financial liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value at</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Fair Value Measurement at</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Prepaid forward purchase liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zNGpWR5NLY12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zBcQXMqTTOY2" style="display: none">Schedule of reconciliation of financial
liability measured at fair value on a recurring basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">7,409,550</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Change in fair value of prepaid forward purchase liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">12,911,503</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">20,321,053</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zoLBIGo0IqXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z6axbXx4rODj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_861_zbRXPdj5KhW6">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company accounts for leases in accordance with ASC 842. </span>The Company entered into two agreements as a lessee to lease office equipment
for general and administrative operations. If any of the following criteria are met, the Company classifies the lease as a finance lease:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease term is for 75% or more of the remaining economic life of the underlying asset, unless the commencement date falls within the last 25% of the economic life of the underlying asset;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The present value of the sum of the lease payments equals or exceeds 90% of the fair value of the underlying asset; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Leases that do not meet any
of the above criteria are accounted for as operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company combines lease
and non-lease components in its contracts under Topic 842, when permissible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Finance
and operating lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. Since the implicit rate for the Company&#8217;s leases is not readily determinable,
the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present
value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized
basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its finance or operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company
has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term
of twelve months or less. Its leases generally do not provide a residual guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
finance or operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease
term for operating lease. Meanwhile, the Company recognizes the finance leases ROU assets and interest on an amortized cost basis. The
amortization of finance ROU assets is recognized on an accretion basis as amortization expense, while the lease liability is increased
to reflect interest on the liability and decreased to reflect the lease payments made during the period. Interest expense on the lease
liability is determined each period during the lease term as the amount that results in a constant periodic interest rate of the </span>office
equipment <span style="background-color: white">on the remaining balance of the liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset
may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from
the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows. For the years ended December 31, 2022 and 2021, </span>the Company did not recognize impairment loss on its finance
and operating lease ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--RelatedPartyPolicyTextBlock_zW3ikgaDVMkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zkWRq3C9mr3e">Related parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject
to common control or common significant influence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zMhejxndWpM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zNRPmrsYJrIc">Recent accounting pronouncements not yet adopted</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging
growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the
adoption of these accounting standards until they would apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, which
is an update to ASU Updated No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive accounting
model on revenue recognition for contracts with customers. The amendments in this update require that an entity (acquirer) recognize and
measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective
for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted,
including adoption in an interim period. The Company has adopted this standard on January 1, 2023, and the adoption did not have a material
impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the FASB issued ASU 2019-05, which is
an update to ASU Update No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured
at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial
Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting
for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized
cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The
amendments in this Update address those stakeholders&#8217; concerns by providing an option to irrevocably elect the fair value option
for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase
comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets.
Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13
while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which
to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies
applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after
December 15, 2022. In March 2022, the FASB issued ASU No. 2022-02, which is to (1) eliminate the accounting guidance for TDRs by creditors
in Subtopic 310-40, Receivables&#8212;Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan
refinancings and restructurings by creditors when a borrower is experiencing financial difficulty, and (2) disclose current-period gross
write offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, Financial
Instruments&#8212;Credit Losses&#8212;Measured at Amortized Cost. ASU 2019-05 is effective for the Company for annual and interim reporting
periods beginning January 1, 2023 as the Company is qualified as an emerging growth company. The Company has adopted this standard on
January 1, 2023, and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfmIHjiMvRu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zaJ77kGpf1n8">Recently adopted accounting pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, &#8220;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. The amendments in this Update simplify the accounting for income
taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments
in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years
beginning after December 15, 2022. Early adoption of the amendments is permitted, including adoption in any interim period for (1) public
business entities for periods for which financial statements have not yet been issued and (2) all other entities for periods for which
financial statements have not yet been made available for issuance. An entity that elects to early adopt the amendments in an interim
period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity
that elects early adoption must adopt all the amendments in the same period. The Company has adopted this standard on January 1, 2022,
and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the Financial Accounting Standards
Board issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities
and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for
convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer
conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment.
The Company early adopted this ASU on January 1, 2022, and the adoption did not have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-08, &#8220;Codification
Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs&#8221;. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021.
Early adoption was permitted, including adoption in an interim period. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10, &#8220;Codification
Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve the codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed.
The amendments also clarify guidance so that an entity can apply the guidance more consistently. ASU 2020-10 is effective for the Company
for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or
interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively.
An entity should apply the amendments at the beginning of the period that includes the adoption date. The adoption of this standard on
January 1, 2022 did not have a material impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive income (loss) and statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929201440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ReverseRecapitalizationTextBlock', window );">Reverse Recapitalization</a></td>
<td class="text"><p id="xdx_802_ecustom--ReverseRecapitalizationTextBlock_zbr9crjZOD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; <span id="xdx_827_zm4Ug66kEmEa">Reverse Recapitalization</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022, the Company consummated the
Business Combination contemplated by the SPA between 8i, EHL, Watermark, and Kwong Yeow Liew, dated April 11, 2022 and amended May 30,
2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination between 8i and EHL was effected by the
purchase by 8i of all of the issued and outstanding shares of EHL from Watermark, resulting in EHL becoming a wholly owned subsidiary
of 8i.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Upon the consummation
of the Business Combination, the following events contemplated by the SPA occurred, based on EUDA&#8217;s capitalization as of November
17, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20221117_zl1rg65nScSj" title="Ordinary shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221117_zlMHyCCRhM2a" title="Ordinary shares, outstanding">1,500,000</span></span> issued and outstanding shares of EHL were converted into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20221116__20221117_zGzbKo7wh5Sk" title="Converted shares">14,000,000</span> shares of the Company&#8217;s <span id="xdx_90A_eus-gaap--CommonStockNoParValue_iI_do_c20221117_z6xJXm9DpvYl" title="Ordinary shares, par value">no</span> par value ordinary shares after giving effect to the exchange ratio of <span id="xdx_906_ecustom--ExchangeRatioPerShare_uUSDPShares_c20221116__20221117_zcPGHtg6aWJf" title="Exchange ratio">9.33</span> (&#8220;Exchange Ratio&#8221;); and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the entitlement of <span id="xdx_901_eus-gaap--ExcessStockSharesIssued_iI_c20221117_zQsXMCyjvlM8" title="Earnout shares">4,000,000</span> shares (&#8220;Earnout Shares&#8221;) of the Company&#8217;s no par value ordinary shares  issued to the Seller subject to the following four triggering events:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zLL1ZnV9BSq1" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Fifteen Dollars ($<span id="xdx_90C_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zTRb6G0BGPIl" title="Share price">15.00</span>) after the Closing Date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zPTwYDZFtCOk" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Twenty Dollars ($<span id="xdx_903_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_z8t70shXeXW2" title="Share price">20.00</span>);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z5Yylc7ZgxFa" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zf0MctxrLzN1" title="Revenue">20,100,000</span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zHd7pW60YWxe" title="Net income">3,600,000</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zteS9tPEwaW2" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z1mvoCyzIofg" title="Revenue">40,100,000</span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z2EiWSDrhp" title="Net income">10,100,000</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In connection
with the closing the Business Combination:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90D_eus-gaap--CommonStockNoParValue_iI_do_c20221117_zB6icRiCHLBk" title="Ordinary shares, par value">no</span> par value public ordinary shares of <span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20221117_zlx85hd0PEuk" title="Public ordinary shares">2,591,545</span>, net of the redemption of <span id="xdx_90E_eus-gaap--TemporaryEquitySharesIssued_iI_c20221117_ztrqDzstJkka" title="Redemption shares">6,033,455</span> shares of Company&#8217;s no par value ordinary shares, remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90D_ecustom--PrivateOrdinarySharesNoParValue_iI_do_c20221117_z9ok4XwrjGW2" title="Private ordinary shares, par value">no</span> par value private ordinary shares of <span id="xdx_900_ecustom--PrivateOrdinarySharesOutstanding_iI_c20221117_z0Cn5NB7sB52" title="Private ordinary shares, outstanding">292,250</span> remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s <span id="xdx_90F_ecustom--FounderSharesNoParValue_iI_do_c20221117_zpC1DFH1mZ1a" title="Founder shares, par value">no</span> par value founder shares of <span id="xdx_90F_ecustom--FounderSharesOutstanding_iI_do_c20221117_zdc0DNfpavY9" title="Founder shares, outstanding">2,156,250</span> remained outstanding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">all 8i&#8217;s rights, consisting of <span id="xdx_90D_ecustom--PublicRightsShares_iI_do_c20221117_zMv0Vnha75J2" title="Public rights shares">8,625,000</span> public rights and <span id="xdx_906_ecustom--PrivateRightsShares_iI_do_c20221117_zK6X1bDKNf34" title="Private rights shares">292,250</span> private rights, automatically converted into an aggregate of <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_do_c20221116__20221117_z5sJxeneivNa" title="Converted shares">891,725</span> of the Company&#8217;s no par value ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--BusinessAcquisitionAxis__custom--BusinessCombinationMember_z96J0QkqAHk3" title="Ordinary shares, issued">200,000</span> shares of the Company&#8217;s no par value ordinary shares were issued to a service provider in connection with the business combination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zerllM4TxsJe" title="Ordinary shares, issued">60,000</span> shares of the Company&#8217;s no par value ordinary shares were issued to a service provider in connection with the closing of transactions contemplated pursuant to certain share purchase agreement. Such issuance of the ordinary share serves the purpose of securing the repayment of $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20221116__20221117_zT4OZU8qZZ4a" title="Repayments of convertible promissory note">300,000</span> convertible promissory note to the service provider;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p id="xdx_89A_ecustom--ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_zBeeqGaFG5A7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued and outstanding immediately following the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B7_zVgBvJgIzF69" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of shares issued and outstanding reverse recapitalization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zb0lTmQofba6" style="border-bottom: Black 1.5pt solid; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_z2g0qVWdUx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">11,073,500</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RedemptionOfOrdinaryShares_z69JroSkZSC6" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6,033,455</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ConversionOfStockSharesConverted1_zVcyOG4GNiY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">891,725</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zAq1VTpujEE7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued to service providers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">260,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_zMYXv5SiTefh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of EHL ordinary shares into 8i ordinary shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,000,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_z7rRd8Ocj1e9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares outstanding</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">20,191,770</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AB_z29Zb4pG6xHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EHL
was determined to be the accounting acquirer given EHL effectively controlled the combined entity after the SPAC Transaction. The transaction
is not a business combination because 8i was not a business. The transaction is accounted for as a reverse recapitalization, which is
equivalent to the issuance of shares by EHL for the net monetary assets of 8i, accompanied by a recapitalization. EHL is determined as
the accounting acquirer and the historical financial statements of EHL became the Company&#8217;s historical financial statements, with
retrospective adjustments to give effect of the reverse recapitalization. The net assets of 8i were recognized as of the closing date
at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Merger are those of EHL and EHL&#8217;s
operations are the only ongoing operations of EHL. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In connection
with the Reverse Recapitalization, the Company raised approximately $<span id="xdx_908_ecustom--ProceedsFromReverseRecapitalization_pn5n6_c20221116__20221118_zG1meDfBrGfl" title="Proceeds from the Reverse Recapitalization">1.3</span> million of proceeds, presented as cash flows from financing activities,
which included the contribution of approximately $<span id="xdx_90E_ecustom--FundsHeldInTrustAccount_pn5n6_c20221116__20221118_zsSJCLygQ6L6" title="Funds held in trust account">87.1</span> million of funds held in 8i&#8217;s trust account, approximately $<span id="xdx_90D_ecustom--FundsHeldInOperatingCashAccount_pn5n6_c20221116__20221118_zNkgJLfaW1bj" title="Funds held in operating cash account">0.2</span> million of
cash held in 8i&#8217;s operating cash account, net of approximately $<span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20221116__20221118_zsBAqBTbunOf" title="Amount paid to redeem public shares">60.8</span> million paid to redeem <span id="xdx_90E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20221116__20221118_zK1FPIE4gAa2" title="Redeem public shares">6,033,455</span> public shares of 8i&#8217;s
ordinary shares, approximately $<span id="xdx_909_eus-gaap--PaymentsOfFinancingCosts_pn5n6_c20221116__20221118_zKWDNB4YQfL4" title="Payments of transaction costs">3.0</span> million in transaction costs incurred by 8i, approximately $<span id="xdx_909_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_pn5n6_c20221116__20221118_zGrn3atMY60j" title="Payments of forward purchase agreements">21.9</span> million prepayment of two forward
purchase agreements, and repayments of a promissory note in the amount of $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_pn4n6_c20221116__20221118_zgOIUP1sDwA" title="Repayments of promissory note related party">0.3</span> million issued to 8i&#8217;s related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_893_ecustom--ScheduleOfFinancialStatementsOfReverseRecapitalization_zsrzfqySb78h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table reconcile the elements of the Reverse Recapitalization to the consolidated statements of cash flows and the changes in shareholders&#8217;
equity (deficit):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zs643UtKtaB4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of financial statements of reverse recapitalization</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221116__20221118_zOxJtSiMfxCd" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November 18, 2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FundsHeldInTrustAccount_zehMN4o63yAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in 8i&#8217;s trust account</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">87,074,185</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FundsHeldInOperatingCashAccount_zt01GCUOfkn2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Funds held in 8i&#8217;s operating cash account</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">248,499</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_iN_di_zzzzDCZVY0F5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: amount paid to redeem public shares of 8i&#8217;s ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(60,839,550</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_iN_di_zpx87L2Bo0d3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payments of transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,965,646</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_iN_di_zA7C4IHEYhW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: payments of forward purchase agreements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21,892,527</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_zSoD2cgzRQia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: repayments of promissory note &#8211; related party of 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(300,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromReverseRecapitalizations_ztFWhTtAiet" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,324,961</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromUnpaidDeferredUnderwritingFee_iN_di_zWqlMe7o9Z7i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unpaid deferred underwriting fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,113,125</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromUnpaidTransactionCostsIncurred_iN_di_zgIdS356acO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unpaid transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(382,600</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsForMergerRelatedCosts_iN_di_z2I5Gil7nk79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,305,580</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--NoncashNetAssetsAssumedValue_zX0HEBOPqic6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Add: non-cash net assets assumed from 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,387,803</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfOrdinarySharesUponTheReverseRecapitalization_zXq9Lb4MbIEj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net contributions from issuance of ordinary shares upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">11,911,459</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AB_ziutALg4KB1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares and corresponding capital amounts and all
per share data related to EHL&#8217;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the <span style="background-color: white">Exchange Ratio</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ReverseRecapitalizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ReverseRecapitalizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668931404976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposition of Subsidiary<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureDispositionOfSubsidiaryAbstract', window );"><strong>Disposition Of Subsidiary</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DispositionOfSubsidiariesTextBlock', window );">Disposition of Subsidiary</a></td>
<td class="text"><p id="xdx_800_ecustom--DispositionOfSubsidiariesTextBlock_zKMBLSoqlxdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_82F_zOiVGXeRmOC1">Disposition of Subsidiary</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline">Disposition of TGC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 1, 2022, SEMA, the Company&#8217;s wholly
owned subsidiary, sold <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zojCpiWNxB9a" title="Ownership interest">100</span>% of the equity interest in TGC to an unrelated individual for a total consideration of SG$ <span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220227__20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_zU32cBat6QA8" title="Consideration received">1.0</span> (&#8220;TGC
transaction&#8221;). TGC is not a significant subsidiary and the disposition of all of the equity interests in TGC did not constitute
a strategic shift that would have a major effect on the Company&#8217;s operations and financial results. As a result, the results of
operations for TGC were not reported as discontinued operations under the guidance of ASC 205 &#8220;<i>Presentation of Financial Statements.</i>&#8221;
For the year ended December 31, 2022, the Company recognized a gain of $<span id="xdx_900_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_z1eew5RitL97" title="Gain loss on disposal of deficit interest">30,055</span> on the disposal of all of the deficit interests in TGC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureDispositionOfSubsidiaryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureDispositionOfSubsidiaryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DispositionOfSubsidiariesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposition of subsidiaries [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DispositionOfSubsidiariesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668931208416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndNontradeReceivableTextBlock', window );">Accounts receivable, net</a></td>
<td class="text"><p id="xdx_802_eus-gaap--AccountsAndNontradeReceivableTextBlock_zmGbnm6GsoY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 6 &#8211; <span style="background-color: white"><span id="xdx_826_zu9ssnZ29rO6">Accounts
receivable, net</span></span></b></p>

<p id="xdx_892_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zMhK0HSTMdbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BC_zHzDNUZ44Kuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of accounts receivable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zcMItTl2T9xl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/>
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_z3ijY3QGHvng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/>
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCztie_z3ep6qxzal53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts receivable<span id="xdx_F43_zWaGns4rARcb">*</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">2,048,941</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">1,883,115</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCztie_zRK6tXjbUUog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(197,438</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(80,799</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCztie_zkvPItfGhR1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,851,503</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,802,316</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zs9ul92a2oP" style="width: 35pt; text-align: right">*</td><td id="xdx_F18_zJxNpVRPZkM1" style="text-align: justify">As of December 31, 2022 and 2021, accounts receivable of up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable">0.6</span></span> million (SGD
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable">0.8</span></span> million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).</td>
</tr></table>

<p id="xdx_8A5_zPN22OAMO2o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_ztLygfgLjhBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from account receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zMTDzXo5MK5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of movements of allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20220101__20221231_zcovL1rvmRAg" style="width: 16%; text-align: right" title="Beginning balance">80,799</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20210101__20211231_zcvGX2FYAFPf" style="width: 16%; text-align: right" title="Beginning balance">37,898</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Addition</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20220101__20221231_z8XAct8nYU8j" style="text-align: right" title="Addition">116,156</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20210101__20211231_z5DdUW9hgWq7" style="text-align: right" title="Addition">43,804</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20220101__20221231_za86uPhprpbf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect">483</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20210101__20211231_znwo3yjlZrM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect">(903</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20220101__20221231_zpF4Zltoi4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">197,438</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20210101__20211231_zVJIDX9L3fo1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">80,799</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AD_zYIOiCa78Gkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNontradeReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI https://asc.fasb.org/topic&amp;trid=2196771<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -URI https://asc.fasb.org/topic&amp;trid=82887179<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNontradeReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668931401456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesTextBlock', window );">Other receivables</a></td>
<td class="text"><p id="xdx_806_eus-gaap--FinancingReceivablesTextBlock_z5HnZ5pwRvYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><b>Note
7 </b></span><b>&#8211; <span style="background-color: white"><span id="xdx_828_zhvb8czeQFGl">Other receivables</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span style="background-color: white"><span>&#160;</span></span></b></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_gL3SOCLFFRCTT-SYHD_zLU1wdUknP36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8B4_zm2o4zebu17c" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zDKDXeHiu4z4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z99WFoJqh6Fg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DivestmentReceivable_iI_zJLBvk7YMAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4E_zsEu6CSI4vDd" style="width: 60%; text-align: left">Receivable from divestment (1)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">3,818,776</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--EmployeeAdavance_iI_zcID7PtGmN9l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,695</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,803</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesGrossCurrent_iI_zbuKkhWbI621" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">772</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">250</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherReceivables_iTI_zrj7Lt6AQ06c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,467</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,821,829</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherReceivablesNetNonCurrent_iI_zUGyuvchwHX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables &#8211; non-current</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(1,830,603</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_zY5ijrVtuv4a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Other receivables &#8211; current</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">7,467</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,991,226</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A2_zGquBdtFUhBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_89E_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zIhFE6hXSJTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from other receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8B6_zqZDXVequpWg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2021</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20220101__20221231_zxKXdlcdjFL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20210101__20211231_zmCGZGwzcF25" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20220101__20221231_ze2dQp5ImR9c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,209,825</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20210101__20211231_z3xmEJVhb1Xh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Write-off</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20220101__20221231_zf6OO450jHxj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,209,825</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20210101__20211231_zaud4Oz7a86f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20220101__20221231_zw6SVgzdNWad" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20210101__20211231_zzbirWUHir8g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zJe59GrryAxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<div id="xdx_C01_gL3SOCLFFRCTT-SYHD_z0qD234omzY7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zd6Pvz8IPeDk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zmtH88VrDzji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#8217;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" title="Investment amount">1.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" title="Investment amount">2,580,000</span>)
    in BPT&#8217;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#8220;Agreement&#8221;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#8217;s
    investment amounted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" title="Investment owned face amount">1,913,096</span>
    (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" title="Investment owned face amount">2,580,000</span>),
    and compensated UGI with the additional amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount">1,905,681</span>(SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount">2,570,000</span>).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received">0.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received">1,200,000</span>)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance">2.8</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance">3,950,000</span>)
    in eight equal quarterly installments with annual <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</span> As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount">0.7</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount">987,500</span>).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.</span></td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C05_gL3SOCLFFRCTT-SYHD_zbdyBPC29sF7">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196816<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929263248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyMk2kn5E6Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 8 &#8211; <span id="xdx_825_zf6b8YFI3Hs8">Property
and equipment, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z5mSdoucpmWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zHVhLfbGLoI5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of property and equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zpTMbdGlLwJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_ztk0nqQP2YN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zG25ePGsgDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office equipment</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">148,387</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">144,051</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zd23T65SSPy2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,724</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">15,917</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zll8szp4GZf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvement</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">2,217</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">20,704</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzHdg_zvTRCTRytXkk" style="vertical-align: bottom; background-color: White">
    <td>Subtotal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">153,328</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">180,672</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzHdg_zHrtvnki6eN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(121,700</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(123,745</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzHdg_zUAXZg8rAIVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">31,628</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">56,927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_z1WWtsDoBedj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2022 and 2021 amounted to $<span id="xdx_904_eus-gaap--Depreciation_c20220101__20221231_zFYeemxvYkSi" title="Depreciation expense">23,347</span> and $<span id="xdx_900_eus-gaap--Depreciation_c20210101__20211231_zpPXFA3mEZFi" title="Depreciation expense">34,523</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929352560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets, net</a></td>
<td class="text"><p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGHgwodzg8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; <span id="xdx_822_z4rXifXJO9Y7">Intangible assets, net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrWdLnkeBuS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Intangible assets
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zheLd0sPrDVe" style="display: none">Schedule
of intangible assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zcyIRETse008" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_zzE61IlI6fNe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedCustomerRelationshipsGross_iI_maFLIANzay9_zRwiwhzpsrZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Customer relationships</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">650,102</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">646,246</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzay9_zhbXYS2amUw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(477,584</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(356,284</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Impairment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zTEvWZD4UnYd" title="Less: Impairment">167,787</span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_904_ecustom--ExchangeRateEffect_c20220101__20221231_z2NPAqwNwf1b" title="Exchange rate effect">4,731</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzay9_zFsJe5o6sdB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">289,962</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AA_zvCsgAwYDaag" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense for the years ended December
31, 2022 and 2021 amounted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zWme17rtLEp6" title="Amortization expense">115,907</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_z0uKtxehJye5" title="Amortization expense">162,825</span>, respectively. The management performed quantitative assessment and determined to
fully impair the carrying value of intangible assets due to the Company&#8217;s limited business development and uncertain surrounding
economic environment. For the year ended December 31, 2022, The Company recorded $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zxhS0JQC4AGj" title="Impairment loss">167,787</span> impairment loss related to intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929263248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_807_eus-gaap--GoodwillDisclosureTextBlock_zy8t5lF1Tp49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 &#8211; <span id="xdx_822_zoKzAW3jSGDl">Goodwill</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfGoodwillTextBlock_zTmbmb4e5ynd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The
changes in the carrying amount of goodwill from Melana reporting unit and Tri-Global reporting unit are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zaVXBpQzDt7b" style="display: none">Schedule
of goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--BusinessAcquisitionAxis_custom--MelanaInternationalPteLimitedMember_zYD13vnzyCac" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Melana</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--BusinessAcquisitionAxis_custom--TriGlobalSecurityPteLimitedMember_zBUWt9d98jUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tri-Global</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zvGbVsnACRs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--Goodwill_iS_z4FHyz86k8F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Balance as of December 31, 2020</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">539,286</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">473,344</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">1,012,630</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_zspcihJYudB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(10,621</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(9,323</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(19,944</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--Goodwill_iS_zbBKMWrIpF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">528,665</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">464,021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">992,686</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--Goodwill_iS_zbqKn29MhMlf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">528,665</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">464,021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">992,686</td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_z74a0yqnTzp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(11,427</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(10,030</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21,457</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_iN_di_znOKDbByjexd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Impairment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(517,238</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(453,991</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(971,229</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--Goodwill_iE_zF56Pdc9x6Ca" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220101__20221231_eus-gaap--Goodwill_iE_zSB1sptjUfLg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8AA_zZG1P5u3sWu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021,
the Company record $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_z4iOefuPl8Ih" title="Impairment loss">971,229</span>
and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zwAbYirFwWy3" title="Impairment loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1357">nil</span></span> impairment loss on good will, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929298064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Forward Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureForwardPurchaseAgreementsAbstract', window );"><strong>Forward Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ForwardPurchaseAgreementsDisclosureTextBlock', window );">Forward Purchase Agreements</a></td>
<td class="text"><p id="xdx_805_ecustom--ForwardPurchaseAgreementsDisclosureTextBlock_zcvGACHMS2T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 &#8211; <span id="xdx_82E_zJCLxrxZRVS6">Forward Purchase Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
November 9, 2022 and November 13, 2022, 8i, EHL, and certain institutional investors, HB Strategies LLC (the &#8220;Seller 1&#8221;) and
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (&#8220;Seller 2&#8221;) entered into an agreement (the &#8220;Prepaid
Forward Agreement 1&#8221; and &#8220;Prepaid Forward Agreement 2&#8221;), respectively, for an equity prepaid forward transaction (the
&#8220;Prepaid Forward Transaction 1&#8221; and &#8220;Prepaid Forward Transaction 2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the terms of the Prepaid Forward Agreements, Seller 1 and Seller 2 may (i) purchase through a broker in the open market, from holders
of Shares other than 8i Acquisition or affiliates thereof, 8i Acquisition&#8217;s ordinary shares, no par value, (the &#8220;Shares&#8221;),
or (ii) reverse Seller 1&#8217;s and Seller 2&#8217;s prior exercise of redemption rights as to Shares in connection with the Business
Combination (all such purchased or reversed Shares, the &#8220;Recycled Shares 1&#8221; and &#8220;Recycled Shares 2&#8221;, respectively).
While Seller 1 and Seller 2 has no obligation to purchase any Shares under the Prepaid Forward Agreement 1 and Prepaid Forward Agreement
2, the aggregate total Recycled Shares 1 and Recycled Shares 2 that may be purchased or reversed under the Prepaid Forward Agreement 1
and Prepaid Forward Agreement 2 shall be no more than <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember_zdunTvhqRqti" title="Number of shares purchased">1,400,000</span> shares and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember_zDtb2O9UQyHi" title="Number of shares purchased">1,125,000</span> shares, respectively. Seller 1 and Seller 2 have
agreed to hold the Recycled Shares 1 and Recycled Shares 2, for the benefit of (a) 8i Acquisition until the closing of the Business Combination
(the &#8220;Closing&#8221;) and (b) the Company after the Closing (each a &#8220;Counterparty&#8221;). Seller 1 and Seller 2 also may
not beneficially own greater than <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zHPSmS187ile" title="Beneficially ownership percentage"><span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zB6YSivLA8I5" title="Beneficially ownership percentage">9.9</span></span>% of issued and outstanding Shares following the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
key terms of the forward contracts are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Sellers can terminate the Transaction no later than
the later of: (a) Third Local Business Day following the Optional Early Termination (&#8220;OET&#8221;); (b) the first Payment Date after
the OET Date which shall specify the quantity by which the Number of Shares is to be reduced (such quantity, the &#8220;Terminated Shares&#8221;)
Seller shall terminate the Transaction in respect of any Shares sold on or prior to the Maturity Date. The Counterparty is entitled to
an amount from the Seller equal to the number of terminated shares multiplied by the Reset Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">-Seller 1 and Seller 2 are entitled to receive the
Maturity Consideration, an amount equal to the product of: (1) Number of Recycled Shares specified in the Pricing Date Notice, less(b)
the number of Terminated Shares multiplied by (2) USD <span id="xdx_907_eus-gaap--ForwardContractIndexedToEquitySettlementShareFairValuePerShare_iI_c20221109__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ForwardContractsMember_zZbPNqu29Yzc" title="Forward contract, fair value per share">2.50</span> (the &#8220;Maturity Consideration&#8221;), in cash. The Company can also pay
the Seller 1 and Seller 2 shares based on the Company&#8217;s average volume weighted average share price (&#8220;VWAP&#8221;) of the
Shares over 30 Scheduled Trading Days ending on the Maturity Date. Such settlement consideration or OET is considered to be an embedded
feature (or instrument) with in the Prepaid Forward Transaction 1 and 2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- <span style="background-color: white">The </span>Prepaid
Forward Transaction 1 and 2 required <span style="background-color: white">physical settlement by repurchase of remaining of the recycled
shares in exchange for cash and if either the amount to be paid or the settlement date varies based on specified conditions, the earlier
of a) first anniversary of the closing of the transactions between Counterparty and EUDA on November 18, 2022 or b) the date specified
by Seller in a written notice to be delivered at Seller&#8217;s discretion (not earlier than the day such notice is effective) after the
occurrence of a VWAP Trigger Event, those instruments shall be measured subsequently at the amount of cash that would be paid under the
conditions specified in the contract if settlement occurred at the reporting date, recognizing the resulting change in that amount from
the previous reporting date as interest cost, which we recorded as change in fair value of prepaid forward purchase liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In accordance
with ASC 480, <i>Distinguishing Liabilities from Equity</i>, the Company has determined that the prepaid forward contract is a financial
instrument other than a share that represent or are indexed to obligations to repurchase the issuer&#8217;s equity shares by transferring
assets, referred to herein as the &#8220;prepaid forward purchase liability&#8221; on its consolidated balance sheets. The Company initially
measure the prepaid forward purchase liability at fair value and measured subsequently at fair value with changes in fair value recognized
in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of the closing
of the Business Combination, the fair value of the prepaid forward purchase liability was $<span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221109_zaMJj0MtG3f1" title="Prepaid forward purchase liability">7,409,550</span> and was recorded on the Company&#8217;s
consolidated balance sheets. Subsequently, the change of fair value of the prepaid forward purchase liability was amounted to a loss of
$<span id="xdx_902_ecustom--ChangeOfFairValueOfPrepaidForwardPurchaseLiability_c20220101__20221231_zk8mdFAp9Kb" title="Change of fair value of prepaid forward purchase liability">12,911,503</span> for the year end December 31, 2022. As of December 31, 2022, the prepaid forward purchase liabilities amounted to $<span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zHmPZ78KJ7M5" title="Prepaid forward purchase liability">20,321,053</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureForwardPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureForwardPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ForwardPurchaseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of forward purchase agreements disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ForwardPurchaseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921899440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to third party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLoanToThirdPartyAbstract', window );"><strong>Loan To Third Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_LoanToThirdPartyTextBlock', window );">Loan to third party</a></td>
<td class="text"><p id="xdx_806_ecustom--LoanToThirdPartyTextBlock_zL285YpqCUo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 &#8211; <span id="xdx_827_ziKYrlXoDPGe">Loan to third party</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 20, 2020, the Company&#8217;s
subsidiary, UGI has entered into a loan agreement with PT total Prima Indonesia (&#8220;PT&#8221;), an unrelated third party. Upon
execution of the loan agreement and supplemental agreement, PT may borrow up to approximately $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zz9LM4qIYGt4" title="Loan borrow up amount">0.7</span>
million (SGD <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_uSGD_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zpjNTXaMDrtf" title="Loan borrow up amount">1,000,000</span>)
from UGI for a period of three years with <span id="xdx_90D_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20201119__20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_znZMGL4TKZl4" title="Loan interest rate">9.00</span>%
annual interest rate. The loan shall be due and payable, including all disbursed loan amount and accrued interest, on the maturity
date. As of December 31, 2022 and 2021, the Company had provided a total of $<span id="xdx_90F_ecustom--LoanAccumulativelyDisbursed_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zbhSDnXagvBl" title="Loan accumulatively disbursed">608,683</span>
(SGD <span id="xdx_905_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zxWWGcujFD3g" title="Loan accumulatively disbursed">816,000</span>)
and $<span id="xdx_906_ecustom--LoanAccumulativelyDisbursed_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zgLDgzDCTmG1" title="Loan accumulatively disbursed">352,959</span>
(SGD <span id="xdx_903_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zE7WpbPZsArh" title="Loan accumulatively disbursed">476,000</span>)
of loan to PT, respectively, and had $<span id="xdx_908_eus-gaap--InterestReceivable_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zTko21MGX8G6" title="Interest receivable">62,766</span>
(SGD <span id="xdx_903_eus-gaap--InterestReceivable_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zroAxy2XF2Y1" title="Interest receivable">84,144</span>)
and $<span id="xdx_901_eus-gaap--InterestReceivable_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zptswBR8l66e" title="Interest receivable">19,003</span>
(SGD <span id="xdx_901_eus-gaap--InterestReceivable_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zhGiqvBn7qoa" title="Interest receivable">25,627</span>)
of interest receivable balance, respectively. However, the Company determined its unlikely to recover such loan to third party upon
expiration of the loan contract due to PT was no longer in business, therefore, the company had recorded a fully allowance against
and wrote off the remaining balance of loan to third party as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021, the
Company has recognized <span id="xdx_907_eus-gaap--InterestIncomeRelatedParty_dxL_c20220101__20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zrjP4Ex1NwK1" title="Interest income from loan to third party::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1401">nil</span></span> and $<span id="xdx_906_eus-gaap--InterestIncomeRelatedParty_c20210101__20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_z2QUkc6cqAY3" title="Interest income from loan to third party">19,071</span> of interest income from loan to third party, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLoanToThirdPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLoanToThirdPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_LoanToThirdPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan to third party [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_LoanToThirdPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929265680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Credit facilities</a></td>
<td class="text"><p id="xdx_800_eus-gaap--ShortTermDebtTextBlock_zh08Du6kRIEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 13 &#8211; <span id="xdx_82C_zrCFg2wk8roj">Credit facilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zmF1bzcg9U3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loans &#8211; bank and private lender</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on short-term bank loans consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zq36MWtvWq1i" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Bank/Private<br/>
 lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/>
Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center">*<span id="xdx_908_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zNb9oHGId5b3" title="Bank/Private lender Name">United Overseas Bank Limited</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zcPdpLsyMHwe" title="Maturities">90 days from disbursement</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zCfVBhT5mU4h" title="Interest Rate">0.25</span>% plus prime rate of <span id="xdx_90E_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_fKg_____zfTw109SRvOj" title="Interest Rate">5.25</span>%</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zxA309aHY1W" title="Collateral/Guarantee">Collateral: Accounts receivable </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zU1uJrnqARda" title="Short term loans - bank and private lender">185,592</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zpWzgzbbh6j3" title="Short term loans - bank and private lender">184,491</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z4BHA2B8rqh5" title="Bank/Private lender Name">FS Capital Ptd. Ltd.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zI7qFSDU1774" title="Maturities">Fully repaid in February, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zNuDnn3QNN28" title="Interest Rate">18.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zvCfKLrWXRyj" title="Collateral/Guarantee">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder, and Kent Ridge Health Private Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zQ5MFLMoFAd" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zpYyfAyUGRL8" title="Short term loans - bank and private lender">20,936</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zMXeUYuTfen1" title="Bank/Private lender Name">Funding Societies Pte. Ltd</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zfXoQB7pA524" title="Maturities">Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zSQFIVgvja5" title="Interest Rate">30.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zUwHlHqO7fMh" title="Collateral/Guarantee">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zBtuoQvS27d" title="Short term loans - bank and private lender">18,648</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zhYCBo1e7Gg7" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1445">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zLUz0RfsiKDd" title="Short term loans - bank and private lender">204,240</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z9IcxqQF0pI4" title="Short term loans - bank and private lender">205,427</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_z6mo09h38t7d" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F11_zGbdAhWmd92k" style="text-align: justify">On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount">593,208</span>
                                                                                                       (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount">800,000</span>)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#8217;s account receivable (see Note 6). The loan bears an average annual interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate">5.50</span>%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.</td>
</tr></table>

<p id="xdx_8A1_zW3FpakUMLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zY63Gd0UPNQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loan &#8211; third party</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zDPEKbNdLZR1" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zWUelSEUsRz8" title="Bank/Private lender Name">Koh Wee Sing</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_fKg_____zohy9rpeA1yd" title="Maturities">Due on demand beginning in July 2022</span>*</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zdeDx9uPfRl2" title="Interest Rate">60.0</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_ztbcHFYM3FFb" title="Collateral/Guarantee">None</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zxzEPGi05kJ4" title="Short term loans - third parties"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z5xGRUTk034g" title="Short term loans - third parties">148,302</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A3_z1EDzRQXpF0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expense pertaining to the above loans for
the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90E_eus-gaap--InterestExpense_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zkRqwaLlo5Lf" title="Interest expense">122,845</span> and $<span id="xdx_908_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zvwZUt2myhBh" title="Interest expense">128,071</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Weighted average interest rate to the above loans
for the years ended December 31, 2022 and 2021 are <span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zjnwdHR3Vu6j" title="Weighted average interest rate">11.0</span>% and <span id="xdx_90B_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z1TcG7S1XL62" title="Weighted average interest rate">6.3</span>%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F02_zkILJEdptxJ7" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F14_zHLspWhHk04" style="text-align: justify">On December 16, 2022, the Company has signed a loan agreement
                                                                                                       (&#8220;Agreement&#8221;) with Kent Ridge Health Pte Ltd (&#8220;KRHPL&#8221;), a related party. Pursuant to the Agreement, KRHPL
                                                                                                       agreed to fully remit the loan payment to Koh Wee Sing on behalf of the Company. As a result, such short-term loan- third party was
                                                                                                       transfer to other payable, related parties under KRHPL&#8217;s balance as of December 31, 2022.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zS0Hd9Z016Yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Promissory note</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on promissory note consist of
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zcPLWGqMCYe7" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zf3uHzslHwm4" title="Bank/Private lender Name">Kaufaman &amp; Canoles, P. C. (&#8220;KC&#8221;)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_fKg_____zw9ZL6sd9fx" title="Maturities">February 15, 2023</span>*</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zU5yjNtaf0Vi" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zeFtooQHWzd" title="Collateral/Guarantee">None</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zYLH44Kwk1Oj" title="Convertible promissory note">170,000</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zIzXFkXVtur3" title="Convertible promissory note"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zpEKxG4NhYhc" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F17_zPRb9fRRhpn6" style="text-align: justify">This promissory note has a default interest of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate">15</span>% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#8220;the Agreement&#8221;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note">100,000</span> within two days of the dates that the Company&#8217;s US counsel,
Loeb &amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note">60,000</span> within two business days after the date the first amendment to the registration
statement is filed with the SEC.</td>
</tr></table>

<p id="xdx_8A1_zDvC8uBoAIGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z6Kq57Fc2mRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; third parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on convertible notes consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zIx7neI1HJM5" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zlNna5WB78N5" title="Bank/Private lender Name">Maxim Group LLC (&#8220;Maxim&#8221;)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zfoXWsI7F5v8" title="Maturities">November 17, 2023</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zjkttMFlHCPh" title="Interest Rate">0.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztXGFtXMJN8f" title="Collateral/Guarantee">Automatically be converted into the Company&#8217;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztsqhZq0sHA4" title="Convertible notes payable">2,113,125</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zf5U7gDmOlBi" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zSsHM3l6l3yl" title="Bank/Private lender Name">Menora Capital Pte Ltd (&#8220;Menora&#8221;)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zIZinwYcTpof" title="Maturities">November 17, 2023</span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zk2TFLc8rWAf" title="Interest Rate">0.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTru3X9M6YHk" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zus0fLgGYue3" title="Convertible notes payable">87,500</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z1YSxfG1CkVk" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zopxcbfv9hXh" title="Bank/Private lender Name">Loeb &amp; Loeb LLP (&#8220;Loeb&#8221;)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zroUwCDFpdXb" title="Maturities">November 17, 2023</span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTyfqJNfkBX" title="Interest Rate">0.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zu8WjfcyB14j" title="Collateral/Guarantee">(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zHTqs3US7m5b" title="Convertible notes payable">300,000</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zvZ8ZSyjqAda" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zpagZK7g6tVe" title="Bank/Private lender Name">Shine Link Limited (&#8220;Shine Link&#8221;)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z9U1S8dyCFGj" title="Maturities">November 17, 2023</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zilIXU8l8SIc" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zVslrOjeWenf" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zQgMBnixlro5" title="Convertible notes payable">119,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zFxmkamWZZld" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z7rF8dRBeDOg" title="Convertible notes">2,619,625</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zhuRXnCbNOUk" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___znbO2pVoMxG3" title="Bank/Private lender Name">8i Holdings 2 Ptd Ltd (&#8220;8i Holding&#8221;)</span> (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPmBWhZaYdel" title="Maturities">November 17, 2023</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVGdVWy5ZHr5" title="Interest Rate">0.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPN6yhISMwJa" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVz4gtl0mjkl" title="Convertible notes payable">82,600</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___ziXyfpdsC1lj" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zjxf3Va2gX8k" title="Bank/Private lender Name">Meng Dong (James) Tan</span> (2)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z4ACxPfpB3rk" title="Maturities">November 17, 2023</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z8dHohPUY0Ll" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zBDEoEI6pFpb" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z0dyAvH33lId" title="Convertible notes payable">700,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z36i6145qhS4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zC1o1ov4Asgj" title="Convertible notes payable">782,600</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zDEMXZWVheW4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1582">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F06_z5wkCNalLiU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zCH2TRI7EMM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Meng Dong (James) Tan, the Company&#8217;s related party who had more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name">10</span>% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zXTuoVGxiL12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z3Xa8GI0PEof" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Meng Dong (James) Tan, the Company&#8217;s related party has more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name">10</span>% ownership of the Company.</span></td></tr>
  </table>
<p id="xdx_8A9_zOzsMuA8L2Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined that the embedded conversion
feature from the convertible notes, related parties and third parties qualifies for the scope exception due to the embedded conversion
feature indexed to the Company&#8217;s stock in accordance with ASC 815-40-15 and meet the equity requirement in accordance with ASC815-40-25.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923584448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other payables and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Other payables and accrued liabilities</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z9MDkjJEGRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 &#8211; <span id="xdx_828_z9cl25epj90f">Other payables and accrued liabilities</span></b></p>

<p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBuhOgPURNs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zftKXCe0kcd4" style="display: none">Schedule of other
payables and accrued liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zSgZCR3P792e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zIpxn6JlxMck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zpQPLdKmIVU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F47_z8HVuhmkRhoa" style="width: 60%; text-align: left">Accrued expenses (i)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">671,743</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">129,029</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maAPAOAzzja_zI4xHyEQc5We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued payroll</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">730,037</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">244,591</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAOAzzja_zafAiA1CKgLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F49_zN5hy8VB081c" style="text-align: left">Accrued interests (ii)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">157,032</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">67,448</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zLoJEYDz1RH9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">34,003</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">47,529</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzzja_z6d9ObFAejjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other payables and accrued liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,592,815</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">488,597</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zU2DIwdDueu">(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued expenses</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_z4IbBhnBkeRa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0B_z6utxZKjB9Nj">(ii)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued interests</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zV7yk6cQZZJg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of accrued interests represented the balance of interest payable from short-term loan &#8211; bank, private lender, and third parties (See Note 13).</span></td></tr>
  </table>
<p id="xdx_8A4_zKZSEqLD8882" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929376608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party balances and transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party balances and transactions</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zP6LmKYQgF4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Note 15 &#8211; <span id="xdx_828_zHj4nySH6Z16">Related
party balances and transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party balances</span></p>

<p id="xdx_89C_ecustom--ScheduleOfRelatedPartyBalancesTableTextBlock_zPZ1uaGCMUMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zfRWSr5yCTk6" style="display: none">Schedule of related
party balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other receivables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_ztoJKWrxBA42" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br/>
December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zyTjiRvJ4dfh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br/>
December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHillCapitalPteLtdMember_z0mfXxXciPC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">KR Hill Capital Pte Ltd</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Related party advance, due on demand</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">239</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">237</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeMedicalPtdLtdMember_zAq8s75D8qZd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Medical Ptd Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">247</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">245</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zHO23HkMDnR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">UG Digital Sdn Bhd</td>
    <td>&#160;</td>
    <td style="text-align: center">UGD, subsidiary of the Company owned 40% of this company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">284,673</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanicLimitedMember_zC0mw7zyTSR8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Janic Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">724</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">720</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZukihealthSDNMember_ziAJ7HyPFp21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Zukihealth SDN</td>
    <td>&#160;</td>
    <td style="text-align: center">Kelvin Chen, Chief Executive Office (&#8220;CEO&#8221;) and shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,173</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JenniferGohMember_ziC0ykyOqEp5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jennifer Goh</td>
    <td>&#160;</td>
    <td style="text-align: center">President, operation manager, and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,527</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FrescoInvestmentPteLtdMember_zq7QNokGLm3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fresco Investment Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Fan Know Hin, an immediate family member of a shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">46</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z7fbUupTuyb1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Cadence Health Pte Ltd<span id="xdx_F44_zQSR0Ta8OmEk">*</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">266,653</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1637">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueFromOtherRelatedParties_iI_zuvDNg31UKsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">267,863</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">297,621</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_zIA3J1Gf4zx7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other receivables -  related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">267,863</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">297,621</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zP8tNp0ijJTb" style="width: 15pt; text-align: right">*</td><td id="xdx_F15_zgC4CpQgx3s8" style="text-align: justify">As of date of <span style="background-color: white">the issuance of these financial statements</span>,
this receivable has been repaid by the related party.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Convertible notes &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Please see Note 13 for details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Account payable &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zBrRVkpdoTJ6" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, <br/>
2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zDQz9HW8SBy2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,<br/>
 2021</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z0mCq6DLSO6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1646">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,459,411</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zvpsHUzGFawi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Account
payable, related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1649">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,459,411</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other payables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zip7jWxR6Se2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zhtnBhies9n5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CheeYinMehMember_zz7vcouE5aP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Chee Yin Meh</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholder of Scotgold Holding Ltd which is the shareholder of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Operating expense paid on behalf of the Company</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">122,739</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">34,512</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamieFanWeiZhiMember_z9QK4EFAzbzj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jamie Fan Wei Zhi</td>
    <td>&#160;</td>
    <td style="text-align: center">An immediate family member of a shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company, and Guarantor fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">40,783</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinChenMember_zBpY8n1QudJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kelvin Chen</td>
    <td>&#160;</td>
    <td style="text-align: center">CEO and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">589,681</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">295,776</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeHealthPteLtdMember_zLHx7qXv6Q8d" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">696,508</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">121,129</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zfpOR0lwSdz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kent Ridge Pacific Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">20,303</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33,483</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WatermarkDevelopmentsLtdMember_zfv4OeX9Bfjc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Watermark Developments Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">55,945</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilkeServicesLtdMember_zNA9ZSroyVse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F48_zmQu2DhV61qj" style="vertical-align: top; text-align: left">Wilke Services Ltd (&#8220;Wilke&#8221;) (1)</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Investment payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,746,628</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MountLockeLimitedMember_zKIL5ddMHgag" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Mount Locke Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,753</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zX7SUmfS20E6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">UG Digital Sdn Bhd</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">UGD, subsidiary of the Company owned 40% of this company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Operating expense paid on behalf of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">33,016</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_zIe3sA7HREPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,521,945</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">3,272,311</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_ztc2s4OuxTI" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other payables &#8211; related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,521,945</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">3,272,311</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zxZa2MGh7q3l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zm2d6c2NZKWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). </span></td></tr>
  </table>
<p id="xdx_8A7_zpFPxEoFU2E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zToPN3CoiZAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zCapYiqAPdR9" style="display: none">Schedule of related
party transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name of Related Party</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Relationship</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Nature</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zurTmBRiKc72" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2022</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zpcv2OHuWiq5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2021</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zl5RS8mBhFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-bottom: 1.5pt; width: 20%; text-align: left">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 20%; text-align: center">Sales of swab test, and other medical related product</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromRelatedParties_zwIhRiOq4kfb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Revenue from related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">135</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">4,640</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_ze3CZo48Hep9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2022</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zNusAPiH0Pig" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2021</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zNFfncj0E74i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Cadence Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Medical service fee provided for the third party medical service revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zY3fPo9wn83k" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    from related parties</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Medical service fee provided for the third party medical service revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">491,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,349,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Rental expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3fkoprXpF84" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOyZQ4ETTLLk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_ztsBbbMgSJ85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent Ridge Pacific Pte Ltd</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of this entity also are the shareholders of the Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office rental</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,954</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143,589</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zgzY3mePmvcj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt">Rental Expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Office rental</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">47,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8A3_zQj6Och3N0Za" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922663008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; equity</a></td>
<td class="text"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfznblAnfTG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16 &#8211; <span id="xdx_82E_ziuigU50LnRe">Shareholders&#8217; equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Capital Contribution</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 20, 2022, the Company received capital
of $<span id="xdx_908_eus-gaap--Capital_iI_c20220920__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztVJWgixa4m3" title="Capital contributions">600,000</span> from an investor for the issuance in 8i acquisition&#8217;s ordinary shares. Such deposit is refundable if the business combination
will not be completed by November 30, 2022. Initially, the Company recognized the subscribed shares deposit liability in accordance with
ASC 480, &#8220;Distinguishing Liabilities from Equity&#8221; on inception. On November 17, 2022, Upon the closing of the Business Combination
with 8i acquisition, the Company issued <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuIjvMLiguE" title="Common stock, shares authorized, unlimited">120,000</span> ordinary shares to this investor and transferred such the subscribed shares deposit liability
into equity as capital contribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Forgiveness of debt by a related party</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2022, the Company and Wilke entered into
a deed of release of debt (&#8220;Deed&#8221;), pursuant to the Deed, upon the closing of the Business Combination, Wilke agrees to release
and discharge the Company from the Obligation to repay to Wilke of $<span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220330__20220331_zJzlKLPZyKt1" title="Forgiveness of debt by a related party">2,763,018</span>. As Wilke&#8217;s is a shareholder of the
Company, such debt forgiveness were treated as an addition to the Company&#8217;s capital during the year ended December
31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Ordinary shares</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue unlimited ordinary
shares of <span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_do_c20221231_zaCuw9jMoO18" title="Ordinary shares, no par value">no</span> par value. Holders of the Company&#8217;s ordinary shares are entitled to one vote for each ordinary share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">-<i>Issuance of ordinary shares to EHL</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220724__20220725_zGWtm18XmmZ7" title="Stock issued during period">4,626,667</span> ordinary
shares (<span id="xdx_909_ecustom--OrdinaryShareBeforeReverseRecapitalization_iI_c20220725_zlZ74xAunDWi" title="Ordinary share before reverse recapitalization">500,000</span> ordinary share before reverse recapitalization) for total consideration of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220724__20220725_zby4WkGXyx61" title="Total consideration">500,000</span> to the shareholder of EHL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares and corresponding capital amounts and all
per share data related to EHL&#8217;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the <span style="background-color: white">Exchange Ratio</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>-Issuance of ordinary shares upon the reverse recapitalization
(See Note 4)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 17, 2022, upon the consummation of the
Business Combination, the Company issued an aggregate total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EightIHoldingsTwoPtdLtdMember_zErY58aPpDSk">6,191,770</span> ordinary shares to 8i and various service provider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_890_ecustom--ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_z80GmA1oLSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued upon the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zf6K3XnLVwLg">Schedule
of reverse recapitalization</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zgcRg6Xenr1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_zzG2plFquwuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 15%; text-align: right">11,073,500</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RedemptionOfOrdinaryShares_zxMwMp166mZf" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6,033,455</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ConversionOfStockSharesConverted1_zHBwDEqARuZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">891,725</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zcAJmygmIXLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued to service providers</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_zLFaxoKqb1O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">6,191,770</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AD_zzq2uO8DNXl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Warrants</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with the reverse
recapitalization, the Company has assumed <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zDVV5lWDMxkl" title="Warrants outstanding">8,917,250</span> Warrants outstanding, which consisted of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zFgO5YE9Cw4c" title="Warrants outstanding">8,625,000</span> Public Warrants and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zOFl2bZJ3ty7" title="Warrants outstanding">292,250</span> Private
Warrants. Both of the Public Warrants and private warrant met the criteria for equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Warrants became exercisable
on the later of (a) the completion of the reverse recapitalization or (b) 12 months from the closing of the initial public offering (&#8220;IPO&#8221;).
The warrants will expire five years after the completion of a reverse recapitalization or earlier upon redemption or liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company had <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z9YrzymsPfo1" title="Warrants outstanding">8,625,000</span> Public Warrants outstanding and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zFQZvRHccI8k" title="Warrants outstanding">292,250</span> Private Warrants outstanding. Each whole Public Warrant and Private
Warrant entitles the registered holder to purchase one-half share of the Company&#8217;s ordinary share at a price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zs3TtM99Kn47" title="Warrant to purchase ordinary share, price per share">11.50</span> per share,
subject to the following conditions discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company may redeem the Public Warrants and Private Warrants in whole and not in part, at a price of $<span id="xdx_909_ecustom--WarrantsRedemptionPrice_c20220101__20221231_zaneHSRPkiYh" title="Warrants redemption price">0.01</span> per warrant:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; at any time while
the warrants are exercisable and prior to their expiration,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; upon not less than
30 days&#8217; prior written notice of redemption to each warrant holder,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; if, and only if,
the reported last sale price of the ordinary shares equals or exceeds $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20221231_zLYx9bInE134" title="Sale price of the ordinary shares">16.50</span> per share (as adjusted for share splits, share dividends,
reorganizations and recapitalizations), for any 20 trading days within a 30 trading days period ending on the third trading business day
prior to the notice of redemption to warrant holders, and,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#9679; if, there is a current
registration statement in effect with respect to the Ordinary Shares underlying the Warrants for each day in the 30-day trading period
and continuing each day thereafter until the Redemption Date or the cashless exercise of the Warrants is exempt from the registration
requirements under the Securities Act of 1933, as amended (the &#8220;Act&#8221;)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If the Company calls the
warrants for redemption as described above, management will have the option to require all holders that wish to exercise the warrants
to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of ordinary shares issuable
upon exercise of the warrants may be adjusted for splits, dividends, recapitalizations and other similar events. Additionally, in no event
will the Company be required to net cash settle the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The only difference between
Public Warrants and Private Warrants is that the Private Warrants will not be transferable, assignable or salable until after the completion
of reverse recapitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGUjZC76KfO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The summary of warrants activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zzr0MdKF5Uth" style="display: none">Schedule
of warrant activities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares Issuable</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average <br/> Remaining <br/> Contractual <br/> Life</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k4YsaJj09j" style="text-align: right" title="Warrants Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zle586Mp5ZOd" style="display: none; text-align: right" title="Ordinary Shares Issuable, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuI9vnNPvPp8" style="text-align: right" title="Weighted Average Exercise Price, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 32%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2tEcJVkBChj" style="width: 14%; text-align: right" title="Warrants Outstanding, Granted">8,917,250</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk9jia2wAIug" style="width: 14%; text-align: right" title="Ordinary Shares Issuable, Granted">4,458,625</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ8n0xDs4CJ7" style="width: 14%; text-align: right" title="Weighted Average Exercise Granted">11.50</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Uz0dEn5Ahi" style="width: 14%; text-align: right" title="Average Remaining Contractual Life,Granted">5.00</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPEAZegbYagh" style="text-align: right" title="Warrants Outstanding, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqRvcI0CV19" style="display: none; text-align: right" title="Ordinary Shares Issuable, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKd6a5gxKJl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1771">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuBRpBJPYxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ordinary Shares Issuable, Exercised"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1773">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022 </span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqz7I5Ro0ma" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">8,917,250</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZGV5NIKUml" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares Issuable, Ending balance">4,458,625</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfmvdnmBM0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending balance">11.50</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfgfRXJMsei" style="padding-bottom: 2.5pt; text-align: right" title="Average Remaining Contractual Life,">4.88</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AE_znjZf6mtcpC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Earnout shares</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the Business Combination, <span style="background-color: white">Watermark
is entitled to the <span id="xdx_908_ecustom--EarnoutShares_iI_c20221117_z3yaAlSoENGj" title="Earnout shares">4,000,000</span>
Earnout Shares of the Company&#8217;s no par value ordinary shares subject to the following four
triggering events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_z7I2xD4C2gA2" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Fifteen Dollars ($<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zioO45nyzk6j" title="Number of additional shares issued">15.00</span>) after the Closing Date (&#8220;Triggering Event 1&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zG1xgo4MJ34l" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#8217;s share price is equal to or greater than Twenty Dollars ($<span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zHrCNVw6hgmk" title="Number of additional shares issued">20.00</span>) (&#8220;Triggering Event 2&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyKq1vRCQwW5" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuzuCeqW4FM4" title="Revenue">20,100,000</span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zwikntQiRO4b" title="Net income">3,600,000</span> (&#8220;Triggering Event 3&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyVK9Ao8Npl5" title="Number of additional shares issued">1,000,000</span> additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zIMlKNFPLAge" title="Revenue">40,100,000</span> and (y) net income attributable to EUDA of at least $<span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zqFqjSmVDPxb" title="Net income">10,100,000</span> (&#8220;Triggering Event 4&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Earnout
Shares are accounted for as equity classified equity instruments, were included as merger consideration as part of the Reverse Recapitalization
and recorded in capital</span>. The fair value of the Earnout Shares was estimated using a model based on multiple stock price paths developed
through the use of a Monte Carlo simulation that incorporates into the valuation the possibility that the market condition targets may
not be satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_898_ecustom--ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_zkrxSCwyG2u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Earnout Shares for Triggering
Event 1 and 2 was estimated using the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zsrpRMLIlhei" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of earnout shares
for triggering event</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Closing date</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221116__20221117_zcGCE22cZ9rk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">November 17, 2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharePriceAsOfClosingDate_zRAWZuTdtPpa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Share price of the Company as of closing date</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">5.21</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AverageDailyReturnRate_dp_uPure_z7DBL6zpBT7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Average daily return rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0">0.02</p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--DailyVolatilityForTriggeringEvent1_dp_zZ2VBZUgxvL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daily volatility for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.74</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--DailyVolatilityForTriggeringEvent2_dp_zpbCH6ark1Zk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Daily volatility for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0">4.30</p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--RiskFreeRateForTriggeringEventOne_dp_zVi2jU7hK501" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.75</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--RiskFreeRateForTriggeringEventTwo_dp_zaUYULj3ClW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.49</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--GrantPriceForTriggingEventOne_zaQcxUq3EBe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant Price for Trigging Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">15.0</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--GrantPriceForTriggingEventTwo_z3lSuOMSi7I1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Grant Price for Trigging Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">20.0</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A3_zQAB6u2oxEU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Company determined the fair value
of the Earnout Shares for Triggering Event 1 and 2 is amounted to $<span id="xdx_90E_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventOneMember_zyywS5HPlvZg" title="Fair value of earnout shares">1,926,610</span> and $<span id="xdx_903_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventTwoMember_zmL8IJ55UEmg" title="Fair value of earnout shares">3,273,019</span>, respectively, and recorded the same amount in consolidated statements of change in shareholders&#8217; equity (deficit) and
consolidated statements of operations and comprehensive income (loss) as earnout share payment for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Company determined that the probabilities
of achieving the revenue and net income thresholds are nil for Triggering Event 3 and 4 and estimated the fair value of the Earnout Shares
of nil.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929177392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zrpXafO6iun3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 17 &#8211;<span id="xdx_829_z5alBoi1aj22"> Income taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>British Virgin Islands</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KRHL and SGGL are incorporated in the British Virgin
Islands and are not subject to tax on income or capital gains under current British Virgin Islands law. In addition, upon payments of
dividends by these entities to their shareholders, no British Virgin Islands withholding tax will be imposed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Vietnam</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary operating in Vietnam
is subject to the Vietnam Income Tax at a standard income tax rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_znefJsdO9JN" title="Foreign income tax rate">20</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Malaysia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary operating in Malaysia
is governed by the income tax laws of Malaysia and the income tax provision in respect of operations in Malaysia is calculated at the
applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof.
Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zLuDvpwO3Yak" title="Foreign income tax rate">24</span>% enterprise income
tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Singapore</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiaries incorporated in Singapore
and is subject to Singapore Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance
with relevant Singapore tax laws. <span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_z4KtS2eEjV12" title="Income tax description">The applicable tax rate is <span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_zsKL6vaATBQ5" title="Foreign income tax rate">17</span>% in Singapore, with 75% of the first $<span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z17NV6d87dW4" title="Taxable income">7,255</span> (SGD <span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z6EBZQcRybQb" title="Taxable income">10,000</span>) taxable income
and 50% of the next $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zg9APfydA9V4" title="Taxable income">137,842</span> (SGD <span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zyjXZunjUH2g" title="Taxable income">190,000</span>) taxable income are exempted from income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zXpPe41qzvhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and foreign components of loss before
income taxes were comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_ziFSmCvuVuV3" style="display: none">Schedule
of components of loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zjH9PVeyKvkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_zKAtD8HE96P4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zty8c8T8eeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Singapore</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(5,400,034</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">930,312</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zGyACxvHKX16" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(19,531,790</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">18,225</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zPMlSqriWVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total loss (income) before income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,931,824</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">948,537</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AE_zuXGiTrb4pr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJEm2njnqpLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z8zw5yCpj5M2" style="display: none">Schedule
of provision for income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zTFi7qbIvTRg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_z0BLIXxcd0F4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_zSdIKhIucPrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Current</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">65,650</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">75,821</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_z3jXFocNLYm2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deferred</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(48,228</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(27,680</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_z4lm9TXIxmI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Provision for income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">17,422</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">48,141</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AC_zzL73rSJesra" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zVCS992fOng2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles Singapore statutory
rates to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zXLp5P8Uow19" style="display: none">Schedule
of effective income tax rate</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zz6LSmlqgw5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zTpHYWL3WU07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_z0uGVyCX6sAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Singapore statutory income tax rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">17.0</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">17.0</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zzJ1jJekuC2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax rate difference outside Singapore <span id="xdx_F46_zNQo6BcZgG44">(1)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(13.3</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.1</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxExemptIncome_pid_dp_zXhXG4014Vxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxable income below exemption threshold</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2.4</td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_z8YJ0GXrWI66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2.9</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">29.8</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_zY13CpOijIs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others <span id="xdx_F44_zoi5p425LcQg">(2)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(0.9</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(39.4</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zzQWY82pIy2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(0.1</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">5.1</td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zLE8wzDmLyza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zCFPCErDySXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zvUE81Un7MEd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zxFItljtEDT" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.</span></td></tr>
  </table>
<p id="xdx_8AD_zSka9sprHmQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUkfkUCI7RE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant components
of the aggregate deferred tax assets and liabilities of the Company as of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zcM8q1Pzzg4" style="display: none">Schedule
of deferred tax assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zdo2j9fZOWhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0XqsOKD6XUj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred Tax Assets/Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzYwk_zbqU7KgOgUqg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">749,309</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">812,715</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTANzYwk_zDROOYfiD1Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allowance for doubtful account<span id="xdx_F4E_zYFMyP1TGDhg">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33,564</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">13,736</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilityNet_iI_maDTANzYwk_z5ZAY0uJdmu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">823</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1898">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYwk_zk1qx9VNeCJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(783,696</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(826,451</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYwk_zqEefreGb4e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1903">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzaoX_zYICzYnBxxwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">49,294</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzaoX_z5NtqG7k2ot8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1909">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">49,294</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F06_zH7RhItHCiA2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1A_z3zULlLWpA9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased">42,755</span> as of December 31, 2022.</span></td>
</tr></table>

<p id="xdx_8A1_zNhoceS2p6ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, the Company had
net operating losses carry forward (including temporary taxable difference of bad debt expense) of approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zS4fiEcjSZze" title="Operating losses carry forward">4.4</span> million and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zC153U1F2Kc3" title="Operating losses carry forward">4.8</span>
million, respectively, from the Company&#8217;s Singapore subsidiaries. The net operating losses from the Singapore subsidiaries can be
carried forward indefinitely. Due to the limited operating history of certain Singapore subsidiaries, the Company is uncertain when these
net operating losses can be utilized. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses
(including temporary taxable difference of bad debt expense) of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zWUOmpGWmkRa" title="Deferred tax assets, operating losses carry forward">0.7</span> million and $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20211231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zc33zuHgyiKj" title="Deferred tax assets, operating losses carry forward">0.8</span> million related to Singapore subsidiaries
as of December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, the Company had
net operating losses carry forward of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_zPvacqmpq7ik" title="Operating losses carry forward">18,000</span> and $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zeBSl8AgbJW4" title="Operating losses carry forward">19,000</span>, respectively, from the Company&#8217;s Vietnam subsidiary. <span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_zhFLnRHG3UGg" title="Operating losses carry forward description">The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.</span> Due to
the Vietnam subsidiary have been operating at losses and the Company believes it is more likely than not that its Vietnam operations will
be unable to fully utilize its deferred tax assets related to the net operating losses in the foreseeable future. As a result, the Company
provided a 100% allowance on deferred tax assets on net operating losses of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_z602ld7w8qj2" title="Deferred tax assets, operating losses carry forward">4,000</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zMjWK0J359u3" title="Deferred tax assets, operating losses carry forward">4,000</span> related to its Vietnam subsidiary
as of December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, the Company had net operating
losses carry forward of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zCMRe980OpB1" title="Operating losses carry forward">15,000</span> from the Company&#8217;s Malaysia subsidiary. The net operating losses from the Malaysia
subsidiary can be carried forward for seven years. Due to the Malaysia subsidiary have been operating at losses and the Company believes
it is more likely than not that its Malaysia operations will be unable to fully utilize its deferred tax assets related to the net operating
losses in the foreseeable future. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses of
approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zWUhV0tS1ski" title="Deferred tax assets, operating losses carry forward">4,000</span> related to its Malaysia subsidiary as of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Uncertain tax positions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates each uncertain tax position
(including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated
with the tax positions. As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions.
The Company did not incur interest and penalties tax for the year ended December 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_895_ecustom--ScheduleOfTaxesPayableTableTextBlock_zxbuH9pHz6Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Taxes payable consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z9nWMz0MpKS5" style="display: none">Schedule
of taxes payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zDcGYLGYVkoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zXvZQgoUd4K9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedGSTTaxesPayableCurrent_iI_maTPCzp1w_zSuZfuCNFxE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">GST taxes payable</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">125,695</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">225,095</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedIncomeTaxesCurrent_iI_maTPCzp1w_z0eWsO3lfjj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income taxes payable</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">60,455</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">82,248</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_iTI_mtTPCzp1w_zmg2voh1nZe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Totals</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">186,150</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">307,343</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A4_zunOrIXdAOZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929301504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentrations risks</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zPIH40SFxH9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 18 &#8211; <span id="xdx_823_zXna5lN7Lt73">Concentrations  risks</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Major customers</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2022 and 2021, no
customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zTovobfOfiA1" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zaNsgn5U49Dd" title="Concentration risk percentage">10</span></span>% or more of the Company&#8217;s total revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022 and 2021, no customer accounted
for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zh7Wpr17vVWf" title="Concentration risk percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zI9iyFYtFh8h" title="Concentration risk percentage">10</span></span>% or more of the total balance of accounts receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Major vendors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December 31, 2022, no vendor accounted
for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoVendorMember_zpOiyZK5geXh" title="Concentration risk percentage">10</span>% or more of the Company&#8217;s total purchases. For the year ended December 31, 2021, one vendor which is the Company&#8217;s
related party accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zeNLcYsJ6y5a" title="Concentration risk percentage">37.3</span>% of the Company&#8217;s total purchases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, two vendors accounted for
<span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zGVonptqQ3Xc" title="Concentration risk percentage">27.9</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zz3FjCjNnZ87" title="Concentration risk percentage">12.1</span>% of the Company&#8217;s total balance of accounts payable, respectively. As of December 31, 2021, one vendor which is the
Company&#8217;s related party accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zpODy6RlWja5" title="Concentration risk percentage">87.2</span>% of the total balance of accounts payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Credit risk</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to significant concentrations of credit risk consist primarily of cash. The Singapore Deposit Insurance Corporation
Limited (SDIC) insures deposits in a Deposit Insurance (DI) Scheme member bank or finance company up to approximately $<span id="xdx_907_eus-gaap--Deposits_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zjAJyOOSPUBl" title="Deposits">57,000</span>
(SGD <span id="xdx_907_eus-gaap--Deposits_iI_uSGD_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zFDaVftMjKAl" title="Deposits">75,000</span>)
per account. As of December 31, 2022 and 2021, the Company had cash balance of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zSAjXjlWusZj" title="Cash balance">138,710</span>
and $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zqEfCScdMxK1" title="Cash balance">180,746</span>
was maintained at DI Scheme banks in Singapore, of $<span id="xdx_90B_eus-gaap--BankOverdrafts_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuhytM0ddrp6" title="Bank balance">0</span>
and $<span id="xdx_90D_eus-gaap--BankOverdrafts_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zaA9mkzk3ohj" title="Bank balance">41,606</span>
was subject to credit risk, respectively. The Federal Deposit Insurance Corporation (FDIC) standard insurance amount is up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zNoSNL8CGM58" title="Cash FDIC">250,000</span>
per depositor per insured bank. As of December 31, 2022 and 2021, the Company had  restricted cash balance of $<span id="xdx_90B_eus-gaap--RestrictedCash_iI_c20221231_ziJm2MEsyNM2" title="Restricted cash">641,461</span>
and $<span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231_zXwqTCDm5kgk" title="Restricted cash::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1984">0</span></span> was
maintained at banks in the United States, of $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuvKPIz6x74d" title="Restricted cash">391,461</span>
and $<span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_ztL1dnl9lkhg" title="Restricted cash::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1988">0</span></span>
was subject to credit risk, respectively. While management believes that these financial institutions are of high credit quality, it
also continually monitors their credit worthiness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is also exposed to risk from accounts
receivable and other receivables. These assets are subjected to credit evaluations. An allowance has been made for estimated unrecoverable
amounts which have been determined by reference to past default experience and the current economic environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915341808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_z36yamL3BM55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 19 &#8211; <span id="xdx_82E_zn5DNKDgyIBf">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022 and
2021, the Company has leased three offices, and one office, respectively, which were classified as operating leases. In addition, the
Company had two office equipment leases which were classified as finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company occupies various
offices under operating lease agreements with a term shorter than twelve months which it elected not to recognize lease assets and lease
liabilities under ASC 842. Instead, the Company recognized the lease payments in profit or loss on a straight-line basis over the lease
term and variable lease payments in the period in which the obligation for those payments is incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&#8217;s lease
agreements do not contain any material residual value guarantees or material restrictive covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recognized lease
expense on a straight-line basis over the lease term for operating lease. Meanwhile, the Company recognized the finance leases ROU assets
and interest on an amortized cost basis. The amortization of finance ROU assets is recognized on an accretion basis as amortization expense,
while the lease liability is increased to reflect interest on the liability and decreased to reflect the lease payments made during the
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The ROU assets and lease
liabilities are determined based on the present value of the future minimum rental payments of the lease as of the adoption date, using
an effective interest rate of <span id="xdx_90C_eus-gaap--OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate_iI_pid_dp_uPure_c20221231_z7pOJ4NUxHkf" title="Effective interest rate">5.25</span>%, which is determined using an incremental borrowing rate with similar term in Singapore.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the weighted average remaining lease terms of the Company&#8217;s operating lease and finance leases are <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKQihOLmG2li" title="Operating lease term">0.69</span> years and <span id="xdx_907_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zPHpfCn6dn6e" title="Finance lease term">2.01</span> years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_zEuaX77mg0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Operating and finance lease
expenses consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zva4W5Cc3jEe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of operating and finance lease expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; text-align: left">Lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 31%; text-align: left">General and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z02GJdR0Isi6" style="width: 14%; text-align: right" title="Lease expenses">114,390</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--OperatingLeaseExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8YRaCVWT2G1" style="width: 14%; text-align: right" title="Lease expenses">62,810</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease expenses &#8211; short-term</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OperatingLeaseExpenseShortTerm_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ3haufxx6Qg" style="text-align: right" title="Lease expenses - short-term">113,055</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseExpenseShortTerm_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsGM83lzv0Je" style="text-align: right" title="Lease expenses - short-term">143,589</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Finance lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of leased asset</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3O1dqy7VBD" style="text-align: right" title="Amortization of leased asset">7,948</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znDHIxe4Tzjl" style="text-align: right" title="Amortization of leased asset">8,153</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense -Interest expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zf2DKu4lGdQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities">1,276</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseInterestExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zHzFNIMwu5vk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities">1,639</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--LeaseCost_c20220101__20221231_zXuIrMiSvqCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses">236,669</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--LeaseCost_c20210101__20211231_z2u05tGTexK8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses">216,191</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zsHhe4ynVdql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z4bF3JJAwasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Weighted-average remaining
term and discount rate related to leases were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;<span id="xdx_8B7_z33Jp2miFTYa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of weighted average remaining term and discount rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining term</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zrKJVK0Me2f7" title="Operating lease, weighted-average remaining term">0.69</span> year</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zzCZShx2g3Sb" title="Operating lease, weighted-average remaining term">1.25</span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKWt37oTrso2" title="Finance leases, weighted-average remaining term">2.01</span> years</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zHvVzkkI36U7" title="Finance leases, weighted-average remaining term">3.00</span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Operating lease</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zdJsEKHuuDU" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate">5.25</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z4c645fgDIx4" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate">5.25</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zZokI2Cnpue8" style="text-align: right" title="Finance leases, weighted-average discount rate">5.25</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zfAld1JBxjki" style="text-align: right" title="Finance leases, weighted-average discount rate">5.25</td>
    <td style="text-align: left">%</td></tr>
  </table>
<p id="xdx_8A1_zG9d63cfbRE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_z73KmCspbejd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table sets
forth the Company&#8217;s minimum lease payments in future periods as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zSmAwDeYnclg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of future minimum lease payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Operating lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Finance lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Twelve months ending December 31, 2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_z5TkiMa5Sj6k" style="width: 14%; text-align: right" title="Operating lease payments, 2023">81,522</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_zBj0F5oLzmwe" style="width: 14%; text-align: right" title="Finance lease payments, 2023">8,151</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_c20221231_z5CMRkqW6N71" style="width: 14%; text-align: right" title="Total 2023">89,673</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Twelve months ending December 31, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zGcD4UX1NxMj" style="text-align: right" title="Operating lease payments, 2024"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_z4BdzkewRGyj" style="text-align: right" title="Finance lease payments, 2024">15,614</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ContractualObligationDueInSecondYear_iI_c20221231_zPK2RPFfFAGf" style="text-align: right" title="Total 2024">15,614</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20221231_zqWjAHy6kPmh" style="text-align: right" title="Total Operating lease payments">81,522</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20221231_zBpcpcCZWHTi" style="text-align: right" title="Total Finance lease payments">23,765</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_c20221231_zY66KBstjHkk" style="text-align: right" title="Total lease payments">105,287</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: discount</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pid_di_c20221231_zHNYt3BVcdDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Operating lease payments, discount">(1,563</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20221231_zbL4SNROjyw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Finance lease payments, discount">(1,564</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractualObligationDiscount_iNI_di_c20221231_zpQcmUJrGt7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total lease payments">(3,127</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Present value of lease liabilities</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20221231_zDKjpPsmED13" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, operating lease payments">79,959</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_c20221231_zLCdbSOaIrge" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, finance lease payments">22,201</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98B_ecustom--ContractualObligationLeaseLiability_iI_c20221231_zAbONJPGacC5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease payments">102,160</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A7_z2O3vH1oe0Fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company minimum short term lease payments to be due within one year amounted to $<span id="xdx_90F_eus-gaap--ShortTermLeasePayments_c20220101__20221231_zShqFY5C3tnb" title="Short term lease payments">25,075</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929259520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z97gDaYoTsq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 20 &#8211; <span id="xdx_820_zdvDPpG9pSve">Commitments and contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is party to certain
legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible
losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
March 30, 2022, the State Courts of the Republic of Singapore had reached a verdict that </span>the Company&#8217;s subsidiaries, KRHSG
and Melana (Defendants) is liable to compensate Jamie Fan Wei Zhi (Plaintiff), the Company&#8217;s related party for failing to procure
the release of the Plaintiff from the guarantees to secure a credit line from United Overseas Bank before December 31, 2020. The Defendants
agree to compensate the Plaintiff the sum of $<span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_c20220101__20221231_zFDZre1WF5E2" title="Compensate amount">3,704</span> (SGD <span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_uSGD_c20220101__20221231_z5ccxlYxcuN4" title="Compensate amount">5,000</span>) per month as guarantor fee starting from January 1, 2021 until the Defendants
procured the release of the Plaintiff as the guarantor of the loan. The Defendants released the Jamie Fan Wei Zhi as the guarantor of
the loan on October 31, 2022. As of December 31, 2022, the Company has paid Jamie Fan Wei Zhi $<span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_z0gJyQsSiHCd" title="Legal payment">74,966</span> (SGD <span id="xdx_909_eus-gaap--LossContingencyDamagesPaidValue_uSGD_c20220101__20221231_zg0kSTSngrTl" title="Legal payment">100,000</span>), and <span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_do_c20221231_zPzPd6PPcPw6" title="Contingent liability balance outstanding">no</span> more balance
outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929232560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment information</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zwpZ64DM5STf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 21 &#8211; <span id="xdx_828_z8TB7ces3og4">Segment information</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company presents segment
information after elimination of inter-company transactions. In general, revenue, cost of revenue and operating expenses are directly
attributable, or are allocated, to each segment. The Company allocates costs and expenses that are not directly attributable to a specific
segment, such as those that support infrastructure across different segments, to different segments mainly on the basis of usage, revenue
or headcount, depending on the nature of the relevant costs and expenses. The Company does not allocate assets to its segments as the
Chief Operating Decision Maker (&#8220;CODM&#8221;) does not evaluate the performance of segments using asset information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company evaluates performance
and determines resource allocations based on a number of factors with the primary measurements being revenues and income/loss from operations
of the Company&#8217;s two reportable segments: 1) Medical Services and 2) Property Management Services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MLIH_zjoOcL57Ylw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following tables present
the summary of each segment&#8217;s revenue, loss from operations, income (loss) before income taxes and net income (loss) which is considered
as a segment operating performance measure, for the years ended December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B0_z4eZA4e9mIg4">Schedule
of segment reporting information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z8ah55WnuA9h" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zrSGorQLJfp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_zKJkRiVaJPA6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zl3ryZVn9in2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,076,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,764,295</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,840,709</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zaMLuK1Pn4W6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,463,593</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,991,371</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,454,964</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zLLEelNKyzpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,613,615</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,800,755</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,414,370</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zSBZ9LCdrvli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,651,826</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,779,966</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,431,792</td><td style="text-align: left">)</td></tr>
  </table>


<p id="xdx_8A9_zyBIyrSXf8Tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zbi74RH6UiDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
of the Company&#8217;s segment net loss before income taxes to the consolidated statement of operation and comprehensive income (loss)&#8217;s
net loss before income taxes for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zpfkpXgIvIX8" style="display: none">Schedule
of consolidated statement of operation and comprehensive income (loss)
net loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zXS513TrVwDk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_zOMhaUDoz60a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Segment loss before income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,414,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_iN_di_zknj3pCpykoj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of prepaid forward purchase liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,911,503</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--EarnoutSharePayment_iN_di_zPE6c6oJ1S65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Earnout share payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,199,629</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--OtherCorporateExpenses_iN_di_zm0mIqCHIh78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other corporate expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,406,322</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zCETa8iJRSp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Consolidated net loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(24,931,824</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_zquxMWINXwS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_C0F_gL3SOSRIBSTB-MLIH_zhbSOpfrzthh"><table cellpadding="0" cellspacing="0" id="xdx_300_134_zFFbIL40VGB7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of segment reporting information (Details)">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zVxPERp1WWMl" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zTNi99oY9Fs5" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_z8ikQOnygo5k">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zGz5sfcm7hve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">5,986,030</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">4,558,520</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">10,544,550</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zD7lB9iowtJ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,186,885</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(41,342</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,228,227</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zFo1MeNfyLA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) before income taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,239,438</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,187,975</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">948,537</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zntSrFKSsDmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,241,091</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,141,487</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">900,396</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_C0E_gL3SOSRIBSTB-MLIH_zGOTHpjMkVNl">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The accounting principles
for the Company&#8217;s revenue by segment are set out in Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2022,
the Company&#8217;s total assets were composed of $<span id="xdx_905_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zbmKTNq76yB1" title="Total assets">2,176,405</span> for medical services, $<span id="xdx_90E_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zq0FYx5BA2m3" title="Total assets">335,068</span> for property management services and $<span id="xdx_909_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z633Pm9fTjOf" title="Total assets">23,117,567</span>
for corporate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of December 31, 2021,
the Company&#8217;s total assets were composed of $<span id="xdx_90D_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z37c18cR0cu5" title="Total assets">1,478,872</span> for medical services and $<span id="xdx_904_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zbLh0WQ3Q2me" title="Total assets">6,412,439</span> for property management services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As substantially all of the
Company&#8217;s long-lived assets are located in Singapore and all of the Company&#8217;s revenue is derived from Singapore, no geographical
information is presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929346960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zuzOVkCGMsug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 22 &#8211; <span id="xdx_82E_zcNpE211EV0i">Subsequent events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated all events and transactions
that occurred after December 31, 2022 up through the date the Company issued these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 9, 2023, James
Tan, who is the former Chief Executive officer of 8i loaned the Company for an amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwvKSPWUo7Lj" title="Loan amount">145,450</span> (the &#8220;Initial Tan Loan&#8221;)
at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrdc6AGExaIh" title="Interest rate percentage">8</span>% interest per annum and was to be repaid by March 31, 2023. The Initial Tan Loan was not timely repaid by March 31, 2023 and was
replaced as disclosed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On February 2, 2023, the
Company entered into a loan agreement (&#8220;Agreement&#8221;) with Alfred Lim, the independent director of the Company, pursuant to
which Alfred Lim granted a loan amounted to $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zsPcwkQXuOWk" title="Loan amount">128,750</span> to the Company at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230202__20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zXOxAWbA5bNd" title="Interest rate percentage">8</span>% interest per annum. The loan was due on March 31, 2023. On March 31, 2023 the Company further extended the maturity date of such
loan to December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 24, 2023, James
Tan loaned the Company an additional $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zbCIDayRCKQf" title="Loan amount">332,750</span> (the &#8220;Tan Second Loan&#8221;) at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230424__20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zcwEjE8Ctpq7" title="Interest rate percentage">8</span>% interest per annum, which matures on the earlier
of June 30, 2023 or within seven days of the Company receiving the proceeds from the sales of securities in the private placement (the
&#8220;Private Placement&#8221;). Pursuant to the terms of the Tan Second Loan, the Company agreed to issue to James Tan a new promissory
note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanFirstLoanMember_zkRq0lx9ib71" title="Loan amount">145,450</span> dated April 24, 2023 (the &#8220;Tan First Loan&#8221;) to replace the Initial Tan Loan. The
Tan First Loan contained the same payment terms as the Tan Second Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 15, 2023, James Tan
entered into a third loan agreement with the Company pursuant to which James Tan agreed to loan the Company an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zUldxfZ1Ilk9" title="Loan amount">22,500</span> (the
&#8220;Tan Third Loan&#8221;), provided that the Company issued a new promissory note to James Tan in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zKGxivdVcAv1" title="Loan amount">700,000</span>
(the &#8220;Tan 2023 Note&#8221;) to replace the James Tan&#8217;s convertible note balance as of December 31, 2023 (see note 13) (the
&#8220;Tan 2022 Note&#8221;). The Tan Third Loan would bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zeiqIaFVcq56" title="Interest rate percentage">8</span>% per annum, and would be repaid upon the earlier of June 30,
2023 or within seven days of the Company receiving the proceeds from the sales of securities in the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On May 15, 2023, the Company
issued to James Tan the Tan 2023 Note to replace the Tan 2022 Note. The Tan 2023 Note was an interest-free convertible promissory note
in the aggregate principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zzWinkIh26gb" title="Loan amount">700,000</span>. On May 15, 2023, James Tan elected to convert the entire unpaid principal in the amount
of $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zv70B64MBabh" title="Conversion of unpaid principal amount">700,000</span> of the Tan 2023 Note into ordinary shares of the Company at $<span id="xdx_900_eus-gaap--CommonStockNoParValue_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z6dwX8c71ju3" title="Ordinary shares per share">1.00</span> per share in accordance with the terms of the Tan 2023 Note.
On May 16, 2023, the Company issued to James Tan <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z17zh96cLhL9" title="Ordinary shares issued">700,000</span> ordinary shares in full satisfaction of the Tan 2023 Note. Pursuant to the terms
of the Tan 2023 Note, the Company has agreed to register the <span id="xdx_901_ecustom--OrdinarySharesAvailableForResale_iI_pid_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zPKW5sl73qPb" title="Ordinary shares available for resale">700,000</span> ordinary shares for resale. The Company refers to these <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zWkLcYVdQoxc" title="Restricted ordinary shares converted">700,000</span> restricted
ordinary shares as the &#8220;Converted Shares.&#8221; <span id="xdx_90D_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zpMWkwmqoqCc" title="Conversion of ordinary shares, description">This conversion is likely resulted in modification of the convertible notes as
the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher than $1.00 and reduced
the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreement (&#8220;Settlement Agreement&#8221;) with James Tan, pursuant to which the Company
agreed to issue to James Tan an aggregate of <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--JamesTanMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5Xn83LZdkS7" title="Ordinary shares issued">478,200</span> restricted ordinary shares of the Company in full satisfaction of all obligations
of the Company under the Tan First Loan and the Tan Second Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreements (&#8220;Settlement Agreements 2&#8221;) with two third parties, Shine Link, and
Menora, and a related party, 8i Holding, pursuant to which the Company agreed to issue to Shine Link, Menora, and 8i Holding <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ShineLinkMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zQgSLj6Z6cJ2" title="Ordinary shares issued">87,500</span>, <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MenoraMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zHLX7osHK2J" title="Ordinary shares issued">119,000</span>,
and <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EightiHoldingMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zjQ3w0HKv452" title="Ordinary shares issued">82,600</span> restricted ordinary shares of the Company, respectively, in full satisfaction of all obligations of the Company under the convertible
notes balance set forth in Note 13 from Shine Link, Menora, and 8i Holding. <span id="xdx_90E_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5UCitQn2lq8" title="Conversion of ordinary shares, description">These conversions are likely resulted in modification of the
convertible notes as the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher
than $1.00 and reduced the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
May 16, 2023, the Company signed settlement agreement (&#8220;Chen Settlement Agreement&#8221;) with </span>Kelvin Chen<span style="background-color: white">,
the CEO of the Company, pursuant to which the Company agreed to issue to Kelvin Chen an aggregate of <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_zZl44HNO4skh" title="Ordinary shares issued">850,306</span> restricted ordinary shares
of the Company in full satisfaction of Kelvin Chen&#8217;s claim for an aggregate amount of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_z2aaH48OMdw2" title="Ordinary shares aggregate amount">850,306</span> provided to KRHSG from time to time
since inception. Upon issuance of the restricted ordinary shares, the balance own to Kelvin Chen reduced to nil. In order to comply with
Nasdaq&#8217;s shareholder approval requirement for issuance of stock to an executive officer of a company pursuant to Nasdaq Listing
Rule 5635(c), the Company and Dr. Chen amended the Chen Settlement Agreement by entering into a Supplemental Agreement (the &#8220;Supplemental
Agreement&#8221;) on June 6, 2023, so that the shares issued to Dr. Chen would be issued at a per share price not less than the closing
bid price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--RangeAxis__srt--MaximumMember_zwKXWZNOpfxb" title="Share price per share">1.47</span> per share on May 15, 2023, the day prior to the execution of the Chen Settlement Agreement. Pursuant to the Supplemental
Agreement, Dr. Chen has agreed to release and discharge KRHSG of all claims in return for <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zhGY4wswNL5f" title="Ordinary shares issued">578,439</span> ordinary shares at $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zGMENy2YPEll" title="Share price per share">1.47</span> per share,
the closing bid price of EUDA ordinary shares on May 15, 2023. Dr. Chen has agreed to forfeit and surrender <span id="xdx_902_ecustom--OrdinarySharesForfeited_iI_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zxsJuOxCsBAk" title="Ordinary shares forfeited">271,867</span> ordinary shares of
the <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zFkCGPb20iF3" title="Ordinary shares issued">850,306</span> ordinary shares issued to him on May 16, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Between
May 16 and May 22, 2023, the Company issued and sold to eight accredited investors an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPv0cxwTk9r3" title="Investors sale of stock and issued">940,000</span> ordinary shares (the &#8220;Placement
Shares&#8221;) at $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zouuncvZXAnf" title="Investors sale of stock price per share">1.00</span> per share for an aggregate to purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq5hcj1QIaB3" title="Investors sale of stock aggregate purchase price">940,000</span> in a private placement in reliance upon the exemption
from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506
promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 8, 2023, the Company
and the Seller 1 and Seller 2 (together, the &#8220; Sellers&#8221;) entered into amendments to the Prepaid Forward Agreements (together,
the &#8220;Amendments&#8221;), to amend the definition of &#8220;Maturity Consideration,&#8221; such that, Maturity Consideration shall
consist of <span id="xdx_90A_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zERqaZKpCb72" title="Ordinary shares to be issued"><span id="xdx_908_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zt5U0FtuUMcj" title="Ordinary shares to be issued">800,000</span></span> ordinary shares of the Company to be issued to the Sellers by the Company. Pursuant to the Prepaid Forward Agreements,
the maturity date of the Prepaid Forward Transaction 1 and 2 (together, the &#8220;Prepaid Forward Transactions&#8221;) (the &#8220;Maturity
Date&#8221;) may be accelerated by the Sellers after any occurrence wherein during any 30 consecutive trading-day period, the dollar volume-weighted
average price of Company&#8217;s ordinary shares for 20 trading days is less than $<span id="xdx_908_eus-gaap--SharePrice_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zXUEz4uhktu3" title="Share price per share">3.00</span> per share. Pursuant to the Amendments, the parties
agreed that the Prepaid Forward Transactions shall be accelerated as of the date of the Amendments, and accordingly, the <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zKT4Dq40Cy5j" title="Ordinary shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zzSp6mQhPTc8" title="Ordinary shares issued">800,000</span></span> ordinary
shares (or <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkLrsvQOtkB9" title="Ordinary shares issued">1,600,000</span> ordinary shares in the aggregate), became immediately due and payable to the Sellers upon execution of the Amendments.
The Amendments provide the Sellers with registration rights for the ordinary shares issuable as Maturity Consideration, and also prohibit
the Sellers from selling such ordinary shares on any exchange business day in an amount greater than <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zkt7DP8QMf0h" title="Debt instrument trading percentage">15</span>% of the daily trading volume of
the Company&#8217;s ordinary shares on such day. In addition, as of June 8, 2023 (the &#8220;Maturity Date&#8221;), the Sellers became
entitled to retain (a) the remaining prepayment amount paid from the Company&#8217;s trust account to the Sellers upon consummation of
the Company&#8217;s business combination, and (b) the remaining ordinary shares held by each Seller that were subject to the Prepaid Forward
Transactions. Pursuant to the Amendments, no other fees, consideration or other amounts are due to the Seller or the Company upon the
Maturity Date.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915404448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSsB6kvupef4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zwCniqxuvEQk">Basis of presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for information pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z3DChkLqzxSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zF6ALmZSU2v3">Principles of consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the
financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been
eliminated upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A subsidiary is an entity in which the Company, directly
or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint
or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_ziE8lyISxu0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86F_zqhn5KtRmAdi">Use of estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated
financial statements include lease classification and liabilities, right-of-use assets, determinations of the useful lives and valuation
of long-lived assets, estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of deferred tax assets, other provisions and contingencies, estimated fair value of earn-out shares, prepaid forward purchase liability
and private warrants. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation and transaction</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zHTqyqU43xT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_zRgjT4PnAlrb">Foreign currency translation and transaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements
of operations and comprehensive income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is United States
Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed in US$. The Company&#8217;s subsidiaries in
Singapore, Vietnam, and Malaysia conduct its businesses and maintain its books and records in the local currency, Singapore Dollars (&#8220;SGD&#8221;),
Vietnamese Dong (&#8220;VND&#8221;), and Malaysian Ringgit (&#8220;MYR&#8221;), as its functional currency, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, for consolidation purposes, assets and
liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation
of Financial Statement&#8221;</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average
rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are
recorded as a separate component of accumulated other comprehensive income (loss) within the statements of shareholders&#8217; equity
(deficit). Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of
cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been
made at the following exchange rates for the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zOSriTLcuXej">Schedule
of foreign currency exchange rates</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Period-end SGD: US$1 exchange rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.34</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.35</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,635.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,855.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end MYR: US$1 exchange rate<span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average SGD: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.38</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.34</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-average VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,409.44</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,935.24</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average MYR: US$1 exchange rate<span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right">*</td><td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</td>
</tr></table>

<p id="xdx_8AE_zKpYTNGnrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NonControllingInterestPolicyTextBlock', window );">Non-controlling interests</a></td>
<td class="text"><p id="xdx_84A_ecustom--NonControllingInterestPolicyTextBlock_zYE5SHVmHsF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zGnl4f1z7Jvi">Non-controlling interests</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the Company&#8217;s non-wholly
owned subsidiaries, a non-controlling interest is recognized to reflect portion of equity that is not attributable, directly or indirectly,
to the Company. The cumulative results of operations attributable to non-controlling interests are also recorded as non-controlling interests
in the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive income (loss). Cash flows
related to transactions with non-controlling interests are presented under financing activities in the consolidated statements of cash
flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq5C34a2q0Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zVLy6WJnWLAc">Segment reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s chief operating decision-maker
is identified as the chief executive officer who reviews financial information presented on a consolidated basis, accompanied by disaggregated
information about revenues by different revenues streams for purposes of allocating resources and evaluating financial performance. Based
on qualitative and quantitative criteria established by Accounting Standards Codification (&#8220;ASC&#8221;) 280, &#8220;Segment Reporting&#8221;,
the Company considers itself to be operating within two operating and reportable segments as set forth in Note 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and restricted cash</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zotmo0AGUb46" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_z5C95HgCqS8b">Cash and restricted cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash represent cash on hand and demand deposits
placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities less
than three months. Restricted cash represents cash held in bank account from 8i which was restricted due to the incomplete
procedures of changing signers as of December 31, 2022. As of the date of the issuance of these financial statements, such
restriction has been lifted and the remaining cash held in bank account has transfer to the Company&#8217;s operating bank account.
Therefore, such restricted cash should be classified as current asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJz3RXlAubL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zPOqmiGawfKf">Accounts receivable, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with its customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial condition, credit
history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.
As of December 31, 2022 and 2021, the Company provided allowance for doubtful accounts of $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zlpZMgdcDzik" title="Allowance for doubtful accounts">197,438</span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zGHVaJ0GDus1" title="Allowance for doubtful accounts">80,799</span>, respectively. For the
years ended December 31, 2022 and 2021, the Company did not write off any allowance for doubtful account against the account receivable
balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Other receivables</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_z4vpRxO1nkdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_865_zsymQJuC8us1">Other receivables</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other receivables primarily include receivables
from investment from the Company&#8217;s Affordable Home project in Indonesia and employee advance, and refundable deposits from
third party service providers. Management regularly reviews the aging of receivables and changes in payment trends and records
allowances when management believes collection of amounts due are at risk. Accounts considered uncollectable are written off against
allowances after exhaustive efforts at collection are made. $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zEjhEcO3zEY8" title="Other receivables allowance for doubtful account">2,209,825</span>
allowance for doubtful account related to other receivable was recorded and written off for the year ended December 31, 2022. <span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_dxL_c20211231_zsJbaTAAdVvd" title="Other receivables allowance for doubtful account::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">Nil</span></span>
allowance for doubtful account related to other receivable was recorded for the year ended December 31, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p id="xdx_84E_ecustom--PrepaidExpensesAndOtherAssetsPolicyTextBlock_zMunaeL9wrni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zykHIuOSgNul">Prepaid expenses and other current assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
primarily include prepaid expenses paid to services providers, and other deposits. Management regularly reviews the aging of such
balances and changes in payment and realization trends and records allowances when management believes collection or realization of
amounts due are at risk. Accounts considered uncollectable are written off against allowances after exhaustive efforts at collection
are made. As of December 31, 2022 and 2021, <span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20221231_zUw43t5ro5Aj" title="Allowance"><span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20211231_zrGIS7vVUmQd" title="Allowance">no</span></span>
allowance for doubtful account related to prepaid expenses was recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zXARoPszRa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zaRi3G7tDwil">Property and equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value.
The estimated useful lives are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z0h1r7koBEI2">Schedule
of property and equipment useful lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected useful lives</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment">3</span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment">3 </span>years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment">Shorter of the lease term or 5 years</span></span></td></tr>
  </table>
<p id="xdx_8AE_zLzJMkKXwnGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost and related accumulated depreciation of assets
sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations
and comprehensive income (loss). Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals
and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of
depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows
that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the
carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. </span>For the years ended
December 31, 2022 and 2021, there was <span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20220101__20221231_z6WGodJ7oX5h" title="Impairment of property and equipment"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20210101__20211231_zFIoeZHOdOic" title="Impairment of property and equipment">no</span></span> impairment of property and equipment recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets, net</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4QpciiqLaml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zYQ9S0iEeFT8">Intangible assets, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Purchased intangible assets
are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue
to be amortized over the Company&#8217;s best estimate of its useful life as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B5_ztDHNIRRQgA">Schedule
of intangible assets net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Categories</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships">6</span> years</span></td></tr>
  </table>
<p id="xdx_8A5_zehZDb2Ho9u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company amortized the
intangible assets using the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up in accordance
with ASC Topic 350 &#8220;<i>Intangibles - Goodwill and Other</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Separately identifiable intangible
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting
from the use of the asset and its eventual disposition. Measurement of any impairment loss for identifiable intangible assets is based
on the amount by which the carrying amount of the assets exceeds the fair value of the assets. $<span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zjvw1S4emLo" title="Impairment of intangible assets">167,787</span> and <span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20210101__20211231_zFcl6YU05hN" title="Impairment of intangible assets::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0868">nil</span></span> impairment of intangibles
assets was recorded for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zjKgluIGYFj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="text-decoration: underline"><span id="xdx_86F_zCo9PuvNtMii">Goodwill</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of operations and comprehensive income (loss). Impairment losses on goodwill
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the carrying value of intangible
assets not subject to amortization, including goodwill, to determine whether impairment may exist annually or more frequently if events
and circumstances indicate that it is more likely than not that an impairment has occurred. Management has determined that the Company
has two reporting units within the entity at which goodwill is monitored for internal management purposes. The Company adopted ASU 2017-04
in 2022, which primary goal is to simplify the goodwill impairment test and provide cost savings for all entities. This is accomplished
by removing the requirement to determine the fair value of individual assets and liabilities in order to calculate a reporting unit&#8217;s
&#8220;implied&#8221; goodwill under current GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in ASU 2017-04 eliminate Step 2 of
the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value
of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting
unit&#8217;s carrying amount exceeds its fair value. If fair value exceeds the carrying amount, no impairment should be recorded. Any
loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Impairment losses on goodwill cannot
be reversed once recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When measuring a goodwill impairment loss, an entity
should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit. The ASU contains
an illustration of the simultaneous equations method to demonstrate this, which reflects a deferred tax benefit from reducing the carrying
amount of tax-deductible goodwill relative to the tax basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An entity may still perform the optional qualitative
assessment for a reporting unit to determine if it is more likely than not that goodwill is impaired. However, this ASU eliminates the
requirement to perform a qualitative assessment for any reporting unit with zero or negative carrying amount. Therefore, the same one-step
impairment assessment will apply to all reporting units. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing qualitative assessment on the two
reporting units and determine that it is more likely than not that the fair value of each reporting unit is less than its carrying amount.
Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zxdgRoAYe1c3" title="Impairment loss on goodwill">971,229</span> was recognized for the year ended
December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended December 31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment for long-lived assets</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zyAO3IcI2ZW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_zzN6hD19dQzg">Impairment for long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 360-10, Long-lived assets,
including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a
significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets
are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use
of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment
is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows
approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, $<span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20220101__20221231_zbzqUjYEcIoc" title="Impairment of long-lived assets">0.2</span> million and <span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_dxL_c20210101__20211231_ziwZdHFyfgN4" title="Impairment of long-lived assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0878">nil</span></span> impairment of long-lived assets was recognized, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zoHy4sXBp72b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zCKIbY0JNRSj">Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, Distinguishing Liabilities
from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s
own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside
of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For issued or
modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of
equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that
its warrants qualify for equity accounting treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
completion of the business combination, all of 8i&#8217;s public and private warrants remain outstanding were replaced by the Company&#8217;s
public and private warrants. The Company treated such warrants replacement as a warrant modification and no  incremental fair value
was recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock', window );">Forward Purchase Receivables and Prepaid Forward Purchase Liabilities</a></td>
<td class="text"><p id="xdx_84D_ecustom--ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_zAbr4mxqpXwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_z0xs9mPGPiI1">Forward Purchase Receivables and Prepaid Forward
Purchase Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The
Company recorded Forward Purchase Receivables on its consolidated balance sheets of $<span id="xdx_90C_ecustom--ForwardPurchaseReceivables_iI_c20221231_zufvipqGptB7" title="Forward purchase receivables">21,892,527</span>
as of December 31, 2022 to account for the Prepayment Amount of the Forward Purchase Agreement, as discussed in Note 11. The
Prepayment Amount will be held in a deposit account until the Valuation Date (the second anniversary of the closing of the Business
Combination, subject to certain acceleration provisions). At the Maturity Date, the Sellers are entitled to received $2.50 per
Recycled Shares (&#8220;Maturity Consideration&#8221;) in cash or in shares. As of December 31, 2022, no shares were sold after
Closing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In
connection with the Forward Purchase Agreement, the Company recognized a liability in accordance with ASC 480-10-25-8 as the Company
has the obligation to pay cash to settle the maturity consideration, referred to herein as the &#8220;prepaid forward purchase
liability&#8221; on its consolidated balance sheets of $<span id="xdx_909_ecustom--PrepaidForwardPurchaseLiability_iI_c20221231_zgkSaEqRPUdh" title="Purchase liability">20,321,053</span>
as of December 31, 2022. Refer to Note 11 for further detail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zHa2YQMTAD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zQWedSe4xpl2">Revenue recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the revenue accounting requirements
of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;Accounting Standards
Codification (&#8220;ASC&#8221;) 606&#8221;). The core principle underlying the revenue recognition of this ASU allows the Company to
recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and
determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers
to a customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To achieve that core principle, the Company applies
five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for a contract with a customer
when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial
substance and collectability is probable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue recognition policies for each type of revenue
stream are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates on a unified technology
health care platform which provide a full continuum of healthcare services integrated with healthcare data analytics to drive
improved outcomes for patients. The Company operates the medical services on a business-to-business (B2B) platform, and serves the
corporate customers involved in various industries. The Company is primarily generating revenue on a per healthcare visit basis for
specialty medical visits for specialist treatment such as cardiology, dermatology and etc, at the time which the single performance obligation was satisfied. Such fees are paid by the corporate
customers on behalf of their employees. <span style="background-color: white">The Company generally bills their corporate customers
for the healthcare visit services on a weekly basis, or in arrears depending on the service, with payment terms generally between 30
to 90 days. There are not significant differences between the timing of revenue recognition and billing. Consequently, the Company
has determined that the Company&#8217;s contracts do not include a financing component. </span>Revenue is recognized in an amount
that reflects the consideration that is expected in exchange for the service at a point in time at the time of the visit. In
addition, the Company&#8217;s contracts do not generally contain refund provisions for fees earned related to services
performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for medical service revenue on
a gross basis as the Company is acting as a principal in these transactions and is responsible for fulfilling the promise to provide the
specified services, which the Company has control of the services and has the ability to direct the service providers to be performed
to obtain substantially all the benefits. In making this determination, the Company also assesses whether it is primarily obligated in
these transactions, is subject to inventory risk, has latitude in establishing prices, or has met several but not all of these indicators
in accordance with ASC 606-10-55-36 through 40.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the medical services revenue
when the control of the specified services is transferred to its customer, which at a point in time at the time after completion of the
visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also operates on a general practice clinic
and generating such revenue on a per healthcare visit basis. Revenues are recognized when the visits are completed at a point in time
at the time of the visit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied at a point in time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company purchases, sells, and installs facial
recognition and temperature measurement monitor system to corporate customer, where the product and the installation are interrelated
and are not capable of being distinct since the customer cannot benefit from the product or installation either on its own. The Company
recognized the products revenue when control of the product is passed to the customer, which is the point in time that the customers are
able to direct the use of and obtain substantially all of the economic benefit of the goods after the installation by the Company&#8217;s
technician. The transfer of control typically occurs at a point in time based on consideration of when the customer has an obligation
to pay for the goods, and physical possession of, legal title to, and the risks and rewards of ownership of the goods has been transferred,
and the customer has accepted the goods. Revenue is recognized net of estimates of variable consideration, including product returns,
customer discounts and allowance. Historically, the Company has not experienced any significant returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Performance obligation satisfied over a period of
time</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company provides property management services
in shopping malls, business office building, or residential apartments to all tenants and property owners. Property management services
include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional
services and also include security property management services provided to all tenants and property owners. Each of the two services
is within separate agreements. The Company identified common area property management services as a single performance obligation as the
kinds of service in the contract are not capable of being distinct and identified the security management services as another single performance
obligation as there is only one service that is to provide security services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the common area property management
revenue and security property management revenue on a straight-line basis over the terms of the common area property management agreement
and security property management agreement, generally over one year period because its customer simultaneously receives and consumes the
benefits provided by the Company throughout the performance obligations period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to apply the practical expedient
to expense costs as incurred for incremental costs to obtain a contract when the amortization period would have been one year or less.
As of December 31, 2022 and 2021, the Company did not have any contract assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized advance payments from its customer
prior to revenue recognition as contract liability until the revenue recognition performance obligation are met. As of December 31, 2022
and 2021, the Company did not have any contract liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zwogmTEuY6ql">Schedule
of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">6,001,439</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">5,010,837</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; general practice</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">63,794</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,712</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practice (related parties)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,065,368</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,728,189</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,046</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">257,841</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management service &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,919,335</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,508,663</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management service &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">844,960</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,049,857</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management service</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,764,295</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,558,520</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,840,709</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,544,550</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AF_zwNQtZ3F5UWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cost of revenues</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Medical Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical supplies
purchased and medical service was provided by Cadence Health Pte. Ltd., a related party, prior to March 2022. Medical supplies purchased
and medical service provided by the third party service providers were insignificant prior to March 2022. Beginning in April 2022, cost
of revenues mainly consists of medical supplies purchased and medical service are provided by third party service providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Product Sales</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of medical product
or equipment purchased for resale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Property Management Services</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues mainly consists of labor expenses
incurred attributable to property management service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of cost of revenues by products/services
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zIQd8Hn75Yi9">Schedule
of cost of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">2,995,778</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">46,849</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; specialty care (related party)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practices</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">45,549</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">427,908</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,532,826</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,824,459</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">59,391</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">167,202</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management services &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,210,703</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,461,981</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management services &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">683,593</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">846,555</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management services</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,894,296</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,308,536</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cost of revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,486,513</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,300,197</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A2_z0IzxNUwrZ11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zjMJr2QoqkRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zr5XE1q82T8i">Advertising costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising is mainly through online and offline promotion
activities. Advertising costs amounted to $<span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zszyCFvLJSLj" title="Advertising cost">21,795</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_c20210101__20211231_zsS5Uxd9nK9j" title="Advertising cost">270,361</span> for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7X9jQrXD66f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86E_zpOYfJHLeqJh">Research and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses include salaries
and other compensation-related expenses to the Company&#8217;s research and product development personnel, and related expenses for the
Company&#8217;s research and product development team. Research and development expenses amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zspS1u46hib6" title="Research and Development cost">17,209</span> and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zxLEZpIcrsY9" title="Research and Development cost">129,265</span> for the years
ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DefinedContributionPlanPolicyTextBlock', window );">Defined contribution plan</a></td>
<td class="text"><p id="xdx_84D_ecustom--DefinedContributionPlanPolicyTextBlock_zz7xjkCOkr5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_862_zCUiQA3XaXMi">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The full-time employees of the Company are entitled
to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages
of the employees&#8217; respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and
make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_z0ATFRFJrw8f" title="Employee expenses">505,591</span> and $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231_zXCCuwdZ0eO9" title="Employee expenses">574,535</span>
for the years ended December 31, 2022 and 2021, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The related contribution plans include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Singapore subsidiaries</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Central Provident Fund (&#8220;CPF&#8221;) &#8211;
<span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--CentralProvidentFundMember_zUu8bYl0NPrk" title="Employee plan description">17.00% based on employee&#8217;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase</span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Skill Development Levy (&#8220;SDL&#8221;) &#8211;
<span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zJvENAmvNVCg" title="Employee plan description">up to 0.25% based on employee&#8217;s monthly salary capped $<span id="xdx_906_eus-gaap--SalariesAndWages_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zlsgb4ysvVoj" title="Monthly salary">8.3</span> (SGD <span id="xdx_90C_eus-gaap--SalariesAndWages_pn4n6_uSGD_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zO9j3tWmsHil" title="Monthly salary">11.25</span>)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Vietnam subsidiary</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Social Insurance Fund (&#8220;SIF&#8221;) &#8211;
<span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zWfExI0ZcJOl" title="Employee plan description">20% based on employee&#8217;s monthly salary</span>;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">- Trade Union Fee &#8211; <span id="xdx_907_ecustom--TradeUnionFeePercentage_iI_pid_dp_c20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zL0wDN9ABgB" title="Trade union fee">2.00%</span> of SIF</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_GoodsAndServicesTaxesPolicyTextBlock', window );">Goods and services taxes (&#8220;GST&#8221;)</a></td>
<td class="text"><p id="xdx_84F_ecustom--GoodsAndServicesTaxesPolicyTextBlock_ztdAswiUWax5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zk8Bn1NLCiC6">Goods and services taxes (&#8220;GST&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue represents the invoiced value of service,
net GST. The GST are based on gross sales price. GST rate is generally 7% in Singapore. Entities that are GST general taxpayers are allowed
to offset qualified input GST paid to suppliers against their output GST liabilities. Net GST balance between input GST and output GST
is recorded in tax payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zkrVaXBFCHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_z96DWJzY5po1">Income taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance
with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are
non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Deferred tax
is calculated using the balance sheet liability method in respect of temporary differences arising from differences between the carrying
amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis. In principle, deferred tax
liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable
that taxable income will be utilized with prior net operating loss carried forwards using tax rates that are expected to apply to the
period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when
it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion or all of the deferred tax assets will not be utilized. Current income taxes
are provided for in accordance with the laws of the relevant tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit
only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is <span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zk2Ix9U7GPQk" title="Income tax likelihood description">greater than 50% likely of being realized
on examination</span>. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. No penalties and
interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021. <span style="background-color: white">As
of December 31, 2022, the tax returns of the Company&#8217;s Singapore entities for the calendar year from 2019 through 2022 remain open
for statutory examination by Singapore tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognize interest and penalties related to unrecognized tax
benefits, if any, on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties
are included on the related tax liability line in the consolidated balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts much of its business activities
in Singapore and is subject to tax in its jurisdiction. As a result of its business activities, the Company&#8217;s subsidiaries file
separate tax returns that are subject to examination by the foreign tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss)</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zLbU2af5srSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_864_zJZj3giURid">Comprehensive income (loss)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive income (loss) consists of two components,
net income and other comprehensive income. Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under
GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net income. Other comprehensive income (loss) consists
of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">(Loss) earnings per share</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zMCDFPoIvl4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zzedsnCQU4vf">(Loss) earnings per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes (loss) earnings per share (&#8220;EPS&#8221;)
in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is
measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect
on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e.,
those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates basic and diluted (loss)/earnings
per share as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zRuz5Eat8IOc" style="display: none">Schedule
of basic and diluted earnings per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Years Ended<br/>
December 31</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net (loss) income</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(24,949,246</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">900,396</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less: Net (income) loss attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(65,124</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">35,567</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Net (loss)/income attributable to common shareholders, basic</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,884,122</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">864,829</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average number of shares outstanding, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">12,029,656</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">9,253,333</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">(Loss)/Earnings per share, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(2.07</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">0.09</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zuN25CFHeBDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of December
31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants are convertible into <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zOB5W99vo8ma" title="Antidilutive shares">1,411,725</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zk0BBegFiS8l" title="Antidilutive shares">4,458,625</span>
of the Company&#8217;s ordinary shares, respectively, were not included in the computation of dilutive loss per share because the inclusion
of such convertible notes and warrants would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzVOHzfqt77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zbaSlXmfzUo">Fair value measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received
for an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Valuation
techniques maximize the use of observable inputs and minimize the use of unobservable inputs. When determining the fair value measurements
for assets and liabilities, we consider the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability. The following summarizes the three levels of inputs required to
measure fair value, of which the first two are considered observable and the third is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Unadjusted quoted prices in active markets
for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Unobservable inputs that are supported by
little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value for certain assets and liabilities
such as cash and restricted cash, accounts receivable, net, other receivables, prepaid expenses and other current assets, loan to third-party,
short-term loans, promissory note, convertible notes, accounts payable, other payables and accrued liabilities, and tax payables have
been determined to approximate carrying amounts due to the short maturities of these instruments. The Company believes that its long-term
loan to third party approximates the fair value based on current yields for debt instruments with similar terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zkN130Ffe2af" style="display: none">Schedule
of fair value hierarchy of financial liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value at</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Fair Value Measurement at</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Prepaid forward purchase liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zNGpWR5NLY12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zBcQXMqTTOY2" style="display: none">Schedule of reconciliation of financial
liability measured at fair value on a recurring basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">7,409,550</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Change in fair value of prepaid forward purchase liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">12,911,503</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">20,321,053</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zoLBIGo0IqXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z6axbXx4rODj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_861_zbRXPdj5KhW6">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company accounts for leases in accordance with ASC 842. </span>The Company entered into two agreements as a lessee to lease office equipment
for general and administrative operations. If any of the following criteria are met, the Company classifies the lease as a finance lease:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease term is for 75% or more of the remaining economic life of the underlying asset, unless the commencement date falls within the last 25% of the economic life of the underlying asset;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The present value of the sum of the lease payments equals or exceeds 90% of the fair value of the underlying asset; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Leases that do not meet any
of the above criteria are accounted for as operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company combines lease
and non-lease components in its contracts under Topic 842, when permissible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Finance
and operating lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. Since the implicit rate for the Company&#8217;s leases is not readily determinable,
the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present
value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized
basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its finance or operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company
has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term
of twelve months or less. Its leases generally do not provide a residual guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
finance or operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease
term for operating lease. Meanwhile, the Company recognizes the finance leases ROU assets and interest on an amortized cost basis. The
amortization of finance ROU assets is recognized on an accretion basis as amortization expense, while the lease liability is increased
to reflect interest on the liability and decreased to reflect the lease payments made during the period. Interest expense on the lease
liability is determined each period during the lease term as the amount that results in a constant periodic interest rate of the </span>office
equipment <span style="background-color: white">on the remaining balance of the liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset
may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from
the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows. For the years ended December 31, 2022 and 2021, </span>the Company did not recognize impairment loss on its finance
and operating lease ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RelatedPartyPolicyTextBlock', window );">Related parties</a></td>
<td class="text"><p id="xdx_842_ecustom--RelatedPartyPolicyTextBlock_zW3ikgaDVMkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zkWRq3C9mr3e">Related parties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject
to common control or common significant influence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recent accounting pronouncements not yet adopted</a></td>
<td class="text"><p id="xdx_844_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zMhejxndWpM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zNRPmrsYJrIc">Recent accounting pronouncements not yet adopted</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all accounting standards updates (&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging
growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the
adoption of these accounting standards until they would apply to private companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU 2021-08, which
is an update to ASU Updated No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive accounting
model on revenue recognition for contracts with customers. The amendments in this update require that an entity (acquirer) recognize and
measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective
for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted,
including adoption in an interim period. The Company has adopted this standard on January 1, 2023, and the adoption did not have a material
impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the FASB issued ASU 2019-05, which is
an update to ASU Update No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured
at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial
Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting
for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized
cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The
amendments in this Update address those stakeholders&#8217; concerns by providing an option to irrevocably elect the fair value option
for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase
comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets.
Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13
while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which
to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies
applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after
December 15, 2022. In March 2022, the FASB issued ASU No. 2022-02, which is to (1) eliminate the accounting guidance for TDRs by creditors
in Subtopic 310-40, Receivables&#8212;Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan
refinancings and restructurings by creditors when a borrower is experiencing financial difficulty, and (2) disclose current-period gross
write offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, Financial
Instruments&#8212;Credit Losses&#8212;Measured at Amortized Cost. ASU 2019-05 is effective for the Company for annual and interim reporting
periods beginning January 1, 2023 as the Company is qualified as an emerging growth company. The Company has adopted this standard on
January 1, 2023, and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfmIHjiMvRu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zaJ77kGpf1n8">Recently adopted accounting pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12, &#8220;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#8221;. The amendments in this Update simplify the accounting for income
taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments
in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years
beginning after December 15, 2022. Early adoption of the amendments is permitted, including adoption in any interim period for (1) public
business entities for periods for which financial statements have not yet been issued and (2) all other entities for periods for which
financial statements have not yet been made available for issuance. An entity that elects to early adopt the amendments in an interim
period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity
that elects early adoption must adopt all the amendments in the same period. The Company has adopted this standard on January 1, 2022,
and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the Financial Accounting Standards
Board issued Accounting Standards Update (ASU) 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities
and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#8217;s accounting for
convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#8217;s own equity such that fewer
conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment.
The Company early adopted this ASU on January 1, 2022, and the adoption did not have a material impact on the Company&#8217;s consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-08, &#8220;Codification
Improvements to Subtopic 310-20, Receivables&#8212;Nonrefundable Fees and Other Costs&#8221;. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021.
Early adoption was permitted, including adoption in an interim period. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, the FASB issued ASU 2020-10, &#8220;Codification
Improvements to Subtopic 205-10, presentation of financial statements&#8221;. The amendments in this Update improve the codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed.
The amendments also clarify guidance so that an entity can apply the guidance more consistently. ASU 2020-10 is effective for the Company
for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or
interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively.
An entity should apply the amendments at the beginning of the period that includes the adoption date. The adoption of this standard on
January 1, 2022 did not have a material impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive income (loss) and statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward Purchase Receivables and Prepaid Forward Purchase Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_GoodsAndServicesTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Good and services taxes [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_GoodsAndServicesTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New accounting pronouncements not yet adopted policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_NonControllingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Controlling Interest [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_NonControllingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RelatedPartyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RelatedPartyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accounting policy of warants text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929271536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and organization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of consolidated financial statement</a></td>
<td class="text"><p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zzrsYIVYtU3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
reflect the activities of EUDA and each of the following entities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B8_zO0MFroHEgr2" style="display: none">Schedule of consolidated financial statement</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_ztt8seKfNKj7" title="Name of company">EUDA Health Limited (&#8220;EHL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company
Incorporated on <span id="xdx_905_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_z0ync8rYeFLe" title="Date of incorporation">June 8, 2021</span> <br/>
A holding Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_zgcbYWPo4abj" title="Ownership percentage">100</span>% owned by EUDA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zUwAwOFjT3ae" title="Name of company">Kent Ridge Healthcare Singapore Pte. Ltd. (&#8220;KRHSG&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_901_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zDe7wPuvozp7" title="Date of incorporation">November 9, 2017</span> <br/>
Multi-care specialty group offering range of specialty care services to patients.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zyMEq0S7QwXf" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zd99RF1PNEQe" title="Name of company">EUDA Private Limited (&#8220;EUDA PL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90A_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zqbIwHB4wP9" title="Date of incorporation">April 13, 2018</span> <br/>
A digital health company that provides a platform to serve the healthcare industry</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zZRNTkRCwAO3" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zClTqn3LSgL9" title="Name of company">Zukitek Vietnam Private Limited Liability Company (&#8220;ZKTV PL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Vietnam company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zIbJX9cpEhxi" title="Date of incorporation">May 2, 2019</span> <br/>
A Research and Development Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zeq5sYBziRI9" title="Ownership percentage">100</span>% owned by EUDA PL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zX4UnAQNcqWi" title="Name of company">Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zA4bi8mmhEid" title="Date of incorporation">March 18, 2019</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTC1BKBCjE3c" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_fKDEp_zHby8OhBz5Ug" title="Name of company">The Good Clinic Private Limited (&#8220;TGC&#8221;)</span>(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90D_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zP7pQMx9TP38" title="Date of incorporation">April 8, 2020</span> <br/>
Medical facility general practice clinic that provides holistic care for various illnesses</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zGVp5NzdxIwb" title="Ownership percentage">100</span>% owned by SEMA</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zjbB0SBuz2hc" title="Name of company">EUDA Doctor Private Limited</span><br/>
(&#8220;ED PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_z21LqjYwPzZ6" title="Date of incorporation">December 1, 2021</span> <br/>
A platform solution for doctors and physicians to find, connect, and collaborate with trusted peers, specialists, and other professionals </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zVVm4RT5bkb1" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zLagWTm6o119" title="Name of company">Kent Ridge Hill Private Limited</span><br/>
(&#8220;KR Hill PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zmeybEREw8Fl" title="Date of incorporation">December 1, 2021</span> <br/>
A B2B2C pharmaceutical and OTC drugs e-commerce platform to promote its drug products </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zhNEsidOtjBd" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zKjP4pd0gpGd" title="Name of company">Kent Ridge Health Limited</span> (&#8220;KRHL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br/>
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zei81uu1GRzc" title="Date of incorporation">June 8, 2021</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_z5AP4aBUTiKj" title="Ownership percentage">100</span>% owned by EHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_za1FjQC2ABA6" title="Name of company">Zukitech Private Limited (&#8220;Zukitech&#8221;)</span> <br/>
(&#8220;ZKT PL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zXGpcJ4eg2Nf" title="Date of incorporation">June 13, 2019</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zyQCIXcWfqib" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_z4WLm1MsH2U1" title="Name of company">Super Gateway Group Limited</span><br/>
(&#8220;SGGL&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A British Virgin Islands company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zeV5hsW0wkk3" title="Date of incorporation">April 18, 2008</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zao2DCaqPzEl" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zMOecuW4Fqi1" title="Name of company">Universal Gateway International Pte. Ltd. (&#8220;UGI&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_900_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zKlwvd3khwCi" title="Date of incorporation">September 30, 2000</span> <br/>
Registered capital of RMB <span id="xdx_90F_ecustom--RegisteredCapital_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_za0HkDmqDWNg" title="Registered capital">5,000,000</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zROkB5aEsc1" title="Ownership percentage">98.3</span>% owned by SGGL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zsewKPcKPdcb" title="Name of company">Melana International Pte. Ltd</span>.<br/>
(&#8220;Melana&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_90B_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zlTxMQFCZW6h" title="Date of incorporation">September 9, 2000</span> <br/>
Property management service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_ziXPMehyxJyc" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zDCItDPyBzsh" title="Name of company">Tri-Global Security Pte. Ltd.</span><br/>
(&#8220;Tri-Global&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zzvYqTMqIBo" title="Date of incorporation">August 10, 2000</span> <br/>
Property security service that services shopping malls, business office building, or residential apartments</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zk6fh7HFQ2qi" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zOOPNxBp4PV1" title="Name of company">UG Digitech Private Limited (&#8220;UGD&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zNkhSBnW2Tu9" title="Date of incorporation">August 16, 2001</span> <br/>
A holding company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_z1qwKbytOAu3" title="Ownership percentage">100</span>% owned by UGI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4aUNoMPGah" title="Name of company">Nosweat Fitness Company Private Limited (&#8220;NFC&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679; <br/>
&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_za8fPS5Rl4Nh" title="Date of incorporation">July 6, 2021</span> <br/>
A virtual personal training platform for fitness enthusiasts </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4oTRX8nSFNe" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zipiYmzHA6ma" title="Name of company">True Cover Private Limited (&#8220;TCPL&#8221;)</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zakOLADYtd2i" title="Date of incorporation">December 1, 2021</span> <br/>
A B2B e-claims healthcare insurance platform </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_z5tDhmcTVXL9" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_fKDIp_zFEmzLZg0sp3" title="Name of company">KR Digital Pte. Ltd. (&#8220;KR Digital&#8221;)</span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;<br/>
&#9679;<br/>
&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Singapore company <br/>
Incorporated on <span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zpXuE3yx6uOb" title="Date of incorporation">December 29, 2021</span> <br/>
Development of software and applications </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zX8VmugoK8Se" title="Ownership percentage">100</span>% owned by KRHL</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_fKDIp_zdUNGwzuWvB1" title="Name of company">Zukihealth Sdn. Bhd. (&#8220;Zukihealth&#8221;)</span> (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; <br/>
&#9679; <br/>
&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Malaysian company <br/>
Incorporated on <span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zD1qRMBHP42c" title="Date of incorporation">February 15, 2018</span> <br/>
Distribution of health care supplement products</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zUKWwA5SnhD9" title="Ownership percentage">100</span>% owned by KR Digital</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation has not been commenced</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F02_z6JKmcmddXa8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zDswtzrNKI4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2022, SEMA, the Company&#8217;s wholly owned subsidiary, sold <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage">100</span>% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ <span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration">1.0</span> (see Note 5).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zy1YdGXNhCJ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zqN3c8c5vTv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 19, 2022, the Company acquired <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage">100</span>% equity interest of KR Digital Pte Ltd, (&#8220;KR Digital&#8221;), a Singapore Company, from Mr. Kelvin Chen, the Company&#8217;s Chief Executive Office (&#8220;CEO&#8221;) and shareholder for total consideration of SG$<span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration">1</span>. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage">100</span>% equity interest of Zukihealth Sdn Bhd, (&#8220;Zukihealth&#8221;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#8217;s CEO and shareholder for total consideration of SG$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration">1</span>. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921139632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock', window );">Schedule of foreign currency exchange rates</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zOSriTLcuXej">Schedule
of foreign currency exchange rates</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">As of<br/>
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Period-end SGD: US$1 exchange rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.34</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">1.35</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,635.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,855.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end MYR: US$1 exchange rate<span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-end : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average SGD: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.38</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.34</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Period-average VND: US$1 exchange rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,409.44</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,935.24</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average MYR: US$1 exchange rate<span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average : US$1 exchange rate<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.39</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right">*</td><td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PropertyPlantAndEquipmentsTextBlock', window );">Schedule of property and equipment useful lives</a></td>
<td class="text"><p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z0h1r7koBEI2">Schedule
of property and equipment useful lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected useful lives</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment">3</span> years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment">3 </span>years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvement</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment">Shorter of the lease term or 5 years</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock', window );">Schedule of intangible assets net</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B5_ztDHNIRRQgA">Schedule
of intangible assets net</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Categories</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer relationships</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships">6</span> years</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock', window );">Schedule of revenue</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zwogmTEuY6ql">Schedule
of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">6,001,439</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">5,010,837</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; general practice</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">63,794</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,712</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practice (related parties)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,065,368</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,728,189</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,046</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">257,841</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management service &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,919,335</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,508,663</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management service &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">844,960</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,049,857</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management service</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,764,295</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,558,520</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,840,709</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,544,550</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfCostOfRevenueTableTextBlock', window );">Schedule of cost of revenue</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zIQd8Hn75Yi9">Schedule
of cost of revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Medical services &#8211; specialty care</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">2,995,778</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">46,849</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical services &#8211; specialty care (related party)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical services &#8211; general practices</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">45,549</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">427,908</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Medical services &#8211; subtotal</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,532,826</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,824,459</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Product sales</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">59,391</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">167,202</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property management services &#8211; common area management</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,210,703</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,461,981</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property management services &#8211; security management</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">683,593</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">846,555</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Property management services</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,894,296</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,308,536</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total cost of revenues</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,486,513</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,300,197</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted earnings per share</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculates basic and diluted (loss)/earnings
per share as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zRuz5Eat8IOc" style="display: none">Schedule
of basic and diluted earnings per share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Years Ended<br/>
December 31</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net (loss) income</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(24,949,246</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">900,396</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Less: Net (income) loss attributable to noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(65,124</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">35,567</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Net (loss)/income attributable to common shareholders, basic</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,884,122</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">864,829</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average number of shares outstanding, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">12,029,656</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">9,253,333</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">(Loss)/Earnings per share, basic and diluted</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(2.07</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">0.09</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of fair value hierarchy of financial liability</a></td>
<td class="text"><p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zkN130Ffe2af" style="display: none">Schedule
of fair value hierarchy of financial liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value at</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Fair Value Measurement at</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2022</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Prepaid forward purchase liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities">20,321,053</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of reconciliation of financial liability measured at fair value on a recurring basis</a></td>
<td class="text"><p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zBcQXMqTTOY2" style="display: none">Schedule of reconciliation of financial
liability measured at fair value on a recurring basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">7,409,550</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Change in fair value of prepaid forward purchase liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">12,911,503</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">20,321,053</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PropertyPlantAndEquipmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PropertyPlantAndEquipmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfCostOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cost of revenue [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfCostOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of finite lived intangible assets useful lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-term intercompany foreign balances, including related intercompany entity, underlying foreign currencies and amounts of intercompany foreign currency transactions that are of a long-term investment nature (that is settlement is not planned or anticipated in the foreseeable future), as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=35711157&amp;loc=d3e42567-110969<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915347472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock', window );">Schedule of shares issued and outstanding reverse recapitalization</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_zBeeqGaFG5A7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued and outstanding immediately following the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B7_zVgBvJgIzF69" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of shares issued and outstanding reverse recapitalization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zb0lTmQofba6" style="border-bottom: Black 1.5pt solid; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_z2g0qVWdUx02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">11,073,500</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RedemptionOfOrdinaryShares_z69JroSkZSC6" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6,033,455</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ConversionOfStockSharesConverted1_zVcyOG4GNiY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">891,725</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zAq1VTpujEE7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued to service providers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">260,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_zMYXv5SiTefh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of EHL ordinary shares into 8i ordinary shares</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,000,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_z7rRd8Ocj1e9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total shares outstanding</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">20,191,770</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization', window );">Schedule of financial statements of reverse recapitalization</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfFinancialStatementsOfReverseRecapitalization_zsrzfqySb78h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table reconcile the elements of the Reverse Recapitalization to the consolidated statements of cash flows and the changes in shareholders&#8217;
equity (deficit):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BA_zs643UtKtaB4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of financial statements of reverse recapitalization</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221116__20221118_zOxJtSiMfxCd" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November 18, 2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FundsHeldInTrustAccount_zehMN4o63yAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in 8i&#8217;s trust account</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">87,074,185</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FundsHeldInOperatingCashAccount_zt01GCUOfkn2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Funds held in 8i&#8217;s operating cash account</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">248,499</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_iN_di_zzzzDCZVY0F5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: amount paid to redeem public shares of 8i&#8217;s ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(60,839,550</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_iN_di_zpx87L2Bo0d3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payments of transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,965,646</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_iN_di_zA7C4IHEYhW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: payments of forward purchase agreements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21,892,527</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_zSoD2cgzRQia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: repayments of promissory note &#8211; related party of 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(300,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromReverseRecapitalizations_ztFWhTtAiet" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,324,961</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromUnpaidDeferredUnderwritingFee_iN_di_zWqlMe7o9Z7i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unpaid deferred underwriting fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,113,125</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromUnpaidTransactionCostsIncurred_iN_di_zgIdS356acO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unpaid transaction costs incurred by 8i</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(382,600</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsForMergerRelatedCosts_iN_di_z2I5Gil7nk79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,305,580</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--NoncashNetAssetsAssumedValue_zX0HEBOPqic6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Add: non-cash net assets assumed from 8i</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,387,803</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfOrdinarySharesUponTheReverseRecapitalization_zXq9Lb4MbIEj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net contributions from issuance of ordinary shares upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">11,911,459</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of financial statements of reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of ordinary shares issued and outstanding of reverse recapitalization [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915347600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts receivable, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zMhK0HSTMdbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BC_zHzDNUZ44Kuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of accounts receivable</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zcMItTl2T9xl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/>
December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_z3ijY3QGHvng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/>
December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCztie_z3ep6qxzal53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts receivable<span id="xdx_F43_zWaGns4rARcb">*</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">2,048,941</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">1,883,115</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCztie_zRK6tXjbUUog" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(197,438</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(80,799</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCztie_zkvPItfGhR1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,851,503</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,802,316</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F00_zs9ul92a2oP" style="width: 35pt; text-align: right">*</td><td id="xdx_F18_zJxNpVRPZkM1" style="text-align: justify">As of December 31, 2022 and 2021, accounts receivable of up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable">0.6</span></span> million (SGD
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable">0.8</span></span> million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).</td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of movements of allowance for doubtful accounts</a></td>
<td class="text"><p id="xdx_891_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_ztLygfgLjhBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from account receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zMTDzXo5MK5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of movements of allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20220101__20221231_zcovL1rvmRAg" style="width: 16%; text-align: right" title="Beginning balance">80,799</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20210101__20211231_zcvGX2FYAFPf" style="width: 16%; text-align: right" title="Beginning balance">37,898</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Addition</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20220101__20221231_z8XAct8nYU8j" style="text-align: right" title="Addition">116,156</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20210101__20211231_z5DdUW9hgWq7" style="text-align: right" title="Addition">43,804</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20220101__20221231_za86uPhprpbf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect">483</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20210101__20211231_znwo3yjlZrM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect">(903</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20220101__20221231_zpF4Zltoi4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">197,438</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20210101__20211231_zVJIDX9L3fo1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">80,799</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922672096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock', window );">Schedule of other receivables</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_gL3SOCLFFRCTT-SYHD_zLU1wdUknP36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span id="xdx_8B4_zm2o4zebu17c" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zDKDXeHiu4z4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_z99WFoJqh6Fg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DivestmentReceivable_iI_zJLBvk7YMAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F4E_zsEu6CSI4vDd" style="width: 60%; text-align: left">Receivable from divestment (1)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">-</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">3,818,776</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--EmployeeAdavance_iI_zcID7PtGmN9l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,695</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,803</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherReceivablesGrossCurrent_iI_zbuKkhWbI621" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">772</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">250</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherReceivables_iTI_zrj7Lt6AQ06c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other receivables</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,467</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,821,829</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OtherReceivablesNetNonCurrent_iI_zUGyuvchwHX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables &#8211; non-current</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(1,830,603</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_zY5ijrVtuv4a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Other receivables &#8211; current</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">7,467</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,991,226</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zd6Pvz8IPeDk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zmtH88VrDzji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#8217;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" title="Investment amount">1.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" title="Investment amount">2,580,000</span>)
    in BPT&#8217;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#8220;Agreement&#8221;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#8217;s
    investment amounted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" title="Investment owned face amount">1,913,096</span>
    (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" title="Investment owned face amount">2,580,000</span>),
    and compensated UGI with the additional amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount">1,905,681</span>(SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount">2,570,000</span>).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received">0.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received">1,200,000</span>)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance">2.8</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance">3,950,000</span>)
    in eight equal quarterly installments with annual <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</span> As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount">0.7</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount">987,500</span>).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.</span></td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of other receivables allowance for doubtful accounts</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zIhFE6hXSJTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Movements
of allowance for doubtful accounts from other receivables are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8B6_zqZDXVequpWg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of other receivables allowance for doubtful accounts</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2022</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>For the Year Ended</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>December 31, 2021</b></p></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20220101__20221231_zxKXdlcdjFL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20210101__20211231_zmCGZGwzcF25" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98E_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20220101__20221231_ze2dQp5ImR9c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,209,825</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td id="xdx_987_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20210101__20211231_z3xmEJVhb1Xh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Write-off</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20220101__20221231_zf6OO450jHxj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,209,825</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20210101__20211231_zaud4Oz7a86f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20220101__20221231_zw6SVgzdNWad" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20210101__20211231_zzbirWUHir8g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss of financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929362320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z5mSdoucpmWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span id="xdx_8B8_zHVhLfbGLoI5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of property and equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zpTMbdGlLwJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_ztk0nqQP2YN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zG25ePGsgDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Office equipment</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">148,387</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">144,051</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zd23T65SSPy2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Medical equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,724</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">15,917</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zll8szp4GZf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvement</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">2,217</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">20,704</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzHdg_zvTRCTRytXkk" style="vertical-align: bottom; background-color: White">
    <td>Subtotal</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">153,328</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">180,672</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzHdg_zHrtvnki6eN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(121,700</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(123,745</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzHdg_zUAXZg8rAIVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">31,628</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">56,927</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923887136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrWdLnkeBuS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Intangible assets
consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zheLd0sPrDVe" style="display: none">Schedule
of intangible assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zcyIRETse008" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20211231_zzE61IlI6fNe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedCustomerRelationshipsGross_iI_maFLIANzay9_zRwiwhzpsrZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Customer relationships</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">650,102</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">646,246</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzay9_zhbXYS2amUw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Accumulated amortization</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(477,584</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(356,284</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Impairment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zTEvWZD4UnYd" title="Less: Impairment">167,787</span></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<span id="xdx_904_ecustom--ExchangeRateEffect_c20220101__20221231_z2NPAqwNwf1b" title="Exchange rate effect">4,731</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzay9_zFsJe5o6sdB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">289,962</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929298064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfGoodwillTextBlock_zTmbmb4e5ynd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The
changes in the carrying amount of goodwill from Melana reporting unit and Tri-Global reporting unit are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zaVXBpQzDt7b" style="display: none">Schedule
of goodwill</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--BusinessAcquisitionAxis_custom--MelanaInternationalPteLimitedMember_zYD13vnzyCac" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Melana</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--BusinessAcquisitionAxis_custom--TriGlobalSecurityPteLimitedMember_zBUWt9d98jUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Tri-Global</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zvGbVsnACRs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20210101__20211231_eus-gaap--Goodwill_iS_z4FHyz86k8F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Balance as of December 31, 2020</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">539,286</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">473,344</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">1,012,630</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_zspcihJYudB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(10,621</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(9,323</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(19,944</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20220101__20221231_eus-gaap--Goodwill_iS_zbBKMWrIpF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2021</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">528,665</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">464,021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">992,686</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--Goodwill_iS_zbqKn29MhMlf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">528,665</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">464,021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">992,686</td>
    <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_z74a0yqnTzp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(11,427</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(10,030</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(21,457</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_iN_di_znOKDbByjexd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Impairment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(517,238</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(453,991</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(971,229</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--Goodwill_iE_zF56Pdc9x6Ca" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2022</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20220101__20221231_eus-gaap--Goodwill_iE_zSB1sptjUfLg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921726416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember', window );">Bank and Private Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term loans</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zmF1bzcg9U3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loans &#8211; bank and private lender</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on short-term bank loans consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zq36MWtvWq1i" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Bank/Private<br/>
 lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/>
Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center">*<span id="xdx_908_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zNb9oHGId5b3" title="Bank/Private lender Name">United Overseas Bank Limited</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zcPdpLsyMHwe" title="Maturities">90 days from disbursement</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zCfVBhT5mU4h" title="Interest Rate">0.25</span>% plus prime rate of <span id="xdx_90E_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_fKg_____zfTw109SRvOj" title="Interest Rate">5.25</span>%</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zxA309aHY1W" title="Collateral/Guarantee">Collateral: Accounts receivable </span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zU1uJrnqARda" title="Short term loans - bank and private lender">185,592</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zpWzgzbbh6j3" title="Short term loans - bank and private lender">184,491</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z4BHA2B8rqh5" title="Bank/Private lender Name">FS Capital Ptd. Ltd.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zI7qFSDU1774" title="Maturities">Fully repaid in February, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zNuDnn3QNN28" title="Interest Rate">18.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zvCfKLrWXRyj" title="Collateral/Guarantee">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder, and Kent Ridge Health Private Limited</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zQ5MFLMoFAd" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zpYyfAyUGRL8" title="Short term loans - bank and private lender">20,936</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zMXeUYuTfen1" title="Bank/Private lender Name">Funding Societies Pte. Ltd</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zfXoQB7pA524" title="Maturities">Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zSQFIVgvja5" title="Interest Rate">30.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zUwHlHqO7fMh" title="Collateral/Guarantee">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zBtuoQvS27d" title="Short term loans - bank and private lender">18,648</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zhYCBo1e7Gg7" title="Short term loans - bank and private lender"><span style="-sec-ix-hidden: xdx2ixbrl1445">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zLUz0RfsiKDd" title="Short term loans - bank and private lender">204,240</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z9IcxqQF0pI4" title="Short term loans - bank and private lender">205,427</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_z6mo09h38t7d" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F11_zGbdAhWmd92k" style="text-align: justify">On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount">593,208</span>
                                                                                                       (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount">800,000</span>)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#8217;s account receivable (see Note 6). The loan bears an average annual interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate">5.50</span>%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.</td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember', window );">Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term loans</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zY63Gd0UPNQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Short-term loan &#8211; third party</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zDPEKbNdLZR1" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zWUelSEUsRz8" title="Bank/Private lender Name">Koh Wee Sing</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_fKg_____zohy9rpeA1yd" title="Maturities">Due on demand beginning in July 2022</span>*</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zdeDx9uPfRl2" title="Interest Rate">60.0</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_ztbcHFYM3FFb" title="Collateral/Guarantee">None</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zxzEPGi05kJ4" title="Short term loans - third parties"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z5xGRUTk034g" title="Short term loans - third parties">148,302</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term loans</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zS0Hd9Z016Yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Promissory note</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on promissory note consist of
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zcPLWGqMCYe7" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zf3uHzslHwm4" title="Bank/Private lender Name">Kaufaman &amp; Canoles, P. C. (&#8220;KC&#8221;)</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_fKg_____zw9ZL6sd9fx" title="Maturities">February 15, 2023</span>*</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zU5yjNtaf0Vi" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zeFtooQHWzd" title="Collateral/Guarantee">None</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zYLH44Kwk1Oj" title="Convertible promissory note">170,000</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zIzXFkXVtur3" title="Convertible promissory note"><span style="-sec-ix-hidden: xdx2ixbrl1493">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0E_zpEKxG4NhYhc" style="width: 35pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F17_zPRb9fRRhpn6" style="text-align: justify">This promissory note has a default interest of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate">15</span>% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#8220;the Agreement&#8221;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note">100,000</span> within two days of the dates that the Company&#8217;s US counsel,
Loeb &amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note">60,000</span> within two business days after the date the first amendment to the registration
statement is filed with the SEC.</td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember', window );">Convertible Notes Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term loans</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z6Kq57Fc2mRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; third parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding balances on convertible notes consist
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zIx7neI1HJM5" style="display: none">Schedule
of short-term loans</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zlNna5WB78N5" title="Bank/Private lender Name">Maxim Group LLC (&#8220;Maxim&#8221;)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zfoXWsI7F5v8" title="Maturities">November 17, 2023</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zjkttMFlHCPh" title="Interest Rate">0.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztXGFtXMJN8f" title="Collateral/Guarantee">Automatically be converted into the Company&#8217;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztsqhZq0sHA4" title="Convertible notes payable">2,113,125</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zf5U7gDmOlBi" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1514">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zSsHM3l6l3yl" title="Bank/Private lender Name">Menora Capital Pte Ltd (&#8220;Menora&#8221;)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zIZinwYcTpof" title="Maturities">November 17, 2023</span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zk2TFLc8rWAf" title="Interest Rate">0.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTru3X9M6YHk" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zus0fLgGYue3" title="Convertible notes payable">87,500</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z1YSxfG1CkVk" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zopxcbfv9hXh" title="Bank/Private lender Name">Loeb &amp; Loeb LLP (&#8220;Loeb&#8221;)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zroUwCDFpdXb" title="Maturities">November 17, 2023</span></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTyfqJNfkBX" title="Interest Rate">0.0</span></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zu8WjfcyB14j" title="Collateral/Guarantee">(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zHTqs3US7m5b" title="Convertible notes payable">300,000</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zvZ8ZSyjqAda" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zpagZK7g6tVe" title="Bank/Private lender Name">Shine Link Limited (&#8220;Shine Link&#8221;)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z9U1S8dyCFGj" title="Maturities">November 17, 2023</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zilIXU8l8SIc" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zVslrOjeWenf" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zQgMBnixlro5" title="Convertible notes payable">119,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zFxmkamWZZld" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z7rF8dRBeDOg" title="Convertible notes">2,619,625</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zhuRXnCbNOUk" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Convertible notes &#8211; related parties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Lender Name</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Maturities</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Interest Rate</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Collateral/<br/> Guarantee</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___znbO2pVoMxG3" title="Bank/Private lender Name">8i Holdings 2 Ptd Ltd (&#8220;8i Holding&#8221;)</span> (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPmBWhZaYdel" title="Maturities">November 17, 2023</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVGdVWy5ZHr5" title="Interest Rate">0.0</span></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%; text-align: center"><span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPN6yhISMwJa" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVz4gtl0mjkl" title="Convertible notes payable">82,600</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___ziXyfpdsC1lj" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zjxf3Va2gX8k" title="Bank/Private lender Name">Meng Dong (James) Tan</span> (2)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z4ACxPfpB3rk" title="Maturities">November 17, 2023</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z8dHohPUY0Ll" title="Interest Rate">0.0</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zBDEoEI6pFpb" title="Collateral/Guarantee">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z0dyAvH33lId" title="Convertible notes payable">700,000</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z36i6145qhS4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zC1o1ov4Asgj" title="Convertible notes payable">782,600</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zDEMXZWVheW4" title="Convertible notes payable"><span style="-sec-ix-hidden: xdx2ixbrl1582">-</span></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F06_z5wkCNalLiU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zCH2TRI7EMM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Meng Dong (James) Tan, the Company&#8217;s related party who had more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name">10</span>% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zXTuoVGxiL12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z3Xa8GI0PEof" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Meng Dong (James) Tan, the Company&#8217;s related party has more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name">10</span>% ownership of the Company.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923870240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other payables and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other payables and accrued liabilities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBuhOgPURNs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zftKXCe0kcd4" style="display: none">Schedule of other
payables and accrued liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zSgZCR3P792e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zIpxn6JlxMck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zpQPLdKmIVU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F47_z8HVuhmkRhoa" style="width: 60%; text-align: left">Accrued expenses (i)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">671,743</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">129,029</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maAPAOAzzja_zI4xHyEQc5We" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued payroll</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">730,037</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">244,591</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAOAzzja_zafAiA1CKgLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F49_zN5hy8VB081c" style="text-align: left">Accrued interests (ii)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">157,032</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">67,448</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zLoJEYDz1RH9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">34,003</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">47,529</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzzja_z6d9ObFAejjl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other payables and accrued liabilities</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,592,815</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">488,597</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F05_zU2DIwdDueu">(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued expenses</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_z4IbBhnBkeRa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0B_z6utxZKjB9Nj">(ii)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued interests</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zV7yk6cQZZJg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of accrued interests represented the balance of interest payable from short-term loan &#8211; bank, private lender, and third parties (See Note 13).</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921732416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party balances and transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock', window );">Schedule of related party balances</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfRelatedPartyBalancesTableTextBlock_zPZ1uaGCMUMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zfRWSr5yCTk6" style="display: none">Schedule of related
party balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other receivables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_ztoJKWrxBA42" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br/>
December 31,<br/>
 2022</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zyTjiRvJ4dfh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of<br/>
December 31,<br/>
 2021</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHillCapitalPteLtdMember_z0mfXxXciPC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">KR Hill Capital Pte Ltd</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Related party advance, due on demand</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">239</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">237</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeMedicalPtdLtdMember_zAq8s75D8qZd" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Medical Ptd Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">247</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">245</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zHO23HkMDnR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">UG Digital Sdn Bhd</td>
    <td>&#160;</td>
    <td style="text-align: center">UGD, subsidiary of the Company owned 40% of this company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">284,673</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanicLimitedMember_zC0mw7zyTSR8" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Janic Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance, due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">724</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">720</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZukihealthSDNMember_ziAJ7HyPFp21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Zukihealth SDN</td>
    <td>&#160;</td>
    <td style="text-align: center">Kelvin Chen, Chief Executive Office (&#8220;CEO&#8221;) and shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Related party advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,173</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JenniferGohMember_ziC0ykyOqEp5" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jennifer Goh</td>
    <td>&#160;</td>
    <td style="text-align: center">President, operation manager, and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Employee advance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,527</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FrescoInvestmentPteLtdMember_zq7QNokGLm3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fresco Investment Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Fan Know Hin, an immediate family member of a shareholder of the Company, is the shareholder of this entity</td>
    <td>&#160;</td>
    <td style="text-align: center">Advance due on demand</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">46</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z7fbUupTuyb1" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Cadence Health Pte Ltd<span id="xdx_F44_zQSR0Ta8OmEk">*</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">266,653</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1637">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueFromOtherRelatedParties_iI_zuvDNg31UKsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">267,863</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">297,621</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_zIA3J1Gf4zx7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other receivables -  related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">267,863</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">297,621</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F09_zP8tNp0ijJTb" style="width: 15pt; text-align: right">*</td><td id="xdx_F15_zgC4CpQgx3s8" style="text-align: justify">As of date of <span style="background-color: white">the issuance of these financial statements</span>,
this receivable has been repaid by the related party.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Convertible notes &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Please see Note 13 for details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Account payable &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zBrRVkpdoTJ6" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, <br/>
2022</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zDQz9HW8SBy2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,<br/>
 2021</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z0mCq6DLSO6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1646">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,459,411</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zvpsHUzGFawi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt">Account
payable, related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">Medical service fee performed for the employee patients of the Company&#8217;s corporate customers</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1649">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">2,459,411</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other payables &#8211; related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zip7jWxR6Se2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zhtnBhies9n5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
    <p style="margin-top: 0; margin-bottom: 0">As of</p>
    <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CheeYinMehMember_zz7vcouE5aP2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 20%; text-align: left">Chee Yin Meh</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">Shareholder of Scotgold Holding Ltd which is the shareholder of the Company</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">Operating expense paid on behalf of the Company</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">122,739</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 12%; text-align: right">34,512</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamieFanWeiZhiMember_z9QK4EFAzbzj" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Jamie Fan Wei Zhi</td>
    <td>&#160;</td>
    <td style="text-align: center">An immediate family member of a shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company, and Guarantor fee</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">40,783</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinChenMember_zBpY8n1QudJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kelvin Chen</td>
    <td>&#160;</td>
    <td style="text-align: center">CEO and shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">589,681</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">295,776</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeHealthPteLtdMember_zLHx7qXv6Q8d" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Kent Ridge Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">696,508</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">121,129</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zfpOR0lwSdz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Kent Ridge Pacific Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">20,303</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33,483</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WatermarkDevelopmentsLtdMember_zfv4OeX9Bfjc" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Watermark Developments Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">55,945</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilkeServicesLtdMember_zNA9ZSroyVse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F48_zmQu2DhV61qj" style="vertical-align: top; text-align: left">Wilke Services Ltd (&#8220;Wilke&#8221;) (1)</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Investment payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,746,628</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MountLockeLimitedMember_zKIL5ddMHgag" style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Mount Locke Limited</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholder of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Operating expense paid on behalf of the Company</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,753</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zX7SUmfS20E6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">UG Digital Sdn Bhd</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">UGD, subsidiary of the Company owned 40% of this company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Operating expense paid on behalf of the Company</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">33,016</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_zIe3sA7HREPe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,521,945</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">3,272,311</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_ztc2s4OuxTI" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Other payables &#8211; related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">1,521,945</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">3,272,311</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0D_zxZa2MGh7q3l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zm2d6c2NZKWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). </span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zToPN3CoiZAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Related party transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zCapYiqAPdR9" style="display: none">Schedule of related
party transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name of Related Party</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Relationship</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Nature</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zurTmBRiKc72" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2022</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zpcv2OHuWiq5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,<br/>
 2021</p></td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zl5RS8mBhFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-bottom: 1.5pt; width: 20%; text-align: left">Cadence Health Pte Ltd</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 24%; text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 20%; text-align: center">Sales of swab test, and other medical related product</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">135</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right">4,640</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromRelatedParties_zwIhRiOq4kfb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Revenue from related parties</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">135</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">4,640</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Purchase from related parties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name of Related Party</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_ze3CZo48Hep9" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2022</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zNusAPiH0Pig" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2021</b></span></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zNFfncj0E74i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Cadence Health Pte Ltd</td>
    <td>&#160;</td>
    <td style="text-align: center">Shareholders of this entity also are the shareholders of the Company</td>
    <td>&#160;</td>
    <td style="text-align: center">Medical service fee provided for the third party medical service revenue</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">491,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,349,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zY3fPo9wn83k" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    from related parties</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Medical service fee provided for the third party medical service revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">491,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,349,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Rental expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3fkoprXpF84" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2022</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zOyZQ4ETTLLk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_ztsBbbMgSJ85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kent Ridge Pacific Pte Ltd</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of this entity also are the shareholders of the Company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office rental</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,954</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143,589</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zgzY3mePmvcj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt">Rental Expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Shareholders of this entity also are the shareholders of the Company</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">Office rental</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">47,954</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Related party balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929262544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock', window );">Schedule of reverse recapitalization</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_z80GmA1oLSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table presents the number of the Company&#8217;s ordinary shares issued upon the Reverse Recapitalization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zf6K3XnLVwLg">Schedule
of reverse recapitalization</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221116__20221117_zgcRg6Xenr1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_zzG2plFquwuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">8i ordinary shares outstanding prior to Reverse Recapitalization</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 15%; text-align: right">11,073,500</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RedemptionOfOrdinaryShares_zxMwMp166mZf" style="vertical-align: bottom; background-color: White">
    <td>Less: redemption of 8i ordinary shares</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(6,033,455</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ConversionOfStockSharesConverted1_zHBwDEqARuZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Conversion of 8i rights</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">891,725</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zcAJmygmIXLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued to service providers</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">260,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_zLFaxoKqb1O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total shares issued upon the Reverse Recapitalization</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">6,191,770</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGUjZC76KfO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The summary of warrants activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zzr0MdKF5Uth" style="display: none">Schedule
of warrant activities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants <br/> Outstanding</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares Issuable</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average <br/> Remaining <br/> Contractual <br/> Life</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k4YsaJj09j" style="text-align: right" title="Warrants Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zle586Mp5ZOd" style="display: none; text-align: right" title="Ordinary Shares Issuable, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuI9vnNPvPp8" style="text-align: right" title="Weighted Average Exercise Price, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 32%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2tEcJVkBChj" style="width: 14%; text-align: right" title="Warrants Outstanding, Granted">8,917,250</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk9jia2wAIug" style="width: 14%; text-align: right" title="Ordinary Shares Issuable, Granted">4,458,625</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ8n0xDs4CJ7" style="width: 14%; text-align: right" title="Weighted Average Exercise Granted">11.50</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Uz0dEn5Ahi" style="width: 14%; text-align: right" title="Average Remaining Contractual Life,Granted">5.00</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPEAZegbYagh" style="text-align: right" title="Warrants Outstanding, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqRvcI0CV19" style="display: none; text-align: right" title="Ordinary Shares Issuable, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKd6a5gxKJl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1771">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuBRpBJPYxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ordinary Shares Issuable, Exercised"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1773">-</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022 </span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqz7I5Ro0ma" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">8,917,250</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZGV5NIKUml" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares Issuable, Ending balance">4,458,625</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfmvdnmBM0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending balance">11.50</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfgfRXJMsei" style="padding-bottom: 2.5pt; text-align: right" title="Average Remaining Contractual Life,">4.88</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock', window );">Schedule of earnout shares for triggering event</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_zkrxSCwyG2u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the Earnout Shares for Triggering
Event 1 and 2 was estimated using the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B2_zsrpRMLIlhei" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of earnout shares
for triggering event</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Closing date</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221116__20221117_zcGCE22cZ9rk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">November 17, 2022</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_400_ecustom--SharePriceAsOfClosingDate_zRAWZuTdtPpa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Share price of the Company as of closing date</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">5.21</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AverageDailyReturnRate_dp_uPure_z7DBL6zpBT7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Average daily return rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0">0.02</p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--DailyVolatilityForTriggeringEvent1_dp_zZ2VBZUgxvL6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Daily volatility for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.74</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--DailyVolatilityForTriggeringEvent2_dp_zpbCH6ark1Zk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Daily volatility for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><p style="margin: 0">4.30</p></td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_ecustom--RiskFreeRateForTriggeringEventOne_dp_zVi2jU7hK501" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free rate for Triggering Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.75</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_ecustom--RiskFreeRateForTriggeringEventTwo_dp_zaUYULj3ClW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free rate for Triggering Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.49</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--GrantPriceForTriggingEventOne_zaQcxUq3EBe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant Price for Trigging Event 1</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">15.0</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--GrantPriceForTriggingEventTwo_z3lSuOMSi7I1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Grant Price for Trigging Event 2</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">20.0</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Earnout Shares for triggering event [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of ordinary shares issued of reverse recapitalization [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923563936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of loss before income taxes</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zXpPe41qzvhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and foreign components of loss before
income taxes were comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_ziFSmCvuVuV3" style="display: none">Schedule
of components of loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zjH9PVeyKvkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_zKAtD8HE96P4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year</p>
                                                                                                                                                 <p style="margin-top: 0; margin-bottom: 0">Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zty8c8T8eeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Singapore</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">(5,400,034</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">930,312</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zGyACxvHKX16" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(19,531,790</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">18,225</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zPMlSqriWVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total loss (income) before income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(24,931,824</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">948,537</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJEm2njnqpLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_z8zw5yCpj5M2" style="display: none">Schedule
of provision for income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zTFi7qbIvTRg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20211231_z0BLIXxcd0F4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_zSdIKhIucPrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Current</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">65,650</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">75,821</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_z3jXFocNLYm2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Deferred</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(48,228</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(27,680</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_z4lm9TXIxmI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Provision for income taxes</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">17,422</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">48,141</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zVCS992fOng2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles Singapore statutory
rates to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zXLp5P8Uow19" style="display: none">Schedule
of effective income tax rate</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zz6LSmlqgw5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20210101__20211231_zTpHYWL3WU07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For
the Year Ended</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_z0uGVyCX6sAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Singapore statutory income tax rate</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">17.0</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">17.0</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zzJ1jJekuC2b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax rate difference outside Singapore <span id="xdx_F46_zNQo6BcZgG44">(1)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(13.3</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.1</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxExemptIncome_pid_dp_zXhXG4014Vxb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxable income below exemption threshold</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2.4</td>
    <td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_z8YJ0GXrWI66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2.9</td>
    <td style="text-align: left">)%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">29.8</td>
    <td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_zY13CpOijIs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others <span id="xdx_F44_zoi5p425LcQg">(2)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(0.9</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(39.4</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zzQWY82pIy2k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">(0.1</td>
    <td style="padding-bottom: 2.5pt; text-align: left">)%</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">5.1</td>
    <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zLE8wzDmLyza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F19_zCFPCErDySXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F01_zvUE81Un7MEd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zxFItljtEDT" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUkfkUCI7RE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant components
of the aggregate deferred tax assets and liabilities of the Company as of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zcM8q1Pzzg4" style="display: none">Schedule
of deferred tax assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zdo2j9fZOWhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_z0XqsOKD6XUj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred Tax Assets/Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzYwk_zbqU7KgOgUqg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">749,309</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">812,715</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTANzYwk_zDROOYfiD1Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allowance for doubtful account<span id="xdx_F4E_zYFMyP1TGDhg">*</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">33,564</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">13,736</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilityNet_iI_maDTANzYwk_z5ZAY0uJdmu8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">823</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1898">-</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYwk_zk1qx9VNeCJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(783,696</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(826,451</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYwk_zqEefreGb4e9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1903">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzaoX_zYICzYnBxxwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1906">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">49,294</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzaoX_z5NtqG7k2ot8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1909">-</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">49,294</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F06_zH7RhItHCiA2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1A_z3zULlLWpA9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased">42,755</span> as of December 31, 2022.</span></td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfTaxesPayableTableTextBlock', window );">Schedule of taxes payable</a></td>
<td class="text"><p id="xdx_895_ecustom--ScheduleOfTaxesPayableTableTextBlock_zxbuH9pHz6Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Taxes payable consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_z9nWMz0MpKS5" style="display: none">Schedule
of taxes payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zDcGYLGYVkoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_zXvZQgoUd4K9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedGSTTaxesPayableCurrent_iI_maTPCzp1w_zSuZfuCNFxE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">GST taxes payable</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">125,695</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 16%; text-align: right">225,095</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccruedIncomeTaxesCurrent_iI_maTPCzp1w_z0eWsO3lfjj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income taxes payable</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">60,455</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">82,248</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_iTI_mtTPCzp1w_zmg2voh1nZe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Totals</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">186,150</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">307,343</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfTaxesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of taxes payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfTaxesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923889584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock', window );">Schedule of operating and finance lease expenses</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_zEuaX77mg0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Operating and finance lease
expenses consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zva4W5Cc3jEe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of operating and finance lease expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 34%; text-align: left">Lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 31%; text-align: left">General and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z02GJdR0Isi6" style="width: 14%; text-align: right" title="Lease expenses">114,390</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--OperatingLeaseExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8YRaCVWT2G1" style="width: 14%; text-align: right" title="Lease expenses">62,810</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease expenses &#8211; short-term</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_ecustom--OperatingLeaseExpenseShortTerm_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ3haufxx6Qg" style="text-align: right" title="Lease expenses - short-term">113,055</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_ecustom--OperatingLeaseExpenseShortTerm_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsGM83lzv0Je" style="text-align: right" title="Lease expenses - short-term">143,589</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Finance lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of leased asset</td>
    <td>&#160;</td>
    <td style="text-align: left">General and administrative</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3O1dqy7VBD" style="text-align: right" title="Amortization of leased asset">7,948</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znDHIxe4Tzjl" style="text-align: right" title="Amortization of leased asset">8,153</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense -Interest expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zf2DKu4lGdQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities">1,276</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseInterestExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zHzFNIMwu5vk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities">1,639</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total lease expenses</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--LeaseCost_c20220101__20221231_zXuIrMiSvqCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses">236,669</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_986_eus-gaap--LeaseCost_c20210101__20211231_z2u05tGTexK8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses">216,191</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of weighted average remaining term and discount rate</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z4bF3JJAwasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Weighted-average remaining
term and discount rate related to leases were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;<span id="xdx_8B7_z33Jp2miFTYa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of weighted average remaining term and discount rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">As of</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining term</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zrKJVK0Me2f7" title="Operating lease, weighted-average remaining term">0.69</span> year</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zzCZShx2g3Sb" title="Operating lease, weighted-average remaining term">1.25</span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKWt37oTrso2" title="Finance leases, weighted-average remaining term">2.01</span> years</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zHvVzkkI36U7" title="Finance leases, weighted-average remaining term">3.00</span> years</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Operating lease</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zdJsEKHuuDU" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate">5.25</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z4c645fgDIx4" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate">5.25</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zZokI2Cnpue8" style="text-align: right" title="Finance leases, weighted-average discount rate">5.25</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zfAld1JBxjki" style="text-align: right" title="Finance leases, weighted-average discount rate">5.25</td>
    <td style="text-align: left">%</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_z73KmCspbejd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table sets
forth the Company&#8217;s minimum lease payments in future periods as of December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;<span id="xdx_8BF_zSmAwDeYnclg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of future minimum lease payments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Operating lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Finance lease</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payments</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Twelve months ending December 31, 2023</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_z5TkiMa5Sj6k" style="width: 14%; text-align: right" title="Operating lease payments, 2023">81,522</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_zBj0F5oLzmwe" style="width: 14%; text-align: right" title="Finance lease payments, 2023">8,151</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_c20221231_z5CMRkqW6N71" style="width: 14%; text-align: right" title="Total 2023">89,673</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Twelve months ending December 31, 2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zGcD4UX1NxMj" style="text-align: right" title="Operating lease payments, 2024"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_z4BdzkewRGyj" style="text-align: right" title="Finance lease payments, 2024">15,614</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_eus-gaap--ContractualObligationDueInSecondYear_iI_c20221231_zPK2RPFfFAGf" style="text-align: right" title="Total 2024">15,614</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20221231_zqWjAHy6kPmh" style="text-align: right" title="Total Operating lease payments">81,522</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20221231_zBpcpcCZWHTi" style="text-align: right" title="Total Finance lease payments">23,765</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_c20221231_zY66KBstjHkk" style="text-align: right" title="Total lease payments">105,287</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: discount</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pid_di_c20221231_zHNYt3BVcdDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Operating lease payments, discount">(1,563</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20221231_zbL4SNROjyw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Finance lease payments, discount">(1,564</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_ecustom--ContractualObligationDiscount_iNI_di_c20221231_zpQcmUJrGt7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total lease payments">(3,127</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Present value of lease liabilities</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20221231_zDKjpPsmED13" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, operating lease payments">79,959</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_c20221231_zLCdbSOaIrge" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, finance lease payments">22,201</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
    <td id="xdx_98B_ecustom--ContractualObligationLeaseLiability_iI_c20221231_zAbONJPGacC5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease payments">102,160</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Future Minimum Lease Payments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating And Finance Lease Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930312304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment reporting information</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MLIH_zjoOcL57Ylw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following tables present
the summary of each segment&#8217;s revenue, loss from operations, income (loss) before income taxes and net income (loss) which is considered
as a segment operating performance measure, for the years ended December 31, 2022 and 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B0_z4eZA4e9mIg4">Schedule
of segment reporting information</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z8ah55WnuA9h" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zrSGorQLJfp4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_zKJkRiVaJPA6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zl3ryZVn9in2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,076,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,764,295</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,840,709</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zaMLuK1Pn4W6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,463,593</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,991,371</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,454,964</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zLLEelNKyzpk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,613,615</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,800,755</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,414,370</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zSBZ9LCdrvli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,651,826</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,779,966</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,431,792</td><td style="text-align: left">)</td></tr>
  </table>


<table cellpadding="0" cellspacing="0" id="xdx_300_134_zFFbIL40VGB7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of segment reporting information (Details)">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zVxPERp1WWMl" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zTNi99oY9Fs5" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_z8ikQOnygo5k">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31, 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Property</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Medical</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Management</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Services</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zGz5sfcm7hve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">5,986,030</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">4,558,520</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 14%; text-align: right">10,544,550</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zD7lB9iowtJ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,186,885</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(41,342</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,228,227</td>
    <td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zFo1MeNfyLA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) before income taxes</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,239,438</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,187,975</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">948,537</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfitLoss_zntSrFKSsDmd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,241,091</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2,141,487</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">900,396</td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zbi74RH6UiDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
of the Company&#8217;s segment net loss before income taxes to the consolidated statement of operation and comprehensive income (loss)&#8217;s
net loss before income taxes for the year ended December 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zpfkpXgIvIX8" style="display: none">Schedule
of consolidated statement of operation and comprehensive income (loss)
net loss before income taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220101__20221231_zXS513TrVwDk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_zOMhaUDoz60a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Segment loss before income tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,414,370</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_iN_di_zknj3pCpykoj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of prepaid forward purchase liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,911,503</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--EarnoutSharePayment_iN_di_zPE6c6oJ1S65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Earnout share payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,199,629</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--OtherCorporateExpenses_iN_di_zm0mIqCHIh78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other corporate expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,406,322</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zCETa8iJRSp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Consolidated net loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(24,931,824</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915253472">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of consolidated financial statement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Apr. 15, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2021 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAHealthLimitedMember', window );">EUDA Health Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">EUDA Health Limited (&#8220;EHL&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePteLtdMember', window );">Kent Ridge Healthcare SingaporePte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Kent Ridge Healthcare Singapore Pte. Ltd. (&#8220;KRHSG&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  09,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember', window );">EUDA Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">EUDA Private Limited (&#8220;EUDA PL&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 13,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember', window );">Zukitek Vietnam Private Limited Liability Company [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Zukitek Vietnam Private Limited Liability Company (&#8220;ZKTV PL&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  02,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember', window );">Singapore Emergency Medical Assistance Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Singapore Emergency Medical Assistance Private Limited (&#8220;SEMA&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember', window );">The Good Clinic Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Good Clinic Private Limited (&#8220;TGC&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  08,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDADoctorPrivateLimitedMember', window );">EUDA Doctor Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">EUDA Doctor Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHillPrivateLimitedMember', window );">Kent Ridge Hill Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Kent Ridge Hill Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthLimitedMember', window );">Kent Ridge Health Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Kent Ridge Health Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitechPrivateLimitedMember', window );">Zukitech Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Zukitech Private Limited (&#8220;Zukitech&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 13,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember', window );">Super Gateway Group Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Super Gateway Group Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 18,  2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UniversalGatewayInternationalPteLtdMember', window );">Universal Gateway International Pvt Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Universal Gateway International Pte. Ltd. (&#8220;UGI&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RegisteredCapital', window );">Registered capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_MelanaInternationalPteLtdMember', window );">Melana International Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Melana International Pte. Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  09,  2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TriGlobalSecurityPteLtdMember', window );">Tri Global Security Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Tri-Global Security Pte. Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 10,  2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UGDigitechPrivateLimitedMember', window );">UG Digitech Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">UG Digitech Private Limited (&#8220;UGD&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 16,  2001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_NosweatFitnessCompanyPrivateLimitedMember', window );">Nosweat Fitness Company Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nosweat Fitness Company Private Limited (&#8220;NFC&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  06,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TrueCoverPrivateLimitedMember', window );">True Cover Private Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">True Cover Private Limited (&#8220;TCPL&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KRDigitalPteLtdMember', window );">KR Digital Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">KR Digital Pte. Ltd. (&#8220;KR Digital&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KRDigitalPteLtdMember', window );">KR Digital Pte Ltd [Member] | Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukihealthSdnBhdMember', window );">Zukihealth Sdn Bhd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NameOfCompany', window );">Name of company</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Zukihealth Sdn. Bhd. (&#8220;Zukihealth&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DateOfIncorporation', window );">Date of incorporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On March 1, 2022, SEMA, the Company&#8217;s wholly owned subsidiary, sold <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage">100</span>% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ <span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration">1.0</span> (see Note 5).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On April 19, 2022, the Company acquired <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage">100</span>% equity interest of KR Digital Pte Ltd, (&#8220;KR Digital&#8221;), a Singapore Company, from Mr. Kelvin Chen, the Company&#8217;s Chief Executive Office (&#8220;CEO&#8221;) and shareholder for total consideration of SG$<span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration">1</span>. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage">100</span>% equity interest of Zukihealth Sdn Bhd, (&#8220;Zukihealth&#8221;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#8217;s CEO and shareholder for total consideration of SG$<span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration">1</span>. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_NameOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_NameOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registeration capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAHealthLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAHealthLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDADoctorPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDADoctorPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHillPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHillPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitechPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukitechPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UniversalGatewayInternationalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UniversalGatewayInternationalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_MelanaInternationalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_MelanaInternationalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TriGlobalSecurityPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TriGlobalSecurityPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UGDigitechPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_UGDigitechPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_NosweatFitnessCompanyPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_NosweatFitnessCompanyPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TrueCoverPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TrueCoverPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KRDigitalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KRDigitalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukihealthSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_ZukihealthSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922551632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of business and organization (Details Narrative) - SGD ($)<br></strong></div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Jul. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember', window );">Kent Ridge Healthcare Singapore Private Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember', window );">EUDA Private Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember', window );">Super Gateway Group Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember', window );">Singapore Emergency Medical Assistance Private Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EUDAPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SuperGatewayGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929372352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Going concern (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="nump">$ 784,485<span></span>
</td>
<td class="nump">$ 189,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922770464">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of foreign currency exchange rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_SGD', window );">Singapore, Dollars</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1', window );">Period-end : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.34<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Period-average : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.38<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_VND', window );">Viet Nam, Dong</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1', window );">Period-end : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,635.00<span></span>
</td>
<td class="nump">22,855.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Period-average : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,409.44<span></span>
</td>
<td class="nump">22,935.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_MYR', window );">Malaysia, Ringgits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1', window );">Period-end : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Period-average : US$1 exchange rate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.39<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateRemeasurement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateRemeasurement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_SGD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_SGD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_VND">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_VND</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_MYR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_MYR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922768640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of property and equipment useful lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Electronic equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Electronic equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold equipment</a></td>
<td class="text">Shorter of the lease term or 5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930259216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of intangible assets net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Customer relationships</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669012744128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,840,709<span></span>
</td>
<td class="nump">$ 10,544,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember', window );">Medical Services Specialty Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,001,439<span></span>
</td>
<td class="nump">5,010,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeMember', window );">Medical Services General Practice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63,794<span></span>
</td>
<td class="nump">712,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember', window );">Medical Services General Practice Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember', window );">Medical Services Sub Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,065,368<span></span>
</td>
<td class="nump">5,728,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember', window );">Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,046<span></span>
</td>
<td class="nump">257,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceCommonAreaManagementMember', window );">Property Management Service Common Area Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,919,335<span></span>
</td>
<td class="nump">3,508,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceSecurityManagementMember', window );">Property Management Service Security Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">844,960<span></span>
</td>
<td class="nump">1,049,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceMember', window );">Property Management Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,764,295<span></span>
</td>
<td class="nump">$ 4,558,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceCommonAreaManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceCommonAreaManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceSecurityManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceSecurityManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922094176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of cost of revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">$ 6,486,513<span></span>
</td>
<td class="nump">$ 6,300,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember', window );">Medical Services Specialty Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">2,995,778<span></span>
</td>
<td class="nump">46,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareRelatedPartyMember', window );">Medical Services Specialty Care Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">491,499<span></span>
</td>
<td class="nump">2,349,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticesMember', window );">Medical Services General Practices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">45,549<span></span>
</td>
<td class="nump">427,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember', window );">Medical Services Sub Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">3,532,826<span></span>
</td>
<td class="nump">2,824,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember', window );">Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">59,391<span></span>
</td>
<td class="nump">167,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesCommonAreaManagementMember', window );">Property Management Services Common Area Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">2,210,703<span></span>
</td>
<td class="nump">2,461,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesSecurityManagementMember', window );">Property Management Services Security Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">683,593<span></span>
</td>
<td class="nump">846,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=EUDA_ProductMangementServicesMember', window );">Product Mangement Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">$ 2,894,296<span></span>
</td>
<td class="nump">$ 3,308,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesSpecialtyCareRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesGeneralPracticesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_MedicalServicesSubTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesCommonAreaManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesCommonAreaManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesSecurityManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_PropertyManagementServicesSecurityManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=EUDA_ProductMangementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=EUDA_ProductMangementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921170272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of basic and diluted earnings per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (24,949,246)<span></span>
</td>
<td class="nump">$ 900,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net (income) loss attributable to noncontrolling interest</a></td>
<td class="num">(65,124)<span></span>
</td>
<td class="nump">35,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss)/income attributable to common shareholders, basic</a></td>
<td class="num">$ (24,884,122)<span></span>
</td>
<td class="nump">$ 864,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, basic and diluted</a></td>
<td class="nump">12,029,656<span></span>
</td>
<td class="nump">9,253,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss)/Earnings per share, basic and diluted</a></td>
<td class="num">$ (2.07)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921179712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of fair value hierarchy of financial liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liabilities</a></td>
<td class="nump">$ 20,321,053<span></span>
</td>
<td class="nump">$ 7,409,550<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liabilities</a></td>
<td class="nump">$ 20,321,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668924585872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilitiesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 7,409,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities', window );">Change in fair value of prepaid forward purchase liabilities</a></td>
<td class="nump">12,911,503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilitiesBalance', window );">Ending balance</a></td>
<td class="nump">$ 20,321,053<span></span>
</td>
<td class="nump">$ 7,409,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In fair value of prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidForwardPurchaseLiabilitiesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid forward purchase liabilities balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidForwardPurchaseLiabilitiesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922284896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 197,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,799<span></span>
</td>
<td class="nump">$ 37,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Other receivables allowance for doubtful account</a></td>
<td class="nump">2,209,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Other receivables allowance for doubtful account</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets', window );">Allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">167,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss on goodwill</a></td>
<td class="nump">971,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of long-lived assets</a></td>
<td class="nump">167,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ForwardPurchaseReceivables', window );">Forward purchase receivables</a></td>
<td class="nump">21,892,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiability', window );">Purchase liability</a></td>
<td class="nump">20,321,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost</a></td>
<td class="nump">21,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development cost</a></td>
<td class="nump">17,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee expenses</a></td>
<td class="nump">$ 505,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 574,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax likelihood description</a></td>
<td class="text">greater than 50% likely of being realized
on examination<span></span>
</td>
<td class="text">greater than 50% likely of being realized
on examination<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares | shares</a></td>
<td class="nump">1,411,725<span></span>
</td>
<td class="nump">1,411,725<span></span>
</td>
<td class="nump">4,458,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=EUDA_CentralProvidentFundMember', window );">Central Provident Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Employee plan description</a></td>
<td class="text">17.00% based on employee&#8217;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase<span></span>
</td>
<td class="text">17.00% based on employee&#8217;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=EUDA_SkillDevelopmentLevyMember', window );">Skill Development Levy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Employee plan description</a></td>
<td class="text">up to 0.25% based on employee&#8217;s monthly salary capped $8.3 (SGD 11.25)<span></span>
</td>
<td class="text">up to 0.25% based on employee&#8217;s monthly salary capped $8.3 (SGD 11.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Monthly salary</a></td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=EUDA_SocialInsuranceFundMember', window );">Social Insurance Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription', window );">Employee plan description</a></td>
<td class="text">20% based on employee&#8217;s monthly salary<span></span>
</td>
<td class="text">20% based on employee&#8217;s monthly salary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_TradeUnionFeePercentage', window );">Trade union fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts prepaid and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ForwardPurchaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward purchase receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ForwardPurchaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidForwardPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid forward purchase liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidForwardPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_TradeUnionFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade union fee percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_TradeUnionFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=EUDA_CentralProvidentFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=EUDA_CentralProvidentFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=EUDA_SkillDevelopmentLevyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=EUDA_SkillDevelopmentLevyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=EUDA_SocialInsuranceFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=EUDA_SocialInsuranceFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668927896736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of shares issued and outstanding reverse recapitalization (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization', window );">8i ordinary shares outstanding prior to Reverse Recapitalization</a></td>
<td class="nump">11,073,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RedemptionOfOrdinaryShares', window );">Less: redemption of 8i ordinary shares</a></td>
<td class="num">(6,033,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of 8i rights</a></td>
<td class="nump">891,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to service providers</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of EHL ordinary shares into 8i ordinary shares</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization', window );">Total shares outstanding</a></td>
<td class="nump">$ 20,191,770<span></span>
</td>
<td class="nump">$ 11,911,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares outstanding prior to reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RedemptionOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RedemptionOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of ordinary shares upon reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669012737200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of financial statements of reverse recapitalization (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 18, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureReverseRecapitalizationAbstract', window );"><strong>Reverse Recapitalization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FundsHeldInTrustAccount', window );">Funds held in 8i&#8217;s trust account</a></td>
<td class="nump">$ 87,074,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FundsHeldInOperatingCashAccount', window );">Funds held in 8i&#8217;s operating cash account</a></td>
<td class="nump">248,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Less: amount paid to redeem public shares of 8i&#8217;s ordinary shares</a></td>
<td class="num">(60,839,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Less: payments of transaction costs incurred by 8i</a></td>
<td class="num">(2,965,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities', window );">Less: payments of forward purchase agreements</a></td>
<td class="num">(21,892,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Less: repayments of promissory note &#8211; related party of 8i</a></td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ProceedsFromReverseRecapitalizations', window );">Proceeds from the Reverse Recapitalization</a></td>
<td class="nump">1,324,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ProceedsFromUnpaidDeferredUnderwritingFee', window );">Less: unpaid deferred underwriting fee</a></td>
<td class="num">(2,113,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ProceedsFromUnpaidTransactionCostsIncurred', window );">Less: unpaid transaction costs incurred by 8i</a></td>
<td class="num">(382,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization</a></td>
<td class="num">(1,305,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_NoncashNetAssetsAssumedValue', window );">Add: non-cash net assets assumed from 8i</a></td>
<td class="nump">14,387,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization', window );">Net contributions from issuance of ordinary shares upon the Reverse Recapitalization</a></td>
<td class="nump">$ 11,911,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureReverseRecapitalizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureReverseRecapitalizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FundsHeldInOperatingCashAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds held in operating cash account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FundsHeldInOperatingCashAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FundsHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds held in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FundsHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares upon the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_NoncashNetAssetsAssumedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash net assets assumed value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_NoncashNetAssetsAssumedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ProceedsFromReverseRecapitalizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from reverse recapitalizations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ProceedsFromReverseRecapitalizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ProceedsFromUnpaidDeferredUnderwritingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from unpaid deferred underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ProceedsFromUnpaidDeferredUnderwritingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ProceedsFromUnpaidTransactionCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from unpaid transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ProceedsFromUnpaidTransactionCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668917127152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2022</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,191,770<span></span>
</td>
<td class="nump">9,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ExchangeRatioPerShare', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,191,770<span></span>
</td>
<td class="nump">4,626,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,840,709<span></span>
</td>
<td class="nump">$ 10,544,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,884,122)<span></span>
</td>
<td class="nump">864,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Public ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,591,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redemption shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,033,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrivateOrdinarySharesNoParValue', window );">Private ordinary shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrivateOrdinarySharesOutstanding', window );">Private ordinary shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FounderSharesNoParValue', window );">Founder shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FounderSharesOutstanding', window );">Founder shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,156,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PublicRightsShares', window );">Public rights shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrivateRightsShares', window );">Private rights shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ProceedsFromReverseRecapitalization', window );">Proceeds from the Reverse Recapitalization</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,324,961<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FundsHeldInTrustAccount', window );">Funds held in trust account</a></td>
<td class="nump">87,074,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FundsHeldInOperatingCashAccount', window );">Funds held in operating cash account</a></td>
<td class="nump">248,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Amount paid to redeem public shares</a></td>
<td class="nump">$ 60,839,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redeem public shares</a></td>
<td class="nump">6,033,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of transaction costs</a></td>
<td class="nump">$ 2,965,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities', window );">Payments of forward purchase agreements</a></td>
<td class="nump">21,892,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of promissory note related party</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=EUDA_BusinessCombinationMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember', window );">First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember', window );">Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ExchangeRatioPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ExchangeRatioPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FounderSharesNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of founder shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FounderSharesNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FounderSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Founder shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FounderSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FundsHeldInOperatingCashAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds held in operating cash account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FundsHeldInOperatingCashAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FundsHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds held in trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FundsHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrivateOrdinarySharesNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private ordinary shares no par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrivateOrdinarySharesNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrivateOrdinarySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private ordinary shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrivateOrdinarySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrivateRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private rights shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrivateRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PublicRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public rights shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PublicRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=EUDA_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=EUDA_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922304912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disposition of Subsidiary (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain loss on disposal of deficit interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,055<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember', window );">The Good Clinic Private Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_SEMAAgreementMember', window );">SEMA Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration received</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain loss on disposal of deficit interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_SEMAAgreementMember', window );">SEMA Agreement [Member] | The Good Clinic Private Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_TheGoodClinicPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_SEMAAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_SEMAAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930263040">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of accounts receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,048,941<span></span>
</td>
<td class="nump">$ 1,883,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(197,438)<span></span>
</td>
<td class="num">(80,799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,851,503<span></span>
</td>
<td class="nump">$ 1,802,316<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2022 and 2021, accounts receivable of up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable">0.6</span></span> million (SGD
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable">0.8</span></span> million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923811168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of accounts receivable (Details) (Pharanthetical)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,851,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember', window );">United Overseas Bank Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669012759840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of movements of allowance for doubtful accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 80,799<span></span>
</td>
<td class="nump">$ 37,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Addition</a></td>
<td class="nump">116,156<span></span>
</td>
<td class="nump">43,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect', window );">Exchange rate effect</a></td>
<td class="nump">483<span></span>
</td>
<td class="num">(903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 197,438<span></span>
</td>
<td class="nump">$ 80,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts receivable exchange rate effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923854240">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of other receivables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DivestmentReceivable', window );">Receivable from divestment (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,818,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_EmployeeAdavance', window );">Employee advance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,695<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">772<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Total other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">3,821,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherReceivablesNetNonCurrent', window );">Other receivables &#8211; non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,830,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables &#8211; current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,467<span></span>
</td>
<td class="nump">$ 1,991,226<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#8217;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" title="Investment amount">1.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" title="Investment amount">2,580,000</span>)
    in BPT&#8217;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#8220;Agreement&#8221;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#8217;s
    investment amounted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" title="Investment owned face amount">1,913,096</span>
    (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" title="Investment owned face amount">2,580,000</span>),
    and compensated UGI with the additional amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount">1,905,681</span>(SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount">2,570,000</span>).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received">0.9</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received">1,200,000</span>)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance">2.8</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance">3,950,000</span>)
    in eight equal quarterly installments with annual <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</span> As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount">0.7</span>
    million (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount">987,500</span>).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DivestmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DivestmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_EmployeeAdavance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Empolyee advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_EmployeeAdavance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherReceivablesNetNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivable net non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherReceivablesNetNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669012759840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of other receivables allowance for doubtful accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AllowanceForDoubtfulOtherReceivableRecoveries', window );">Addition</a></td>
<td class="nump">2,209,825<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs', window );">Write-off</a></td>
<td class="num">(2,209,825)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AllowanceForDoubtfulOtherReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful other receivable recoveries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AllowanceForDoubtfulOtherReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful other receivable write offs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915055456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of other receivables (Details) (Paranthetical)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jan. 18, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 18, 2018 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 2,580,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Investment owned face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,913,096<span></span>
</td>
<td class="nump">$ 2,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_InvestmentOwnedAdditionalAmountAtMarketValues', window );">Additional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,905,681<span></span>
</td>
<td class="nump">2,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_InstallmentReceived', window );">Installment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Remaining balance</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt intrument interest rate, description</a></td>
<td class="text">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherReceivableInstallmentAmount', window );">Other installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 987,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_InstallmentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_InstallmentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_InvestmentOwnedAdditionalAmountAtMarketValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment owned additional amount at market values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_InvestmentOwnedAdditionalAmountAtMarketValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherReceivableInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivable installment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherReceivableInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For investments which are quantified by principal amount, the principle balance held at close of period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6438156&amp;loc=d3e57880-113973<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6431724&amp;loc=d3e32938-113948<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915034672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of property and equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 153,328<span></span>
</td>
<td class="nump">$ 180,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(121,700)<span></span>
</td>
<td class="num">(123,745)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">31,628<span></span>
</td>
<td class="nump">56,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">148,387<span></span>
</td>
<td class="nump">144,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">15,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 2,217<span></span>
</td>
<td class="nump">$ 20,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=EUDA_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929395520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 23,347<span></span>
</td>
<td class="nump">$ 34,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923778672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of intangible assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedCustomerRelationshipsGross', window );">Customer relationships</a></td>
<td class="nump">$ 650,102<span></span>
</td>
<td class="nump">$ 646,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(477,584)<span></span>
</td>
<td class="num">(356,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Less: Impairment</a></td>
<td class="nump">167,787<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ExchangeRateEffect', window );">Exchange rate effect</a></td>
<td class="nump">4,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 289,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange rate effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedCustomerRelationshipsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date to an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedCustomerRelationshipsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922937680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 992,686<span></span>
</td>
<td class="nump">$ 1,012,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Foreign currency translation adjustment</a></td>
<td class="num">(21,457)<span></span>
</td>
<td class="num">(19,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">(971,229)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">992,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=EUDA_MelanaInternationalPteLimitedMember', window );">Melana International Pte Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">528,665<span></span>
</td>
<td class="nump">539,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Foreign currency translation adjustment</a></td>
<td class="num">(11,427)<span></span>
</td>
<td class="num">(10,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">(517,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">528,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=EUDA_TriGlobalSecurityPteLimitedMember', window );">TriGlobal Security Pte Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">464,021<span></span>
</td>
<td class="nump">473,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments', window );">Foreign currency translation adjustment</a></td>
<td class="num">(10,030)<span></span>
</td>
<td class="num">(9,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">(453,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 464,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=EUDA_MelanaInternationalPteLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=EUDA_MelanaInternationalPteLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=EUDA_TriGlobalSecurityPteLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=EUDA_TriGlobalSecurityPteLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930250720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets, net (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 115,907<span></span>
</td>
<td class="nump">$ 162,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on intangible assets</a></td>
<td class="nump">$ 167,787<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668923777296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 971,229<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922965952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Forward Purchase Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PrepaidForwardPurchaseLiabilities', window );">Prepaid forward purchase liability</a></td>
<td class="nump">$ 7,409,550<span></span>
</td>
<td class="nump">$ 20,321,053<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability', window );">Change of fair value of prepaid forward purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,911,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare', window );">Forward contract, fair value per share</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementOneMember', window );">Prepaid Forward Agreement 1 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementOneMember', window );">Prepaid Forward Agreement 1 [Member] | Maximum [Member] | Institutional Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Beneficially ownership percentage</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementTwoMember', window );">Prepaid Forward Agreement 2 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementTwoMember', window );">Prepaid Forward Agreement 2 [Member] | Maximum [Member] | Institutional Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Beneficially ownership percentage</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change of fair value of prepaid forward purchase liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share that would be issued upon settlement of forward contract indexed to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_InstitutionalInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_InstitutionalInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_PrepaidForwardAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915075456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan to third party (Details Narrative) - PT Total Prima Indonesia [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 20, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2020 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan borrow up amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Loan interest rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_LoanAccumulativelyDisbursed', window );">Loan accumulatively disbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 608,683<span></span>
</td>
<td class="nump">$ 352,959<span></span>
</td>
<td class="nump">$ 816,000<span></span>
</td>
<td class="nump">$ 476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,766<span></span>
</td>
<td class="nump">19,003<span></span>
</td>
<td class="nump">$ 84,144<span></span>
</td>
<td class="nump">$ 25,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeRelatedParty', window );">Interest income from loan to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 19,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_LoanAccumulativelyDisbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan accumulatively disbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_LoanAccumulativelyDisbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest-bearing assets owed to the entity by related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=EUDA_PTTotalPrimaIndonesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=EUDA_PTTotalPrimaIndonesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668916603520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of short-term loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 204,240<span></span>
</td>
<td class="nump">$ 205,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,619,625<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember', window );">Bank and Private Lender [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204,240<span></span>
</td>
<td class="nump">205,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember', window );">Convertible Notes Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,619,625<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesRelatedPartiesMember', window );">Convertible Notes Related Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 782,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember', window );">United Overseas Bank Limited [Member] | Bank and Private Lender [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">United Overseas Bank Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">90 days from disbursement<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ShortTermDebtInterestRate', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Collateral: Accounts receivable<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 185,592<span></span>
</td>
<td class="nump">184,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember', window );">United Overseas Bank Limited [Member] | Bank and Private Lender [Member] | Prime Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ShortTermDebtInterestRate', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_FSCapitalPtdLtdMember', window );">FS Capital Ptd Ltd [Member] | Bank and Private Lender [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">FS Capital Ptd. Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Fully repaid in February, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder, and Kent Ridge Health Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_FundingSocietiesPteLtdMember', window );">Funding Societies Pte. Ltd [Member] | Bank and Private Lender [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Funding Societies Pte. Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Guaranteed by Kelvin Chen Weiwen, the Company&#8217;s CEO and shareholder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loans - bank and private lender</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,648<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KohWeeSingMember', window );">Koh Wee Sing [Member] | Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Koh Wee Sing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTerms', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Due on demand beginning in July 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Short term loans - third parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">148,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember', window );">Kaufaman &amp; Canoles, P.C. (KC) [Member] | Promissory Note [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Kaufaman & Canoles, P. C. (&#8220;KC&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MaximGroupLlcMember', window );">Maxim Group LLC [Member] | Convertible Notes Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Maxim Group LLC (&#8220;Maxim&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Automatically be converted into the Company&#8217;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,113,125<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MenoraCapitalPteLtdMember', window );">Menora Capital Pte Ltd [Member] | Convertible Notes Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Menora Capital Pte Ltd (&#8220;Menora&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 87,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_LoebAndLoebLlpMember', window );">Loeb and Loeb LLP [Member] | Convertible Notes Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Loeb & Loeb LLP (&#8220;Loeb&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_ShineLinkLimitedMember', window );">Shine Link Limited [Member] | Convertible Notes Third Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Shine Link Limited (&#8220;Shine Link&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_EightIHoldingsTwoPtdLtdMember', window );">8i Holdings Two Ptd Ltd [Member] | Convertible Notes Related Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">8i Holdings 2 Ptd Ltd (&#8220;8i Holding&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 82,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember', window );">Meng Dong James Tan [Member] | Convertible Notes Related Parties [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLender', window );">Bank/Private lender Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">Meng Dong (James) Tan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral/Guarantee</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">Right to convert into the Company&#8217;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">Nov. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount">593,208</span>
                                                                                                       (SGD <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount">800,000</span>)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#8217;s account receivable (see Note 6). The loan bears an average annual interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate">5.50</span>%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On December 16, 2022, the Company has signed a loan agreement
                                                                                                       (&#8220;Agreement&#8221;) with Kent Ridge Health Pte Ltd (&#8220;KRHPL&#8221;), a related party. Pursuant to the Agreement, KRHPL
                                                                                                       agreed to fully remit the loan payment to Koh Wee Sing on behalf of the Company. As a result, such short-term loan- third party was
                                                                                                       transfer to other payable, related parties under KRHPL&#8217;s balance as of December 31, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">This promissory note has a default interest of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate">15</span>% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#8220;the Agreement&#8221;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note">100,000</span> within two days of the dates that the Company&#8217;s US counsel,
Loeb &amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note">60,000</span> within two business days after the date the first amendment to the registration
statement is filed with the SEC.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Mr. Meng Dong (James) Tan, the Company&#8217;s related party who had more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name">10</span>% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Mr. Meng Dong (James) Tan, the Company&#8217;s related party has more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name">10</span>% ownership of the Company.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ShortTermDebtInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term debt interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ShortTermDebtInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender or type of lender, such as bank, insurance entity, pension fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ConvertibleNotesRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_FSCapitalPtdLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_FSCapitalPtdLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_FundingSocietiesPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_FundingSocietiesPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KohWeeSingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_KohWeeSingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MaximGroupLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_MaximGroupLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MenoraCapitalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_MenoraCapitalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_LoebAndLoebLlpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_LoebAndLoebLlpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_ShineLinkLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_ShineLinkLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_EightIHoldingsTwoPtdLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_EightIHoldingsTwoPtdLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922174960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of short-term loans (Details) (Paranthetical)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th">
<div>Aug. 21, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2019 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember', window );">United Overseas Bank Limited [Member] | Bank and Private Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan borrow up amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 593,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember', window );">Kaufaman &amp; Canoles, P.C. (KC) [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember', window );">Kaufaman &amp; Canoles, P.C. (KC) [Member] | Promissory Note [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember', window );">Kaufaman &amp; Canoles, P.C. (KC) [Member] | Promissory Note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime', window );">Interest Rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember', window );">Meng Dong James Tan [Member] | 8i Holdings Two Ptd Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_UnitedOverseasBankLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_BankAndPrivateLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_KaufamanAndCanolesPcKcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=EUDA_MengDongJamesTanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EightIHoldingsTwoPtdLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=EUDA_EightIHoldingsTwoPtdLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669021206272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit facilities (Details Narrative) - Third Parties [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 122,845<span></span>
</td>
<td class="nump">$ 128,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=EUDA_ThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922787184">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of other payables and accrued liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (i)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 671,743<span></span>
</td>
<td class="nump">$ 129,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">730,037<span></span>
</td>
<td class="nump">244,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interests (ii)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">157,032<span></span>
</td>
<td class="nump">67,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,003<span></span>
</td>
<td class="nump">47,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total other payables and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,592,815<span></span>
</td>
<td class="nump">$ 488,597<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The balance of accrued interests represented the balance of interest payable from short-term loan &#8211; bank, private lender, and third parties (See Note 13).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668916443504">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of related party balances (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 267,863<span></span>
</td>
<td class="nump">$ 297,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,521,945<span></span>
</td>
<td class="nump">3,272,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KRHillCapitalPteLtdMember', window );">KR Hill Capital Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeMedicalPtdLtdMember', window );">Kent Ridge Medical Ptd Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">247<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_UGDigitalSdnBhdMember', window );">UG Digital Sdn. Bhd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">284,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,016<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JanicLimitedMember', window );">Janic Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">724<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_ZukihealthSDNMember', window );">Zukihealth SDN [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JenniferGohMember', window );">Jennifer Goh [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_FrescoInvestmentPteLtdMember', window );">Fresco Investment Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember', window );">Cadence Health Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Other receivables - related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">266,653<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Account payable, related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,459,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CheeYinMehMember', window );">Chee Yin Meh [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122,739<span></span>
</td>
<td class="nump">34,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JamieFanWeiZhiMember', window );">Jamie Fan Wei Zhi [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">40,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KelvinChenMember', window );">Kelvin Chen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">589,681<span></span>
</td>
<td class="nump">295,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeHealthPteLtdMember', window );">Kent Ridge Health Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">696,508<span></span>
</td>
<td class="nump">121,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember', window );">Kent Ridge Pacific Pte Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,303<span></span>
</td>
<td class="nump">33,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WatermarkDevelopmentsLtdMember', window );">Watermark Developments Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,945<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WilkeServicesLtdMember', window );">Wilke Services Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,746,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_MountLockeLimitedMember', window );">Mount Locke Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Other payables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,753<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of date of <span style="background-color: white">the issuance of these financial statements</span>,
this receivable has been repaid by the related party.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KRHillCapitalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KRHillCapitalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeMedicalPtdLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeMedicalPtdLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_UGDigitalSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_UGDigitalSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JanicLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JanicLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_ZukihealthSDNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_ZukihealthSDNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JenniferGohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JenniferGohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_FrescoInvestmentPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_FrescoInvestmentPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CheeYinMehMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CheeYinMehMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JamieFanWeiZhiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_JamieFanWeiZhiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KelvinChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KelvinChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeHealthPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgeHealthPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WatermarkDevelopmentsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WatermarkDevelopmentsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WilkeServicesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_WilkeServicesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_MountLockeLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_MountLockeLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668921139168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of related party transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 4,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember', window );">Cadence Health Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_PurchaseFromRelatedParties', window );">Purchase from related parties</a></td>
<td class="nump">491,499<span></span>
</td>
<td class="nump">2,349,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember', window );">Kent Ridge Pacific Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rental Expenses</a></td>
<td class="nump">$ 47,954<span></span>
</td>
<td class="nump">$ 143,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_PurchaseFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from purchases of related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_PurchaseFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_CadenceHealthPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_KentRidgePacificPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668924445376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of reverse recapitalization (Details) - shares<br></strong></div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization', window );">8i ordinary shares outstanding prior to Reverse Recapitalization</a></td>
<td class="nump">11,073,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RedemptionOfOrdinaryShares', window );">Less: redemption of 8i ordinary shares</a></td>
<td class="num">(6,033,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of 8i rights</a></td>
<td class="nump">891,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to service providers</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Total shares issued upon the Reverse Recapitalization</a></td>
<td class="nump">6,191,770<span></span>
</td>
<td class="nump">4,626,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares outstanding prior to reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RedemptionOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RedemptionOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668916969552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of warrant activities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Ending balance</a></td>
<td class="nump">8,917,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ordinary Shares Issuable, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ClassOfWarrantOrRightOutstandingGranted', window );">Warrants Outstanding, Granted</a></td>
<td class="nump">8,917,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Ordinary Shares Issuable, Granted</a></td>
<td class="nump">4,458,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Granted | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted', window );">Average Remaining Contractual Life,Granted</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ClassOfWarrantOrRightOutstandingForfeited', window );">Warrants Outstanding, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Ordinary Shares Issuable, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ClassOfWarrantOrRightOutstandingExercised', window );">Warrants Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Ordinary Shares Issuable, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding, Ending balance</a></td>
<td class="nump">8,917,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ordinary Shares Issuable, Ending balance</a></td>
<td class="nump">4,458,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Average Remaining Contractual Life,</a></td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ClassOfWarrantOrRightOutstandingExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant outstanding exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ClassOfWarrantOrRightOutstandingExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ClassOfWarrantOrRightOutstandingForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant outstanding forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ClassOfWarrantOrRightOutstandingForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ClassOfWarrantOrRightOutstandingGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant outstanding granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ClassOfWarrantOrRightOutstandingGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share award equity instruments other than options outstanding weighted average remaining contractual terms granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930100672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of earnout shares for triggering event (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 17, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_SharePriceAsOfClosingDate', window );">Share price of the Company as of closing date</a></td>
<td class="nump">$ 5.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AverageDailyReturnRate', window );">Average daily return rate</a></td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DailyVolatilityForTriggeringEvent1', window );">Daily volatility for Triggering Event 1</a></td>
<td class="nump">4.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DailyVolatilityForTriggeringEvent2', window );">Daily volatility for Triggering Event 2</a></td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RiskFreeRateForTriggeringEventOne', window );">Risk-free rate for Triggering Event 1</a></td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_RiskFreeRateForTriggeringEventTwo', window );">Risk-free rate for Triggering Event 2</a></td>
<td class="nump">4.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_GrantPriceForTriggingEventOne', window );">Grant Price for Trigging Event 1</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_GrantPriceForTriggingEventTwo', window );">Grant Price for Trigging Event 2</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AverageDailyReturnRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average daily return rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AverageDailyReturnRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DailyVolatilityForTriggeringEvent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Daily volatility for triggering event 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DailyVolatilityForTriggeringEvent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DailyVolatilityForTriggeringEvent2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Daily volatility for triggering event 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DailyVolatilityForTriggeringEvent2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_GrantPriceForTriggingEventOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant price for trigging event one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_GrantPriceForTriggingEventOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_GrantPriceForTriggingEventTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant price for trigging event two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_GrantPriceForTriggingEventTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RiskFreeRateForTriggeringEventOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk free rate for triggering event one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RiskFreeRateForTriggeringEventOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_RiskFreeRateForTriggeringEventTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk free rate for triggering event two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_RiskFreeRateForTriggeringEventTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_SharePriceAsOfClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price as of closing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_SharePriceAsOfClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668914019616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares authorized, unlimited</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Forgiveness of debt by a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,763,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="nump">6,191,770<span></span>
</td>
<td class="nump">4,626,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinaryShareBeforeReverseRecapitalization', window );">Ordinary share before reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,917,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase ordinary share, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_WarrantsRedemptionPrice', window );">Warrants redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price of the ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_EarnoutShares', window );">Earnout shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,840,709<span></span>
</td>
<td class="nump">$ 10,544,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,884,122)<span></span>
</td>
<td class="nump">$ 864,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=EUDA_TriggeringEventOneMember', window );">Triggering Event One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FairValueOfEarnoutShares', window );">Fair value of earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=EUDA_TriggeringEventTwoMember', window );">Triggering Event Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_FairValueOfEarnoutShares', window );">Fair value of earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,273,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember', window );">First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Number of additional shares issued</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember', window );">Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Number of additional shares issued</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=EUDA_PublicWarrantMember', window );">Public Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=EUDA_PrivateWarrantMember', window );">Private Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Capital', window );">Capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares authorized, unlimited</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_EightIHoldingsTwoPtdLtdMember', window );">8i Holdings Two Ptd Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="nump">6,191,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_EarnoutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_EarnoutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_FairValueOfEarnoutShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of earnout shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_FairValueOfEarnoutShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinaryShareBeforeReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares before reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinaryShareBeforeReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_WarrantsRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_WarrantsRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=EUDA_TriggeringEventOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=EUDA_TriggeringEventOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=EUDA_TriggeringEventTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=EUDA_TriggeringEventTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_SecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=EUDA_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=EUDA_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=EUDA_PrivateWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=EUDA_PrivateWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_EightIHoldingsTwoPtdLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=EUDA_EightIHoldingsTwoPtdLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139669012735936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of components of loss before income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Singapore</a></td>
<td class="num">$ (5,400,034)<span></span>
</td>
<td class="nump">$ 930,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(19,531,790)<span></span>
</td>
<td class="nump">18,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total loss (income) before income taxes</a></td>
<td class="num">$ (24,931,824)<span></span>
</td>
<td class="nump">$ 948,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929262544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 65,650<span></span>
</td>
<td class="nump">$ 75,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(48,228)<span></span>
</td>
<td class="num">(27,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 17,422<span></span>
</td>
<td class="nump">$ 48,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915248880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of effective income tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Singapore statutory income tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Tax rate difference outside Singapore</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Taxable income below exemption threshold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="nump">29.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(39.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915257440">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of deferred tax assets and liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 749,309<span></span>
</td>
<td class="nump">$ 812,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful account</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,564<span></span>
</td>
<td class="nump">13,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DeferredTaxAssetsLeaseLiabilityNet', window );">Net lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">823<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(783,696)<span></span>
</td>
<td class="num">(826,451)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Customer relationships</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 49,294<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased">42,755</span> as of December 31, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DeferredTaxAssetsLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DeferredTaxAssetsLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668931354480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of deferred tax assets and liabilities (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance on all deferred tax assets increased</a></td>
<td class="nump">$ 42,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929431168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of taxes payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_AccruedGSTTaxesPayableCurrent', window );">GST taxes payable</a></td>
<td class="nump">$ 125,695<span></span>
</td>
<td class="nump">$ 225,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">60,455<span></span>
</td>
<td class="nump">82,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Totals</a></td>
<td class="nump">$ 186,150<span></span>
</td>
<td class="nump">$ 307,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_AccruedGSTTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GST taxes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_AccruedGSTTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915131648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details Narrative)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate</a></td>
<td class="num">(13.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxable income</a></td>
<td class="nump">$ 17,422<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 48,141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating losses carry forward</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating losses carry forward</a></td>
<td class="nump">749,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">812,715<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=EUDA_SingaporeSubsidiariesMember', window );">Singapore Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating losses carry forward</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_VN', window );">VIET NAM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating losses carry forward</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating losses carry forward</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating losses carry forward description</a></td>
<td class="text">The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MY', window );">MALAYSIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating losses carry forward</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets, operating losses carry forward</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax description</a></td>
<td class="text">The applicable tax rate is 17% in Singapore, with 75% of the first $7,255 (SGD 10,000) taxable income
and 50% of the next $137,842 (SGD 190,000) taxable income are exempted from income tax.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">The applicable tax rate is 17% in Singapore, with 75% of the first $7,255 (SGD 10,000) taxable income
and 50% of the next $137,842 (SGD 190,000) taxable income are exempted from income tax.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE | 75% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxable income</a></td>
<td class="nump">$ 7,255<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE | 50% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxable income</a></td>
<td class="nump">$ 137,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=EUDA_SingaporeSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=EUDA_SingaporeSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_VN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_VN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_SeventyFivePercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_SeventyFivePercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=EUDA_FiftyPercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=EUDA_FiftyPercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668913999984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations risks (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash balance</a></td>
<td class="nump">$ 143,024<span></span>
</td>
<td class="nump">$ 189,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">641,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember', window );">Credit Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash balance</a></td>
<td class="nump">138,710<span></span>
</td>
<td class="nump">180,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BankOverdrafts', window );">Bank balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 391,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | No Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | No Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | One Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">27.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis=us-gaap_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=EUDA_NoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=EUDA_NoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=EUDA_NoVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=EUDA_NoVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=EUDA_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=EUDA_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=EUDA_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=EUDA_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=EUDA_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=EUDA_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915296896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of operating and finance lease expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased asset</a></td>
<td class="nump">$ 7,948<span></span>
</td>
<td class="nump">$ 8,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expenses</a></td>
<td class="nump">236,669<span></span>
</td>
<td class="nump">216,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expenses</a></td>
<td class="nump">114,390<span></span>
</td>
<td class="nump">62,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OperatingLeaseExpenseShortTerm', window );">Lease expenses - short-term</a></td>
<td class="nump">113,055<span></span>
</td>
<td class="nump">143,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased asset</a></td>
<td class="nump">7,948<span></span>
</td>
<td class="nump">8,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">$ 1,276<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OperatingLeaseExpenseShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expense short term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OperatingLeaseExpenseShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668929176832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of weighted average remaining term and discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining term</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, weighted-average remaining term</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, weighted-average discount rate</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668915361376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of future minimum lease payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating lease payments, 2023</a></td>
<td class="nump">$ 81,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance lease payments, 2023</a></td>
<td class="nump">8,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Total 2023</a></td>
<td class="nump">89,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating lease payments, 2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance lease payments, 2024</a></td>
<td class="nump">15,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Total 2024</a></td>
<td class="nump">15,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Operating lease payments</a></td>
<td class="nump">81,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total Finance lease payments</a></td>
<td class="nump">23,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total lease payments</a></td>
<td class="nump">105,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Total Operating lease payments, discount</a></td>
<td class="num">(1,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Total Finance lease payments, discount</a></td>
<td class="num">(1,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ContractualObligationDiscount', window );">Total lease payments</a></td>
<td class="num">(3,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities, operating lease payments</a></td>
<td class="nump">79,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities, finance lease payments</a></td>
<td class="nump">22,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_ContractualObligationLeaseLiability', window );">Total lease payments</a></td>
<td class="nump">$ 102,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ContractualObligationDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ContractualObligationDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_ContractualObligationLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_ContractualObligationLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668916658096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate', window );">Effective interest rate</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease term</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease term</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short term lease payments</a></td>
<td class="nump">$ 25,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage points added to the reference rate to compute the variable rate on the lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668930243760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details Narrative) - 12 months ended Dec. 31, 2022<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>SGD ($)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Compensate amount</a></td>
<td class="nump">$ 3,704<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Legal payment</a></td>
<td class="nump">74,966<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liability balance outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922593056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of segment reporting information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (12,057,771)<span></span>
</td>
<td class="num">$ (1,228,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(24,931,824)<span></span>
</td>
<td class="nump">948,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(24,949,246)<span></span>
</td>
<td class="nump">900,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember', window );">Medical Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,076,414<span></span>
</td>
<td class="nump">5,986,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,463,593)<span></span>
</td>
<td class="num">(1,186,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(2,613,615)<span></span>
</td>
<td class="num">(1,239,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,651,826)<span></span>
</td>
<td class="num">(1,241,091)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember', window );">Property Management Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,764,295<span></span>
</td>
<td class="nump">4,558,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,991,371)<span></span>
</td>
<td class="num">(41,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(2,800,755)<span></span>
</td>
<td class="nump">2,187,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,779,966)<span></span>
</td>
<td class="nump">2,141,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_ConsolidatedMember', window );">Consolidated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">9,840,709<span></span>
</td>
<td class="nump">10,544,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,454,964)<span></span>
</td>
<td class="num">(1,228,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(5,414,370)<span></span>
</td>
<td class="nump">948,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (5,431,792)<span></span>
</td>
<td class="nump">$ 900,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_ConsolidatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=EUDA_ConsolidatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668922785152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Segment loss before income tax</a></td>
<td class="nump">$ 5,414,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities', window );">Change in fair value of prepaid forward purchase liabilities</a></td>
<td class="num">(12,911,503)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_EarnoutSharePayment', window );">Earnout share payment</a></td>
<td class="num">(5,199,629)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OtherCorporateExpenses', window );">Other corporate expenses</a></td>
<td class="num">(1,406,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(LOSS) INCOME BEFORE INCOME TAXES</a></td>
<td class="num">$ (24,931,824)<span></span>
</td>
<td class="nump">$ 948,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_EarnoutSharePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout share payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_EarnoutSharePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In fair value of prepaid forward purchase liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OtherCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other corporate expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OtherCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668924609568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment information (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 25,629,040<span></span>
</td>
<td class="nump">$ 7,999,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember', window );">Medical Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,176,405<span></span>
</td>
<td class="nump">1,478,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember', window );">Property Management Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">335,068<span></span>
</td>
<td class="nump">$ 6,412,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 23,117,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=EUDA_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=EUDA_PropertyManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139668917742576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>May 22, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Jan. 09, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Restricted ordinary shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investors sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Investors sale of stock and issued</a></td>
<td class="nump">940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investors sale of stock price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Investors sale of stock aggregate purchase price</a></td>
<td class="nump">$ 940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument trading percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,306<span></span>
</td>
<td class="nump">578,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockTypeOfStockConverted', window );">Conversion of ordinary shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These conversions are likely resulted in modification of the
convertible notes as the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher
than $1.00 and reduced the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesForfeited', window );">Ordinary shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Settlement Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tan Second Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tan First Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tan Third Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tan 2023 Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of unpaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesAvailableForResale', window );">Ordinary shares available for resale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Restricted ordinary shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockTypeOfStockConverted', window );">Conversion of ordinary shares, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This conversion is likely resulted in modification of the convertible notes as
the five-day VWAP Price of the Company&#8217;s ordinary shares immediately preceding the conversion date is higher than $1.00 and reduced
the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Alfred Lim [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | James Tan [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Shine Link [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Menora [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 8i Holding [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Kelvin Chen [Member] | Chen Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Ordinary shares aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Seller One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesToBeIssued', window );">Ordinary shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Seller Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_EUDA_OrdinarySharesToBeIssued', window );">Ordinary shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinarySharesAvailableForResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares available for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinarySharesAvailableForResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinarySharesForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinarySharesForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_EUDA_OrdinarySharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">EUDA_OrdinarySharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>EUDA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockTypeOfStockConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of stock (i.e. preferred, common, treasury, etc.) being converted in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockTypeOfStockConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=EUDA_TanSecondLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=EUDA_TanSecondLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=EUDA_TanFirstLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=EUDA_TanFirstLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=EUDA_TanThirdLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=EUDA_TanThirdLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=EUDA_TanTwoThousandTwentyThreeNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=EUDA_TanTwoThousandTwentyThreeNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_AlfredLimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_AlfredLimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_JamesTanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_JamesTanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_ShineLinkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_ShineLinkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_MenoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_MenoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_EightiHoldingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_EightiHoldingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_KelvinChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_KelvinChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=EUDA_ChenSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=EUDA_ChenSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_SellerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_SellerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=EUDA_SellerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=EUDA_SellerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:EUDA="http://euda.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="euda-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">EUDA:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">EUDA:RedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2023-06-19</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-24</instant>
        </period>
    </context>
    <context id="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-24</startDate>
            <endDate>2021-07-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-07-24_custom_EUDAPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-24</instant>
        </period>
    </context>
    <context id="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-24</startDate>
            <endDate>2021-07-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-01_custom_SuperGatewayGroupLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="From2021-08-012021-08-01_custom_SuperGatewayGroupLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAHealthLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EUDAHealthLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAHealthLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthcareSingaporePteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EUDAPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDAPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitekVietnamPrivateLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitekVietnamPrivateLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TheGoodClinicPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDADoctorPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EUDADoctorPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EUDADoctorPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHillPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgeHillPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHillPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgeHealthLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KentRidgeHealthLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitechPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ZukitechPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukitechPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SuperGatewayGroupLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SuperGatewayGroupLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UniversalGatewayInternationalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UniversalGatewayInternationalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:MelanaInternationalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MelanaInternationalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:MelanaInternationalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TriGlobalSecurityPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TriGlobalSecurityPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TriGlobalSecurityPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UGDigitechPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UGDigitechPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:UGDigitechPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:NosweatFitnessCompanyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:NosweatFitnessCompanyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TrueCoverPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TrueCoverPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TrueCoverPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KRDigitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukihealthSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ZukihealthSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:ZukihealthSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="From2022-03-012022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:SingaporeEmergencyMedicalAssistancePrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-19_custom_KRDigitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="From2022-04-192022-04-19_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-15_custom_KRDigitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="From2022-04-152022-04-15_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:KRDigitalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_currency_SGD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_currency_SGD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:SGD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_currency_VND">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:VND</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_currency_VND">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:VND</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_currency_MYR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MYR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_currency_MYR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:MYR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CentralProvidentFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:CentralProvidentFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SkillDevelopmentLevyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SocialInsuranceFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SocialInsuranceFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SocialInsuranceFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">EUDA:SocialInsuranceFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticeRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSubTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServiceCommonAreaManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceCommonAreaManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServiceCommonAreaManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceCommonAreaManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServiceSecurityManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceSecurityManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServiceSecurityManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceSecurityManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesSpecialtyCareRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:MedicalServicesGeneralPracticesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServicesCommonAreaManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesCommonAreaManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServicesCommonAreaManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesCommonAreaManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServicesSecurityManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesSecurityManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServicesSecurityManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:PropertyManagementServicesSecurityManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ProductMangementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductMangementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ProductMangementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">EUDA:ProductMangementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="From2022-11-162022-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="From2022-11-162022-11-17_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-17_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="From2022-11-162022-11-17_custom_SecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-17_custom_SecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-17_custom_BusinessCombinationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="AsOf2022-11-17_custom_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="From2022-11-162022-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-02_custom_SEMAAgreementMember_custom_TheGoodClinicPrivateLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:TheGoodClinicPrivateLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-02</instant>
        </period>
    </context>
    <context id="From2022-02-272022-03-02_custom_SEMAAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-27</startDate>
            <endDate>2022-03-02</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SEMAAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SEMAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-01-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2018-01-18</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">EUDA:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MelanaInternationalPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TriGlobalSecurityPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MelanaInternationalPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TriGlobalSecurityPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:MelanaInternationalPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">EUDA:TriGlobalSecurityPteLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-11-082022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="From2022-11-082022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember_custom_InstitutionalInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:InstitutionalInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="AsOf2022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember_custom_InstitutionalInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:InstitutionalInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:PrepaidForwardAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="AsOf2022-11-09_us-gaap_ForwardContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="AsOf2022-11-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-20</instant>
        </period>
    </context>
    <context id="From2020-11-192020-11-20_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PTTotalPrimaIndonesiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">EUDA:PTTotalPrimaIndonesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FSCapitalPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:FundingSocietiesPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KohWeeSingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MaximGroupLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MenoraCapitalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:LoebAndLoebLlpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:ShineLinkLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ConvertibleNotesThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ConvertibleNotesRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ConvertibleNotesRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-21</instant>
        </period>
    </context>
    <context id="From2019-08-202019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:UnitedOverseasBankLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:BankAndPrivateLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-20</startDate>
            <endDate>2019-08-21</endDate>
        </period>
    </context>
    <context id="From2023-02-142023-02-15_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-14</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SettlementAgreementMember_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:KaufamanAndCanolesPcKcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">EUDA:MengDongJamesTanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">EUDA:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KRHillCapitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KRHillCapitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KRHillCapitalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KRHillCapitalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgeMedicalPtdLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeMedicalPtdLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KentRidgeMedicalPtdLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeMedicalPtdLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UGDigitalSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:UGDigitalSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_UGDigitalSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:UGDigitalSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_JanicLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JanicLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_JanicLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JanicLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ZukihealthSDNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:ZukihealthSDNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ZukihealthSDNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:ZukihealthSDNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_JenniferGohMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JenniferGohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_JenniferGohMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JenniferGohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FrescoInvestmentPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:FrescoInvestmentPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_FrescoInvestmentPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:FrescoInvestmentPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CadenceHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CadenceHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CheeYinMehMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CheeYinMehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CheeYinMehMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CheeYinMehMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_JamieFanWeiZhiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JamieFanWeiZhiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_JamieFanWeiZhiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:JamieFanWeiZhiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KelvinChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KelvinChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgeHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KentRidgeHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgeHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_KentRidgePacificPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_KentRidgePacificPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WatermarkDevelopmentsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WatermarkDevelopmentsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WatermarkDevelopmentsLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WatermarkDevelopmentsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WilkeServicesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WilkeServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WilkeServicesLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:WilkeServicesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MountLockeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:MountLockeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MountLockeLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:MountLockeLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:CadenceHealthPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:KentRidgePacificPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-20_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-20</instant>
        </period>
    </context>
    <context id="AsOf2022-11-17_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="From2022-03-302022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-242022-07-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <startDate>2022-07-24</startDate>
            <endDate>2022-07-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="From2022-11-162022-11-17_custom_EightIHoldingsTwoPtdLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">EUDA:EightIHoldingsTwoPtdLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PublicWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EUDA:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PrivateWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">EUDA:PrivateWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TriggeringEventOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">EUDA:TriggeringEventOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TriggeringEventTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">EUDA:TriggeringEventTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_VN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_SG">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:SeventyFivePercentageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">EUDA:FiftyPercentageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SingaporeSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">EUDA:SingaporeSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SingaporeSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">EUDA:SingaporeSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_country_VN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_country_VN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:NoVendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:OneVendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">EUDA:OneVendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis">us-gaap:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MedicalServicesMember36611421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MedicalServicesMember36611453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PropertyManagementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PropertyManagementServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">EUDA:PropertyManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-09</instant>
        </period>
    </context>
    <context id="From2023-01-092023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:AlfredLimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="From2023-02-022023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:AlfredLimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanSecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="From2023-04-242023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanSecondLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanFirstLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanFirstLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanThirdLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanThirdLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">EUDA:TanTwoThousandTwentyThreeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_JamesTanMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:JamesTanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_ShineLinkMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:ShineLinkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_MenoraMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:MenoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_EightiHoldingMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:EightiHoldingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:KelvinChenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:ChenSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">EUDA:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-22</instant>
        </period>
    </context>
    <context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:SellerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">EUDA:SellerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001847846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001847846</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0021">D8</dei:EntityIncorporationStateCountryCode>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0063"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ForwardPurchaseReceivables
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:OtherReceivablesNonCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:LoanToThirdParty
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ShortTermLoansThirdParties
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0125"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:PromissoryNote
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ConvertibleNotesRelatedParties
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:AccountsPayableRelatedParty
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:PrepaidForwardPurchaseLiabilities
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0195">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0197">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <EUDA:EarnoutSharePayment
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueCapitalContributions
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueCapitalContributions
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueCapitalContributions
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:EarnoutPayment
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInNotesReceivableCurrent
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ProceedsFromReverseRecapitalization
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:RepaymentsToShorttermLoansThirdParties
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ConversionOfDebtIntoPromissoryNote
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ConversionOfDebtsIntoConvertibleNotes
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:ForgivenessOfDebtByRelatedParty
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:IssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2021-12-31_currency_MYR"
      id="xdx2ixbrl0804"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2021-12-31_currency_MYR"
      id="xdx2ixbrl0807"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_currency_MYR"
      id="xdx2ixbrl0816"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_currency_MYR"
      id="xdx2ixbrl0819"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="xdx2ixbrl0868"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0878"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:PrepaidForwardPurchaseLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1015"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:PrepaidForwardPurchaseLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1017"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:DivestmentReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1207"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:OtherReceivablesNetNonCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:AllowanceForDoubtfulOtherReceivableRecoveries
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1233"
      unitRef="USD"
      xsi:nil="true"/>
    <EUDA:AllowanceForDoubtfulOtherReceivableWriteOffs
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember"
      id="xdx2ixbrl1347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLimitedMember"
      id="xdx2ixbrl1351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLimitedMember"
      id="xdx2ixbrl1352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeRelatedParty
      contextRef="From2022-01-012022-12-31_custom_PTTotalPrimaIndonesiaMember"
      id="xdx2ixbrl1401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember"
      id="xdx2ixbrl1431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2021-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember"
      id="xdx2ixbrl1445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember"
      id="xdx2ixbrl1468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember"
      id="xdx2ixbrl1493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember"
      id="xdx2ixbrl1514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember"
      id="xdx2ixbrl1538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_ConvertibleNotesThirdPartiesMember"
      id="xdx2ixbrl1554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="xdx2ixbrl1566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="xdx2ixbrl1578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_custom_ConvertibleNotesRelatedPartiesMember"
      id="xdx2ixbrl1582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_UGDigitalSdnBhdMember"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_ZukihealthSDNMember"
      id="xdx2ixbrl1627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_JenniferGohMember"
      id="xdx2ixbrl1630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_FrescoInvestmentPteLtdMember"
      id="xdx2ixbrl1633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember"
      id="xdx2ixbrl1637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember"
      id="xdx2ixbrl1646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember"
      id="xdx2ixbrl1649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_JamieFanWeiZhiMember"
      id="xdx2ixbrl1655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_WatermarkDevelopmentsLtdMember"
      id="xdx2ixbrl1668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_WilkeServicesLtdMember"
      id="xdx2ixbrl1670"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_MountLockeLimitedMember"
      id="xdx2ixbrl1674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_UGDigitalSdnBhdMember"
      id="xdx2ixbrl1677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1753"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1755"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1757"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <EUDA:ClassOfWarrantOrRightOutstandingForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1767"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1769"
      unitRef="Shares"
      xsi:nil="true"/>
    <EUDA:ClassOfWarrantOrRightOutstandingExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1771"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1773"
      unitRef="Shares"
      xsi:nil="true"/>
    <EUDA:DeferredTaxAssetsLeaseLiabilityNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1898"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1903"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1906"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1909"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember"
      id="xdx2ixbrl1988"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl2046"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-40678</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">EUDA HEALTH HOLDINGS LIMITED</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">1 Pemimpin Drive #12-07</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">One Pemimpin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2022-01-01to2022-12-31">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">576151</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">65</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">6268 6821</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember">Ordinary     Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember">EUDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-12-31_custom_OrdinarySharesMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember">Redeemable     Warrants</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember">EUDAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-12-31_custom_RedeemableWarrantsMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-12-31">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="-5" unitRef="USD">84000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-06-19" decimals="INF" unitRef="Shares">24777509</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">5395</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Marcum Asia CPAs LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">New York, NY</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">143024</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189996</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">641461</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1851503</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1802316</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7467</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1991226</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">267863</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">297621</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">222633</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71495</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <EUDA:ForwardPurchaseReceivables contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">21892527</EUDA:ForwardPurchaseReceivables>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25026478</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4352654</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">31628</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56927</us-gaap:PropertyPlantAndEquipmentNet>
    <EUDA:OtherReceivablesNonCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1830603</EUDA:OtherReceivablesNonCurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">478061</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">289962</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">992686</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">76528</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">79862</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16345</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">24372</us-gaap:FinanceLeaseRightOfUseAsset>
    <EUDA:LoanToThirdParty contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">371962</EUDA:LoanToThirdParty>
    <us-gaap:OtherAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">570934</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3589447</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25629040</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7999028</us-gaap:Assets>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">204240</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">205427</us-gaap:ShortTermBankLoansAndNotesPayable>
    <EUDA:ShortTermLoansThirdParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">148302</EUDA:ShortTermLoansThirdParties>
    <EUDA:PromissoryNote contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">170000</EUDA:PromissoryNote>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2619625</us-gaap:ConvertibleNotesPayableCurrent>
    <EUDA:ConvertibleNotesRelatedParties contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">782600</EUDA:ConvertibleNotesRelatedParties>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1635483</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">359716</us-gaap:AccountsPayableCurrent>
    <EUDA:AccountsPayableRelatedParty contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2459411</EUDA:AccountsPayableRelatedParty>
    <EUDA:OtherPayablesAndAccruedLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1592815</EUDA:OtherPayablesAndAccruedLiabilities>
    <EUDA:OtherPayablesAndAccruedLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">488597</EUDA:OtherPayablesAndAccruedLiabilities>
    <EUDA:OtherPayablesRelatedParties contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1521945</EUDA:OtherPayablesRelatedParties>
    <EUDA:OtherPayablesRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3272311</EUDA:OtherPayablesRelatedParties>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">79959</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">63478</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7186</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11447</us-gaap:FinanceLeaseLiabilityCurrent>
    <EUDA:PrepaidForwardPurchaseLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiabilities>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">186150</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">307343</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29121056</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7316032</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">49294</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16384</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15015</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17268</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15015</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">82946</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29136071</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7398978</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">20191770</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">9333333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">21308969</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">334863</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-24703789</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">180333</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-125689</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6036</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-3520509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">521232</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13478</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">78818</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-3507031</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">600050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25629040</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7999028</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">6065233</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">5723549</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember"
      decimals="0"
      unitRef="USD">135</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember"
      decimals="0"
      unitRef="USD">4640</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">11046</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">257841</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">3764295</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">4558520</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">9840709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">10544550</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">3041327</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">474757</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesRelatedPartiesMember"
      decimals="0"
      unitRef="USD">491499</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesRelatedPartiesMember"
      decimals="0"
      unitRef="USD">2349702</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">59391</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">167202</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">2894296</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">3308536</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6486513</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6300197</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3354196</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4244353</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1902865</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1258442</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7153248</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4084873</us-gaap:GeneralAndAdministrativeExpense>
    <EUDA:EarnoutSharePayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5199629</EUDA:EarnoutSharePayment>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1139016</us-gaap:AssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17209</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">129265</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">15411967</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5472580</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12057771</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1228227</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">120082</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">127126</us-gaap:InterestExpenseOther>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">30055</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12911503</EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">127477</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">386828</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1917062</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-12874053</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2176764</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24931824</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">948537</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17422</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">48141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-65124</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">35567</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24884122</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">864829</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-131941</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">17009</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-25081187</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">917405</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-65340</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">35584</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-25015847</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">881821</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">12029656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">9253333</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9253333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">334863</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-684496</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-10956</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">43234</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-317355</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">864829</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">35567</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">16992</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">17</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">17009</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9253333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">334863</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">180333</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">6036</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">78818</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">600050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-24884122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-65124</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-24884122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-65124</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <EUDA:StockIssuedDuringPeriodSharesCapitalContributions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">120000</EUDA:StockIssuedDuringPeriodSharesCapitalContributions>
    <EUDA:StockIssuedDuringPeriodValueCapitalContributions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">600000</EUDA:StockIssuedDuringPeriodValueCapitalContributions>
    <EUDA:StockIssuedDuringPeriodValueCapitalContributions
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">600000</EUDA:StockIssuedDuringPeriodValueCapitalContributions>
    <EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2763018</EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty>
    <EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2763018</EUDA:StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty>
    <EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5199629</EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament>
    <EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5</EUDA:StockIssuedDuringPeriodValueEarnoutSharesPayament>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4626667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <EUDA:StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6191770</EUDA:StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">11911459</EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11911459</EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-131725</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-216</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-131941</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20191770</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">21308969</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-24703789</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-125689</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">13478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-3507031</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">23347</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">34523</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">115907</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">162825</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">109056</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">58602</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7948</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8153</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2872789</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">43804</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-48228</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-27680</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1917062</us-gaap:InvestmentIncomeNet>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">30055</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <EUDA:EarnoutPayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5199629</EUDA:EarnoutPayment>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">971229</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">167787</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <EUDA:ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12911503</EUDA:ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">174824</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">263950</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInNotesReceivableCurrent
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19071</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1582724</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-55692</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">22749</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">18010</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1268701</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">353560</us-gaap:IncreaseDecreaseInAccountsPayable>
    <EUDA:IncreaseDecreaseInAccountsPayableRelatedParty
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-2396931</EUDA:IncreaseDecreaseInAccountsPayableRelatedParty>
    <EUDA:IncreaseDecreaseInAccountsPayableRelatedParty
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1022714</EUDA:IncreaseDecreaseInAccountsPayableRelatedParty>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1084437</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4360</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-114133</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">107188</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-105719</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-62124</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1526828</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">443920</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">18137</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1957</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">246664</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">354226</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3405</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-268206</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-356183</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">600000</us-gaap:ProceedsFromContributedCapital>
    <EUDA:ProceedsFromReverseRecapitalization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1324961</EUDA:ProceedsFromReverseRecapitalization>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1305580</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <EUDA:RepaymentsFromOtherReceivableRelatedParties
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">30670</EUDA:RepaymentsFromOtherReceivableRelatedParties>
    <EUDA:RepaymentsFromOtherReceivableRelatedParties
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36189</EUDA:RepaymentsFromOtherReceivableRelatedParties>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">72548</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">87812</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">74895</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">66801</us-gaap:RepaymentsOfShortTermDebt>
    <EUDA:RepaymentsToShorttermLoansThirdParties
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">312553</EUDA:RepaymentsToShorttermLoansThirdParties>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1347745</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">93666</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6502</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6686</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2488947</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-168373</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-99424</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">19865</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">594489</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-60771</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189996</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">250767</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">784485</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189996</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">156339</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">30185</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">19588</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">110835</us-gaap:InterestPaidNet>
    <EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">105350</EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability>
    <EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">125834</EUDA:InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability>
    <EUDA:InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">319158</EUDA:InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary>
    <EUDA:ConversionOfDebtIntoPromissoryNote
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">170000</EUDA:ConversionOfDebtIntoPromissoryNote>
    <EUDA:ConversionOfDebtsIntoConvertibleNotes
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">206500</EUDA:ConversionOfDebtsIntoConvertibleNotes>
    <EUDA:ForgivenessOfDebtByRelatedParty
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2763018</EUDA:ForgivenessOfDebtByRelatedParty>
    <EUDA:IssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">11911459</EUDA:IssuanceOfOrdinarySharesUponReverseRecapitalization>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">143024</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189996</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">641461</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">784485</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189996</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zKQMxfp0Fkph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 1&#x2013; &lt;span id="xdx_828_zNqFg2jPDEB"&gt;Nature of business and organization&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;EUDA Health Holdings Limited, which until November
17, 2022 was known as 8i Acquisition 2 Corp. (the &#x201c;Company&#x201d;, &#x201c;EUDA&#x201d; or &#x201c;8i&#x201d;) is a company incorporated
on January 21, 2021, under the laws of the British Virgin Islands for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a &#x201c;Initial
Business Combination&#x201d;). The Company is an &#x201c;emerging growth company&#x201d;, as defined in Section 2(a) of the Securities Act
of 1933, as amended (the &#x201c;Securities Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS
Act&#x201d;). The Company&#x2019;s efforts to identify a prospective target business were not limited to a particular industry or geographic
location (excluding China). The Articles of Association prohibited the Company from undertaking the Initial Business Combination with
any entity that conducts a majority of its business or is headquartered in China (including Hong Kong and Macau).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 17, 2022 (the &#x201c;Closing Date&#x201d;),
EUDA Health Holdings Limited, a British Virgin Islands business company (formerly known as 8i Acquisition 2 Corp.) (the &#x201c;Company&#x201d;),
consummated the business combination contemplated by the Share Purchase Agreement (the &#x201c;SPA&#x201d;) between 8i Acquisition 2 Corp.,
a BVI business company (&#x201c;8i&#x201d;), EUDA Health Limited, a British Virgin Islands business company (&#x201c;EHL&#x201d;), Watermark
Developments Limited, a British Virgin Islands business company (&#x201c;Watermark&#x201d; or the &#x201c;Seller&#x201d;), and Kwong Yeow
Liew, dated April 11, 2022 and amended May 30, 2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination
between 8i and EHL was effected by the purchase by 8i of all of the issued and outstanding shares of EHL from the Seller (the &#x201c;Share
Purchase&#x201d;), resulting in EHL becoming a wholly owned subsidiary of 8i. In addition, in connection with the consummation of the Share
Purchase, 8i has changed its name to &#x201c;EUDA Health Holdings Limited.&#x201d; &lt;span style="background-color: white"&gt;See Note 4 - Reverse
Recapitalization for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company, through its subsidiaries, operates its
business in two segments, 1) engaged in the healthcare specialty group (other than general practice) business offering range of specialty
care services to patients, and engaged in the medical facility general practice clinic that provides holistic care for various illnesses,
and 2) engaged in the property management service that services shopping malls, business office building, or residential apartments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reorganization under EUDA Health Limited (&#x201c;EHL&#x201d;)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 3, 2021, EHL completed a reverse recapitalization
(&#x201c;Reorganization&#x201d;) under common control of its then existing shareholders, who collectively owned all of the equity interests
of Kent Ridge Health Private Limited (&#x201c;KRHPL&#x201d;), a holding company incorporated under the laws of the Singapore prior to the
Reorganization, through the following transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2021, EHL acquired &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zr02GQ456Lkf" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests in Kent Ridge Healthcare Singapore Private Limited (&#x201c;KRHSG&#x201d;) through KRHPL for consideration of SG$&lt;span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z4LfnmqH9Cjc" title="Consideration"&gt;1.0&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2021, EHL acquired &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zfvys17pJ3hd" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests in EUDA Private Limited (&#x201c;EUDA PL&#x201d;) through KRHPL for consideration of SG$&lt;span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_z9Xmt3BimM8a" title="Consideration"&gt;1.0&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 1, 2021, Kent Ridge Health Limited (&#x201c;KRHL&#x201d;), EHL&#x2019;s wholly owned subsidiary, acquired &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zOhCDKBHIvx8" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests in Super Gateway Group Limited (&#x201c;SGGL&#x201d;) through KRHPL for consideration of SG$&lt;span id="xdx_903_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210801__20210801__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zvLfN0Bs7tSf" title="Consideration"&gt;1.0&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 3, 2021, EHL acquired &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTNwSVY0eqh9" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests in Singapore Emergency Medical Assistance Private Limited (&#x201c;SEMA&#x201d;) through KRHPL for no consideration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Before and after the Reorganization, the Company,
together with its subsidiaries (as indicated above), is effectively controlled by the same shareholders, and therefore the Reorganization
is considered as a recapitalization of entities under common control in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;)
805-50-25. The consolidation of the Company and its subsidiaries have been accounted for at historical cost and prepared on the basis
as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated
financial statements in accordance with ASC 805-50-45-5.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reorganization under KRHPL&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#x201c;KRHSG Agreement&#x201d;) with the sole shareholder of KRHSG who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the KRHSG Agreement, KRHPL will acquire &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_z62K6jKh6Zfi" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests
in KRHSG (&#x201c;Reorganization of KRHSG&#x201d;) for a total consideration of SG$&lt;span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePrivateLimitedMember_zoT5ljnFNSrf" title="Consideration"&gt;1.0&lt;/span&gt; (&#x201c;Total Consideration&#x201d;). The transaction
was completed and effective on January 3, 2020. Since KRHSG and KRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of KRHSG are prepared on the basis as
if the restructuring of KRHSG became effective as of the beginning of the first period presented in the accompanying consolidated financial
statements of EHL.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#x201c;EUDA PL Agreement&#x201d;) with the sole shareholder of EUDA PL who is under common control
of the majority shareholders of KRHPL on December 2, 2019. Pursuant to the EUDA PL Agreement, KRHPL will acquire &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zmZCeMevBZ25" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests
in EUDA PL (&#x201c;Reorganization of EUDA PL&#x201d;) for a total consideration of SG$&lt;span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20210724__20210724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zKznHPSUl4Jh" title="Consideration"&gt;1.0&lt;/span&gt; (&#x201c;Total Consideration&#x201d;). The transaction
was completed and effective on January 3, 2020. Since EUDA PL and LRHPL are effectively controlled by the same shareholders of EHL, and
therefore the Reorganization is under common control at carrying value. The financial statements of EUDA PL are prepared on the basis
as if the restructuring of EUDA PL became effective as of the beginning of the first period presented in the accompanying consolidated
financial statements of EHL.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prior to the Reorganization, KRHPL entered into a
Sales and Purchase of Shares Agreement (&#x201c;SEMA Agreement&#x201d;) with the sole shareholder of SEMA who is effectively controlled
by the same shareholders of KRHPL on December 31, 2019. Pursuant to the SEMA PL Agreement, KRHPL will acquire &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210803__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_z3QxUw59Vmq2" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interests
in SEMA (&#x201c;Reorganization of SEMA&#x201d;) for no consideration. SEMA is a holding company and has no operations prior to December
31, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zzrsYIVYtU3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
reflect the activities of EUDA and each of the following entities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zO0MFroHEgr2" style="display: none"&gt;Schedule of consolidated financial statement&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_ztt8seKfNKj7" title="Name of company"&gt;EUDA Health Limited (&#x201c;EHL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company
Incorporated on &lt;span id="xdx_905_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_z0ync8rYeFLe" title="Date of incorporation"&gt;June 8, 2021&lt;/span&gt; &lt;br/&gt;
A holding Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_zgcbYWPo4abj" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EUDA&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zUwAwOFjT3ae" title="Name of company"&gt;Kent Ridge Healthcare Singapore Pte. Ltd. (&#x201c;KRHSG&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_901_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zDe7wPuvozp7" title="Date of incorporation"&gt;November 9, 2017&lt;/span&gt; &lt;br/&gt;
Multi-care specialty group offering range of specialty care services to patients.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zyMEq0S7QwXf" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zd99RF1PNEQe" title="Name of company"&gt;EUDA Private Limited (&#x201c;EUDA PL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90A_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zqbIwHB4wP9" title="Date of incorporation"&gt;April 13, 2018&lt;/span&gt; &lt;br/&gt;
A digital health company that provides a platform to serve the healthcare industry&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zZRNTkRCwAO3" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zClTqn3LSgL9" title="Name of company"&gt;Zukitek Vietnam Private Limited Liability Company (&#x201c;ZKTV PL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Vietnam company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zIbJX9cpEhxi" title="Date of incorporation"&gt;May 2, 2019&lt;/span&gt; &lt;br/&gt;
A Research and Development Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zeq5sYBziRI9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EUDA PL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zX4UnAQNcqWi" title="Name of company"&gt;Singapore Emergency Medical Assistance Private Limited (&#x201c;SEMA&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zA4bi8mmhEid" title="Date of incorporation"&gt;March 18, 2019&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTC1BKBCjE3c" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_fKDEp_zHby8OhBz5Ug" title="Name of company"&gt;The Good Clinic Private Limited (&#x201c;TGC&#x201d;)&lt;/span&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90D_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zP7pQMx9TP38" title="Date of incorporation"&gt;April 8, 2020&lt;/span&gt; &lt;br/&gt;
Medical facility general practice clinic that provides holistic care for various illnesses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zGVp5NzdxIwb" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by SEMA&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zjbB0SBuz2hc" title="Name of company"&gt;EUDA Doctor Private Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;ED PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_z21LqjYwPzZ6" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A platform solution for doctors and physicians to find, connect, and collaborate with trusted peers, specialists, and other professionals &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zVVm4RT5bkb1" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zLagWTm6o119" title="Name of company"&gt;Kent Ridge Hill Private Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;KR Hill PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zmeybEREw8Fl" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A B2B2C pharmaceutical and OTC drugs e-commerce platform to promote its drug products &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zhNEsidOtjBd" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zKjP4pd0gpGd" title="Name of company"&gt;Kent Ridge Health Limited&lt;/span&gt; (&#x201c;KRHL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company &lt;br/&gt;
Incorporated on &lt;span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zei81uu1GRzc" title="Date of incorporation"&gt;June 8, 2021&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_z5AP4aBUTiKj" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_za1FjQC2ABA6" title="Name of company"&gt;Zukitech Private Limited (&#x201c;Zukitech&#x201d;)&lt;/span&gt; &lt;br/&gt;
(&#x201c;ZKT PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zXGpcJ4eg2Nf" title="Date of incorporation"&gt;June 13, 2019&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zyQCIXcWfqib" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_z4WLm1MsH2U1" title="Name of company"&gt;Super Gateway Group Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;SGGL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zeV5hsW0wkk3" title="Date of incorporation"&gt;April 18, 2008&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zao2DCaqPzEl" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zMOecuW4Fqi1" title="Name of company"&gt;Universal Gateway International Pte. Ltd. (&#x201c;UGI&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_900_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zKlwvd3khwCi" title="Date of incorporation"&gt;September 30, 2000&lt;/span&gt; &lt;br/&gt;
Registered capital of RMB &lt;span id="xdx_90F_ecustom--RegisteredCapital_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_za0HkDmqDWNg" title="Registered capital"&gt;5,000,000&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zROkB5aEsc1" title="Ownership percentage"&gt;98.3&lt;/span&gt;% owned by SGGL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zsewKPcKPdcb" title="Name of company"&gt;Melana International Pte. Ltd&lt;/span&gt;.&lt;br/&gt;
(&#x201c;Melana&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90B_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zlTxMQFCZW6h" title="Date of incorporation"&gt;September 9, 2000&lt;/span&gt; &lt;br/&gt;
Property management service that services shopping malls, business office building, or residential apartments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_ziXPMehyxJyc" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zDCItDPyBzsh" title="Name of company"&gt;Tri-Global Security Pte. Ltd.&lt;/span&gt;&lt;br/&gt;
(&#x201c;Tri-Global&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zzvYqTMqIBo" title="Date of incorporation"&gt;August 10, 2000&lt;/span&gt; &lt;br/&gt;
Property security service that services shopping malls, business office building, or residential apartments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zk6fh7HFQ2qi" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zOOPNxBp4PV1" title="Name of company"&gt;UG Digitech Private Limited (&#x201c;UGD&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zNkhSBnW2Tu9" title="Date of incorporation"&gt;August 16, 2001&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_z1qwKbytOAu3" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4aUNoMPGah" title="Name of company"&gt;Nosweat Fitness Company Private Limited (&#x201c;NFC&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_za8fPS5Rl4Nh" title="Date of incorporation"&gt;July 6, 2021&lt;/span&gt; &lt;br/&gt;
A virtual personal training platform for fitness enthusiasts &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4oTRX8nSFNe" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zipiYmzHA6ma" title="Name of company"&gt;True Cover Private Limited (&#x201c;TCPL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zakOLADYtd2i" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A B2B e-claims healthcare insurance platform &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_z5tDhmcTVXL9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_fKDIp_zFEmzLZg0sp3" title="Name of company"&gt;KR Digital Pte. Ltd. (&#x201c;KR Digital&#x201d;)&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zpXuE3yx6uOb" title="Date of incorporation"&gt;December 29, 2021&lt;/span&gt; &lt;br/&gt;
Development of software and applications &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zX8VmugoK8Se" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_fKDIp_zdUNGwzuWvB1" title="Name of company"&gt;Zukihealth Sdn. Bhd. (&#x201c;Zukihealth&#x201d;)&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Malaysian company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zD1qRMBHP42c" title="Date of incorporation"&gt;February 15, 2018&lt;/span&gt; &lt;br/&gt;
Distribution of health care supplement products&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zUKWwA5SnhD9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KR Digital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F02_z6JKmcmddXa8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zDswtzrNKI4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 1, 2022, SEMA, the Company&#x2019;s wholly owned subsidiary, sold &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ &lt;span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration"&gt;1.0&lt;/span&gt; (see Note 5).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zy1YdGXNhCJ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zqN3c8c5vTv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 19, 2022, the Company acquired &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage"&gt;100&lt;/span&gt;% equity interest of KR Digital Pte Ltd, (&#x201c;KR Digital&#x201d;), a Singapore Company, from Mr. Kelvin Chen, the Company&#x2019;s Chief Executive Office (&#x201c;CEO&#x201d;) and shareholder for total consideration of SG$&lt;span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration"&gt;1&lt;/span&gt;. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage"&gt;100&lt;/span&gt;% equity interest of Zukihealth Sdn Bhd, (&#x201c;Zukihealth&#x201d;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#x2019;s CEO and shareholder for total consideration of SG$&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration"&gt;1&lt;/span&gt;. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zTQLonPtSSH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-07-24_custom_EUDAPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-08-01_custom_SuperGatewayGroupLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-08-012021-08-01_custom_SuperGatewayGroupLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-07-242021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-07-24_custom_EUDAPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-07-242021-07-24_custom_EUDAPrivateLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-08-03_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zzrsYIVYtU3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
reflect the activities of EUDA and each of the following entities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zO0MFroHEgr2" style="display: none"&gt;Schedule of consolidated financial statement&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Background&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_ztt8seKfNKj7" title="Name of company"&gt;EUDA Health Limited (&#x201c;EHL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company
Incorporated on &lt;span id="xdx_905_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_z0ync8rYeFLe" title="Date of incorporation"&gt;June 8, 2021&lt;/span&gt; &lt;br/&gt;
A holding Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAHealthLimitedMember_zgcbYWPo4abj" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EUDA&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zUwAwOFjT3ae" title="Name of company"&gt;Kent Ridge Healthcare Singapore Pte. Ltd. (&#x201c;KRHSG&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_901_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zDe7wPuvozp7" title="Date of incorporation"&gt;November 9, 2017&lt;/span&gt; &lt;br/&gt;
Multi-care specialty group offering range of specialty care services to patients.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthcareSingaporePteLtdMember_zyMEq0S7QwXf" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zd99RF1PNEQe" title="Name of company"&gt;EUDA Private Limited (&#x201c;EUDA PL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90A_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zqbIwHB4wP9" title="Date of incorporation"&gt;April 13, 2018&lt;/span&gt; &lt;br/&gt;
A digital health company that provides a platform to serve the healthcare industry&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDAPrivateLimitedMember_zZRNTkRCwAO3" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zClTqn3LSgL9" title="Name of company"&gt;Zukitek Vietnam Private Limited Liability Company (&#x201c;ZKTV PL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Vietnam company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zIbJX9cpEhxi" title="Date of incorporation"&gt;May 2, 2019&lt;/span&gt; &lt;br/&gt;
A Research and Development Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitekVietnamPrivateLimitedLiabilityCompanyMember_zeq5sYBziRI9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EUDA PL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zX4UnAQNcqWi" title="Name of company"&gt;Singapore Emergency Medical Assistance Private Limited (&#x201c;SEMA&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zA4bi8mmhEid" title="Date of incorporation"&gt;March 18, 2019&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zTC1BKBCjE3c" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_fKDEp_zHby8OhBz5Ug" title="Name of company"&gt;The Good Clinic Private Limited (&#x201c;TGC&#x201d;)&lt;/span&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90D_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zP7pQMx9TP38" title="Date of incorporation"&gt;April 8, 2020&lt;/span&gt; &lt;br/&gt;
Medical facility general practice clinic that provides holistic care for various illnesses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zGVp5NzdxIwb" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by SEMA&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zjbB0SBuz2hc" title="Name of company"&gt;EUDA Doctor Private Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;ED PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_z21LqjYwPzZ6" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A platform solution for doctors and physicians to find, connect, and collaborate with trusted peers, specialists, and other professionals &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EUDADoctorPrivateLimitedMember_zVVm4RT5bkb1" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zLagWTm6o119" title="Name of company"&gt;Kent Ridge Hill Private Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;KR Hill PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zmeybEREw8Fl" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A B2B2C pharmaceutical and OTC drugs e-commerce platform to promote its drug products &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHillPrivateLimitedMember_zhNEsidOtjBd" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zKjP4pd0gpGd" title="Name of company"&gt;Kent Ridge Health Limited&lt;/span&gt; (&#x201c;KRHL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company &lt;br/&gt;
Incorporated on &lt;span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_zei81uu1GRzc" title="Date of incorporation"&gt;June 8, 2021&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KentRidgeHealthLimitedMember_z5AP4aBUTiKj" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by EHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_za1FjQC2ABA6" title="Name of company"&gt;Zukitech Private Limited (&#x201c;Zukitech&#x201d;)&lt;/span&gt; &lt;br/&gt;
(&#x201c;ZKT PL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zXGpcJ4eg2Nf" title="Date of incorporation"&gt;June 13, 2019&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukitechPrivateLimitedMember_zyQCIXcWfqib" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_z4WLm1MsH2U1" title="Name of company"&gt;Super Gateway Group Limited&lt;/span&gt;&lt;br/&gt;
(&#x201c;SGGL&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A British Virgin Islands company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zeV5hsW0wkk3" title="Date of incorporation"&gt;April 18, 2008&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SuperGatewayGroupLimitedMember_zao2DCaqPzEl" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zMOecuW4Fqi1" title="Name of company"&gt;Universal Gateway International Pte. Ltd. (&#x201c;UGI&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_900_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zKlwvd3khwCi" title="Date of incorporation"&gt;September 30, 2000&lt;/span&gt; &lt;br/&gt;
Registered capital of RMB &lt;span id="xdx_90F_ecustom--RegisteredCapital_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_za0HkDmqDWNg" title="Registered capital"&gt;5,000,000&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UniversalGatewayInternationalPteLtdMember_zROkB5aEsc1" title="Ownership percentage"&gt;98.3&lt;/span&gt;% owned by SGGL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zsewKPcKPdcb" title="Name of company"&gt;Melana International Pte. Ltd&lt;/span&gt;.&lt;br/&gt;
(&#x201c;Melana&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90B_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_zlTxMQFCZW6h" title="Date of incorporation"&gt;September 9, 2000&lt;/span&gt; &lt;br/&gt;
Property management service that services shopping malls, business office building, or residential apartments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MelanaInternationalPteLtdMember_ziXPMehyxJyc" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zDCItDPyBzsh" title="Name of company"&gt;Tri-Global Security Pte. Ltd.&lt;/span&gt;&lt;br/&gt;
(&#x201c;Tri-Global&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_904_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zzvYqTMqIBo" title="Date of incorporation"&gt;August 10, 2000&lt;/span&gt; &lt;br/&gt;
Property security service that services shopping malls, business office building, or residential apartments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TriGlobalSecurityPteLtdMember_zk6fh7HFQ2qi" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zOOPNxBp4PV1" title="Name of company"&gt;UG Digitech Private Limited (&#x201c;UGD&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_zNkhSBnW2Tu9" title="Date of incorporation"&gt;August 16, 2001&lt;/span&gt; &lt;br/&gt;
A holding company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--UGDigitechPrivateLimitedMember_z1qwKbytOAu3" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by UGI&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4aUNoMPGah" title="Name of company"&gt;Nosweat Fitness Company Private Limited (&#x201c;NFC&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_903_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_za8fPS5Rl4Nh" title="Date of incorporation"&gt;July 6, 2021&lt;/span&gt; &lt;br/&gt;
A virtual personal training platform for fitness enthusiasts &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NosweatFitnessCompanyPrivateLimitedMember_z4oTRX8nSFNe" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zipiYmzHA6ma" title="Name of company"&gt;True Cover Private Limited (&#x201c;TCPL&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_906_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_zakOLADYtd2i" title="Date of incorporation"&gt;December 1, 2021&lt;/span&gt; &lt;br/&gt;
A B2B e-claims healthcare insurance platform &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TrueCoverPrivateLimitedMember_z5tDhmcTVXL9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_fKDIp_zFEmzLZg0sp3" title="Name of company"&gt;KR Digital Pte. Ltd. (&#x201c;KR Digital&#x201d;)&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;br/&gt;
&#x25cf;&lt;br/&gt;
&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 35%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Singapore company &lt;br/&gt;
Incorporated on &lt;span id="xdx_909_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zpXuE3yx6uOb" title="Date of incorporation"&gt;December 29, 2021&lt;/span&gt; &lt;br/&gt;
Development of software and applications &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zX8VmugoK8Se" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KRHL&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--NameOfCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_fKDIp_zdUNGwzuWvB1" title="Name of company"&gt;Zukihealth Sdn. Bhd. (&#x201c;Zukihealth&#x201d;)&lt;/span&gt; (2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;br/&gt;
&#x25cf; &lt;br/&gt;
&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A Malaysian company &lt;br/&gt;
Incorporated on &lt;span id="xdx_90E_ecustom--DateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zD1qRMBHP42c" title="Date of incorporation"&gt;February 15, 2018&lt;/span&gt; &lt;br/&gt;
Distribution of health care supplement products&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ZukihealthSdnBhdMember_zUKWwA5SnhD9" title="Ownership percentage"&gt;100&lt;/span&gt;% owned by KR Digital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operation has not been commenced&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F02_z6JKmcmddXa8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zDswtzrNKI4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 1, 2022, SEMA, the Company&#x2019;s wholly owned subsidiary, sold &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1" title="Ownership percentage"&gt;100&lt;/span&gt;% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ &lt;span id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4" title="Consideration"&gt;1.0&lt;/span&gt; (see Note 5).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zy1YdGXNhCJ1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zqN3c8c5vTv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 19, 2022, the Company acquired &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd" title="Ownership percentage"&gt;100&lt;/span&gt;% equity interest of KR Digital Pte Ltd, (&#x201c;KR Digital&#x201d;), a Singapore Company, from Mr. Kelvin Chen, the Company&#x2019;s Chief Executive Office (&#x201c;CEO&#x201d;) and shareholder for total consideration of SG$&lt;span id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2" title="Consideration"&gt;1&lt;/span&gt;. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7" title="Ownership percentage"&gt;100&lt;/span&gt;% equity interest of Zukihealth Sdn Bhd, (&#x201c;Zukihealth&#x201d;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#x2019;s CEO and shareholder for total consideration of SG$&lt;span id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi" title="Consideration"&gt;1&lt;/span&gt;. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember">EUDA Health Limited (&#x201c;EHL&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_EUDAHealthLimitedMember">2021-06-08</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_EUDAHealthLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">Kent Ridge Healthcare Singapore Pte. Ltd. (&#x201c;KRHSG&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember">2017-11-09</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_KentRidgeHealthcareSingaporePteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember">EUDA Private Limited (&#x201c;EUDA PL&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_EUDAPrivateLimitedMember">2018-04-13</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_EUDAPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">Zukitek Vietnam Private Limited Liability Company (&#x201c;ZKTV PL&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember">2019-05-02</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_ZukitekVietnamPrivateLimitedLiabilityCompanyMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">Singapore Emergency Medical Assistance Private Limited (&#x201c;SEMA&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember">2019-03-18</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany
      contextRef="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember"
      id="Fact000679">The Good Clinic Private Limited (&#x201c;TGC&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_TheGoodClinicPrivateLimitedMember">2020-04-08</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_TheGoodClinicPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember">EUDA Doctor Private Limited</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_EUDADoctorPrivateLimitedMember">2021-12-01</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_EUDADoctorPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember">Kent Ridge Hill Private Limited</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_KentRidgeHillPrivateLimitedMember">2021-12-01</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_KentRidgeHillPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember">Kent Ridge Health Limited</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_KentRidgeHealthLimitedMember">2021-06-08</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_KentRidgeHealthLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember">Zukitech Private Limited (&#x201c;Zukitech&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_ZukitechPrivateLimitedMember">2019-06-13</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_ZukitechPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember">Super Gateway Group Limited</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SuperGatewayGroupLimitedMember">2008-04-18</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SuperGatewayGroupLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember">Universal Gateway International Pte. Ltd. (&#x201c;UGI&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_UniversalGatewayInternationalPteLtdMember">2000-09-30</EUDA:DateOfIncorporation>
    <EUDA:RegisteredCapital
      contextRef="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember"
      decimals="0"
      unitRef="USD">5000000</EUDA:RegisteredCapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_UniversalGatewayInternationalPteLtdMember"
      decimals="INF"
      unitRef="Pure">0.983</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember">Melana International Pte. Ltd</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLtdMember">2000-09-09</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_MelanaInternationalPteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember">Tri-Global Security Pte. Ltd.</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLtdMember">2000-08-10</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_TriGlobalSecurityPteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember">UG Digitech Private Limited (&#x201c;UGD&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_UGDigitechPrivateLimitedMember">2001-08-16</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_UGDigitechPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">Nosweat Fitness Company Private Limited (&#x201c;NFC&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember">2021-07-06</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_NosweatFitnessCompanyPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany contextRef="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember">True Cover Private Limited (&#x201c;TCPL&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_TrueCoverPrivateLimitedMember">2021-12-01</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_TrueCoverPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany
      contextRef="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember"
      id="Fact000753">KR Digital Pte. Ltd. (&#x201c;KR Digital&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_KRDigitalPteLtdMember">2021-12-29</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_KRDigitalPteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <EUDA:NameOfCompany
      contextRef="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember"
      id="Fact000759">Zukihealth Sdn. Bhd. (&#x201c;Zukihealth&#x201d;)</EUDA:NameOfCompany>
    <EUDA:DateOfIncorporation contextRef="From2022-01-012022-12-31_custom_ZukihealthSdnBhdMember">2018-02-15</EUDA:DateOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_ZukihealthSdnBhdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-03-012022-03-01_custom_SingaporeEmergencyMedicalAssistancePrivateLimitedMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-19_custom_KRDigitalPteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-04-192022-04-19_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="SGD">1</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-15_custom_KRDigitalPteLtdMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-04-152022-04-15_custom_KRDigitalPteLtdMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="SGD">1</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zDcc1z2Lds37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2013; &lt;span id="xdx_82F_zKuph1zEvmn3"&gt;Going concern&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In assessing the Company&#x2019;s going concern,
the Company monitors and analyzes its cash on-hand and its operating and capital expenditure commitments. The Company&#x2019;s
liquidity needs are to meet its working capital requirements, operating expenses and capital expenditure obligations. Debt financing
in the form of short-term borrowings from bank, private lender, third parties and related parties and cash generated from operations
have been utilized to finance the working capital requirements of the Company. As of December 31, 2022, the Company&#x2019;s negative
working capital deficit was approximately $&lt;span id="xdx_908_ecustom--WorkingCapital_iI_pn5n6_c20221231_zBHHUd4E5RPh" title="Working capital"&gt;4.1&lt;/span&gt;
million, and the Company had cash and restricted cash of approximately $&lt;span&gt;&lt;span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_pn5n6_c20221231_zrvGci6Apb7h" title="Cash and restricted cash"&gt;0.8&lt;/span&gt;&lt;/span&gt;
million. The Company has experienced recurring losses from operations and negative cash flows from operating activities since 2020.
In addition, the Company had, and may potentially continue to have, an ongoing need to raise additional cash from outside sources to
fund its expansion plan and related operations. Successful transition to attaining profitable operations is dependent upon achieving
a level of revenues adequate to support the Company&#x2019;s cost structure. In connection with the Company&#x2019;s assessment of
going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Update
(&#x201c;ASU&#x201d;) 2014-15, &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going
Concern,&#x201d; management has determined that these conditions raise substantial doubt about the Company&#x2019;s ability to
continue as a going concern within one year after the date that these consolidated financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the Company is unable to generate sufficient funds
to finance the working capital requirements of the Company within the normal operating cycle of a twelve-month period from the date of
these financial statements are issued, the Company may have to consider supplementing its available sources of funds through the following
sources:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;other available sources of financing from Singapore banks and other financial institutions or private lender;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;financial support and credit guarantee commitments from the Company&#x2019;s related parties; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;equity financing. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company can make no assurances that required financings
will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one or all of these events
does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be a material
adverse effect on the Company and would materially adversely affect its ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements have been prepared
assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the
outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <EUDA:WorkingCapital contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">4100000</EUDA:WorkingCapital>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zPF0MauuHu" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3 &#x2013; &lt;span id="xdx_829_zm7DM01RW2zd"&gt;Summary of significant accounting
policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSsB6kvupef4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zwCniqxuvEQk"&gt;Basis of presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for information pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z3DChkLqzxSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zF6ALmZSU2v3"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include the
financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been
eliminated upon consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A subsidiary is an entity in which the Company, directly
or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint
or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_ziE8lyISxu0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zqhn5KtRmAdi"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#x2019;s consolidated
financial statements include lease classification and liabilities, right-of-use assets, determinations of the useful lives and valuation
of long-lived assets, estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of deferred tax assets, other provisions and contingencies, estimated fair value of earn-out shares, prepaid forward purchase liability
and private warrants. Actual results could differ from these estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zHTqyqU43xT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zRgjT4PnAlrb"&gt;Foreign currency translation and transaction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements
of operations and comprehensive income (loss).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is United States
Dollars (&#x201c;US$&#x201d;) and the accompanying financial statements have been expressed in US$. The Company&#x2019;s subsidiaries in
Singapore, Vietnam, and Malaysia conduct its businesses and maintain its books and records in the local currency, Singapore Dollars (&#x201c;SGD&#x201d;),
Vietnamese Dong (&#x201c;VND&#x201d;), and Malaysian Ringgit (&#x201c;MYR&#x201d;), as its functional currency, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In general, for consolidation purposes, assets and
liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#x201c;&lt;i&gt;Translation
of Financial Statement&#x201d;&lt;/i&gt;, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average
rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are
recorded as a separate component of accumulated other comprehensive income (loss) within the statements of shareholders&#x2019; equity
(deficit). Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of
cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Translation of foreign currencies into US$1 have been
made at the following exchange rates for the respective periods:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zOSriTLcuXej"&gt;Schedule
of foreign currency exchange rates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Period-end SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.35&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,635.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,855.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end MYR: US$1 exchange rate&lt;span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.38&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-average VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,409.44&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,935.24&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average MYR: US$1 exchange rate&lt;span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify"&gt;The Company did not have any Malaysia subsidiary prior to April 19, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AE_zKpYTNGnrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--NonControllingInterestPolicyTextBlock_zYE5SHVmHsF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zGnl4f1z7Jvi"&gt;Non-controlling interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;For the Company&#x2019;s non-wholly
owned subsidiaries, a non-controlling interest is recognized to reflect portion of equity that is not attributable, directly or indirectly,
to the Company. The cumulative results of operations attributable to non-controlling interests are also recorded as non-controlling interests
in the Company&#x2019;s consolidated balance sheets and consolidated statements of operations and comprehensive income (loss). Cash flows
related to transactions with non-controlling interests are presented under financing activities in the consolidated statements of cash
flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq5C34a2q0Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zVLy6WJnWLAc"&gt;Segment reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s chief operating decision-maker
is identified as the chief executive officer who reviews financial information presented on a consolidated basis, accompanied by disaggregated
information about revenues by different revenues streams for purposes of allocating resources and evaluating financial performance. Based
on qualitative and quantitative criteria established by Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, &#x201c;Segment Reporting&#x201d;,
the Company considers itself to be operating within two operating and reportable segments as set forth in Note 21.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zotmo0AGUb46" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5C95HgCqS8b"&gt;Cash and restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash represent cash on hand and demand deposits
placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities less
than three months. Restricted cash represents cash held in bank account from 8i which was restricted due to the incomplete
procedures of changing signers as of December 31, 2022. As of the date of the issuance of these financial statements, such
restriction has been lifted and the remaining cash held in bank account has transfer to the Company&#x2019;s operating bank account.
Therefore, such restricted cash should be classified as current asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJz3RXlAubL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zPOqmiGawfKf"&gt;Accounts receivable, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with its customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Management also periodically evaluates individual customer&#x2019;s financial condition, credit
history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
The Company&#x2019;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.
As of December 31, 2022 and 2021, the Company provided allowance for doubtful accounts of $&lt;span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zlpZMgdcDzik" title="Allowance for doubtful accounts"&gt;197,438&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zGHVaJ0GDus1" title="Allowance for doubtful accounts"&gt;80,799&lt;/span&gt;, respectively. For the
years ended December 31, 2022 and 2021, the Company did not write off any allowance for doubtful account against the account receivable
balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_z4vpRxO1nkdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zsymQJuC8us1"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other receivables primarily include receivables
from investment from the Company&#x2019;s Affordable Home project in Indonesia and employee advance, and refundable deposits from
third party service providers. Management regularly reviews the aging of receivables and changes in payment trends and records
allowances when management believes collection of amounts due are at risk. Accounts considered uncollectable are written off against
allowances after exhaustive efforts at collection are made. $&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zEjhEcO3zEY8" title="Other receivables allowance for doubtful account"&gt;2,209,825&lt;/span&gt;
allowance for doubtful account related to other receivable was recorded and written off for the year ended December 31, 2022. &lt;span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_dxL_c20211231_zsJbaTAAdVvd" title="Other receivables allowance for doubtful account::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;Nil&lt;/span&gt;&lt;/span&gt;
allowance for doubtful account related to other receivable was recorded for the year ended December 31, 2021&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--PrepaidExpensesAndOtherAssetsPolicyTextBlock_zMunaeL9wrni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zykHIuOSgNul"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets
primarily include prepaid expenses paid to services providers, and other deposits. Management regularly reviews the aging of such
balances and changes in payment and realization trends and records allowances when management believes collection or realization of
amounts due are at risk. Accounts considered uncollectable are written off against allowances after exhaustive efforts at collection
are made. As of December 31, 2022 and 2021, &lt;span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20221231_zUw43t5ro5Aj" title="Allowance"&gt;&lt;span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20211231_zrGIS7vVUmQd" title="Allowance"&gt;no&lt;/span&gt;&lt;/span&gt;
allowance for doubtful account related to prepaid expenses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zXARoPszRa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zaRi3G7tDwil"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value.
The estimated useful lives are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z0h1r7koBEI2"&gt;Schedule
of property and equipment useful lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment"&gt;3 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment"&gt;Shorter of the lease term or 5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zLzJMkKXwnGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The cost and related accumulated depreciation of assets
sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations
and comprehensive income (loss). Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals
and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of
depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows
that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the
carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. &lt;/span&gt;For the years ended
December 31, 2022 and 2021, there was &lt;span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20220101__20221231_z6WGodJ7oX5h" title="Impairment of property and equipment"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20210101__20211231_zFIoeZHOdOic" title="Impairment of property and equipment"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of property and equipment recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4QpciiqLaml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zYQ9S0iEeFT8"&gt;Intangible assets, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Purchased intangible assets
are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue
to be amortized over the Company&#x2019;s best estimate of its useful life as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_8B5_ztDHNIRRQgA"&gt;Schedule
of intangible assets net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Categories&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships"&gt;6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zehZDb2Ho9u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company amortized the
intangible assets using the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up in accordance
with ASC Topic 350 &#x201c;&lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Separately identifiable intangible
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting
from the use of the asset and its eventual disposition. Measurement of any impairment loss for identifiable intangible assets is based
on the amount by which the carrying amount of the assets exceeds the fair value of the assets. $&lt;span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zjvw1S4emLo" title="Impairment of intangible assets"&gt;167,787&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20210101__20211231_zFcl6YU05hN" title="Impairment of intangible assets::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;nil&lt;/span&gt;&lt;/span&gt; impairment of intangibles
assets was recorded for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zjKgluIGYFj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zCo9PuvNtMii"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of operations and comprehensive income (loss). Impairment losses on goodwill
are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews the carrying value of intangible
assets not subject to amortization, including goodwill, to determine whether impairment may exist annually or more frequently if events
and circumstances indicate that it is more likely than not that an impairment has occurred. Management has determined that the Company
has two reporting units within the entity at which goodwill is monitored for internal management purposes. The Company adopted ASU 2017-04
in 2022, which primary goal is to simplify the goodwill impairment test and provide cost savings for all entities. This is accomplished
by removing the requirement to determine the fair value of individual assets and liabilities in order to calculate a reporting unit&#x2019;s
&#x201c;implied&#x201d; goodwill under current GAAP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The amendments in ASU 2017-04 eliminate Step 2 of
the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value
of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting
unit&#x2019;s carrying amount exceeds its fair value. If fair value exceeds the carrying amount, no impairment should be recorded. Any
loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Impairment losses on goodwill cannot
be reversed once recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When measuring a goodwill impairment loss, an entity
should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit. The ASU contains
an illustration of the simultaneous equations method to demonstrate this, which reflects a deferred tax benefit from reducing the carrying
amount of tax-deductible goodwill relative to the tax basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An entity may still perform the optional qualitative
assessment for a reporting unit to determine if it is more likely than not that goodwill is impaired. However, this ASU eliminates the
requirement to perform a qualitative assessment for any reporting unit with zero or negative carrying amount. Therefore, the same one-step
impairment assessment will apply to all reporting units. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing qualitative assessment on the two
reporting units and determine that it is more likely than not that the fair value of each reporting unit is less than its carrying amount.
Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $&lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zxdgRoAYe1c3" title="Impairment loss on goodwill"&gt;971,229&lt;/span&gt; was recognized for the year ended
December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zyAO3IcI2ZW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zzN6hD19dQzg"&gt;Impairment for long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 360-10, Long-lived assets,
including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a
significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets
are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use
of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment
is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows
approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, $&lt;span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20220101__20221231_zbzqUjYEcIoc" title="Impairment of long-lived assets"&gt;0.2&lt;/span&gt; million and &lt;span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_dxL_c20210101__20211231_ziwZdHFyfgN4" title="Impairment of long-lived assets::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;nil&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets was recognized, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zoHy4sXBp72b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zCKIbY0JNRSj"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s
own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside
of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For issued or
modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of
equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that
its warrants qualify for equity accounting treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upon
completion of the business combination, all of 8i&#x2019;s public and private warrants remain outstanding were replaced by the Company&#x2019;s
public and private warrants. The Company treated such warrants replacement as a warrant modification and no  incremental fair value
was recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_zAbr4mxqpXwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z0xs9mPGPiI1"&gt;Forward Purchase Receivables and Prepaid Forward
Purchase Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company recorded Forward Purchase Receivables on its consolidated balance sheets of $&lt;span id="xdx_90C_ecustom--ForwardPurchaseReceivables_iI_c20221231_zufvipqGptB7" title="Forward purchase receivables"&gt;21,892,527&lt;/span&gt;
as of December 31, 2022 to account for the Prepayment Amount of the Forward Purchase Agreement, as discussed in Note 11. The
Prepayment Amount will be held in a deposit account until the Valuation Date (the second anniversary of the closing of the Business
Combination, subject to certain acceleration provisions). At the Maturity Date, the Sellers are entitled to received $2.50 per
Recycled Shares (&#x201c;Maturity Consideration&#x201d;) in cash or in shares. As of December 31, 2022, no shares were sold after
Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
connection with the Forward Purchase Agreement, the Company recognized a liability in accordance with ASC 480-10-25-8 as the Company
has the obligation to pay cash to settle the maturity consideration, referred to herein as the &#x201c;prepaid forward purchase
liability&#x201d; on its consolidated balance sheets of $&lt;span id="xdx_909_ecustom--PrepaidForwardPurchaseLiability_iI_c20221231_zgkSaEqRPUdh" title="Purchase liability"&gt;20,321,053&lt;/span&gt;
as of December 31, 2022. Refer to Note 11 for further detail.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zHa2YQMTAD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zQWedSe4xpl2"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the revenue accounting requirements
of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201c;Accounting Standards
Codification (&#x201c;ASC&#x201d;) 606&#x201d;). The core principle underlying the revenue recognition of this ASU allows the Company to
recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and
determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers
to a customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To achieve that core principle, the Company applies
five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for a contract with a customer
when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial
substance and collectability is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue recognition policies for each type of revenue
stream are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Medical Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied at a point in time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company operates on a unified technology
health care platform which provide a full continuum of healthcare services integrated with healthcare data analytics to drive
improved outcomes for patients. The Company operates the medical services on a business-to-business (B2B) platform, and serves the
corporate customers involved in various industries. The Company is primarily generating revenue on a per healthcare visit basis for
specialty medical visits for specialist treatment such as cardiology, dermatology and etc, at the time which the single performance obligation was satisfied. Such fees are paid by the corporate
customers on behalf of their employees. &lt;span style="background-color: white"&gt;The Company generally bills their corporate customers
for the healthcare visit services on a weekly basis, or in arrears depending on the service, with payment terms generally between 30
to 90 days. There are not significant differences between the timing of revenue recognition and billing. Consequently, the Company
has determined that the Company&#x2019;s contracts do not include a financing component. &lt;/span&gt;Revenue is recognized in an amount
that reflects the consideration that is expected in exchange for the service at a point in time at the time of the visit. In
addition, the Company&#x2019;s contracts do not generally contain refund provisions for fees earned related to services
performed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for medical service revenue on
a gross basis as the Company is acting as a principal in these transactions and is responsible for fulfilling the promise to provide the
specified services, which the Company has control of the services and has the ability to direct the service providers to be performed
to obtain substantially all the benefits. In making this determination, the Company also assesses whether it is primarily obligated in
these transactions, is subject to inventory risk, has latitude in establishing prices, or has met several but not all of these indicators
in accordance with ASC 606-10-55-36 through 40.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes the medical services revenue
when the control of the specified services is transferred to its customer, which at a point in time at the time after completion of the
visit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also operates on a general practice clinic
and generating such revenue on a per healthcare visit basis. Revenues are recognized when the visits are completed at a point in time
at the time of the visit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Product Sales&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied at a point in time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company purchases, sells, and installs facial
recognition and temperature measurement monitor system to corporate customer, where the product and the installation are interrelated
and are not capable of being distinct since the customer cannot benefit from the product or installation either on its own. The Company
recognized the products revenue when control of the product is passed to the customer, which is the point in time that the customers are
able to direct the use of and obtain substantially all of the economic benefit of the goods after the installation by the Company&#x2019;s
technician. The transfer of control typically occurs at a point in time based on consideration of when the customer has an obligation
to pay for the goods, and physical possession of, legal title to, and the risks and rewards of ownership of the goods has been transferred,
and the customer has accepted the goods. Revenue is recognized net of estimates of variable consideration, including product returns,
customer discounts and allowance. Historically, the Company has not experienced any significant returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Property Management Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied over a period of
time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides property management services
in shopping malls, business office building, or residential apartments to all tenants and property owners. Property management services
include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional
services and also include security property management services provided to all tenants and property owners. Each of the two services
is within separate agreements. The Company identified common area property management services as a single performance obligation as the
kinds of service in the contract are not capable of being distinct and identified the security management services as another single performance
obligation as there is only one service that is to provide security services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes the common area property management
revenue and security property management revenue on a straight-line basis over the terms of the common area property management agreement
and security property management agreement, generally over one year period because its customer simultaneously receives and consumes the
benefits provided by the Company throughout the performance obligations period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has elected to apply the practical expedient
to expense costs as incurred for incremental costs to obtain a contract when the amortization period would have been one year or less.
As of December 31, 2022 and 2021, the Company did not have any contract assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognized advance payments from its customer
prior to revenue recognition as contract liability until the revenue recognition performance obligation are met. As of December 31, 2022
and 2021, the Company did not have any contract liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Disaggregated information of revenues by products/services
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zwogmTEuY6ql"&gt;Schedule
of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;6,001,439&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;5,010,837&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; general practice&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;63,794&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,712&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practice (related parties)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,065,368&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,728,189&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,046&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;257,841&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management service &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,919,335&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,508,663&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management service &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;844,960&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,049,857&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management service&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,764,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,558,520&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,840,709&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;10,544,550&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zwNQtZ3F5UWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Medical Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of medical supplies
purchased and medical service was provided by Cadence Health Pte. Ltd., a related party, prior to March 2022. Medical supplies purchased
and medical service provided by the third party service providers were insignificant prior to March 2022. Beginning in April 2022, cost
of revenues mainly consists of medical supplies purchased and medical service are provided by third party service providers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Product Sales&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of medical product
or equipment purchased for resale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Property Management Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of labor expenses
incurred attributable to property management service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Disaggregated information of cost of revenues by products/services
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zIQd8Hn75Yi9"&gt;Schedule
of cost of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;2,995,778&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;46,849&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; specialty care (related party)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,349,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practices&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,549&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;427,908&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,532,826&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,824,459&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;59,391&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;167,202&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management services &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,210,703&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,461,981&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management services &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;683,593&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;846,555&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management services&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,894,296&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,308,536&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total cost of revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,486,513&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,300,197&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_z0IzxNUwrZ11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zjMJr2QoqkRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zr5XE1q82T8i"&gt;Advertising costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advertising is mainly through online and offline promotion
activities. Advertising costs amounted to $&lt;span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zszyCFvLJSLj" title="Advertising cost"&gt;21,795&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AdvertisingExpense_c20210101__20211231_zsS5Uxd9nK9j" title="Advertising cost"&gt;270,361&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7X9jQrXD66f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zpOYfJHLeqJh"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses include salaries
and other compensation-related expenses to the Company&#x2019;s research and product development personnel, and related expenses for the
Company&#x2019;s research and product development team. Research and development expenses amounted to $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zspS1u46hib6" title="Research and Development cost"&gt;17,209&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zxLEZpIcrsY9" title="Research and Development cost"&gt;129,265&lt;/span&gt; for the years
ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--DefinedContributionPlanPolicyTextBlock_zz7xjkCOkr5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zCUiQA3XaXMi"&gt;Defined
contribution plan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The full-time employees of the Company are entitled
to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages
of the employees&#x2019; respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and
make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_z0ATFRFJrw8f" title="Employee expenses"&gt;505,591&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231_zXCCuwdZ0eO9" title="Employee expenses"&gt;574,535&lt;/span&gt;
for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The related contribution plans include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Singapore subsidiaries&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Central Provident Fund (&#x201c;CPF&#x201d;) &#x2013;
&lt;span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--CentralProvidentFundMember_zUu8bYl0NPrk" title="Employee plan description"&gt;17.00% based on employee&#x2019;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase&lt;/span&gt;;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Skill Development Levy (&#x201c;SDL&#x201d;) &#x2013;
&lt;span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zJvENAmvNVCg" title="Employee plan description"&gt;up to 0.25% based on employee&#x2019;s monthly salary capped $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zlsgb4ysvVoj" title="Monthly salary"&gt;8.3&lt;/span&gt; (SGD &lt;span id="xdx_90C_eus-gaap--SalariesAndWages_pn4n6_uSGD_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zO9j3tWmsHil" title="Monthly salary"&gt;11.25&lt;/span&gt;)&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Vietnam subsidiary&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Social Insurance Fund (&#x201c;SIF&#x201d;) &#x2013;
&lt;span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zWfExI0ZcJOl" title="Employee plan description"&gt;20% based on employee&#x2019;s monthly salary&lt;/span&gt;;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Trade Union Fee &#x2013; &lt;span id="xdx_907_ecustom--TradeUnionFeePercentage_iI_pid_dp_c20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zL0wDN9ABgB" title="Trade union fee"&gt;2.00%&lt;/span&gt; of SIF&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--GoodsAndServicesTaxesPolicyTextBlock_ztdAswiUWax5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zk8Bn1NLCiC6"&gt;Goods and services taxes (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue represents the invoiced value of service,
net GST. The GST are based on gross sales price. GST rate is generally 7% in Singapore. Entities that are GST general taxpayers are allowed
to offset qualified input GST paid to suppliers against their output GST liabilities. Net GST balance between input GST and output GST
is recorded in tax payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zkrVaXBFCHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_z96DWJzY5po1"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes in accordance
with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are
non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Deferred tax
is calculated using the balance sheet liability method in respect of temporary differences arising from differences between the carrying
amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis. In principle, deferred tax
liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable
that taxable income will be utilized with prior net operating loss carried forwards using tax rates that are expected to apply to the
period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when
it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion or all of the deferred tax assets will not be utilized. Current income taxes
are provided for in accordance with the laws of the relevant tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An uncertain tax position is recognized as a benefit
only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is &lt;span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zk2Ix9U7GPQk" title="Income tax likelihood description"&gt;greater than 50% likely of being realized
on examination&lt;/span&gt;. For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. No penalties and
interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021. &lt;span style="background-color: white"&gt;As
of December 31, 2022, the tax returns of the Company&#x2019;s Singapore entities for the calendar year from 2019 through 2022 remain open
for statutory examination by Singapore tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognize interest and penalties related to unrecognized tax
benefits, if any, on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties
are included on the related tax liability line in the consolidated balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company conducts much of its business activities
in Singapore and is subject to tax in its jurisdiction. As a result of its business activities, the Company&#x2019;s subsidiaries file
separate tax returns that are subject to examination by the foreign tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zLbU2af5srSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zJZj3giURid"&gt;Comprehensive income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive income (loss) consists of two components,
net income and other comprehensive income. Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under
GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net income. Other comprehensive income (loss) consists
of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zMCDFPoIvl4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zzedsnCQU4vf"&gt;(Loss) earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes (loss) earnings per share (&#x201c;EPS&#x201d;)
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is
measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect
on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e.,
those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates basic and diluted (loss)/earnings
per share as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zRuz5Eat8IOc" style="display: none"&gt;Schedule
of basic and diluted earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Years Ended&lt;br/&gt;
December 31&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net (loss) income&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;(24,949,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;900,396&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Less: Net (income) loss attributable to noncontrolling interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(65,124&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,567&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Net (loss)/income attributable to common shareholders, basic&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,884,122&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;864,829&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average number of shares outstanding, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,029,656&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,253,333&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(Loss)/Earnings per share, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2.07&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.09&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zuN25CFHeBDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December
31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants are convertible into &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zOB5W99vo8ma" title="Antidilutive shares"&gt;1,411,725&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zk0BBegFiS8l" title="Antidilutive shares"&gt;4,458,625&lt;/span&gt;
of the Company&#x2019;s ordinary shares, respectively, were not included in the computation of dilutive loss per share because the inclusion
of such convertible notes and warrants would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzVOHzfqt77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zbaSlXmfzUo"&gt;Fair value measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price that would be received
for an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Valuation
techniques maximize the use of observable inputs and minimize the use of unobservable inputs. When determining the fair value measurements
for assets and liabilities, we consider the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability. The following summarizes the three levels of inputs required to
measure fair value, of which the first two are considered observable and the third is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - Unadjusted quoted prices in active markets
for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - Unobservable inputs that are supported by
little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value for certain assets and liabilities
such as cash and restricted cash, accounts receivable, net, other receivables, prepaid expenses and other current assets, loan to third-party,
short-term loans, promissory note, convertible notes, accounts payable, other payables and accrued liabilities, and tax payables have
been determined to approximate carrying amounts due to the short maturities of these instruments. The Company believes that its long-term
loan to third party approximates the fair value based on current yields for debt instruments with similar terms.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zkN130Ffe2af" style="display: none"&gt;Schedule
of fair value hierarchy of financial liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Carrying Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Fair Value Measurement at&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zNGpWR5NLY12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zBcQXMqTTOY2" style="display: none"&gt;Schedule of reconciliation of financial
liability measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Beginning balance&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;7,409,550&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Change in fair value of prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,911,503&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,321,053&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zoLBIGo0IqXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z6axbXx4rODj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zbRXPdj5KhW6"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for leases in accordance with ASC 842. &lt;/span&gt;The Company entered into two agreements as a lessee to lease office equipment
for general and administrative operations. If any of the following criteria are met, the Company classifies the lease as a finance lease:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease term is for 75% or more of the remaining economic life of the underlying asset, unless the commencement date falls within the last 25% of the economic life of the underlying asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The present value of the sum of the lease payments equals or exceeds 90% of the fair value of the underlying asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Leases that do not meet any
of the above criteria are accounted for as operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company combines lease
and non-lease components in its contracts under Topic 842, when permissible.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Finance
and operating lease right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. Since the implicit rate for the Company&#x2019;s leases is not readily determinable,
the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present
value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized
basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its finance or operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company
has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term
of twelve months or less. Its leases generally do not provide a residual guarantee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
finance or operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease
term for operating lease. Meanwhile, the Company recognizes the finance leases ROU assets and interest on an amortized cost basis. The
amortization of finance ROU assets is recognized on an accretion basis as amortization expense, while the lease liability is increased
to reflect interest on the liability and decreased to reflect the lease payments made during the period. Interest expense on the lease
liability is determined each period during the lease term as the amount that results in a constant periodic interest rate of the &lt;/span&gt;office
equipment &lt;span style="background-color: white"&gt;on the remaining balance of the liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset
may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from
the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows. For the years ended December 31, 2022 and 2021, &lt;/span&gt;the Company did not recognize impairment loss on its finance
and operating lease ROU assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RelatedPartyPolicyTextBlock_zW3ikgaDVMkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zkWRq3C9mr3e"&gt;Related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject
to common control or common significant influence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zMhejxndWpM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zNRPmrsYJrIc"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and impact
of all accounting standards updates (&#x201c;ASUs&#x201d;). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging
growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the
adoption of these accounting standards until they would apply to private companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2021, the FASB issued ASU 2021-08, which
is an update to ASU Updated No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive accounting
model on revenue recognition for contracts with customers. The amendments in this update require that an entity (acquirer) recognize and
measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective
for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted,
including adoption in an interim period. The Company has adopted this standard on January 1, 2023, and the adoption did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2019, the FASB issued ASU 2019-05, which is
an update to ASU Update No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured
at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial
Instruments&#x2014;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting
for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized
cost basis, in accordance with Subtopic 326-30, Financial Instruments&#x2014; Credit Losses&#x2014;Available-for-Sale Debt Securities. The
amendments in this Update address those stakeholders&#x2019; concerns by providing an option to irrevocably elect the fair value option
for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase
comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets.
Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13
while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which
to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies
applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after
December 15, 2022. In March 2022, the FASB issued ASU No. 2022-02, which is to (1) eliminate the accounting guidance for TDRs by creditors
in Subtopic 310-40, Receivables&#x2014;Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan
refinancings and restructurings by creditors when a borrower is experiencing financial difficulty, and (2) disclose current-period gross
write offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, Financial
Instruments&#x2014;Credit Losses&#x2014;Measured at Amortized Cost. ASU 2019-05 is effective for the Company for annual and interim reporting
periods beginning January 1, 2023 as the Company is qualified as an emerging growth company. The Company has adopted this standard on
January 1, 2023, and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfmIHjiMvRu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zaJ77kGpf1n8"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. The amendments in this Update simplify the accounting for income
taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments
in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years
beginning after December 15, 2022. Early adoption of the amendments is permitted, including adoption in any interim period for (1) public
business entities for periods for which financial statements have not yet been issued and (2) all other entities for periods for which
financial statements have not yet been made available for issuance. An entity that elects to early adopt the amendments in an interim
period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity
that elects early adoption must adopt all the amendments in the same period. The Company has adopted this standard on January 1, 2022,
and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2020, the Financial Accounting Standards
Board issued Accounting Standards Update (ASU) 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities
and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s accounting for
convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity such that fewer
conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment.
The Company early adopted this ASU on January 1, 2022, and the adoption did not have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-08, &#x201c;Codification
Improvements to Subtopic 310-20, Receivables&#x2014;Nonrefundable Fees and Other Costs&#x201d;. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021.
Early adoption was permitted, including adoption in an interim period. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10, &#x201c;Codification
Improvements to Subtopic 205-10, presentation of financial statements&#x201d;. The amendments in this Update improve the codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed.
The amendments also clarify guidance so that an entity can apply the guidance more consistently. ASU 2020-10 is effective for the Company
for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or
interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively.
An entity should apply the amendments at the beginning of the period that includes the adoption date. The adoption of this standard on
January 1, 2022 did not have a material impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s
consolidated balance sheets, statements of operations and comprehensive income (loss) and statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSsB6kvupef4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zwCniqxuvEQk"&gt;Basis of presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for information pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z3DChkLqzxSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zF6ALmZSU2v3"&gt;Principles of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements include the
financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been
eliminated upon consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A subsidiary is an entity in which the Company, directly
or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint
or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_ziE8lyISxu0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zqhn5KtRmAdi"&gt;Use of estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#x2019;s consolidated
financial statements include lease classification and liabilities, right-of-use assets, determinations of the useful lives and valuation
of long-lived assets, estimates of allowances for doubtful accounts, estimates of impairment of long-lived assets and goodwill, valuation
of deferred tax assets, other provisions and contingencies, estimated fair value of earn-out shares, prepaid forward purchase liability
and private warrants. Actual results could differ from these estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zHTqyqU43xT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zRgjT4PnAlrb"&gt;Foreign currency translation and transaction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Transactions denominated in currencies other than
the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction.
Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency
using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the consolidated statements
of operations and comprehensive income (loss).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The reporting currency of the Company is United States
Dollars (&#x201c;US$&#x201d;) and the accompanying financial statements have been expressed in US$. The Company&#x2019;s subsidiaries in
Singapore, Vietnam, and Malaysia conduct its businesses and maintain its books and records in the local currency, Singapore Dollars (&#x201c;SGD&#x201d;),
Vietnamese Dong (&#x201c;VND&#x201d;), and Malaysian Ringgit (&#x201c;MYR&#x201d;), as its functional currency, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In general, for consolidation purposes, assets and
liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#x201c;&lt;i&gt;Translation
of Financial Statement&#x201d;&lt;/i&gt;, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average
rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are
recorded as a separate component of accumulated other comprehensive income (loss) within the statements of shareholders&#x2019; equity
(deficit). Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of
cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Translation of foreign currencies into US$1 have been
made at the following exchange rates for the respective periods:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zOSriTLcuXej"&gt;Schedule
of foreign currency exchange rates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Period-end SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.35&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,635.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,855.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end MYR: US$1 exchange rate&lt;span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.38&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-average VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,409.44&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,935.24&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average MYR: US$1 exchange rate&lt;span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify"&gt;The Company did not have any Malaysia subsidiary prior to April 19, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AE_zKpYTNGnrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_zGJ0xYm8XlI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zOSriTLcuXej"&gt;Schedule
of foreign currency exchange rates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zTs2Qt20CxL" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231_zHCSVy4vswqh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;As of&lt;br/&gt;
December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--SGD_zEXZjv4mWhmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Period-end SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1.35&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--VND_zHqppv4Epgq8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,635.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,855.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_ziYa7GsQ9aQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end MYR: US$1 exchange rate&lt;span id="xdx_F4E_zA7wzb6B9Xx9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateRemeasurement1_iI_hsrt--CurrencyAxis__currency--MYR_zwllc0Wh0Yle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-end : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--SGD_zHtHG9GEokNf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average SGD: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.38&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--VND_zZrfh3NecZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Period-average VND: US$1 exchange rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,409.44&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,935.24&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zrIu7pFp0hm9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average MYR: US$1 exchange rate&lt;span id="xdx_F4E_zPGE0uBZbKQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hsrt--CurrencyAxis__currency--MYR_zB4fdNRM5MM7" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average : US$1 exchange rate&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0A_z5thFOluvsdb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F11_zLKYZ08v0noa" style="text-align: justify"&gt;The Company did not have any Malaysia subsidiary prior to April 19, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2022-12-31_currency_SGD"
      decimals="INF"
      unitRef="Pure">1.34</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2021-12-31_currency_SGD"
      decimals="INF"
      unitRef="Pure">1.35</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2022-12-31_currency_VND"
      decimals="INF"
      unitRef="Pure">23635.00</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2021-12-31_currency_VND"
      decimals="INF"
      unitRef="Pure">22855.00</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2022-12-31_currency_MYR"
      decimals="INF"
      id="Fact000803"
      unitRef="Pure">4.40</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateRemeasurement1
      contextRef="AsOf2022-12-31_currency_MYR"
      decimals="INF"
      unitRef="Pure">4.40</us-gaap:ForeignCurrencyExchangeRateRemeasurement1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_currency_SGD"
      decimals="INF"
      unitRef="Pure">1.38</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_currency_SGD"
      decimals="INF"
      unitRef="Pure">1.34</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_currency_VND"
      decimals="INF"
      unitRef="Pure">23409.44</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_currency_VND"
      decimals="INF"
      unitRef="Pure">22935.24</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_currency_MYR"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">4.39</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_currency_MYR"
      decimals="INF"
      unitRef="Pure">4.39</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <EUDA:NonControllingInterestPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--NonControllingInterestPolicyTextBlock_zYE5SHVmHsF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zGnl4f1z7Jvi"&gt;Non-controlling interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;For the Company&#x2019;s non-wholly
owned subsidiaries, a non-controlling interest is recognized to reflect portion of equity that is not attributable, directly or indirectly,
to the Company. The cumulative results of operations attributable to non-controlling interests are also recorded as non-controlling interests
in the Company&#x2019;s consolidated balance sheets and consolidated statements of operations and comprehensive income (loss). Cash flows
related to transactions with non-controlling interests are presented under financing activities in the consolidated statements of cash
flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</EUDA:NonControllingInterestPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zq5C34a2q0Qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zVLy6WJnWLAc"&gt;Segment reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s chief operating decision-maker
is identified as the chief executive officer who reviews financial information presented on a consolidated basis, accompanied by disaggregated
information about revenues by different revenues streams for purposes of allocating resources and evaluating financial performance. Based
on qualitative and quantitative criteria established by Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, &#x201c;Segment Reporting&#x201d;,
the Company considers itself to be operating within two operating and reportable segments as set forth in Note 21.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zotmo0AGUb46" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5C95HgCqS8b"&gt;Cash and restricted cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash represent cash on hand and demand deposits
placed with banks or other financial institutions which are unrestricted as to withdrawal or use and have original maturities less
than three months. Restricted cash represents cash held in bank account from 8i which was restricted due to the incomplete
procedures of changing signers as of December 31, 2022. As of the date of the issuance of these financial statements, such
restriction has been lifted and the remaining cash held in bank account has transfer to the Company&#x2019;s operating bank account.
Therefore, such restricted cash should be classified as current asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJz3RXlAubL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zPOqmiGawfKf"&gt;Accounts receivable, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are recorded at the invoiced amount
less an allowance for any uncollectible accounts and do not bear interest, which are due after 30 to 90 days, depending on the credit
term with its customers. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical
collection trends and aging of receivables. Management also periodically evaluates individual customer&#x2019;s financial condition, credit
history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are
charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
The Company&#x2019;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.
As of December 31, 2022 and 2021, the Company provided allowance for doubtful accounts of $&lt;span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zlpZMgdcDzik" title="Allowance for doubtful accounts"&gt;197,438&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20211231_zGHVaJ0GDus1" title="Allowance for doubtful accounts"&gt;80,799&lt;/span&gt;, respectively. For the
years ended December 31, 2022 and 2021, the Company did not write off any allowance for doubtful account against the account receivable
balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">197438</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">80799</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_z4vpRxO1nkdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zsymQJuC8us1"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other receivables primarily include receivables
from investment from the Company&#x2019;s Affordable Home project in Indonesia and employee advance, and refundable deposits from
third party service providers. Management regularly reviews the aging of receivables and changes in payment trends and records
allowances when management believes collection of amounts due are at risk. Accounts considered uncollectable are written off against
allowances after exhaustive efforts at collection are made. $&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zEjhEcO3zEY8" title="Other receivables allowance for doubtful account"&gt;2,209,825&lt;/span&gt;
allowance for doubtful account related to other receivable was recorded and written off for the year ended December 31, 2022. &lt;span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iI_dxL_c20211231_zsJbaTAAdVvd" title="Other receivables allowance for doubtful account::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;Nil&lt;/span&gt;&lt;/span&gt;
allowance for doubtful account related to other receivable was recorded for the year ended December 31, 2021&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2209825</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <EUDA:PrepaidExpensesAndOtherAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_ecustom--PrepaidExpensesAndOtherAssetsPolicyTextBlock_zMunaeL9wrni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zykHIuOSgNul"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets
primarily include prepaid expenses paid to services providers, and other deposits. Management regularly reviews the aging of such
balances and changes in payment and realization trends and records allowances when management believes collection or realization of
amounts due are at risk. Accounts considered uncollectable are written off against allowances after exhaustive efforts at collection
are made. As of December 31, 2022 and 2021, &lt;span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20221231_zUw43t5ro5Aj" title="Allowance"&gt;&lt;span id="xdx_906_ecustom--AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets_iI_do_c20211231_zrGIS7vVUmQd" title="Allowance"&gt;no&lt;/span&gt;&lt;/span&gt;
allowance for doubtful account related to prepaid expenses was recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:PrepaidExpensesAndOtherAssetsPolicyTextBlock>
    <EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets>
    <EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</EUDA:AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zXARoPszRa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zaRi3G7tDwil"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value.
The estimated useful lives are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z0h1r7koBEI2"&gt;Schedule
of property and equipment useful lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment"&gt;3 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment"&gt;Shorter of the lease term or 5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zLzJMkKXwnGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The cost and related accumulated depreciation of assets
sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of operations
and comprehensive income (loss). Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals
and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of
depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. An asset is considered impaired if its carrying amount exceeds the future net undiscounted cash flows
that the asset is expected to generate. If such asset is considered to be impaired, the impairment recognized is the amount by which the
carrying amount of the asset, if any, exceeds its fair value determined using a discounted cash flow model. &lt;/span&gt;For the years ended
December 31, 2022 and 2021, there was &lt;span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20220101__20221231_z6WGodJ7oX5h" title="Impairment of property and equipment"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20210101__20211231_zFIoeZHOdOic" title="Impairment of property and equipment"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of property and equipment recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <EUDA:PropertyPlantAndEquipmentsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_ecustom--PropertyPlantAndEquipmentsTextBlock_zu8tjzihijVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z0h1r7koBEI2"&gt;Schedule
of property and equipment useful lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected useful lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zEYWkwnYkNB1" title="Electronic equipment"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zbYSEFjQf8I1" title="Electronic equipment"&gt;3 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z8ipAH8Lxik6" title="Leasehold equipment"&gt;Shorter of the lease term or 5 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:PropertyPlantAndEquipmentsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_custom_MedicalEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">Shorter of the lease term or 5 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z4QpciiqLaml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zYQ9S0iEeFT8"&gt;Intangible assets, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Purchased intangible assets
are recognized and measured at fair value upon acquisition. Separately identifiable intangible assets that have determinable lives continue
to be amortized over the Company&#x2019;s best estimate of its useful life as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_8B5_ztDHNIRRQgA"&gt;Schedule
of intangible assets net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Categories&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships"&gt;6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zehZDb2Ho9u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company amortized the
intangible assets using the pattern in which the economic benefits of the intangible assets are consumed or otherwise used up in accordance
with ASC Topic 350 &#x201c;&lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Separately identifiable intangible
assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting
from the use of the asset and its eventual disposition. Measurement of any impairment loss for identifiable intangible assets is based
on the amount by which the carrying amount of the assets exceeds the fair value of the assets. $&lt;span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231_zjvw1S4emLo" title="Impairment of intangible assets"&gt;167,787&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20210101__20211231_zFcl6YU05hN" title="Impairment of intangible assets::XDX::0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;nil&lt;/span&gt;&lt;/span&gt; impairment of intangibles
assets was recorded for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <EUDA:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_z9l5raTB82ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_8B5_ztDHNIRRQgA"&gt;Schedule
of intangible assets net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Categories&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zE0tldkE4Clf" title="Customer relationships"&gt;6&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">167787</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zjKgluIGYFj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zCo9PuvNtMii"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Goodwill represents the excess of the consideration
paid of an acquisition over the fair value of the net identifiable assets of the acquired subsidiaries at the date of acquisition. Goodwill
is not amortized and is tested for impairment at least annually, more often when circumstances indicate impairment may have occurred.
Goodwill is carried at cost less accumulated impairment losses. If impairment exists, goodwill is immediately written off to its fair
value and the loss is recognized in the consolidated statements of operations and comprehensive income (loss). Impairment losses on goodwill
are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews the carrying value of intangible
assets not subject to amortization, including goodwill, to determine whether impairment may exist annually or more frequently if events
and circumstances indicate that it is more likely than not that an impairment has occurred. Management has determined that the Company
has two reporting units within the entity at which goodwill is monitored for internal management purposes. The Company adopted ASU 2017-04
in 2022, which primary goal is to simplify the goodwill impairment test and provide cost savings for all entities. This is accomplished
by removing the requirement to determine the fair value of individual assets and liabilities in order to calculate a reporting unit&#x2019;s
&#x201c;implied&#x201d; goodwill under current GAAP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The amendments in ASU 2017-04 eliminate Step 2 of
the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value
of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting
unit&#x2019;s carrying amount exceeds its fair value. If fair value exceeds the carrying amount, no impairment should be recorded. Any
loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Impairment losses on goodwill cannot
be reversed once recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When measuring a goodwill impairment loss, an entity
should consider the income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit. The ASU contains
an illustration of the simultaneous equations method to demonstrate this, which reflects a deferred tax benefit from reducing the carrying
amount of tax-deductible goodwill relative to the tax basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An entity may still perform the optional qualitative
assessment for a reporting unit to determine if it is more likely than not that goodwill is impaired. However, this ASU eliminates the
requirement to perform a qualitative assessment for any reporting unit with zero or negative carrying amount. Therefore, the same one-step
impairment assessment will apply to all reporting units. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022, management evaluated the recoverability of goodwill by performing qualitative assessment on the two
reporting units and determine that it is more likely than not that the fair value of each reporting unit is less than its carrying amount.
Therefore, management performed quantitative assessment, fully impairment loss on goodwill of $&lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zxdgRoAYe1c3" title="Impairment loss on goodwill"&gt;971,229&lt;/span&gt; was recognized for the year ended
December 31, 2022, as the carrying amount of each reporting unit is in excess of its fair value for the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">971229</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zyAO3IcI2ZW" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zzN6hD19dQzg"&gt;Impairment for long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 360-10, Long-lived assets,
including property and equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a
significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an
asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets
are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use
of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment
is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows
approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and 2021, $&lt;span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20220101__20221231_zbzqUjYEcIoc" title="Impairment of long-lived assets"&gt;0.2&lt;/span&gt; million and &lt;span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_dxL_c20210101__20211231_ziwZdHFyfgN4" title="Impairment of long-lived assets::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;nil&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets was recognized, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-01to2022-12-31"
      decimals="-5"
      unitRef="USD">200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <EUDA:WarrantsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zoHy4sXBp72b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zCKIbY0JNRSj"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific
terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 480, Distinguishing Liabilities
from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the
warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether
the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s
own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside
of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For issued or
modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of
equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that
its warrants qualify for equity accounting treatment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upon
completion of the business combination, all of 8i&#x2019;s public and private warrants remain outstanding were replaced by the Company&#x2019;s
public and private warrants. The Company treated such warrants replacement as a warrant modification and no  incremental fair value
was recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:WarrantsPolicyTextBlock>
    <EUDA:ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_ecustom--ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock_zAbr4mxqpXwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z0xs9mPGPiI1"&gt;Forward Purchase Receivables and Prepaid Forward
Purchase Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company recorded Forward Purchase Receivables on its consolidated balance sheets of $&lt;span id="xdx_90C_ecustom--ForwardPurchaseReceivables_iI_c20221231_zufvipqGptB7" title="Forward purchase receivables"&gt;21,892,527&lt;/span&gt;
as of December 31, 2022 to account for the Prepayment Amount of the Forward Purchase Agreement, as discussed in Note 11. The
Prepayment Amount will be held in a deposit account until the Valuation Date (the second anniversary of the closing of the Business
Combination, subject to certain acceleration provisions). At the Maturity Date, the Sellers are entitled to received $2.50 per
Recycled Shares (&#x201c;Maturity Consideration&#x201d;) in cash or in shares. As of December 31, 2022, no shares were sold after
Closing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
connection with the Forward Purchase Agreement, the Company recognized a liability in accordance with ASC 480-10-25-8 as the Company
has the obligation to pay cash to settle the maturity consideration, referred to herein as the &#x201c;prepaid forward purchase
liability&#x201d; on its consolidated balance sheets of $&lt;span id="xdx_909_ecustom--PrepaidForwardPurchaseLiability_iI_c20221231_zgkSaEqRPUdh" title="Purchase liability"&gt;20,321,053&lt;/span&gt;
as of December 31, 2022. Refer to Note 11 for further detail.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock>
    <EUDA:ForwardPurchaseReceivables contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">21892527</EUDA:ForwardPurchaseReceivables>
    <EUDA:PrepaidForwardPurchaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiability>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zHa2YQMTAD5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zQWedSe4xpl2"&gt;Revenue recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows the revenue accounting requirements
of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201c;Accounting Standards
Codification (&#x201c;ASC&#x201d;) 606&#x201d;). The core principle underlying the revenue recognition of this ASU allows the Company to
recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and
determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers
to a customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To achieve that core principle, the Company applies
five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for a contract with a customer
when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial
substance and collectability is probable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue recognition policies for each type of revenue
stream are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Medical Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied at a point in time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company operates on a unified technology
health care platform which provide a full continuum of healthcare services integrated with healthcare data analytics to drive
improved outcomes for patients. The Company operates the medical services on a business-to-business (B2B) platform, and serves the
corporate customers involved in various industries. The Company is primarily generating revenue on a per healthcare visit basis for
specialty medical visits for specialist treatment such as cardiology, dermatology and etc, at the time which the single performance obligation was satisfied. Such fees are paid by the corporate
customers on behalf of their employees. &lt;span style="background-color: white"&gt;The Company generally bills their corporate customers
for the healthcare visit services on a weekly basis, or in arrears depending on the service, with payment terms generally between 30
to 90 days. There are not significant differences between the timing of revenue recognition and billing. Consequently, the Company
has determined that the Company&#x2019;s contracts do not include a financing component. &lt;/span&gt;Revenue is recognized in an amount
that reflects the consideration that is expected in exchange for the service at a point in time at the time of the visit. In
addition, the Company&#x2019;s contracts do not generally contain refund provisions for fees earned related to services
performed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for medical service revenue on
a gross basis as the Company is acting as a principal in these transactions and is responsible for fulfilling the promise to provide the
specified services, which the Company has control of the services and has the ability to direct the service providers to be performed
to obtain substantially all the benefits. In making this determination, the Company also assesses whether it is primarily obligated in
these transactions, is subject to inventory risk, has latitude in establishing prices, or has met several but not all of these indicators
in accordance with ASC 606-10-55-36 through 40.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes the medical services revenue
when the control of the specified services is transferred to its customer, which at a point in time at the time after completion of the
visit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also operates on a general practice clinic
and generating such revenue on a per healthcare visit basis. Revenues are recognized when the visits are completed at a point in time
at the time of the visit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Product Sales&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied at a point in time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company purchases, sells, and installs facial
recognition and temperature measurement monitor system to corporate customer, where the product and the installation are interrelated
and are not capable of being distinct since the customer cannot benefit from the product or installation either on its own. The Company
recognized the products revenue when control of the product is passed to the customer, which is the point in time that the customers are
able to direct the use of and obtain substantially all of the economic benefit of the goods after the installation by the Company&#x2019;s
technician. The transfer of control typically occurs at a point in time based on consideration of when the customer has an obligation
to pay for the goods, and physical possession of, legal title to, and the risks and rewards of ownership of the goods has been transferred,
and the customer has accepted the goods. Revenue is recognized net of estimates of variable consideration, including product returns,
customer discounts and allowance. Historically, the Company has not experienced any significant returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Property Management Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Performance obligation satisfied over a period of
time&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides property management services
in shopping malls, business office building, or residential apartments to all tenants and property owners. Property management services
include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional
services and also include security property management services provided to all tenants and property owners. Each of the two services
is within separate agreements. The Company identified common area property management services as a single performance obligation as the
kinds of service in the contract are not capable of being distinct and identified the security management services as another single performance
obligation as there is only one service that is to provide security services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes the common area property management
revenue and security property management revenue on a straight-line basis over the terms of the common area property management agreement
and security property management agreement, generally over one year period because its customer simultaneously receives and consumes the
benefits provided by the Company throughout the performance obligations period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has elected to apply the practical expedient
to expense costs as incurred for incremental costs to obtain a contract when the amortization period would have been one year or less.
As of December 31, 2022 and 2021, the Company did not have any contract assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognized advance payments from its customer
prior to revenue recognition as contract liability until the revenue recognition performance obligation are met. As of December 31, 2022
and 2021, the Company did not have any contract liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Disaggregated information of revenues by products/services
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zwogmTEuY6ql"&gt;Schedule
of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;6,001,439&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;5,010,837&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; general practice&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;63,794&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,712&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practice (related parties)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,065,368&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,728,189&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,046&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;257,841&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management service &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,919,335&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,508,663&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management service &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;844,960&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,049,857&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management service&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,764,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,558,520&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,840,709&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;10,544,550&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zwNQtZ3F5UWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(1) Medical Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of medical supplies
purchased and medical service was provided by Cadence Health Pte. Ltd., a related party, prior to March 2022. Medical supplies purchased
and medical service provided by the third party service providers were insignificant prior to March 2022. Beginning in April 2022, cost
of revenues mainly consists of medical supplies purchased and medical service are provided by third party service providers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(2) Product Sales&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of medical product
or equipment purchased for resale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(3) Property Management Services&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of revenues mainly consists of labor expenses
incurred attributable to property management service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Disaggregated information of cost of revenues by products/services
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zIQd8Hn75Yi9"&gt;Schedule
of cost of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;2,995,778&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;46,849&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; specialty care (related party)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,349,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practices&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,549&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;427,908&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,532,826&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,824,459&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;59,391&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;167,202&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management services &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,210,703&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,461,981&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management services &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;683,593&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;846,555&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management services&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,894,296&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,308,536&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total cost of revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,486,513&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,300,197&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_z0IzxNUwrZ11" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfPrincipalTransactionsRevenueTextBlock_zeTT75XLwWof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zwogmTEuY6ql"&gt;Schedule
of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_znG9eudFPEg5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_zBOiw3CyO7Fc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zBUy6ftJCjk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;6,001,439&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;5,010,837&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeMember_zTz4cnwPgxOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; general practice&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;63,794&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,712&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticeRelatedPartiesMember_zKJhuFqHKlYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practice (related parties)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zS0sVa1A3xph" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,065,368&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,728,189&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_z37gPYFzz1wd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;11,046&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;257,841&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceCommonAreaManagementMember_z88sp3SOYReh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management service &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,919,335&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,508,663&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceSecurityManagementMember_zJcbMe03QIF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management service &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;844,960&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,049,857&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--PropertyManagementServiceMember_zgt7LCFPTAYa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management service&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,764,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,558,520&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zWKPmp09K8r2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,840,709&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;10,544,550&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember"
      decimals="0"
      unitRef="USD">6001439</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember"
      decimals="0"
      unitRef="USD">5010837</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeMember"
      decimals="0"
      unitRef="USD">63794</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeMember"
      decimals="0"
      unitRef="USD">712712</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember"
      decimals="0"
      unitRef="USD">135</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticeRelatedPartiesMember"
      decimals="0"
      unitRef="USD">4640</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember"
      decimals="0"
      unitRef="USD">6065368</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember"
      decimals="0"
      unitRef="USD">5728189</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">11046</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">257841</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceCommonAreaManagementMember"
      decimals="0"
      unitRef="USD">2919335</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceCommonAreaManagementMember"
      decimals="0"
      unitRef="USD">3508663</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceSecurityManagementMember"
      decimals="0"
      unitRef="USD">844960</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceSecurityManagementMember"
      decimals="0"
      unitRef="USD">1049857</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServiceMember"
      decimals="0"
      unitRef="USD">3764295</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServiceMember"
      decimals="0"
      unitRef="USD">4558520</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">9840709</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">10544550</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <EUDA:ScheduleOfCostOfRevenueTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfCostOfRevenueTableTextBlock_zv1P6oJxYPWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zIQd8Hn75Yi9"&gt;Schedule
of cost of revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_zuHloabLauJ4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20211231_znqb0af8ZbZ6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareMember_zz4ExAydOqbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Medical services &#x2013; specialty care&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;2,995,778&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;46,849&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSpecialtyCareRelatedPartyMember_zTPCFphkG2n" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical services &#x2013; specialty care (related party)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,349,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesGeneralPracticesMember_zMJG1FWGDpVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; general practices&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,549&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;427,908&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--MedicalServicesSubTotalMember_zjZ5W64aY7s9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Medical services &#x2013; subtotal&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,532,826&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,824,459&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductSalesMember_zLURDCotqN78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Product sales&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;59,391&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;167,202&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesCommonAreaManagementMember_zsUOkCPHKuP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property management services &#x2013; common area management&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,210,703&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,461,981&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--PropertyManagementServicesSecurityManagementMember_zyd0eH4dN5v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property management services &#x2013; security management&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;683,593&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;846,555&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CostOfRevenue_i01_hsrt--ProductOrServiceAxis__custom--ProductMangementServicesMember_zE5gPbWypE61" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Property management services&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,894,296&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,308,536&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CostOfRevenue_i01_zPIhZqYyqF03" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total cost of revenues&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,486,513&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,300,197&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfCostOfRevenueTableTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember"
      decimals="0"
      unitRef="USD">2995778</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareMember"
      decimals="0"
      unitRef="USD">46849</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember"
      decimals="0"
      unitRef="USD">491499</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesSpecialtyCareRelatedPartyMember"
      decimals="0"
      unitRef="USD">2349702</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesGeneralPracticesMember"
      decimals="0"
      unitRef="USD">45549</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesGeneralPracticesMember"
      decimals="0"
      unitRef="USD">427908</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesSubTotalMember"
      decimals="0"
      unitRef="USD">3532826</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesSubTotalMember"
      decimals="0"
      unitRef="USD">2824459</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">59391</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_ProductSalesMember"
      decimals="0"
      unitRef="USD">167202</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesCommonAreaManagementMember"
      decimals="0"
      unitRef="USD">2210703</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesCommonAreaManagementMember"
      decimals="0"
      unitRef="USD">2461981</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesSecurityManagementMember"
      decimals="0"
      unitRef="USD">683593</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesSecurityManagementMember"
      decimals="0"
      unitRef="USD">846555</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_custom_ProductMangementServicesMember"
      decimals="0"
      unitRef="USD">2894296</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31_custom_ProductMangementServicesMember"
      decimals="0"
      unitRef="USD">3308536</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6486513</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">6300197</us-gaap:CostOfRevenue>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--AdvertisingCostsPolicyTextBlock_zjMJr2QoqkRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zr5XE1q82T8i"&gt;Advertising costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advertising is mainly through online and offline promotion
activities. Advertising costs amounted to $&lt;span id="xdx_905_eus-gaap--AdvertisingExpense_c20220101__20221231_zszyCFvLJSLj" title="Advertising cost"&gt;21,795&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AdvertisingExpense_c20210101__20211231_zsS5Uxd9nK9j" title="Advertising cost"&gt;270,361&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">21795</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">270361</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7X9jQrXD66f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zpOYfJHLeqJh"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses include salaries
and other compensation-related expenses to the Company&#x2019;s research and product development personnel, and related expenses for the
Company&#x2019;s research and product development team. Research and development expenses amounted to $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zspS1u46hib6" title="Research and Development cost"&gt;17,209&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zxLEZpIcrsY9" title="Research and Development cost"&gt;129,265&lt;/span&gt; for the years
ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17209</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">129265</us-gaap:ResearchAndDevelopmentExpense>
    <EUDA:DefinedContributionPlanPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_ecustom--DefinedContributionPlanPolicyTextBlock_zz7xjkCOkr5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zCUiQA3XaXMi"&gt;Defined
contribution plan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The full-time employees of the Company are entitled
to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages
of the employees&#x2019; respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and
make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231_z0ATFRFJrw8f" title="Employee expenses"&gt;505,591&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231_zXCCuwdZ0eO9" title="Employee expenses"&gt;574,535&lt;/span&gt;
for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The related contribution plans include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Singapore subsidiaries&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Central Provident Fund (&#x201c;CPF&#x201d;) &#x2013;
&lt;span id="xdx_904_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--CentralProvidentFundMember_zUu8bYl0NPrk" title="Employee plan description"&gt;17.00% based on employee&#x2019;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase&lt;/span&gt;;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Skill Development Levy (&#x201c;SDL&#x201d;) &#x2013;
&lt;span id="xdx_90A_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zJvENAmvNVCg" title="Employee plan description"&gt;up to 0.25% based on employee&#x2019;s monthly salary capped $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_pn5n6_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zlsgb4ysvVoj" title="Monthly salary"&gt;8.3&lt;/span&gt; (SGD &lt;span id="xdx_90C_eus-gaap--SalariesAndWages_pn4n6_uSGD_c20220101__20221231__us-gaap--PlanNameAxis__custom--SkillDevelopmentLevyMember_zO9j3tWmsHil" title="Monthly salary"&gt;11.25&lt;/span&gt;)&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Vietnam subsidiary&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Social Insurance Fund (&#x201c;SIF&#x201d;) &#x2013;
&lt;span id="xdx_90E_eus-gaap--EmployeeStockOwnershipPlanESOPPlanDescription_c20220101__20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zWfExI0ZcJOl" title="Employee plan description"&gt;20% based on employee&#x2019;s monthly salary&lt;/span&gt;;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Trade Union Fee &#x2013; &lt;span id="xdx_907_ecustom--TradeUnionFeePercentage_iI_pid_dp_c20221231__us-gaap--PlanNameAxis__custom--SocialInsuranceFundMember_zL0wDN9ABgB" title="Trade union fee"&gt;2.00%&lt;/span&gt; of SIF&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:DefinedContributionPlanPolicyTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">505591</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">574535</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription contextRef="From2022-01-012022-12-31_custom_CentralProvidentFundMember">17.00% based on employee&#x2019;s monthly salary for employees aged 55 and below, reduces progressively to 7.5% as age increase</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember">up to 0.25% based on employee&#x2019;s monthly salary capped $8.3 (SGD 11.25)</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember"
      decimals="-5"
      unitRef="USD">8300000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2022-01-012022-12-31_custom_SkillDevelopmentLevyMember"
      decimals="-4"
      unitRef="SGD">11250000</us-gaap:SalariesAndWages>
    <us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription contextRef="From2022-01-012022-12-31_custom_SocialInsuranceFundMember">20% based on employee&#x2019;s monthly salary</us-gaap:EmployeeStockOwnershipPlanESOPPlanDescription>
    <EUDA:TradeUnionFeePercentage
      contextRef="AsOf2022-12-31_custom_SocialInsuranceFundMember"
      decimals="INF"
      unitRef="Pure">0.0200</EUDA:TradeUnionFeePercentage>
    <EUDA:GoodsAndServicesTaxesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_ecustom--GoodsAndServicesTaxesPolicyTextBlock_ztdAswiUWax5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zk8Bn1NLCiC6"&gt;Goods and services taxes (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue represents the invoiced value of service,
net GST. The GST are based on gross sales price. GST rate is generally 7% in Singapore. Entities that are GST general taxpayers are allowed
to offset qualified input GST paid to suppliers against their output GST liabilities. Net GST balance between input GST and output GST
is recorded in tax payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:GoodsAndServicesTaxesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zkrVaXBFCHc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_z96DWJzY5po1"&gt;Income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes in accordance
with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are
non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Deferred tax
is calculated using the balance sheet liability method in respect of temporary differences arising from differences between the carrying
amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis. In principle, deferred tax
liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable
that taxable income will be utilized with prior net operating loss carried forwards using tax rates that are expected to apply to the
period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when
it is related to items credited or charged directly to equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion or all of the deferred tax assets will not be utilized. Current income taxes
are provided for in accordance with the laws of the relevant tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An uncertain tax position is recognized as a benefit
only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is &lt;span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zk2Ix9U7GPQk" title="Income tax likelihood description"&gt;greater than 50% likely of being realized
on examination&lt;/span&gt;. For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. No penalties and
interest incurred related to underpayment of income tax for the years ended December 31, 2022 and 2021. &lt;span style="background-color: white"&gt;As
of December 31, 2022, the tax returns of the Company&#x2019;s Singapore entities for the calendar year from 2019 through 2022 remain open
for statutory examination by Singapore tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognize interest and penalties related to unrecognized tax
benefits, if any, on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties
are included on the related tax liability line in the consolidated balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company conducts much of its business activities
in Singapore and is subject to tax in its jurisdiction. As a result of its business activities, the Company&#x2019;s subsidiaries file
separate tax returns that are subject to examination by the foreign tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="From2022-01-01to2022-12-31">greater than 50% likely of being realized
on examination</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zLbU2af5srSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zJZj3giURid"&gt;Comprehensive income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Comprehensive income (loss) consists of two components,
net income and other comprehensive income. Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under
GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net income. Other comprehensive income (loss) consists
of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zMCDFPoIvl4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zzedsnCQU4vf"&gt;(Loss) earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes (loss) earnings per share (&#x201c;EPS&#x201d;)
in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is
measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect
on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e.,
those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates basic and diluted (loss)/earnings
per share as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zRuz5Eat8IOc" style="display: none"&gt;Schedule
of basic and diluted earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Years Ended&lt;br/&gt;
December 31&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net (loss) income&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;(24,949,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;900,396&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Less: Net (income) loss attributable to noncontrolling interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(65,124&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,567&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Net (loss)/income attributable to common shareholders, basic&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,884,122&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;864,829&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average number of shares outstanding, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,029,656&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,253,333&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(Loss)/Earnings per share, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2.07&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.09&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zuN25CFHeBDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December
31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants are convertible into &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zOB5W99vo8ma" title="Antidilutive shares"&gt;1,411,725&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zk0BBegFiS8l" title="Antidilutive shares"&gt;4,458,625&lt;/span&gt;
of the Company&#x2019;s ordinary shares, respectively, were not included in the computation of dilutive loss per share because the inclusion
of such convertible notes and warrants would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPtB3zf8u6Kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company calculates basic and diluted (loss)/earnings
per share as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zRuz5Eat8IOc" style="display: none"&gt;Schedule
of basic and diluted earnings per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zQN4vdwDziK5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20211231_zoYueogu3X4i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Years Ended&lt;br/&gt;
December 31&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProfitLoss_zmQYH2TMEnUk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net (loss) income&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;(24,949,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;900,396&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zpyXeecHKeti" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Less: Net (income) loss attributable to noncontrolling interest&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(65,124&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;35,567&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zOOP6WFrWSIc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Net (loss)/income attributable to common shareholders, basic&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,884,122&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;864,829&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zepqXHxxmHX1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average number of shares outstanding, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,029,656&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,253,333&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EarningsPerShareBasic_pid_zpLBiHkgUaMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;(Loss)/Earnings per share, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2.07&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.09&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24949246</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-65124</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">35567</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24884122</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">864829</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">12029656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">9253333</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      unitRef="Shares">1411725</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      unitRef="Shares">4458625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zzVOHzfqt77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zbaSlXmfzUo"&gt;Fair value measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value is defined as the price that would be received
for an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Valuation
techniques maximize the use of observable inputs and minimize the use of unobservable inputs. When determining the fair value measurements
for assets and liabilities, we consider the principal or most advantageous market in which it would transact and considers assumptions
that market participants would use when pricing the asset or liability. The following summarizes the three levels of inputs required to
measure fair value, of which the first two are considered observable and the third is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - Unadjusted quoted prices in active markets
for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable
or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - Unobservable inputs that are supported by
little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value for certain assets and liabilities
such as cash and restricted cash, accounts receivable, net, other receivables, prepaid expenses and other current assets, loan to third-party,
short-term loans, promissory note, convertible notes, accounts payable, other payables and accrued liabilities, and tax payables have
been determined to approximate carrying amounts due to the short maturities of these instruments. The Company believes that its long-term
loan to third party approximates the fair value based on current yields for debt instruments with similar terms.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zkN130Ffe2af" style="display: none"&gt;Schedule
of fair value hierarchy of financial liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Carrying Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Fair Value Measurement at&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zNGpWR5NLY12" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zBcQXMqTTOY2" style="display: none"&gt;Schedule of reconciliation of financial
liability measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Beginning balance&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;7,409,550&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Change in fair value of prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,911,503&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,321,053&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zoLBIGo0IqXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_zY53z9zrPUU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth by level within the
fair value hierarchy our financial liability that were accounted for at fair value on a recurring basis as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zkN130Ffe2af" style="display: none"&gt;Schedule
of fair value hierarchy of financial liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Carrying Value at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Fair Value Measurement at&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zc5TxMnybdA9" style="width: 18%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHQQpds0lUS2" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zX3J4AkXmSQ4" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvIANnmY2be" style="width: 10%; text-align: right" title="Prepaid forward purchase liabilities"&gt;20,321,053&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <EUDA:PrepaidForwardPurchaseLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiabilities>
    <EUDA:PrepaidForwardPurchaseLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_z18ahSb3gOa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a reconciliation of the beginning
and ending balance of the financial liability measured at fair value on a recurring basis for the year ended December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zBcQXMqTTOY2" style="display: none"&gt;Schedule of reconciliation of financial
liability measured at fair value on a recurring basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220101__20221231_zCzTbuwfNFS2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iS_zYnTPYlFr7Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Beginning balance&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;7,409,550&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_zMZIb9f3Ohf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Change in fair value of prepaid forward purchase liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,911,503&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidForwardPurchaseLiabilitiesBalance_iE_zb28myy4hEIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,321,053&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <EUDA:PrepaidForwardPurchaseLiabilitiesBalance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7409550</EUDA:PrepaidForwardPurchaseLiabilitiesBalance>
    <EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12911503</EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities>
    <EUDA:PrepaidForwardPurchaseLiabilitiesBalance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiabilitiesBalance>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_z6axbXx4rODj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zbRXPdj5KhW6"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for leases in accordance with ASC 842. &lt;/span&gt;The Company entered into two agreements as a lessee to lease office equipment
for general and administrative operations. If any of the following criteria are met, the Company classifies the lease as a finance lease:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease transfers ownership of the underlying asset to the lessee by the end of the lease term;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease grants the lessee an option to purchase the underlying asset that the Company is reasonably certain to exercise;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The lease term is for 75% or more of the remaining economic life of the underlying asset, unless the commencement date falls within the last 25% of the economic life of the underlying asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The present value of the sum of the lease payments equals or exceeds 90% of the fair value of the underlying asset; or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Leases that do not meet any
of the above criteria are accounted for as operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company combines lease
and non-lease components in its contracts under Topic 842, when permissible.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Finance
and operating lease right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. Since the implicit rate for the Company&#x2019;s leases is not readily determinable,
the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present
value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized
basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its finance or operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company
has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term
of twelve months or less. Its leases generally do not provide a residual guarantee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
finance or operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease
term for operating lease. Meanwhile, the Company recognizes the finance leases ROU assets and interest on an amortized cost basis. The
amortization of finance ROU assets is recognized on an accretion basis as amortization expense, while the lease liability is increased
to reflect interest on the liability and decreased to reflect the lease payments made during the period. Interest expense on the lease
liability is determined each period during the lease term as the amount that results in a constant periodic interest rate of the &lt;/span&gt;office
equipment &lt;span style="background-color: white"&gt;on the remaining balance of the liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the
recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset
may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from
the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows. For the years ended December 31, 2022 and 2021, &lt;/span&gt;the Company did not recognize impairment loss on its finance
and operating lease ROU assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <EUDA:RelatedPartyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_ecustom--RelatedPartyPolicyTextBlock_zW3ikgaDVMkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zkWRq3C9mr3e"&gt;Related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject
to common control or common significant influence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:RelatedPartyPolicyTextBlock>
    <EUDA:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_ecustom--NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_zMhejxndWpM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zNRPmrsYJrIc"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and impact
of all accounting standards updates (&#x201c;ASUs&#x201d;). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging
growth company and has elected the extended transition period for complying with new or revised accounting standards, which delays the
adoption of these accounting standards until they would apply to private companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2021, the FASB issued ASU 2021-08, which
is an update to ASU Updated No. 2014-09, Revenue from Contracts with Customers (Topic 606), which provides a single comprehensive accounting
model on revenue recognition for contracts with customers. The amendments in this update require that an entity (acquirer) recognize and
measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. ASU 2021-08 is effective
for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption was permitted,
including adoption in an interim period. The Company has adopted this standard on January 1, 2023, and the adoption did not have a material
impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2019, the FASB issued ASU 2019-05, which is
an update to ASU Update No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured
at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial
Instruments&#x2014;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting
for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized
cost basis, in accordance with Subtopic 326-30, Financial Instruments&#x2014; Credit Losses&#x2014;Available-for-Sale Debt Securities. The
amendments in this Update address those stakeholders&#x2019; concerns by providing an option to irrevocably elect the fair value option
for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase
comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets.
Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13
while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which
to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies
applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after
December 15, 2022. In March 2022, the FASB issued ASU No. 2022-02, which is to (1) eliminate the accounting guidance for TDRs by creditors
in Subtopic 310-40, Receivables&#x2014;Troubled Debt Restructurings by Creditors, while enhancing disclosure requirements for certain loan
refinancings and restructurings by creditors when a borrower is experiencing financial difficulty, and (2) disclose current-period gross
write offs by year of origination for financing receivables and net investments in leases within the scope of Subtopic 326-20, Financial
Instruments&#x2014;Credit Losses&#x2014;Measured at Amortized Cost. ASU 2019-05 is effective for the Company for annual and interim reporting
periods beginning January 1, 2023 as the Company is qualified as an emerging growth company. The Company has adopted this standard on
January 1, 2023, and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfmIHjiMvRu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zaJ77kGpf1n8"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12, &#x201c;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&#x201d;. The amendments in this Update simplify the accounting for income
taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and
simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments
in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years
beginning after December 15, 2022. Early adoption of the amendments is permitted, including adoption in any interim period for (1) public
business entities for periods for which financial statements have not yet been issued and (2) all other entities for periods for which
financial statements have not yet been made available for issuance. An entity that elects to early adopt the amendments in an interim
period should reflect any adjustments as of the beginning of the annual period that includes that interim period. Additionally, an entity
that elects early adoption must adopt all the amendments in the same period. The Company has adopted this standard on January 1, 2022,
and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2020, the Financial Accounting Standards
Board issued Accounting Standards Update (ASU) 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities
and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer&#x2019;s accounting for
convertible instruments and the guidance on the derivative scope exception for contracts in an entity&#x2019;s own equity such that fewer
conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment.
The Company early adopted this ASU on January 1, 2022, and the adoption did not have a material impact on the Company&#x2019;s consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-08, &#x201c;Codification
Improvements to Subtopic 310-20, Receivables&#x2014;Nonrefundable Fees and Other Costs&#x201d;. The amendments in this Update represent
changes to clarify the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies
and providing clarifications. ASU 2020-08 is effective for the Company for annual and interim reporting periods beginning January 1, 2021.
Early adoption was permitted, including adoption in an interim period. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The adoption of this standard on January 1, 2021 did not have a material impact on its
consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2020, the FASB issued ASU 2020-10, &#x201c;Codification
Improvements to Subtopic 205-10, presentation of financial statements&#x201d;. The amendments in this Update improve the codification by
ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements
is codified in the disclosure section of the codification. That reduce the likelihood that the disclosure requirement would be missed.
The amendments also clarify guidance so that an entity can apply the guidance more consistently. ASU 2020-10 is effective for the Company
for annual and interim reporting periods beginning January 1, 2022. Early application of the amendments is permitted for any annual or
interim period for which financial statements are available to be issued. The amendments in this Update should be applied retrospectively.
An entity should apply the amendments at the beginning of the period that includes the adoption date. The adoption of this standard on
January 1, 2022 did not have a material impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Except as mentioned above, the Company does not believe
other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s
consolidated balance sheets, statements of operations and comprehensive income (loss) and statements of cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <EUDA:ReverseRecapitalizationTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_ecustom--ReverseRecapitalizationTextBlock_zbr9crjZOD05" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 4 &#x2013; &lt;span id="xdx_827_zm4Ug66kEmEa"&gt;Reverse Recapitalization&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 17, 2022, the Company consummated the
Business Combination contemplated by the SPA between 8i, EHL, Watermark, and Kwong Yeow Liew, dated April 11, 2022 and amended May 30,
2022, June 10, 2022, and September 7, 2022. As contemplated by the SPA, a business combination between 8i and EHL was effected by the
purchase by 8i of all of the issued and outstanding shares of EHL from Watermark, resulting in EHL becoming a wholly owned subsidiary
of 8i.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Upon the consummation
of the Business Combination, the following events contemplated by the SPA occurred, based on EUDA&#x2019;s capitalization as of November
17, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;all &lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20221117_zl1rg65nScSj" title="Ordinary shares, issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221117_zlMHyCCRhM2a" title="Ordinary shares, outstanding"&gt;1,500,000&lt;/span&gt;&lt;/span&gt; issued and outstanding shares of EHL were converted into &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20221116__20221117_zGzbKo7wh5Sk" title="Converted shares"&gt;14,000,000&lt;/span&gt; shares of the Company&#x2019;s &lt;span id="xdx_90A_eus-gaap--CommonStockNoParValue_iI_do_c20221117_z6xJXm9DpvYl" title="Ordinary shares, par value"&gt;no&lt;/span&gt; par value ordinary shares after giving effect to the exchange ratio of &lt;span id="xdx_906_ecustom--ExchangeRatioPerShare_uUSDPShares_c20221116__20221117_zcPGHtg6aWJf" title="Exchange ratio"&gt;9.33&lt;/span&gt; (&#x201c;Exchange Ratio&#x201d;); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;the entitlement of &lt;span id="xdx_901_eus-gaap--ExcessStockSharesIssued_iI_c20221117_zQsXMCyjvlM8" title="Earnout shares"&gt;4,000,000&lt;/span&gt; shares (&#x201c;Earnout Shares&#x201d;) of the Company&#x2019;s no par value ordinary shares  issued to the Seller subject to the following four triggering events:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zLL1ZnV9BSq1" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#x2019;s share price is equal to or greater than Fifteen Dollars ($&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zTRb6G0BGPIl" title="Share price"&gt;15.00&lt;/span&gt;) after the Closing Date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zPTwYDZFtCOk" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#x2019;s share price is equal to or greater than Twenty Dollars ($&lt;span id="xdx_903_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_z8t70shXeXW2" title="Share price"&gt;20.00&lt;/span&gt;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z5Yylc7ZgxFa" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $&lt;span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zf0MctxrLzN1" title="Revenue"&gt;20,100,000&lt;/span&gt; and (y) net income attributable to EUDA of at least $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zHd7pW60YWxe" title="Net income"&gt;3,600,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zteS9tPEwaW2" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z1mvoCyzIofg" title="Revenue"&gt;40,100,000&lt;/span&gt; and (y) net income attributable to EUDA of at least $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z2EiWSDrhp" title="Net income"&gt;10,100,000&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In connection
with the closing the Business Combination:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;all 8i&#x2019;s &lt;span id="xdx_90D_eus-gaap--CommonStockNoParValue_iI_do_c20221117_zB6icRiCHLBk" title="Ordinary shares, par value"&gt;no&lt;/span&gt; par value public ordinary shares of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20221117_zlx85hd0PEuk" title="Public ordinary shares"&gt;2,591,545&lt;/span&gt;, net of the redemption of &lt;span id="xdx_90E_eus-gaap--TemporaryEquitySharesIssued_iI_c20221117_ztrqDzstJkka" title="Redemption shares"&gt;6,033,455&lt;/span&gt; shares of Company&#x2019;s no par value ordinary shares, remained outstanding;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;all 8i&#x2019;s &lt;span id="xdx_90D_ecustom--PrivateOrdinarySharesNoParValue_iI_do_c20221117_z9ok4XwrjGW2" title="Private ordinary shares, par value"&gt;no&lt;/span&gt; par value private ordinary shares of &lt;span id="xdx_900_ecustom--PrivateOrdinarySharesOutstanding_iI_c20221117_z0Cn5NB7sB52" title="Private ordinary shares, outstanding"&gt;292,250&lt;/span&gt; remained outstanding;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;all 8i&#x2019;s &lt;span id="xdx_90F_ecustom--FounderSharesNoParValue_iI_do_c20221117_zpC1DFH1mZ1a" title="Founder shares, par value"&gt;no&lt;/span&gt; par value founder shares of &lt;span id="xdx_90F_ecustom--FounderSharesOutstanding_iI_do_c20221117_zdc0DNfpavY9" title="Founder shares, outstanding"&gt;2,156,250&lt;/span&gt; remained outstanding;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;all 8i&#x2019;s rights, consisting of &lt;span id="xdx_90D_ecustom--PublicRightsShares_iI_do_c20221117_zMv0Vnha75J2" title="Public rights shares"&gt;8,625,000&lt;/span&gt; public rights and &lt;span id="xdx_906_ecustom--PrivateRightsShares_iI_do_c20221117_zK6X1bDKNf34" title="Private rights shares"&gt;292,250&lt;/span&gt; private rights, automatically converted into an aggregate of &lt;span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_do_c20221116__20221117_z5sJxeneivNa" title="Converted shares"&gt;891,725&lt;/span&gt; of the Company&#x2019;s no par value ordinary shares;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--BusinessAcquisitionAxis__custom--BusinessCombinationMember_z96J0QkqAHk3" title="Ordinary shares, issued"&gt;200,000&lt;/span&gt; shares of the Company&#x2019;s no par value ordinary shares were issued to a service provider in connection with the business combination;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zerllM4TxsJe" title="Ordinary shares, issued"&gt;60,000&lt;/span&gt; shares of the Company&#x2019;s no par value ordinary shares were issued to a service provider in connection with the closing of transactions contemplated pursuant to certain share purchase agreement. Such issuance of the ordinary share serves the purpose of securing the repayment of $&lt;span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20221116__20221117_zT4OZU8qZZ4a" title="Repayments of convertible promissory note"&gt;300,000&lt;/span&gt; convertible promissory note to the service provider;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_zBeeqGaFG5A7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table presents the number of the Company&#x2019;s ordinary shares issued and outstanding immediately following the Reverse Recapitalization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zVgBvJgIzF69" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of shares issued and outstanding reverse recapitalization&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221116__20221117_zb0lTmQofba6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_z2g0qVWdUx02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;8i ordinary shares outstanding prior to Reverse Recapitalization&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;11,073,500&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RedemptionOfOrdinaryShares_z69JroSkZSC6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less: redemption of 8i ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,033,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConversionOfStockSharesConverted1_zVcyOG4GNiY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion of 8i rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;891,725&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zAq1VTpujEE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shares issued to service providers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;260,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_zMYXv5SiTefh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of EHL ordinary shares into 8i ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,000,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_z7rRd8Ocj1e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total shares outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,191,770&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_z29Zb4pG6xHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;EHL
was determined to be the accounting acquirer given EHL effectively controlled the combined entity after the SPAC Transaction. The transaction
is not a business combination because 8i was not a business. The transaction is accounted for as a reverse recapitalization, which is
equivalent to the issuance of shares by EHL for the net monetary assets of 8i, accompanied by a recapitalization. EHL is determined as
the accounting acquirer and the historical financial statements of EHL became the Company&#x2019;s historical financial statements, with
retrospective adjustments to give effect of the reverse recapitalization. The net assets of 8i were recognized as of the closing date
at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Merger are those of EHL and EHL&#x2019;s
operations are the only ongoing operations of EHL. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In connection
with the Reverse Recapitalization, the Company raised approximately $&lt;span id="xdx_908_ecustom--ProceedsFromReverseRecapitalization_pn5n6_c20221116__20221118_zG1meDfBrGfl" title="Proceeds from the Reverse Recapitalization"&gt;1.3&lt;/span&gt; million of proceeds, presented as cash flows from financing activities,
which included the contribution of approximately $&lt;span id="xdx_90E_ecustom--FundsHeldInTrustAccount_pn5n6_c20221116__20221118_zsSJCLygQ6L6" title="Funds held in trust account"&gt;87.1&lt;/span&gt; million of funds held in 8i&#x2019;s trust account, approximately $&lt;span id="xdx_90D_ecustom--FundsHeldInOperatingCashAccount_pn5n6_c20221116__20221118_zNkgJLfaW1bj" title="Funds held in operating cash account"&gt;0.2&lt;/span&gt; million of
cash held in 8i&#x2019;s operating cash account, net of approximately $&lt;span id="xdx_905_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20221116__20221118_zsBAqBTbunOf" title="Amount paid to redeem public shares"&gt;60.8&lt;/span&gt; million paid to redeem &lt;span id="xdx_90E_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20221116__20221118_zK1FPIE4gAa2" title="Redeem public shares"&gt;6,033,455&lt;/span&gt; public shares of 8i&#x2019;s
ordinary shares, approximately $&lt;span id="xdx_909_eus-gaap--PaymentsOfFinancingCosts_pn5n6_c20221116__20221118_zKWDNB4YQfL4" title="Payments of transaction costs"&gt;3.0&lt;/span&gt; million in transaction costs incurred by 8i, approximately $&lt;span id="xdx_909_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_pn5n6_c20221116__20221118_zGrn3atMY60j" title="Payments of forward purchase agreements"&gt;21.9&lt;/span&gt; million prepayment of two forward
purchase agreements, and repayments of a promissory note in the amount of $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_pn4n6_c20221116__20221118_zgOIUP1sDwA" title="Repayments of promissory note related party"&gt;0.3&lt;/span&gt; million issued to 8i&#x2019;s related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfFinancialStatementsOfReverseRecapitalization_zsrzfqySb78h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table reconcile the elements of the Reverse Recapitalization to the consolidated statements of cash flows and the changes in shareholders&#x2019;
equity (deficit):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zs643UtKtaB4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of financial statements of reverse recapitalization&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221116__20221118_zOxJtSiMfxCd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;November 18, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FundsHeldInTrustAccount_zehMN4o63yAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Funds held in 8i&#x2019;s trust account&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;87,074,185&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FundsHeldInOperatingCashAccount_zt01GCUOfkn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Funds held in 8i&#x2019;s operating cash account&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;248,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_iN_di_zzzzDCZVY0F5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: amount paid to redeem public shares of 8i&#x2019;s ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(60,839,550&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_iN_di_zpx87L2Bo0d3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: payments of transaction costs incurred by 8i&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,965,646&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_iN_di_zA7C4IHEYhW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: payments of forward purchase agreements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(21,892,527&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_zSoD2cgzRQia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: repayments of promissory note &#x2013; related party of 8i&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ProceedsFromReverseRecapitalizations_ztFWhTtAiet" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Proceeds from the Reverse Recapitalization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,324,961&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ProceedsFromUnpaidDeferredUnderwritingFee_iN_di_zWqlMe7o9Z7i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unpaid deferred underwriting fee&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,113,125&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ProceedsFromUnpaidTransactionCostsIncurred_iN_di_zgIdS356acO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unpaid transaction costs incurred by 8i&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(382,600&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PaymentsForMergerRelatedCosts_iN_di_z2I5Gil7nk79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,305,580&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NoncashNetAssetsAssumedValue_zX0HEBOPqic6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Add: non-cash net assets assumed from 8i&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,387,803&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IssuanceOfOrdinarySharesUponTheReverseRecapitalization_zXq9Lb4MbIEj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net contributions from issuance of ordinary shares upon the Reverse Recapitalization&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,911,459&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_ziutALg4KB1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The shares and corresponding capital amounts and all
per share data related to EHL&#x2019;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the &lt;span style="background-color: white"&gt;Exchange Ratio&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:ReverseRecapitalizationTextBlock>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">1500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">1500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">14000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-11-17"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <EUDA:ExchangeRatioPerShare
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="USDPShares">9.33</EUDA:ExchangeRatioPerShare>
    <us-gaap:ExcessStockSharesIssued contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">4000000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17_custom_FirstAnniversaryMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-17_custom_FirstAnniversaryMember"
      decimals="INF"
      unitRef="USDPShares">15.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17_custom_SecondAnniversaryMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-17_custom_SecondAnniversaryMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">3600000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">40100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">10100000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-11-17"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">2591545</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesIssued contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">6033455</us-gaap:TemporaryEquitySharesIssued>
    <EUDA:PrivateOrdinarySharesNoParValue
      contextRef="AsOf2022-11-17"
      decimals="INF"
      unitRef="USDPShares">0</EUDA:PrivateOrdinarySharesNoParValue>
    <EUDA:PrivateOrdinarySharesOutstanding contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">292250</EUDA:PrivateOrdinarySharesOutstanding>
    <EUDA:FounderSharesNoParValue
      contextRef="AsOf2022-11-17"
      decimals="INF"
      unitRef="USDPShares">0</EUDA:FounderSharesNoParValue>
    <EUDA:FounderSharesOutstanding contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">2156250</EUDA:FounderSharesOutstanding>
    <EUDA:PublicRightsShares contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">8625000</EUDA:PublicRightsShares>
    <EUDA:PrivateRightsShares contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">292250</EUDA:PrivateRightsShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">891725</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-11-17_custom_BusinessCombinationMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-11-17_custom_SharePurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">60000</us-gaap:CommonStockSharesIssued>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2022-11-162022-11-17"
      decimals="0"
      unitRef="USD">300000</us-gaap:RepaymentsOfConvertibleDebt>
    <EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_ecustom--ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock_zBeeqGaFG5A7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table presents the number of the Company&#x2019;s ordinary shares issued and outstanding immediately following the Reverse Recapitalization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zVgBvJgIzF69" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of shares issued and outstanding reverse recapitalization&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221116__20221117_zb0lTmQofba6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_z2g0qVWdUx02" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;8i ordinary shares outstanding prior to Reverse Recapitalization&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;11,073,500&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RedemptionOfOrdinaryShares_z69JroSkZSC6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less: redemption of 8i ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,033,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ConversionOfStockSharesConverted1_zVcyOG4GNiY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion of 8i rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;891,725&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zAq1VTpujEE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shares issued to service providers&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;260,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_zMYXv5SiTefh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of EHL ordinary shares into 8i ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,000,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization_z7rRd8Ocj1e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total shares outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,191,770&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock>
    <EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">11073500</EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization>
    <EUDA:RedemptionOfOrdinaryShares
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">-6033455</EUDA:RedemptionOfOrdinaryShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">891725</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">260000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">14000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization
      contextRef="From2022-11-162022-11-17"
      decimals="0"
      unitRef="USD">20191770</EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization>
    <EUDA:ProceedsFromReverseRecapitalization
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">1300000</EUDA:ProceedsFromReverseRecapitalization>
    <EUDA:FundsHeldInTrustAccount
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">87100000</EUDA:FundsHeldInTrustAccount>
    <EUDA:FundsHeldInOperatingCashAccount
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">200000</EUDA:FundsHeldInOperatingCashAccount>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">60800000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2022-11-162022-11-18"
      decimals="INF"
      unitRef="Shares">6033455</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">3000000.0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities
      contextRef="From2022-11-162022-11-18"
      decimals="-5"
      unitRef="USD">21900000</us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-11-162022-11-18"
      decimals="-4"
      unitRef="USD">300000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <EUDA:ScheduleOfFinancialStatementsOfReverseRecapitalization contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_ecustom--ScheduleOfFinancialStatementsOfReverseRecapitalization_zsrzfqySb78h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table reconcile the elements of the Reverse Recapitalization to the consolidated statements of cash flows and the changes in shareholders&#x2019;
equity (deficit):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zs643UtKtaB4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of financial statements of reverse recapitalization&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221116__20221118_zOxJtSiMfxCd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;November 18, 2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--FundsHeldInTrustAccount_zehMN4o63yAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Funds held in 8i&#x2019;s trust account&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;87,074,185&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FundsHeldInOperatingCashAccount_zt01GCUOfkn2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Funds held in 8i&#x2019;s operating cash account&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;248,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_iN_di_zzzzDCZVY0F5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: amount paid to redeem public shares of 8i&#x2019;s ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(60,839,550&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PaymentsOfFinancingCosts_iN_di_zpx87L2Bo0d3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: payments of transaction costs incurred by 8i&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,965,646&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsForPurchaseOfSecuritiesOperatingActivities_iN_di_zA7C4IHEYhW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: payments of forward purchase agreements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(21,892,527&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_zSoD2cgzRQia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: repayments of promissory note &#x2013; related party of 8i&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(300,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ProceedsFromReverseRecapitalizations_ztFWhTtAiet" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Proceeds from the Reverse Recapitalization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,324,961&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ProceedsFromUnpaidDeferredUnderwritingFee_iN_di_zWqlMe7o9Z7i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unpaid deferred underwriting fee&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,113,125&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ProceedsFromUnpaidTransactionCostsIncurred_iN_di_zgIdS356acO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unpaid transaction costs incurred by 8i&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(382,600&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PaymentsForMergerRelatedCosts_iN_di_z2I5Gil7nk79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,305,580&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NoncashNetAssetsAssumedValue_zX0HEBOPqic6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Add: non-cash net assets assumed from 8i&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,387,803&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IssuanceOfOrdinarySharesUponTheReverseRecapitalization_zXq9Lb4MbIEj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net contributions from issuance of ordinary shares upon the Reverse Recapitalization&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,911,459&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfFinancialStatementsOfReverseRecapitalization>
    <EUDA:FundsHeldInTrustAccount
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">87074185</EUDA:FundsHeldInTrustAccount>
    <EUDA:FundsHeldInOperatingCashAccount
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">248499</EUDA:FundsHeldInOperatingCashAccount>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">60839550</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">2965646</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">21892527</us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">300000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <EUDA:ProceedsFromReverseRecapitalizations
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">1324961</EUDA:ProceedsFromReverseRecapitalizations>
    <EUDA:ProceedsFromUnpaidDeferredUnderwritingFee
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">2113125</EUDA:ProceedsFromUnpaidDeferredUnderwritingFee>
    <EUDA:ProceedsFromUnpaidTransactionCostsIncurred
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">382600</EUDA:ProceedsFromUnpaidTransactionCostsIncurred>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">1305580</us-gaap:PaymentsForMergerRelatedCosts>
    <EUDA:NoncashNetAssetsAssumedValue
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">14387803</EUDA:NoncashNetAssetsAssumedValue>
    <EUDA:IssuanceOfOrdinarySharesUponTheReverseRecapitalization
      contextRef="From2022-11-162022-11-18"
      decimals="0"
      unitRef="USD">11911459</EUDA:IssuanceOfOrdinarySharesUponTheReverseRecapitalization>
    <EUDA:DispositionOfSubsidiariesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_ecustom--DispositionOfSubsidiariesTextBlock_zKMBLSoqlxdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2013; &lt;span id="xdx_82F_zOiVGXeRmOC1"&gt;Disposition of Subsidiary&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;Disposition of TGC&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 1, 2022, SEMA, the Company&#x2019;s wholly
owned subsidiary, sold &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TheGoodClinicPrivateLimitedMember_zojCpiWNxB9a" title="Ownership interest"&gt;100&lt;/span&gt;% of the equity interest in TGC to an unrelated individual for a total consideration of SG$ &lt;span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220227__20220302__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_zU32cBat6QA8" title="Consideration received"&gt;1.0&lt;/span&gt; (&#x201c;TGC
transaction&#x201d;). TGC is not a significant subsidiary and the disposition of all of the equity interests in TGC did not constitute
a strategic shift that would have a major effect on the Company&#x2019;s operations and financial results. As a result, the results of
operations for TGC were not reported as discontinued operations under the guidance of ASC 205 &#x201c;&lt;i&gt;Presentation of Financial Statements.&lt;/i&gt;&#x201d;
For the year ended December 31, 2022, the Company recognized a gain of $&lt;span id="xdx_900_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SEMAAgreementMember_z1eew5RitL97" title="Gain loss on disposal of deficit interest"&gt;30,055&lt;/span&gt; on the disposal of all of the deficit interests in TGC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:DispositionOfSubsidiariesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-02_custom_SEMAAgreementMember_custom_TheGoodClinicPrivateLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-02-272022-03-02_custom_SEMAAgreementMember"
      decimals="0"
      unitRef="SGD">1.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="From2022-01-012022-12-31_custom_SEMAAgreementMember"
      decimals="0"
      unitRef="USD">30055</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:AccountsAndNontradeReceivableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_eus-gaap--AccountsAndNontradeReceivableTextBlock_zmGbnm6GsoY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Note 6 &#x2013; &lt;span style="background-color: white"&gt;&lt;span id="xdx_826_zu9ssnZ29rO6"&gt;Accounts
receivable, net&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zMhK0HSTMdbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BC_zHzDNUZ44Kuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of accounts receivable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zcMItTl2T9xl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_z3ijY3QGHvng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCztie_z3ep6qxzal53" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts receivable&lt;span id="xdx_F43_zWaGns4rARcb"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;2,048,941&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1,883,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCztie_zRK6tXjbUUog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(197,438&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(80,799&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCztie_zkvPItfGhR1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,851,503&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,802,316&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F00_zs9ul92a2oP" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F18_zJxNpVRPZkM1" style="text-align: justify"&gt;As of December 31, 2022 and 2021, accounts receivable of up to approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable"&gt;0.6&lt;/span&gt;&lt;/span&gt; million (SGD
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable"&gt;0.8&lt;/span&gt;&lt;/span&gt; million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A5_zPN22OAMO2o9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_ztLygfgLjhBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Movements
of allowance for doubtful accounts from account receivables are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zMTDzXo5MK5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of movements of allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20220101__20221231_zcovL1rvmRAg" style="width: 16%; text-align: right" title="Beginning balance"&gt;80,799&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20210101__20211231_zcvGX2FYAFPf" style="width: 16%; text-align: right" title="Beginning balance"&gt;37,898&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Addition&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20220101__20221231_z8XAct8nYU8j" style="text-align: right" title="Addition"&gt;116,156&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20210101__20211231_z5DdUW9hgWq7" style="text-align: right" title="Addition"&gt;43,804&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20220101__20221231_za86uPhprpbf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect"&gt;483&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20210101__20211231_znwo3yjlZrM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect"&gt;(903&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20220101__20221231_zpF4Zltoi4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;197,438&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20210101__20211231_zVJIDX9L3fo1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;80,799&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zYIOiCa78Gkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfOtherAssetsTableTextBlock_zMhK0HSTMdbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BC_zHzDNUZ44Kuk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of accounts receivable&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231_zcMItTl2T9xl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_z3ijY3QGHvng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCztie_z3ep6qxzal53" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts receivable&lt;span id="xdx_F43_zWaGns4rARcb"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;2,048,941&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;1,883,115&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCztie_zRK6tXjbUUog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(197,438&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(80,799&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCztie_zkvPItfGhR1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,851,503&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,802,316&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F00_zs9ul92a2oP" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F18_zJxNpVRPZkM1" style="text-align: justify"&gt;As of December 31, 2022 and 2021, accounts receivable of up to approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb" title="Accounts receivable"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg" title="Accounts receivable"&gt;0.6&lt;/span&gt;&lt;/span&gt; million (SGD
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik" title="Accounts receivable"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb" title="Accounts receivable"&gt;0.8&lt;/span&gt;&lt;/span&gt; million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001165"
      unitRef="USD">2048941</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">1883115</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">197438</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">80799</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1851503</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1802316</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember"
      decimals="-5"
      unitRef="USD">600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember"
      decimals="-5"
      unitRef="USD">600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember"
      decimals="-5"
      unitRef="SGD">800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember"
      decimals="-5"
      unitRef="SGD">800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_ztLygfgLjhBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Movements
of allowance for doubtful accounts from account receivables are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zMTDzXo5MK5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of movements of allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20220101__20221231_zcovL1rvmRAg" style="width: 16%; text-align: right" title="Beginning balance"&gt;80,799&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20210101__20211231_zcvGX2FYAFPf" style="width: 16%; text-align: right" title="Beginning balance"&gt;37,898&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Addition&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20220101__20221231_z8XAct8nYU8j" style="text-align: right" title="Addition"&gt;116,156&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_c20210101__20211231_z5DdUW9hgWq7" style="text-align: right" title="Addition"&gt;43,804&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20220101__20221231_za86uPhprpbf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect"&gt;483&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_c20210101__20211231_znwo3yjlZrM3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exchange rate effect"&gt;(903&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20220101__20221231_zpF4Zltoi4Oc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;197,438&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20210101__20211231_zVJIDX9L3fo1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;80,799&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">80799</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">37898</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">116156</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">43804</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">483</EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect>
    <EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-903</EUDA:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">197438</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">80799</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FinancingReceivablesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--FinancingReceivablesTextBlock_z5HnZ5pwRvYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Note
7 &lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#x2013; &lt;span style="background-color: white"&gt;&lt;span id="xdx_828_zhvb8czeQFGl"&gt;Other receivables&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;span style="background-color: white"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_gL3SOCLFFRCTT-SYHD_zLU1wdUknP36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B4_zm2o4zebu17c" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of other receivables&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zDKDXeHiu4z4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_z99WFoJqh6Fg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DivestmentReceivable_iI_zJLBvk7YMAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4E_zsEu6CSI4vDd" style="width: 60%; text-align: left"&gt;Receivable from divestment (1)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;3,818,776&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EmployeeAdavance_iI_zcID7PtGmN9l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee advance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,695&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,803&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherReceivablesGrossCurrent_iI_zbuKkhWbI621" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;772&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;250&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherReceivables_iTI_zrj7Lt6AQ06c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,821,829&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OtherReceivablesNetNonCurrent_iI_zUGyuvchwHX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables &#x2013; non-current&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,830,603&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_zY5ijrVtuv4a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Other receivables &#x2013; current&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,467&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,991,226&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zGquBdtFUhBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zIhFE6hXSJTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Movements
of allowance for doubtful accounts from other receivables are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8B6_zqZDXVequpWg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of other receivables allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20220101__20221231_zxKXdlcdjFL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20210101__20211231_zmCGZGwzcF25" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Addition&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20220101__20221231_ze2dQp5ImR9c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,209,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20210101__20211231_z3xmEJVhb1Xh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Write-off&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20220101__20221231_zf6OO450jHxj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,209,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20210101__20211231_zaud4Oz7a86f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20220101__20221231_zw6SVgzdNWad" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20210101__20211231_zzbirWUHir8g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zJe59GrryAxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;div id="xdx_C01_gL3SOCLFFRCTT-SYHD_z0qD234omzY7"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0B_zd6Pvz8IPeDk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zmtH88VrDzji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#x2019;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" title="Investment amount"&gt;1.9&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" title="Investment amount"&gt;2,580,000&lt;/span&gt;)
    in BPT&#x2019;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#x201c;Agreement&#x201d;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#x2019;s
    investment amounted to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" title="Investment owned face amount"&gt;1,913,096&lt;/span&gt;
    (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" title="Investment owned face amount"&gt;2,580,000&lt;/span&gt;),
    and compensated UGI with the additional amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount"&gt;1,905,681&lt;/span&gt;(SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount"&gt;2,570,000&lt;/span&gt;).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received"&gt;0.9&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received"&gt;1,200,000&lt;/span&gt;)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance"&gt;2.8&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance"&gt;3,950,000&lt;/span&gt;)
    in eight equal quarterly installments with annual &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description"&gt;interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.&lt;/span&gt; As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount"&gt;0.7&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount"&gt;987,500&lt;/span&gt;).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_C05_gL3SOCLFFRCTT-SYHD_zbdyBPC29sF7"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FinancingReceivablesTextBlock>
    <us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock_gL3SOCLFFRCTT-SYHD_zLU1wdUknP36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B4_zm2o4zebu17c" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of other receivables&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zDKDXeHiu4z4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_z99WFoJqh6Fg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DivestmentReceivable_iI_zJLBvk7YMAu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F4E_zsEu6CSI4vDd" style="width: 60%; text-align: left"&gt;Receivable from divestment (1)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;3,818,776&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EmployeeAdavance_iI_zcID7PtGmN9l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee advance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6,695&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,803&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherReceivablesGrossCurrent_iI_zbuKkhWbI621" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;772&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;250&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherReceivables_iTI_zrj7Lt6AQ06c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total other receivables&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,821,829&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OtherReceivablesNetNonCurrent_iI_zUGyuvchwHX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables &#x2013; non-current&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,830,603&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherReceivablesNetCurrent_iI_zY5ijrVtuv4a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Other receivables &#x2013; current&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,467&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,991,226&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0B_zd6Pvz8IPeDk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zmtH88VrDzji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#x2019;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd" title="Investment amount"&gt;1.9&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk" title="Investment amount"&gt;2,580,000&lt;/span&gt;)
    in BPT&#x2019;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#x201c;Agreement&#x201d;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#x2019;s
    investment amounted to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2" title="Investment owned face amount"&gt;1,913,096&lt;/span&gt;
    (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1" title="Investment owned face amount"&gt;2,580,000&lt;/span&gt;),
    and compensated UGI with the additional amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l" title="Additional amount"&gt;1,905,681&lt;/span&gt;(SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5" title="Additional amount"&gt;2,570,000&lt;/span&gt;).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k" title="Installment received"&gt;0.9&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d" title="Installment received"&gt;1,200,000&lt;/span&gt;)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1" title="Remaining balance"&gt;2.8&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db" title="Remaining balance"&gt;3,950,000&lt;/span&gt;)
    in eight equal quarterly installments with annual &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2" title="Debt intrument interest rate, description"&gt;interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.&lt;/span&gt; As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb" title="Other installment amount"&gt;0.7&lt;/span&gt;
    million (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA" id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g" title="Other installment amount"&gt;987,500&lt;/span&gt;).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock>
    <EUDA:DivestmentReceivable
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001208"
      unitRef="USD">3818776</EUDA:DivestmentReceivable>
    <EUDA:EmployeeAdavance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6695</EUDA:EmployeeAdavance>
    <EUDA:EmployeeAdavance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2803</EUDA:EmployeeAdavance>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">772</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">250</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivables contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7467</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3821829</us-gaap:OtherReceivables>
    <EUDA:OtherReceivablesNetNonCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1830603</EUDA:OtherReceivablesNetNonCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7467</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1991226</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zIhFE6hXSJTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Movements
of allowance for doubtful accounts from other receivables are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8B6_zqZDXVequpWg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of other receivables allowance for doubtful accounts&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20220101__20221231_zxKXdlcdjFL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iS_c20210101__20211231_zmCGZGwzcF25" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Addition&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20220101__20221231_ze2dQp5ImR9c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,209,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--AllowanceForDoubtfulOtherReceivableRecoveries_c20210101__20211231_z3xmEJVhb1Xh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Addition"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Write-off&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20220101__20221231_zf6OO450jHxj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,209,825&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--AllowanceForDoubtfulOtherReceivableWriteOffs_iN_di_c20210101__20211231_zaud4Oz7a86f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-off"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20220101__20221231_zw6SVgzdNWad" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iE_c20210101__20211231_zzbirWUHir8g" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <EUDA:AllowanceForDoubtfulOtherReceivableRecoveries
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2209825</EUDA:AllowanceForDoubtfulOtherReceivableRecoveries>
    <EUDA:AllowanceForDoubtfulOtherReceivableWriteOffs
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2209825</EUDA:AllowanceForDoubtfulOtherReceivableWriteOffs>
    <us-gaap:InvestmentOwnedAtFairValue contextRef="AsOf2018-01-18" decimals="-5" unitRef="USD">1900000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue contextRef="AsOf2018-01-18" decimals="0" unitRef="SGD">2580000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue contextRef="AsOf2021-03-01" decimals="0" unitRef="USD">1913096</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue contextRef="AsOf2021-03-01" decimals="0" unitRef="SGD">2580000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <EUDA:InvestmentOwnedAdditionalAmountAtMarketValues contextRef="AsOf2021-03-01" decimals="0" unitRef="USD">1905681</EUDA:InvestmentOwnedAdditionalAmountAtMarketValues>
    <EUDA:InvestmentOwnedAdditionalAmountAtMarketValues contextRef="AsOf2021-03-01" decimals="0" unitRef="SGD">2570000</EUDA:InvestmentOwnedAdditionalAmountAtMarketValues>
    <EUDA:InstallmentReceived contextRef="AsOf2021-03-01" decimals="-5" unitRef="USD">900000</EUDA:InstallmentReceived>
    <EUDA:InstallmentReceived contextRef="AsOf2021-03-01" decimals="0" unitRef="SGD">1200000</EUDA:InstallmentReceived>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2022-05-31" decimals="-5" unitRef="USD">2800000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="AsOf2022-05-31" decimals="0" unitRef="SGD">3950000</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2022-05-012022-05-31">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</us-gaap:DebtInstrumentInterestRateTerms>
    <EUDA:OtherReceivableInstallmentAmount contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">700000</EUDA:OtherReceivableInstallmentAmount>
    <EUDA:OtherReceivableInstallmentAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="SGD">987500</EUDA:OtherReceivableInstallmentAmount>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zyMk2kn5E6Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Note 8 &#x2013; &lt;span id="xdx_825_zf6b8YFI3Hs8"&gt;Property
and equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z5mSdoucpmWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span id="xdx_8B8_zHVhLfbGLoI5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of property and equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zpTMbdGlLwJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_ztk0nqQP2YN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zG25ePGsgDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office equipment&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;148,387&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;144,051&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zd23T65SSPy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,724&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,917&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zll8szp4GZf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvement&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,217&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,704&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzHdg_zvTRCTRytXkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;153,328&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;180,672&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzHdg_zHrtvnki6eN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(121,700&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,745&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzHdg_zUAXZg8rAIVd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,628&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_z1WWtsDoBedj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense for the years ended December
31, 2022 and 2021 amounted to $&lt;span id="xdx_904_eus-gaap--Depreciation_c20220101__20221231_zFYeemxvYkSi" title="Depreciation expense"&gt;23,347&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20210101__20211231_zpPXFA3mEZFi" title="Depreciation expense"&gt;34,523&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z5mSdoucpmWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment, net consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span id="xdx_8B8_zHVhLfbGLoI5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of property and equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zpTMbdGlLwJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_ztk0nqQP2YN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zG25ePGsgDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Office equipment&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;148,387&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;144,051&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MedicalEquipmentMember_zd23T65SSPy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Medical equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,724&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,917&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zll8szp4GZf9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvement&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,217&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,704&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzHdg_zvTRCTRytXkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;153,328&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;180,672&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzHdg_zHrtvnki6eN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(121,700&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,745&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzHdg_zUAXZg8rAIVd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;31,628&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,927&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">148387</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">144051</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      unitRef="USD">2724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_MedicalEquipmentMember"
      decimals="0"
      unitRef="USD">15917</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">2217</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">20704</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">153328</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">180672</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">121700</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">123745</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">31628</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56927</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">23347</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">34523</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGHgwodzg8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 9 &#x2013; &lt;span id="xdx_822_z4rXifXJO9Y7"&gt;Intangible assets, net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrWdLnkeBuS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Intangible assets
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zheLd0sPrDVe" style="display: none"&gt;Schedule
of intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zcyIRETse008" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zzE61IlI6fNe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedCustomerRelationshipsGross_iI_maFLIANzay9_zRwiwhzpsrZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Customer relationships&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;650,102&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;646,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzay9_zhbXYS2amUw4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(477,584&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(356,284&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Impairment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zTEvWZD4UnYd" title="Less: Impairment"&gt;167,787&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(&lt;span id="xdx_904_ecustom--ExchangeRateEffect_c20220101__20221231_z2NPAqwNwf1b" title="Exchange rate effect"&gt;4,731&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzay9_zFsJe5o6sdB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total intangible assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;289,962&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zvCsgAwYDaag" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization expense for the years ended December
31, 2022 and 2021 amounted to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zWme17rtLEp6" title="Amortization expense"&gt;115,907&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_z0uKtxehJye5" title="Amortization expense"&gt;162,825&lt;/span&gt;, respectively. The management performed quantitative assessment and determined to
fully impair the carrying value of intangible assets due to the Company&#x2019;s limited business development and uncertain surrounding
economic environment. For the year ended December 31, 2022, The Company recorded $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEludGFuZ2libGUgYXNzZXRzLCBuZXQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zxhS0JQC4AGj" title="Impairment loss"&gt;167,787&lt;/span&gt; impairment loss related to intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zrWdLnkeBuS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Intangible assets
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zheLd0sPrDVe" style="display: none"&gt;Schedule
of intangible assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zcyIRETse008" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20211231_zzE61IlI6fNe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedCustomerRelationshipsGross_iI_maFLIANzay9_zRwiwhzpsrZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Customer relationships&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;650,102&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;646,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzay9_zhbXYS2amUw4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(477,584&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(356,284&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Impairment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20220101__20221231_zTEvWZD4UnYd" title="Less: Impairment"&gt;167,787&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(&lt;span id="xdx_904_ecustom--ExchangeRateEffect_c20220101__20221231_z2NPAqwNwf1b" title="Exchange rate effect"&gt;4,731&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzay9_zFsJe5o6sdB3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total intangible assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;289,962&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedCustomerRelationshipsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">650102</us-gaap:FiniteLivedCustomerRelationshipsGross>
    <us-gaap:FiniteLivedCustomerRelationshipsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">646246</us-gaap:FiniteLivedCustomerRelationshipsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">477584</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">356284</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">167787</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <EUDA:ExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4731</EUDA:ExchangeRateEffect>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">289962</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">115907</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">162825</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">167787</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_eus-gaap--GoodwillDisclosureTextBlock_zy8t5lF1Tp49" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 10 &#x2013; &lt;span id="xdx_822_zoKzAW3jSGDl"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfGoodwillTextBlock_zTmbmb4e5ynd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The
changes in the carrying amount of goodwill from Melana reporting unit and Tri-Global reporting unit are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zaVXBpQzDt7b" style="display: none"&gt;Schedule
of goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B3_us-gaap--BusinessAcquisitionAxis_custom--MelanaInternationalPteLimitedMember_zYD13vnzyCac" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Melana&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B5_us-gaap--BusinessAcquisitionAxis_custom--TriGlobalSecurityPteLimitedMember_zBUWt9d98jUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Tri-Global&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_zvGbVsnACRs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20210101__20211231_eus-gaap--Goodwill_iS_z4FHyz86k8F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Balance as of December 31, 2020&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;539,286&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;473,344&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;1,012,630&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_zspcihJYudB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,621&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,323&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20220101__20221231_eus-gaap--Goodwill_iS_zbBKMWrIpF06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;528,665&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,021&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;992,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_434_c20220101__20221231_eus-gaap--Goodwill_iS_zbqKn29MhMlf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;528,665&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,021&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;992,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_z74a0yqnTzp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency translation adjustment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(11,427&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(10,030&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(21,457&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_iN_di_znOKDbByjexd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(517,238&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(453,991&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(971,229&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_436_c20220101__20221231_eus-gaap--Goodwill_iE_zF56Pdc9x6Ca" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20220101__20221231_eus-gaap--Goodwill_iE_zSB1sptjUfLg" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AA_zZG1P5u3sWu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2022 and 2021,
the Company record $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_z4iOefuPl8Ih" title="Impairment loss"&gt;971,229&lt;/span&gt;
and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEdvb2R3aWxsIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zwAbYirFwWy3" title="Impairment loss::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;nil&lt;/span&gt;&lt;/span&gt; impairment loss on good will, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfGoodwillTextBlock_zTmbmb4e5ynd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The
changes in the carrying amount of goodwill from Melana reporting unit and Tri-Global reporting unit are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zaVXBpQzDt7b" style="display: none"&gt;Schedule
of goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B3_us-gaap--BusinessAcquisitionAxis_custom--MelanaInternationalPteLimitedMember_zYD13vnzyCac" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Melana&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B5_us-gaap--BusinessAcquisitionAxis_custom--TriGlobalSecurityPteLimitedMember_zBUWt9d98jUa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Tri-Global&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_zvGbVsnACRs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43F_c20210101__20211231_eus-gaap--Goodwill_iS_z4FHyz86k8F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Balance as of December 31, 2020&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;539,286&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;473,344&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;1,012,630&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_zspcihJYudB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,621&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,323&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,944&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_433_c20220101__20221231_eus-gaap--Goodwill_iS_zbBKMWrIpF06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;528,665&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,021&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;992,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_434_c20220101__20221231_eus-gaap--Goodwill_iS_zbqKn29MhMlf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;528,665&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,021&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;992,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GoodwillTranslationAndPurchaseAccountingAdjustments_z74a0yqnTzp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign currency translation adjustment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(11,427&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(10,030&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(21,457&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_iN_di_znOKDbByjexd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(517,238&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(453,991&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(971,229&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_436_c20220101__20221231_eus-gaap--Goodwill_iE_zF56Pdc9x6Ca" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20220101__20221231_eus-gaap--Goodwill_iE_zSB1sptjUfLg" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="AsOf2020-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">539286</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2020-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">473344</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1012630</us-gaap:Goodwill>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2021-01-012021-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">-10621</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2021-01-012021-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">-9323</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-19944</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">528665</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">464021</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">992686</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">528665</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">464021</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">992686</us-gaap:Goodwill>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">-11427</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">-10030</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-21457</us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31_custom_MelanaInternationalPteLimitedMember"
      decimals="0"
      unitRef="USD">517238</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31_custom_TriGlobalSecurityPteLimitedMember"
      decimals="0"
      unitRef="USD">453991</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">971229</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">971229</us-gaap:GoodwillImpairmentLoss>
    <EUDA:ForwardPurchaseAgreementsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_805_ecustom--ForwardPurchaseAgreementsDisclosureTextBlock_zcvGACHMS2T6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 11 &#x2013; &lt;span id="xdx_82E_zJCLxrxZRVS6"&gt;Forward Purchase Agreements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
November 9, 2022 and November 13, 2022, 8i, EHL, and certain institutional investors, HB Strategies LLC (the &#x201c;Seller 1&#x201d;) and
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (&#x201c;Seller 2&#x201d;) entered into an agreement (the &#x201c;Prepaid
Forward Agreement 1&#x201d; and &#x201c;Prepaid Forward Agreement 2&#x201d;), respectively, for an equity prepaid forward transaction (the
&#x201c;Prepaid Forward Transaction 1&#x201d; and &#x201c;Prepaid Forward Transaction 2&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Pursuant
to the terms of the Prepaid Forward Agreements, Seller 1 and Seller 2 may (i) purchase through a broker in the open market, from holders
of Shares other than 8i Acquisition or affiliates thereof, 8i Acquisition&#x2019;s ordinary shares, no par value, (the &#x201c;Shares&#x201d;),
or (ii) reverse Seller 1&#x2019;s and Seller 2&#x2019;s prior exercise of redemption rights as to Shares in connection with the Business
Combination (all such purchased or reversed Shares, the &#x201c;Recycled Shares 1&#x201d; and &#x201c;Recycled Shares 2&#x201d;, respectively).
While Seller 1 and Seller 2 has no obligation to purchase any Shares under the Prepaid Forward Agreement 1 and Prepaid Forward Agreement
2, the aggregate total Recycled Shares 1 and Recycled Shares 2 that may be purchased or reversed under the Prepaid Forward Agreement 1
and Prepaid Forward Agreement 2 shall be no more than &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember_zdunTvhqRqti" title="Number of shares purchased"&gt;1,400,000&lt;/span&gt; shares and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20221108__20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember_zDtb2O9UQyHi" title="Number of shares purchased"&gt;1,125,000&lt;/span&gt; shares, respectively. Seller 1 and Seller 2 have
agreed to hold the Recycled Shares 1 and Recycled Shares 2, for the benefit of (a) 8i Acquisition until the closing of the Business Combination
(the &#x201c;Closing&#x201d;) and (b) the Company after the Closing (each a &#x201c;Counterparty&#x201d;). Seller 1 and Seller 2 also may
not beneficially own greater than &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementOneMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zHPSmS187ile" title="Beneficially ownership percentage"&gt;&lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221109__us-gaap--TypeOfArrangementAxis__custom--PrepaidForwardAgreementTwoMember__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InstitutionalInvestorsMember_zB6YSivLA8I5" title="Beneficially ownership percentage"&gt;9.9&lt;/span&gt;&lt;/span&gt;% of issued and outstanding Shares following the Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
key terms of the forward contracts are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- Sellers can terminate the Transaction no later than
the later of: (a) Third Local Business Day following the Optional Early Termination (&#x201c;OET&#x201d;); (b) the first Payment Date after
the OET Date which shall specify the quantity by which the Number of Shares is to be reduced (such quantity, the &#x201c;Terminated Shares&#x201d;)
Seller shall terminate the Transaction in respect of any Shares sold on or prior to the Maturity Date. The Counterparty is entitled to
an amount from the Seller equal to the number of terminated shares multiplied by the Reset Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;-Seller 1 and Seller 2 are entitled to receive the
Maturity Consideration, an amount equal to the product of: (1) Number of Recycled Shares specified in the Pricing Date Notice, less(b)
the number of Terminated Shares multiplied by (2) USD &lt;span id="xdx_907_eus-gaap--ForwardContractIndexedToEquitySettlementShareFairValuePerShare_iI_c20221109__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ForwardContractsMember_zZbPNqu29Yzc" title="Forward contract, fair value per share"&gt;2.50&lt;/span&gt; (the &#x201c;Maturity Consideration&#x201d;), in cash. The Company can also pay
the Seller 1 and Seller 2 shares based on the Company&#x2019;s average volume weighted average share price (&#x201c;VWAP&#x201d;) of the
Shares over 30 Scheduled Trading Days ending on the Maturity Date. Such settlement consideration or OET is considered to be an embedded
feature (or instrument) with in the Prepaid Forward Transaction 1 and 2.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;- &lt;span style="background-color: white"&gt;The &lt;/span&gt;Prepaid
Forward Transaction 1 and 2 required &lt;span style="background-color: white"&gt;physical settlement by repurchase of remaining of the recycled
shares in exchange for cash and if either the amount to be paid or the settlement date varies based on specified conditions, the earlier
of a) first anniversary of the closing of the transactions between Counterparty and EUDA on November 18, 2022 or b) the date specified
by Seller in a written notice to be delivered at Seller&#x2019;s discretion (not earlier than the day such notice is effective) after the
occurrence of a VWAP Trigger Event, those instruments shall be measured subsequently at the amount of cash that would be paid under the
conditions specified in the contract if settlement occurred at the reporting date, recognizing the resulting change in that amount from
the previous reporting date as interest cost, which we recorded as change in fair value of prepaid forward purchase liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In accordance
with ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, the Company has determined that the prepaid forward contract is a financial
instrument other than a share that represent or are indexed to obligations to repurchase the issuer&#x2019;s equity shares by transferring
assets, referred to herein as the &#x201c;prepaid forward purchase liability&#x201d; on its consolidated balance sheets. The Company initially
measure the prepaid forward purchase liability at fair value and measured subsequently at fair value with changes in fair value recognized
in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of the closing
of the Business Combination, the fair value of the prepaid forward purchase liability was $&lt;span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221109_zaMJj0MtG3f1" title="Prepaid forward purchase liability"&gt;7,409,550&lt;/span&gt; and was recorded on the Company&#x2019;s
consolidated balance sheets. Subsequently, the change of fair value of the prepaid forward purchase liability was amounted to a loss of
$&lt;span id="xdx_902_ecustom--ChangeOfFairValueOfPrepaidForwardPurchaseLiability_c20220101__20221231_zk8mdFAp9Kb" title="Change of fair value of prepaid forward purchase liability"&gt;12,911,503&lt;/span&gt; for the year end December 31, 2022. As of December 31, 2022, the prepaid forward purchase liabilities amounted to $&lt;span id="xdx_90D_ecustom--PrepaidForwardPurchaseLiabilities_iI_c20221231_zHmPZ78KJ7M5" title="Prepaid forward purchase liability"&gt;20,321,053&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:ForwardPurchaseAgreementsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-11-082022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-11-082022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">1125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-11-09_custom_PrepaidForwardAgreementOneMember_srt_MaximumMember_custom_InstitutionalInvestorsMember"
      decimals="INF"
      unitRef="Pure">0.099</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-11-09_custom_PrepaidForwardAgreementTwoMember_srt_MaximumMember_custom_InstitutionalInvestorsMember"
      decimals="INF"
      unitRef="Pure">0.099</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare
      contextRef="AsOf2022-11-09_us-gaap_ForwardContractsMember"
      decimals="INF"
      unitRef="USDPShares">2.50</us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare>
    <EUDA:PrepaidForwardPurchaseLiabilities contextRef="AsOf2022-11-09" decimals="0" unitRef="USD">7409550</EUDA:PrepaidForwardPurchaseLiabilities>
    <EUDA:ChangeOfFairValueOfPrepaidForwardPurchaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12911503</EUDA:ChangeOfFairValueOfPrepaidForwardPurchaseLiability>
    <EUDA:PrepaidForwardPurchaseLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20321053</EUDA:PrepaidForwardPurchaseLiabilities>
    <EUDA:LoanToThirdPartyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_ecustom--LoanToThirdPartyTextBlock_zL285YpqCUo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 12 &#x2013; &lt;span id="xdx_827_ziKYrlXoDPGe"&gt;Loan to third party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 20, 2020, the Company&#x2019;s
subsidiary, UGI has entered into a loan agreement with PT total Prima Indonesia (&#x201c;PT&#x201d;), an unrelated third party. Upon
execution of the loan agreement and supplemental agreement, PT may borrow up to approximately $&lt;span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zz9LM4qIYGt4" title="Loan borrow up amount"&gt;0.7&lt;/span&gt;
million (SGD &lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_uSGD_c20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zpjNTXaMDrtf" title="Loan borrow up amount"&gt;1,000,000&lt;/span&gt;)
from UGI for a period of three years with &lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_c20201119__20201120__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_znZMGL4TKZl4" title="Loan interest rate"&gt;9.00&lt;/span&gt;%
annual interest rate. The loan shall be due and payable, including all disbursed loan amount and accrued interest, on the maturity
date. As of December 31, 2022 and 2021, the Company had provided a total of $&lt;span id="xdx_90F_ecustom--LoanAccumulativelyDisbursed_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zbhSDnXagvBl" title="Loan accumulatively disbursed"&gt;608,683&lt;/span&gt;
(SGD &lt;span id="xdx_905_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zxWWGcujFD3g" title="Loan accumulatively disbursed"&gt;816,000&lt;/span&gt;)
and $&lt;span id="xdx_906_ecustom--LoanAccumulativelyDisbursed_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zgLDgzDCTmG1" title="Loan accumulatively disbursed"&gt;352,959&lt;/span&gt;
(SGD &lt;span id="xdx_903_ecustom--LoanAccumulativelyDisbursed_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zE7WpbPZsArh" title="Loan accumulatively disbursed"&gt;476,000&lt;/span&gt;)
of loan to PT, respectively, and had $&lt;span id="xdx_908_eus-gaap--InterestReceivable_iI_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zTko21MGX8G6" title="Interest receivable"&gt;62,766&lt;/span&gt;
(SGD &lt;span id="xdx_903_eus-gaap--InterestReceivable_iI_uSGD_c20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zroAxy2XF2Y1" title="Interest receivable"&gt;84,144&lt;/span&gt;)
and $&lt;span id="xdx_901_eus-gaap--InterestReceivable_iI_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zptswBR8l66e" title="Interest receivable"&gt;19,003&lt;/span&gt;
(SGD &lt;span id="xdx_901_eus-gaap--InterestReceivable_iI_uSGD_c20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zhGiqvBn7qoa" title="Interest receivable"&gt;25,627&lt;/span&gt;)
of interest receivable balance, respectively. However, the Company determined its unlikely to recover such loan to third party upon
expiration of the loan contract due to PT was no longer in business, therefore, the company had recorded a fully allowance against
and wrote off the remaining balance of loan to third party as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2022 and 2021, the
Company has recognized &lt;span id="xdx_907_eus-gaap--InterestIncomeRelatedParty_dxL_c20220101__20221231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_zrjP4Ex1NwK1" title="Interest income from loan to third party::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1401"&gt;nil&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--InterestIncomeRelatedParty_c20210101__20211231__dei--LegalEntityAxis__custom--PTTotalPrimaIndonesiaMember_z2QUkc6cqAY3" title="Interest income from loan to third party"&gt;19,071&lt;/span&gt; of interest income from loan to third party, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</EUDA:LoanToThirdPartyTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="SGD">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2020-11-192020-11-20_custom_PTTotalPrimaIndonesiaMember"
      decimals="INF"
      unitRef="Pure">0.0900</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <EUDA:LoanAccumulativelyDisbursed
      contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="USD">608683</EUDA:LoanAccumulativelyDisbursed>
    <EUDA:LoanAccumulativelyDisbursed
      contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="SGD">816000</EUDA:LoanAccumulativelyDisbursed>
    <EUDA:LoanAccumulativelyDisbursed
      contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="USD">352959</EUDA:LoanAccumulativelyDisbursed>
    <EUDA:LoanAccumulativelyDisbursed
      contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="SGD">476000</EUDA:LoanAccumulativelyDisbursed>
    <us-gaap:InterestReceivable
      contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="USD">62766</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="AsOf2022-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="SGD">84144</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="USD">19003</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="AsOf2021-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="SGD">25627</us-gaap:InterestReceivable>
    <us-gaap:InterestIncomeRelatedParty
      contextRef="From2021-01-012021-12-31_custom_PTTotalPrimaIndonesiaMember"
      decimals="0"
      unitRef="USD">19071</us-gaap:InterestIncomeRelatedParty>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--ShortTermDebtTextBlock_zh08Du6kRIEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 13 &#x2013; &lt;span id="xdx_82C_zrCFg2wk8roj"&gt;Credit facilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zmF1bzcg9U3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Short-term loans &#x2013; bank and private lender&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on short-term bank loans consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zq36MWtvWq1i" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Bank/Private&lt;br/&gt;
 lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt;
Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;*&lt;span id="xdx_908_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zNb9oHGId5b3" title="Bank/Private lender Name"&gt;United Overseas Bank Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zcPdpLsyMHwe" title="Maturities"&gt;90 days from disbursement&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zCfVBhT5mU4h" title="Interest Rate"&gt;0.25&lt;/span&gt;% plus prime rate of &lt;span id="xdx_90E_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_fKg_____zfTw109SRvOj" title="Interest Rate"&gt;5.25&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zxA309aHY1W" title="Collateral/Guarantee"&gt;Collateral: Accounts receivable &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zU1uJrnqARda" title="Short term loans - bank and private lender"&gt;185,592&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zpWzgzbbh6j3" title="Short term loans - bank and private lender"&gt;184,491&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z4BHA2B8rqh5" title="Bank/Private lender Name"&gt;FS Capital Ptd. Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zI7qFSDU1774" title="Maturities"&gt;Fully repaid in February, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zNuDnn3QNN28" title="Interest Rate"&gt;18.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zvCfKLrWXRyj" title="Collateral/Guarantee"&gt;Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder, and Kent Ridge Health Private Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zQ5MFLMoFAd" title="Short term loans - bank and private lender"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zpYyfAyUGRL8" title="Short term loans - bank and private lender"&gt;20,936&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zMXeUYuTfen1" title="Bank/Private lender Name"&gt;Funding Societies Pte. Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zfXoQB7pA524" title="Maturities"&gt;Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zSQFIVgvja5" title="Interest Rate"&gt;30.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zUwHlHqO7fMh" title="Collateral/Guarantee"&gt;Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zBtuoQvS27d" title="Short term loans - bank and private lender"&gt;18,648&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zhYCBo1e7Gg7" title="Short term loans - bank and private lender"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1445"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zLUz0RfsiKDd" title="Short term loans - bank and private lender"&gt;204,240&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z9IcxqQF0pI4" title="Short term loans - bank and private lender"&gt;205,427&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F06_z6mo09h38t7d" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F11_zGbdAhWmd92k" style="text-align: justify"&gt;On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount"&gt;593,208&lt;/span&gt;
                                                                                                       (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount"&gt;800,000&lt;/span&gt;)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#x2019;s account receivable (see Note 6). The loan bears an average annual interest rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate"&gt;5.50&lt;/span&gt;%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zW3FpakUMLT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zY63Gd0UPNQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Short-term loan &#x2013; third party&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zDPEKbNdLZR1" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zWUelSEUsRz8" title="Bank/Private lender Name"&gt;Koh Wee Sing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_fKg_____zohy9rpeA1yd" title="Maturities"&gt;Due on demand beginning in July 2022&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zdeDx9uPfRl2" title="Interest Rate"&gt;60.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_ztbcHFYM3FFb" title="Collateral/Guarantee"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zxzEPGi05kJ4" title="Short term loans - third parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z5xGRUTk034g" title="Short term loans - third parties"&gt;148,302&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_z1EDzRQXpF0l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Interest expense pertaining to the above loans for
the years ended December 31, 2022 and 2021 amounted to $&lt;span id="xdx_90E_eus-gaap--InterestExpense_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zkRqwaLlo5Lf" title="Interest expense"&gt;122,845&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zvwZUt2myhBh" title="Interest expense"&gt;128,071&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Weighted average interest rate to the above loans
for the years ended December 31, 2022 and 2021 are &lt;span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zjnwdHR3Vu6j" title="Weighted average interest rate"&gt;11.0&lt;/span&gt;% and &lt;span id="xdx_90B_eus-gaap--ShortTermDebtWeightedAverageInterestRate_iI_dp_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z1TcG7S1XL62" title="Weighted average interest rate"&gt;6.3&lt;/span&gt;%, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F02_zkILJEdptxJ7" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F14_zHLspWhHk04" style="text-align: justify"&gt;On December 16, 2022, the Company has signed a loan agreement
                                                                                                       (&#x201c;Agreement&#x201d;) with Kent Ridge Health Pte Ltd (&#x201c;KRHPL&#x201d;), a related party. Pursuant to the Agreement, KRHPL
                                                                                                       agreed to fully remit the loan payment to Koh Wee Sing on behalf of the Company. As a result, such short-term loan- third party was
                                                                                                       transfer to other payable, related parties under KRHPL&#x2019;s balance as of December 31, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zS0Hd9Z016Yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Promissory note&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on promissory note consist of
the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zcPLWGqMCYe7" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zf3uHzslHwm4" title="Bank/Private lender Name"&gt;Kaufaman &amp;amp; Canoles, P. C. (&#x201c;KC&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_fKg_____zw9ZL6sd9fx" title="Maturities"&gt;February 15, 2023&lt;/span&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zU5yjNtaf0Vi" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zeFtooQHWzd" title="Collateral/Guarantee"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zYLH44Kwk1Oj" title="Convertible promissory note"&gt;170,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zIzXFkXVtur3" title="Convertible promissory note"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0E_zpEKxG4NhYhc" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F17_zPRb9fRRhpn6" style="text-align: justify"&gt;This promissory note has a default interest of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate"&gt;15&lt;/span&gt;% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#x201c;the Agreement&#x201d;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note"&gt;100,000&lt;/span&gt; within two days of the dates that the Company&#x2019;s US counsel,
Loeb &amp;amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note"&gt;60,000&lt;/span&gt; within two business days after the date the first amendment to the registration
statement is filed with the SEC.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zDvC8uBoAIGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z6Kq57Fc2mRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible notes &#x2013; third parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on convertible notes consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zIx7neI1HJM5" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zlNna5WB78N5" title="Bank/Private lender Name"&gt;Maxim Group LLC (&#x201c;Maxim&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zfoXWsI7F5v8" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zjkttMFlHCPh" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztXGFtXMJN8f" title="Collateral/Guarantee"&gt;Automatically be converted into the Company&#x2019;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztsqhZq0sHA4" title="Convertible notes payable"&gt;2,113,125&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zf5U7gDmOlBi" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zSsHM3l6l3yl" title="Bank/Private lender Name"&gt;Menora Capital Pte Ltd (&#x201c;Menora&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zIZinwYcTpof" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zk2TFLc8rWAf" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTru3X9M6YHk" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zus0fLgGYue3" title="Convertible notes payable"&gt;87,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z1YSxfG1CkVk" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zopxcbfv9hXh" title="Bank/Private lender Name"&gt;Loeb &amp;amp; Loeb LLP (&#x201c;Loeb&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zroUwCDFpdXb" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTyfqJNfkBX" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zu8WjfcyB14j" title="Collateral/Guarantee"&gt;(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zHTqs3US7m5b" title="Convertible notes payable"&gt;300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zvZ8ZSyjqAda" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1538"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zpagZK7g6tVe" title="Bank/Private lender Name"&gt;Shine Link Limited (&#x201c;Shine Link&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z9U1S8dyCFGj" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zilIXU8l8SIc" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zVslrOjeWenf" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zQgMBnixlro5" title="Convertible notes payable"&gt;119,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zFxmkamWZZld" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z7rF8dRBeDOg" title="Convertible notes"&gt;2,619,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zhuRXnCbNOUk" title="Convertible notes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible notes &#x2013; related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___znbO2pVoMxG3" title="Bank/Private lender Name"&gt;8i Holdings 2 Ptd Ltd (&#x201c;8i Holding&#x201d;)&lt;/span&gt; (1)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPmBWhZaYdel" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVGdVWy5ZHr5" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPN6yhISMwJa" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVz4gtl0mjkl" title="Convertible notes payable"&gt;82,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___ziXyfpdsC1lj" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zjxf3Va2gX8k" title="Bank/Private lender Name"&gt;Meng Dong (James) Tan&lt;/span&gt; (2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z4ACxPfpB3rk" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z8dHohPUY0Ll" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zBDEoEI6pFpb" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z0dyAvH33lId" title="Convertible notes payable"&gt;700,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z36i6145qhS4" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zC1o1ov4Asgj" title="Convertible notes payable"&gt;782,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zDEMXZWVheW4" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F06_z5wkCNalLiU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zCH2TRI7EMM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Meng Dong (James) Tan, the Company&#x2019;s related party who had more than &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name"&gt;10&lt;/span&gt;% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F09_zXTuoVGxiL12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_z3Xa8GI0PEof" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Meng Dong (James) Tan, the Company&#x2019;s related party has more than &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name"&gt;10&lt;/span&gt;% ownership of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zOzsMuA8L2Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined that the embedded conversion
feature from the convertible notes, related parties and third parties qualifies for the scope exception due to the embedded conversion
feature indexed to the Company&#x2019;s stock in accordance with ASC 815-40-15 and meet the equity requirement in accordance with ASC815-40-25.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2022-01-012022-12-31_custom_BankAndPrivateLenderMember">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zmF1bzcg9U3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Short-term loans &#x2013; bank and private lender&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on short-term bank loans consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zq36MWtvWq1i" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Bank/Private&lt;br/&gt;
 lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt;
Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;*&lt;span id="xdx_908_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zNb9oHGId5b3" title="Bank/Private lender Name"&gt;United Overseas Bank Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zcPdpLsyMHwe" title="Maturities"&gt;90 days from disbursement&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zCfVBhT5mU4h" title="Interest Rate"&gt;0.25&lt;/span&gt;% plus prime rate of &lt;span id="xdx_90E_ecustom--ShortTermDebtInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_fKg_____zfTw109SRvOj" title="Interest Rate"&gt;5.25&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zxA309aHY1W" title="Collateral/Guarantee"&gt;Collateral: Accounts receivable &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zU1uJrnqARda" title="Short term loans - bank and private lender"&gt;185,592&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_fKg_____zpWzgzbbh6j3" title="Short term loans - bank and private lender"&gt;184,491&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z4BHA2B8rqh5" title="Bank/Private lender Name"&gt;FS Capital Ptd. Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zI7qFSDU1774" title="Maturities"&gt;Fully repaid in February, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zNuDnn3QNN28" title="Interest Rate"&gt;18.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zvCfKLrWXRyj" title="Collateral/Guarantee"&gt;Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder, and Kent Ridge Health Private Limited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zQ5MFLMoFAd" title="Short term loans - bank and private lender"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FSCapitalPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zpYyfAyUGRL8" title="Short term loans - bank and private lender"&gt;20,936&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zMXeUYuTfen1" title="Bank/Private lender Name"&gt;Funding Societies Pte. Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_905_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zfXoQB7pA524" title="Maturities"&gt;Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zSQFIVgvja5" title="Interest Rate"&gt;30.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zUwHlHqO7fMh" title="Collateral/Guarantee"&gt;Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zBtuoQvS27d" title="Short term loans - bank and private lender"&gt;18,648&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--FundingSocietiesPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zhYCBo1e7Gg7" title="Short term loans - bank and private lender"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1445"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_zLUz0RfsiKDd" title="Short term loans - bank and private lender"&gt;204,240&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShortTermBankLoansAndNotesPayable_iI_pp0p0_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z9IcxqQF0pI4" title="Short term loans - bank and private lender"&gt;205,427&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F06_z6mo09h38t7d" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F11_zGbdAhWmd92k" style="text-align: justify"&gt;On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh" title="Loan borrow up amount"&gt;593,208&lt;/span&gt;
                                                                                                       (SGD &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq" title="Loan borrow up amount"&gt;800,000&lt;/span&gt;)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#x2019;s account receivable (see Note 6). The loan bears an average annual interest rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76" title="Loan interest rate"&gt;5.50&lt;/span&gt;%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermDebtLender
      contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      id="Fact001409">United Overseas Bank Limited</us-gaap:ShortTermDebtLender>
    <us-gaap:ShortTermDebtTerms
      contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      id="Fact001411">90 days from disbursement</us-gaap:ShortTermDebtTerms>
    <EUDA:ShortTermDebtInterestRate
      contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">0.0025</EUDA:ShortTermDebtInterestRate>
    <EUDA:ShortTermDebtInterestRate
      contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember_us-gaap_PrimeRateMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Pure">0.0525</EUDA:ShortTermDebtInterestRate>
    <us-gaap:DebtInstrumentCollateral
      contextRef="From2022-01-012022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      id="Fact001417">Collateral: Accounts receivable</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">185592</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2021-12-31_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">184491</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">FS Capital Ptd. Ltd.</us-gaap:ShortTermDebtLender>
    <us-gaap:ShortTermDebtTerms contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">Fully repaid in February, 2022</us-gaap:ShortTermDebtTerms>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember"
      decimals="INF"
      unitRef="Pure">0.180</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember">Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder, and Kent Ridge Health Private Limited</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2021-12-31_custom_FSCapitalPtdLtdMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="USD">20936</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">Funding Societies Pte. Ltd</us-gaap:ShortTermDebtLender>
    <us-gaap:ShortTermDebtTerms contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">Due monthly from April 2022 to March 2023 (Extended to July 31, 2024)</us-gaap:ShortTermDebtTerms>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember"
      decimals="INF"
      unitRef="Pure">0.300</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember">Guaranteed by Kelvin Chen Weiwen, the Company&#x2019;s CEO and shareholder</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2022-12-31_custom_FundingSocietiesPteLtdMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="USD">18648</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2022-12-31_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="USD">204240</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2021-12-31_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="USD">205427</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="USD">593208</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="0"
      unitRef="SGD">800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2019-08-202019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember"
      decimals="INF"
      unitRef="Pure">0.0550</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2022-01-012022-12-31_custom_ThirdPartiesMember">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zY63Gd0UPNQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Short-term loan &#x2013; third party&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zDPEKbNdLZR1" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zWUelSEUsRz8" title="Bank/Private lender Name"&gt;Koh Wee Sing&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShortTermDebtTerms_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_fKg_____zohy9rpeA1yd" title="Maturities"&gt;Due on demand beginning in July 2022&lt;/span&gt;*&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zdeDx9uPfRl2" title="Interest Rate"&gt;60.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_ztbcHFYM3FFb" title="Collateral/Guarantee"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_90C_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_zxzEPGi05kJ4" title="Short term loans - third parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KohWeeSingMember__us-gaap--ShortTermDebtTypeAxis__custom--ThirdPartiesMember_z5xGRUTk034g" title="Short term loans - third parties"&gt;148,302&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">Koh Wee Sing</us-gaap:ShortTermDebtLender>
    <us-gaap:ShortTermDebtTerms
      contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember"
      id="Fact001462">Due on demand beginning in July 2022</us-gaap:ShortTermDebtTerms>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.600</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2021-12-31_custom_KohWeeSingMember_custom_ThirdPartiesMember"
      decimals="0"
      unitRef="USD">148302</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_custom_ThirdPartiesMember"
      decimals="0"
      unitRef="USD">122845</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31_custom_ThirdPartiesMember"
      decimals="0"
      unitRef="USD">128071</us-gaap:InterestExpense>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="AsOf2022-12-31_custom_ThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.110</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="AsOf2021-12-31_custom_ThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.063</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2022-01-012022-12-31_custom_PromissoryNoteMember">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zS0Hd9Z016Yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Promissory note&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on promissory note consist of
the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zcPLWGqMCYe7" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zf3uHzslHwm4" title="Bank/Private lender Name"&gt;Kaufaman &amp;amp; Canoles, P. C. (&#x201c;KC&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_fKg_____zw9ZL6sd9fx" title="Maturities"&gt;February 15, 2023&lt;/span&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_pid_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zU5yjNtaf0Vi" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zeFtooQHWzd" title="Collateral/Guarantee"&gt;None&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zYLH44Kwk1Oj" title="Convertible promissory note"&gt;170,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zIzXFkXVtur3" title="Convertible promissory note"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0E_zpEKxG4NhYhc" style="width: 35pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td id="xdx_F17_zPRb9fRRhpn6" style="text-align: justify"&gt;This promissory note has a default interest of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8" title="Interest Rate"&gt;15&lt;/span&gt;% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#x201c;the Agreement&#x201d;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll" title="Convertible promissory note"&gt;100,000&lt;/span&gt; within two days of the dates that the Company&#x2019;s US counsel,
Loeb &amp;amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka" title="Convertible promissory note"&gt;60,000&lt;/span&gt; within two business days after the date the first amendment to the registration
statement is filed with the SEC.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">Kaufaman &amp; Canoles, P. C. (&#x201c;KC&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember"
      id="Fact001485">2023-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember"
      decimals="0"
      unitRef="USD">170000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2023-02-142023-02-15_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31_custom_SettlementAgreementMember_custom_KaufamanAndCanolesPcKcMember_custom_PromissoryNoteMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31_custom_PromissoryNoteMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2022-01-012022-12-31_custom_ConvertibleNotesThirdPartiesMember">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShortTermDebtTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z6Kq57Fc2mRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible notes &#x2013; third parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Outstanding balances on convertible notes consist
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zIx7neI1HJM5" style="display: none"&gt;Schedule
of short-term loans&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zlNna5WB78N5" title="Bank/Private lender Name"&gt;Maxim Group LLC (&#x201c;Maxim&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zfoXWsI7F5v8" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zjkttMFlHCPh" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztXGFtXMJN8f" title="Collateral/Guarantee"&gt;Automatically be converted into the Company&#x2019;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_ztsqhZq0sHA4" title="Convertible notes payable"&gt;2,113,125&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MaximGroupLlcMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zf5U7gDmOlBi" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zSsHM3l6l3yl" title="Bank/Private lender Name"&gt;Menora Capital Pte Ltd (&#x201c;Menora&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zIZinwYcTpof" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zk2TFLc8rWAf" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTru3X9M6YHk" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zus0fLgGYue3" title="Convertible notes payable"&gt;87,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MenoraCapitalPteLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z1YSxfG1CkVk" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1526"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zopxcbfv9hXh" title="Bank/Private lender Name"&gt;Loeb &amp;amp; Loeb LLP (&#x201c;Loeb&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zroUwCDFpdXb" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zTyfqJNfkBX" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zu8WjfcyB14j" title="Collateral/Guarantee"&gt;(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zHTqs3US7m5b" title="Convertible notes payable"&gt;300,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--LoebAndLoebLlpMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zvZ8ZSyjqAda" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1538"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zpagZK7g6tVe" title="Bank/Private lender Name"&gt;Shine Link Limited (&#x201c;Shine Link&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z9U1S8dyCFGj" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zilIXU8l8SIc" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zVslrOjeWenf" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zQgMBnixlro5" title="Convertible notes payable"&gt;119,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--ShineLinkLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zFxmkamWZZld" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_z7rF8dRBeDOg" title="Convertible notes"&gt;2,619,625&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesThirdPartiesMember_zhuRXnCbNOUk" title="Convertible notes"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Convertible notes &#x2013; related parties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Lender Name&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Maturities&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Interest Rate&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Collateral/&lt;br/&gt; Guarantee&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___znbO2pVoMxG3" title="Bank/Private lender Name"&gt;8i Holdings 2 Ptd Ltd (&#x201c;8i Holding&#x201d;)&lt;/span&gt; (1)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPmBWhZaYdel" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVGdVWy5ZHr5" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 26%; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zPN6yhISMwJa" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___zVz4gtl0mjkl" title="Convertible notes payable"&gt;82,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--EightIHoldingsTwoPtdLtdMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMSk___ziXyfpdsC1lj" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_eus-gaap--ShortTermDebtLender_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zjxf3Va2gX8k" title="Bank/Private lender Name"&gt;Meng Dong (James) Tan&lt;/span&gt; (2)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z4ACxPfpB3rk" title="Maturities"&gt;November 17, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z8dHohPUY0Ll" title="Interest Rate"&gt;0.0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCollateral_c20220101__20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___zBDEoEI6pFpb" title="Collateral/Guarantee"&gt;Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z0dyAvH33lId" title="Convertible notes payable"&gt;700,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_fMik___z36i6145qhS4" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zC1o1ov4Asgj" title="Convertible notes payable"&gt;782,600&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesRelatedPartiesMember_zDEMXZWVheW4" title="Convertible notes payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F06_z5wkCNalLiU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zCH2TRI7EMM" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Meng Dong (James) Tan, the Company&#x2019;s related party who had more than &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g" title="Bank/Private lender Name"&gt;10&lt;/span&gt;% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F09_zXTuoVGxiL12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_z3Xa8GI0PEof" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Meng Dong (James) Tan, the Company&#x2019;s related party has more than &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5" title="Bank/Private lender Name"&gt;10&lt;/span&gt;% ownership of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">Maxim Group LLC (&#x201c;Maxim&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember">Automatically be converted into the Company&#x2019;s ordinary shares at $5.00 per share if the balance is not being repaid by the maturity date</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_MaximGroupLlcMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="0"
      unitRef="USD">2113125</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">Menora Capital Pte Ltd (&#x201c;Menora&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember">Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_MenoraCapitalPteLtdMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="0"
      unitRef="USD">87500</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">Loeb &amp; Loeb LLP (&#x201c;Loeb&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember">(1) 60,000 of the Company ordinary share has been issued to Loeb, which is subject to be returned and cancellation if the Company repaid the full or part of the convertible note, and (2) Loeb has the right to sell the ordinary shares in public market and the earning from the sales should be offset the remaining balance of the convertible note</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_LoebAndLoebLlpMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ShortTermDebtLender contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">Shine Link Limited (&#x201c;Shine Link&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral contextRef="From2022-01-012022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember">Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_ShineLinkLimitedMember_custom_ConvertibleNotesThirdPartiesMember"
      decimals="0"
      unitRef="USD">119000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_ConvertibleNotesThirdPartiesMember"
      decimals="0"
      unitRef="USD">2619625</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ShortTermDebtLender
      contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001556">8i Holdings 2 Ptd Ltd (&#x201c;8i Holding&#x201d;)</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001558">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      decimals="INF"
      id="Fact001560"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral
      contextRef="From2022-01-012022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001562">Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_EightIHoldingsTwoPtdLtdMember_custom_ConvertibleNotesRelatedPartiesMember"
      decimals="0"
      id="Fact001564"
      unitRef="USD">82600</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ShortTermDebtLender
      contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001568">Meng Dong (James) Tan</us-gaap:ShortTermDebtLender>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001570">2023-11-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      decimals="INF"
      id="Fact001572"
      unitRef="Pure">0.000</us-gaap:ShortTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentCollateral
      contextRef="From2022-01-012022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      id="Fact001574">Right to convert into the Company&#x2019;s ordinary shares equal to the unpaid Principal Amount as of the Maturity Date divided by the five day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the maturity date if the balance is not being repaid by the maturity date</us-gaap:DebtInstrumentCollateral>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_ConvertibleNotesRelatedPartiesMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">700000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_custom_ConvertibleNotesRelatedPartiesMember"
      decimals="0"
      unitRef="USD">782600</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_MengDongJamesTanMember_custom_EightIHoldingsTwoPtdLtdMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z9MDkjJEGRy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 14 &#x2013; &lt;span id="xdx_828_z9cl25epj90f"&gt;Other payables and accrued liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBuhOgPURNs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zftKXCe0kcd4" style="display: none"&gt;Schedule of other
payables and accrued liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zSgZCR3P792e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zIpxn6JlxMck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zpQPLdKmIVU1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F47_z8HVuhmkRhoa" style="width: 60%; text-align: left"&gt;Accrued expenses (i)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;671,743&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;129,029&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maAPAOAzzja_zI4xHyEQc5We" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued payroll&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;730,037&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;244,591&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAOAzzja_zafAiA1CKgLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F49_zN5hy8VB081c" style="text-align: left"&gt;Accrued interests (ii)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;157,032&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;67,448&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zLoJEYDz1RH9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,003&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,529&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzzja_z6d9ObFAejjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other payables and accrued liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,592,815&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;488,597&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F05_zU2DIwdDueu"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued expenses&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_z4IbBhnBkeRa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F0B_z6utxZKjB9Nj"&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued interests&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zV7yk6cQZZJg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance of accrued interests represented the balance of interest payable from short-term loan &#x2013; bank, private lender, and third parties (See Note 13).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zKZSEqLD8882" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBuhOgPURNs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zftKXCe0kcd4" style="display: none"&gt;Schedule of other
payables and accrued liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zSgZCR3P792e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zIpxn6JlxMck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zpQPLdKmIVU1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F47_z8HVuhmkRhoa" style="width: 60%; text-align: left"&gt;Accrued expenses (i)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;671,743&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;129,029&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maAPAOAzzja_zI4xHyEQc5We" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued payroll&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;730,037&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;244,591&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_pp0p0_maAPAOAzzja_zafAiA1CKgLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F49_zN5hy8VB081c" style="text-align: left"&gt;Accrued interests (ii)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;157,032&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;67,448&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzzja_zLoJEYDz1RH9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,003&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,529&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzzja_z6d9ObFAejjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other payables and accrued liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,592,815&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;488,597&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F05_zU2DIwdDueu"&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued expenses&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_z4IbBhnBkeRa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F0B_z6utxZKjB9Nj"&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued interests&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zV7yk6cQZZJg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance of accrued interests represented the balance of interest payable from short-term loan &#x2013; bank, private lender, and third parties (See Note 13).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001594"
      unitRef="USD">671743</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001595"
      unitRef="USD">129029</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">730037</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">244591</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001600"
      unitRef="USD">157032</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001601"
      unitRef="USD">67448</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">34003</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">47529</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1592815</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">488597</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zP6LmKYQgF4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Note 15 &#x2013; &lt;span id="xdx_828_zHj4nySH6Z16"&gt;Related
party balances and transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Related party balances&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfRelatedPartyBalancesTableTextBlock_zPZ1uaGCMUMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zfRWSr5yCTk6" style="display: none"&gt;Schedule of related
party balances&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other receivables &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_ztoJKWrxBA42" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zyTjiRvJ4dfh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHillCapitalPteLtdMember_z0mfXxXciPC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;KR Hill Capital Pte Ltd&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;239&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;237&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeMedicalPtdLtdMember_zAq8s75D8qZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Medical Ptd Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;245&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zHO23HkMDnR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;UG Digital Sdn Bhd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;UGD, subsidiary of the Company owned 40% of this company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;284,673&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanicLimitedMember_zC0mw7zyTSR8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Janic Limited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;724&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZukihealthSDNMember_ziAJ7HyPFp21" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Zukihealth SDN&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Kelvin Chen, Chief Executive Office (&#x201c;CEO&#x201d;) and shareholder of the Company, is the shareholder of this entity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,173&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JenniferGohMember_ziC0ykyOqEp5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jennifer Goh&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;President, operation manager, and shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Employee advance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,527&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FrescoInvestmentPteLtdMember_zq7QNokGLm3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Fresco Investment Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Fan Know Hin, an immediate family member of a shareholder of the Company, is the shareholder of this entity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Advance due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z7fbUupTuyb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Cadence Health Pte Ltd&lt;span id="xdx_F44_zQSR0Ta8OmEk"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;266,653&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1637"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DueFromOtherRelatedParties_iI_zuvDNg31UKsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;267,863&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;297,621&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_zIA3J1Gf4zx7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Other receivables -  related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;267,863&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;297,621&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F09_zP8tNp0ijJTb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F15_zgC4CpQgx3s8" style="text-align: justify"&gt;As of date of &lt;span style="background-color: white"&gt;the issuance of these financial statements&lt;/span&gt;,
this receivable has been repaid by the related party.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible notes &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Please see Note 13 for details.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Account payable &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zBrRVkpdoTJ6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zDQz9HW8SBy2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z0mCq6DLSO6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee performed for the employee patients of the Company&#x2019;s corporate customers&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,459,411&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zvpsHUzGFawi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Account
payable, related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee performed for the employee patients of the Company&#x2019;s corporate customers&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,459,411&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other payables &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zip7jWxR6Se2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zhtnBhies9n5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CheeYinMehMember_zz7vcouE5aP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Chee Yin Meh&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;Shareholder of Scotgold Holding Ltd which is the shareholder of the Company&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;122,739&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;34,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamieFanWeiZhiMember_z9QK4EFAzbzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jamie Fan Wei Zhi&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;An immediate family member of a shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company, and Guarantor fee&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,783&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinChenMember_zBpY8n1QudJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kelvin Chen&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;CEO and shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;589,681&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;295,776&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeHealthPteLtdMember_zLHx7qXv6Q8d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Health Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;696,508&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;121,129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zfpOR0lwSdz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Pacific Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20,303&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33,483&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WatermarkDevelopmentsLtdMember_zfv4OeX9Bfjc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Watermark Developments Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;55,945&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilkeServicesLtdMember_zNA9ZSroyVse" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F48_zmQu2DhV61qj" style="vertical-align: top; text-align: left"&gt;Wilke Services Ltd (&#x201c;Wilke&#x201d;) (1)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Investment payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,746,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MountLockeLimitedMember_zKIL5ddMHgag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Mount Locke Limited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,753&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1674"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zX7SUmfS20E6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;UG Digital Sdn Bhd&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;UGD, subsidiary of the Company owned 40% of this company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,016&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1677"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_zIe3sA7HREPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,521,945&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,272,311&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_ztc2s4OuxTI" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Other payables &#x2013; related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,521,945&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,272,311&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zxZa2MGh7q3l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zm2d6c2NZKWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zpFPxEoFU2E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zToPN3CoiZAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Related party transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zCapYiqAPdR9" style="display: none"&gt;Schedule of related
party transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Relationship&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zurTmBRiKc72" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zpcv2OHuWiq5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zl5RS8mBhFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; padding-bottom: 1.5pt; width: 20%; text-align: left"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 24%; text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 20%; text-align: center"&gt;Sales of swab test, and other medical related product&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromRelatedParties_zwIhRiOq4kfb" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Revenue from related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Purchase from related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_ze3CZo48Hep9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zNusAPiH0Pig" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zNFfncj0E74i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Medical service fee provided for the third party medical service revenue&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,349,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zY3fPo9wn83k" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Purchase
    from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee provided for the third party medical service revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;491,499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,349,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Rental expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Related Party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z3fkoprXpF84" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zOyZQ4ETTLLk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_ztsBbbMgSJ85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kent Ridge Pacific Pte Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office rental&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;47,954&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;143,589&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zgzY3mePmvcj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"&gt;Rental Expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Office rental&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;47,954&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;143,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A3_zQj6Och3N0Za" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_ecustom--ScheduleOfRelatedPartyBalancesTableTextBlock_zPZ1uaGCMUMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zfRWSr5yCTk6" style="display: none"&gt;Schedule of related
party balances&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other receivables &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_ztoJKWrxBA42" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31,&lt;br/&gt;
 2022&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zyTjiRvJ4dfh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt;
December 31,&lt;br/&gt;
 2021&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KRHillCapitalPteLtdMember_z0mfXxXciPC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;KR Hill Capital Pte Ltd&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;239&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;237&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeMedicalPtdLtdMember_zAq8s75D8qZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Medical Ptd Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;247&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;245&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zHO23HkMDnR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;UG Digital Sdn Bhd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;UGD, subsidiary of the Company owned 40% of this company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;284,673&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanicLimitedMember_zC0mw7zyTSR8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Janic Limited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance, due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;724&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZukihealthSDNMember_ziAJ7HyPFp21" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Zukihealth SDN&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Kelvin Chen, Chief Executive Office (&#x201c;CEO&#x201d;) and shareholder of the Company, is the shareholder of this entity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Related party advance due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,173&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JenniferGohMember_ziC0ykyOqEp5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jennifer Goh&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;President, operation manager, and shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Employee advance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,527&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FrescoInvestmentPteLtdMember_zq7QNokGLm3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Fresco Investment Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Fan Know Hin, an immediate family member of a shareholder of the Company, is the shareholder of this entity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Advance due on demand&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DueFromOtherRelatedParties_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z7fbUupTuyb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Cadence Health Pte Ltd&lt;span id="xdx_F44_zQSR0Ta8OmEk"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;266,653&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1637"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DueFromOtherRelatedParties_iI_zuvDNg31UKsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;267,863&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;297,621&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromOtherRelatedParties_iI_zIA3J1Gf4zx7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Other receivables -  related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;267,863&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;297,621&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F09_zP8tNp0ijJTb" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F15_zgC4CpQgx3s8" style="text-align: justify"&gt;As of date of &lt;span style="background-color: white"&gt;the issuance of these financial statements&lt;/span&gt;,
this receivable has been repaid by the related party.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible notes &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Please see Note 13 for details.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Account payable &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zBrRVkpdoTJ6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zDQz9HW8SBy2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_z0mCq6DLSO6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee performed for the employee patients of the Company&#x2019;s corporate customers&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,459,411&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zvpsHUzGFawi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt"&gt;Account
payable, related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee performed for the employee patients of the Company&#x2019;s corporate customers&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,459,411&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other payables &#x2013; related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zip7jWxR6Se2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zhtnBhies9n5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of&lt;/p&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CheeYinMehMember_zz7vcouE5aP2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Chee Yin Meh&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;Shareholder of Scotgold Holding Ltd which is the shareholder of the Company&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;122,739&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;34,512&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JamieFanWeiZhiMember_z9QK4EFAzbzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Jamie Fan Wei Zhi&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;An immediate family member of a shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company, and Guarantor fee&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,783&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KelvinChenMember_zBpY8n1QudJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kelvin Chen&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;CEO and shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;589,681&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;295,776&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgeHealthPteLtdMember_zLHx7qXv6Q8d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Health Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;696,508&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;121,129&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zfpOR0lwSdz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Kent Ridge Pacific Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20,303&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33,483&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WatermarkDevelopmentsLtdMember_zfv4OeX9Bfjc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Watermark Developments Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;55,945&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WilkeServicesLtdMember_zNA9ZSroyVse" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F48_zmQu2DhV61qj" style="vertical-align: top; text-align: left"&gt;Wilke Services Ltd (&#x201c;Wilke&#x201d;) (1)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Investment payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,746,628&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MountLockeLimitedMember_zKIL5ddMHgag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Mount Locke Limited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholder of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,753&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1674"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UGDigitalSdnBhdMember_zX7SUmfS20E6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;UG Digital Sdn Bhd&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;UGD, subsidiary of the Company owned 40% of this company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Operating expense paid on behalf of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,016&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1677"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_zIe3sA7HREPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,521,945&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,272,311&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DueToOtherRelatedPartiesCurrentAndNoncurrent_iI_ztc2s4OuxTI" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Other payables &#x2013; related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,521,945&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,272,311&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0D_zxZa2MGh7q3l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zm2d6c2NZKWg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_KRHillCapitalPteLtdMember"
      decimals="0"
      unitRef="USD">239</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_KRHillCapitalPteLtdMember"
      decimals="0"
      unitRef="USD">237</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_KentRidgeMedicalPtdLtdMember"
      decimals="0"
      unitRef="USD">247</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_KentRidgeMedicalPtdLtdMember"
      decimals="0"
      unitRef="USD">245</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_UGDigitalSdnBhdMember"
      decimals="0"
      unitRef="USD">284673</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_JanicLimitedMember"
      decimals="0"
      unitRef="USD">724</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_JanicLimitedMember"
      decimals="0"
      unitRef="USD">720</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_ZukihealthSDNMember"
      decimals="0"
      unitRef="USD">3173</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_JenniferGohMember"
      decimals="0"
      unitRef="USD">8527</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2021-12-31_custom_FrescoInvestmentPteLtdMember"
      decimals="0"
      unitRef="USD">46</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties
      contextRef="AsOf2022-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      id="Fact001636"
      unitRef="USD">266653</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">267863</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">297621</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">267863</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">297621</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">2459411</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">2459411</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_CheeYinMehMember"
      decimals="0"
      unitRef="USD">122739</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CheeYinMehMember"
      decimals="0"
      unitRef="USD">34512</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_JamieFanWeiZhiMember"
      decimals="0"
      unitRef="USD">40783</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_KelvinChenMember"
      decimals="0"
      unitRef="USD">589681</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_KelvinChenMember"
      decimals="0"
      unitRef="USD">295776</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_KentRidgeHealthPteLtdMember"
      decimals="0"
      unitRef="USD">696508</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_KentRidgeHealthPteLtdMember"
      decimals="0"
      unitRef="USD">121129</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">20303</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">33483</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_WatermarkDevelopmentsLtdMember"
      decimals="0"
      unitRef="USD">55945</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_WilkeServicesLtdMember"
      decimals="0"
      id="Fact001671"
      unitRef="USD">2746628</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_MountLockeLimitedMember"
      decimals="0"
      unitRef="USD">3753</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_UGDigitalSdnBhdMember"
      decimals="0"
      unitRef="USD">33016</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1521945</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3272311</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1521945</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3272311</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zToPN3CoiZAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Related party transactions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zCapYiqAPdR9" style="display: none"&gt;Schedule of related
party transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue from related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Relationship&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zurTmBRiKc72" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zpcv2OHuWiq5" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;br/&gt;
 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zl5RS8mBhFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; padding-bottom: 1.5pt; width: 20%; text-align: left"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 24%; text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 20%; text-align: center"&gt;Sales of swab test, and other medical related product&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromRelatedParties_zwIhRiOq4kfb" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Revenue from related parties&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;135&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,640&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Purchase from related parties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Name of Related Party&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_ze3CZo48Hep9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zNusAPiH0Pig" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zNFfncj0E74i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Cadence Health Pte Ltd&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Medical service fee provided for the third party medical service revenue&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,499&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,349,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--PurchaseFromRelatedParties_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CadenceHealthPteLtdMember_zY3fPo9wn83k" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Purchase
    from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Medical service fee provided for the third party medical service revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;491,499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,349,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Rental expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Related Party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z3fkoprXpF84" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zOyZQ4ETTLLk" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_ztsBbbMgSJ85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 20%; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kent Ridge Pacific Pte Ltd&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office rental&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;47,954&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;143,589&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PaymentsForRent_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KentRidgePacificPteLtdMember_zgzY3mePmvcj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: bottom; text-align: left; padding-bottom: 2.5pt"&gt;Rental Expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Shareholders of this entity also are the shareholders of the Company&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;Office rental&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;47,954&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;143,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">135</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">4640</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">135</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4640</us-gaap:RevenueFromRelatedParties>
    <EUDA:PurchaseFromRelatedParties
      contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">491499</EUDA:PurchaseFromRelatedParties>
    <EUDA:PurchaseFromRelatedParties
      contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">2349702</EUDA:PurchaseFromRelatedParties>
    <EUDA:PurchaseFromRelatedParties
      contextRef="From2022-01-012022-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">491499</EUDA:PurchaseFromRelatedParties>
    <EUDA:PurchaseFromRelatedParties
      contextRef="From2021-01-012021-12-31_custom_CadenceHealthPteLtdMember"
      decimals="0"
      unitRef="USD">2349702</EUDA:PurchaseFromRelatedParties>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">47954</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">143589</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">47954</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2021-01-012021-12-31_custom_KentRidgePacificPteLtdMember"
      decimals="0"
      unitRef="USD">143589</us-gaap:PaymentsForRent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfznblAnfTG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 16 &#x2013; &lt;span id="xdx_82E_ziuigU50LnRe"&gt;Shareholders&#x2019; equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Capital Contribution&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 20, 2022, the Company received capital
of $&lt;span id="xdx_908_eus-gaap--Capital_iI_c20220920__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_ztVJWgixa4m3" title="Capital contributions"&gt;600,000&lt;/span&gt; from an investor for the issuance in 8i acquisition&#x2019;s ordinary shares. Such deposit is refundable if the business combination
will not be completed by November 30, 2022. Initially, the Company recognized the subscribed shares deposit liability in accordance with
ASC 480, &#x201c;Distinguishing Liabilities from Equity&#x201d; on inception. On November 17, 2022, Upon the closing of the Business Combination
with 8i acquisition, the Company issued &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zuIjvMLiguE" title="Common stock, shares authorized, unlimited"&gt;120,000&lt;/span&gt; ordinary shares to this investor and transferred such the subscribed shares deposit liability
into equity as capital contribution.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Forgiveness of debt by a related party&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 31, 2022, the Company and Wilke entered into
a deed of release of debt (&#x201c;Deed&#x201d;), pursuant to the Deed, upon the closing of the Business Combination, Wilke agrees to release
and discharge the Company from the Obligation to repay to Wilke of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_c20220330__20220331_zJzlKLPZyKt1" title="Forgiveness of debt by a related party"&gt;2,763,018&lt;/span&gt;. As Wilke&#x2019;s is a shareholder of the
Company, such debt forgiveness were treated as an addition to the Company&#x2019;s capital during the year ended December
31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Ordinary shares&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is authorized to issue unlimited ordinary
shares of &lt;span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_do_c20221231_zaCuw9jMoO18" title="Ordinary shares, no par value"&gt;no&lt;/span&gt; par value. Holders of the Company&#x2019;s ordinary shares are entitled to one vote for each ordinary share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;-&lt;i&gt;Issuance of ordinary shares to EHL&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 25, 2022, the Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220724__20220725_zGWtm18XmmZ7" title="Stock issued during period"&gt;4,626,667&lt;/span&gt; ordinary
shares (&lt;span id="xdx_909_ecustom--OrdinaryShareBeforeReverseRecapitalization_iI_c20220725_zlZ74xAunDWi" title="Ordinary share before reverse recapitalization"&gt;500,000&lt;/span&gt; ordinary share before reverse recapitalization) for total consideration of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220724__20220725_zby4WkGXyx61" title="Total consideration"&gt;500,000&lt;/span&gt; to the shareholder of EHL.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The shares and corresponding capital amounts and all
per share data related to EHL&#x2019;s outstanding ordinary shares prior to the Reverse Recapitalization have been retroactively adjusted
using the &lt;span style="background-color: white"&gt;Exchange Ratio&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;-Issuance of ordinary shares upon the reverse recapitalization
(See Note 4)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 17, 2022, upon the consummation of the
Business Combination, the Company issued an aggregate total of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EightIHoldingsTwoPtdLtdMember_zErY58aPpDSk"&gt;6,191,770&lt;/span&gt; ordinary shares to 8i and various service provider.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_z80GmA1oLSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table presents the number of the Company&#x2019;s ordinary shares issued upon the Reverse Recapitalization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zf6K3XnLVwLg"&gt;Schedule
of reverse recapitalization&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221116__20221117_zgcRg6Xenr1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_zzG2plFquwuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;8i ordinary shares outstanding prior to Reverse Recapitalization&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;11,073,500&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--RedemptionOfOrdinaryShares_zxMwMp166mZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less: redemption of 8i ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,033,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConversionOfStockSharesConverted1_zHBwDEqARuZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion of 8i rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;891,725&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zcAJmygmIXLj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares issued to service providers&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;260,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_zLFaxoKqb1O" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares issued upon the Reverse Recapitalization&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,191,770&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zzq2uO8DNXl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In connection with the reverse
recapitalization, the Company has assumed &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zDVV5lWDMxkl" title="Warrants outstanding"&gt;8,917,250&lt;/span&gt; Warrants outstanding, which consisted of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zFgO5YE9Cw4c" title="Warrants outstanding"&gt;8,625,000&lt;/span&gt; Public Warrants and &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zOFl2bZJ3ty7" title="Warrants outstanding"&gt;292,250&lt;/span&gt; Private
Warrants. Both of the Public Warrants and private warrant met the criteria for equity classification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Warrants became exercisable
on the later of (a) the completion of the reverse recapitalization or (b) 12 months from the closing of the initial public offering (&#x201c;IPO&#x201d;).
The warrants will expire five years after the completion of a reverse recapitalization or earlier upon redemption or liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022,
the Company had &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_z9YrzymsPfo1" title="Warrants outstanding"&gt;8,625,000&lt;/span&gt; Public Warrants outstanding and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--PrivateWarrantMember_zFQZvRHccI8k" title="Warrants outstanding"&gt;292,250&lt;/span&gt; Private Warrants outstanding. Each whole Public Warrant and Private
Warrant entitles the registered holder to purchase one-half share of the Company&#x2019;s ordinary share at a price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zs3TtM99Kn47" title="Warrant to purchase ordinary share, price per share"&gt;11.50&lt;/span&gt; per share,
subject to the following conditions discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company may redeem the Public Warrants and Private Warrants in whole and not in part, at a price of $&lt;span id="xdx_909_ecustom--WarrantsRedemptionPrice_c20220101__20221231_zaneHSRPkiYh" title="Warrants redemption price"&gt;0.01&lt;/span&gt; per warrant:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#x25cf; at any time while
the warrants are exercisable and prior to their expiration,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#x25cf; upon not less than
30 days&#x2019; prior written notice of redemption to each warrant holder,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#x25cf; if, and only if,
the reported last sale price of the ordinary shares equals or exceeds $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20221231_zLYx9bInE134" title="Sale price of the ordinary shares"&gt;16.50&lt;/span&gt; per share (as adjusted for share splits, share dividends,
reorganizations and recapitalizations), for any 20 trading days within a 30 trading days period ending on the third trading business day
prior to the notice of redemption to warrant holders, and,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#x25cf; if, there is a current
registration statement in effect with respect to the Ordinary Shares underlying the Warrants for each day in the 30-day trading period
and continuing each day thereafter until the Redemption Date or the cashless exercise of the Warrants is exempt from the registration
requirements under the Securities Act of 1933, as amended (the &#x201c;Act&#x201d;)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;If the Company calls the
warrants for redemption as described above, management will have the option to require all holders that wish to exercise the warrants
to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. The exercise price and number of ordinary shares issuable
upon exercise of the warrants may be adjusted for splits, dividends, recapitalizations and other similar events. Additionally, in no event
will the Company be required to net cash settle the warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The only difference between
Public Warrants and Private Warrants is that the Private Warrants will not be transferable, assignable or salable until after the completion
of reverse recapitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGUjZC76KfO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of warrants activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zzr0MdKF5Uth" style="display: none"&gt;Schedule
of warrant activities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ordinary Shares Issuable&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k4YsaJj09j" style="text-align: right" title="Warrants Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zle586Mp5ZOd" style="display: none; text-align: right" title="Ordinary Shares Issuable, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuI9vnNPvPp8" style="text-align: right" title="Weighted Average Exercise Price, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2tEcJVkBChj" style="width: 14%; text-align: right" title="Warrants Outstanding, Granted"&gt;8,917,250&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk9jia2wAIug" style="width: 14%; text-align: right" title="Ordinary Shares Issuable, Granted"&gt;4,458,625&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ8n0xDs4CJ7" style="width: 14%; text-align: right" title="Weighted Average Exercise Granted"&gt;11.50&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Uz0dEn5Ahi" style="width: 14%; text-align: right" title="Average Remaining Contractual Life,Granted"&gt;5.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPEAZegbYagh" style="text-align: right" title="Warrants Outstanding, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqRvcI0CV19" style="display: none; text-align: right" title="Ordinary Shares Issuable, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKd6a5gxKJl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1771"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuBRpBJPYxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ordinary Shares Issuable, Exercised"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1773"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2022 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqz7I5Ro0ma" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance"&gt;8,917,250&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZGV5NIKUml" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares Issuable, Ending balance"&gt;4,458,625&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfmvdnmBM0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending balance"&gt;11.50&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfgfRXJMsei" style="padding-bottom: 2.5pt; text-align: right" title="Average Remaining Contractual Life,"&gt;4.88&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_znjZf6mtcpC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Earnout shares&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of the Business Combination, &lt;span style="background-color: white"&gt;Watermark
is entitled to the &lt;span id="xdx_908_ecustom--EarnoutShares_iI_c20221117_z3yaAlSoENGj" title="Earnout shares"&gt;4,000,000&lt;/span&gt;
Earnout Shares of the Company&#x2019;s no par value ordinary shares subject to the following four
triggering events:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_z7I2xD4C2gA2" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if during the period beginning on the Closing Date and ending on the first anniversary of the Closing Date, the Company&#x2019;s share price is equal to or greater than Fifteen Dollars ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--FirstAnniversaryMember_zioO45nyzk6j" title="Number of additional shares issued"&gt;15.00&lt;/span&gt;) after the Closing Date (&#x201c;Triggering Event 1&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221116__20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zG1xgo4MJ34l" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if during the period beginning on the first anniversary of the Closing Date and ending on the second anniversary of the Closing Date, the Company&#x2019;s share price is equal to or greater than Twenty Dollars ($&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20221117__us-gaap--AwardTypeAxis__custom--SecondAnniversaryMember_zHrCNVw6hgmk" title="Number of additional shares issued"&gt;20.00&lt;/span&gt;) (&#x201c;Triggering Event 2&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyKq1vRCQwW5" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2023 and ending December 31, 2023, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $&lt;span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zuzuCeqW4FM4" title="Revenue"&gt;20,100,000&lt;/span&gt; and (y) net income attributable to EUDA of at least $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20230101__20231231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zwikntQiRO4b" title="Net income"&gt;3,600,000&lt;/span&gt; (&#x201c;Triggering Event 3&#x201d;);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zyVK9Ao8Npl5" title="Number of additional shares issued"&gt;1,000,000&lt;/span&gt; additional Earnout Shares to be issued if the consolidated audited financial statements of EUDA for the fiscal year commencing January 1, 2024 and ending December 31, 2024, reflect that EUDA has achieved both of the following financial metrics for such fiscal year: (x) revenues of at least $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zIMlKNFPLAge" title="Revenue"&gt;40,100,000&lt;/span&gt; and (y) net income attributable to EUDA of at least $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_uUSD_c20240101__20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zqFqjSmVDPxb" title="Net income"&gt;10,100,000&lt;/span&gt; (&#x201c;Triggering Event 4&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Earnout
Shares are accounted for as equity classified equity instruments, were included as merger consideration as part of the Reverse Recapitalization
and recorded in capital&lt;/span&gt;. The fair value of the Earnout Shares was estimated using a model based on multiple stock price paths developed
through the use of a Monte Carlo simulation that incorporates into the valuation the possibility that the market condition targets may
not be satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_zkrxSCwyG2u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Earnout Shares for Triggering
Event 1 and 2 was estimated using the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zsrpRMLIlhei" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule of earnout shares
for triggering event&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Closing date&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221116__20221117_zcGCE22cZ9rk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;November 17, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--SharePriceAsOfClosingDate_zRAWZuTdtPpa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Share price of the Company as of closing date&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;5.21&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AverageDailyReturnRate_dp_uPure_z7DBL6zpBT7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Average daily return rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.02&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DailyVolatilityForTriggeringEvent1_dp_zZ2VBZUgxvL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Daily volatility for Triggering Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.74&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DailyVolatilityForTriggeringEvent2_dp_zpbCH6ark1Zk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Daily volatility for Triggering Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;4.30&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RiskFreeRateForTriggeringEventOne_dp_zVi2jU7hK501" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate for Triggering Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--RiskFreeRateForTriggeringEventTwo_dp_zaUYULj3ClW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate for Triggering Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.49&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GrantPriceForTriggingEventOne_zaQcxUq3EBe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Grant Price for Trigging Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15.0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--GrantPriceForTriggingEventTwo_z3lSuOMSi7I1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Grant Price for Trigging Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20.0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zQAB6u2oxEU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result, the Company determined the fair value
of the Earnout Shares for Triggering Event 1 and 2 is amounted to $&lt;span id="xdx_90E_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventOneMember_zyywS5HPlvZg" title="Fair value of earnout shares"&gt;1,926,610&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--FairValueOfEarnoutShares_c20220101__20221231__srt--StatementScenarioAxis__custom--TriggeringEventTwoMember_zmL8IJ55UEmg" title="Fair value of earnout shares"&gt;3,273,019&lt;/span&gt;, respectively, and recorded the same amount in consolidated statements of change in shareholders&#x2019; equity (deficit) and
consolidated statements of operations and comprehensive income (loss) as earnout share payment for the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, Company determined that the probabilities
of achieving the revenue and net income thresholds are nil for Triggering Event 3 and 4 and estimated the fair value of the Earnout Shares
of nil.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:Capital
      contextRef="AsOf2022-09-20_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:Capital>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-11-17_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Shares">120000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2022-03-302022-03-31"
      decimals="0"
      unitRef="USD">2763018</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-242022-07-25"
      decimals="INF"
      unitRef="Shares">4626667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <EUDA:OrdinaryShareBeforeReverseRecapitalization contextRef="AsOf2022-07-25" decimals="INF" unitRef="Shares">500000</EUDA:OrdinaryShareBeforeReverseRecapitalization>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-242022-07-25"
      decimals="0"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17_custom_EightIHoldingsTwoPtdLtdMember"
      decimals="INF"
      unitRef="Shares">6191770</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <EUDA:ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock_z80GmA1oLSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table presents the number of the Company&#x2019;s ordinary shares issued upon the Reverse Recapitalization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zf6K3XnLVwLg"&gt;Schedule
of reverse recapitalization&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221116__20221117_zgcRg6Xenr1h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--OrdinarySharesOutstandingPriorToReverseRecapitalization_zzG2plFquwuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;8i ordinary shares outstanding prior to Reverse Recapitalization&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: right"&gt;11,073,500&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--RedemptionOfOrdinaryShares_zxMwMp166mZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Less: redemption of 8i ordinary shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,033,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConversionOfStockSharesConverted1_zHBwDEqARuZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Conversion of 8i rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;891,725&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zcAJmygmIXLj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shares issued to service providers&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;260,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_zLFaxoKqb1O" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total shares issued upon the Reverse Recapitalization&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,191,770&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock>
    <EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">11073500</EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization>
    <EUDA:RedemptionOfOrdinaryShares
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">-6033455</EUDA:RedemptionOfOrdinaryShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">891725</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">260000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Shares">6191770</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">8917250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PublicWarrantMember"
      decimals="INF"
      unitRef="Shares">8625000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PrivateWarrantMember"
      decimals="INF"
      unitRef="Shares">292250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PublicWarrantMember"
      decimals="INF"
      unitRef="Shares">8625000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_PrivateWarrantMember"
      decimals="INF"
      unitRef="Shares">292250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <EUDA:WarrantsRedemptionPrice
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</EUDA:WarrantsRedemptionPrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">16.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGUjZC76KfO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The summary of warrants activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zzr0MdKF5Uth" style="display: none"&gt;Schedule
of warrant activities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants &lt;br/&gt; Outstanding&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Ordinary Shares Issuable&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k4YsaJj09j" style="text-align: right" title="Warrants Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zle586Mp5ZOd" style="display: none; text-align: right" title="Ordinary Shares Issuable, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuI9vnNPvPp8" style="text-align: right" title="Weighted Average Exercise Price, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2tEcJVkBChj" style="width: 14%; text-align: right" title="Warrants Outstanding, Granted"&gt;8,917,250&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk9jia2wAIug" style="width: 14%; text-align: right" title="Ordinary Shares Issuable, Granted"&gt;4,458,625&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ8n0xDs4CJ7" style="width: 14%; text-align: right" title="Weighted Average Exercise Granted"&gt;11.50&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Uz0dEn5Ahi" style="width: 14%; text-align: right" title="Average Remaining Contractual Life,Granted"&gt;5.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingForfeited_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPEAZegbYagh" style="text-align: right" title="Warrants Outstanding, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqRvcI0CV19" style="display: none; text-align: right" title="Ordinary Shares Issuable, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKd6a5gxKJl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1771"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHuBRpBJPYxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ordinary Shares Issuable, Exercised"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1773"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2022 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqz7I5Ro0ma" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance"&gt;8,917,250&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAZGV5NIKUml" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares Issuable, Ending balance"&gt;4,458,625&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjfmvdnmBM0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending balance"&gt;11.50&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOfgfRXJMsei" style="padding-bottom: 2.5pt; text-align: right" title="Average Remaining Contractual Life,"&gt;4.88&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <EUDA:ClassOfWarrantOrRightOutstandingGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">8917250</EUDA:ClassOfWarrantOrRightOutstandingGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4458625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <EUDA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember">P5Y</EUDA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">8917250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4458625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember">P4Y10M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <EUDA:EarnoutShares contextRef="AsOf2022-11-17" decimals="INF" unitRef="Shares">4000000</EUDA:EarnoutShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17_custom_FirstAnniversaryMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-17_custom_FirstAnniversaryMember"
      decimals="INF"
      unitRef="USDPShares">15.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-162022-11-17_custom_SecondAnniversaryMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-17_custom_SecondAnniversaryMember"
      decimals="INF"
      unitRef="USDPShares">20.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">3600000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">40100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">10100000</us-gaap:NetIncomeLoss>
    <EUDA:ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_ecustom--ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock_zkrxSCwyG2u5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Earnout Shares for Triggering
Event 1 and 2 was estimated using the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zsrpRMLIlhei" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule of earnout shares
for triggering event&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Closing date&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221116__20221117_zcGCE22cZ9rk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;November 17, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--SharePriceAsOfClosingDate_zRAWZuTdtPpa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Share price of the Company as of closing date&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;5.21&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AverageDailyReturnRate_dp_uPure_z7DBL6zpBT7g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Average daily return rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;0.02&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DailyVolatilityForTriggeringEvent1_dp_zZ2VBZUgxvL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Daily volatility for Triggering Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.74&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DailyVolatilityForTriggeringEvent2_dp_zpbCH6ark1Zk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Daily volatility for Triggering Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;4.30&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RiskFreeRateForTriggeringEventOne_dp_zVi2jU7hK501" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate for Triggering Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--RiskFreeRateForTriggeringEventTwo_dp_zaUYULj3ClW1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free rate for Triggering Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.49&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--GrantPriceForTriggingEventOne_zaQcxUq3EBe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Grant Price for Trigging Event 1&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15.0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--GrantPriceForTriggingEventTwo_z3lSuOMSi7I1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Grant Price for Trigging Event 2&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20.0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock>
    <EUDA:SharePriceAsOfClosingDate
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="USDPShares">5.21</EUDA:SharePriceAsOfClosingDate>
    <EUDA:AverageDailyReturnRate
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Pure">0.0002</EUDA:AverageDailyReturnRate>
    <EUDA:DailyVolatilityForTriggeringEvent1
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Pure">0.0474</EUDA:DailyVolatilityForTriggeringEvent1>
    <EUDA:DailyVolatilityForTriggeringEvent2
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Pure">0.0430</EUDA:DailyVolatilityForTriggeringEvent2>
    <EUDA:RiskFreeRateForTriggeringEventOne
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Pure">0.0475</EUDA:RiskFreeRateForTriggeringEventOne>
    <EUDA:RiskFreeRateForTriggeringEventTwo
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="Pure">0.0449</EUDA:RiskFreeRateForTriggeringEventTwo>
    <EUDA:GrantPriceForTriggingEventOne
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="USDPShares">15.0</EUDA:GrantPriceForTriggingEventOne>
    <EUDA:GrantPriceForTriggingEventTwo
      contextRef="From2022-11-162022-11-17"
      decimals="INF"
      unitRef="USDPShares">20.0</EUDA:GrantPriceForTriggingEventTwo>
    <EUDA:FairValueOfEarnoutShares
      contextRef="From2022-01-012022-12-31_custom_TriggeringEventOneMember"
      decimals="0"
      unitRef="USD">1926610</EUDA:FairValueOfEarnoutShares>
    <EUDA:FairValueOfEarnoutShares
      contextRef="From2022-01-012022-12-31_custom_TriggeringEventTwoMember"
      decimals="0"
      unitRef="USD">3273019</EUDA:FairValueOfEarnoutShares>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zrpXafO6iun3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 17 &#x2013;&lt;span id="xdx_829_z5alBoi1aj22"&gt; Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;British Virgin Islands&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;KRHL and SGGL are incorporated in the British Virgin
Islands and are not subject to tax on income or capital gains under current British Virgin Islands law. In addition, upon payments of
dividends by these entities to their shareholders, no British Virgin Islands withholding tax will be imposed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Vietnam&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s subsidiary operating in Vietnam
is subject to the Vietnam Income Tax at a standard income tax rate of &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_znefJsdO9JN" title="Foreign income tax rate"&gt;20&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Malaysia&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s subsidiary operating in Malaysia
is governed by the income tax laws of Malaysia and the income tax provision in respect of operations in Malaysia is calculated at the
applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof.
Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zLuDvpwO3Yak" title="Foreign income tax rate"&gt;24&lt;/span&gt;% enterprise income
tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Singapore&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries incorporated in Singapore
and is subject to Singapore Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance
with relevant Singapore tax laws. &lt;span id="xdx_909_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_z4KtS2eEjV12" title="Income tax description"&gt;The applicable tax rate is &lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--SG_zsKL6vaATBQ5" title="Foreign income tax rate"&gt;17&lt;/span&gt;% in Singapore, with 75% of the first $&lt;span id="xdx_907_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z17NV6d87dW4" title="Taxable income"&gt;7,255&lt;/span&gt; (SGD &lt;span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--SeventyFivePercentageMember_z6EBZQcRybQb" title="Taxable income"&gt;10,000&lt;/span&gt;) taxable income
and 50% of the next $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zg9APfydA9V4" title="Taxable income"&gt;137,842&lt;/span&gt; (SGD &lt;span id="xdx_902_eus-gaap--IncomeTaxExpenseBenefit_uSGD_c20220101__20221231__srt--StatementGeographicalAxis__country--SG__us-gaap--AwardTypeAxis__custom--FiftyPercentageMember_zyjXZunjUH2g" title="Taxable income"&gt;190,000&lt;/span&gt;) taxable income are exempted from income tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zXpPe41qzvhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The United States and foreign components of loss before
income taxes were comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_ziFSmCvuVuV3" style="display: none"&gt;Schedule
of components of loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zjH9PVeyKvkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year&lt;/p&gt;
                                                                                                                                                 &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20211231_zKAtD8HE96P4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year&lt;/p&gt;
                                                                                                                                                 &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zty8c8T8eeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;(5,400,034&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;930,312&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zGyACxvHKX16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,531,790&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,225&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zPMlSqriWVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total loss (income) before income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,931,824&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;948,537&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zuXGiTrb4pr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJEm2njnqpLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The provision for income taxes consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z8zw5yCpj5M2" style="display: none"&gt;Schedule
of provision for income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zTFi7qbIvTRg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_z0BLIXxcd0F4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_zSdIKhIucPrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Current&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;65,650&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;75,821&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_z3jXFocNLYm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(48,228&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,680&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_z4lm9TXIxmI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,422&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,141&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zzL73rSJesra" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zVCS992fOng2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reconciles Singapore statutory
rates to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zXLp5P8Uow19" style="display: none"&gt;Schedule
of effective income tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zz6LSmlqgw5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For
the Year Ended&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zTpHYWL3WU07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For
the Year Ended&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_z0uGVyCX6sAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Singapore statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;17.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;17.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zzJ1jJekuC2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax rate difference outside Singapore &lt;span id="xdx_F46_zNQo6BcZgG44"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(13.3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.1&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxExemptIncome_pid_dp_zXhXG4014Vxb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Taxable income below exemption threshold&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2.4&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_z8YJ0GXrWI66" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;29.8&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_zY13CpOijIs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others &lt;span id="xdx_F44_zoi5p425LcQg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.9&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39.4&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zzQWY82pIy2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.1&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.1&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F04_zLE8wzDmLyza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_zCFPCErDySXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F01_zvUE81Un7MEd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zxFItljtEDT" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zSka9sprHmQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUkfkUCI7RE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth the significant components
of the aggregate deferred tax assets and liabilities of the Company as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zcM8q1Pzzg4" style="display: none"&gt;Schedule
of deferred tax assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zdo2j9fZOWhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z0XqsOKD6XUj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred Tax Assets/Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzYwk_zbqU7KgOgUqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;749,309&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;812,715&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTANzYwk_zDROOYfiD1Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Allowance for doubtful account&lt;span id="xdx_F4E_zYFMyP1TGDhg"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33,564&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;13,736&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilityNet_iI_maDTANzYwk_z5ZAY0uJdmu8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;823&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYwk_zk1qx9VNeCJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(783,696&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(826,451&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYwk_zqEefreGb4e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1903"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzaoX_zYICzYnBxxwh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,294&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzaoX_z5NtqG7k2ot8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liabilities, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1909"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;49,294&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F06_zH7RhItHCiA2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z3zULlLWpA9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased"&gt;42,755&lt;/span&gt; as of December 31, 2022.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zNhoceS2p6ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022 and 2021, the Company had
net operating losses carry forward (including temporary taxable difference of bad debt expense) of approximately $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20221231_zS4fiEcjSZze" title="Operating losses carry forward"&gt;4.4&lt;/span&gt; million and $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zC153U1F2Kc3" title="Operating losses carry forward"&gt;4.8&lt;/span&gt;
million, respectively, from the Company&#x2019;s Singapore subsidiaries. The net operating losses from the Singapore subsidiaries can be
carried forward indefinitely. Due to the limited operating history of certain Singapore subsidiaries, the Company is uncertain when these
net operating losses can be utilized. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses
(including temporary taxable difference of bad debt expense) of approximately $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zWUOmpGWmkRa" title="Deferred tax assets, operating losses carry forward"&gt;0.7&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20211231__srt--ConsolidatedEntitiesAxis__custom--SingaporeSubsidiariesMember_zc33zuHgyiKj" title="Deferred tax assets, operating losses carry forward"&gt;0.8&lt;/span&gt; million related to Singapore subsidiaries
as of December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022 and 2021, the Company had
net operating losses carry forward of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_zPvacqmpq7ik" title="Operating losses carry forward"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zeBSl8AgbJW4" title="Operating losses carry forward"&gt;19,000&lt;/span&gt;, respectively, from the Company&#x2019;s Vietnam subsidiary. &lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__country--VN_zhFLnRHG3UGg" title="Operating losses carry forward description"&gt;The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.&lt;/span&gt; Due to
the Vietnam subsidiary have been operating at losses and the Company believes it is more likely than not that its Vietnam operations will
be unable to fully utilize its deferred tax assets related to the net operating losses in the foreseeable future. As a result, the Company
provided a 100% allowance on deferred tax assets on net operating losses of approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--VN_z602ld7w8qj2" title="Deferred tax assets, operating losses carry forward"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--VN_zMjWK0J359u3" title="Deferred tax assets, operating losses carry forward"&gt;4,000&lt;/span&gt; related to its Vietnam subsidiary
as of December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022, the Company had net operating
losses carry forward of approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zCMRe980OpB1" title="Operating losses carry forward"&gt;15,000&lt;/span&gt; from the Company&#x2019;s Malaysia subsidiary. The net operating losses from the Malaysia
subsidiary can be carried forward for seven years. Due to the Malaysia subsidiary have been operating at losses and the Company believes
it is more likely than not that its Malaysia operations will be unable to fully utilize its deferred tax assets related to the net operating
losses in the foreseeable future. As a result, the Company provided a 100% allowance on deferred tax assets on net operating losses of
approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zWUhV0tS1ski" title="Deferred tax assets, operating losses carry forward"&gt;4,000&lt;/span&gt; related to its Malaysia subsidiary as of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates each uncertain tax position
(including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated
with the tax positions. As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions.
The Company did not incur interest and penalties tax for the year ended December 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfTaxesPayableTableTextBlock_zxbuH9pHz6Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Taxes payable consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z9nWMz0MpKS5" style="display: none"&gt;Schedule
of taxes payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zDcGYLGYVkoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_zXvZQgoUd4K9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedGSTTaxesPayableCurrent_iI_maTPCzp1w_zSuZfuCNFxE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;GST taxes payable&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;125,695&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;225,095&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedIncomeTaxesCurrent_iI_maTPCzp1w_z0eWsO3lfjj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income taxes payable&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,455&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82,248&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_iTI_mtTPCzp1w_zmg2voh1nZe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;186,150&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;307,343&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zunOrIXdAOZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31_country_VN"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31_country_MY"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2022-01-012022-12-31_country_SG">The applicable tax rate is 17% in Singapore, with 75% of the first $7,255 (SGD 10,000) taxable income
and 50% of the next $137,842 (SGD 190,000) taxable income are exempted from income tax.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31_country_SG"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember"
      decimals="0"
      unitRef="USD">7255</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_country_SG_custom_SeventyFivePercentageMember"
      decimals="0"
      unitRef="SGD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember"
      decimals="0"
      unitRef="USD">137842</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_country_SG_custom_FiftyPercentageMember"
      decimals="0"
      unitRef="SGD">190000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zXpPe41qzvhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The United States and foreign components of loss before
income taxes were comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_ziFSmCvuVuV3" style="display: none"&gt;Schedule
of components of loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zjH9PVeyKvkh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year&lt;/p&gt;
                                                                                                                                                 &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20211231_zKAtD8HE96P4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year&lt;/p&gt;
                                                                                                                                                 &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zty8c8T8eeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Singapore&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;(5,400,034&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;930,312&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zGyACxvHKX16" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,531,790&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,225&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zPMlSqriWVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total loss (income) before income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,931,824&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;948,537&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-5400034</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">930312</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-19531790</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">18225</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24931824</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">948537</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zJEm2njnqpLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The provision for income taxes consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_z8zw5yCpj5M2" style="display: none"&gt;Schedule
of provision for income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zTFi7qbIvTRg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210101__20211231_z0BLIXxcd0F4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Year Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_zSdIKhIucPrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Current&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;65,650&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;75,821&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_z3jXFocNLYm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(48,228&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,680&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_z4lm9TXIxmI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,422&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,141&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">65650</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">75821</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-48228</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-27680</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">17422</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">48141</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zVCS992fOng2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reconciles Singapore statutory
rates to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zXLp5P8Uow19" style="display: none"&gt;Schedule
of effective income tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zz6LSmlqgw5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For
the Year Ended&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20210101__20211231_zTpHYWL3WU07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For
the Year Ended&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_z0uGVyCX6sAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Singapore statutory income tax rate&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;17.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;17.0&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zzJ1jJekuC2b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax rate difference outside Singapore &lt;span id="xdx_F46_zNQo6BcZgG44"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(13.3&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.1&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxExemptIncome_pid_dp_zXhXG4014Vxb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Taxable income below exemption threshold&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2.4&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_z8YJ0GXrWI66" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2.9&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;29.8&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_zY13CpOijIs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others &lt;span id="xdx_F44_zoi5p425LcQg"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.9&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39.4&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zzQWY82pIy2k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.1&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.1&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F04_zLE8wzDmLyza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F19_zCFPCErDySXc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F01_zvUE81Un7MEd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zxFItljtEDT" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.170</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.170</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="Fact001872"
      unitRef="Pure">-0.133</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact001873"
      unitRef="Pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.298</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="Fact001881"
      unitRef="Pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact001882"
      unitRef="Pure">-0.394</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.051</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zUkfkUCI7RE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth the significant components
of the aggregate deferred tax assets and liabilities of the Company as of:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zcM8q1Pzzg4" style="display: none"&gt;Schedule
of deferred tax assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zdo2j9fZOWhi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_z0XqsOKD6XUj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred Tax Assets/Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzYwk_zbqU7KgOgUqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;749,309&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;812,715&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_maDTANzYwk_zDROOYfiD1Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Allowance for doubtful account&lt;span id="xdx_F4E_zYFMyP1TGDhg"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;33,564&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;13,736&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilityNet_iI_maDTANzYwk_z5ZAY0uJdmu8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;823&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzYwk_zk1qx9VNeCJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(783,696&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(826,451&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzYwk_zqEefreGb4e9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax assets, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1903"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzaoX_zYICzYnBxxwh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,294&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzaoX_z5NtqG7k2ot8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liabilities, net&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1909"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;49,294&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F06_zH7RhItHCiA2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z3zULlLWpA9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe" title="Valuation allowance on all deferred tax assets increased"&gt;42,755&lt;/span&gt; as of December 31, 2022.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">749309</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">812715</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001894"
      unitRef="USD">33564</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001895"
      unitRef="USD">13736</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <EUDA:DeferredTaxAssetsLeaseLiabilityNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">823</EUDA:DeferredTaxAssetsLeaseLiabilityNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">783696</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">826451</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">49294</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">49294</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">42755</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-5" unitRef="USD">4400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="-5" unitRef="USD">4800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_SingaporeSubsidiariesMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31_custom_SingaporeSubsidiariesMember"
      decimals="-5"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_VN"
      decimals="0"
      unitRef="USD">18000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_country_VN"
      decimals="0"
      unitRef="USD">19000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2022-01-012022-12-31_country_VN">The
net operating losses from the Vietnam subsidiary can be carried forward for five years and expiring from the year 2025 to 2027.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_VN"
      decimals="0"
      unitRef="USD">4000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31_country_VN"
      decimals="0"
      unitRef="USD">4000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">15000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">4000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <EUDA:ScheduleOfTaxesPayableTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_ecustom--ScheduleOfTaxesPayableTableTextBlock_zxbuH9pHz6Tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Taxes payable consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_z9nWMz0MpKS5" style="display: none"&gt;Schedule
of taxes payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zDcGYLGYVkoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_zXvZQgoUd4K9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedGSTTaxesPayableCurrent_iI_maTPCzp1w_zSuZfuCNFxE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;GST taxes payable&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;125,695&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;225,095&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccruedIncomeTaxesCurrent_iI_maTPCzp1w_z0eWsO3lfjj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income taxes payable&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,455&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82,248&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_iTI_mtTPCzp1w_zmg2voh1nZe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;186,150&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;307,343&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfTaxesPayableTableTextBlock>
    <EUDA:AccruedGSTTaxesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">125695</EUDA:AccruedGSTTaxesPayableCurrent>
    <EUDA:AccruedGSTTaxesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">225095</EUDA:AccruedGSTTaxesPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">60455</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">82248</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">186150</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">307343</us-gaap:TaxesPayableCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zPIH40SFxH9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 18 &#x2013; &lt;span id="xdx_823_zXna5lN7Lt73"&gt;Concentrations  risks&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(a) Major customers&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2022 and 2021, no
customer accounted for &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zTovobfOfiA1" title="Concentration risk percentage"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zaNsgn5U49Dd" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of the Company&#x2019;s total revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022 and 2021, no customer accounted
for &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zh7Wpr17vVWf" title="Concentration risk percentage"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoCustomerMember_zI9iyFYtFh8h" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% or more of the total balance of accounts receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(b) Major vendors&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended December 31, 2022, no vendor accounted
for &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--NoVendorMember_zpOiyZK5geXh" title="Concentration risk percentage"&gt;10&lt;/span&gt;% or more of the Company&#x2019;s total purchases. For the year ended December 31, 2021, one vendor which is the Company&#x2019;s
related party accounted for approximately &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zeNLcYsJ6y5a" title="Concentration risk percentage"&gt;37.3&lt;/span&gt;% of the Company&#x2019;s total purchases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2022, two vendors accounted for
&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zGVonptqQ3Xc" title="Concentration risk percentage"&gt;27.9&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zz3FjCjNnZ87" title="Concentration risk percentage"&gt;12.1&lt;/span&gt;% of the Company&#x2019;s total balance of accounts payable, respectively. As of December 31, 2021, one vendor which is the
Company&#x2019;s related party accounted for approximately &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zpODy6RlWja5" title="Concentration risk percentage"&gt;87.2&lt;/span&gt;% of the total balance of accounts payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;(c) Credit risk&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to significant concentrations of credit risk consist primarily of cash. The Singapore Deposit Insurance Corporation
Limited (SDIC) insures deposits in a Deposit Insurance (DI) Scheme member bank or finance company up to approximately $&lt;span id="xdx_907_eus-gaap--Deposits_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zjAJyOOSPUBl" title="Deposits"&gt;57,000&lt;/span&gt;
(SGD &lt;span id="xdx_907_eus-gaap--Deposits_iI_uSGD_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zFDaVftMjKAl" title="Deposits"&gt;75,000&lt;/span&gt;)
per account. As of December 31, 2022 and 2021, the Company had cash balance of $&lt;span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zSAjXjlWusZj" title="Cash balance"&gt;138,710&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zqEfCScdMxK1" title="Cash balance"&gt;180,746&lt;/span&gt;
was maintained at DI Scheme banks in Singapore, of $&lt;span id="xdx_90B_eus-gaap--BankOverdrafts_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuhytM0ddrp6" title="Bank balance"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--BankOverdrafts_iI_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zaA9mkzk3ohj" title="Bank balance"&gt;41,606&lt;/span&gt;
was subject to credit risk, respectively. The Federal Deposit Insurance Corporation (FDIC) standard insurance amount is up to $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zNoSNL8CGM58" title="Cash FDIC"&gt;250,000&lt;/span&gt;
per depositor per insured bank. As of December 31, 2022 and 2021, the Company had  restricted cash balance of $&lt;span id="xdx_90B_eus-gaap--RestrictedCash_iI_c20221231_ziJm2MEsyNM2" title="Restricted cash"&gt;641,461&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231_zXwqTCDm5kgk" title="Restricted cash::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;0&lt;/span&gt;&lt;/span&gt; was
maintained at banks in the United States, of $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_c20221231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_zuvKPIz6x74d" title="Restricted cash"&gt;391,461&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--RestrictedCash_iI_dxL_c20211231__us-gaap--ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis__us-gaap--CreditRiskMember_ztL1dnl9lkhg" title="Restricted cash::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;0&lt;/span&gt;&lt;/span&gt;
was subject to credit risk, respectively. While management believes that these financial institutions are of high credit quality, it
also continually monitors their credit worthiness.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is also exposed to risk from accounts
receivable and other receivables. These assets are subjected to credit evaluations. An allowance has been made for estimated unrecoverable
amounts which have been determined by reference to past default experience and the current economic environment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_NoCustomerMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_NoVendorMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember"
      decimals="INF"
      unitRef="Pure">0.373</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorOneMember"
      decimals="INF"
      unitRef="Pure">0.279</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_VendorTwoMember"
      decimals="INF"
      unitRef="Pure">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_AccountsPayableMember_us-gaap_CustomerConcentrationRiskMember_custom_OneVendorMember"
      decimals="INF"
      unitRef="Pure">0.872</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Deposits
      contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">57000</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="SGD">75000</us-gaap:Deposits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">138710</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">180746</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BankOverdrafts
      contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">0</us-gaap:BankOverdrafts>
    <us-gaap:BankOverdrafts
      contextRef="AsOf2021-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">41606</us-gaap:BankOverdrafts>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">641461</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2022-12-31_us-gaap_CreditRiskMember"
      decimals="0"
      unitRef="USD">391461</us-gaap:RestrictedCash>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80F_eus-gaap--LesseeOperatingLeasesTextBlock_z36yamL3BM55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 19 &#x2013; &lt;span id="xdx_82E_zn5DNKDgyIBf"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022 and
2021, the Company has leased three offices, and one office, respectively, which were classified as operating leases. In addition, the
Company had two office equipment leases which were classified as finance leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company occupies various
offices under operating lease agreements with a term shorter than twelve months which it elected not to recognize lease assets and lease
liabilities under ASC 842. Instead, the Company recognized the lease payments in profit or loss on a straight-line basis over the lease
term and variable lease payments in the period in which the obligation for those payments is incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company&#x2019;s lease
agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company recognized lease
expense on a straight-line basis over the lease term for operating lease. Meanwhile, the Company recognized the finance leases ROU assets
and interest on an amortized cost basis. The amortization of finance ROU assets is recognized on an accretion basis as amortization expense,
while the lease liability is increased to reflect interest on the liability and decreased to reflect the lease payments made during the
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The ROU assets and lease
liabilities are determined based on the present value of the future minimum rental payments of the lease as of the adoption date, using
an effective interest rate of &lt;span id="xdx_90C_eus-gaap--OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate_iI_pid_dp_uPure_c20221231_z7pOJ4NUxHkf" title="Effective interest rate"&gt;5.25&lt;/span&gt;%, which is determined using an incremental borrowing rate with similar term in Singapore.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022,
the weighted average remaining lease terms of the Company&#x2019;s operating lease and finance leases are &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKQihOLmG2li" title="Operating lease term"&gt;0.69&lt;/span&gt; years and &lt;span id="xdx_907_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zPHpfCn6dn6e" title="Finance lease term"&gt;2.01&lt;/span&gt; years, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_zEuaX77mg0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Operating and finance lease
expenses consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BF_zva4W5Cc3jEe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of operating and finance lease expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Classification&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;Lease expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 31%; text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z02GJdR0Isi6" style="width: 14%; text-align: right" title="Lease expenses"&gt;114,390&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--OperatingLeaseExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8YRaCVWT2G1" style="width: 14%; text-align: right" title="Lease expenses"&gt;62,810&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease expenses &#x2013; short-term&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--OperatingLeaseExpenseShortTerm_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ3haufxx6Qg" style="text-align: right" title="Lease expenses - short-term"&gt;113,055&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OperatingLeaseExpenseShortTerm_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsGM83lzv0Je" style="text-align: right" title="Lease expenses - short-term"&gt;143,589&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization of leased asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3O1dqy7VBD" style="text-align: right" title="Amortization of leased asset"&gt;7,948&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znDHIxe4Tzjl" style="text-align: right" title="Amortization of leased asset"&gt;8,153&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense -Interest expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zf2DKu4lGdQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities"&gt;1,276&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseInterestExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zHzFNIMwu5vk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities"&gt;1,639&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LeaseCost_c20220101__20221231_zXuIrMiSvqCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses"&gt;236,669&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--LeaseCost_c20210101__20211231_z2u05tGTexK8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses"&gt;216,191&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zsHhe4ynVdql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z4bF3JJAwasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Weighted-average remaining
term and discount rate related to leases were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;span id="xdx_8B7_z33Jp2miFTYa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of weighted average remaining term and discount rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average remaining term&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zrKJVK0Me2f7" title="Operating lease, weighted-average remaining term"&gt;0.69&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zzCZShx2g3Sb" title="Operating lease, weighted-average remaining term"&gt;1.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKWt37oTrso2" title="Finance leases, weighted-average remaining term"&gt;2.01&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zHvVzkkI36U7" title="Finance leases, weighted-average remaining term"&gt;3.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Operating lease&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zdJsEKHuuDU" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z4c645fgDIx4" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zZokI2Cnpue8" style="text-align: right" title="Finance leases, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zfAld1JBxjki" style="text-align: right" title="Finance leases, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zG9d63cfbRE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_z73KmCspbejd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following table sets
forth the Company&#x2019;s minimum lease payments in future periods as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BF_zSmAwDeYnclg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of future minimum lease payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Operating lease&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Finance lease&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payments&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payments&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Twelve months ending December 31, 2023&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_z5TkiMa5Sj6k" style="width: 14%; text-align: right" title="Operating lease payments, 2023"&gt;81,522&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_zBj0F5oLzmwe" style="width: 14%; text-align: right" title="Finance lease payments, 2023"&gt;8,151&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_c20221231_z5CMRkqW6N71" style="width: 14%; text-align: right" title="Total 2023"&gt;89,673&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Twelve months ending December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zGcD4UX1NxMj" style="text-align: right" title="Operating lease payments, 2024"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_z4BdzkewRGyj" style="text-align: right" title="Finance lease payments, 2024"&gt;15,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligationDueInSecondYear_iI_c20221231_zPK2RPFfFAGf" style="text-align: right" title="Total 2024"&gt;15,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20221231_zqWjAHy6kPmh" style="text-align: right" title="Total Operating lease payments"&gt;81,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20221231_zBpcpcCZWHTi" style="text-align: right" title="Total Finance lease payments"&gt;23,765&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_c20221231_zY66KBstjHkk" style="text-align: right" title="Total lease payments"&gt;105,287&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: discount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pid_di_c20221231_zHNYt3BVcdDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Operating lease payments, discount"&gt;(1,563&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20221231_zbL4SNROjyw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Finance lease payments, discount"&gt;(1,564&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractualObligationDiscount_iNI_di_c20221231_zpQcmUJrGt7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total lease payments"&gt;(3,127&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20221231_zDKjpPsmED13" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, operating lease payments"&gt;79,959&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_c20221231_zLCdbSOaIrge" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, finance lease payments"&gt;22,201&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractualObligationLeaseLiability_iI_c20221231_zAbONJPGacC5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease payments"&gt;102,160&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_z2O3vH1oe0Fl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022,
the Company minimum short term lease payments to be due within one year amounted to $&lt;span id="xdx_90F_eus-gaap--ShortTermLeasePayments_c20220101__20221231_zShqFY5C3tnb" title="Short term lease payments"&gt;25,075&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0525</us-gaap:OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P0Y8M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P2Y3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock_zEuaX77mg0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Operating and finance lease
expenses consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BF_zva4W5Cc3jEe" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of operating and finance lease expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Classification&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;Lease expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 31%; text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z02GJdR0Isi6" style="width: 14%; text-align: right" title="Lease expenses"&gt;114,390&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--OperatingLeaseExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8YRaCVWT2G1" style="width: 14%; text-align: right" title="Lease expenses"&gt;62,810&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease expenses &#x2013; short-term&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--OperatingLeaseExpenseShortTerm_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ3haufxx6Qg" style="text-align: right" title="Lease expenses - short-term"&gt;113,055&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--OperatingLeaseExpenseShortTerm_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsGM83lzv0Je" style="text-align: right" title="Lease expenses - short-term"&gt;143,589&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization of leased asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z3O1dqy7VBD" style="text-align: right" title="Amortization of leased asset"&gt;7,948&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znDHIxe4Tzjl" style="text-align: right" title="Amortization of leased asset"&gt;8,153&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense -Interest expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zf2DKu4lGdQg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities"&gt;1,276&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseInterestExpense_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zHzFNIMwu5vk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest on lease liabilities"&gt;1,639&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total lease expenses&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--LeaseCost_c20220101__20221231_zXuIrMiSvqCe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses"&gt;236,669&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--LeaseCost_c20210101__20211231_z2u05tGTexK8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease expenses"&gt;216,191&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">114390</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">62810</us-gaap:OperatingLeaseExpense>
    <EUDA:OperatingLeaseExpenseShortTerm
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">113055</EUDA:OperatingLeaseExpenseShortTerm>
    <EUDA:OperatingLeaseExpenseShortTerm
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">143589</EUDA:OperatingLeaseExpenseShortTerm>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">7948</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">8153</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2022-01-012022-12-31_us-gaap_InterestExpenseMember"
      decimals="0"
      unitRef="USD">1276</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-01-012021-12-31_us-gaap_InterestExpenseMember"
      decimals="0"
      unitRef="USD">1639</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">236669</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">216191</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_z4bF3JJAwasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Weighted-average remaining
term and discount rate related to leases were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;span id="xdx_8B7_z33Jp2miFTYa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of weighted average remaining term and discount rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average remaining term&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating lease&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zrKJVK0Me2f7" title="Operating lease, weighted-average remaining term"&gt;0.69&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zzCZShx2g3Sb" title="Operating lease, weighted-average remaining term"&gt;1.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zKWt37oTrso2" title="Finance leases, weighted-average remaining term"&gt;2.01&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zHvVzkkI36U7" title="Finance leases, weighted-average remaining term"&gt;3.00&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Operating lease&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zdJsEKHuuDU" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_z4c645fgDIx4" style="width: 16%; text-align: right" title="Operating lease, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20221231_zZokI2Cnpue8" style="text-align: right" title="Finance leases, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_dp_c20211231_zfAld1JBxjki" style="text-align: right" title="Finance leases, weighted-average discount rate"&gt;5.25&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P0Y8M8D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31">P1Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31">P2Y3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0525</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0525</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-12-31" decimals="INF" unitRef="Pure">0.0525</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-12-31" decimals="INF" unitRef="Pure">0.0525</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <EUDA:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--ScheduleOfFutureMinimumLeasePaymentsTableTextBlock_z73KmCspbejd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following table sets
forth the Company&#x2019;s minimum lease payments in future periods as of December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;span id="xdx_8BF_zSmAwDeYnclg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of future minimum lease payments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Operating lease&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Finance lease&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payments&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payments&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Twelve months ending December 31, 2023&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_z5TkiMa5Sj6k" style="width: 14%; text-align: right" title="Operating lease payments, 2023"&gt;81,522&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20221231_zBj0F5oLzmwe" style="width: 14%; text-align: right" title="Finance lease payments, 2023"&gt;8,151&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_c20221231_z5CMRkqW6N71" style="width: 14%; text-align: right" title="Total 2023"&gt;89,673&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Twelve months ending December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_zGcD4UX1NxMj" style="text-align: right" title="Operating lease payments, 2024"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20221231_z4BdzkewRGyj" style="text-align: right" title="Finance lease payments, 2024"&gt;15,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligationDueInSecondYear_iI_c20221231_zPK2RPFfFAGf" style="text-align: right" title="Total 2024"&gt;15,614&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20221231_zqWjAHy6kPmh" style="text-align: right" title="Total Operating lease payments"&gt;81,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20221231_zBpcpcCZWHTi" style="text-align: right" title="Total Finance lease payments"&gt;23,765&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_c20221231_zY66KBstjHkk" style="text-align: right" title="Total lease payments"&gt;105,287&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: discount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pid_di_c20221231_zHNYt3BVcdDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Operating lease payments, discount"&gt;(1,563&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20221231_zbL4SNROjyw4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Finance lease payments, discount"&gt;(1,564&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ContractualObligationDiscount_iNI_di_c20221231_zpQcmUJrGt7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total lease payments"&gt;(3,127&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--OperatingLeaseLiability_iI_c20221231_zDKjpPsmED13" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, operating lease payments"&gt;79,959&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiability_iI_c20221231_zLCdbSOaIrge" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Present value of lease liabilities, finance lease payments"&gt;22,201&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ContractualObligationLeaseLiability_iI_c20221231_zAbONJPGacC5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total lease payments"&gt;102,160&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</EUDA:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">81522</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">8151</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89673</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15614</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15614</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">81522</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">23765</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:ContractualObligation contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">105287</us-gaap:ContractualObligation>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1563</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1564</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <EUDA:ContractualObligationDiscount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3127</EUDA:ContractualObligationDiscount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">79959</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">22201</us-gaap:FinanceLeaseLiability>
    <EUDA:ContractualObligationLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">102160</EUDA:ContractualObligationLeaseLiability>
    <us-gaap:ShortTermLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">25075</us-gaap:ShortTermLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z97gDaYoTsq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 20 &#x2013; &lt;span id="xdx_820_zdvDPpG9pSve"&gt;Commitments and contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, the Company is party to certain
legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible
losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
March 30, 2022, the State Courts of the Republic of Singapore had reached a verdict that &lt;/span&gt;the Company&#x2019;s subsidiaries, KRHSG
and Melana (Defendants) is liable to compensate Jamie Fan Wei Zhi (Plaintiff), the Company&#x2019;s related party for failing to procure
the release of the Plaintiff from the guarantees to secure a credit line from United Overseas Bank before December 31, 2020. The Defendants
agree to compensate the Plaintiff the sum of $&lt;span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_c20220101__20221231_zFDZre1WF5E2" title="Compensate amount"&gt;3,704&lt;/span&gt; (SGD &lt;span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_uSGD_c20220101__20221231_z5ccxlYxcuN4" title="Compensate amount"&gt;5,000&lt;/span&gt;) per month as guarantor fee starting from January 1, 2021 until the Defendants
procured the release of the Plaintiff as the guarantor of the loan. The Defendants released the Jamie Fan Wei Zhi as the guarantor of
the loan on October 31, 2022. As of December 31, 2022, the Company has paid Jamie Fan Wei Zhi $&lt;span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20220101__20221231_z0gJyQsSiHCd" title="Legal payment"&gt;74,966&lt;/span&gt; (SGD &lt;span id="xdx_909_eus-gaap--LossContingencyDamagesPaidValue_uSGD_c20220101__20221231_zg0kSTSngrTl" title="Legal payment"&gt;100,000&lt;/span&gt;), and &lt;span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_do_c20221231_zPzPd6PPcPw6" title="Contingent liability balance outstanding"&gt;no&lt;/span&gt; more balance
outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3704</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="SGD">5000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">74966</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="SGD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zwpZ64DM5STf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 21 &#x2013; &lt;span id="xdx_828_z8TB7ces3og4"&gt;Segment information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company presents segment
information after elimination of inter-company transactions. In general, revenue, cost of revenue and operating expenses are directly
attributable, or are allocated, to each segment. The Company allocates costs and expenses that are not directly attributable to a specific
segment, such as those that support infrastructure across different segments, to different segments mainly on the basis of usage, revenue
or headcount, depending on the nature of the relevant costs and expenses. The Company does not allocate assets to its segments as the
Chief Operating Decision Maker (&#x201c;CODM&#x201d;) does not evaluate the performance of segments using asset information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company evaluates performance
and determines resource allocations based on a number of factors with the primary measurements being revenues and income/loss from operations
of the Company&#x2019;s two reportable segments: 1) Medical Services and 2) Property Management Services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MLIH_zjoOcL57Ylw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following tables present
the summary of each segment&#x2019;s revenue, loss from operations, income (loss) before income taxes and net income (loss) which is considered
as a segment operating performance measure, for the years ended December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_z4eZA4e9mIg4"&gt;Schedule
of segment reporting information&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z8ah55WnuA9h" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zrSGorQLJfp4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_zKJkRiVaJPA6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Property&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zl3ryZVn9in2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,076,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,764,295&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,840,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zaMLuK1Pn4W6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,463,593&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,991,371&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,454,964&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zLLEelNKyzpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,613,615&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,800,755&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,414,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfitLoss_zSBZ9LCdrvli" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,651,826&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,779,966&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,431,792&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zyBIyrSXf8Tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zbi74RH6UiDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation
of the Company&#x2019;s segment net loss before income taxes to the consolidated statement of operation and comprehensive income (loss)&#x2019;s
net loss before income taxes for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zpfkpXgIvIX8" style="display: none"&gt;Schedule
of consolidated statement of operation and comprehensive income (loss)
net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220101__20221231_zXS513TrVwDk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_zOMhaUDoz60a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Segment loss before income tax&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,414,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_iN_di_zknj3pCpykoj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of prepaid forward purchase liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,911,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EarnoutSharePayment_iN_di_zPE6c6oJ1S65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Earnout share payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,199,629&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherCorporateExpenses_iN_di_zm0mIqCHIh78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other corporate expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,406,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zCETa8iJRSp" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Consolidated net loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,931,824&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zquxMWINXwS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;div id="xdx_C0F_gL3SOSRIBSTB-MLIH_zhbSOpfrzthh"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_300_134_zFFbIL40VGB7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of segment reporting information (Details)"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zVxPERp1WWMl" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zTNi99oY9Fs5" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_z8ikQOnygo5k"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Property&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zGz5sfcm7hve" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;5,986,030&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;4,558,520&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;10,544,550&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zD7lB9iowtJ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,186,885&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(41,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,228,227&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zFo1MeNfyLA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income (loss) before income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,239,438&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,187,975&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;948,537&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfitLoss_zntSrFKSsDmd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,241,091&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,141,487&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;900,396&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_C0E_gL3SOSRIBSTB-MLIH_zGOTHpjMkVNl"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The accounting principles
for the Company&#x2019;s revenue by segment are set out in Note 3.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2022,
the Company&#x2019;s total assets were composed of $&lt;span id="xdx_905_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zbmKTNq76yB1" title="Total assets"&gt;2,176,405&lt;/span&gt; for medical services, $&lt;span id="xdx_90E_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zq0FYx5BA2m3" title="Total assets"&gt;335,068&lt;/span&gt; for property management services and $&lt;span id="xdx_909_eus-gaap--Assets_iI_c20221231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z633Pm9fTjOf" title="Total assets"&gt;23,117,567&lt;/span&gt;
for corporate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December 31, 2021,
the Company&#x2019;s total assets were composed of $&lt;span id="xdx_90D_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z37c18cR0cu5" title="Total assets"&gt;1,478,872&lt;/span&gt; for medical services and $&lt;span id="xdx_904_eus-gaap--Assets_iI_c20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zbLh0WQ3Q2me" title="Total assets"&gt;6,412,439&lt;/span&gt; for property management services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As substantially all of the
Company&#x2019;s long-lived assets are located in Singapore and all of the Company&#x2019;s revenue is derived from Singapore, no geographical
information is presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MLIH_zjoOcL57Ylw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The following tables present
the summary of each segment&#x2019;s revenue, loss from operations, income (loss) before income taxes and net income (loss) which is considered
as a segment operating performance measure, for the years ended December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B0_z4eZA4e9mIg4"&gt;Schedule
of segment reporting information&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_z8ah55WnuA9h" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zrSGorQLJfp4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_zKJkRiVaJPA6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Property&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zl3ryZVn9in2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,076,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,764,295&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,840,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zaMLuK1Pn4W6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,463,593&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,991,371&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,454,964&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zLLEelNKyzpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,613,615&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,800,755&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,414,370&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfitLoss_zSBZ9LCdrvli" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,651,826&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,779,966&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,431,792&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;table cellpadding="0" cellspacing="0" id="xdx_300_134_zFFbIL40VGB7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of segment reporting information (Details)"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalServicesMember_zVxPERp1WWMl" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--PropertyManagementServicesMember_zTNi99oY9Fs5" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__us-gaap--StatementBusinessSegmentsAxis__custom--ConsolidatedMember_z8ikQOnygo5k"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Property&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Medical&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Management&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Services&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zGz5sfcm7hve" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Revenues&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;5,986,030&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;4,558,520&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;10,544,550&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zD7lB9iowtJ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,186,885&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(41,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,228,227&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zFo1MeNfyLA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income (loss) before income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,239,438&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,187,975&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;948,537&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProfitLoss_zntSrFKSsDmd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net income (loss)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,241,091&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,141,487&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;900,396&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421"
      decimals="0"
      unitRef="USD">6076414</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421"
      decimals="0"
      unitRef="USD">3764295</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">9840709</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421"
      decimals="0"
      unitRef="USD">-2463593</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421"
      decimals="0"
      unitRef="USD">-2991371</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">-5454964</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421"
      decimals="0"
      unitRef="USD">-2613615</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421"
      decimals="0"
      unitRef="USD">-2800755</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">-5414370</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_custom_MedicalServicesMember36611421"
      decimals="0"
      unitRef="USD">-2651826</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_custom_PropertyManagementServicesMember36611421"
      decimals="0"
      unitRef="USD">-2779966</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">-5431792</us-gaap:ProfitLoss>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zbi74RH6UiDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation
of the Company&#x2019;s segment net loss before income taxes to the consolidated statement of operation and comprehensive income (loss)&#x2019;s
net loss before income taxes for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zpfkpXgIvIX8" style="display: none"&gt;Schedule
of consolidated statement of operation and comprehensive income (loss)
net loss before income taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20220101__20221231_zXS513TrVwDk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_zOMhaUDoz60a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Segment loss before income tax&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,414,370&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities_iN_di_zknj3pCpykoj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of prepaid forward purchase liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,911,503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EarnoutSharePayment_iN_di_zPE6c6oJ1S65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Earnout share payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,199,629&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherCorporateExpenses_iN_di_zm0mIqCHIh78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other corporate expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,406,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zCETa8iJRSp" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Consolidated net loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(24,931,824&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5414370</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12911503</EUDA:IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities>
    <EUDA:EarnoutSharePayment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5199629</EUDA:EarnoutSharePayment>
    <EUDA:OtherCorporateExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1406322</EUDA:OtherCorporateExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-24931824</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453"
      decimals="0"
      unitRef="USD">5986030</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453"
      decimals="0"
      unitRef="USD">4558520</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">10544550</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453"
      decimals="0"
      unitRef="USD">-1186885</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453"
      decimals="0"
      unitRef="USD">-41342</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">-1228227</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453"
      decimals="0"
      unitRef="USD">-1239438</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453"
      decimals="0"
      unitRef="USD">2187975</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">948537</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_custom_MedicalServicesMember36611453"
      decimals="0"
      unitRef="USD">-1241091</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_custom_PropertyManagementServicesMember36611453"
      decimals="0"
      unitRef="USD">2141487</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_custom_ConsolidatedMember"
      decimals="0"
      unitRef="USD">900396</us-gaap:ProfitLoss>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">2176405</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">335068</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_us-gaap_CorporateMember"
      decimals="0"
      unitRef="USD">23117567</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_custom_MedicalServicesMember"
      decimals="0"
      unitRef="USD">1478872</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_custom_PropertyManagementServicesMember"
      decimals="0"
      unitRef="USD">6412439</us-gaap:Assets>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zuzOVkCGMsug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 22 &#x2013; &lt;span id="xdx_82E_zcNpE211EV0i"&gt;Subsequent events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluated all events and transactions
that occurred after December 31, 2022 up through the date the Company issued these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On January 9, 2023, James
Tan, who is the former Chief Executive officer of 8i loaned the Company for an amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwvKSPWUo7Lj" title="Loan amount"&gt;145,450&lt;/span&gt; (the &#x201c;Initial Tan Loan&#x201d;)
at &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230109__20230109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zrdc6AGExaIh" title="Interest rate percentage"&gt;8&lt;/span&gt;% interest per annum and was to be repaid by March 31, 2023. The Initial Tan Loan was not timely repaid by March 31, 2023 and was
replaced as disclosed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On February 2, 2023, the
Company entered into a loan agreement (&#x201c;Agreement&#x201d;) with Alfred Lim, the independent director of the Company, pursuant to
which Alfred Lim granted a loan amounted to $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zsPcwkQXuOWk" title="Loan amount"&gt;128,750&lt;/span&gt; to the Company at &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230202__20230202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--AlfredLimMember_zXOxAWbA5bNd" title="Interest rate percentage"&gt;8&lt;/span&gt;% interest per annum. The loan was due on March 31, 2023. On March 31, 2023 the Company further extended the maturity date of such
loan to December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On April 24, 2023, James
Tan loaned the Company an additional $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zbCIDayRCKQf" title="Loan amount"&gt;332,750&lt;/span&gt; (the &#x201c;Tan Second Loan&#x201d;) at &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230424__20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanSecondLoanMember_zcwEjE8Ctpq7" title="Interest rate percentage"&gt;8&lt;/span&gt;% interest per annum, which matures on the earlier
of June 30, 2023 or within seven days of the Company receiving the proceeds from the sales of securities in the private placement (the
&#x201c;Private Placement&#x201d;). Pursuant to the terms of the Tan Second Loan, the Company agreed to issue to James Tan a new promissory
note in the principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230424__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanFirstLoanMember_zkRq0lx9ib71" title="Loan amount"&gt;145,450&lt;/span&gt; dated April 24, 2023 (the &#x201c;Tan First Loan&#x201d;) to replace the Initial Tan Loan. The
Tan First Loan contained the same payment terms as the Tan Second Loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On May 15, 2023, James Tan
entered into a third loan agreement with the Company pursuant to which James Tan agreed to loan the Company an additional $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zUldxfZ1Ilk9" title="Loan amount"&gt;22,500&lt;/span&gt; (the
&#x201c;Tan Third Loan&#x201d;), provided that the Company issued a new promissory note to James Tan in the principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zKGxivdVcAv1" title="Loan amount"&gt;700,000&lt;/span&gt;
(the &#x201c;Tan 2023 Note&#x201d;) to replace the James Tan&#x2019;s convertible note balance as of December 31, 2023 (see note 13) (the
&#x201c;Tan 2022 Note&#x201d;). The Tan Third Loan would bear interest at &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanThirdLoanMember_zeiqIaFVcq56" title="Interest rate percentage"&gt;8&lt;/span&gt;% per annum, and would be repaid upon the earlier of June 30,
2023 or within seven days of the Company receiving the proceeds from the sales of securities in the Private Placement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On May 15, 2023, the Company
issued to James Tan the Tan 2023 Note to replace the Tan 2022 Note. The Tan 2023 Note was an interest-free convertible promissory note
in the aggregate principal amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zzWinkIh26gb" title="Loan amount"&gt;700,000&lt;/span&gt;. On May 15, 2023, James Tan elected to convert the entire unpaid principal in the amount
of $&lt;span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zv70B64MBabh" title="Conversion of unpaid principal amount"&gt;700,000&lt;/span&gt; of the Tan 2023 Note into ordinary shares of the Company at $&lt;span id="xdx_900_eus-gaap--CommonStockNoParValue_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z6dwX8c71ju3" title="Ordinary shares per share"&gt;1.00&lt;/span&gt; per share in accordance with the terms of the Tan 2023 Note.
On May 16, 2023, the Company issued to James Tan &lt;span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_z17zh96cLhL9" title="Ordinary shares issued"&gt;700,000&lt;/span&gt; ordinary shares in full satisfaction of the Tan 2023 Note. Pursuant to the terms
of the Tan 2023 Note, the Company has agreed to register the &lt;span id="xdx_901_ecustom--OrdinarySharesAvailableForResale_iI_pid_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zPKW5sl73qPb" title="Ordinary shares available for resale"&gt;700,000&lt;/span&gt; ordinary shares for resale. The Company refers to these &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zWkLcYVdQoxc" title="Restricted ordinary shares converted"&gt;700,000&lt;/span&gt; restricted
ordinary shares as the &#x201c;Converted Shares.&#x201d; &lt;span id="xdx_90D_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--TanTwoThousandTwentyThreeNoteMember_zpMWkwmqoqCc" title="Conversion of ordinary shares, description"&gt;This conversion is likely resulted in modification of the convertible notes as
the five-day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the conversion date is higher than $1.00 and reduced
the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
May 16, 2023, the Company signed settlement agreement (&#x201c;Settlement Agreement&#x201d;) with James Tan, pursuant to which the Company
agreed to issue to James Tan an aggregate of &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--JamesTanMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5Xn83LZdkS7" title="Ordinary shares issued"&gt;478,200&lt;/span&gt; restricted ordinary shares of the Company in full satisfaction of all obligations
of the Company under the Tan First Loan and the Tan Second Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
May 16, 2023, the Company signed settlement agreements (&#x201c;Settlement Agreements 2&#x201d;) with two third parties, Shine Link, and
Menora, and a related party, 8i Holding, pursuant to which the Company agreed to issue to Shine Link, Menora, and 8i Holding &lt;span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ShineLinkMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zQgSLj6Z6cJ2" title="Ordinary shares issued"&gt;87,500&lt;/span&gt;, &lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--MenoraMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zHLX7osHK2J" title="Ordinary shares issued"&gt;119,000&lt;/span&gt;,
and &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EightiHoldingMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zjQ3w0HKv452" title="Ordinary shares issued"&gt;82,600&lt;/span&gt; restricted ordinary shares of the Company, respectively, in full satisfaction of all obligations of the Company under the convertible
notes balance set forth in Note 13 from Shine Link, Menora, and 8i Holding. &lt;span id="xdx_90E_eus-gaap--ConversionOfStockTypeOfStockConverted_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z5UCitQn2lq8" title="Conversion of ordinary shares, description"&gt;These conversions are likely resulted in modification of the
convertible notes as the five-day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the conversion date is higher
than $1.00 and reduced the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
May 16, 2023, the Company signed settlement agreement (&#x201c;Chen Settlement Agreement&#x201d;) with &lt;/span&gt;Kelvin Chen&lt;span style="background-color: white"&gt;,
the CEO of the Company, pursuant to which the Company agreed to issue to Kelvin Chen an aggregate of &lt;span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_zZl44HNO4skh" title="Ordinary shares issued"&gt;850,306&lt;/span&gt; restricted ordinary shares
of the Company in full satisfaction of Kelvin Chen&#x2019;s claim for an aggregate amount of $&lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pid_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--KelvinChenMember__us-gaap--TypeOfArrangementAxis__custom--ChenSettlementAgreementMember_z2aaH48OMdw2" title="Ordinary shares aggregate amount"&gt;850,306&lt;/span&gt; provided to KRHSG from time to time
since inception. Upon issuance of the restricted ordinary shares, the balance own to Kelvin Chen reduced to nil. In order to comply with
Nasdaq&#x2019;s shareholder approval requirement for issuance of stock to an executive officer of a company pursuant to Nasdaq Listing
Rule 5635(c), the Company and Dr. Chen amended the Chen Settlement Agreement by entering into a Supplemental Agreement (the &#x201c;Supplemental
Agreement&#x201d;) on June 6, 2023, so that the shares issued to Dr. Chen would be issued at a per share price not less than the closing
bid price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__srt--RangeAxis__srt--MaximumMember_zwKXWZNOpfxb" title="Share price per share"&gt;1.47&lt;/span&gt; per share on May 15, 2023, the day prior to the execution of the Chen Settlement Agreement. Pursuant to the Supplemental
Agreement, Dr. Chen has agreed to release and discharge KRHSG of all claims in return for &lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230515__20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zhGY4wswNL5f" title="Ordinary shares issued"&gt;578,439&lt;/span&gt; ordinary shares at $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230515__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zGMENy2YPEll" title="Share price per share"&gt;1.47&lt;/span&gt; per share,
the closing bid price of EUDA ordinary shares on May 15, 2023. Dr. Chen has agreed to forfeit and surrender &lt;span id="xdx_902_ecustom--OrdinarySharesForfeited_iI_c20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zxsJuOxCsBAk" title="Ordinary shares forfeited"&gt;271,867&lt;/span&gt; ordinary shares of
the &lt;span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230516__20230516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zFkCGPb20iF3" title="Ordinary shares issued"&gt;850,306&lt;/span&gt; ordinary shares issued to him on May 16, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;Between
May 16 and May 22, 2023, the Company issued and sold to eight accredited investors an aggregate of &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPv0cxwTk9r3" title="Investors sale of stock and issued"&gt;940,000&lt;/span&gt; ordinary shares (the &#x201c;Placement
Shares&#x201d;) at $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zouuncvZXAnf" title="Investors sale of stock price per share"&gt;1.00&lt;/span&gt; per share for an aggregate to purchase price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230516__20230522__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq5hcj1QIaB3" title="Investors sale of stock aggregate purchase price"&gt;940,000&lt;/span&gt; in a private placement in reliance upon the exemption
from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and Rule 506
promulgated thereunder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On June 8, 2023, the Company
and the Seller 1 and Seller 2 (together, the &#x201c; Sellers&#x201d;) entered into amendments to the Prepaid Forward Agreements (together,
the &#x201c;Amendments&#x201d;), to amend the definition of &#x201c;Maturity Consideration,&#x201d; such that, Maturity Consideration shall
consist of &lt;span id="xdx_90A_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zERqaZKpCb72" title="Ordinary shares to be issued"&gt;&lt;span id="xdx_908_ecustom--OrdinarySharesToBeIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zt5U0FtuUMcj" title="Ordinary shares to be issued"&gt;800,000&lt;/span&gt;&lt;/span&gt; ordinary shares of the Company to be issued to the Sellers by the Company. Pursuant to the Prepaid Forward Agreements,
the maturity date of the Prepaid Forward Transaction 1 and 2 (together, the &#x201c;Prepaid Forward Transactions&#x201d;) (the &#x201c;Maturity
Date&#x201d;) may be accelerated by the Sellers after any occurrence wherein during any 30 consecutive trading-day period, the dollar volume-weighted
average price of Company&#x2019;s ordinary shares for 20 trading days is less than $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zXUEz4uhktu3" title="Share price per share"&gt;3.00&lt;/span&gt; per share. Pursuant to the Amendments, the parties
agreed that the Prepaid Forward Transactions shall be accelerated as of the date of the Amendments, and accordingly, the &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerOneMember_zKT4Dq40Cy5j" title="Ordinary shares issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--SellerTwoMember_zzSp6mQhPTc8" title="Ordinary shares issued"&gt;800,000&lt;/span&gt;&lt;/span&gt; ordinary
shares (or &lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkLrsvQOtkB9" title="Ordinary shares issued"&gt;1,600,000&lt;/span&gt; ordinary shares in the aggregate), became immediately due and payable to the Sellers upon execution of the Amendments.
The Amendments provide the Sellers with registration rights for the ordinary shares issuable as Maturity Consideration, and also prohibit
the Sellers from selling such ordinary shares on any exchange business day in an amount greater than &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zkt7DP8QMf0h" title="Debt instrument trading percentage"&gt;15&lt;/span&gt;% of the daily trading volume of
the Company&#x2019;s ordinary shares on such day. In addition, as of June 8, 2023 (the &#x201c;Maturity Date&#x201d;), the Sellers became
entitled to retain (a) the remaining prepayment amount paid from the Company&#x2019;s trust account to the Sellers upon consummation of
the Company&#x2019;s business combination, and (b) the remaining ordinary shares held by each Seller that were subject to the Prepaid Forward
Transactions. Pursuant to the Amendments, no other fees, consideration or other amounts are due to the Seller or the Company upon the
Maturity Date.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">145450</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-01-092023-01-09_us-gaap_SubsequentEventMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember"
      decimals="0"
      unitRef="USD">128750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-02-022023-02-02_us-gaap_SubsequentEventMember_custom_AlfredLimMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember"
      decimals="0"
      unitRef="USD">332750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-04-242023-04-24_us-gaap_SubsequentEventMember_custom_TanSecondLoanMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-04-24_us-gaap_SubsequentEventMember_custom_TanFirstLoanMember"
      decimals="0"
      unitRef="USD">145450</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember"
      decimals="0"
      unitRef="USD">22500</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="0"
      unitRef="USD">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanThirdLoanMember"
      decimals="INF"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="0"
      unitRef="USD">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="0"
      unitRef="USD">700000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:CommonStockNoParValue>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="INF"
      unitRef="Shares">700000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <EUDA:OrdinarySharesAvailableForResale
      contextRef="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="INF"
      unitRef="Shares">700000</EUDA:OrdinarySharesAvailableForResale>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember"
      decimals="INF"
      unitRef="Shares">700000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockTypeOfStockConverted contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_TanTwoThousandTwentyThreeNoteMember">This conversion is likely resulted in modification of the convertible notes as
the five-day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the conversion date is higher than $1.00 and reduced
the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</us-gaap:ConversionOfStockTypeOfStockConverted>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_JamesTanMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">478200</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_ShineLinkMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">87500</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_MenoraMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">119000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_EightiHoldingMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">82600</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConversionOfStockTypeOfStockConverted contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">These conversions are likely resulted in modification of the
convertible notes as the five-day VWAP Price of the Company&#x2019;s ordinary shares immediately preceding the conversion date is higher
than $1.00 and reduced the carrying amount of the convertible debt instrument with a corresponding increase in additional paid-in capital.</us-gaap:ConversionOfStockTypeOfStockConverted>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">850306</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_KelvinChenMember_custom_ChenSettlementAgreementMember"
      decimals="0"
      unitRef="USD">850306</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:SharePrice>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-152023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">578439</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-15_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:SharePrice>
    <EUDA:OrdinarySharesForfeited
      contextRef="AsOf2023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">271867</EUDA:OrdinarySharesForfeited>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-05-162023-05-16_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Shares">850306</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">940000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-05-162023-05-22_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">940000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <EUDA:OrdinarySharesToBeIssued
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember"
      decimals="INF"
      unitRef="Shares">800000</EUDA:OrdinarySharesToBeIssued>
    <EUDA:OrdinarySharesToBeIssued
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember"
      decimals="INF"
      unitRef="Shares">800000</EUDA:OrdinarySharesToBeIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerOneMember"
      decimals="INF"
      unitRef="Shares">800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_custom_SellerTwoMember"
      decimals="INF"
      unitRef="Shares">800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-06-08_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000188"
          xlink:label="Fact000188"
          xlink:type="locator"/>
        <link:footnote id="Footnote000220" xlink:label="Footnote000220" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to reverse recapitalization effected on November 17, 2022</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000188"
          xlink:to="Footnote000220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000189"
          xlink:label="Fact000189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000189"
          xlink:to="Footnote000220"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000679"
          xlink:label="Fact000679"
          xlink:type="locator"/>
        <link:footnote id="Footnote000764" xlink:label="Footnote000764" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On March 1, 2022, SEMA, the Company&#x2019;s wholly owned subsidiary, sold <xhtml:span
  id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zD1JvvGVr8d1"
  title="Ownership percentage">100</xhtml:span>% of the equity interest in TGC to an unrelated individual third party for a total consideration of SG$ <xhtml:span
  id="xdx_909_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220301__20220301__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SingaporeEmergencyMedicalAssistancePrivateLimitedMember_zKFYzFUEh5J4"
  title="Consideration">1.0</xhtml:span> (see Note 5).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000679"
          xlink:to="Footnote000764"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000753"
          xlink:label="Fact000753"
          xlink:type="locator"/>
        <link:footnote id="Footnote000769" xlink:label="Footnote000769" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On April 19, 2022, the Company acquired <xhtml:span
  id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_znYpPcn2aYFd"
  title="Ownership percentage">100</xhtml:span>% equity interest of KR Digital Pte Ltd, (&#x201c;KR Digital&#x201d;), a Singapore Company, from Mr. Kelvin Chen, the Company&#x2019;s Chief Executive Office (&#x201c;CEO&#x201d;) and shareholder for total consideration of SG$<xhtml:span
  id="xdx_904_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220419__20220419__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOxLG2MTZoa2"
  title="Consideration">1</xhtml:span>. Prior to the acquisition of KR Digital, on April 15, 2022, KR Digital acquired <xhtml:span
  id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember_zluPsjBi18M7"
  title="Ownership percentage">100</xhtml:span>% equity interest of Zukihealth Sdn Bhd, (&#x201c;Zukihealth&#x201d;), a Malaysia corporation, from Mr. Kelvin Chen, the Company&#x2019;s CEO and shareholder for total consideration of SG$<xhtml:span
  id="xdx_907_eus-gaap--BusinessCombinationConsiderationTransferred1_uSGD_c20220415__20220415__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--KRDigitalPteLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZqJ6Iq9sHPi"
  title="Consideration">1</xhtml:span>. Both KR Digital and Zukihealth have no operations prior to the acquisition in April 2022. KR Digital, through Zukihealth, is expected to carry out the distribution of health care products business.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000753"
          xlink:to="Footnote000769"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000759"
          xlink:label="Fact000759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000759"
          xlink:to="Footnote000769"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000803"
          xlink:label="Fact000803"
          xlink:type="locator"/>
        <link:footnote id="Footnote000820" xlink:label="Footnote000820" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company did not have any Malaysia subsidiary prior to April 19, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000803"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0804"
          xlink:label="xdx2ixbrl0804"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0804"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000815"
          xlink:label="Fact000815"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000815"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0816"
          xlink:label="xdx2ixbrl0816"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0816"
          xlink:to="Footnote000820"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001165"
          xlink:label="Fact001165"
          xlink:type="locator"/>
        <link:footnote id="Footnote001173" xlink:label="Footnote001173" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December 31, 2022 and 2021, accounts receivable of up to approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z4xDU01VhSnb"
  title="Accounts receivable"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"
      id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zf8k8TiDZ9Mg"
      title="Accounts receivable">0.6</xhtml:span></xhtml:span> million (SGD
<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"
  id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_zBb3GcT6s7ik"
  title="Accounts receivable"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGFjY291bnRzIHJlY2VpdmFibGUgKERldGFpbHMpIChQaGFyYW50aGV0aWNhbCkA"
      id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pn5n6_uSGD_c20211231__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember_z1PFb0KBbwqb"
      title="Accounts receivable">0.8</xhtml:span></xhtml:span> million) were pledged to the short term loan from United Overseas Bank Limited (See Note 13).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001165"
          xlink:to="Footnote001173"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001166"
          xlink:label="Fact001166"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001166"
          xlink:to="Footnote001173"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1207"
          xlink:label="xdx2ixbrl1207"
          xlink:type="locator"/>
        <link:footnote id="Footnote001242" xlink:label="Footnote001242" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    balance of receivable from divestment represented the amount due from BPT, an unrelated third party. On January 1, 2018, the
    Company&#x2019;s subsidiary, UGI entered into an investment agreement with BPT, to invest approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_pn5n6_c20180118_zenOpL2qnKwd"
  title="Investment amount">1.9</xhtml:span>
    million (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_uSGD_c20180118_zrpU1QLF8zjk"
  title="Investment amount">2,580,000</xhtml:span>)
    in BPT&#x2019;s affordable home program in Indonesia. On March 1, 2021, both parties entered into a mutual termination agreement
    (&#x201c;Agreement&#x201d;) to terminate the investment agreement. Upon execution of this Agreement, BPT agreed to repay UGI&#x2019;s
    investment amounted to $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_909_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20210301_zmV2Yy9dAwP2"
  title="Investment owned face amount">1,913,096</xhtml:span>
    (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90C_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_uSGD_c20210301_zAfGO9J1fdC1"
  title="Investment owned face amount">2,580,000</xhtml:span>),
    and compensated UGI with the additional amount of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_904_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_c20210301_z4Ryres6TS7l"
  title="Additional amount">1,905,681</xhtml:span>(SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_909_ecustom--InvestmentOwnedAdditionalAmountAtMarketValues_iI_uSGD_c20210301_zZmVdgQBZEo5"
  title="Additional amount">2,570,000</xhtml:span>).
    The Company recognized the compensation portion (the excess of the settled amount over the original invested amount) from investment
    as other income for the year ended December 31, 2021. In May 2022, the Company has collected approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_908_ecustom--InstallmentReceived_iI_pn5n6_c20210301_z0Y2ww17822k"
  title="Installment received">0.9</xhtml:span>
    million (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_908_ecustom--InstallmentReceived_iI_uSGD_c20210301_z4vgNaMTDQ3d"
  title="Installment received">1,200,000</xhtml:span>)
    and signed an installment payments agreement with the BPT to repay the remaining balance of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_pn5n6_c20220531_zu9dCueWR3N1"
  title="Remaining balance">2.8</xhtml:span>
    million (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--InvestmentOwnedBalancePrincipalAmount_iI_uSGD_c20220531_z9HUqVAD40Db"
  title="Remaining balance">3,950,000</xhtml:span>)
    in eight equal quarterly installments with annual <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--DebtInstrumentInterestRateTerms_c20220501__20220531_zHXffbsvaYz2"
  title="Debt intrument interest rate, description">interest
    rate of 3% beginning on July 31, 2022, October 31, 2022, January 31, 2023, April 30, 2023, July 31, 2023, October 31, 2023, January
    31, 2024, and April 30, 2024.</xhtml:span> As of the date of the issuance of these financial statements, the Company has collected two
    scheduled quarterly installments of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90C_ecustom--OtherReceivableInstallmentAmount_iI_pn5n6_c20221231_zUPRddRlJolb"
  title="Other installment amount">0.7</xhtml:span>
    million (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIG90aGVyIHJlY2VpdmFibGVzIChEZXRhaWxzKSAoUGFyYW50aGV0aWNhbCkA"
  id="xdx_90E_ecustom--OtherReceivableInstallmentAmount_iI_uSGD_c20221231_z6xi1O1fHw3g"
  title="Other installment amount">987,500</xhtml:span>).
    However, due to the skipped repayments from BPT on January 31, 2023 and forward, Company determined the remaining balance due from
    BPT is at risk and more likely than not the Company will be able to recover such balance. As a result, the Company fully wrote off
    the remaining balance of receivable from divestment due from BPT for the year ended December 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1207"
          xlink:to="Footnote001242"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001208"
          xlink:label="Fact001208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001208"
          xlink:to="Footnote001242"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001409"
          xlink:label="Fact001409"
          xlink:type="locator"/>
        <link:footnote id="Footnote001450" xlink:label="Footnote001450" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On August 21, 2019, KRHSG entered into a revolving line of credit
                                                                                                       agreement with United Overseas Limited pursuant to which KRHSG may borrow up to approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z1zbP2Zl0BAh"
  title="Loan borrow up amount">593,208</xhtml:span>
                                                                                                       (SGD <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uSGD_c20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_z8B8IKo4Ufq"
  title="Loan borrow up amount">800,000</xhtml:span>)
                                                                                                       for operation purposes. The loan was guaranteed by Jamie Fan Wei Zhi, an immediate family member of a shareholder of the Company, and
                                                                                                       secured by KRHSG&#x2019;s account receivable (see Note 6). The loan bears an average annual interest rate of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_dp_c20190820__20190821__us-gaap--LineOfCreditFacilityAxis__custom--UnitedOverseasBankLimitedMember__us-gaap--ShortTermDebtTypeAxis__custom--BankAndPrivateLenderMember_znI1htBIlb76"
  title="Loan interest rate">5.50</xhtml:span>%
                                                                                                       and its due within 90 days from the loan disbursement. The Company released  Jamie Fan Wei Zhi as the guarantor of this loan on
                                                                                                       October 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001409"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001411"
          xlink:label="Fact001411"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001411"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001413"
          xlink:label="Fact001413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001413"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001415"
          xlink:label="Fact001415"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001415"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001417"
          xlink:label="Fact001417"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001417"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001419"
          xlink:label="Fact001419"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001419"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001421"
          xlink:label="Fact001421"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001421"
          xlink:to="Footnote001450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001462"
          xlink:label="Fact001462"
          xlink:type="locator"/>
        <link:footnote id="Footnote001479" xlink:label="Footnote001479" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On December 16, 2022, the Company has signed a loan agreement
                                                                                                       (&#x201c;Agreement&#x201d;) with Kent Ridge Health Pte Ltd (&#x201c;KRHPL&#x201d;), a related party. Pursuant to the Agreement, KRHPL
                                                                                                       agreed to fully remit the loan payment to Koh Wee Sing on behalf of the Company. As a result, such short-term loan- third party was
                                                                                                       transfer to other payable, related parties under KRHPL&#x2019;s balance as of December 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001462"
          xlink:to="Footnote001479"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001485"
          xlink:label="Fact001485"
          xlink:type="locator"/>
        <link:footnote id="Footnote001494" xlink:label="Footnote001494" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This promissory note has a default interest of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_902_eus-gaap--ShortTermDebtWeightedAverageInterestRateOverTime_dp_c20230214__20230215__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhRjsrucMMM8"
  title="Interest Rate">15</xhtml:span>% per annum beginning on February 15, 2023 until
paid in full. In June 2023, the Company and KC has entered into a settlement agreement (&#x201c;the Agreement&#x201d;) to settle the promissory
note. Pursuant to the Agreement, the Company shall pay KC (1) $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--KaufamanAndCanolesPcKcMember__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zpVPI5QNLFll"
  title="Convertible promissory note">100,000</xhtml:span> within two days of the dates that the Company&#x2019;s US counsel,
Loeb &amp; Loeb, confirm that it has received from KC all information and documents necessary for them to prepare an amended S-1 registration
statement covering the resale of securities, and (2) $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--PromissoryNoteMember_zfMVkG6Nh9Ka"
  title="Convertible promissory note">60,000</xhtml:span> within two business days after the date the first amendment to the registration
statement is filed with the SEC.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001485"
          xlink:to="Footnote001494"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001556"
          xlink:label="Fact001556"
          xlink:type="locator"/>
        <link:footnote id="Footnote001583" xlink:label="Footnote001583" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mr. Meng Dong (James) Tan, the Company&#x2019;s related party who had more than <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_z9WGKIz07E0g"
  title="Bank/Private lender Name">10</xhtml:span>% ownership of the Company, is the sole shareholder and director of 8i Holdings 2 Pte. Ltd. Mr. Tan has sole voting and dispositive power over the shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001556"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001558"
          xlink:label="Fact001558"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001558"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001560"
          xlink:label="Fact001560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001560"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001562"
          xlink:label="Fact001562"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001562"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001564"
          xlink:label="Fact001564"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001564"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1566"
          xlink:label="xdx2ixbrl1566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1566"
          xlink:to="Footnote001583"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001568"
          xlink:label="Fact001568"
          xlink:type="locator"/>
        <link:footnote id="Footnote001586" xlink:label="Footnote001586" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mr. Meng Dong (James) Tan, the Company&#x2019;s related party has more than <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHNob3J0LXRlcm0gbG9hbnMgKERldGFpbHMpIChQYXJhbnRoZXRpY2FsKQA_"
  id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20221231__us-gaap--LineOfCreditFacilityAxis__custom--MengDongJamesTanMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EightIHoldingsTwoPtdLtdMember_zJnkKcvkkyP5"
  title="Bank/Private lender Name">10</xhtml:span>% ownership of the Company.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001568"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001570"
          xlink:label="Fact001570"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001570"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001572"
          xlink:label="Fact001572"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001572"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001574"
          xlink:label="Fact001574"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001574"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001576"
          xlink:label="Fact001576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001576"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1578"
          xlink:label="xdx2ixbrl1578"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1578"
          xlink:to="Footnote001586"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001594"
          xlink:label="Fact001594"
          xlink:type="locator"/>
        <link:footnote id="Footnote001608" xlink:label="Footnote001608" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance of accrued expenses represented amount due to third parties service providers which include marketing consulting service, IT related professional service, legal, audit and accounting fees, and other miscellaneous office related expenses.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001594"
          xlink:to="Footnote001608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001595"
          xlink:label="Fact001595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001595"
          xlink:to="Footnote001608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001600"
          xlink:label="Fact001600"
          xlink:type="locator"/>
        <link:footnote id="Footnote001609" xlink:label="Footnote001609" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance of accrued interests represented the balance of interest payable from short-term loan &#x2013; bank, private lender, and third parties (See Note 13).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001600"
          xlink:to="Footnote001609"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001601"
          xlink:label="Fact001601"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001601"
          xlink:to="Footnote001609"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001636"
          xlink:label="Fact001636"
          xlink:type="locator"/>
        <link:footnote id="Footnote001644" xlink:label="Footnote001644" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of date of <xhtml:span style="background-color: white">the issuance of these financial statements</xhtml:span>,
this receivable has been repaid by the related party.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001636"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1637"
          xlink:label="xdx2ixbrl1637"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1637"
          xlink:to="Footnote001644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1670"
          xlink:label="xdx2ixbrl1670"
          xlink:type="locator"/>
        <link:footnote id="Footnote001684" xlink:label="Footnote001684" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Upon
    the closing of the Business Combination, such balance was forgiven by its related party (see Note 16). </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1670"
          xlink:to="Footnote001684"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001671"
          xlink:label="Fact001671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001671"
          xlink:to="Footnote001684"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001872"
          xlink:label="Fact001872"
          xlink:type="locator"/>
        <link:footnote id="Footnote001886" xlink:label="Footnote001886" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">It is due to tax rate difference of the entities incorporated in Vietnam and British Virgin Islands.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001872"
          xlink:to="Footnote001886"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001873"
          xlink:label="Fact001873"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001873"
          xlink:to="Footnote001886"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001881"
          xlink:label="Fact001881"
          xlink:type="locator"/>
        <link:footnote id="Footnote001887" xlink:label="Footnote001887" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Others
    mainly consisted of income such as offshore investment income, 2021 return to provision adjustment, and COVID-19 related government
    grant which is non-taxable under local tax laws.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001881"
          xlink:to="Footnote001887"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001882"
          xlink:label="Fact001882"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001882"
          xlink:to="Footnote001887"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001894"
          xlink:label="Fact001894"
          xlink:type="locator"/>
        <link:footnote id="Footnote001911" xlink:label="Footnote001911" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The valuation allowance on
                                                                                                                                                                 all deferred tax assets decreased by $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGRlZmVycmVkIHRheCBhc3NldHMgYW5kIGxpYWJpbGl0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90C_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zUk7JoNyXIxe"
  title="Valuation allowance on all deferred tax assets increased">42,755</xhtml:span> as of December 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001894"
          xlink:to="Footnote001911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001895"
          xlink:label="Fact001895"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001895"
          xlink:to="Footnote001911"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&CX(#!\G+7%(G3N&A+DNP]G^1CG2>E+79NX>H90#U4Q!8*9XQ3H%5FZP4.E
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MPI^+)$N@?G^(8_GR(2M@]R38^#]02P,$%     @ ^(G<5FI#(F8*"P   S4
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M/!.%,I#?SW.9$;=OU UVOWNZ^C]02P,$%     @ ^(G<5J-TU>!I"P  AB(
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MV:;ZG]>KIJV!6OYW:,<\WWQX/N2@%\U>K\U/3X!%&E/?F2>O_O,_)I?C'\]
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M/FSG'_ZO4** =,V(=(DT\ LG,@(? G0Q6].OX:]"398<)QBIWZKR0KP$4E9
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M4,*>F@9,.D=:012Z-@GP:;U%7;8!A;+5*)TZ\_(YPV>U,[J4"*+#8^C'WFJ
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M]A6CL+]_=IFO/)"A945Q$[)?.H#ER30=3Y?IY>)2 486LW0VFR4LW9Z_[YW
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MTVH_M-4>IU2KJFVK'?UY:S2<,SX OV\JP(E\P 7NJ_HK@??J_P!02P,$%
M  @ ^(G<5LBLL/_-!P  /10  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULK5A;;^.V$G[7KR"\Q2(+J+8D6[[D!B2[6[0]>PF2W5.<1UH:VSPKD2I)
MQ4E__9DA)=E.+!<%SD-B29[Y.-=OQKK<*OW#;  L>RH+::X&&VNK\]'(9!LH
MN1FJ"B1^LU*ZY!9O]7ID*@T\=TIE,4JB:#HJN9"#ZTOW[$Y?7ZK:%D+"G6:F
M+DNNGV^A4-NK03QH']R+]<;2@]'U9<77\ #V>W6G\6[4H>2B!&F$DDS#ZFIP
M$Y_?3DC>"?Q;P-;L73/R9*G4#[KY+;\:1&00%)!90N#X\0COH2@(",WXL\$<
M=$>2XOYUB_Z+\QU]67(#[U7QA\CMYFHP'[ <5KPN[+W:_@J-/RGA9:HP[C_;
M>MDD';"L-E:5C3):4 KI/_E3$X<]A7G4HY T"HFSVQ_DK/S +;^^U&K+-$DC
M&ETX5YTV&B<D)>7!:OQ6H)Z]OH='T ;8/62\$I87XB].X;H<640GF5'6(-UZ
MI*0'*4[89R7MQK"/,H?\$&"$9G6V):UMM\E)Q ^0#=DX#ED2)<D)O''GZ]CA
MC?\/OGJDR7$DZI1S4_$,K@;8"@;T(PRNW[Z)I]'%"3LGG9V34^C_R,Z32,?M
M_*(LL E[^V:>Q/$%ZSN-?97LBWJ$<@F:Q3.?A9#9#;#WJJRX?&:9DJZ9+>3T
M/+BM#1I@# DLA?0P*&2AK HGM7QV  ]W-VP)=@L@V5R$[..OGT+V!TI@G^D?
M(>,R9__:*KEF_P&,W2?LQ9#E#N&FTJ)@<5,53I(C26#%L<_\F8VC,/"&_EY+
M8''4VDV"#U!9[T_CSI#=F#X#484M6X>R/8=VACM0M)UMN6&P6B'3=!!!5>ML
M@WQ!]RBJ5HP7!7T0OC"F1E'21Z8T%B\$>FLV'--$0H2ZTJK<CPI^A5Q#<D(Z
M@26@773/V7:CBN*9J:U$6%,OC<@%DFR 4',Q9-\K-)P.[E*&G@2-,<?2YA.]
M0E"UI1.P2*3MC153659K#7GH*!*=0@._?[AQ-3:[0+W#TN+.Q[:Z@K:ZSH.W
M;Q;3V>+"A2H.TR@*HRAB\80^W*54;#$<CSM!,@ M$[8 K )+L)VP%THO$*E5
MC]/AT>=)U/<\C)O+<3CMA9WLQ.+=Y6^N^*6?/\%6V(U/0:$,A;0O](=1F(LN
MB.A[$J8+C,LD9=,P&H_#29J>DEXD89)&)_'B='I*1M-4,Z&K&V%<\5%)A=,D
M]0'R1[ YFC5+=L8D^['"^VD3Q"8TW_:+*[!\60!S#$5%1H&1M>O3ID(;PNFL
M4AK;!<N[;9B>=A)E"=@&%K S=J5,@'VD=\X><.W)ZP*H.4ZCZP9#O\ (OK;6
M/3C]@+K_A<'[.$AH2C.K^ID8V2Z:C:D=@D]8+.=X9(Y=Z+YS#?X*_ZPK#_8N
M>*\D >^D?5*[G#T<N(F&T* 0&65$/8H<55GB\_<"BCCH52HD ARQ:-?#P3>%
MOAV+!'4;V32+"#H@5LV!Z$](;]@27/9XEJE:NF+DV9^UT%@I:USN/"MZ(L;;
MPDTHJS'S?D U-(XWCC*>&5\A>DMB[]DWS:7AKEV'KD3M[D$@J&%L_U#(>(VY
M0\_)[$/)5V 8Z]8)- 97:V)$WEM1(=*[R#:H%0"Z^\@+HCJ,1SM*N,1L[0H6
MB=G-#^5]D[C;EPK_4SJX,6"-+X30&4&M)3R=\U='#QV2.$@$-T%?%JA'Z+L-
M<H72(L,\KS!$,A.4<8NM6+H6;XJ'HE;"T1;_&P0,"?)IH '3:RJ?;\;S_^+&
M[$_ Z%!)--70$DE?A'V&*%#[\6%;T$Y6K:7XRWG> K4D3DM)P.V^N9DRUIM'
M#+M6*M\*FOS(9JBIJ4.X7 NBO.8P.D'C!C-D7RO0SB"SHP4Z[C/H-8574["4
M@3: S0+21BU0.WTOBY*2]@*Y5HZ[=]][A&'?E.HCH\,-4'-!XYY72!5/HO14
M^Q.+AV,VGPUC%@T3I/[A?#>NV'B(4R,>+O"[\=$Y0-' =!?>?"AV)7/*KC92
M-*A4(?RR>%AQ&3<;ML*S3%>GN*')M6,MWSNX11'?-?%TW88T<88_\T0F[+O#
M\=!7V;V#8;=.S_W"$_Q2RQQK'8J<3-B;NU9C);<MAA&=SW $3,)XGO;K-,G%
M-#M/6^5D,@\GBT4S.GCI'E9<.$:E20(EJ^IE(;*]_7,?]M5LB<+Y>!&F./;?
M-:@5?]YE:8_GJ!<HNGX[;%;ALR1<3--P.ID>U4?:VG*=LVZ!YFL-373/DCB<
MX\J1)K-.5\.^-A9BB92HT%Y)/W3:GSD:_-):<8T9]>U]UJXC[X([K3( C*M;
MND\66AR.DPEZ$#?GU](%$VL$G).8'M!;+5PF5@#D;QR/PSA).YL;G;\/U7B>
MT-[Y,E#^=T^6:9K8\%2!-- 3_-;QIC]ZW3I#OZ(T3.=TV$V>GV/\Y,^NDO9X
M$3_JDF86A0D-Q+$^QMJ<1^/@"TJY>2N6M:<8)[0_GUZ64MW^+.FUZB=:?A;X
M-TD7CBT:3?(?21,O$2+W->\4FP+W$KC,!M@47HFXFN^'8X\X#]:0EU8>,'&O
MI1N.TV9)/PS=4.+M"N*'$N1!W6W]'Y\\[[![4F7'7AF,]E[IE$3^].**5@[T
MS;_=Z9YV[\9N_"NAG;A_L?:9Z[7 ;!2P0M5H.$L'?@-L;ZRJW NBI;)6E>YR
M QR+F 3P^Y7"1FINZ(#NC>'U_P!02P,$%     @ ^(G<5KIT.-I8 @  :@4
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M0^,-:'^EJ7T."W_ \'3._P902P,$%     @ ^(G<5AML)Z9B!P  $1(  !D
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M,SAD:/P\_15>M,_H,WJ<'[;]2ML>;'/9)K0.;A@;%>3,].A>F]]_#M\Y0Z"
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M+P8R.)1E1<75BMDTN[0V$<BF"%0@5Y3640\AC/KNF7@O40.<\VS"X(QE/'6
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M;D)ZW<B^]1/2#0/O2QIZNDI :^<]:<@FLRYK]'*MI\[2NJW1EUQ@!T?=VN!
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M4-D!^'TLD;";AE6PN([?^Q=02P,$%     @ ^(G<5DS,Y_.4"0  3!@  !D
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M<'&>OC'DNY&9!-8Q@"@B1U(@O.7QI-D+#R1TTGI5RRWCS%A8PW76!8],H4S
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M73GA#5(,A O1*4=6 /1_'  <</19"9(+OH'0W&6_VV!N/,:L 6EGSU@-* +
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MQJ0+@9N_OE4(I$96@]3D+0J-^M#??_(/12LMDU]@Y-N\=8^^_]]?@D<;6N8
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M9^-QE._*%FU%Q'+E0IQB4I\10SD\>O)!@F/()1L_8-1B(> FKSB0TD/-7"N
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M2?(@4ARP/ONH]415U<'T16]9&K0PP^'L 0!(U:HZ97AGF ''Q@3T)N'OH(/
MP*3\L<A*/PLJTT3-4SRN7R33R?Q1VXU/8)B-9S#\0_(J!RG29V0LZ'CA[3#.
MM8;$03,Y\:+;G%1?3BLX"T(-D9AI'FCX/;JTZP-K(Z'!+V1??*PRC<\Z \1$
MBD)Q<XT>BV;Z90<0QFIE'[>'G DFD"B?O308[?R:DN$US/G[5S>O79PS$MIS
MC'5^"YH\O'4 E1!?_C'(Q*9K\AUG502QTOA>E(F'WUW-EC"6I818ES_\@]U0
M%$/X,CSH2T?\>A<Q=Q]*K78'E)K\F;") >.\.>8P#@56T(<%+]PV,;N?C6*6
MV(,Z9/U)#K^'VY#%F.#D&AXP8P;=49X9E20=I9.?S8JL@YAG:,&.DVC'P [L
M1U5K>LX*3*1!11L@41\E?SE<=#A>@EYNA"ZG);MP/8H\H=6K"1_))H?:VK8M
MHJRXG-() M:85(<63TVI[T#B"F:)I%+<0@)L/'<\"2NQ6H3BDJH>4I(@L(<#
M#=M:*E*2%>:?A\TMO\!^050P?,0L$%%Z1:'BXJ.YB(&3 @-7+\AO& U0',59
MC((OFU?9I=T[-(2)8"F)S#0)D0ZSHQ0$#&[7%XC/=_')I36<A$_:GU8@HQ[0
M,.$H(\(.\C_[-63$#D@4%+'\T#6KD:MN>Z@E0!!EJPYA2[);N*?BR@_Y'AR&
MQ"G@2(8,<+H!DOBWQW##00D%3"^AP,))\AO,;R18/N#>FGV+&UV)-R95D%[E
M#B'WAQ50UF0H@5]"V\/C2QXL 58R$E;'P5LX,F8,2]H&V>LI&<!-2\.+.@9G
MI7#<A?DJ.#K:4LHUTQD,M/46)<XL\,:*,0[L,Z9FXRE3WTL!!/7Q)K]T8B,U
MB*[W8,!(!MGW9^19?>IBS-!B.B$7<D%&AZY$ZQO)P",M#22@J^MYNIQ?@FH#
M"%J6$DM'6@FB36^:5WI/XFL2NLP##G4BT1D8%2A,9_/EV94FCD56;[2* 'K>
MNK"6/2@-1-XI8!$I/#TD&3#'V&F%43IJWZD25'1Q&3RLL(M3Y3)<WO=1N<>3
M03E-%P#.Z7(QAL=SG_@T'T]\^H73U!2PIRIAC(\RC)4#0T<W7B(%1$C@9P.Z
M%LH-R$('!;G?.'S=RU&_.0'LIVJ"-N_SL^EUFNA:2')[@XPW6VM(GL8;@"K+
M+ON+Z<4+/^3 M.;1;#D8(A;FUA5E?TJM+99VBJ-W,/1!1<1;S&69AY2CEVCG
M407RS(V@!M[0\>K2C<2HQ#3!!>2B:N- D+-@SKJ6#";VS)[7EA+(4/"(TOY8
MF=0(!3))%NPH)-*N*>(BQ(A5DX6L>'^J(QY94LJX@DR0"!E<7JZFT'?/*5AB
MV[I2$"Q[1:6TR(U)K+X6GS-\2+VNPFY<EM=.05& W& X3>8@"MN$CYBN>B^'
M$V-"3-Y(MT$% S0%,D=R'!2K]7K8=8C+.H^#D;#5[@B!:!C[_Y+G^0L/:3EC
M&LDXZJR3I/!P]^E3Y^$=PS08O0KOQKZSL!@.@ 0S&;S@?Y_5Y-DW/:3C:(+6
M*HJR*1(DW14GG9-W-*ID*283]F!D!:,=FH?(98J+NW_A/"7#2]-L^+@TQ=/V
MCICR'&;H'R)AUG,T9S<OHF-I8*QFF_M03)W)^)DZUJQ07\_<[%)?T1VBH2G#
M]4G(\PY# .BB8C0 G #C)M7)<G$5F$5"-0D"BZ.F?J"*SL:AKG7'S81L%Z>R
M-6JG!C6)UJD8+C#>10?ID4Z2(6;B:I*28(R:27O<V\17*#.<>]T+HWX^>Y%H
MQ/.-7N"SY,/@<;J3&"08X0%PI /+11E:R.FEUJ[ORJJH;D'HL%D!9[&F2@!%
MUI*30WW=[*[.R/*ML7F''>Z&7Z.W'+E!)^MM36("G6_P#'!$3!/*BF.;KXD.
M;VKT]4@4]P:%>/2R24HZ[,[VI'&W%1)_!%1N<MJ?:A5G;77F-(SGK^>O7[B]
MI8Y$BI\':-^^(@-HR''NJ^*>$0^O//K;0+5'AUS>#1K(PUPK,::RK,#800N#
MI8?@P+)G+3O)<,.&3$KPZ]'MBYY@:,B/&,3A]"H-I\5SV^1TDIC?B44 Z -;
MVMMU&BF-WI^,D8C%*6)!><\.PR;)#<ZUM6*?)^%QI6198&<\[.#]E0V*38+.
MH[EA'<CY2JIPNXI&'AXX#Z.N\1X(X^-_L/9W'(TS3,GM#TNN*?R_E_PJKZ:,
MJQ'!"%=FVP=,H%Q,C4^E%7==HL$_(54/ZW3IRW( +F.M3S8HI#ZGZAP3E 4;
MC<V)>+%Y)&XF-N.0-"G)PIH*E075/9R)881D=ZY9@-0F2VYK] HP%L>J#$>O
M<.T$U)!%M"#;'S[7V'Y=58KA:O;(5Y%AXNQ =K8,%*;S(%Q@C"LJ14*:\ *+
M/=9ZP2=->N52A<H[:2G @$;J"XB71"@]DB@J.A,^ZA/%1)1T7D/$CFI%!<2$
M@8BQ#DT:9/"0H%XJR;7+?N=-Y4U<WK$C>F$*A',(N?"N-J8Y<G&)6ID^<,FN
M%@258=9GB>G-E!"6TL;1@=\B?N2EK\PA=8\)GE(B=F?QRJ%'J@!:VW),HC.#
M-5;=855-I7&&]%_00E#_72[/%A?P4ET=;N^2\VDW;DYDDA/$7GEI+#8$)]M#
M"8K5$G%8M.,PV=WEL/2Y:4A .>^M9\TR1(P&TE=B[BM4!8"*1[/&B@AYF:\I
MZ"Y@'%)&X4G<PPDAOBB@*!(.-,)).&2<:U8,20VF8UUTKTZ2Y_,7F-=&E?-N
MLN(_(I>HU0%+65@@_LR6T3.0(2O89B2+=4ED"YP$P81R\RX(EI: OZ0Y@GJQ
M8\=8EXN0/TT4NKWL1H-(9=[,)=E2O)@DB='Y**E?9WN2YP%"*TN5@<@ELT8F
M4*I[T.D_%*841]F$TQ.'"F86)Y;87:J'6)@VP>D&HS2QW-ZY"3H54HR,"BJ*
MRM#%_%P+0(<GYIW:CKUC70(MHQ402+'L4_;L*3(H2^KF.>CWHL#2%>L=R@E3
M+@FR('!G JK0K*"0  %<*D.08M4,H:;3JF.]#AT/CL3HJ2(AQ'H6#NN-6.E4
M2J&-,$+O[XX-D:X]!;$U/&B:%/86OB0S! #2%YI DJR9P ]D3<)HY0>L)'.7
M[V-(N8HO 5U+C2]9$2Y7*]6[M[WV$L=.HS,I*E2-E;=%Z>V:&J, #\*RVL+5
M!);CQ$'GYA8_J:803Y(?7.6/CI!#"^9 0O3?H"3%692AE"43 6U:O/ YMT&$
M\:>H4&1=R=1;A*&G/6K%;#](]PLBAY3%(,=K[JK]'B&RRXBH.26$BX'!Y[S8
MD!I+*=L-*Z48)(E*+/LC)9B+$C<%;FY:1H6)W_+P.EC80Z66Z5DVNG"U 7']
MTW5ALY*66,#4#>9GX@=QFB!A%MM\-[M4ZNC6&3L+494.!2QBB+JTAEL7',?7
MY4IX/ 4DWU'8A%0&?J@"<+BX\492F0*/5T>7\T7=G@P\$G#']2D6+0W(?'RA
M59KLV&2>P&2(2?I%LF@JH#RUN)(/IK]$TUMB3>2@*I%6EE[JU2J-@>#M9M6I
M1@6X1X!IG*F=5/,1U(C$HCC_G?40EYW#BIQ+[!D_3(</YM$59-X)Y+5$FA4A
M1H&60DA6=ITA6PSES"B$EUSYZ+G24A&<T<?(XI( W26(6:#*SECM;\SFR8N)
M3P<IK"U<=);$D)*T0)(I)MT#\=V@$<90)C<5SJ"\A2A+7/(KO(N3G_"Z4&CR
M4T8:9K4HK#C$RM<K<K#$\!V@GY]:_*=7S]7?,<E>&\36C5:O47N A'J'1VA<
M&=A!1=XKWX$O$)TUQ4FORBFJ04)N>S*4RWSJUMUZ)AA(Y.M'1K4HPUX*JZ,3
M,E\Z<CI6_T'ULOXQ=;^9&:T[^[]XS-1[Z4FOO>_J@B0+SKY*O V-E*0ODHMT
M.IVEYXMK^'N93F?3]&IQ>?K]GG9VL4@OK\^3R]D\A?\^X<7G6EU"#-,ODMEB
MF9RG%^?3D>4?5IPN <N^6*:+BRM8].7\*IU=71O5OAK2OF:S='I^D<R7E^G5
M^<R,R )N])  !H_-T^O9=;J U2W2Y?0JO;A8/&FX(9YS=7Z>7E],$US<=7JU
MO!P="6![<9[.KQ$NR^55NIQ/S:^T?X=]7R0PS/DTO9SB"<+Q+<_QV2E@>M-&
M>#IH.^\]A?)*(?[RAKT'SK!P$"?7WJ7'<_9[;/U"NVA(CM]D&Q1/DQ_8AOX!
M2QW\V&XF*24M>!PXIKYV]/L,9I 2D.\[TSNMF'7.[O1=3C!:0XM#84"'"J3F
MP46\MK=Y67)98*ELS6D!2,O-)P(P&0<@EQL.=S%:!:QO>/B40Q72921"::^)
M?[(^+GN'-^H)6L13YBVR%4XE1::,XY'=XM,CTN0CA'G=7<4G$^C."/]_$&J@
M0M= ZRZOX._S"[CSUT]^.2*UQQ?)^350_.MK&'(!1.AR^@EDNTG.ET!BKI/S
M^65Z/;UZ JD&HKF8IU=SH,7P[WEZONR2ZB50U^L9)<H#4,8H8O,XK9[/D!@N
MX*_SBUEZ?35*^IM18GUQ!6N_7@#1O@"2NAP?"#9WC;3Z C:\ "ZQ7%P(K>XA
M)'+=\RL8<[:@OQ?3:3J[OAR-"_+E7>>/E'?%] U0VMEY<:(V_O@8)^JZ=@=.
MPF]R=]O57%W1L*ST;K?T-_HF*BYZYHJF3Y+^P!S%PG(W!:%= @N<7TZ!X<]&
MH>2K3L['JT[^ KLB\LXI5O>VJ(CT#0+K,XI/GAH_.?F#J[OGM/^LH-H')BCB
M!](K/$2D[DPOM7OQ1$WB.IQ1;5#AS(#3#4;V%5J-LC.N6.S,)P_<VFPW><*.
MX^.>(16X3F;SZW1^L1P];E^S<3Y>L_$MALA;[IY%;(8TBB(;#IG[C!J-,H'I
M3< Q/8>B."-[F7/RJM+M/"&U#[G2@!5N+R@E"LJ-U%\[L9.>OSV,G,[6ZUHL
M!X$-MO$.M\"V"W<1E5+ BC6JJ[>VT3AXMWA!@3"B1K$U#;UH.A:H[^B?; 8;
MV[#"5]A[%+Z"+0>]/ DQ#140IB#/</,.[S\56D2;NTA./XI8" K1%)@=<*;E
M)<C4(/__RDNEH7M#NIO[9=#P*"IB<I:\L:AE%BA&W9.%*OG^4/I\EC<?OG>!
MB,*8S.QR,IW^V9^/'H(O,8REW(LCGX#$FCLLR[!ZW7+)KG/LX9Q*BA;)Z+?8
M/HIZ("$0+R?+/Y,M[-:RN0+#><^2F]\QY.IM<'%_M/<^?>;F[8^]-1_V.-YT
M,E]^PL+7V7X/3WZ17$T6H+W!R]J?*FPO ^NI*#_F7=D<:L*B"(0W[_H@G'\*
M_,ZP2]*&^M3"T]];K\_-Z2#&Z)&OOSD?K[_YUX$PQ.RC]8VQ_GKSJVYCD$1]
M1D'.3YDSB-J* E)=:7:7+:@!(@9](C "DR'X@RB:@SI'0;"X1^[R"3U#=N8\
M#"6Y_#/2"'>!)B!+<\4/"0ZL>7"52V$'0-#$Y<:>$PDSV&XQSY S,#B5;7^@
M%?K"MJR.X;N^;'A>8Y25/AJ4_Y@D/_$.772W!J[XD8E3N[>-.(U< [KL(U)?
M#HL;0R-?'&_^6'$\+;HPG)(P_OJIDGA^S-,A+WGXU$ 9-=]MM?NT1%4'U3RR
MCZY^:Y2MJUV*E#1O\P8U#;)X(IFB4O)J7FWM+JRQ:;";#P>%L). G&R"'Y/D
M'8=.:A$75R\63DBCY[3^'E>&+S.R U>U]]@2V=0?Q-C0[U6(M=1\+0DS.&OO
M16\3E:H5 &'AM20W  VK:B16<;]#%J$E%7@XP&J@8L7I:C?B=GEBPUE   Y-
MVB@H)?CB71E&38>E-:(N>IW0#*WX@^A!-H&A3<?0#0O_Q;VUQN..I4*G3"3(
MR@4<; (,ON!8$8J (^,0^7]=JP]*^]9*7Y(PT@QC5#>MW!6F0/E:K?S.!:!U
M0+EJ-:,?_A"DSS22[;+I0 +Q3/LBU-*QP1?]DBVZ0^2BGWMV/YA<)G6]LNAR
M^4&XI@"-[?J/H?^#$MS&3@3E#KHJV6!S YP\U256^[R4AH9>VTX?+7_14/E]
M[:!6AQ$5 SUV?31Y<-"3Y(T490K)EHFL<EL)FQP098OLP0GW3JRE*27GF75>
MS)M5\9@8@R;NQY$&Y#<5(=V0R]'5<A&N/00+S4URD2G1# ^:4=$ _<Q(/B8G
M%-7N^9CY*#N)/^]\;]C;BAR#*FLBL\60$2U?172E7Y"V0(QIVB0JE>.B6]1Y
M>DO)A-)H=@GBENS,.7GU+F#=QF!1R2O24@;JMNCV)1BBHW<Y*="+[%IBS/$=
M(-@6TX>8\Q!YG4]GU\[00:8]3;,$=8("<?%N'2B ,%PEX+Z?J(<4@]XVWS&0
MM#=@. 6M+KB?V![*4SL@JZK5^<(/573Q^43974F&&6W%$C:?':X,&!<&I$KY
M]8$P:&B5AL/$)$'6\759.:S"D[)P'4/)=#%X) 4:2,&! QK"9K5!2SX3"I,:
M01MHJ$0K.9+LGP=@H!MN%$7NQ$PK<IP>/AW$I4CIV^; 8%Q,18B)CB,$Z^D@
M"XD]TC&UARYC(J0O)CH?+R;ZYG15QT&)\C/JBXY,D8S]%KH-,%;%A6(WK&W(
MT[%YK#O81 KTCE2OY&S0)G!6I\XND%)9>I&.*BDYD[6<!FA(P(U;6%'4FRW<
M7:'Z!5*E0,TFD@J.L<$L$,C](-+B=_:4I2N,N/I>K[ENU,/<M5Y*?.?L;DL;
M8H9>+"4Q?D--FT^W4WX4&7T=I_EX':?G/]*F7*E]#.DE  ZBXF<4<#HY08>X
M4!>)1H$\\+CJS-]]N%&=^50L]_S"]U_\+ASI!D>2MR?ZJ,_WTU:6$E'$;091
MI.:D_$U>4*<+6 'UE82OX4\@;\:7(V\";$JHO*5751XL1@7A4]()."ZY$14,
M<,8Q"9-YZ^=.(OL +4I:G5CT*FI@-H\IT4<2=.MZ:W6+?3RWD]L)NE9+<@QP
M-\FUM#),I1Z>U 21>@,O"#UI8(S<V;#:)B.@IUAZR3LWKBY".B6XYJ*<$:/U
M,S940BA'MV6+*:$?3J[9*XR8A0O/G'5@D3S/)W:"C3:Q,3C+.VIDDQ/R@$)U
MU<J/I%ZXGUX,D P14M8'W]H[PHX(MU7[; 9PB?']I>*[\0LZY2KMC]&_+(8$
MI)Z7M!$WJ?_U)Y G:\R+,&AJD<LGL/DB>3X_3Z_/K]/Y^47R N,>IM-T<7UA
M?@26_"499Y[SLR\89 /MC <;,3^_6*:S^3F,N5BFRXO+8/*7RF(Z0XGS,:3M
MJ8""UWEU=0YCSFF=5Q?P>7YMWEH,Z"YI?__H7K[R0&*K,HPFO'[I )1G\W0Z
MOTXOEA<)0&2Y2!>+A6'J]O*[W@D,C8 +G4PO:8G3R?2Z$T!E8@G:!\5M_"7W
ME]+C84@VP@L,?,7&5U;K\[M'J/?\+#V?S=++.8:\G"^OTHOYN O(5]Z:CU?>
M^MX7& N2(H;-9I]1B.O$\$GP/:4QL3]"TJC($LJTX"%(<\=@QXWA4IE:P8T2
M/G/?NGI+T=A.?$XE_Y\*%!?'* E:[3]2^XSBK3#/K&Q=7?4P382M5G]7!5VR
M!_[@>(Z/^0YUDB"9H5HA!,1R FR3#QD0O??DH>P]*P5H-;NK7U4X B:#9-!<
M!<JJC[Q7V$HV'=7R;EJ.6D2'%B:J"C!<;XE<CT AYX)-.5 (ICWLF/&PN6@(
MFCP";I>,.'B\NB4VYH1UUB3=GZ@J9S3M,%=-HX&Y3V^!;I>&ZU,3< .OGC+Z
M %PI)V-H6M\VK]&J#;*S]L*0=C+!0:CYCJ.,\D[+,__@E^CVL44R2\Z2WTIG
M?/WC4%%D22W)S:P<::$]/C*.Q5[[RMH!&$AXY)'G,/+//6R2@'FT!^@")-].
M.UETUD#:-R ?RZP#\WW57[2LUJMDE+-'._G*]VF6%;F'/' P?&J=E=3 MZKK
M:E5QAO?J&():4(;2O+>A*9D\'ZTXBJ4G5U3%<AA@"SJ*_@4,%,L]VL)H(0;>
M;=D27KJ2GJ+)'@4+]+4@&DZ,IZ<:7/16]FO\,&Y3S5S#-]?X).WA3MNI]SQT
M.@JG<BY!=\NTW\?P5 _$%,2$3*I2 .J?<0PB%K>NVS,Z _R=1L2,V@9M.<C%
MTCY?"Y8H#AY=FGR4Y ZQE41TBR#O/4,-"9&&Q-<PB;GBJI8?N<]*I[9F$W;=
MI@V$O;^#O%-74C 6"EVW1#&.-US:%F<W$9 D"C%82J__B0\D$&@?<UML^%IN
M[*J-"AN2DJ27E9(1NE11F\FS'PA[IQ^9* 9M#DPP_5T. E6]OH.+=P@[JWM#
M$[-;RDQ?N\*LR%BBYDVDN=0HX-2N'_.I-N6Q2#R\F.W06LP;/<>_<[N.UI"\
MP)_"1C>PN'YH>S_ 4"FD$E2A$^;#B7)6D<<GJE'U!= 6_B_X,CZ:G$UD6  /
MAHAJL#L]BX*7I*2 ^KCDF:&S.=%):_ P5"D=*]OM3T:;&,5K=6LPG[6&_@D8
M'RBLV_TBN4S/I]<8E&W><$UE0-N8H)XJ-Q:=SPP#T6?I<KHPW\40?7)U,5\E
M;SY>)8]:2 X+QY]1YHY'B^K41=[D@G\_84"Y.I]/S%_^='UQ>?T5H:"TKM2Z
M3?W4SZ!(ERLW3#X(K!%@U0)B*3)1?M!FF%\-S'2K12W=""AI[UWM.3VLX:F[
M99O8H<<-OX^..9+M%XOK-'9H"<2/!.DOEW]V_6F<HPF]#SBIRQO6-I)#BTKA
M&RD#S6E?Z$QUPC_@)F:7!VUD"FR3A,$\W>3DL4GB;:@!*Y(AFL,N/@&74(1]
M&PJ2+K0/Q_743=\71GIS8UG2</K>L; =BF4/5SR&<GLY<3YP$X<.6[+PE)AH
M2>UR2-0]-#9$,&8E)Q$,A;?,V9&E\@B72BV/KM[WJKH/"J9F?6;5A YH&K#K
M(,&*H;;A'PT7VBS/>!W>DJ[.#U\+A<OY<CT]N'E28'N/@DA#14<F4J.9!^VL
M@HM.G57;,X2*6DE_^=E7]PNE0-LE<=WFBNT)# WC1$P/M3JXY+(=PT.X<84(
MJ$'/&HZ:'#3*5;H^'251C32RRC98521LSIA&Q?0.]#0!V"?^K5 W(-Y9=W<1
M93$$Y<Q/02#O:\T"!W,"#HP?(\L11VVM+2+50-:C8$$>HB3U8YT7&BQE/HD%
MP=!B*KY:J37DZQ/2]?:7)EPF6S*<4.A(C2WO\[KB^$Y"/,Y'#X5'N5I2<OP@
M=1Q\JZ9VB YUD,5'HG6+ E%Q+1=QRGU[I=\OF6>T0(WUFTI-I^+/IK*-SSMT
M;, J&^#ZQ84:A:WP&#F QKH5:'2*\HQ.[JK?A;-@F$'"31X=OLZDYW9N,UQ<
MUY&T8NW6E=*7T^MT+=;S0)ZL72[B AU17JWJ*Z)PT:0<BZ)U?K@+R=C*NI%+
MG8.3FRO!#)X&$*U]L 4:*S $M'%IM,F[UEWX'C[X>F^N'?CM(4,)P;*/VCP%
MGISH+V;\)CAQ"BQK!).=DSX."GD\K[MP]X (6F<9U$.SI#K?)XKT-H&$[B#8
M ;FC#Y56'I6NBY3O(K%?"(\HE=D)W=$1]O='HF#-]8.<\A6-)+!)@X+E,4,Y
M2A=Q<J-04*A41(V6'@=4<8Z"O)($KPS(*#L,$]X<7"\T]8Z]T]'U]'06&Q40
M3O*H3!F50900L&#00/S3VEM1B5<.D=0D<C(GR2APR]T^E::3A5ZC,%1D[.AE
M'0.EKZOCNS0&/4^$A@1G*2YIJ[UK:,W:L8/KI&K,IEKW>HUT3C:(-/UF+\Y<
M$77BX38LCS?!H= E=<<]WJ7&6;[,6)N:N#T&5K5A!X<'6QCK2H6G?$$U&>VQ
M!9#+A8FZRJ=#O6: WYVA>2GH.>.#T\A&&4;SA%#OU#]0<AHMBW'1^)@@1^DZ
MH:14BX';L/+J;^OJL!<Z(D10MH;A_<&ZW(CNWN4GF_F8_FZY5X':"9I3AH*@
M0L*(_KSPU;D7CU7GCI+;AQ3I\1%.I95%PR8?M*@KV_S%!)VYPEX2!>E[6Z:F
MXPG0M@K2CC9.2NJ4^TM]O*<,RI^DR8X4DD(2([9/JCQ3.R$E-"P;D'<!I8GN
M*+:'K^6N_I^W$\7Z!I#IO&&T?>-")3@+H*D>V^(Q#+PRWJ7K"H/5SLD;&,/=
MFD?C718^5W,QGJN))?E1G/65RH%,EM5!)'T6%8\H+7#/U4$T^HQ4SD^=MQMZ
M)SXQH>S4U,>S3^X(1@%)V'K/S]&XXN\'*O[>A-7?&U]U_7W4;XXXF71T838
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M'51QSRE>C,S<W6(H#=U4W"-%(D)E%]#\2$I3O5B"V66S\P]02P,$%     @
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MN!0<)PE-P/=Y79O="RVPO_T^_Q=02P,$%     @ ^(G<5B]6#R*B!   ] L
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULG5;;;MLX$'WW5Q!J43B
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M#T[=Z.AH##5H-MVPM5#Z&]1/I,$[S/.;?HQ]"^\_!O?<;(2R('%-J?'5. _
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M%G#V,N(,:88FX/.91$HJ;VB#ZN/9Z=]02P,$%     @ ^(G<5N1)22QA P
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MOF=4U4<--PK9;=]_:!\TI#;U\*6>T1%@EVCJ\B%=;I9-,[&P7<ELFAKL$#N
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M>Y?B"Y==]]A-M-C:CFTE-/9_=EAAPPW2',#]M1!ZF!@'8PN__!=02P,$%
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MLU[45@LJS4>E!5BTYI5P[,PX(ZP"B=JD0:5YJ#0?E19@T9J"CTT=Q]S5N;I
MCMLJS-*<J;,SU"9-^_ #XR'-V3UV5!SC8_T556_25J>6YA2=IQ6U0X)*"[!H
M!UGVR2O=XA7_ Q4;EDH2PUKC^[V)GG1Q>&M^6%$\*]_R/G.E>%(N;H%J>\4!
M>O^:<_6Z4KPXKO]W8?$#4$L#!!0    ( /B)W%9B!SS990(  /0%   9
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M#5GU:-5$B])V+?="0P]DAUOH:ZDT!V!_(X1^FA@#3:>\_ ]02P,$%     @
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MYZB59.G3/^PYQFZ5'GD$JDT'S[#E&78JS2%C*>6OK'FGUALS-VI)1P>L^>@
MY,<M^?&[U+Q;Y>6:G[0\)YU*UX#'>*%X1JX$GGGWX(!,9^$[!=^8OCAZ.J.C
M Y:^$7]G^)T&$[\RVYW%?T%E62AM0;LV90L@W(D27!!$:3+8_]<(=UJC +WV
M%P!#4E5)6W?)=K6]9)S5K?5I>WU#F5.]9M*@[QQ-HZ,1GE&Z;OKUQ*K2-]J5
MLMBV_;# BQ)HMP'?YTK9[<0Y:*]>TW]02P,$%     @ ^(G<5I?WF@@_ @
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MG48JRP\+>A/!. =:S[7&D^$2M*]L\@=02P,$%     @ ^(G<5HNJ*!"<!
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M^Q+]5"20J "6C+8-F5Q"?B!:Q$>([Y"#OT?$)F0DH-5_=\>:<)RV@DZ-Y]S
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M'_= $^"5@7R_94Q<!M4"[7W:\A]02P,$%     @ ^(G<5O+X?7\_ P  XP@
M !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULK99M;],P$,>_BA40VJ31
M/*?M:"/M 002H(D)>(%XX2;7QL*QB^VTX]MS=KK0-EFU%_1%&SMW?]_O;-]U
MMI7JEZX #'FHN=!SKS)F?>G[NJB@IGHDUR#PS5*JFAH<JI6OUPIHZ9QJ[D=!
MD/DU9<++9V[N3N4SV1C.!-PIHINZINK/-7"YG7NA]SCQA:TJ8R?\?+:F*[@'
M\W5]IW#D=RHEJT%H)@51L)Q[5^'ES<3:.X-O#+9Z[YE8DH64O^S@0SGW AL0
M<"B,5:#XLX$;X-P*81B_=YI>MZ1UW']^5'_GV)%E037<2/Z=E:::>Q./E+"D
M#3=?Y/8]['A2JU=(KMTWV;:VV=0C1:.-K'?.&$'-1/M+'W9YV',(LR<<HIU#
M=.R0/.$0[QQB!]I&YK!NJ:'Y3,DM4=8:U>R#RXWS1AHF["[>&X5O&?J9_!Z/
M1=EP(')IT\$*0D5)2L8; R4!J@03*TW6@#M?407D[!8,95R?D]?DZ_TM.7MY
M/O,-1F+U_&*WZG6[:O3$JF%$/DEA*DW>BA+*0P$?$3J.Z)'C.CJI> O%B,3A
M!8F"*!H(Z.;Y[N&)<.(NK;'3BY_0NRH*V0B#N2-WDK."@28_KA;:*#RW/X<2
MUNHEPWKV+E_J-2U@[N%EU: VX.6O7H19\&8(]C^)': G'7IR2CW_C*7GC$N-
M)X2)0M8P1-M*I$["%II-_CI*ILDT2K*9O]E'Z5M.@R">_C,["#+M@DQ/!OD1
MM+XD+M0VR'-B0R;4&,46C:$+O!)&$B'QK3!*<F[WD@D#F#$SA-0NF.TC96D8
M)4<\?;,X3;/Q,$[6X63/S+G?XO1 <++&JNGN<"5Y"4I?M!=^B"4;VI[)) GM
MW3K Z5M.LF0238=YQAW/^"3/=U=]L0#1#2AL)D0T]0)+$!8I1Z )-B1ML%3A
MKEST"]<0T[B7^! O^S1+CT]<WW :I3%^AIDF'=/D)-/91[<_;WLE]9GQM^KC
M@ST9!>.CX/M6P2@XW@U_KU_4H%:NC6KB2E9;<KO9KE-?N09U-'^-';QMN/]D
MVO;_B:H5$YIP6*)D,!KC$5%M2VT'1JY=5UI(@SW./5;X+P24-<#W2RG-X\ N
MT/VOR?\"4$L#!!0    ( /B)W%8 Z\U^00,  /81   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4T+GAM;+686V_3,!2 _\I10 BDL=QZV48;B2U"3 )4,6T\
M(![<Y'2U<.)@.^WV[[&3+#2BC=K*?6GMQ.>SSU>?*LYDS<5ON414\)2Q7$Z=
MI5+%E>O*9(D9D>>\P%S?67"1$:6[XM&5A4"25D$9<P//&[D9H;D33:IK,Q%-
M>*D8S7$F0)991L3S-3*^GCJ^\W+A.WU<*G/!C28%><0[5/?%3.B>VU)2FF$N
M*<]!X&+J?/2O8C\P =6(!XIKN=$&D\J<\]^F<YM.'<^L"!DFRB"(_EKA#3)F
M2'H=?QJHT\YI C?;+_1/5?(ZF3F1>,/9#YJJY=2Y<"#%!2F9^L[7G[%):&AX
M"6>R^H1U/78\<B II>)9$ZQ7D-&\_B9/C8B- '^P(R!H H)] \(F(-PW8- $
M#"HS=2J5AY@H$DT$7X,PHS7--"J95;1.G^;F=[]30M^E.DY%=WHCI25#X M8
M$"I@15B)L*0HB$B6S]5UFI,\H80!HV1.&57/\#9&12B3[^ ]W-_%\/;UNXFK
M]((,UDV:R:_KR8,=D\>8G$/HGT'@!<&6\)O^\&]\=0[>Y<[P>/_9_6ZXJRVV
M*H-695#QPIT\+0I3N,9<MQ3,&,DAIC)A7)8"X><7?1MN%6;RUS97-7VPG6[J
M_TH6),&IHPM<HEBA$[UYY8^\#]O,V83%EF =JV%K->RC1S.!!:$IZ+^X-1$I
M%*7>EKK0V[U(46ZS65.'%=7\^:VBP L#WQN&$W>U:>K_@>.!=SD<>MUQ<>\R
MMTN GOP';?Z#WOP_F:)\,$5Y!K=Y42IY!E]PA0Q\^/D5LSF*K;NIEWKH;K()
MBRW!.C:'K<WA26MT:-.J35AL"=:Q.FJMCDY2H[W4O4JJ%GD$9[=(2[".R'$K
M<GQDL0>]Q=Y+/71;VH3%EF =FQ>MS8N3%ON%3:LV8;$E6,?J96OU\B3%WDL]
MH-B/X.P6:0G6$>E[_YZ]O2/+/>PM]W[LH3O3*BVV1>LJW3C.^">M^09O2ZU-
M6FR+UE7[[WCC]S[G'UWX#7:/1_'^!1RLR^JQQ=TX8YLW(E^)>*2Y!(8+C??.
MQSH_4;]DJ#N*%]6Q>\Z5/L17S262%(49H.\O.%<O'7.2;U_U1'\!4$L#!!0
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MF+]8FT<'S$,$/K%,+@4(LYC$=8"^FLMV0NA^0A?(B!B0Z 2X\"U #D+@U^L
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MF( BT[^Z.6D],+5!&.T>'#EQ4&-K,=OI?(S5:AG%%MJ:X_[.8?64\$7YEH
MY0F_]3'O[=7MFPCGY?G[QO4+^"Y8OT]0P:Q?;_B$^8)F B1DKB"=$U_MV'S]
MQL#ZBV1Y>21^QJ1D:?EQ290GN6Z@[L\9D_=?M('M>QN3?P!02P,$%     @
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M)%Y8XX6=>!.>ZPE[ 1-ZMVSE"1L\@Z';]_9I.N,=2=.O:?J=-+-7^QZ6HP[
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M/Q>:S]S)=#(_F!%I5K0FGNMZWD1_:&79G22V>8R1!8F3*%WK/3$V'NP)DA9
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MD%FU0OGWYS0MWE]4'>R>['K]?U!+ P04    " #XB=Q6YI;VC;(#   .%
M&0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6S%F%MOVS84@/_*@38,'3!$
M%U]RF2W L;JL0+T&];H]%'N@I6.+J"1J)&UWP'[\2$J1K<+FXHY#7F)1TOE(
M?B(9\DSVC'\2.:*$SV51B:F72UG?^;Y(<RR)N&(U5NK)FO&22%7D&U_4'$EF
M@LK"CX)@[)>$5EX\,?<>>3QA6UG0"A\YB&U9$O[7/19L/_5"[^G&>[K)I;[A
MQY.:;'")\D/]R%7)[R@9+;$2E%7 <3WU9N%=$@YU@'GC-XI[<70-NBLKQC[I
MPIMLZ@6Z15A@*C6"J)\=SK$H-$FUX\\6ZG5UZL#CZR?Z3Z;SJC,K(G#.BM]I
M)O.I=^-!AFNR+>1[MO\9VPZ--"]EA3!_8=^^&WB0;H5D91NL6E#2JODEGUL1
M1P%1="8@:@.BYP8,VH#!<P.&;8!1[3==,1X2(DD\X6P/7+^M:/K"R#31JONT
MTM]]*;EZ2E6<C!,J:B:H^09L#<OM2M",JA$ KQ*4A!8"?B&<$_UUOI_X4E6I
M _VTQ<\;?'0&'T:P8)7,!;RN,LSZ %^UM6MP]-3@^\A*7!!^!4'T T1!%,'R
M(8%7WYYLF!V38'H%@[#%?%B>PR3/QX2G,;U>#KK/,C#<P1FN&L8%6;'&.\S4
M!Z@VJ*:;!%)EO?([F2,'F9,*^D$?WRHFO)%8BC].=.R^:<#P= /T<G,G:I+B
MU%/KB4"^0R_^[IMP'/QX2K9+6.((UA,_[,0/;?3X02V54# A0$V(S$P.4NB9
MH=82FE()M)*HJI6GE%K1ERIM8",#TZOW+AX$P6@T\7?'KKZB2K!H&G6:1E9-
MO^8(#XQE,%=/: J/G.Z(1'A+2RHQ@X\++%?(3PX\*_E22RYAB2-8S^BX,SI^
MZ1D_=BG>)2QQ!.N)O^[$7UN'\KM]A5SDM+9.;2OC4G<-[.9H:H=?3&M'U?6$
MW'1";JQ"EJ\7,YAM.#;#S3:5K:!+K;B$)8Y@/8&WG<#;EY[*MR[%NX0ECF ]
M\6%PV,T&UK$[9^I$DJ&V:,XE*2J;V2F#+6AT?A+.[75=*L85K6_F:)\?_G\;
M&SO[TO'6TOYM:^.JTKZPZ" L^IIE$/Z&_[+YL5=ZL4F7M,05K2_\<.0)7_S,
M$SH]]#BE):YH??N'<T]H/_@\;QO40BQ;E[F]GHNM.*(U5ORC1$F)?&,23@)2
MMJUDDX+H[G9)K9E)Y7QQ?ZZ3728!<\ TF;(%X1M:"2APK9#!U;5:YGB3?&H*
MDM4F';-B4K+27.9(U/\L_8)ZOF9,/A5T!5T*,/X'4$L#!!0    ( /B)W%;?
M3^? V@(  -D'   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*U5WV_:
M,!#^5ZRLFCJI);^!,HA$0=,F;5)5UNVAVH-)#HCJQ)GM0/O?[^RD&:6&]6$/
M$/M\WW?WG>WS>,?%@]P */)8L%).G(U2U<AU9;J!@LH>KZ#$E147!54X%6M7
M5@)H9D %<P//Z[L%S4LG&1O;C4C&O%8L+^%&$%D7!15/U\#X;N+XSK/A-E]O
ME#:XR;BB:UB NJMN!,[<CB7+"RAESDLB8#5QIOYH/M#^QN%'#CNY-R9:R9+S
M!SWYDDT<3R<$#%*E&2A^MC #QC01IO&[Y72ZD!JX/WYF_V2THY8EE3#C[&>>
MJ<W$&3HD@Q6MF;KEN\_0ZHDU7\J9-/]DU_IZ#DEKJ7C1@C&#(B^;+WULZ[ '
M\,,C@* %!(> Z @@; 'A6P%1"XA,91HII@YSJF@R%GQ'A/9&-CTPQ31HE)^7
M>ML72N!JCCB5+/ <934#PE>X!RFO2R5Q.U/(MW2)YO,Y*)HS^8%<DKO%G)R?
M?1B["@-KN)NV069-D.!(D#FD/1+Z%R3P@L "G[\=[K^$NRBWTQQTF@/#%Q[A
MFPG(<D6^<BG)_70IE<#3]\LFJ^&)[#SZ1HYD15.8.'CE)(@M.,G[=W[?^V@3
M^9_(7D@..\GA*?9D^GIK+2E>GR:Y]ZU%:D"Q >DNLTT"+QI>1;A5VWW]K_W\
MX3#T_;CS>R$MZJ1%IZ4Q;%VT3(%@$R09KY=J5;/N,-LR;@C[>YE<^E>#*!P>
M9&SQ&WJ#JRM[PG&7<'PRX>]<46:[;!>D!&7+-[94+O9C+SS(U^;G!:'?MR?<
M=PX,@T[!X%\'82IUQ\";"<421'>Y"2TS<TTOK-T$(75%%">TJ@1_S+%O WLB
M9\3K]?$WM)UT=Z^Y%2#6YI&0Q) W%Z"S=N_0M>G7A_;^:-:WV0>CF7FWW+_T
MS:/WC8IU7DK"8(6AO-X 2RN:AZ29*%Z9UKKD"ANU&6[P[06A'7!]Q;EZGN@
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MUN@?K.JV]D;+HAO2!\SGI!2(PDQY.;US%89735XUD6QANI@IDZHG,L-<]<7
MM8':GS$FWR>Z,6HZ[?@/4$L#!!0    ( /B)W%;( R@*RP(  (<'   9
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M#I=X4X(T ?@]%T+O)B9!<_<FOP%02P,$%     @ ^(G<5O?&9Z0#!   H L
M !D   !X;"]W;W)K<VAE971S+W-H965T-C0N>&ULK5;;;MLX$'W/5PS4;I$"
MBD5*MBZ);:"Q]]("BP2Y[#X4^T!+M$U4(K4D92=_OZ0D*TXLN]W%OMCD:.;,
M.</;C+="?E-K2C4\%3E7$V>M=7GI>2I=TX*H@2@I-U^60A9$FZE<>:J4E&1U
M4)%[/D*A5Q#&G>FXMMW*Z5A4.F><WDI055$0^7Q-<[&=.-C9&>[8:JVMP9N.
M2[*B]U0_EK?2S+P.)6,%Y8H)#I(N)\XG?#G'R ;4'G\PNE5[8[!2%D)\LY//
MV<1!EA'-::HM!#%_&SJC>6Z1#(^_6U"GRVD#]\<[]%]J\4;,@B@Z$_F?+-/K
MB1,[D-$EJ7)])[:_T5;0R.*E(E?U+VQ;7^1 6BDMBC;8,"@8;_[)4UN(O0 <
M' GPVP#_;<#P2$#0!@0_&C!L X9U91HI=1WF1)/I6(HM2.MMT.R@+F8=;>0S
M;M?]7DOSE9DX/;TW&RFK<@IB"4*OJ32+F5*V(8N<*CB?4TU8KC["!3S>S^'\
M_<>QITU:&^RE;8I9D\(_DF).TP$$V 4?^7Y/^/S'P_'K<,^([13[G6*_Q@N.
MX-WMZ?OZ::&T-'OOKSY9#<ZP'\<>R$M5DI1.''/B%)4;ZDP_O,,ANNH3^3^!
MO9(<=)*#4^A[DF$I10&9.6I*F].KX1SWK>CU:;RON+=>)X/Z)4)?J1J<48UC
M[ZW--(AQ'$7AV-OT5&'856%XDO7/19F+9TJ!9!O"4]HGH4$(]U*'83+J\C;\
M#IW\& 7]Y$8=N=%)<C?V[*D^2J.#;%'DOV%TZ../4#^AL",4GB3T(#3)#Z^$
M/H;A(<-A&+VA>.@4Q#Z._:2?9M31C+Y?MU=WUH=W!A=? 1?\(JVD-+N\C_1)
MV'^Q6:,#71<X#E!X;$/$G;#X/PH[(2H^.#D]*W'HA),$^_Z1XY4X;PP8O;PM
MZ'OWQ,.:GBU(;L^;?6+D\9M(TKK27-,,C'8@A:B,.:M:U^O;!Q<(AXI+FI/&
MB\D,2B+U\P!N.'PAO#*]"]1O!8Y="W,V$T5)^'-=O.A*F09GH5C&C)\+C[]^
M!IM0&C#&M;#PC'>,R$I26H^V3*\; L:I\0!2EE(\,=-ZT/P9W@,>)."[HQBY
M""'#(<&!BY+PM0V-W##&UA8U-F2BL&NZM'KF#V((W&34S%A-3>DS:7+8Z@4_
MP8*N&.>,K\ T35\JDWGWLKIPDVJQ,)OFQ;*K2&L)7/A42I9#@';S?8C@ "+H
M(,Y:R]"N0?8:9C@P,B)(XL@=(=3W7GE[#4I!Y:IN]!2D=H6;9ZRS=LWD==US
MO;4GE[.DSX[1Y:SI/KV7!$WO^CN1IF8*<KHTR0Q3L_5ETPXV$RW*ND%:"&W:
MK7JX-BTTE=;!?%\*H7<3FZ!KRJ?_ %!+ P04    " #XB=Q63AON1*P"  !3
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RM5EUOTS 4_2M60&B3
MV)*F;3I&&ZD?3/ P:5HU]H!X<).;QIIC%]MIQ[_GVDE#-]+ -%X:?YWC<^SK
M>SO>2?6@<P!#'@LN],3+C=E<^KY.<BBH/I<;$#B32550@UVU]O5& 4T=J.!^
M& 217U FO'CLQFY4/):EX4S C2*Z+ JJ?LZ R]W$ZWG[@5NVSHT=\./QAJYA
M">9N<Z.PYS<L*2M :"8%49!-O&GO<CZRZ]V"KPQV^J!-K).5E ^V\R6=>($5
M!!P28QDH?K8P!\XM$<KX47-ZS986>-C>LU\Y[^AE137,);]GJ<DGWH5'4LAH
MR<VMW'V&VL_0\B62:_=+=O7:P"-)J8TL:C J*)BHOO2Q/H<#0"\Z @AK0/@<
M,#@"Z-> OC-:*7.V%M30>*SDCBB[&MELPYV-0Z,;)NPM+HW"688X$R\Q+-*2
M Y$9D28'A5>3 -O2%0=-*,=;IB(!@O%"4EFN3%9R//M$EL)H<K( 0QG7I^2,
MW"T7Y.3MZ=@W*,N2^TDM859)"(](Z(7D6@J3:_))I) ^)?#13V,JW)N:A9V,
M"TC.2;_WGH1!&+8(FO\[O-<AI]^<<=_Q]8_PW1Z<Z+?I2AN%P?N][: JGD$[
MCWW0EWI#$YAX^&(UJ"UX\;LWO2CXV&;R/Y$]L3QH+ ^ZV.,9K)D03*SQC7$;
M0&UN.RG:!9(VHZ_G>>)QV'@<=GJ<IBFSJ:C-6H6,'-(FTFT<AL&'BW X]K>'
MTCMW>+GTJ)$>=4J_5\S F<RR-NW1']K/VL5W[O%R\:-&_*A3/&:)OP16)_X%
M@?5ZGLJ@?Y"?"U!K5[8T<4FTRFK-:%,9IZX@/!N?8<6L"MQOFJK<7E.%+TX3
M#AE2!N<CC"Q5E;"J8^3&58&5-%A37#/'J@_*+L#Y3$JS[]@-FO\1\2]02P,$
M%     @ ^(G<5N:&2@J2!   "QP  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C8N>&ULK9E=CZHX&,?O]U,T[$OF)!-Y$\59-9DSB#+)Y$QF<G8O-GM1H2HY
M0-VVZCG??EM 1A0YDCQ>*"W/_]>G]D^!=GR@[!O?$"+0]S3)^$3;"+%]T'4>
M;DB*>8]N22;/K"A+L9!%MM;YEA$<Y:(TT2W#&.@ICC-M.L[K7MET3'<BB3/R
MRA#?I2EF/SZ3A!XFFJD=*][B]4:H"GTZWN(U>2?BZ_:5R9)>4:(X)1F/:888
M64VT1_,A, TER"/^BLF!GQPCU94EI=]4(8@FFJ$R(@D)A4)@^;,G3R1)%$GF
M\5\)U:HVE?#T^$CW\\[+SBPQ)T\T^3N.Q&:BN1J*R KO$O%&#PM2=LA1O) F
M//]&AR+6&6@HW'%!TU(L,TCCK/C%W\L_XD3@&E<$5BFPS@26=45@EP+[5D&_
M%/3/!>85@5,*G%M;&)2"P:V"82D8WBIP2X%[JV!4"D:Y'8KQRP??PP)/QXP>
M$%/1DJ8.<@?E:CGF<:;,_BZ8/!M+G9B^RZLGVB4$T16B8D.8='!(XCU>)H2C
M.X\('"?\$[I[Q0QG,D#$(4X^C74A&U<(/2P;^EPT9%UIR$0O5.HYFF41B>IZ
M729=96X=,_]LM0)?\ ]DF_?(,BP+?7WWT-UO36D]M5,\$O9NP7A=,._S:YA9
MASY=I_@_H[ >,@J,V=*G>1?,]6P6[9AGG/60Z2J,Z;9D$W3!-&93LY%=70!V
MSK6O<-].[/[/XY(+)N???YO\77#ZS1QU4WK@6QR2B2;O.IRP/=&F?_QJ#HP_
MFUP)"?,@83-(F \)FT/"%I"P  A6,W"_,G"_C3X-LCWA0CY_"(13NLM$DW=;
M$5V]"PGS(&$S2)@/"9M#PA8%S,EAZFEV/S5'AOJ,]?VI+2_C+,>MQ=4<YU2.
M<VYU'#UD)$(KF7F+^5II7<T'"?,@83-(F.\T#+%I&Z-!?8CGEW'G0UQ8!C*Y
M  A6,]^@,M^@U7R/412KUR2<M#BN%='5<9 P#Q(V@X3Y!6Q0GU2<@6N>.>XR
MSG*&#8Z#3"X @M4<-ZP<-_S)=,<%3I)\OBM>CL[?7PK3M5*ZF@X2YD'"9I P
M?W@Q?37=R.:78:;5$+> S"T @M4\YU:><UL]]T;40E6<K=$2)S@+29/AW,NY
MWVWX5YY:F^KJ)4C8[+(']LBY[($/V>@<$K: A 5 L)KC1I7C1JV.\\A2H#@3
M;)=/=/*(R$;DC(<%N4<1X2&+M^K&V^3$=O21]0N2'\53BTWV[VA)UG&6FYQF
MZ'F7?*Q]W*,OH:!+PDYJGG&VPZR*L>_1XY;%";*-8_D485\@[ J1YU'6]N\1
MSJ(ZJM]KFI%;^]CU*H*$S2!A/B1L#@E;0,("(%CM4C.-CT57H_6*^)*OM,8G
M#Q;7GV7;45V?*TK:Z90[;+AG> UQ(W?HG,?-0+/S06ES4-H"E!9 T0H#ZB<;
M "EAZWSWB*-0>:I82:IJJQVJQWQ?YJS^R7SPS(9ZWWR8-]4OU$Y7OA'QT6RQ
M3?:"F9S=.4K(2J9@](;22JS8>2H*@F[S;8DE%8*F^>&&X(@P%2#/KR@5QX)J
MH-K_F_X/4$L#!!0    ( /B)W%:.^?&P3@,  " .   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8W+GAM;+57T6Z;,!3]%8M-4R>U!1L(:9<@K>VF56JUJ%FW
MAVD/#MPTJ 93VR3MW\\&2DE"45NE+PF&>X[/N;Z&Z]&*BUNY %#H/F69'%L+
MI?)CVY;1 E(J#WD.F7XRYR*E2@_%C2US 30N02FSB>,,[)0FF16.RGL3$8YX
MH5B2P40@6:0I%0\GP/AJ;&'K\<95<K-0YH8=CG)Z U-0U_E$Z)'=L,1)"IE,
M>(8$S,?65WQ\BCT#*"-^)["2K6MDK,PXOS6#\WAL.481,(B4H:#Z;PFGP)AA
MTCKN:E*KF=, V]>/[-]+\]K,C$HXY>Q/$JO%V!I:*(8Y+9BZXJL?4!OR#5_$
MF2Q_T:J*]7T+1854/*W!6D&:9-4_O:\3T0)HH]T 4@/(2P%N#7!+HY6RTM89
M530<";Y"PD1K-G-1YJ9$:S=)9I9QJH1^FFB<"J>Z+N*" >)SE M='4(]()K%
M".Z*)-?KI=#>&2B:,/D9':#KZ1G:^_AY9"L]MV&PHWJ>DVH>\LP\9Q =(A?O
M(^(0T@$_?3D<K\-M[;BQ31K;I.1SG^&;U%;WT811[=$X_M8X_GNAP]&Y@E3^
MZ[):<7O=W&;C'<N<1C"V],Z2()9@A9\^X('SI<OXCLC6TN V:7#[V,-I,5-<
M4=9ELD+Z)=*\#)8A]EV7#$?VLBV_(VSH# +2A*T)\QIA7J^P"Y#R6._QJ$@+
M1A7$>FMJ_U%"S>;ODEOQ#5HZ#C#!@>-LZ.V,<P//[Q;L-X+]7L&_GDNCOS6?
MBP=;6=R.\@=').C6-&@T#7HU_9S/DPC:=7T)Z0Q$9TWW4KVVIG=$MN8Z:%P'
M[[BU@UVF84=D:VD8-FD8OGEK#[>J#7M#=QAL%&57F.?XN+LJCQIA1[W"+B%.
M(LI>6):]7*]=CQV1K=G&SM.7UGG'PJS)=Y2)7;&MIZ+5=. W%V<-;9<="8BW
M49L=4=@_PL^\,?%37X![O[?ZPZ-[P@5G,3I/=3^T!+,XLK=$^QE?O3+OT0_@
MIX8 N^]9I+WMQJM3L2.V]50\M2"XOP?I+5)OJ^TA!&^^0+NBG,#Q-HK4;K7O
MYNQT2<5-DDG$8*YQSF&@"41U'*D&BN=E1S_C2I\/RLN%/L*!, 'Z^9QS]3@P
MAX3F4!C^!U!+ P04    " #XB=Q6MY"42F$"  "S!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6RM5,MNVS 0_!5"+8H$2"/KX:1(90&QG:(]I# 2
MI#T4/=#2VB)"D0JY?N3ONZ1DU4F=M(=>))+:F9T=<3?;:'-O*P!DVUHJ.PHJ
MQ.8B#&U10<WMJ6Y T9>%-C5'VIIE:!L#O/2@6H;Q8' 6UERH(,_\V<SDF5ZA
M% IFAME577/S. :I-Z,@"G8'-V)9H3L(\ZSA2[@%O&MFAG9ASU**&I056C$#
MBU%P&5U,4A?O [X)V-B]-7.5S+6^=YLOY2@8.$$@H4#'P.FUA@E(Z8A(QD/'
M&?0I'7!_O6/_Y&NG6N;<PD3+[Z+$:A1\"%@)"[Z2>*,WGZ&K9^CX"BVM?[)-
M&SNDX&)E4=<=F!340K5OONU\V -$9R\ X@X0/P>D+P"2#I#X0EMEOJPI1YYG
M1F^8<='$YA;>&X^F:H1R?_$6#7T5A,-\9NA"&'QD7)4,'E:BH5^$)TS1!3J:
M G(A+?O*C>'.[F/VGMW=3MG1V^,L1$KO2,*B2S5N4\4OI(IB=JT55I9=J1+*
MIP0AZ>[%QSOQX_A5QBD4IRR)3E@\B.,#@B;_#H]>D9/T7B:>+_F+ER=L)KE"
M;^G5SE+VXW)NT="U_7G(NI8Y/<SL6OG"-KR 44"]:L&L(<C?O8G.!A\/E?V?
MR)Z8D/8FI*^QDZE$6@CNFQ2V-&TL'"JX91EZ%C=JUGF<).EY%J[W*_DS*DF'
M<=)'M1+#O?M?@UGZL6!9H5<*V]O4G_:3Y](WW+/S,4VD=H#\IFG'V34W2Z$L
MD[ @RL'I.6DR[8AH-Z@;WV5SC=2S?EG15 7C NC[0FO<;5R"?D[GOP!02P,$
M%     @ ^(G<5M=G0=X) P  Q0@  !D   !X;"]W;W)K<VAE971S+W-H965T
M-CDN>&ULK59M;YLP$/XK%INF3FI+> G0+D'*2[=56J6J6;</TSXX< E6#6:V
M2;K]^MDFH7DAJ)KV)=CF[KGGN=SY&*P9?Q(9@$3/.2W$T,JD+*]M6R09Y%A<
MLA(*]6;!>(ZEVO*E+4H..#5..;7=7B^P<TP**QZ8LWL>#U@E*2G@GB-1Y3GF
MO\= V7IH.=;VX($L,ZD/['A0XB7,0#Z6]USM[ 8E)3D4@K "<5@,K9%S/8FT
MO3'X1F M=M9(*YDS]J0WM^G0ZFE"0"&1&@&KQPHF0*D&4C1^;3"M)J1VW%UO
MT3\:[4K+' N8,/J=I#(;6I&%4EC@BLH'MOX,&SU]C9<P*LPO6M>V?<]"224D
MRS?.BD%.BOJ)GS=YV'%P@A,.[L;!/73P3SAX&P?/"*V9&5E3+'$\X&R-N+96
M:'IA<F.\E1I2Z']Q)KEZ2Y2?C&>J+-** F(+1 J)BR69JQT6 J1 9U.0F%#Q
M'EV@Q]D4G;U]/["E"JN=[6038ER'<$^$<%QTQPJ9"713I)#N ]B*;T/:W9(>
MNYV(4T@ND>><([?GNBV$)J]W=SKH>$T./8/GG<#[Q%BZ)I0B7*3H]B6)HSJ)
M4R(2RD3% ?T8S87DJG1_MJ6QCN*W1]'M?"U*G,#04OTJ@*_ BM^]<8+>A[84
M_">PO83X34+\+O1X8NH6N&ISBG6WBHR4HDURC=,W./K"6<5!O^?TU)^ZVA73
M8N8'KA\T9GLT^PW-?B?-+R#$-1HE2957BB>D".>,2_+'<&ZC6^,%.SPN_##L
M1_X!WQ8[KQ^X.W9[A(.&</ *PK=YB0E7-ZELHQ@<A7:",(S" X:=@=K+ W54
M1M@H"#L5W#PGF6H/0%SE&\%BH6[S-A7AD0H_])P##9VA_K'$HT9(U"GD*Y.8
M'M^8YZB 5D&=:*_*=ZTY.NH$-[JZ"MR#PK)W)H)JQ*49E (EK"ID?<\VI\TL
M'ID1=' ^5C.Z'JDO,/6 O\-\20J!*"P49.\R5*1X/33KC62EF3MS)M5M8):9
M^LX K@W4^P5C<KO1 9HOE_@O4$L#!!0    ( /B)W%8])+C__@,  *$1   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+58;6_;-A#^*X16#"VP1B(E
MRU9F&ZB3=0O0 $'<;A^*?:"ELZU5(CV2CIM_/U)2]&++7.(Z7V*)NGOXW.7>
MR/&.BV]R#:#0]SQC<N*LE=I<NJZ,UY!3><$WP/27)1<Y5?I5K%RY$4"30BG/
M7.)YH9O3E#G3<;%V)Z9COE59RN!.(+G-<RH>9Y#QW<3!SM/"?;I:*[/@3L<;
MNH(YJ"^;.Z'?W!HE27-@,N4,"5A.G _X\@I'1J&0^#.%G6P](V/*@O-OYN4F
MF3B>8009Q,I 4/WS %>0909)\_BW G7J/8UB^_D)_6-AO#9F025<\>RO-%'K
MB3-R4 )+NLW4/=_] 95! X,7\TP6?]&NE T"!\5;J7A>*6L&><K*7_J]<D1+
M 8='%$BE0/85CNW@5PI^86C)K##KFBHZ'0N^0\)(:S3S4/BFT-;6I,S\&^=*
MZ*^IUE/3N8Z+9)L!XDNTXCS9I5F&WEZ#HFDFWZ'WZ,O\&KU]\V[L*KV;T7'C
M"GE6(I,CR)B@6\[46J+?6 ))%\#5-&NNY(GKC%@1KR&^0#[^!1&/D!Y"5\]7
MQQ8Z?NTZO\#SC^#=@U1B&ZNM2-D*77&I$&4)TLL@'@!]_:3ET8V"7/[=Y[T2
M/.@'-]E[*3<TAHFCT[- =*8__X1#[]<^R\\$UO%#4/LAL*%/9S2C+(8^&TO%
M0:%H"LK#-(I(. K'[D.;_:$8]C )?:^6ZQ ;U,0&5F(ZSW46,YU&0@"+'Y$2
ME,F,EO4C^4=GERY(JH]X"1RV&+TG.!@,]XCWB.$H"H)^WF'-.[3ROLDW-!7'
MJ(6'>T9#3$BTQ\VZ1W](($LT#&ORPU.CP:KX+$:E9<,##^Q%58?XJ"8^LA*_
M!4V<HANF0+ B1FB&[A2@3VF>*DC0UUO(%R!ZD]D*_=)D/A-8QPM1[87H-8M:
M=$X_G FLXP?L-8W1.S60*\UV! [(* P'>RG8)^='Y%BDXE;3QJ]5V2KD;LW"
M =DO;;UR7F@Z9R]WTG G/U#=*N7.M@,\)/YHGY]UEU.CH^G]V-I2K=%Q0C/N
MK7,5D"7,NN2;AHWM'?NS2'_/^$+7MSGH$$K5X[,+G1WYI1E^+K2N'YKY  ]>
ML]AAZ_CQ8E^<":WKBV;FP/:APQ;0AR-'$ 9>JQ14%O3(#7W_V#B$FY$"VV>*
M'REWA\."+F->:[2LN/?(13[QCU!OA@ILGRK^I]J-#G<-=(N(#ES[&C,!;H8"
M;.VUUN XH4OW5[OHX!2P%V4E>;=UV,U!K(H[ (EBOF6J/$O6J_4]PX?B=+VW
M/C/W#\4ANH$I+R]NJ5BE3*(,EAK2NQAJ4J*\#RA?%-\41^H%5_J 7CRN@28@
MC(#^ON1</;V8#>I;F>E_4$L#!!0    ( /B)W%8GP% XDP(  )(&   9
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M.3HYM^)TNSE:@U3MAV^IR(ZR/Y9VV:)V ?9^I13M#)>@7]_9;U!+ P04
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MMQ^^"RS3_U"@\4^_\1ZFF..<S+.8)M<)/W!#H1Q]B6;/!'TB."[GHA-J']#
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MV#P0;![ 0 T+M,)8+="P@[ZM$\P=J)B[@T#7OAJ+PV:X*]!PF=T%.A! &,!
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MK,[R0YDM^ _-3+*RS!+^YYQ@R@'L!/K]4T83MO[ "EC_N-'Y_P%02P,$%
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M-$^YL=/AB]GFN$@1Q!*V3$J6ZRI37'-4\.$6->.I^CCUM?%F;?RH1IY7R/0
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M=I1V@7F^%$+O!M9!\T] ^!=02P,$%     @ ^(G<5J""]3'! @  "0@  !D
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M0[40J@F49H:Z+O:\ERSV/&BQ!]4"J$:A&H-J'*J%4$V@-#/N=;'GV8N]YYU
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M/79&#LJAP#553WS[!=IZ(L.7<2KM$VV;V.B#@[):*EZV8*V@)*QYXUW;AP.
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M;]@+2@Q?(;BROV37[LU2CQ2-TJ+:@]&#BM7M/[W?!^( $$1G .$>$#X%Q&<
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M971S+W-H965T.#DN>&UL?511;],P$/XK5D!HD]#2NNV&1AIII2#V,*E:V7A
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M1O%QQ<(Y$_D _?V"<_5ZD4]0'W.=_@]02P,$%     @ ^(G<5A:,VU1N P
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M1)@7]/.4<_4\,(U>TZ?'?P%02P,$%     @ ^(G<5GM /P"A @  !0@  !D
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M-8L3)DH#_7[)N7J]*3_0GI'._@-02P,$%     @ ^(G<5A<<K(Y, P  80D
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M%O@& F4-<'XEI3ET[ +-JVKR U!+ P04    " #XB=Q689%)LPL#   8#0
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M'M!_Z0R#>L!@=\#@F0'#>L#PI0-&]8#12P>,ZP'CEPZ8U ,F+QUP7@\X?^F
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MZUXXO;[<;G#>7E\HN][=_OSG:.8VTSQ=5Q</.EC@9'9Y>>2A?IF71+TCNWK
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MIE!-HYI!-4MI_J4UFRR___JMZU^25;G$FF:K6?1C5GX=6D:%IVG;#J@6HYI
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M.LN*WVZ<E?Y]EG_=SG'Q_U!+ P04    " #XB=Q6MT!T!C$#  #J$@  #0
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MM@DM $P0P.35 -F;&PX@YPCD?$3(38 ('[!,[]B70W2I4P0R?37(BY(K +E
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M04Z"W/Q!7H+\_$%!@L+\05&"XOQ!28+2_$%9@O+\046"ROQ!IE,9.T!2A35
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M5>\(T#NJWA&@=ZPVFP#TCJIW!.@=5>\(T#NJWA&@=U*]$T#OI'HG@-Y)]4X
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ^(G<5IE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #XB=Q68#O?=AH(  !2.0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ^(G<5L\RN/Q-"0
M9"L  !@              ("!7A   'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( /B)W%:]G+:UK@(  $8'   8              " @>$9
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #XB=Q6%=%3
M]38)  !&+@  &               @('%'   >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ ^(G<5AY1Z<.[!P  %38  !@
M ("!,28  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /B)
MW%9J0R)F"@L   ,U   8              " @2(N  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #XB=Q6HW35X&D+  "&(@  &
M        @(%B.0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ ^(G<5OJU&H\]!0  0 P  !@              ("! 44  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /B)W%8]_FPC%2L   "'   8
M              " @71*  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #XB=Q6R*RP_\T'   ]%   &0              @(&_=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /B)W%:Z=#C:6 (
M &H%   9              " @<-]  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ ^(G<5F=K7UHG P  2 <  !D              ("!
M4H   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #XB=Q6
M3SZ& ?D#   K"0  &0              @(&P@P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( /B)W%9B\HHP 0,  *,&   9
M      " @>"'  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ ^(G<5B \D$($ P  FP8  !D              ("!&(L  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #XB=Q6OD3C!$ #  !&!P
M&0              @(%3C@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( /B)W%8;;">F8@<  !$2   9              " @<J1  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ^(G<5OYLR,$!
M P  <P8  !D              ("!8YD  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #XB=Q68$3="#P(  "T&   &0
M@(&;G   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /B)
MW%98!O)*: ,  /@'   9              " @0ZE  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ ^(G<5JHQ0W*;!@  FA<  !D
M         ("!K:@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #XB=Q63,SG\Y0)  !,&   &0              @(%_KP  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /B)W%:"VBXOE@@  !L6
M   9              " @4JY  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ ^(G<5I^5XIWZ P  M0@  !D              ("!%\(
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #XB=Q6Y9@<
M>$D&  ".$   &0              @(%(Q@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( /B)W%88\_1 )@,  -L&   9
M  " @<C,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M^(G<5LCR**7#!@  KQ   !D              ("!)=   'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #XB=Q6?5Y"2?D%  #V#P  &0
M            @($?UP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( /B)W%;N[R$8_#P  &/3   9              " @4_=  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ^(G<5KX08 G^!
M> X  !D              ("!@AH! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #XB=Q6SFI.G'8'   )%P  &0              @(&W
M'P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /B)W%8O
M5@\BH@0  /0+   9              " @60G 0!X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ ^(G<5II56(LT P  \@<  !D
M     ("!/2P! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /B)W%:MHS:4>P<  $@;   9              "
M@3T] 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ^(G<
M5N1)22QA P  P <  !D              ("![T0! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " #XB=Q6_X"7IJ\&    &   &0
M        @(&'2 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( /B)W%9_!,"N/@0  !8+   9              " @6U/ 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ ^(G<5M!NGQ;A!0  '!
M !D              ("!XE,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " #XB=Q67K<4G$ $  !^"P  &0              @('Z60$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /B)W%8#%)IZ
MD@0  ,X+   9              " @7%> 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ ^(G<5M-458<X$0  H@$! !D
M ("!.F,! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #X
MB=Q6YNR'F#P$  #'(   &0              @(&I= $ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( /B)W%9B!SS990(  /0%   9
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M970U,2YX;6Q02P$"% ,4    " #XB=Q6E 7K;9X$  !;&P  &0
M    @(&^B0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M /B)W%;R^'U_/P,  .,(   9              " @9.. 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ ^(G<5@#KS7Y! P  ]A$  !D
M             ("!"9(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " #XB=Q6+V[FM=4"  "9!P  &0              @(&!E0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /B)W%:';?^C<@<
M ,,Q   9              " @8V8 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ ^(G<5N3I9E@< P  (PH  !D              ("!
M-J ! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #XB=Q6
M]H@D1M4#  !B"P  &0              @(&)HP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( /B)W%8X$(!X=0H  .5U   9
M      " @96G 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ ^(G<5N:6]HVR P  #A0  !D              ("!0;(! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #XB=Q6WT_GP-H"  #9!P
M&0              @($JM@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( /B)W%9Z2\ 1T (  '4+   9              " @3NY 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ ^(G<5L@#* K+
M @  AP<  !D              ("!0KP! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " #XB=Q6]\9GI ,$  "@"P  &0
M@(%$OP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( /B)
MW%9.&^Y$K (  %,(   9              " @7[# 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ ^(G<5N:&2@J2!   "QP  !D
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M=#<P+GAM;%!+ 0(4 Q0    ( /B)W%8GP% XDP(  )(&   9
M  " @;S8 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M^(G<5FT:P4A; @  R@4  !D              ("!AML! 'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    " #XB=Q6REW'^64$   4&P  &0
M            @($8W@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    ( /B)W%:Y U@6LP,  #41   9              " @;3B 0!X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ ^(G<5J]L[RN7#0
MZ&@  !D              ("!GN8! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    " #XB=Q6@P\LP7,%  #-*@  &0              @(%L
M] $ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( /B)W%:H
MNI.6DP(  & &   9              " @1;Z 0!X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @ ^(G<5E"X>H+# P  IPH  !D
M     ("!X/P! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /B)W%:@@O4QP0(   D(   9              "
M@9,2 @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ ^(G<
M5H\X<M^H"@  S8,  !D              ("!BQ4" 'AL+W=O<FMS:&5E=',O
M<VAE970X-"YX;6Q02P$"% ,4    " #XB=Q67OLWFK("   &!P  &0
M        @(%J( ( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0
M   ( /B)W%:"R:N.FP(  .$&   9              " @5,C @!X;"]W;W)K
M<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ ^(G<5C&)J-OL P  OPL
M !D              ("!)28" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q0
M2P$"% ,4    " #XB=Q6[.PB)70#   Q"P  &0              @(%(*@(
M>&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( /B)W%9O=2=S
M5 (  .P$   9              " @?,M @!X;"]W;W)K<VAE971S+W-H965T
M.#DN>&UL4$L! A0#%     @ ^(G<5K5U53%= @  ,P8  !D
M ("!?C " 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " #X
MB=Q6_9GJ4Y &   B*@  &0              @($2,P( >&PO=V]R:W-H965T
M<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( /B)W%9<C&8PB04  /(J   9
M          " @=DY @!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#
M%     @ ^(G<5A:,VU1N P  Z0P  !D              ("!F3\" 'AL+W=O
M<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " #XB=Q6["T/-G<"  "V
M!P  &0              @($^0P( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM
M;%!+ 0(4 Q0    ( /B)W%9,B]3%&P,  +,+   9              " @>Q%
M @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ ^(G<5GM
M/P"A @  !0@  !D              ("!/DD" 'AL+W=O<FMS:&5E=',O<VAE
M970Y-BYX;6Q02P$"% ,4    " #XB=Q64PP**(4"  "7!@  &0
M    @($63 ( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    (
M /B)W%:5.FU.EP0  "\5   9              " @=). @!X;"]W;W)K<VAE
M971S+W-H965T.3@N>&UL4$L! A0#%     @ ^(G<5A<<K(Y, P  80D  !D
M             ("!H%," 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"
M% ,4    " #XB=Q689%)LPL#   8#0  &@              @($C5P( >&PO
M=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " #XB=Q6K2>'!C(0
M  #7_0  &@              @(%F6@( >&PO=V]R:W-H965T<R]S:&5E=#$P
M,2YX;6Q02P$"% ,4    " #XB=Q6MT!T!C$#  #J$@  #0
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:+GAM;%!+!08     ;0!M /0=  !&? (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>347</ContextCount>
  <ElementCount>466</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>151</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Change in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Change in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Nature of business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/NatureOfBusinessAndOrganization</Role>
      <ShortName>Nature of business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/GoingConcern</Role>
      <ShortName>Going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Reverse Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ReverseRecapitalization</Role>
      <ShortName>Reverse Recapitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Disposition of Subsidiary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/DispositionOfSubsidiary</Role>
      <ShortName>Disposition of Subsidiary</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Accounts receivable, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts receivable, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/OtherReceivables</Role>
      <ShortName>Other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Intangible assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Forward Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ForwardPurchaseAgreements</Role>
      <ShortName>Forward Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Loan to third party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/LoanToThirdParty</Role>
      <ShortName>Loan to third party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Credit facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/CreditFacilities</Role>
      <ShortName>Credit facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Other payables and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/OtherPayablesAndAccruedLiabilities</Role>
      <ShortName>Other payables and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Related party balances and transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/RelatedPartyBalancesAndTransactions</Role>
      <ShortName>Related party balances and transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Shareholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Concentrations risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ConcentrationsRisks</Role>
      <ShortName>Concentrations risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SegmentInformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Nature of business and organization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/NatureOfBusinessAndOrganizationTables</Role>
      <ShortName>Nature of business and organization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/NatureOfBusinessAndOrganization</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Reverse Recapitalization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ReverseRecapitalizationTables</Role>
      <ShortName>Reverse Recapitalization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/ReverseRecapitalization</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Accounts receivable, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts receivable, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/AccountsReceivableNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/OtherReceivablesTables</Role>
      <ShortName>Other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/OtherReceivables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Intangible assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/IntangibleAssetsNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/Goodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Credit facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/CreditFacilitiesTables</Role>
      <ShortName>Credit facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/CreditFacilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Other payables and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables</Role>
      <ShortName>Other payables and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/OtherPayablesAndAccruedLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Related party balances and transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>Related party balances and transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/RelatedPartyBalancesAndTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Shareholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/ShareholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Segment information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SegmentInformationTables</Role>
      <ShortName>Segment information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://euda.com/role/SegmentInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of consolidated financial statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails</Role>
      <ShortName>Schedule of consolidated financial statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Nature of business and organization (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative</Role>
      <ShortName>Nature of business and organization (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/NatureOfBusinessAndOrganizationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Going concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>Going concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/GoingConcern</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails</Role>
      <ShortName>Schedule of foreign currency exchange rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of property and equipment useful lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails</Role>
      <ShortName>Schedule of property and equipment useful lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of intangible assets net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>Schedule of intangible assets net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfRevenueDetails</Role>
      <ShortName>Schedule of revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of cost of revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfCostOfRevenueDetails</Role>
      <ShortName>Schedule of cost of revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Schedule of basic and diluted earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails</Role>
      <ShortName>Schedule of fair value hierarchy of financial liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of significant accounting policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails</Role>
      <ShortName>Schedule of shares issued and outstanding reverse recapitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails</Role>
      <ShortName>Schedule of financial statements of reverse recapitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Reverse Recapitalization (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ReverseRecapitalizationDetailsNarrative</Role>
      <ShortName>Reverse Recapitalization (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/ReverseRecapitalizationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative</Role>
      <ShortName>Disposition of Subsidiary (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/DispositionOfSubsidiary</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Schedule of accounts receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfAccountsReceivableDetails</Role>
      <ShortName>Schedule of accounts receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical</Role>
      <ShortName>Schedule of accounts receivable (Details) (Pharanthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Schedule of movements of allowance for doubtful accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Schedule of other receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfOtherReceivablesDetails</Role>
      <ShortName>Schedule of other receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Schedule of other receivables allowance for doubtful accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical</Role>
      <ShortName>Schedule of other receivables (Details) (Paranthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Property and equipment, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>Property and equipment, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - Schedule of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - Schedule of goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>Schedule of goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - Intangible assets, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>Intangible assets, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - Goodwill (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/GoodwillDetailsNarrative</Role>
      <ShortName>Goodwill (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/GoodwillTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative</Role>
      <ShortName>Forward Purchase Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/ForwardPurchaseAgreements</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - Loan to third party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/LoanToThirdPartyDetailsNarrative</Role>
      <ShortName>Loan to third party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/LoanToThirdParty</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - Schedule of short-term loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfShort-termLoansDetails</Role>
      <ShortName>Schedule of short-term loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical</Role>
      <ShortName>Schedule of short-term loans (Details) (Paranthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - Credit facilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/CreditFacilitiesDetailsNarrative</Role>
      <ShortName>Credit facilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/CreditFacilitiesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails</Role>
      <ShortName>Schedule of other payables and accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - Schedule of related party balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails</Role>
      <ShortName>Schedule of related party balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - Schedule of related party transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails</Role>
      <ShortName>Schedule of related party transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - Schedule of reverse recapitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfReverseRecapitalizationDetails</Role>
      <ShortName>Schedule of reverse recapitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - Schedule of warrant activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfWarrantActivitiesDetails</Role>
      <ShortName>Schedule of warrant activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails</Role>
      <ShortName>Schedule of earnout shares for triggering event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>00000084 - Disclosure - Shareholders??? equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/ShareholdersEquityTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>00000085 - Disclosure - Schedule of components of loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Schedule of components of loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>00000086 - Disclosure - Schedule of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>00000087 - Disclosure - Schedule of effective income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of effective income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical</Role>
      <ShortName>Schedule of deferred tax assets and liabilities (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>00000090 - Disclosure - Schedule of taxes payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfTaxesPayableDetails</Role>
      <ShortName>Schedule of taxes payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>00000091 - Disclosure - Income taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/IncomeTaxesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>00000092 - Disclosure - Concentrations risks (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ConcentrationsRisksDetailsNarrative</Role>
      <ShortName>Concentrations risks (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/ConcentrationsRisks</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails</Role>
      <ShortName>Schedule of operating and finance lease expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails</Role>
      <ShortName>Schedule of weighted average remaining term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>00000095 - Disclosure - Schedule of future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Schedule of future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>00000096 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/LeasesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>00000097 - Disclosure - Commitments and contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>00000098 - Disclosure - Schedule of segment reporting information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfSegmentReportingInformationDetails</Role>
      <ShortName>Schedule of segment reporting information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>00000100 - Disclosure - Segment information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>Segment information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/SegmentInformationTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>00000101 - Disclosure - Subsequent events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://euda.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://euda.com/role/SubsequentEvents</ParentRole>
      <Position>101</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept InterestIncomeRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 123, 19175</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 126, 19379</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromOtherRelatedParties in us-gaap/2022 used in 20 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 136, 137, 138, 139, 140, 19895, 19899, 19909, 19913, 19927, 19937, 19941, 19955, 19969, 19983, 19993, 20007, 20011, 20021, 20025</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 141, 142, 20099, 20114</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOtherRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 22 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 143, 144, 145, 146, 147, 20162, 20166, 20180, 20190, 20194, 20204, 20208, 20218, 20222, 20232, 20250, 20260, 20274, 20288, 20292, 20302, 20306</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 13558, 13562</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 16825</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 20371, 20375, 20385, 20389</Log>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-K, CurrentFiscalYearEndDate value, --12-31, should match the Entity Registrant Fiscal Year End Date "07/31" on record within EDGAR. form10-k.htm 4307</Log>
    <Log type="Warning">[dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 10-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. form10-k.htm </Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill -  form10-k.htm 27, 103</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>euda-20221231.xsd</File>
    <File>euda-20221231_cal.xml</File>
    <File>euda-20221231_def.xml</File>
    <File>euda-20221231_lab.xml</File>
    <File>euda-20221231_pre.xml</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex23-2.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-5.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>report_001.jpg</File>
    <File>report_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="975">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 975,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 347,
   "dts": {
    "calculationLink": {
     "local": [
      "euda-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "euda-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "euda-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "euda-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "euda-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 777,
   "entityCount": 1,
   "hidden": {
    "http://euda.com/20221231": 40,
    "http://fasb.org/us-gaap/2022": 95,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 139
   },
   "keyCustom": 116,
   "keyStandard": 350,
   "memberCustom": 111,
   "memberStandard": 35,
   "nsprefix": "EUDA",
   "nsuri": "http://euda.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://euda.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ReverseRecapitalizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Reverse Recapitalization",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://euda.com/role/ReverseRecapitalization",
     "shortName": "Reverse Recapitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ReverseRecapitalizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000100 - Disclosure - Segment information (Details Narrative)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://euda.com/role/SegmentInformationDetailsNarrative",
     "shortName": "Segment information (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_MedicalServicesMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000101 - Disclosure - Subsequent events (Details Narrative)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://euda.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2023-06-08_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:DispositionOfSubsidiariesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Disposition of Subsidiary",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://euda.com/role/DispositionOfSubsidiary",
     "shortName": "Disposition of Subsidiary",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:DispositionOfSubsidiariesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Accounts receivable, net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://euda.com/role/AccountsReceivableNet",
     "shortName": "Accounts receivable, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNontradeReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Other receivables",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://euda.com/role/OtherReceivables",
     "shortName": "Other receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancingReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Property and equipment, net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://euda.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Intangible assets, net",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://euda.com/role/IntangibleAssetsNet",
     "shortName": "Intangible assets, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://euda.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ForwardPurchaseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Forward Purchase Agreements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://euda.com/role/ForwardPurchaseAgreements",
     "shortName": "Forward Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ForwardPurchaseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:LoanToThirdPartyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Loan to third party",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://euda.com/role/LoanToThirdParty",
     "shortName": "Loan to third party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:LoanToThirdPartyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Credit facilities",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://euda.com/role/CreditFacilities",
     "shortName": "Credit facilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://euda.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Other payables and accrued liabilities",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://euda.com/role/OtherPayablesAndAccruedLiabilities",
     "shortName": "Other payables and accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Related party balances and transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://euda.com/role/RelatedPartyBalancesAndTransactions",
     "shortName": "Related party balances and transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Shareholders\u2019 equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://euda.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://euda.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Concentrations risks",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://euda.com/role/ConcentrationsRisks",
     "shortName": "Concentrations risks",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://euda.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://euda.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Segment information",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://euda.com/role/SegmentInformation",
     "shortName": "Segment information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Subsequent events",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://euda.com/role/SubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Summary of significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://euda.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Nature of business and organization (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://euda.com/role/NatureOfBusinessAndOrganizationTables",
     "shortName": "Nature of business and organization (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Summary of significant accounting policies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Reverse Recapitalization (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://euda.com/role/ReverseRecapitalizationTables",
     "shortName": "Reverse Recapitalization (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Accounts receivable, net (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://euda.com/role/AccountsReceivableNetTables",
     "shortName": "Accounts receivable, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Other receivables (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://euda.com/role/OtherReceivablesTables",
     "shortName": "Other receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Property and equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://euda.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Intangible assets, net (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://euda.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible assets, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://euda.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_BankAndPrivateLenderMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Credit facilities (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://euda.com/role/CreditFacilitiesTables",
     "shortName": "Credit facilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_BankAndPrivateLenderMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Other payables and accrued liabilities (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables",
     "shortName": "Other payables and accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Related party balances and transactions (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://euda.com/role/RelatedPartyBalancesAndTransactionsTables",
     "shortName": "Related party balances and transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Shareholders\u2019 equity (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://euda.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders\u2019 equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Income taxes (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://euda.com/role/IncomeTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://euda.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Segment information (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://euda.com/role/SegmentInformationTables",
     "shortName": "Segment information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_EUDAHealthLimitedMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:NameOfCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Schedule of consolidated financial statement (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
     "shortName": "Schedule of consolidated financial statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_EUDAHealthLimitedMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "EUDA:NameOfCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Nature of business and organization (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
     "shortName": "Nature of business and organization (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-07-24_custom_KentRidgeHealthcareSingaporePrivateLimitedMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "EUDA:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Going concern (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://euda.com/role/GoingConcernDetailsNarrative",
     "shortName": "Going concern (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "EUDA:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_currency_SGD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateRemeasurement1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of foreign currency exchange rates (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails",
     "shortName": "Schedule of foreign currency exchange rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_currency_SGD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateRemeasurement1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:PropertyPlantAndEquipmentsTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Schedule of property and equipment useful lives (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails",
     "shortName": "Schedule of property and equipment useful lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:PropertyPlantAndEquipmentsTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_OfficeEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Change in Shareholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit",
     "shortName": "Consolidated Statements of Change in Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Schedule of intangible assets net (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails",
     "shortName": "Schedule of intangible assets net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_CustomerRelationshipsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Schedule of revenue (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://euda.com/role/ScheduleOfRevenueDetails",
     "shortName": "Schedule of revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of cost of revenue (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
     "shortName": "Schedule of cost of revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfCostOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_MedicalServicesSpecialtyCareMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Schedule of basic and diluted earnings per share (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails",
     "shortName": "Schedule of basic and diluted earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:PrepaidForwardPurchaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Schedule of fair value hierarchy of financial liability (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails",
     "shortName": "Schedule of fair value hierarchy of financial liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "decimals": "0",
      "lang": null,
      "name": "EUDA:PrepaidForwardPurchaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:PrepaidForwardPurchaseLiabilitiesBalance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Schedule of reconciliation of financial liability measured at fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "EUDA:PrepaidForwardPurchaseLiabilitiesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - Summary of significant accounting policies (Details Narrative)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of significant accounting policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Schedule of shares issued and outstanding reverse recapitalization (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails",
     "shortName": "Schedule of shares issued and outstanding reverse recapitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-17",
      "decimals": "0",
      "lang": null,
      "name": "EUDA:StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFinancialStatementsOfReverseRecapitalization",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-18",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:FundsHeldInTrustAccount",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Schedule of financial statements of reverse recapitalization (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails",
     "shortName": "Schedule of financial statements of reverse recapitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFinancialStatementsOfReverseRecapitalization",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-18",
      "decimals": "0",
      "lang": null,
      "name": "EUDA:ProceedsFromReverseRecapitalizations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Reverse Recapitalization (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
     "shortName": "Reverse Recapitalization (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-11-17",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://euda.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - Disposition of Subsidiary (Details Narrative)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
     "shortName": "Disposition of Subsidiary (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "EUDA:DispositionOfSubsidiariesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-02-272022-03-02_custom_SEMAAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "SGD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - Schedule of accounts receivable (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://euda.com/role/ScheduleOfAccountsReceivableDetails",
     "shortName": "Schedule of accounts receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - Schedule of accounts receivable (Details) (Pharanthetical)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
     "shortName": "Schedule of accounts receivable (Details) (Pharanthetical)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_UnitedOverseasBankLimitedMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - Schedule of movements of allowance for doubtful accounts (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails",
     "shortName": "Schedule of movements of allowance for doubtful accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:AccountsAndNontradeReceivableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:DivestmentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - Schedule of other receivables (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://euda.com/role/ScheduleOfOtherReceivablesDetails",
     "shortName": "Schedule of other receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:DivestmentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:AllowanceForDoubtfulOtherReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - Schedule of other receivables allowance for doubtful accounts (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails",
     "shortName": "Schedule of other receivables allowance for doubtful accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:AllowanceForDoubtfulOtherReceivableRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-01-18",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - Schedule of other receivables (Details) (Paranthetical)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical",
     "shortName": "Schedule of other receivables (Details) (Paranthetical)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FinancingReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-01-18",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - Schedule of property and equipment (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Schedule of property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - Property and equipment, net (Details Narrative)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "Property and equipment, net (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedCustomerRelationshipsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - Schedule of intangible assets (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://euda.com/role/ScheduleOfIntangibleAssetsDetails",
     "shortName": "Schedule of intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedCustomerRelationshipsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Nature of business and organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://euda.com/role/NatureOfBusinessAndOrganization",
     "shortName": "Nature of business and organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - Schedule of goodwill (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://euda.com/role/ScheduleOfGoodwillDetails",
     "shortName": "Schedule of goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - Intangible assets, net (Details Narrative)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://euda.com/role/IntangibleAssetsNetDetailsNarrative",
     "shortName": "Intangible assets, net (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - Goodwill (Details Narrative)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://euda.com/role/GoodwillDetailsNarrative",
     "shortName": "Goodwill (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "EUDA:ForwardPurchaseAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-11-09",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:PrepaidForwardPurchaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - Forward Purchase Agreements (Details Narrative)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
     "shortName": "Forward Purchase Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "EUDA:ForwardPurchaseAgreementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "EUDA:ChangeOfFairValueOfPrepaidForwardPurchaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "EUDA:LoanToThirdPartyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - Loan to third party (Details Narrative)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://euda.com/role/LoanToThirdPartyDetailsNarrative",
     "shortName": "Loan to third party (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "EUDA:LoanToThirdPartyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-11-20_custom_PTTotalPrimaIndonesiaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - Schedule of short-term loans (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://euda.com/role/ScheduleOfShort-termLoansDetails",
     "shortName": "Schedule of short-term loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_BankAndPrivateLenderMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_PromissoryNoteMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - Schedule of short-term loans (Details) (Paranthetical)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
     "shortName": "Schedule of short-term loans (Details) (Paranthetical)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-08-21_custom_UnitedOverseasBankLimitedMember_custom_BankAndPrivateLenderMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_ThirdPartiesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - Credit facilities (Details Narrative)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://euda.com/role/CreditFacilitiesDetailsNarrative",
     "shortName": "Credit facilities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_ThirdPartiesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - Schedule of other payables and accrued liabilities (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails",
     "shortName": "Schedule of other payables and accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - Schedule of related party balances (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
     "shortName": "Schedule of related party balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfRelatedPartyBalancesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Going concern",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://euda.com/role/GoingConcern",
     "shortName": "Going concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - Schedule of related party transactions (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails",
     "shortName": "Schedule of related party transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "EUDA:OrdinarySharesOutstandingPriorToReverseRecapitalization",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000081 - Disclosure - Schedule of reverse recapitalization (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
     "shortName": "Schedule of reverse recapitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000082 - Disclosure - Schedule of warrant activities (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
     "shortName": "Schedule of warrant activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "EUDA:ClassOfWarrantOrRightOutstandingGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "EUDA:SharePriceAsOfClosingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000083 - Disclosure - Schedule of earnout shares for triggering event (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails",
     "shortName": "Schedule of earnout shares for triggering event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-11-162022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "EUDA:SharePriceAsOfClosingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "EUDA:ReverseRecapitalizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-11-17",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000084 - Disclosure - Shareholders\u2019 equity (Details Narrative)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://euda.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "Shareholders\u2019 equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-03-302022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentDecreaseForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000085 - Disclosure - Schedule of components of loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails",
     "shortName": "Schedule of components of loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000086 - Disclosure - Schedule of provision for income taxes (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "Schedule of provision for income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000087 - Disclosure - Schedule of effective income tax rate (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "shortName": "Schedule of effective income tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000088 - Disclosure - Schedule of deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000089 - Disclosure - Schedule of deferred tax assets and liabilities (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical",
     "shortName": "Schedule of deferred tax assets and liabilities (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Summary of significant accounting policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://euda.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfTaxesPayableTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:AccruedGSTTaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000090 - Disclosure - Schedule of taxes payable (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://euda.com/role/ScheduleOfTaxesPayableDetails",
     "shortName": "Schedule of taxes payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfTaxesPayableTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "EUDA:AccruedGSTTaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000091 - Disclosure - Income taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://euda.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000092 - Disclosure - Concentrations risks (Details Narrative)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://euda.com/role/ConcentrationsRisksDetailsNarrative",
     "shortName": "Concentrations risks (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000093 - Disclosure - Schedule of operating and finance lease expenses (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails",
     "shortName": "Schedule of operating and finance lease expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000094 - Disclosure - Schedule of weighted average remaining term and discount rate (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails",
     "shortName": "Schedule of weighted average remaining term and discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000095 - Disclosure - Schedule of future minimum lease payments (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "Schedule of future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "EUDA:ScheduleOfFutureMinimumLeasePaymentsTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000096 - Disclosure - Leases (Details Narrative)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://euda.com/role/LeasesDetailsNarrative",
     "shortName": "Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000097 - Disclosure - Commitments and contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000098 - Disclosure - Schedule of segment reporting information (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
     "shortName": "Schedule of segment reporting information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_MedicalServicesMember36611421",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000099 - Disclosure - Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails",
     "shortName": "Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 151,
   "tag": {
    "EUDA_AccountsPayableRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable related party.",
        "label": "Accounts payable - related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedParty",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AccruedGSTTaxesPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/ScheduleOfTaxesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GST taxes payable.",
        "label": "GST taxes payable"
       }
      }
     },
     "localname": "AccruedGSTTaxesPayableCurrent",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfTaxesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AlfredLimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alfred Lim [Member]",
        "label": "Alfred Lim [Member]"
       }
      }
     },
     "localname": "AlfredLimMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful accounts prepaid and other current assets.",
        "label": "Allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPrepaidAndOtherCurrentAssets",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful accounts receivable exchange rate effect.",
        "label": "Exchange rate effect"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableExchangeRateEffect",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AllowanceForDoubtfulOtherReceivableRecoveries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful other receivable recoveries.",
        "label": "AllowanceForDoubtfulOtherReceivableRecoveries",
        "verboseLabel": "Addition"
       }
      }
     },
     "localname": "AllowanceForDoubtfulOtherReceivableRecoveries",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AllowanceForDoubtfulOtherReceivableWriteOffs": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful other receivable write offs.",
        "label": "AllowanceForDoubtfulOtherReceivableWriteOffs",
        "negatedLabel": "Write-off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulOtherReceivableWriteOffs",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_AverageDailyReturnRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average daily return rate.",
        "label": "Average daily return rate"
       }
      }
     },
     "localname": "AverageDailyReturnRate",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_BankAndPrivateLenderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank and Private Lender [Member]",
        "label": "Bank and Private Lender [Member]"
       }
      }
     },
     "localname": "BankAndPrivateLenderMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_BusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination [Member]",
        "label": "Business Combination [Member]"
       }
      }
     },
     "localname": "BusinessCombinationMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_CadenceHealthPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cadence Health Pte Ltd [Member]",
        "label": "Cadence Health Pte Ltd [Member]"
       }
      }
     },
     "localname": "CadenceHealthPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_CentralProvidentFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Central Provident Fund [Member]",
        "label": "Central Provident Fund [Member]"
       }
      }
     },
     "localname": "CentralProvidentFundMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of prepaid forward purchase liabilities.",
        "label": "Change in fair value of prepaid forward purchase liabilities"
       }
      }
     },
     "localname": "ChangeInFairValueOfPrepaidForwardPurhcaseLiabilities",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ChangeOfFairValueOfPrepaidForwardPurchaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change of fair value of prepaid forward purchase liability.",
        "label": "Change of fair value of prepaid forward purchase liability"
       }
      }
     },
     "localname": "ChangeOfFairValueOfPrepaidForwardPurchaseLiability",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_CheeYinMehMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chee Yin Meh [Member]",
        "label": "Chee Yin Meh [Member]"
       }
      }
     },
     "localname": "CheeYinMehMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ChenSettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chen Settlement Agreement [Member]",
        "label": "Chen Settlement Agreement [Member]"
       }
      }
     },
     "localname": "ChenSettlementAgreementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ClassOfWarrantOrRightOutstandingExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant outstanding exercised.",
        "label": "Warrants Outstanding, Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingExercised",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_ClassOfWarrantOrRightOutstandingForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant outstanding forfeited.",
        "label": "Warrants Outstanding, Forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingForfeited",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_ClassOfWarrantOrRightOutstandingGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant outstanding granted.",
        "label": "Warrants Outstanding, Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingGranted",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_ConsolidatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated [Member]",
        "label": "Consolidated [Member]"
       }
      }
     },
     "localname": "ConsolidatedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ContractualObligationDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation discount.",
        "label": "Contractual obligation discount",
        "negatedLabel": "Total lease payments"
       }
      }
     },
     "localname": "ContractualObligationDiscount",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ContractualObligationLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation lease liability.",
        "label": "Contractual obligation lease liability",
        "verboseLabel": "Total lease payments"
       }
      }
     },
     "localname": "ContractualObligationLeaseLiability",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ConversionOfDebtIntoPromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of debt into promissory note.",
        "label": "Conversion of debt into a promissory note"
       }
      }
     },
     "localname": "ConversionOfDebtIntoPromissoryNote",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ConversionOfDebtsIntoConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of debts into convertible notes.",
        "label": "Conversion of debts into convertible notes"
       }
      }
     },
     "localname": "ConversionOfDebtsIntoConvertibleNotes",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ConvertibleNotesRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes related parties.",
        "label": "Convertible notes - related parties"
       }
      }
     },
     "localname": "ConvertibleNotesRelatedParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ConvertibleNotesRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes Related Parties [Member]",
        "label": "Convertible Notes Related Parties [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesRelatedPartiesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ConvertibleNotesThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes Third Parties [Member]",
        "label": "Convertible Notes Third Parties [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesThirdPartiesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_DailyVolatilityForTriggeringEvent1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daily volatility for triggering event 1.",
        "label": "Daily volatility for Triggering Event 1"
       }
      }
     },
     "localname": "DailyVolatilityForTriggeringEvent1",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_DailyVolatilityForTriggeringEvent2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daily volatility for triggering event 2.",
        "label": "Daily volatility for Triggering Event 2"
       }
      }
     },
     "localname": "DailyVolatilityForTriggeringEvent2",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_DateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of incorporation.",
        "label": "Date of incorporation"
       }
      }
     },
     "localname": "DateOfIncorporation",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "EUDA_DeferredTaxAssetsLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability net.",
        "label": "Net lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilityNet",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_DefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan [Policy Text Block]",
        "label": "Defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_DisclosureDispositionOfSubsidiaryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition Of Subsidiary"
       }
      }
     },
     "localname": "DisclosureDispositionOfSubsidiaryAbstract",
     "nsuri": "http://euda.com/20221231",
     "xbrltype": "stringItemType"
    },
    "EUDA_DisclosureForwardPurchaseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Purchase Agreements"
       }
      }
     },
     "localname": "DisclosureForwardPurchaseAgreementsAbstract",
     "nsuri": "http://euda.com/20221231",
     "xbrltype": "stringItemType"
    },
    "EUDA_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Schedule Of Future Minimum Lease Payments",
        "verboseLabel": "Schedule Of Weighted Average Remaining Term And Discount Rate"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://euda.com/20221231",
     "xbrltype": "stringItemType"
    },
    "EUDA_DisclosureLoanToThirdPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan To Third Party"
       }
      }
     },
     "localname": "DisclosureLoanToThirdPartyAbstract",
     "nsuri": "http://euda.com/20221231",
     "xbrltype": "stringItemType"
    },
    "EUDA_DisclosureReverseRecapitalizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization",
        "terseLabel": "Schedule Of Financial Statements Of Reverse Recapitalization",
        "verboseLabel": "Schedule Of Shares Issued And Outstanding Reverse Recapitalization"
       }
      }
     },
     "localname": "DisclosureReverseRecapitalizationAbstract",
     "nsuri": "http://euda.com/20221231",
     "xbrltype": "stringItemType"
    },
    "EUDA_DispositionOfSubsidiariesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposition of subsidiaries [Text Block]",
        "label": "Disposition of Subsidiary"
       }
      }
     },
     "localname": "DispositionOfSubsidiariesTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiary"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_DivestmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestment receivable.",
        "label": "Receivable from divestment (1)"
       }
      }
     },
     "localname": "DivestmentReceivable",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_EUDADoctorPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EUDA Doctor Private Limited [Member]",
        "label": "EUDA Doctor Private Limited [Member]"
       }
      }
     },
     "localname": "EUDADoctorPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_EUDAHealthLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EUDA Health Limited [Member]",
        "label": "EUDA Health Limited [Member]"
       }
      }
     },
     "localname": "EUDAHealthLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_EUDAPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EUDA Private Limited [Member]",
        "label": "EUDA Private Limited [Member]"
       }
      }
     },
     "localname": "EUDAPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_EarnoutPayment": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout payment.",
        "label": "Earnout payment"
       }
      }
     },
     "localname": "EarnoutPayment",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_EarnoutSharePayment": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout share payment.",
        "label": "Earnout share payment",
        "negatedLabel": "Earnout share payment"
       }
      }
     },
     "localname": "EarnoutSharePayment",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_EarnoutShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout shares.",
        "label": "EarnoutShares",
        "verboseLabel": "Earnout shares"
       }
      }
     },
     "localname": "EarnoutShares",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_EightIHoldingsTwoPtdLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8i Holdings Two Ptd Ltd [Member]",
        "label": "8i Holdings Two Ptd Ltd [Member]"
       }
      }
     },
     "localname": "EightIHoldingsTwoPtdLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_EightiHoldingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8i Holding [Member]",
        "label": "8i Holding [Member]"
       }
      }
     },
     "localname": "EightiHoldingMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_EmployeeAdavance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Empolyee advance.",
        "label": "Employee advance"
       }
      }
     },
     "localname": "EmployeeAdavance",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ExchangeRateEffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of exchange rate effect.",
        "label": "ExchangeRateEffect",
        "verboseLabel": "Exchange rate effect"
       }
      }
     },
     "localname": "ExchangeRateEffect",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ExchangeRatioPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio per share.",
        "label": "Exchange ratio"
       }
      }
     },
     "localname": "ExchangeRatioPerShare",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_FSCapitalPtdLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FS Capital Ptd Ltd [Member]",
        "label": "FS Capital Ptd Ltd [Member]"
       }
      }
     },
     "localname": "FSCapitalPtdLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_FairValueOfEarnoutShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of earnout shares.",
        "label": "Fair value of earnout shares"
       }
      }
     },
     "localname": "FairValueOfEarnoutShares",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_FiftyPercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "50% [Member]",
        "label": "50% [Member]"
       }
      }
     },
     "localname": "FiftyPercentageMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_FirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Anniversary [Member]",
        "label": "First Anniversary [Member]"
       }
      }
     },
     "localname": "FirstAnniversaryMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ForgivenessOfDebtByRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of debt by related party.",
        "label": "ForgivenessOfDebtByRelatedParty",
        "verboseLabel": "Forgiveness of debt by a related party"
       }
      }
     },
     "localname": "ForgivenessOfDebtByRelatedParty",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ForwardPurchaseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure of forward purchase agreements disclosure [Text Block]",
        "label": "ForwardPurchaseAgreementsDisclosureTextBlock",
        "verboseLabel": "Forward Purchase Agreements"
       }
      }
     },
     "localname": "ForwardPurchaseAgreementsDisclosureTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ForwardPurchaseReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward purchase receivables.",
        "label": "Forward purchase receivables"
       }
      }
     },
     "localname": "ForwardPurchaseReceivables",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward Purchase Receivables and Prepaid Forward Purchase Liabilities [Policy Text Block]",
        "label": "Forward Purchase Receivables and Prepaid Forward Purchase Liabilities"
       }
      }
     },
     "localname": "ForwardPurchaseReceivablesAndPrepaidForwardPurchaseLiabilitiesPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_FounderSharesNoParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the par value of founder shares.",
        "label": "Founder shares, par value"
       }
      }
     },
     "localname": "FounderSharesNoParValue",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_FounderSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder shares outstanding.",
        "label": "Founder shares, outstanding"
       }
      }
     },
     "localname": "FounderSharesOutstanding",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_FrescoInvestmentPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresco Investment Pte Ltd [Member]",
        "label": "Fresco Investment Pte Ltd [Member]"
       }
      }
     },
     "localname": "FrescoInvestmentPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_FundingSocietiesPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Societies Pte. Ltd [Member]",
        "label": "Funding Societies Pte. Ltd [Member]"
       }
      }
     },
     "localname": "FundingSocietiesPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_FundsHeldInOperatingCashAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds held in operating cash account.",
        "label": "Funds held in 8i\u2019s operating cash account",
        "verboseLabel": "Funds held in operating cash account"
       }
      }
     },
     "localname": "FundsHeldInOperatingCashAccount",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_FundsHeldInTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds held in trust account.",
        "label": "Funds held in 8i\u2019s trust account",
        "verboseLabel": "Funds held in trust account"
       }
      }
     },
     "localname": "FundsHeldInTrustAccount",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_GoodsAndServicesTaxesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Good and services taxes [Policy Text Block]",
        "label": "Goods and services taxes (\u201cGST\u201d)"
       }
      }
     },
     "localname": "GoodsAndServicesTaxesPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_GrantPriceForTriggingEventOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant price for trigging event one.",
        "label": "Grant Price for Trigging Event 1"
       }
      }
     },
     "localname": "GrantPriceForTriggingEventOne",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_GrantPriceForTriggingEventTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant price for trigging event two.",
        "label": "Grant Price for Trigging Event 2"
       }
      }
     },
     "localname": "GrantPriceForTriggingEventTwo",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_IncreaseDecreaseInAccountsPayableRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payables - related party.",
        "label": "Accounts payables - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParty",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In fair value of prepaid forward purchase liabilities.",
        "label": "IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities",
        "negatedLabel": "Change in fair value of prepaid forward purchase liabilities",
        "verboseLabel": "Change in fair value of prepaid forward purchase liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfPrepaidForwardPurchaseLiabilities",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails",
      "http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of operating right of use asset and lease liability.",
        "label": "Initial recognition of operating right of use asset and lease liability"
       }
      }
     },
     "localname": "InitialRecognitionOfOperatingRightOfUseAssetAndLeaseLiability",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of payables to former subsidiary upon disposal of subsidiary.",
        "label": "Initial recognition of payables to former subsidiary upon disposal of subsidiary"
       }
      }
     },
     "localname": "InitialRecognitionOfPayablesToFormerSubsidiaryUponDisposalOfSubsidiary",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_InstallmentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Installment received.",
        "label": "Installment received"
       }
      }
     },
     "localname": "InstallmentReceived",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_InstitutionalInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutional Investors [Member]",
        "label": "Institutional Investors [Member]"
       }
      }
     },
     "localname": "InstitutionalInvestorsMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_InvestmentOwnedAdditionalAmountAtMarketValues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment owned additional amount at market values.",
        "label": "Additional amount"
       }
      }
     },
     "localname": "InvestmentOwnedAdditionalAmountAtMarketValues",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_IssuanceOfOrdinarySharesUponReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares upon reverse recapitalization.",
        "label": "IssuanceOfOrdinarySharesUponReverseRecapitalization",
        "verboseLabel": "Issuance of ordinary shares upon the Reverse Recapitalization"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesUponReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_IssuanceOfOrdinarySharesUponTheReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares upon the reverse recapitalization.",
        "label": "Net contributions from issuance of ordinary shares upon the Reverse Recapitalization"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesUponTheReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_JamesTanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "James Tan [Member]",
        "label": "James Tan [Member]"
       }
      }
     },
     "localname": "JamesTanMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_JamieFanWeiZhiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jamie Fan Wei Zhi [Member]",
        "label": "Jamie Fan Wei Zhi [Member]"
       }
      }
     },
     "localname": "JamieFanWeiZhiMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_JanicLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janic Limited [Member]",
        "label": "Janic Limited [Member]"
       }
      }
     },
     "localname": "JanicLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_JenniferGohMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jennifer Goh [Member]",
        "label": "Jennifer Goh [Member]"
       }
      }
     },
     "localname": "JenniferGohMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KRDigitalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KR Digital Pte Ltd [Member]",
        "label": "KR Digital Pte Ltd [Member]"
       }
      }
     },
     "localname": "KRDigitalPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KRHillCapitalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KR Hill Capital Pte Ltd [Member]",
        "label": "KR Hill Capital Pte Ltd [Member]"
       }
      }
     },
     "localname": "KRHillCapitalPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KaufamanAndCanolesPcKcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kaufaman &amp; Canoles, P.C. (KC) [Member]",
        "label": "Kaufaman &amp; Canoles, P.C. (KC) [Member]"
       }
      }
     },
     "localname": "KaufamanAndCanolesPcKcMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KelvinChenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kelvin Chen [Member]",
        "label": "Kelvin Chen [Member]"
       }
      }
     },
     "localname": "KelvinChenMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeHealthLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Health Limited [Member]",
        "label": "Kent Ridge Health Limited [Member]"
       }
      }
     },
     "localname": "KentRidgeHealthLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeHealthPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Health Pte Ltd [Member]",
        "label": "Kent Ridge Health Pte Ltd [Member]"
       }
      }
     },
     "localname": "KentRidgeHealthPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeHealthcareSingaporePrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Healthcare Singapore Private Limited [Member]",
        "label": "Kent Ridge Healthcare Singapore Private Limited [Member]"
       }
      }
     },
     "localname": "KentRidgeHealthcareSingaporePrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeHealthcareSingaporePteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Healthcare SingaporePte Ltd [Member]",
        "label": "Kent Ridge Healthcare SingaporePte Ltd [Member]"
       }
      }
     },
     "localname": "KentRidgeHealthcareSingaporePteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeHillPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Hill Private Limited [Member]",
        "label": "Kent Ridge Hill Private Limited [Member]"
       }
      }
     },
     "localname": "KentRidgeHillPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgeMedicalPtdLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Medical Ptd Ltd [Member]",
        "label": "Kent Ridge Medical Ptd Ltd [Member]"
       }
      }
     },
     "localname": "KentRidgeMedicalPtdLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KentRidgePacificPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kent Ridge Pacific Pte Ltd [Member]",
        "label": "Kent Ridge Pacific Pte Ltd [Member]"
       }
      }
     },
     "localname": "KentRidgePacificPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_KohWeeSingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Koh Wee Sing [Member]",
        "label": "Koh Wee Sing [Member]"
       }
      }
     },
     "localname": "KohWeeSingMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_LoanAccumulativelyDisbursed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan accumulatively disbursed.",
        "label": "Loan accumulatively disbursed"
       }
      }
     },
     "localname": "LoanAccumulativelyDisbursed",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_LoanToThirdParty": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to third party.",
        "label": "Loan to third party"
       }
      }
     },
     "localname": "LoanToThirdParty",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_LoanToThirdPartyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to third party [Text Block]",
        "label": "LoanToThirdPartyTextBlock",
        "verboseLabel": "Loan to third party"
       }
      }
     },
     "localname": "LoanToThirdPartyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/LoanToThirdParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_LoebAndLoebLlpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loeb and Loeb LLP [Member]",
        "label": "Loeb and Loeb LLP [Member]"
       }
      }
     },
     "localname": "LoebAndLoebLlpMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MaximGroupLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maxim Group LLC [Member]",
        "label": "Maxim Group LLC [Member]"
       }
      }
     },
     "localname": "MaximGroupLlcMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesGeneralPracticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services General Practice [Member]",
        "label": "Medical Services General Practice [Member]"
       }
      }
     },
     "localname": "MedicalServicesGeneralPracticeMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesGeneralPracticeRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services General Practice Related Parties [Member]",
        "label": "Medical Services General Practice Related Parties [Member]"
       }
      }
     },
     "localname": "MedicalServicesGeneralPracticeRelatedPartiesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesGeneralPracticesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services General Practices [Member]",
        "label": "Medical Services General Practices [Member]"
       }
      }
     },
     "localname": "MedicalServicesGeneralPracticesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services [Member]",
        "label": "Medical Services [Member]"
       }
      }
     },
     "localname": "MedicalServicesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services Related Parties [Member]",
        "label": "Medical Services Related Parties [Member]"
       }
      }
     },
     "localname": "MedicalServicesRelatedPartiesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesSpecialtyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services Specialty Care [Member]",
        "label": "Medical Services Specialty Care [Member]"
       }
      }
     },
     "localname": "MedicalServicesSpecialtyCareMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesSpecialtyCareRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services Specialty Care Related Party [Member]",
        "label": "Medical Services Specialty Care Related Party [Member]"
       }
      }
     },
     "localname": "MedicalServicesSpecialtyCareRelatedPartyMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MedicalServicesSubTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Services Sub Total [Member]",
        "label": "Medical Services Sub Total [Member]"
       }
      }
     },
     "localname": "MedicalServicesSubTotalMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MelanaInternationalPteLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melana International Pte Limited [Member]",
        "label": "Melana International Pte Limited [Member]"
       }
      }
     },
     "localname": "MelanaInternationalPteLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MelanaInternationalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melana International Pte Ltd [Member]",
        "label": "Melana International Pte Ltd [Member]"
       }
      }
     },
     "localname": "MelanaInternationalPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MengDongJamesTanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meng Dong James Tan [Member]",
        "label": "Meng Dong James Tan [Member]"
       }
      }
     },
     "localname": "MengDongJamesTanMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MenoraCapitalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menora Capital Pte Ltd [Member]",
        "label": "Menora Capital Pte Ltd [Member]"
       }
      }
     },
     "localname": "MenoraCapitalPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MenoraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menora [Member]",
        "label": "Menora [Member]"
       }
      }
     },
     "localname": "MenoraMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_MountLockeLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mount Locke Limited [Member]",
        "label": "Mount Locke Limited [Member]"
       }
      }
     },
     "localname": "MountLockeLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_NameOfCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of Company.",
        "label": "Name of company"
       }
      }
     },
     "localname": "NameOfCompany",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "EUDA_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New accounting pronouncements not yet adopted policy [Policy Text Block]",
        "label": "Recent accounting pronouncements not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_NoCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Customer [Member]",
        "label": "No Customer [Member]"
       }
      }
     },
     "localname": "NoCustomerMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_NoVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Vendor [Member]",
        "label": "No Vendor [Member]"
       }
      }
     },
     "localname": "NoVendorMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_NonControllingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Controlling Interest [Policy Text Block]",
        "label": "Non-controlling interests"
       }
      }
     },
     "localname": "NonControllingInterestPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_NoncashNetAssetsAssumedValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash net assets assumed value.",
        "label": "Add: non-cash net assets assumed from 8i"
       }
      }
     },
     "localname": "NoncashNetAssetsAssumedValue",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_NosweatFitnessCompanyPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nosweat Fitness Company Private Limited [Member]",
        "label": "Nosweat Fitness Company Private Limited [Member]"
       }
      }
     },
     "localname": "NosweatFitnessCompanyPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_OneVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Vendor [Member]",
        "label": "One Vendor [Member]"
       }
      }
     },
     "localname": "OneVendorMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_OperatingLeaseExpenseShortTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expense short term.",
        "label": "Lease expenses - short-term"
       }
      }
     },
     "localname": "OperatingLeaseExpenseShortTerm",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OrdinaryShareBeforeReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares before reverse recapitalization.",
        "label": "Ordinary share before reverse recapitalization"
       }
      }
     },
     "localname": "OrdinaryShareBeforeReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_OrdinarySharesAvailableForResale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares available for resale.",
        "label": "Ordinary shares available for resale"
       }
      }
     },
     "localname": "OrdinarySharesAvailableForResale",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_OrdinarySharesForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares forfeited.",
        "label": "Ordinary shares forfeited"
       }
      }
     },
     "localname": "OrdinarySharesForfeited",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary Shares [Member]",
        "label": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_OrdinarySharesOutstandingPriorToReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares outstanding prior to reverse recapitalization.",
        "label": "8i ordinary shares outstanding prior to Reverse Recapitalization"
       }
      }
     },
     "localname": "OrdinarySharesOutstandingPriorToReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_OrdinarySharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares to be issued.",
        "label": "Ordinary shares to be issued"
       }
      }
     },
     "localname": "OrdinarySharesToBeIssued",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_OtherCorporateExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate expenses.",
        "label": "OtherCorporateExpenses",
        "negatedLabel": "Other corporate expenses"
       }
      }
     },
     "localname": "OtherCorporateExpenses",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OtherPayablesAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other payables and accrued liabilities.",
        "label": "Other payables and accrued liabilities"
       }
      }
     },
     "localname": "OtherPayablesAndAccruedLiabilities",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OtherPayablesRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other payables related parties.",
        "label": "Other payables - related parties"
       }
      }
     },
     "localname": "OtherPayablesRelatedParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OtherReceivableInstallmentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivable installment amount.",
        "label": "Other installment amount"
       }
      }
     },
     "localname": "OtherReceivableInstallmentAmount",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OtherReceivablesNetNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivable net non current.",
        "label": "Other receivables \u2013 non-current"
       }
      }
     },
     "localname": "OtherReceivablesNetNonCurrent",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_OtherReceivablesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other receivables non current.",
        "label": "Other receivables - non-current"
       }
      }
     },
     "localname": "OtherReceivablesNonCurrent",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_PTTotalPrimaIndonesiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PT Total Prima Indonesia [Member]",
        "label": "PT Total Prima Indonesia [Member]"
       }
      }
     },
     "localname": "PTTotalPrimaIndonesiaMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PrepaidExpensesAndOtherAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other assets [Policy Text Block]",
        "label": "PrepaidExpensesAndOtherAssetsPolicyTextBlock",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_PrepaidForwardAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Forward Agreement 1 [Member]",
        "label": "Prepaid Forward Agreement 1 [Member]"
       }
      }
     },
     "localname": "PrepaidForwardAgreementOneMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PrepaidForwardAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Forward Agreement 2 [Member]",
        "label": "Prepaid Forward Agreement 2 [Member]"
       }
      }
     },
     "localname": "PrepaidForwardAgreementTwoMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PrepaidForwardPurchaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid forward purchase liabilities.",
        "label": "Prepaid forward purchase liabilities",
        "verboseLabel": "Prepaid forward purchase liability"
       }
      }
     },
     "localname": "PrepaidForwardPurchaseLiabilities",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_PrepaidForwardPurchaseLiabilitiesBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid forward purchase liabilities balance.",
        "label": "PrepaidForwardPurchaseLiabilitiesBalance",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "PrepaidForwardPurchaseLiabilitiesBalance",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfReconciliationOfFinancialLiabilityMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_PrepaidForwardPurchaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid forward purchase liability.",
        "label": "Purchase liability"
       }
      }
     },
     "localname": "PrepaidForwardPurchaseLiability",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_PrivateOrdinarySharesNoParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private ordinary shares no par value.",
        "label": "Private ordinary shares, par value"
       }
      }
     },
     "localname": "PrivateOrdinarySharesNoParValue",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_PrivateOrdinarySharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private ordinary shares outstanding.",
        "label": "Private ordinary shares, outstanding"
       }
      }
     },
     "localname": "PrivateOrdinarySharesOutstanding",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_PrivateRightsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private rights shares.",
        "label": "Private rights shares"
       }
      }
     },
     "localname": "PrivateRightsShares",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_PrivateWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Warrant [Member]",
        "label": "Private Warrant [Member]"
       }
      }
     },
     "localname": "PrivateWarrantMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ProceedsFromReverseRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from reverse recapitalization.",
        "label": "Proceeds from the Reverse Recapitalization"
       }
      }
     },
     "localname": "ProceedsFromReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ProceedsFromReverseRecapitalizations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from reverse recapitalizations.",
        "label": "ProceedsFromReverseRecapitalizations",
        "verboseLabel": "Proceeds from the Reverse Recapitalization"
       }
      }
     },
     "localname": "ProceedsFromReverseRecapitalizations",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ProceedsFromUnpaidDeferredUnderwritingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from unpaid deferred underwriting fee.",
        "label": "ProceedsFromUnpaidDeferredUnderwritingFee",
        "negatedLabel": "Less: unpaid deferred underwriting fee"
       }
      }
     },
     "localname": "ProceedsFromUnpaidDeferredUnderwritingFee",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ProceedsFromUnpaidTransactionCostsIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from unpaid transaction costs incurred.",
        "label": "ProceedsFromUnpaidTransactionCostsIncurred",
        "negatedLabel": "Less: unpaid transaction costs incurred by 8i"
       }
      }
     },
     "localname": "ProceedsFromUnpaidTransactionCostsIncurred",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ProductMangementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Mangement Services [Member]",
        "label": "Product Mangement Services [Member]"
       }
      }
     },
     "localname": "ProductMangementServicesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales [Member]",
        "label": "Product Sales [Member]"
       }
      }
     },
     "localname": "ProductSalesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note.",
        "label": "Promissory note"
       }
      }
     },
     "localname": "PromissoryNote",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note [Member]",
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServiceCommonAreaManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Service Common Area Management [Member]",
        "label": "Property Management Service Common Area Management [Member]"
       }
      }
     },
     "localname": "PropertyManagementServiceCommonAreaManagementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Service [Member]",
        "label": "Property Management Service [Member]"
       }
      }
     },
     "localname": "PropertyManagementServiceMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServiceSecurityManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Service Security Management [Member]",
        "label": "Property Management Service Security Management [Member]"
       }
      }
     },
     "localname": "PropertyManagementServiceSecurityManagementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServicesCommonAreaManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Services Common Area Management [Member]",
        "label": "Property Management Services Common Area Management [Member]"
       }
      }
     },
     "localname": "PropertyManagementServicesCommonAreaManagementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Services [Member]",
        "label": "Property Management Services [Member]"
       }
      }
     },
     "localname": "PropertyManagementServicesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyManagementServicesSecurityManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Management Services Security Management [Member]",
        "label": "Property Management Services Security Management [Member]"
       }
      }
     },
     "localname": "PropertyManagementServicesSecurityManagementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PropertyPlantAndEquipmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipments [Text Block]",
        "label": "Schedule of property and equipment useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentsTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_PublicRightsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public rights shares.",
        "label": "Public rights shares"
       }
      }
     },
     "localname": "PublicRightsShares",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_PublicWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Warrant [Member]",
        "label": "Public Warrant [Member]"
       }
      }
     },
     "localname": "PublicWarrantMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_PurchaseFromRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from purchases of related parties.",
        "label": "Purchase from related parties"
       }
      }
     },
     "localname": "PurchaseFromRelatedParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_RedeemableWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Warrants [Member]",
        "label": "Redeemable Warrants [Member]"
       }
      }
     },
     "localname": "RedeemableWarrantsMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_RedemptionOfOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of ordinary shares.",
        "label": "Less: redemption of 8i ordinary shares"
       }
      }
     },
     "localname": "RedemptionOfOrdinaryShares",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_RegisteredCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registeration capital.",
        "label": "Registered capital"
       }
      }
     },
     "localname": "RegisteredCapital",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_RelatedPartyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party [Policy Text Block]",
        "label": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_RepaymentsFromOtherReceivableRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments from other receivable related parties.",
        "label": "Repayments from other receivable - related parties"
       }
      }
     },
     "localname": "RepaymentsFromOtherReceivableRelatedParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_RepaymentsToShorttermLoansThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments to short term loans third parties.",
        "label": "RepaymentsToShorttermLoansThirdParties",
        "negatedLabel": "Repayments to short-term loans - third parties"
       }
      }
     },
     "localname": "RepaymentsToShorttermLoansThirdParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ReverseRecapitalizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization [Text Block]",
        "label": "ReverseRecapitalizationTextBlock",
        "verboseLabel": "Reverse Recapitalization"
       }
      }
     },
     "localname": "ReverseRecapitalizationTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_RiskFreeRateForTriggeringEventOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk free rate for triggering event one.",
        "label": "Risk-free rate for Triggering Event 1"
       }
      }
     },
     "localname": "RiskFreeRateForTriggeringEventOne",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_RiskFreeRateForTriggeringEventTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk free rate for triggering event two.",
        "label": "Risk-free rate for Triggering Event 2"
       }
      }
     },
     "localname": "RiskFreeRateForTriggeringEventTwo",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_SEMAAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEMA Agreement [Member]",
        "label": "SEMA Agreement [Member]"
       }
      }
     },
     "localname": "SEMAAgreementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ScheduleOfCostOfRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cost of revenue [Table Text Block]",
        "label": "Schedule of cost of revenue"
       }
      }
     },
     "localname": "ScheduleOfCostOfRevenueTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Earnout Shares for triggering event [Table Text Block]",
        "label": "Schedule of earnout shares for triggering event"
       }
      }
     },
     "localname": "ScheduleOfEarnoutSharesForTriggeringEventTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfFinancialStatementsOfReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of financial statements of reverse recapitalization.",
        "label": "Schedule of financial statements of reverse recapitalization"
       }
      }
     },
     "localname": "ScheduleOfFinancialStatementsOfReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of finite lived intangible assets useful lives [Table Text Block]",
        "label": "Schedule of intangible assets net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfFutureMinimumLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Future Minimum Lease Payments [Table Text Block]",
        "label": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating And Finance Lease Expenses [Table Text Block]",
        "label": "Schedule of operating and finance lease expenses"
       }
      }
     },
     "localname": "ScheduleOfOperatingAndFinanceLeaseExpensesTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of ordinary shares issued and outstanding of reverse recapitalization [Table Text Block]",
        "label": "Schedule of shares issued and outstanding reverse recapitalization"
       }
      }
     },
     "localname": "ScheduleOfOrdinarySharesIssuedAndOutstandingOfReverseRecapitalizationTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of ordinary shares issued of reverse recapitalization [Table Text Block]",
        "label": "Schedule of reverse recapitalization"
       }
      }
     },
     "localname": "ScheduleOfOrdinarySharesIssuedOfReverseRecapitalizationTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfRelatedPartyBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Related party balances [Table Text Block]",
        "label": "Schedule of related party balances"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyBalancesTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_ScheduleOfTaxesPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of taxes payable [Table Text Block]",
        "label": "Schedule of taxes payable"
       }
      }
     },
     "localname": "ScheduleOfTaxesPayableTableTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_SecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Anniversary [Member]",
        "label": "Second Anniversary [Member]"
       }
      }
     },
     "localname": "SecondAnniversaryMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SellerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seller One [Member]",
        "label": "Seller One [Member]"
       }
      }
     },
     "localname": "SellerOneMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SellerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seller Two [Member]",
        "label": "Seller Two [Member]"
       }
      }
     },
     "localname": "SellerTwoMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement [Member]",
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "localname": "SettlementAgreementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SeventyFivePercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "75% [Member]",
        "label": "75% [Member]"
       }
      }
     },
     "localname": "SeventyFivePercentageMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share award equity instruments other than options outstanding weighted average remaining contractual terms granted.",
        "label": "Average Remaining Contractual Life,Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsGranted",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "EUDA_SharePriceAsOfClosingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price as of closing date.",
        "label": "Share price of the Company as of closing date"
       }
      }
     },
     "localname": "SharePriceAsOfClosingDate",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfEarnoutSharesForTriggeringEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement [Member]",
        "label": "Share Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ShineLinkLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shine Link Limited [Member]",
        "label": "Shine Link Limited [Member]"
       }
      }
     },
     "localname": "ShineLinkLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ShineLinkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shine Link [Member]",
        "label": "Shine Link [Member]"
       }
      }
     },
     "localname": "ShineLinkMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ShortTermDebtInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term debt interest rate.",
        "label": "Interest Rate"
       }
      }
     },
     "localname": "ShortTermDebtInterestRate",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_ShortTermLoansThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term loans third parties.",
        "label": "Short term loans - third parties"
       }
      }
     },
     "localname": "ShortTermLoansThirdParties",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_SingaporeEmergencyMedicalAssistancePrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Singapore Emergency Medical Assistance Private Limited [Member]",
        "label": "Singapore Emergency Medical Assistance Private Limited [Member]"
       }
      }
     },
     "localname": "SingaporeEmergencyMedicalAssistancePrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SingaporeSubsidiariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Singapore Subsidiaries [Member]",
        "label": "Singapore Subsidiaries [Member]"
       }
      }
     },
     "localname": "SingaporeSubsidiariesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SkillDevelopmentLevyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Skill Development Levy [Member]",
        "label": "Skill Development Levy [Member]"
       }
      }
     },
     "localname": "SkillDevelopmentLevyMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_SocialInsuranceFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Insurance Fund [Member]",
        "label": "Social Insurance Fund [Member]"
       }
      }
     },
     "localname": "SocialInsuranceFundMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_StockIssuedDuringPeriodSharesCapitalContributions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares capital contributions.",
        "label": "Capital contributions, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCapitalContributions",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issuance of ordinary shares upon the Reverse Recapitalization.",
        "label": "Issuance of ordinary shares upon the reverse recapitalization , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceofordinarysharesupontheReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "EUDA_StockIssuedDuringPeriodValueCapitalContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value capital contributions.",
        "label": "Capital contributions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCapitalContributions",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_StockIssuedDuringPeriodValueEarnoutSharesPayament": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value earnout shares payment.",
        "label": "Earnout shares payment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEarnoutSharesPayament",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value forgiveness of debt by related party.",
        "label": "Forgiveness of debt by a related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueForgivenessOfDebtByRelatedParty",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value issuance of ordinary shares upon reverse recapitalization.",
        "label": "Issuance of ordinary shares upon the Reverse Recapitalization",
        "verboseLabel": "Total shares outstanding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponReverseRecapitalization",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_SuperGatewayGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Super Gateway Group Limited [Member]",
        "label": "Super Gateway Group Limited [Member]"
       }
      }
     },
     "localname": "SuperGatewayGroupLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TanFirstLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tan First Loan [Member]",
        "label": "Tan First Loan [Member]"
       }
      }
     },
     "localname": "TanFirstLoanMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TanSecondLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tan Second Loan [Member]",
        "label": "Tan Second Loan [Member]"
       }
      }
     },
     "localname": "TanSecondLoanMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TanThirdLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tan Third Loan [Member]",
        "label": "Tan Third Loan [Member]"
       }
      }
     },
     "localname": "TanThirdLoanMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TanTwoThousandTwentyThreeNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tan 2023 Note [Member]",
        "label": "Tan 2023 Note [Member]"
       }
      }
     },
     "localname": "TanTwoThousandTwentyThreeNoteMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TheGoodClinicPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Good Clinic Private Limited [Member]",
        "label": "The Good Clinic Private Limited [Member]"
       }
      }
     },
     "localname": "TheGoodClinicPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Parties [Member]",
        "label": "Third Parties [Member]"
       }
      }
     },
     "localname": "ThirdPartiesMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative",
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TradeUnionFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade union fee percent.",
        "label": "Trade union fee"
       }
      }
     },
     "localname": "TradeUnionFeePercentage",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "EUDA_TriGlobalSecurityPteLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TriGlobal Security Pte Limited [Member]",
        "label": "TriGlobal Security Pte Limited [Member]"
       }
      }
     },
     "localname": "TriGlobalSecurityPteLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TriGlobalSecurityPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tri Global Security Pte Ltd [Member]",
        "label": "Tri Global Security Pte Ltd [Member]"
       }
      }
     },
     "localname": "TriGlobalSecurityPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TriggeringEventOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Triggering Event One [Member]",
        "label": "Triggering Event One [Member]"
       }
      }
     },
     "localname": "TriggeringEventOneMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TriggeringEventTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Triggering Event Two [Member]",
        "label": "Triggering Event Two [Member]"
       }
      }
     },
     "localname": "TriggeringEventTwoMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_TrueCoverPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Cover Private Limited [Member]",
        "label": "True Cover Private Limited [Member]"
       }
      }
     },
     "localname": "TrueCoverPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_UGDigitalSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UG Digital Sdn. Bhd. [Member]",
        "label": "UG Digital Sdn. Bhd. [Member]"
       }
      }
     },
     "localname": "UGDigitalSdnBhdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_UGDigitechPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UG Digitech Private Limited [Member]",
        "label": "UG Digitech Private Limited [Member]"
       }
      }
     },
     "localname": "UGDigitechPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_UnitedOverseasBankLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Overseas Bank Limited [Member]",
        "label": "United Overseas Bank Limited [Member]"
       }
      }
     },
     "localname": "UnitedOverseasBankLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_UniversalGatewayInternationalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Universal Gateway International Pvt Ltd [Member]",
        "label": "Universal Gateway International Pvt Ltd [Member]"
       }
      }
     },
     "localname": "UniversalGatewayInternationalPteLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor One [Member]",
        "label": "Vendor One [Member]"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Two [Member]",
        "label": "Vendor Two [Member]"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_WarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The accounting policy of warants text block.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyTextBlock",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "EUDA_WarrantsRedemptionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant redemption price.",
        "label": "Warrants redemption price"
       }
      }
     },
     "localname": "WarrantsRedemptionPrice",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "EUDA_WatermarkDevelopmentsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watermark Developments Ltd [Member]",
        "label": "Watermark Developments Ltd [Member]"
       }
      }
     },
     "localname": "WatermarkDevelopmentsLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_WilkeServicesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wilke Services Ltd [Member]",
        "label": "Wilke Services Ltd [Member]"
       }
      }
     },
     "localname": "WilkeServicesLtdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/GoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "EUDA_ZukihealthSDNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zukihealth SDN [Member]",
        "label": "Zukihealth SDN [Member]"
       }
      }
     },
     "localname": "ZukihealthSDNMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ZukihealthSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zukihealth Sdn Bhd [Member]",
        "label": "Zukihealth Sdn Bhd [Member]"
       }
      }
     },
     "localname": "ZukihealthSdnBhdMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ZukitechPrivateLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zukitech Private Limited [Member]",
        "label": "Zukitech Private Limited [Member]"
       }
      }
     },
     "localname": "ZukitechPrivateLimitedMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "EUDA_ZukitekVietnamPrivateLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zukitek Vietnam Private Limited Liability Company [Member]",
        "label": "Zukitek Vietnam Private Limited Liability Company [Member]"
       }
      }
     },
     "localname": "ZukitekVietnamPrivateLimitedLiabilityCompanyMember",
     "nsuri": "http://euda.com/20221231",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MALAYSIA"
       }
      }
     },
     "localname": "MY",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE"
       }
      }
     },
     "localname": "SG",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "country_VN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIET NAM"
       }
      }
     },
     "localname": "VN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_MYR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Malaysia, Ringgits"
       }
      }
     },
     "localname": "MYR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_SGD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore, Dollars"
       }
      }
     },
     "localname": "SGD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_VND": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Viet Nam, Dong"
       }
      }
     },
     "localname": "VND",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r692",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r692",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r692",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r692",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r692",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer.",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r272",
      "r522",
      "r523",
      "r526",
      "r527",
      "r565",
      "r633",
      "r638",
      "r759",
      "r762",
      "r763",
      "r829",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r272",
      "r522",
      "r523",
      "r526",
      "r527",
      "r565",
      "r633",
      "r638",
      "r759",
      "r762",
      "r763",
      "r829",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r344",
      "r667",
      "r765",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r454",
      "r574",
      "r607",
      "r634",
      "r635",
      "r664",
      "r673",
      "r680",
      "r764",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r454",
      "r574",
      "r607",
      "r634",
      "r635",
      "r664",
      "r673",
      "r680",
      "r764",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r344",
      "r667",
      "r765",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r340",
      "r578",
      "r665",
      "r678",
      "r756",
      "r757",
      "r765",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r340",
      "r578",
      "r665",
      "r678",
      "r756",
      "r757",
      "r765",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r446",
      "r454",
      "r480",
      "r481",
      "r482",
      "r572",
      "r574",
      "r607",
      "r634",
      "r635",
      "r664",
      "r673",
      "r680",
      "r752",
      "r764",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r446",
      "r454",
      "r480",
      "r481",
      "r482",
      "r572",
      "r574",
      "r607",
      "r634",
      "r635",
      "r664",
      "r673",
      "r680",
      "r752",
      "r764",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r455",
      "r727",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r286",
      "r455",
      "r702",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r723",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Schedule of consolidated financial statement"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganizationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r341",
      "r342",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r666",
      "r679",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r618",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r637",
      "r639",
      "r666",
      "r679",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r286",
      "r455",
      "r702",
      "r703",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r732",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndNontradeReceivableTextBlock": {
     "auth_ref": [
      "r354",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.",
        "label": "Accounts and Nontrade Receivable [Text Block]",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsAndNontradeReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/AccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "verboseLabel": "Other payables and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/OtherPayablesAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "totalLabel": "Total other payables and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20",
      "r677"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r177",
      "r193",
      "r211",
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Account payable, related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Schedule of movements of allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r239",
      "r346",
      "r347",
      "r649"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "totalLabel": "Total accounts receivable, net",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails",
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r7",
      "r186",
      "r203"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfTaxesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfTaxesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses (i)"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r109",
      "r231"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r242",
      "r601",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r251",
      "r252",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r36",
      "r39",
      "r158",
      "r558",
      "r608",
      "r609",
      "r709",
      "r710",
      "r711",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising cost"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r91",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Schedule of other receivables allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/OtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Other receivables allowance for doubtful account"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesAllowanceForDoubtfulAccountsDetails",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r243",
      "r350",
      "r358",
      "r359",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r243",
      "r350",
      "r358"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Addition"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfMovementsOfAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Other receivables allowance for doubtful account"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r63",
      "r96",
      "r102"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r63",
      "r106"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Impairment loss on long-lived assets and goodwill"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r184",
      "r202",
      "r235",
      "r268",
      "r318",
      "r330",
      "r336",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r522",
      "r526",
      "r533",
      "r677",
      "r760",
      "r761",
      "r811"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r227",
      "r244",
      "r268",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r522",
      "r526",
      "r533",
      "r677",
      "r760",
      "r761",
      "r811"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankOverdrafts": {
     "auth_ref": [
      "r27",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.",
        "label": "Bank balance"
       }
      }
     },
     "localname": "BankOverdrafts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r519",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r519",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r148",
      "r149",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Consideration",
        "verboseLabel": "Consideration received"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "verboseLabel": "Capital contributions"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r65",
      "r229",
      "r648"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash",
        "verboseLabel": "Cash balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r65",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Total cash and restricted cash",
        "verboseLabel": "Cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/GoingConcernDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r59",
      "r65",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH AND RESTRICTED CASH, end of the year",
        "periodStartLabel": "CASH AND RESTRICTED CASH, beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r172"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash FDIC"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r268",
      "r290",
      "r291",
      "r294",
      "r296",
      "r300",
      "r301",
      "r356",
      "r400",
      "r403",
      "r404",
      "r405",
      "r409",
      "r410",
      "r428",
      "r429",
      "r431",
      "r435",
      "r441",
      "r533",
      "r636",
      "r701",
      "r718",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant to purchase ordinary share, price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding",
        "periodEndLabel": "Warrants Outstanding, Ending balance",
        "periodStartLabel": "Warrants Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r194",
      "r209"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r393",
      "r394",
      "r620",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r724",
      "r725",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Ordinary shares, par value",
        "terseLabel": "Ordinary shares per share",
        "verboseLabel": "Ordinary shares, no par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".",
        "label": "Common stock, shares authorized, unlimited"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "authorizedUnlimitedItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Ordinary shares, issued",
        "terseLabel": "Ordinary shares issued",
        "verboseLabel": "Common stock, shares authorized, unlimited"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheetsParenthetical",
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Public ordinary shares"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r677"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary shares, no par value, unlimited shares authorized, 20,191,770 shares and 9,333,333 shares outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r40",
      "r247",
      "r249",
      "r258",
      "r596",
      "r604"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMIT"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r154",
      "r155",
      "r161",
      "r247",
      "r249",
      "r257",
      "r595",
      "r603"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Less: Comprehensive (loss) income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r161",
      "r247",
      "r249",
      "r256",
      "r594",
      "r602"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "TOTAL COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r78",
      "r79",
      "r169",
      "r170",
      "r344",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r78",
      "r79",
      "r169",
      "r170",
      "r344",
      "r614",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r78",
      "r79",
      "r169",
      "r170",
      "r344",
      "r619",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentrations risks"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisks"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r78",
      "r79",
      "r169",
      "r170",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r80",
      "r169",
      "r171",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r78",
      "r79",
      "r169",
      "r170",
      "r344",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Total lease payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Total 2023"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Total 2024"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of 8i rights",
        "terseLabel": "Restricted ordinary shares converted",
        "verboseLabel": "Converted shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockTypeOfStockConverted": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of stock (i.e. preferred, common, treasury, etc.) being converted in a noncash (or part noncash) transaction.",
        "label": "Conversion of ordinary shares, description"
       }
      }
     },
     "localname": "ConversionOfStockTypeOfStockConverted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r8",
      "r188",
      "r204",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible promissory note"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible notes",
        "verboseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r46",
      "r268",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r533",
      "r760"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Total Cost of Revenues",
        "verboseLabel": "Total cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COST OF REVENUES"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk that a borrower will fail to pay interest or principal on a loan or debt security when due.",
        "label": "Credit Risk [Member]"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r503",
      "r511",
      "r721"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r77",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Ordinary shares aggregate amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Ordinary shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of unpaid principal amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r185",
      "r188",
      "r200",
      "r272",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r544",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCollateral": {
     "auth_ref": [
      "r29",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided.",
        "label": "Collateral/Guarantee"
       }
      }
     },
     "localname": "DebtInstrumentCollateral",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "verboseLabel": "Forgiveness of debt by a related party"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r174",
      "r176",
      "r411",
      "r544",
      "r660",
      "r661"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r29",
      "r174",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r29",
      "r174",
      "r427",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt instrument trading percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt intrument interest rate, description"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r245",
      "r659",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Maturities"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30",
      "r272",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r544",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r63",
      "r143",
      "r504",
      "r510",
      "r511",
      "r721"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred taxes benefits",
        "verboseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r10",
      "r11",
      "r187",
      "r199",
      "r498"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r491",
      "r492"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r141",
      "r796"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards",
        "verboseLabel": "Deferred tax assets, operating losses carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r141",
      "r796"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful account"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r141",
      "r796"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Deposits": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.",
        "label": "Deposits"
       }
      }
     },
     "localname": "Deposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r107"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedParties": {
     "auth_ref": [
      "r177",
      "r212",
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other.",
        "label": "Other receivables - related parties"
       }
      }
     },
     "localname": "DueFromOtherRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r240",
      "r402",
      "r403",
      "r404",
      "r408",
      "r409",
      "r410",
      "r562",
      "r650",
      "r722"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r177",
      "r192",
      "r211",
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related parties classified as other.",
        "label": "Other payables \u2013 related parties"
       }
      }
     },
     "localname": "DueToOtherRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r20",
      "r402",
      "r403",
      "r404",
      "r408",
      "r409",
      "r410",
      "r562",
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Short term loans - third parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r259",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r287",
      "r290",
      "r294",
      "r295",
      "r296",
      "r298",
      "r530",
      "r531",
      "r597",
      "r605",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "(Loss)/Earnings per share, basic and diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "(LOSS) EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES*"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "(Loss) earnings per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r804"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "EFFECT OF EXCHANGE RATE CHANGES"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r270",
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Singapore statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r794",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r794",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Tax rate difference outside Singapore",
        "verboseLabel": "Foreign income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "verboseLabel": "Others"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r794",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Taxable income below exemption threshold"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee expenses"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDescription": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the plan, including the basis for determining contributions, the employee groups covered, and the nature and effect of significant matters affecting comparability of information for all periods presented. For leveraged ESOPs and pension reversion ESOPs, the description generally includes the basis for releasing shares and how dividends on allocated and unallocated shares are used.",
        "label": "Employee plan description"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r117",
      "r223",
      "r251",
      "r252",
      "r253",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r285",
      "r299",
      "r357",
      "r443",
      "r484",
      "r485",
      "r486",
      "r506",
      "r507",
      "r529",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r558",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage",
        "terseLabel": "Beneficially ownership percentage",
        "verboseLabel": "Ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Earnout shares"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).",
        "label": "Schedule of fair value hierarchy of financial liability"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r419",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r532",
      "r569",
      "r570",
      "r571",
      "r660",
      "r661",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r419",
      "r447",
      "r452",
      "r532",
      "r569",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r419",
      "r447",
      "r452",
      "r532",
      "r570",
      "r660",
      "r661",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r419",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r532",
      "r571",
      "r660",
      "r661",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Schedule of reconciliation of financial liability measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r419",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r569",
      "r570",
      "r571",
      "r660",
      "r661",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r547",
      "r551",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r546",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Present value of lease liabilities, finance lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease liabilities - non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Total Finance lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance lease payments, 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance lease payments, 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Total Finance lease payments, discount"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r548",
      "r552"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r547",
      "r551",
      "r676"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Amortization of finance right-of-use assets",
        "verboseLabel": "Amortization of leased asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r554",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance leases, weighted-average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r553",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance leases, weighted-average remaining term",
        "verboseLabel": "Finance lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LeasesDetailsNarrative",
      "http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancingReceivablesTextBlock": {
     "auth_ref": [
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financing receivable.",
        "label": "Financing Receivables [Text Block]",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "FinancingReceivablesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/OtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedCustomerRelationshipsGross": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date to an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life.",
        "label": "Finite-Lived Customer Relationships, Gross",
        "verboseLabel": "Customer relationships"
       }
      }
     },
     "localname": "FiniteLivedCustomerRelationshipsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Customer relationships"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r233",
      "r381"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r101",
      "r579"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateRemeasurement1": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to remeasure amounts denominated in a currency other than functional currency into functional currency.",
        "label": "Period-end : US$1 exchange rate*"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateRemeasurement1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Period-average : US$1 exchange rate*"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign currency translation and transaction"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value per share that would be issued upon settlement of forward contract indexed to equity.",
        "label": "Forward contract, fair value per share"
       }
      }
     },
     "localname": "ForwardContractIndexedToEquitySettlementShareFairValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": {
     "auth_ref": [
      "r713",
      "r714",
      "r716",
      "r821",
      "r823"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.",
        "label": "Gain on disposal of subsidiary",
        "negatedLabel": "Gain on disposal of subsidiary",
        "verboseLabel": "Gain loss on disposal of deficit interest"
       }
      }
     },
     "localname": "GainOrLossOnSaleOfStockInSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/StatementsOfCashFlows",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r232",
      "r365",
      "r593",
      "r658",
      "r677",
      "r740",
      "r747"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r378",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r63",
      "r366",
      "r371",
      "r377",
      "r658"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Impairment loss on goodwill",
        "negatedLabel": "Impairment",
        "verboseLabel": "Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/GoodwillDetailsNarrative",
      "http://euda.com/role/ScheduleOfGoodwillDetails",
      "http://euda.com/role/StatementsOfCashFlows",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r144",
      "r748"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r45",
      "r268",
      "r318",
      "r329",
      "r335",
      "r338",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r533",
      "r657",
      "r760"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r63",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r716",
      "r751"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment loss on intangible assets",
        "terseLabel": "Less: Impairment",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://euda.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://euda.com/role/StatementsOfCashFlows",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r63",
      "r106",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of property and equipment"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment for long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r269",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Singapore"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r181",
      "r195",
      "r214",
      "r318",
      "r329",
      "r335",
      "r338",
      "r598",
      "r657"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Total loss (income) before income taxes",
        "totalLabel": "(LOSS) INCOME BEFORE INCOME TAXES",
        "verboseLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails",
      "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails",
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r269",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfComponentsOfLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r268",
      "r276",
      "r318",
      "r329",
      "r335",
      "r338",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r531",
      "r533",
      "r657",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Segment loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfConsolidatedStatementOfOperationAndComprehensiveIncomeLossNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r384",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r495",
      "r496",
      "r502",
      "r508",
      "r514",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income tax description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r136",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income tax likelihood description"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r271",
      "r284",
      "r285",
      "r316",
      "r493",
      "r509",
      "r515",
      "r606"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "PROVISION FOR INCOME TAXES",
        "terseLabel": "Taxable income",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r250",
      "r489",
      "r490",
      "r496",
      "r497",
      "r501",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income tax"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInNotesReceivableCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.",
        "label": "Increase (Decrease) in Notes Receivable, Current",
        "negatedLabel": "Interest receivable from loan to third party"
       }
      }
     },
     "localname": "IncreaseDecreaseInNotesReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r715",
      "r806"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Other payables and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r100",
      "r575",
      "r576",
      "r577",
      "r579",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r95",
      "r99"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r175",
      "r197",
      "r254",
      "r312",
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest-bearing assets owed to the entity by related party.",
        "label": "Interest income from loan to third party"
       }
      }
     },
     "localname": "InterestIncomeRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r261",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interests (ii)"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r707"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment income",
        "negatedLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r215",
      "r616",
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment amount"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "auth_ref": [
      "r216",
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.",
        "label": "Remaining balance"
       }
      }
     },
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "auth_ref": [
      "r163",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount on the investment owned.",
        "label": "Investment owned face amount"
       }
      }
     },
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r555",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease expenses"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total Operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating lease payments, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Operating lease payments, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Total Operating lease payments, discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r268",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r523",
      "r526",
      "r527",
      "r533",
      "r656",
      "r760",
      "r811",
      "r812"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r190",
      "r207",
      "r677",
      "r720",
      "r738",
      "r803"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r228",
      "r268",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r523",
      "r526",
      "r527",
      "r533",
      "r677",
      "r760",
      "r811",
      "r812"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r8",
      "r9",
      "r268",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r523",
      "r526",
      "r527",
      "r533",
      "r760",
      "r811",
      "r812"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Other Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r23",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Loan interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r23",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Loan borrow up amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r23",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfAccountsReceivableDetailsPharanthetical",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r395",
      "r702"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Contingent liability balance outstanding"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r753",
      "r754",
      "r755"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Legal payment"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r753",
      "r754",
      "r755"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Compensate amount"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of risks inherent in servicing assets and servicing liabilities.",
        "label": "Servicing Assets and Servicing Liabilities Risk [Axis]"
       }
      }
     },
     "localname": "ManagingRisksInherentInServicingAssetsAndServicingLiabilitiesByTypeOfRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r34",
      "r189",
      "r206",
      "r268",
      "r356",
      "r400",
      "r403",
      "r404",
      "r405",
      "r409",
      "r410",
      "r533"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r64",
      "r196",
      "r213",
      "r226",
      "r246",
      "r248",
      "r253",
      "r268",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r292",
      "r318",
      "r329",
      "r335",
      "r338",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r531",
      "r533",
      "r657",
      "r760"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net income",
        "totalLabel": "NET (LOSS) INCOME ATTRIBUTABLE TO EUDA HEALTH HOLDINGS LIMITED"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r157",
      "r160",
      "r246",
      "r248",
      "r284",
      "r285",
      "r711"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Less: Net (income) loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r287",
      "r288",
      "r293",
      "r296",
      "r318",
      "r329",
      "r335",
      "r338",
      "r657"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net (loss)/income attributable to common shareholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r151",
      "r443",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income (Expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r318",
      "r329",
      "r335",
      "r338",
      "r657"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Loss from operations",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r805"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities, operating lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability - non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of operating right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r554",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r553",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease, weighted-average remaining term",
        "verboseLabel": "Operating lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LeasesDetailsNarrative",
      "http://euda.com/role/ScheduleOfWeightedAverageRemainingTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage points added to the reference rate to compute the variable rate on the lessor's operating lease.",
        "label": "Effective interest rate"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating losses carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating losses carry forward description"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Nature of business and organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/NatureOfBusinessAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Others"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r183",
      "r201",
      "r234"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "totalLabel": "Total Other Assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "FOREIGN CURRENCY TRANSLATION ADJUSTMENT",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "totalLabel": "Total other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Others"
       }
      }
     },
     "localname": "OtherReceivablesGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other receivables",
        "verboseLabel": "Other receivables \u2013 current"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.",
        "label": "Payments for Merger Related Costs",
        "negatedLabel": "Less: payment and accrued expenses of transaction costs related to the Reverse Recapitalization"
       }
      }
     },
     "localname": "PaymentsForMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.",
        "label": "Payments of forward purchase agreements",
        "negatedLabel": "Less: payments of forward purchase agreements"
       }
      }
     },
     "localname": "PaymentsForPurchaseOfSecuritiesOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Rental Expenses"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of transaction costs",
        "negatedLabel": "Less: payments of transaction costs incurred by 8i"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for financing costs associated with business combinations.",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedLabel": "Payments of merger costs"
       }
      }
     },
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r53",
      "r520"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Cash acquired through business combination"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedLabel": "Cash released upon disposal of a subsidiary"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Payments to Acquire Notes Receivable",
        "negatedLabel": "Loan to third party"
       }
      }
     },
     "localname": "PaymentsToAcquireNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r708"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid expenses - non-current"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "verboseLabel": "Capital contributions"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Issuance of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Borrowings from other payables - related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from short-term loans - bank and private lender"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r226",
      "r246",
      "r248",
      "r262",
      "r268",
      "r276",
      "r284",
      "r285",
      "r318",
      "r329",
      "r335",
      "r338",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r521",
      "r524",
      "r525",
      "r531",
      "r533",
      "r598",
      "r657",
      "r674",
      "r675",
      "r711",
      "r760"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net income (loss)",
        "totalLabel": "NET (LOSS) INCOME",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/StatementsOfCashFlows",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Leasehold equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r108",
      "r230"
     ],
     "calculation": {
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r110",
      "r208",
      "r599",
      "r677"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "PROPERTY AND EQUIPMENT, NET",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Electronic equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r260",
      "r360"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r733",
      "r735",
      "r736",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Schedule of consolidated statement of operation and comprehensive income (loss) net loss before income taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r453",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r453",
      "r561",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r559",
      "r560",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related party balances and transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/RelatedPartyBalancesAndTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of convertible promissory note"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of promissory note related party",
        "negatedLabel": "Less: repayments of promissory note \u2013 related party of 8i"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayments to short-term loans - bank and private lender"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r135",
      "r219",
      "r819"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "verboseLabel": "Research and Development cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r704",
      "r717",
      "r820",
      "r822"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r704",
      "r717"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r119",
      "r205",
      "r611",
      "r613",
      "r677"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r223",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r285",
      "r357",
      "r484",
      "r485",
      "r486",
      "r506",
      "r507",
      "r529",
      "r608",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r309",
      "r310",
      "r328",
      "r333",
      "r334",
      "r340",
      "r341",
      "r344",
      "r444",
      "r445",
      "r578"
     ],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfRevenueDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r344",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r44",
      "r218",
      "r402",
      "r403",
      "r404",
      "r408",
      "r409",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r255",
      "r268",
      "r309",
      "r310",
      "r328",
      "r333",
      "r334",
      "r340",
      "r341",
      "r344",
      "r356",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r533",
      "r598",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The nature of risks inherent in servicing assets and servicing liabilities."
       }
      }
     },
     "localname": "RisksInherentInServicingAssetsAndServicingLiabilitiesTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ConcentrationsRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r712"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Monthly salary"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Investors sale of stock aggregate purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Investors sale of stock and issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale price of the ordinary shares",
        "verboseLabel": "Investors sale of stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of other payables and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/OtherPayablesAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock": {
     "auth_ref": [
      "r90",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss of financing receivable, classified as current.",
        "label": "Schedule of other receivables"
       }
      }
     },
     "localname": "ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/OtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfFairValueHierarchyOfFinancialLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r97",
      "r100",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r658",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-term intercompany foreign balances, including related intercompany entity, underlying foreign currencies and amounts of intercompany foreign currency transactions that are of a long-term investment nature (that is settlement is not planned or anticipated in the foreseeable future), as of the balance sheet date.",
        "label": "Schedule of foreign currency exchange rates"
       }
      }
     },
     "localname": "ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers.",
        "label": "Schedule of revenue"
       }
      }
     },
     "localname": "ScheduleOfPrincipalTransactionsRevenueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfCostOfRevenueDetails",
      "http://euda.com/role/ScheduleOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://euda.com/role/ScheduleOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfRelatedPartyBalancesDetails",
      "http://euda.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of related party transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r88",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r88",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of segment reporting information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative",
      "http://euda.com/role/CreditFacilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of short-term loans"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r120",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of warrant activities"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of weighted average remaining term and discount rate"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r344",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r389",
      "r392",
      "r658",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r318",
      "r321",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted Average Exercise Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Average Remaining Contractual Life,"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Ordinary Shares Issuable, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Ordinary Shares Issuable, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Ordinary Shares Issuable, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Ordinary Shares Issuable, Ending balance",
        "periodStartLabel": "Ordinary Shares Issuable, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Number of shares purchased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price",
        "terseLabel": "Share price per share",
        "verboseLabel": "Number of additional shares issued"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r19",
      "r210"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short term loans - bank and private lender"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender or type of lender, such as bank, insurance entity, pension fund.",
        "label": "Bank/Private lender Name"
       }
      }
     },
     "localname": "ShortTermDebtLender",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative",
      "http://euda.com/role/CreditFacilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTerms": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.",
        "label": "Maturities"
       }
      }
     },
     "localname": "ShortTermDebtTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Credit facilities"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative",
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative",
      "http://euda.com/role/CreditFacilitiesTables",
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Weighted average interest rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/CreditFacilitiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time.",
        "label": "Short-Term Debt, Weighted Average Interest Rate, over Time",
        "verboseLabel": "Interest Rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermLeasePayments": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.",
        "label": "Short term lease payments"
       }
      }
     },
     "localname": "ShortTermLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r225",
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r344",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r385",
      "r389",
      "r392",
      "r658",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://euda.com/role/SegmentInformationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r268",
      "r290",
      "r291",
      "r294",
      "r296",
      "r300",
      "r301",
      "r356",
      "r400",
      "r403",
      "r404",
      "r405",
      "r409",
      "r410",
      "r428",
      "r429",
      "r431",
      "r435",
      "r441",
      "r533",
      "r636",
      "r701",
      "r718",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r117",
      "r223",
      "r251",
      "r252",
      "r253",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r285",
      "r299",
      "r357",
      "r443",
      "r484",
      "r485",
      "r486",
      "r506",
      "r507",
      "r529",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r558",
      "r608",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Cover",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails",
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r299",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/Cover",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/IncomeTaxesDetailsNarrative",
      "http://euda.com/role/LoanToThirdPartyDetailsNarrative",
      "http://euda.com/role/NatureOfBusinessAndOrganizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfConsolidatedFinancialStatementDetails",
      "http://euda.com/role/ScheduleOfForeignCurrencyExchangeRatesDetails",
      "http://euda.com/role/ScheduleOfOperatingAndFinanceLeaseExpensesDetails",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit",
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r13",
      "r14",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Conversion of EHL ordinary shares into 8i ordinary shares",
        "verboseLabel": "Converted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Shares issued to service providers"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
      "http://euda.com/role/ScheduleOfSharesIssuedAndOutstandingReverseRecapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r117",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of ordinary shares, shares",
        "terseLabel": "Total shares issued upon the Reverse Recapitalization",
        "verboseLabel": "Number of additional shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfReverseRecapitalizationDetails",
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r117",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of ordinary shares",
        "verboseLabel": "Total consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquityDetailsNarrative",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Redeem public shares"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Amount paid to redeem public shares",
        "negatedLabel": "Less: amount paid to redeem public shares of 8i\u2019s ordinary shares"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfFinancialStatementsOfReverseRecapitalizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r16",
      "r17",
      "r92",
      "r677",
      "r720",
      "r738",
      "r803"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Euda Health Holdings Limited Shareholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r151",
      "r152",
      "r159",
      "r223",
      "r224",
      "r252",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r357",
      "r443",
      "r484",
      "r485",
      "r486",
      "r506",
      "r507",
      "r529",
      "r534",
      "r535",
      "r539",
      "r558",
      "r609",
      "r610",
      "r720",
      "r738",
      "r803"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Shareholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/StatementsOfChangeInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r267",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r540",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r540",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r540",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r540",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Going concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/GoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://euda.com/role/BalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://euda.com/role/ScheduleOfTaxesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes payable",
        "totalLabel": "Totals"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/BalanceSheets",
      "http://euda.com/role/ScheduleOfTaxesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Redemption shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r348",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/DispositionOfSubsidiaryDetailsNarrative",
      "http://euda.com/role/ForwardPurchaseAgreementsDetailsNarrative",
      "http://euda.com/role/ReverseRecapitalizationDetailsNarrative",
      "http://euda.com/role/ScheduleOfShort-termLoansDetailsParanthetical",
      "http://euda.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation allowance on all deferred tax assets increased"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfShort-termLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfWarrantActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r289",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r287",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://euda.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122596-111746",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196816",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "https://asc.fasb.org/topic&trid=2196771",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "326",
   "URI": "https://asc.fasb.org/topic&trid=82887179",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122596-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r682": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r683": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r684": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r685": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r686": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r687": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r688": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r689": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r691": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r692": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r693": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r694": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r695": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r696": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r697": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r698": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r699": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0001493152-23-022805-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-022805-xbrl.zip
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M"5T<G1X?GQS]_>9Z(ND.,L(/3S'"#SKRD_?OWQ_)U()4H7R:T;A@_>Y(),\
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M/(/%E.@$RTD3E@HWT8=V_'I<5%SR48OQ-@S1!LQB> MSBUR?Y(3):1.3@E=
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MZ.N]TS9A;8PRI3KAH?@1-%N&/3@V<,(EC-(8CN;5H^>7"//)&(&X/((^A E
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MZG8&6VA\4.,WLOP,951=8U-3_>Z%N""=@Q605PP 3&)>I^%O84-T.XT/:MR
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MG-FP 48V, \A75[&Z8.5R"6@_C1]97LH0=?SCSG%":)<E]=D$2;XGT*W)NJ
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MHT8/-85O;K$&+/!,XJ=#]SY+1&/X[$#+8H ;U'^'KE\%P%"^,XR,MK%C^*E
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M<WOS.P[O42R^^(]R7&/8D1-:>=\/ONK9'SSBWH2QV."S,S8#G]C6*(J=U#P
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M06ZRNKI486.$1].L5CUF3#&UC75#M;BOP"MJ/H;)#W%E@4V8KVFV+2Q3,P$
M=;UQJ772F%M@,8QOD+>D"#*V!@PK$V4Z -?[E%D!)@ZF$CO;-%>8TI0\<;4K
M1-T<Y'J_A(FWG36?]LZS--DPB\4C^?JB,^ZC)CC7P3-X_X$)8/Q5T*1C_\1'
ML2I,0*[#9=@J@;'NTZJISK>AJT4UWG6D#%XE>H;'7QV-[]=OORF6AA;"=00-
M6Q< IL>7//SMA[:S(@,@3 ]O'>O!]OF+R=0!LA%:")@"WOFD /^MPWX*>-L]
MSEQ19( #QG0OW)L+F 1\TED](PS7F!X*J"\/@G (]U,$@N(8N%'!8;8T #B@
M*ER'XV )^+1TZI<AC2NF=3!0.RZC>1WY_JFDQ@^D=D0QW%&E9WD_>'NYJ$Z=
M[MS ".A13K2EQB6U8\:_2:<P^I )" #U*)]J5!Y8$CZIK]4'@"C/".A1KM:H
M.J 4?%*<WD&29>#51JA0@\8@]S@^G61W,'/D]W3ZEJ71C];G*5L.(EO&NCK'
M6*W21-!CNJHHC72]'-02E\XJVIGT:?K<\IO+R>X9A-,HRE>Y2-DT7KMONY)H
MAG6]TL'*@@O")_75J!19-W4; -$%1WOD88?(M9< 5FQ'$?FD99E71G=1O7W#
M6V$PD6<9P?=YQ@/=NY1;K#3)F#ACT28C0P11S4(>"K]_.W,?.34K7]03SJ.I
M\@4G*1&,FY0NC_1OKQY0?2K!^*2\FM-YFLQL/#LSI.NU">5-[8?[J#' ^]_M
M+JT2R/4B[*@G\$/HOE72=N1WX+U**YK?CYJ2^<Q^'KV-3WM/Q[V>/B_A/7V"
M9WOX?AFI$5']+:5M?RRJ;I#5SM>O.KYVGPC2>;#[2! FLV#O,T'QG> 9_](O
M;KH:?2+LVS<DG>LBN;U!K@)1\9 @[Y[ =P\21MD?.%N>Y31C(B3;ZXJ\KIW]
M;Z:-9CHA<VTA6S0EQ:B=9>27T:R]'*DSDWO#7!M&LWI:^6H1_*'[,Y^JXRG@
MC&<WU%'PBX3)9%OXEY#\0#62- &M!L;U,E?JH.EA&/GV:4U_0@EC*^;E=K,5
M3C#-BDZ(1E49 5VO>ZB^@!(8ORZG_H! V3=748G3.M*U0VZ4MY)R_U:%N(1W
MM5J'F' 2SQBY"]VFJQKO^GH&= WH^?5),[>((D8);QUYS@QVG(I[G\;=R@#F
M^@('5$\@[GU2UY8Q.7+3N"[UP=Z8_9;8,S4ZFEZ>HL-94L]+G[SCKVF2[K-D
MW \T(,[Z'8G,4DF&./%2D]\^VO52,>I![FZDY-FK"?8IQ,DUX>OD.OD6BI;V
M/(UXE>Q>H-8XRA!@UUN"K>HL)#*^X\P()KR0[!P5?UXEE\R1$:4;_&&E;M7N
M?9&Z=L?!&AV"60_7K-A-.E@&$YQKE]YVI<+DX)//>)5LF%$HWI3@I&JKT5L'
MNW;G[0VADF._%%.YBU4F&R<Y8W%WE"*]5W+QF)&0R1LGS")<,9E1VQJ743_J
MVF.:0*(JC[[%]_<R6)E>1#_59EG$F_JXNC[&]8R7Z97VPO'U[9'^MFR4<^PC
M2I#VR%<)X'JA C6K9-4K[Y%98$C&JC',]>)JI5KNG==4DT?+88^#?L6Q'5"Y
M7D(0_766D%?KJZ6JIRKD'K9$>O /N5[C(TGNI]HE=/<!+IEO@!?EHP/1TQT)
M$QI&0AS)3/Q4*FOV_WD1<YDO68SU/=?[S31S:5QM^30O-?+LM$-YO=LHBZG&
MF5,_AYI',U8_AP,SZ'09T+F9KA*[7L=\M@R3!6-*5+OLU9PW;R;N%3&_@A<Q
M%U\(<!+4O_'?X3JEOP7%IX)GY<>FJ-SF[T1>QNF#HCS[M05G#%-0H'(5B' 2
MF!^TP4P.'Y^^4]XE9/<2/3-2&T,S !L<_\X> 0,D2ZW\5'[M.6)[882%(-0*
MV1_E>LOOK9(VIGU2RNF*>RO_%/1=SYLO,JG59()S?D#<5W$PP?BD2NVC075V
MS*?$UIB<GQOW57=7X?DT 30/$M4Y4.L=C,#Y$71?=5N*RB<M"Z8I(^XR)>=I
M?I_-\[AJ\JSU<S10KEN(#^'Y&(7BDQ*ESGS0 S(CH.NNY -X3"#1^*3-J6IZ
MQNMAWEMK=D4^_RYV':\;>F]5]JM^[:Q:_;TQT)4QR]MB(S8Y[ZZ$-G;\V_&J
M1V-WMZKT:1;5>.?=S?NO%JTD?-+9CD(YGF7^,!-3C#>[I&B+Y8(B<-XHO;\Y
MLY/5!"\[E=EV7>7Z,@+5_G=#Y;R]>K\MM8_\O%K$TEV&*LRY11'"&_V;CS!H
MH*H]SN;82,DK]U0FO'S,K*+:^#8"' -0S1YG<6REY;FJ12G)CGB-.P6!!:K7
MXZ0.7$*>*[:T-,:\NQD2J%2/TSM0Z7BNTL:S>EU,KNTSRUYG?X#R<7%=UO[9
M1TL<0/WYF/+IP.W/X!,7;\WO<P%]=E)O?&!(@64+/N:?AF#_9Y@B)=VUBU;=
MMG(5$N 4\#BSU4%F?JM<\:*2U1Z@0@%4M\\I+UMY^:1L!??%J52_@L96'(Z.
M_HL# 7J7GD9_YI@@1BO34?9T$X=)QC9C7A2[5IR35"?E%C@\+8C4:+59%F M
M,*_"#HG\1GK#0LL2I*>5E3UTJQ".WQK]F%.<\+;(5#18L]"H!.EIR64/C2J$
MX[=&J\L;M?/RHHO_Z7S.[">+I&RT#,+F:?5E#\U;"-&KV:"01%%NV,\/:<7A
MK 0Q0F@F>EA<49KS4LKK>>UA.<T$-X-ZZG5H="@7(\+$XY,'72=:M/'GE]/0
M["Q<XVSWT(9>H6UPGOH9W;2I%LSXB<TZ';R;/Z&(.3L%%>K*[N)!> "DI]X#
M0$]@%CU<=*7=NYY_063!C[9$II4_V4"M;(8U(D]=!HMEV4UT$U0LWJ)U21N?
MC8TCRUHN75VA8X7!T[L8P(7;05A>+>#:OO-MF9+L#I'5.;K7)6#4()Y>P^AF
M*UO%X9/N=E/O>@[4G0;$TWL7<-T9Q3'IUGF7"AI8%+CZG(8)O5MB MXU]<">
MWK6PWC A(O(J.-YWTG9GRO#]4H;R]+9%MRU3)12?=LWZS<D;@AF3ZS"NG#&U
M%@U@OE[8@.L1)!>OEB/GE_^?GX%LPAB)ZEC*XMM(A+>4O\.R_XO:R!M$<#J3
MSPS+'D@7CY$HN+YE\_EB/D>1KB_0Q'2XSB^YD;O<:-'VN-C+!LH^"U.7_^XA
MS/%R,#X+TRZF=[:I%JQ=S^OL7B>]!+L5X3FFZY2&\2>2YFO^2!:F4=%!&LUV
M#:35&ZT/M+G..WDQQ7U0!&3I3-=8[FN8Y01=SZL37T;X-5F$23-WN]=P[4UP
M&'#VXI0R8/9#@84W6+LO\8C7K],]3*.TB?N4,M&?I<P!) IBWS:)%2!!5,&,
MT[V.+PKRQ )ZO$CP'$>\ZJ4HX12-*F,<U??1/8+?-0DND7'QTAVZ(-SB"]9;
MA*-P8TKLU\D_?M$DOX0.U$<?@Q);K$-<M(]JN3F_1^QQD]@:-)=W6W^!0:F5
MK\?5&SCLT7K2I+6"#<@6^'^"I-[58E!2E7> ]JA\V:12@-5('&N25A5F]>(R
MI2Q_;5)908M]"U7P8XJS>;M92>NK)JT[R" 4H&.265VS;Z?MM;RY5L-'H:;Q
M6MCI@B"T'^COD2<9JA(^J! $=0RC4,PSA'?I-D6HV(<D(\7!@BP-,@X8K/?O
MNPQ*X!E!,YQ=AE'S%L$>@9)1*L"">0UNO%VGK':G^FL/=8)/)#-4[$/K$I-8
MYV&!*XC;KI ,;$%W"<:/8<P35K1J15XT)E>P(1FH$E,Q)8+[$I=@)]O#-HY?
M(_4<;B=;LE5[C83_\O;D^,UO8IL=;5K7[DJTDR@9J@(BR J0<=8:=SJ3K(P%
M;C']H2!.LD_[D $I0,?9L7ALI:!+LD75X)'$M5IAT=N*+Y;BT:8%2I2N\XED
MCFH8Q!*)]G&,LT;0HFC'-4_)2NTHGTC&J00,<!URI/#DGK+5QQ_YWBBMYXED
ME'9@ =J,:#-AT9,VBCKI$44%SRK48S4W-T3==VK_^J5DUP"Q=_"LP#A:KW:0
MOG1<26;.1EOC,J<(?G7<2-9/%0*/37MK=*FC7#**JAAS;,J;P::.:,E82B'G
MV-0J8D\=T9(EU42@8Y/?$HKJ2)>L;'M .C;55:BI(U6RL170V,0UHRH=D9*=
ME6*K25:;-LC2T2^96EBH-?[&;8RY-%S]VI+'!$5>HQM;*033<2$;5F4@-OXN
MLXW(=!1+QK,>EXU-8Q'.Z,B3+&0!,KK6I:!"1Z1D$5M"B]$ICI9HEL?B L[N
M/9[R-#F,M^_RG*,LQ+&"$<E*5EBY8QC5W_F95X@#NGT*Z%F)VY$;7W[]:TAX
MV+Y![2Q*UA3DT)>X@RWR\:SL[H -QE"+S:T=N$U(^FX&-MX#K!__4NW\DT/@
MVOR;%UB#J$0;H!)O0#CBT:??CK\V__,[1?,\_LSDJV=1#I1K+*Y;G=(@%[@#
MWHIU2C9;_%0=:Z\D$UYG#3>=UL)GG8P9'A,F.=(R(%OO&@.D0# AR?R.#XQP
M.?^[MV_3S T#'T.*(U&;$?.KA+S=-]N:>'F)<(NT+$F&O\[2/4<L%LFL0!V@
M$G? UD] .?8)^=PVV_T;1B0DT?*)_:XRD-M^,EIV91>BOO,Q_,&&?R!85E\0
MO]\:X<K/?YIT17$;(VZIB\-_F>,OS%=CW,Q.LUT[XH2!L0V<Z8K/#NU>^4KK
MCI"]SZO$L2I)",*L+D8&$'(,!25B/DVPLX+R=B"K_TIR8VPR> Y< K'@*;\E
MSJ8#\]ORC/F-"2_D4B3\M!-#SN77)H98_33 XEN%+[?[FM@%>6Z02+G!Z;8+
MR2FGQ39O*P:]NR1[Z+0R TX$H.?0,-\EMTF=XYUL=BM*GT ,O9:<)64IE)/U
M*J>R=3/QM=9S"N6D=FVR.2E?;LW4&WN.ZZ'<%&++-(D>0AUXV8=S?7L$HJ'F
M4Y8@4?A417\:Q^D#SVNV/.=FT0O?$HWKNRQ=5-M%4(9;:!,^)V[>5F^8T\+\
MM27*F-_67OWW6AOE:3?9X-D^_O'MQY=T4WDV.MUIC8HV!%Q5'Q#,5Y_@2:)@
M5GYD)Y/I?+OF0:J606W0E\JGJLZXZ*Q";00G<^B]'F_,JU2.S&!*96MTVB7:
MEL74*E,;=2E2EX[]/&4?5.W3E7HH9TT%VFDR]=,TP+GV\R :DEL) $3AE9\7
M1?DJ%^?9YVC-EC\N0]]UC(2DDUG].>8.[8Z'^X)K[[##A!A:O-XXCHI")UB&
M0<H.:4N>'.08FN=+6N.C/3>3#Y<<VYWB[41^&CC37#QJ;1^BA7/6"Z6BZBRG
M6;HJV]#Q^ILE7IM:.@/!75LBF,[D=BAPT?ADDC3<UK;3^K;9:=8J<;DV,WVU
M;2DT;TS*;ONM:C-UV^X;[9G^8EO=.7)<IJY$T-O -U)>6E4[.V&!SY[4#?1+
M*9]/39&/3['R$BB,!2F+H[D4.B%7S8NB,&:DC$W+Q5%'YZMLSSG<]LC3KFEM
M4H9N$04QQS1ASJ6=!W/*Y8TVY:)F:**,2[,V'3;3I&1+2Y6Z@WEF+EW73CWM
MB74*K&/WX^AP]S1<]6)<0Q#@(S@X)F?9BPZL07EP=;!HJS\YYV 8[Y&S7Q++
M6&:2BL6= *@*6V%<.^_#ZE C%I^46+T54S(->"&]?;SK[GL#*4\O#I\4U]4^
MV%J#J7O,#:1(() G'=SJ]:_RA3>M\Z--89+VZVY3EO/NV*E?VM.Q]%:;'MAG
M:?_2WJ1U_Y9UE6^-]P <%Y#^P?U]7CM<=0C5<J,M&WDH4 7A%M>$?/ + 6F>
M%;7!ERFY(WBQ0+PB6_3)T'*E+0Y!!>*J%)@7$V1;W$4SC?'9E"Z.@@*_MW)1
MB.8*J8,(\"Q=K=.D*.WYG%+Z$?&+6;7;IEJU&6X85JCY3VP(#>X%]@#O74J=
M\J+7!E.&CDU.*(?:9,2Z0BCFI".NBK:L;+)L6>(W\[1,:4L_4(6OQI"XDS<A
M3^=HCIB_,&/,E/GX!)J4>*M-2LQ*Q(*I\G"19R8\RDA(O&N/&-M'N_&,)5IV
M3W'SPEVVJ3W-BVRQYGC1"HGK[(-.5PV_N(-P?(IZ)/+9?U2_NWA<HX0[9121
MS2Z/&,;:2D.+*3# MUSG./K,E,%$/>"$4CR%)-$N&CQLKQ"V;V4<$@+H.M4!
MT2&4EY]@A?,;GH5PJZEEL63;@%UG./JL0;4PO'H=IZ)[ZPNVM'I5:Z\=ROET
MK%$CLDN@:2@#^>(LZ'2CGH8J(?B728,Y[S<ASP?J#H+?:C-L5IZ\.!M&$U;C
MB\"RS*3JHI5WVI1;$4J61ZBNXY(Z2\9D=^O@(1V-,L/\Z=L=C"X.9(!QO3]H
M&*E[%R#.?7(L2H)K&1?H:64;B&M''J E,Q-^;=UR+DR?U'S74H?7DOH:/XW9
MTA$<QH"41&_K$.ZF(F?[E%TRJS_.6 9^VM37.VT6/:TP"S-9])- 0<R1!ZC$
M/N6IAYCQ:':Z860M6$2["C'O^</?[ZT>@&*QJRF7^4Y[Z_*A_$@0%E\)2/69
M0)20%3V'BB]-G>.\S'FGNB^,FE6^*A[@+-_=U/*K3;G/!<Y@52 ME5N]O#LZ
M;T4S1]@*E/+J52?("3</97]\& MR39^N7[Z;.M*B<^4M6O,:]F11ZX"IG63:
M'#HMVV&2"NM^8\P)&ZKM.EAN>^]L=U!Q3XR?;A&T9'O;]GR$9UM9W&]]UO5.
M&XWL==/<]=#<;;N\1968$C6"J@.69_QL[!=1N>[NE$QJD0I9!,<OY/BEK5GJ
M=%._\38#C(F6!OJ-MQK4+)1N&O_7/=O!V&_^!5!+ P04    " #XB=Q6,1<&
M 6=2   C+@4 %0   &5U9&$M,C R,C$R,S%?9&5F+GAM;.U]ZW/C.)+G]XNX
M_T'7&W'1&['5U7:]YW$;?E9[QK9\MJOK9KXH8!*2,$41&I"4[?GK#R IB1*9
M $B!!*C1QL1VV0; S/SAD9E(9/[IOU]FP6"!641H^.>?CG[Y]:<!#CWJDW#R
MYY^^/;PY>3B[NOII$,4H]%% 0_SGGT+ZTW__G__Y/P;\__[TO]Z\&5P2'/A_
M&)Q3[\U5.*9_'-RB&?[#X"L.,4,Q97\<_(Z"1/R&7I( L\$9G<T#'&/^A^S#
M?QA\^.7H"QJ\>:,Q[N\X]"G[=G^U&G<:Q_/H#V_?/C\__Q+2!7JF[$?TBT=G
M>@,^Q"A.HM5HO[[\FO]?UOU/ 0E__$'\OR<4X0&75QC]X24B?_Y)?#?_[/.[
M7RB;O#W^]=>CM__OYOK!F^(9>D-"(3</_[3L)4:IZG?TY<N7M^E?ETU++5^>
M6+#\QKNW2W)6(_._^O&J0['QA[?9'XM-B63H M$1^4.4<G)-/12G,T1)T0!L
M(7YZLVSV1OSJS='QFW='O[Q$_D]+G%)A,QK@>SP>B/]RH%=?Q8F/!*YOQ1_>
MGE$^;SF5:9<IP^,__R0:\)&/CX^.LW'_8Z-1_#KG\S<B8OK]-'C;X)NG*!"R
M>9AB'$>J;U<V-DS#'6(XC*<X)AX*:A%4V7-WZL1JPC,^<C0<#^=B!^#S)CH)
M?;'J&9[B,"(+?,7WF!F^II%2B$W',\O)V12%$_Z5ARF7VI0&/M^X+OZ9D/CU
M'(^)1^(Z;&@/9I@'%$TO _I<2^2E3KO3=,NW6X:'X],D(B&.!)9#-D$A^5>*
MK8HZS>Z[T_F5\D/PC/(%PY1$5;4U@%XRFR'V.AP_D$E(^-1 87SB>30)8_ZY
M.QKPR8+5<-8:97>J[['0)WA##\U)C )-7!7==J?KG$1S&A$Q*)=%\A01GW"Y
MJ.A2=-N=KAR+B'..R0(]!?@6*_<3::?=:1KR@X&MQU;.,:C][I3<,<IW_?B5
M+W.Q1\[%OJ0A'T6WW>FZ"KF6-"&<V9,HXL>I!DV2+B9V*^H_DT"I VRWV_W+
MEY0](^;?)<R;<LWN9,)P=GJH2%%VW)VV:XK"1_HX)?PSB$\'%4E0^]TI.6/8
M)_$E\DC ]Q+UBH+:&UK;=^@U7:A\??"MA"78OR;H29,V_1%,G"8!UT8R-'+]
M57SRD:$P0EZJ#*I/%NTA#)S9):5.>3Z#/4SL4D(O?D0O:E KFAJ8]4(E"N-<
M:[\GT0_UQ(>[&-@/,-]HE"1LMC(AA=F,Q.G6EAHNJ>*%0QWE3:.K@3F+)^(+
MPBG"9EK*&MS#A-;[%.%_)GSXBX7.,0*U[TK_-JN'F]?'%0;3HY:"5VN0KB2O
M1WJ3L5JS@O1(UNK<DN6A1Z%&5_-6B!YI\EZM621ZQ&EU;L4ZT:-/V=&<I:)'
M4'5K\_JX'C7R7EWHYC760(UQ.M'3=?>^F@.UH;-KGBR*?D;U=]WU"W0PI3OK
MD5'5M@T]51,G13\#E'E3["<!5Y"XBAYQE<(7<_B2A'SZ$A2L/.KG.$8D4!/<
M;+C6=<7\>[>("?-L@7?4&J'AS/KNZQ*MT]?DC+FD#'/-]"QAC!MVKQ<O7GH_
M=,\QCFK/EQJ#F>2A2JWY%N%Q$EQSJ=5GH]YX)CFI4(!J4Z\>PR3%PE@($UR;
MRNI^9O?"*&Y.GZRW22I/440\/M'.29#P7?8"L9!O -$=9NGY7ION>N,9W4D0
M86D4RV\$,\2\*3=Z5X?&4O=[K;^G-!G6[ SW^';,OX*R6[CRQV^XOL%/&O\D
M7A$[#'DWO@URV0M$ZN]!;7RU*\](W3-OMU%-8IVND>@JBKBY(M2%)$YCSS@5
M@%.D-JZ[?L'HBBVI=%&VY9E@=(?!6_-_U9V8-8=I+4J@+MTUAS$YI\JNN=HS
M1SE$)_3>\86*M(/;&@]HDI<;NE@NM),@H,_">\%5\G.:/,5<>5U25AN09N.:
MY&S;JUJ;!<4 ;=)J%(H=!N\ C[MF2Z;.:&W;C4:,1>.2!QSW=<^%FL.T:=GN
M;-:V.+N77O_:- (=6[E1J8M]C2',W;+4]W[)^[48+U:7U-H#F8\GJTNR;G^S
M%A5E\9L8LYGX>OUE+^_?/J4-C[0:@YF_3:P[+W3[&]<@I'>$S72C.D.:]1*5
M+PX;.'V4@[1%<_&&<R>Z)0.9]CN;<%-T[W7Y+I:5<'#QI=5LHJM&,$FM<"#3
M),[<5OS,>V1D,L'"PYC&N]6FO=YX;=RNU_9.:H]@]O9B-J=A9G2+EV6G>$P9
M+ERP-[C1J#>B84MK0<1C6X[X+CSHC6-T_H_'6*RSM:#$;6;]::\SC$FZS_$8
M,WZN\R]E^CX_$'<Y7.N-USTGM9ZB&AG<)(_I+,Y5E]K02#H;C0&J;W$JN[82
MXU];_=4?PJ@&G+TG#B=\RF67)3@-7+IXF>,P:J+_UAO0J$Z#R63*-< 3KDRA
M">\Z0T3<.S]R RB]C(Y2EV2CK;/YV$;ORA(13'3#OSQ+9JE8^8HKVOLU;L9T
MAS(5-5?;3R#MU>J+E/IKM_901GT&66S?/9YS<Y]_N1#D5]_3H3U66Q&#JYO:
M0K(#.-?!+8Y-*:8MD]!&[&=M*T)[!/-OF.K'8^CUEU&*F+<DMJIQD0 @9\LR
M=8Q(UO(AI6O*AV!>\H3?^&0FYH)X^)5_J"B-U2@DC-_RIF_S-F\K!VB?[M7'
MWOA4'%[UB"[W[H#B]$MO9GCV)!+8U")WLVO[M"+QG+P.A6F']ND*:7Q2E[1E
MGT[G)!ZC)(@;3\IE]TV:^:^Y@B/VN6O^XP;=^"7&H8_])>5B0)TL2S&)1<,\
M/];1X(U(II6(797_,VN9D[ D(J#>QI<#D4F*LK+(HB6O8Q0]I0PGT9L)0O.W
M8F-\BX,X6OXFW2I3$>:_&*W.+,XION+_7!T\ 7K"0?K94=ZXJNU;NU2GKQ$T
M*,[;;5.[!OJ$+>G.9XGF4LRFYA\\KKSQJ7$1I%_CTSL[,9>4C1F=*469BXU*
M.2C*EA/RTX R'[,__W3TZYJ6@$;8__-/,4LJ6.X8H+, 11'7#V/J_3AY(3JS
MJ]S%*&R5YZ@*IDWI Q!!O%:@90N7(HGG^8D, 5+5UB@29>5 !0,H8:JD'(+B
M^-=^8C$ZJB#<%!S+8W'7W:TQ7BEW$&3OFD)6MA8NOIV?C(;,)R%BK]F]SDVN
M_)6@$&VKFK: Q*8:"DA9,LNI!L7@WM1T<P*D>X]]C&=B_\RO_N02AIJ/JA:J
M,U*64@UN/4:.@0A[OTSHXJV/2;;K\'^L-QO^PVBI:3[R$2NDSIL46XP^VA&T
M6B6J(A22K9%=72W:$TZ,+PBZ#-"D6K8;39P6;IG25O67&M(]QY''R+R8+0<0
M<J%E/V2]33"X672[5]SC"8GR:Z450_+-H[*+TR"H*0=5D&[1. G#! 69=UT.
M0K%E+V1?(A@2^?MN1?Y_$\1BS()7':EO->Z%X*MHAF3_H6-%183AI:+2$?YV
MZUY(OY)H2/P?NQ7_PQ0'@;BU0J'6["^W[P4$ -D0")_L@9!%%W+6]'%8=>D=
M%)N40VA\[A:-.\P(%1>\3 .'K<:]0*"*9DCV7VS(_B+T=26?-^V1W(L4RSS\
M78K]DD0>"C+Z+OGOJESW!49*S7LA_FJJC;O&=H+@;Q@Q;0!6C7LD_DV:0>%W
M9 %G": *I$EW'JBUT^*7$@W*OR.;]R*,2?PJZEW=)H"?F#?;;N6TO"N)!>7<
MD:&;$;5T?82Q*.DED_5FRQ[(NX)@4.8=&;@986=IP'9P%?KXY:_X52;TK:8]
MD'H5Q:#8.S)L,\KN&!&9FAZ(I]Y8MMOV0/"5)(.2[\B:S4A[1"]7/F<B38\E
MY*4& .C2 QQDE(-P=&3.9A2*8&,VIP5_]YEXA,!>SZ@O/0*D'7L C9I^$*".
M;-Z,SA/?9R+G:_8?P=>1#):*YCT  Z(:O #KR/Z%J#NN!\%Q+R$XED/0D?T+
M4?>N'@3O>@G!.SD$'5G!&]2=\7\.V2-]!F[?@<;]$?\6S:#P.S6!<]I2;H8L
M?3V>%1=6(;#5HS\P5!$.8M&IF;R<)YFZH+,*LI;]D7V18%#FG9K).6%W-(I1
M\'<R5VFG5>W[(_\RV2 *'5G-^8P0;A0H[&JCB=.R+E,*BK<CTUB<.2<,(WA:
M%UNX+=QM0D'9=F3G7E-QJS.EH=2'O-W*:1E7$@O*N2MS5;R&B\#M8?5GIR6[
M224DTL:/#FJ*]#LC,:='Y 9(PMR#!-S\539U6M0PQ:#8.S(Y'])$_2)UP0WG
M@Y%UJIQ-F9?;.2UP@%Q0VAU9EW<,BSF N9*?!L.))[5L.!Y#.S7<WFGI*\@&
M4>C(S-PB+ZWKP.IB4>K5)T2JB0=QZ<CD?!!U4+A*=73\]"B>C0,[T58KI^5>
M22PHYX[,S%OZR)"H7O+P.GNB ?R$IZ*AT]*&Z 4%WI%%N4%5M:@WFC@MY#*E
MH'@[LBB7BVQ9N@Z.Z*AJZ;2P08)!F7=D::XWMHG67CWITUX]T=BK.[(TET2M
M,HP-GP(R0?"+0$F'7D@?HAL"XGU7+U[3]UJ%5&"7_!_5$%0V=5KX,,6@V+MZ
M"IOX1.213 FL*$\&(*#HY388.L2#N'1Z3_H=!\%?0_H</F 4T1#[F6$ANZT
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M<?;?J_"2*Z._HR#AM-TQS%53_Y*R9\3\NX3K/KS)-4%/)"#B3A8PF'8;M%_
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MQ-B7'JC*?ET?K_JKAM;DHIMMLLYKXLHYN"Y0*2LMN'QVJSN$K5S>'?@PZLD
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MA@FH[FG;& 0HC$Y?-_ZB:R76&LX9\U$78-"0;"!%YRU,/9[D9F>=,1RP19O
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MZ0N4#9@" 2YX-*#$S?GOQ?][0A'FO_G_4$L#!!0    ( /B)W%9+].H'O;
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M2F0*;Y'CS?>[]/F'3?4;96?7_VH[N_[DM]6'FX$5_:]<=+((#.W@[N?>.U<
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M9_?7X+8)LG2#<9C?$A:T6>&OT\,A3=C%4]GHI==SG*O!S(Q!P@:U$K2C!%/
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M@S(U"$[+;$ 4Z\#AFAE0]2DN96!!&1BG00)IWE7O+#\$+VQ;.0G))]D)AYU
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MN+A/$[$C,5%P-MX8 6\&'Z6T=Q=B#%'H0+HL:6HYL@HLI:ZGU83 '@L7[^W
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M2*,C>211GJ?9"TI2];CGOBL4 X=: TX@BR5>55?1_LG)Z/$":I=Y7H:T:W9
M&RD?^\D#B*)-Y$H$S LMQB6=LD))^V0Z%3]S)@]SC77.V@H,\2P!<T5\*@T4
ME"J7/6F_1&++[(3#3@BA>E&ED'><>E(->Y!+4BP,AF,ZA-P5JE*^]G(Y^C8Z
MNUKVI:A$QG%B;[P.OAIR2:C@@4P*X (V":2AT4D.4<:G8ZGAG4JU7Q7/>B4S
M@Z&PCXF5?IHNE@1#'24\&6WJ(8WZ(0".B&4GMQW8=$K.2W1;#7%J#6A+/R.T
M0&N\-Z7^RA>DKO0W8AYEV8SC$7&4D8-QTJH-6$G/1J)7U:"O]BEREKHGJ%QG
MW+;DG=K=1%IM8!9+0!)L6.;:JY?>-X8)TBS:\I4JS=I<6=(TXX; C/CGH%<G
M4BO3IC$EU&WO#7IZ&7P-)ZN:\!'<:3.JZ=3<9E,S,Z*?24VM X:NAD#Y#&H2
M-AHG3W-UR'U+^K(JR],]6I4?PDH5'!]R:X /#KDETF!XIH4HKHG41KW3X^VL
M8AV4 ^[!K$9X>$^F.O>DOVUFKR;M>)R^FINIF+_J&P%#W;'(!<M[VDX]<7T#
MCLXL D7PAEHPV:X)YV%#EL9Q@42&^F"H.P*TV \WBZU_^MT?W[][]V=PW'W$
MSS@IQQBC@5XA[W9NJ8'=GU1*A,'P38>0GT8R^?(:TH4I);DS4&=0T#)%*^WL
MUH ><IN!12KJG2-F^+A$*W6"BBDH<K;7J1*:Y;<I<;#209&3<EH!4PRQ5R"N
M+^*=*6I<O ])Z*9@%<BBY,24NU]%NOF\R/,3#KLY LHL=_?X"_M*?-/+2!-:
M)CA+U.*-W"J77\2:0:=CFB RVT!T5" _3_[<!,>("!K40G)=MI1-BVC*PPSO
M">^B9US>P:7I054;N79->"H_:FR<I,2H5A^,BQD!6K"L:RIWE9/E7B.H; 5]
M2]OY#LS.K*'ANIU:^V8 4EJYDVO;QFNCMFZGUY+>D'9_K^,@SY?;7P.:C;98
M9H\T='!Y*O(B2$(R9$D>G%[-Z24"0R-ZL>L:'8AU0PPQ<_&@I7R..J)OT!7>
M14E"B[L\ :DV,CI/\GV:+(]4MLPRVE[?R3L6E^F195,U)S_]*C)VCWB8%\GB
M;?&[$-]-AW9SVX\9$0FR%U2N+!!=5Y2[Y_] [SC_=.A N]X'U=/+[U.6;!N'
M@X#Y#]3WT?M[3<+02_?@1:&]"A\Q06=<Q(=<$-<_E(^Y_'.1WCFI%-'\*\XV
M48[10Q9MIG!%LN3/FCD2LTB<_=%8U5V:9SMCVMS.9GK>UV$CP)I-;BN=USO<
MR6<%8@*[^,%7,309/[B))ZU07C%G)IK/2E_]RZD=3IF%^2(I-_SA34BM\;V*
M5W^J;G$S-;4$]_H=RT1/Q'QF>B$_)$V\.-5SZ<QT!@_E$1^"*&&UGLM*.:<@
M9MDG%;->F#@=IIN$:/Y@/@\1I'<'!/W)<*=$E?]IU%%'']U%6_QF6H^D6VC=
MIMD61R,7QQUE,,MCSB#C!7*C"8/EMG#-%LF-UNN=B<L7)Y5QITP:WOK_MO=M
MS9'CQII_!2^[ZXG0.(['Y\3>GM12JRV/6E)(U3-QCF/#09$H%:-99)D7J>O\
M^D4"X!57LE2%+.\^>-S=E9G\@$P "2"1>>R/GH7//*L#C[QE'GPQ^+ [:3/]
MM\X?-F07+A&M[[QHB1@PHUDBE 9Y+Q$=9W!;7037;XGHN/X9EPB3,9_FDV>^
M/&@'SBF^%WRXG;"1_@N#UT ]MQ"LTR80%9>PG_/DH! L4Q)1P_S*_]_G2O2\
M9@<\H4((;>BD[9XQA9RU+?Z_$)+RSV3+Q^B7V4$I_B:/V\<]QF'FR16^".-9
M>-''5,]I)JD% ,_?3S]BKRRX&SCF-26?#B^97WN5%17[NJ;^B(OXM!=V-L#C
M6S,=97#3](*GUK)A]&0'#)#L#%Z!@D%'^9Y$%?Q++$20Y'CUM*6=7D=IMG^B
M=5/FIE*")LJ3V8D=:F<D>C(<%F+%9II"$J F)2<_9FEUCNJW DIT0P7XFZ)<
ME>GK*X6'SI_?V'3Y)UV3?+A.9B+^3>C,Q<V"PW2\<4[-B#.2MXZ3K(N2]+R$
M,Y,_A3*J7Q8U]A=,1O7+?*,Z[<9ON5&9-F)^1O7+D8SJ*:V^WY24PN2I8G[(
MM>N7!]/)3,J[ 9U%.3EP&)0O3"6?">/[><T8^0)WVBG*CGGU7LQO*&="8DV#
M!GA:$^,X!VOJ82ZQIF/-3?PTBV\"6L2.><G!<#(K\@+>69"5&H?U^$"<6@[G
M$8>)O=D<?PHR0S5,/PX&!$:CFW:LU-B-QCS=.(SFX)GF\)P@(J.4Z0:T_?6D
M&3[&D$:WR.(G; 5'QK"4DI+B5Q+#*5_ZTO#CQ&!U/[?;(N?)RL2=H$A9INUK
M/2G&2I]VH&J)3Z G%3!<M#G7HJ;>%&7ZGS2Y($V>I5L4L;+C L77-"XI)(MD
M4E(V?]#*F+;=S1>N?K2E&>8RTAHF;';H"WAJCP,*.-E-F!BH8!&-LGONPT\8
M]\5C9+XTUQ*BGBPT,(T!%&*6N"!Y =H@;\!U)(>O_::XIZ+,:Z R >0T_Z/.
M29G#?3)7<'Z3.K_0GQ6'DS@;K]WDR L7P:8"D0*TG)$"])BWX_ILIWPP+4GN
M.F;$-VO,@ZU/[LJZM4H36H;4VU$B-T^;B==V^^\-U1BP6?3$P9T_;6O:J":^
MI>Q^K.2OU?0>[D!9P1,[^C;7:; N0;AMV!.]P:Q)S;R6-F]\,5I?+F2,P8Z6
MXA^.Y-2TB)]H0K<\H(8W1;>"&DE/YJXXP':^B8$NN"EY@#-.@&5'+BPC^"SX
M'$'M0+X \P:PE9?[5J:5VDA^TNA!!^B12V2@#6Y&G@"5T"5&/HY<&D\YQRID
M\CDJ<[9\BR,@W8B8$)QL.M$"ZR:1T:]8_%XCLJFR)8V'9H\YVKK@.NWXZGY%
MN*]0L4U[6#SQ@*$4)4D*$_.T4,21QE,7<O^P=@XM,^W)1ID+;C?@3(3!YUL?
M=,K9(2,7IU%@(=1[-)YDZ>Z3ZD-Y(PAR3O.&[:P>=G(77(D#$D&WBG[0ZIK]
MH:K3V#!>#I)X2@?@ YH^G,,.$!?<K#^N#8JGP;BC77'XIB6$I=^POZ:OTS/<
MCQ"(W,XG#3_0S*6T<[;R<1,TMT/P:R#7:D%S/O^HRZAU^7GE$ZBI"7??1<:^
M\'J;UY3UNK;RVA$_=V+G[X-M9'8K]6?0&?LF^4/*Y?[4WBV(OY(:OA-\)I65
M6+NFRS)VGVA.UZFIH*"+Z:3'F%X-&)U76CG06*T73"760C %FKVNZ9JR[R<S
ME.%@P;>%] 6LA.E+OJ +BY=*SD85<U7P6!9O:05'K1 :B&H:_KQ>T[CN"J.Q
M-D&@]1,%S:99*E[5UC<4[C.SYSJJ&X9A/R(V=-*'2#[EA/Z!73&TZ@\0BV9I
M^+BV&+=XI&K9!@/E0YX\GF2L2"]^1'&=,D98'5-C_.W'B,8V6GP[8^YP<<D]
MJ_'BV1C%SY>C@B22%JYAFAHB3PB>\Q*?#N#K*-Q%"IH#NE*1A&U &)HZU_XG
M8L[*W/78-=8-^:O:)8!]I7@G]$=[8UTS\ZPV118^<-NGR5<;2$IRF[>>.".Z
MK"I:5W#^+];,C+4/LA4=T+&SOH)M8"SHHKF#9L8GSFI S6^7LG?G$MA8XQ=,
MG(5$+<]9C#">PZ?[I_R5'YP]4J:)W'24=+A8;&/(IQ/F#AJ;3&R[\@]JCQ*G
M#2Q8-^JZ,^59W:,7$-ZT;0US&[&.&_FD;H&LQ.*T O!LC97%1S8B?X7;CZNH
M+/?KHH3\:^:7;#,DG/9-V^RFZ<Z9/=C16.A\S$HP$ZU)T3*)VZAXR(;/8-D?
MVG^3I[I/M*+E&ZTN\^0RCLLFRJK.DV*;]NNB>:G73<9^*YJ\]K;K#_A04//_
ML(ZRCI*#OX)W,'U4TY1<<2T+OV5()!.)!->Q<GM-6W<';V'OTNB%YX1B\X N
M^,V'ZW2YO;R;T.?V<K($-[]Y.'7S=P:T)&N)\4W9WL<GZ(Y$%AYSH#FZ^)_"
M[G+Z"N_6?6ZMYY]*W-&J^E\H3R24-JFSG)TTJ*E-YC,;W4DGL1H"EV:9DGGZ
M:DGY!BGBQ!<DIP<O@A]I.NTLG%*1@MK=:I4CD"&9H!OL:4J.[>#(#56-=JIJ
MMG4O1>8.V*IOTAV>34UWL#!HCF]4T8@EA'W9P%L#N ;T."<N"U+K!);UY#AF
M,74-G\[-[:7$Y1;V'H9^F2_FE/:XM)%#&YTK(_BNX4#@4S/^3?7>B/@+2=0E
M&FY[>2JE8[UTXYMKFGQY7O%8Z\=H#Y?,,G15MW]R,)PN[;T/\#[[O8TZN(EY
M0U12+#ZO1- DV0GRX/.@;,4@?%]O2Q[TIYS9G+"'4YB1.+@A^2*<VM'M(/[6
MQY2.J G':+:0G3@HVNGCV"!JGZB$>D...FX17:3[A[;*\.(-79SO(+P_VJ8Y
M;^0UK>(RW6FR\7ESG?ZYIK,)AM<7.A8TT[T?3O.DSSS/COA\W\2<-A=;#3D)
M;?.$"Z8]OC/XB)\=K8 E.&%>+,(9A![,CC1X&$494!EG0"17X/>()X@90><R
M+ 'O=7Y?+-9TX#GD#I*,BV/BA_Q;9;JEG", QQQC:IC?G#/E/H,YR !YWISD
MZX"<YAD^Z!^*D@(:J)FS@G79T#$FXI,^N[<"'B<JUU&BL3(K/+64P8"8 #7Y
M&Z?_/_@LZ"[-*8^K]FWX@"&H)2G K=;44>.UJ"E$'ZL"'L*9$)J6C-2/7JDQ
M_[&5):AY:<!;#6Q C]?$5)!V(RO!R'8=4W 3NZ:[HDHMT;OMSZ>]"A^#&N\-
MQ&]H3&("2'7EQ<^A$N%'U>8R3^#_H/+[6Y1!S??+FKMUS$,SESGQ83SQ,8Q7
MA:HYL-4*5M6&O$09BC"[3U'^_8$U.2FCM7& 3HE..4SU (=&-*9 ,V2UL*:V
M $1H; $,\^;Z]NHVKYJ2)M:P$@/M:2O;6>!.9QF%$(V=V-!IIPX@#FXK3[2J
MRS2N*9\%#4V;$IW2.O0 AV8QIL"VQFC1*?5W.R(2,ZK@5M$?ZD"$D;RF<!X
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M^,@(-+WX-\]@HFX!&"<8;]3>,TSGENX8Y U_(P]&?1*_:55\HF*2=*_X0]I
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M6!^M>U($B.PL4,.52% F^$)8ZT#^!>D_300)G%],_G',(3 1S:W1,%"XA48
M&Q'@SM'XNQ9=I]6NJ*+L2UDT.\;!_@X1SVD.!2S$+<JDEEJ([R/P:8(V^WAF
MWYMV"XEP3)QSB(KTL()4NF <Z1N%L^B'-?CMG_;#;$2*K^R@1V!0LV J'I>=
M+\B;MNX\:YQ[]-NNR V91A6M+9"!19.'0%="%^;+.L=%Z,-7%02V\+'M.-:\
M'^;00Y]MV)BMV<6 0-OS<*I''';&4*G89)0CL]![.+B.$MK?V6O5-8\3T2YF
M)F EJUL;#PK#K14P"' (60]^?*+#'+S!DP&K$JT,B'3GAU-_5 7^[H -@YZF
M17[!]\Z*JBGM0\Z##9'.YJ#5I&]HBQ4+9M)S8U#@EZ)(WM,L\U2<A1R1PGQ0
M*BEE) \2_;3[K&&"A\O7DE)^,NW0UFQF+$[)(LR:7::WD!!:A>N@5='=!^W-
M*C128M&7&Z"2'\O$$=AMM#V[\9P;%XI"-&\>V@*CI^EX>81DSNV2OT'H*!V_
MW+![GW8.1!KV!*J,6LYV,7V&@L(%7<'V!8H$#5_1]6[R8Y&EL?:!D1<C(MW-
MPVL<B\.-GN )6,"H#X_IMC4"DW6XF:D1J<L#I'JT@D@ULHC;\/EXU5D?W\I8
M-#6;&8M'LPBS&D?I+R1<\*O^<9/'\//E13089T/6A,8.GW&-7W&Q?Q2C-?RH
M-9U9W*1Y6M.[](TFYA71R81(H_Y8G4<R//*5,?_,N1$JLSV;8(8[;;;'</7G
M1J3>!:"-)SHP5C5*1Z?F)UI11@Z7;-?TC68%GUSD*F(>M1YLB!0[!ZWJ'PE>
M$>;1<_>Y<='IM,OGX#%03;2(M.>$J,EG(+-1(%2.V-:*K:R'?BSDB%3D@]*T
MOV]W]<$U-/3%S6F./T49!)R8-AY.1BPYI&?C-6PXG )"';)F6?$.WV< KXOF
MI5XW67?66-)MVFR[39(CC]Y"40@T_5$M4 YV6GF\$FLKL<OZ! \;A%"^:H9.
MQ*>4AC>$DZCOB'R8\)PBS,!J>H5I8PZMM6\YS#?7=$W+DB;?\H26[V4*)\,W
M5#<?>W)BU)\?8)L2K1)P:')51GD5Q6!;_#'HK:C,EGBHTL2*5Y=.Q&YEFD0$
M?B#-EA3UD;#V",_&@,B9]<-I?.H,*Z+NK3-"/\@K+?0L 8C4N RWQQ76!1F[
M/U=L#*8U@:3ZH?-$^WBSB'- >V=\1N%1Z@QLT@+VIX(Y4[HGZK.XL:QKRT ;
M=P\^4I!J]G?F3-&']7J18COF,]*KBGF!6CLAX2*OFFW#%^5KNBMIG/*M#?MS
M1GDUG3RYW$*%&['EF96 \J-D(YJ//[Q)FM6U_0 9?N&"=-\0\5N#KUS@3&\Y
MN N\:JJZV$J_$7;.FW1G3ICHQ8C(*.;AU;PJZ&X]2<M/1@+"YD\<-&]Z"3BP
MUJ%!.I3J*06GAN>"MZI;<Q\ZG "& D.L^O8\%@82+"NX!=E4)RHIOJ%V3[5K
MK)WC/(;0$.C<X<)X@Y5D&^0/^YVFKQN8 IB+'KUVJ57!H![8/ZW2K3:;\UP9
MB/2Y&+I:[VV44^V"M,*(E-8GE@5Y%P2V001$!E+\=4-7Q2!C MN260Z+S-2(
ME.D!<JHVQ@+)?]L#/<D5^K@'+.@VK^JR <?W:U0W;'^UOV80M;HQ4F/2C1ND
MHAO&0GJ>"])R$6 +>1*GOF2Q#!T[!R(5>0+5G]EI7N*$'D7J"Z3YRILK Y$Z
M%T/W>GF%5NL\3\RGJ()[G2U$\O%]QV59@FL,\\BG?4\B+W<N(=+EOL@?=D +
M)P[UOI]XAO5>[YOM"RWU3M#QOXM@4Q*DN=KBNC]ST63X>3+X/J1L'-))#(2#
MN(!<%3\+'$0 &:PTX[*]C):C.3=[5OL7ANR*;1%%NRO6!9#WGB83O_<+$UW#
M$GL3I>5O4=88G/[PN/X9QL,QNN,(XT4=)'()J!E2(J'R827 :C9 '##WW0A
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M3P,.!4W)<>K)B-*JKM'!#N<+K)YN17#4=[?1(U20%::_AD(&6(QS^>IT,J9
MI 4#,,V3X6$Z8409I;H2WM_R!#+6-SD#^?E'S$@OM_ WG3H6"4*DM</P>Z:E
MNNC+HU^0H5 BI!(A%D$5ID4V,$L (MTOP^VHVH11TWQCRZLG1OP(Y^$E2U]%
MM*8$J.S-K=18]NI^()7L[ST7*3HVTNH*C6[&=NFGH3$/:CT9H'IJ*^/5A;*6
M/832N"=[592[HH1@.9E;2]&3G@R+:ASHM/?T"KFF]X?_=,?^Q/ZY_2?VGQ>F
M//8O_Q=02P,$%     @ ^(G<5M<,*%:R=   $:8' !4   !E=61A+3(P,C(Q
M,C,Q7W!R92YX;6SMO6USXSB2+OK]1MS_H-,;L=$;<7JZJ_JU9G;N";_6>,=E
MZ=JN[CO[I8,F(0E;%*D!2=N:7W\!DI(HD@ 2)*$$W=J8[:JRD4GDDWA))!*9
M__E_7E?AY)FPA,;17[]Z]Z?OOIJ0R(\#&BW^^M7GAV_.'BYN;KZ:)*D7!5X8
M1^2O7T7Q5__G__F__Z\)_[___%_??#.YIB0,_CRYC/UO;J)Y_)?)G;<B?YY\
M)!%A7AJSOTQ^]<),_"2^IB%ADXMXM0Y)2O@OB@__>?+CG]Y]\";?? /@^RN)
M@IA]OK_9\5VFZ3KY\[??OKR\_"F*G[V7F'U)_N3'*QC#A]1+LV3'[;O7[\K_
M*\C_,Z31ES^+_SQY"9EPO*+DSZ\)_>M7XKOE9U^^_U/,%M^^_^Z[=]_^?Y]N
M'_PE67G?T$C@YI.OME2"2QO=NP\?/GR;_W;;M-'R]8F%VV]\_^VV.SO._+=4
MT;[2DX3^.<F[=QO[7IJK7?N9B;2%^-<WVV;?B!]]\^[]-]^_^]-K$GRU!3]'
MD,4AN2?SB?B3:V_W59(%GE#6M^(7WU[$?##R7N8D2T;F?_U*-."<W[]_][[@
M^V\'C=+-F@_*A(HQ]=7DVP[?//="@<W#DI TT7V[M?' ?9AYC$3IDJ34]T*C
M#K52]N^=F")DQ3DGT_ET+:8U'S?)612(J<S(DD0)?28W?.%8D=LXT8+8E=^P
MDEPLO6C!O_*PY*@MXS#@J]'5/S.:;B[)G/HT-1$#S&Q@&;QD>1W&+T:0-XCZ
M]^F.KZ&,3.?G64(CD@A=3MG"B^B_<MWJ>@<D[]_/CS'?V2YB/F&8ME-M;0?0
M7K9:>6PSG3_0143YT/"B],SWXRQ*^>=F<<@'"]&KTXA+_U[?$V$D\(:^MZ:I
M%P+UJB'KWZ]+FJSCA JF'(OL*:$!Y;CH^J4AZ]^O4A<)EYS09^\I)'=$NYXH
MB?KW:<HW!K;GK1UCLO;]>S)C,5_UTPV?YF*-7(MU"8"/AJQ_OVXB;B4M*!?V
M+$GX=@KHDX)DB-4J#EYHJ+4!ZNWZ?_DZ9B\>"V89\Y?<LCM;,%+L'KJN: G[
M]^TV]J+'^'%)^6<\/AQT79*U[]^3"T8"FEY[/@WY6J*?4;+V \WMF;?))RJ?
M'WPI81D);JGW!.P;G,,0NTG(K9%"&Z7]*C[YR+PH\?S<&-3O+& 6 ^S9#:-.
MNS]+*898I81=_.B]ZI7:TG2 42],HB@MK?9[FGS1#WPYR0#K >$+C;8+AZV&
M0&&UHFF^M.4'E]SP(A'$> .0#C!FR4)\07@ZV IDK,DIAK!ZGQ+RSXRSOWJ&
M;".R]L>ROX>UPX>WQS4'ID>0@6?$Y%C(P[K>A9>U4Q"LRR!B2R</6 \!I,.?
M0F!=4U-9.Y' .@<BMG(Z@?5/2SC<2076H?;6P]OCL-ZHJ8YAFQO, 0,^1['3
MH6N?(2,;-CMP9]'0#6J_0^>OA& HVQG6C;:V-NQ4H)XT= /TS%^2( NY@<1-
M](2;%($8P]<TXL.7>N'.HWY)4H^&^@YW8V?=5BR_=^<Q<3Q[)CVM1AF[87WW
MIIV&T XY8JYC1KAE>I$QQ@]VFZM7/[\?NN<Z3HS'BP&S(65H,VL^)V2>A;<<
M-7,QS/@-*4F+ 63<>SV/(7LL#@M11HQ[V4XW[%J8I-W[IZ(>LI?G7D)]/M N
M:9CQ5?;*8Q%? )(98?G^;MQO,WZ#KB0>97EHRM\H81[SE_S0N]LTMK;?QGQ-
MZ<)VV!'N\^68?\4K;N&:'__$[0V^TP1GZ:ZSTXB3\6608R\T8KX&V?CJL3PC
MIGM>/ZY#ZCJ?(\E-DO#CBC 7LC0/*..]D#A%C/7:]PN#SMB&29<42]X0@O9@
M;LW_93HP#=E8BQ(P[;<AFR''5-,U9SQRM"R.TM\9GZ@>.+BM,\,A9?D4/V\G
MVED8QB_">\%-\LLX>TJY\;KMF;%"NO$=4K*Z5]58! T#FWT=5!4]F!]!'[-N
M4\:$F^USXR"'Q<&1ESCN3?<%0S8V3[:]C[461_?6ZV_<1PFAE1L54]T;L!CN
MEL7<^Z6FLQ@O9MI58T;#QY.9=AE*/^R)*F;I-REA*_%U\VFOIK??TXY;F@&S
MX6\33<<%E'YP"T)Y1]C--C)A.:R7J'EQV,'IHV5BJ\_5&\Y>_58P&MKO/(2;
MXOA>E]_$M!(.+CZUN@UT'8<A>RL<R'&6%FXKON<],KI8$.%AS./=C/MNQL_&
M[;JQ=Q+,8=C;B]4ZCHI#MWA9=D[F,2.5"_8.-QIF' <^:3U3\8*6:[R/## ^
M@X[_^9R(>;8'2MQFF@][")LA^WU)YH3Q?9U_J;#W^8;89W,UXW=\28R>H@["
M?$@9\U%<FB[&JE$0#QH#9'[BU)):B?$W-G_A+ :U@(OWQ-&"#[GBLH3D@4M7
MKVL2)5WL7S.&@]HTA"Z6W (\X\:4M^"D*X^*>^='?@#*+Z.3W"79:>GLSGO0
MN[),!!-]XE]>9:L<5C[CJN=]@YLQ**NAHN:,_01**JLO4LSGKC&K07T&16S?
M/5GSXS[_<B7(S]S3 >9E*V)P=U-;278@SW5P1]*A#%/+7; 1^VE\B@!S&/X-
MDWD\!HQ>U5.NKH33YI+>\A\<D)#7E$0!";:,1*\A>592FHJ&9=J;=Y-O1(Z<
M3.#*_UJT+#NQ[488^P=?#D4NF;B6N&6;ER?/&),0_T^+^/G;@-!O!2KB+SD\
M.33\'[_G'SI[2KC%X._>4(?>$PES_K_S-K4FW_;NU=Q+GO)D-EGRS<+SUD77
M2)@FVY_L^UC^X/?=7,KCC5LZ6C:LMZOWMJK*,W;8<X_Y6\;\KP=Z;.;@*5M\
MN\[-Z6_\)0UW0V#.XI4,OO*#L;+7,>,']+]^]>Z[[]#QYN.=W/"_)@#,*VV1
M<9?@J@:_TOU2 >\=4,!%Z"4)WU'3V/]R]DHA>FB2C%$=32EVTP)+*=4N7<;"
M=I=KHZVM8VJ0#:V:1MHD*57151/-??KJ\^79[U,6\+,>VQ0>U4]D];3?+RL(
MB[;M374 [^:U)6CE V2+J;SO#>4/B>P]"0@_;/)I5SK<U>C*FP,1_AX789VX
M?5$VM+*VEMTCY]AN9!VV ()L"V/YYK_%N-%C%%C/^/<#T8?KT%NTXUIK @3V
M'2JRK6)A07M)$I_1=34QA03A@Y;8"[$9T"U"(JT0]V1!D])]NY-!O61(2+ 7
M:J-%1"DVDBK.HBCSPL*%I=; 84L@\#\X 7R;D$AX_[^9QU+"P@T$\D9C(.H_
M.H&Z1%0LJT1$N>0/+"#(-UL#H?_)">AEPB)A_[ D82@\PEX$&O=M[8'X_^P$
M_G*!'=! $;;#I8$KH4("U,,OSNFA(3:2*F:$T5A<FS" $AJ-@?!_< )^B:BH
MP%]% 13V75/P@<HAU&MR(F%^31/?"XL>7?.?M3EV*UUO:0[%'O<TJY47%?]_
M$(^!T:\TAF*/>\#5R'IDY(M4*I7.*!<<>6LH]KA'6YVT1P;_*DIINA&U8.XR
MB>.7-VNV@H*->YR528<"\M:9$:6BUHT*Z'I+*-BXIUB5E"B 7Q 1\1C>1 %Y
M_3O9J!!O-(5"CGMZ5<J)@OF,49'GY('Z^O6DV1:*.NZ952TI"NR/WNM-P+N=
M9Y81:.G1EY) E8![8 7)C:(+$:3'UG'%:WTA@G?9YB(.E,N^AA"J%]R3K $&
M*-HY"P(F$B46?PA)WJETTMH<?(OE@"84\CJ"_WLS_-_#\<<]X6KE=03_[\WP
M_QZ./^XI5RLO)OX7_*]3]AB_2*[/I8VAV..><C6R8B*?]W_*\F>6115.'?P-
M"J@.7#C\JJ5&G0*%10 9_]N64.!=. BW2XD)^"Q.4B_\;[K6&:+M[:'@NW D
M5DE\;/=F,0"$7T06*U5K @4:]Q3<*M>QL16J9L23#^C#%E!D<8^V;5(=&=C;
M6%S*+.-(Z19NMH("C'M&E4EW[,59/!%+I*M"Y=?@H#W<I;<NSY'Q_(W1E/=
MO)?-HM(?)+G DS2%XHQ[L%3*>63,'_+,U>(M[R?><T;WN2,. 6]K!T4;]Q@I
ME_#(4,\8$2HGW'S/(];$\U(VG<]EJ[.J/11ZW%.D7F)<%>0ISIFI(EJHH.K
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M[QFBPW+71]E>TAP[,3M(,4I1T151NN*3>^(3/FB>0G)'4JT^U%38:=MA"QM
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MP@I@G\CJB; 6M 6%B@ [WELS;JKWWWJY+<4M/"XIR]].Y]%/"J#;&F)'6!L
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M/EE-4<*^%R$+T;F;B!^,5[K<9#\T,CR4Y!.ZIT?V I4]NB?KF.5KIM8%)*?
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M\3,-^-^OLRA0AMFK"-!>RDD@:YK(>G$MN1<?OM PO!3NS+@H#D2>U<]'501
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M/Y'@/$OYD<W4VR6A1_=7'L]CHD007>&/9+6.F<<V5__,:+J!6=U*HK=;\ .
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M8B#)G9LN$%^CB@:[]$WW*?1&W8MU,3O[&'\T,X4==S0BF<I6S[$S1E8T6XD
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M-S.(W)8@O_ "$OGD;_G, >"M: \%&WE7TTIL"^DE(?^@T2>B7BV:S:"X(B_
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M!Q2ZE!%@WZ8,I5PU(*-6]B5Y2O=O1BZ)SX@H]<:Y<(@BDBA<2 !2[(CH@08
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M4%9#*#N1+;TTMNV@[NI.3^FHQB1C4JN[NGA#1L-8**0C=:%NMP88.;9+!3I
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M*RPV.@J'XHG6_2QW-WJMW,N8-V&0EFQ,"2,[B837" .-TKK3P5''E#1)4E6
MC_$]^K%YQ'1_@M/I7],X,QA,C-7]OT*)X]&V[I$J3K*W.:-'LD)F"O3AU&
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MQPZZ- $CKEM!M$,8.?/$1,7"O9G">S.%F(DB?0AT]""ML--HF]W?/Y'QFX?
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M&29 (H1MV2D-@^!-%F&%$;6-)J](&R\.=RKBHP%))[DFQ$*8@(7*@(>PS F
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M!Y(/92B3.<F(7>O2)K3XM-!SV^=.UY54RN=L,?J1N31)]038-U;X>)[2OK7
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MFZ6NL%]@SBB222+$ T5EJ*!<J-V7,-!.<@B4@\(-W8K@DP0^UG<7*N)[*N&
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M)JS/0FB$SON]"3R%'8-5P*8!'!]GM\L:5R3W-4@N4X@W1%U%#4=;2" PQ"+
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MOY-E";K72IV_\TQW3HTFM<'QM(OSO:C%54V=9=+)ZF5\4:SADU_2!'7L@[1
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MQG-AX*!'?H[L4+:T>'II+32TIKN-*75 <C%4VR0@&IZUALU4%YF,46L[6\N
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M>2TV4,@-9IK B!Y#;D)@HLOB9'X*)J*SD?&%WV%X1Z#25L@WIMN!B?765U>
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M.RP(.&";P LXQA9P\'[6HF1)=);28+X/UA!^%&&;-YN<PJ!.=* :'Q48'G6
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MC&B(9#U3JY2^%JAO]/0N%W6#%^'<3MY4J]$I&(Y"_I,1=KN8R<=R(KR1U2.
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MY8A3D7)<!/$ _^[P)$;IT9$=J4)E;>-#+VJTB)H336@TKP./Q;D.:F[\Y(D
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M6S('I?<1^@EI>#W;ZLK+][,9'X9N>OLI=R-F]ERM3QZ."5S'L?$9!,6_)Y)
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M95I:E &!6EJ41UI$D8PN'O]Q0SQ7B%<V!;)^.(Y*/G'VP^'QO=)IAK:XO&#
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M'==V6[U(+7GKQ-0M?-9IX;5MS1 PK&ZH#CL(M)2^BH%&1V-27U@L8$ \LWL
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M U)0:*#B?;4]?%[>HQH=F1XQ&J(9*R% .I)*]5+%%!)C^*(.[SR@K&X""X(
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M5IC@P2* $LT?>ZON ZGR,;GR1$>JV**Z9 L3-%+A6*@&P,WVK VT<?HT462
MIP,023H(!B3G8UA!2(<]I2=4MAFS5*20*:T2*0P*T[ ?9,58C^"EX&P'K8/(
MDY<ZAX(0@4 _!/OQ65$L,EK+?IIBU4QQ<LOM!C*['YD)N#&K*_VZ,16=G=1*
M2465Y,PIU"EGAT$0^5+:1HQ\-,&=P:"$';_PP9/6ENN >J00"WY*OQFT"*)D
M%\63HK(%E3<!(Q-\,<Y_)/DXM"&C&IT!(T!N6&K_8<-PP8+(K6TS(@3()H&L
M3-NN]&$IA**#N,6<RBV:62$R.T7P![W[D<56L+TFL"H&567H'R-MS^#S!)A6
M^]_MS5T#"+(12RHK;_1 /AAHAEK&"3<IR&IL5=>Q7*A*#DEZB-65_]W:W)]F
MC-JF<1Q5KZV#96U8KN&X@=%FE!WNC9^.8F3ICCN]J.@%.(V""A'[1-%4%#:T
M<"E'C]8A73RC:@ABD1<5TL2_:4;'^L9)9_P1.!.7V0^#()$T(4.#40:Z0>U(
M$CJ-WHOE==(3DXZ%JM *?!FMZ$;'#V/"T2)O@QR'<52=7U)7<?,"R42:5#X1
M19&>D=+'0U>-7(]H*=6/Z.(*>)JEAY8AJ.C@>M8.QE49<<$#;*7'4:[V24*1
M2$JA!5+AII+HS-65!VX+P(92FOVR*2H:D,X\^HH25DF^=++:HZC6!D ZO@Q)
MIC*H#@DL,W@+I_@QX%7&C-,U1R!#S#:23LF)@7HK11+8($"NK!X,W"?F63)D
MZ/A8]K)!*090_Y9HB0!-(M.5L4>B0R8G9(Q9B9"HB !S/A2\H;)B_&=4<Y":
MFJPT^,$YA9XHL)HJ2U;"#L1!U%='%JE@J=&%BE*3$R^W0):5Q,:JQVV.)EJ<
MX)'A)C0-.%E?7*9S!@H3VK"0_5M#NXYU/'%1<L3:FT".JJ\ VQ -0E-* T+#
M U45HW:"R<%3*/<HZY/D$U&7I-[_-]B-#N^IN(Q,,(+AZ:( = ,E-'"/J6:5
MR8JC1^$AYC#B(OP@MH84.*(-227#4G%X+*6+K2T8 Y/U3=A2M?(Q\(63V@6*
MC0W$IRE6YC%IW,) L=Z*5U$%J&1=*6<JH(]*%!.H'"WE"%IRQ6/Y*0/8'F]S
MQ\<)^Z$(>,;.#=><@[7M&RU\V^H*Y27*%YLII_0\5YF5)RS-4^76Q]>_GY]L
M5 \,K ;F'9 IH.X=%2%\HG@U(BGRBRR./<O)=0.WXH<%S@2F6;"F[HFII!'#
M4@V@)PF"^KY,<DAA10X4C \P[()CJWQ"$DEVY&(H?P^,/:YR*S*)3R-L1.D6
M:LJQ2;T09/$<4'JI2@[^+^MT?X[^130:+=M]H#Q^>E",?J)P L[ *DG%$)AX
M>^[*&D^R%#"[_*UQ8E0/JIM[QH.R/!^HGGU'6;D.NJ9DHEKTVZW]U$^IO!9+
MWZV01VY<TT5)+:T<YF,L;W7E0_4G6$%/^%$60$;+NVXW5 'R#[6?Z&F'QUXH
MB<@4WY%T_]GXL"5_V?+D6X!=@>%(VF"A#T@\AY2(C[:ZKYQQ59=#M&PC+925
M4RYU8O&M&Q]V?C)2XE4ZZ;"6?;ZS"N-^V/W):%'W-6F7J?(=68$>26.#8?$<
M"@MM>!5L*D<\>.*H3VN52H6VK5:I[JU'+!4Q)/;&P8T$(?&$S+&U>? ?0! Z
M9NMH#\EH<?24.N!@$CZ1&_WHFR\G-ZDQ*O^1^9GOK@?FT%=U>.(Z7<2#!XX\
MKNIB913%CZ$O(PUHQR!$TZ5%X"":K LRI;]D5%+*TP/ @TA4\L2ZM',>0@^6
M?$#OT:M,-P1J0SN(_%X<R6@RT*7HKC(IX>(UZ,KTM@N\X5-0SL<$D<IJWS",
MAX, \.P>'8CI*[Q?EV(=9 :/!"=1T$_4@$B+Q2U,$4TE&5^#J<G* ;!ZN^ S
M ?.+)BT;,VP,RLG4$JRS*J%%P3T@H-:QA#PED1N861 H)D!4RUU!BX88'J1*
M2K)AM=#Z@)$CZR'2<LOON#_D*1R0)T\<*V5EJN@!G#BP'LG,0TT$RX*=G&P9
M+8Q3Z8/#89T22%/7V8@E%QJ$L5A42]H,,86_;L@,"/S3DSDY<!VI<$-*3S\8
MJ%_3HJQ@4[E#:V5UA8XCH#W.@U %RE7]#>LKB_8X9KQ]BO&..9PI-1DF>-$0
MEM:5D.GN5#T[15J$X[B/434_!: >0+2"\ 0'A SPL(M#1297BI;X4-:F\2</
M(L-+4@A^73?!JL>2JL2^"A1E]J7E0AQ'ET$2%*6VE!$D17!F26%Z?QD\L6J;
M6;(8/SD/$7#54BV=B8B=Z2$_)7J.R7K&U95A*I4/0JL>'4WRA*72&C!W6$12
M40D1PG;[C]8F9]K@:>F<#C@Q_;X+K$CDO,1>T&8Z;O^:$$3D 4:^O)_RQ=&"
M1%$L"WZBPTPRP3&(OQ2ITIQ65#QQ3PI,(6,(IBP"HT ;:-,6CT5[5-"(]6F1
M66>P1R9L64C66X\./H)7[/F2#*603OHM\:A&-Y7!P%R 0IOPXI+SMCHA0JL2
MZ5R<>H@5""V73-^62P=[?+ +>5P,0W.@]$87;[+QT<VW(L\6@[I1W582$$!^
M5&5=25$*6 FAS&>K&"BXYVGZ8T$087[$X;%U(D0]E3Z)HZ:ZGHH71#%6D".!
M"%38@_0[\)J*(:LPAX^V!1X^35G+D;/2DFRG9 T2Z6'P]RXZ$A)IU2A@E*J=
M'Z TM2.T*.2-HVF3RASA6YHV?Q82#$JT""]U6'L]WI5UB8[(KD]6$=[<Y'04
M'N8_6!Z3JL]+442VFF*.=7G*3!7^=*08D;D%BGUT>'\V2BY'>JADZGA$B1Q4
MXLOHV%$:("@6E%J/WQ*=;T '\,73%7UG)U",S:KZI#A&P/@RE7U=D9)K14I-
M5Z2\;T5*<1BM^!TK/C\<GL?&Y'$;U#+'&P]U8YIWW8+/XO "A"@9T?78M/P:
MFXN?/XK#=]N2!>*464_E))35.VA(@B-(4GIDE%XYEAC]V;AALA:(&@+3*= D
MJP0FG/#\8*,MK3-ECZAXM4'*EJIWP5D2*5-3^CHR914?'P;R[5Z?.RA/J:/!
M!5X-EHM3 B_N]!.E$2@#&4=YL*@H4*XK^IKD_#(,MR21)8K8R"'#KJO2%AWT
M1A]#&PL:4/NGAL2>">IT-#8&P,(//-Y-9Z-]"MI5US%PV>5NUU9Y1I]RCC@C
M2>V(M91G #U/P%!8%HV=&M#-2 HKHH,I*J)W?7I\ FX4G7V3IKH/QJ8M?N"[
M\&P9QXIP&=]7RXV1?(KRJ2PM!06:#+?/C,4H)6YEI;Y)'1+08>R/1Z@M4J.2
MX\*5ER/=(17@DO5BD:>6RA#"K\@10\,6C\M%/DH C@F75?ITEA[[WX1XS!$K
M,7P\F0+O:P+4U:N!]O11I+BV)0"")6#2207_!WB#L:O>YS*HE!+B!*UWZQ%I
MBZ"1/GH5D+DMYTQFM^QHHH9,.UZZ$]2[ZJ)Z2SKM29078]SD-_:'V51YIE9/
MQ9Q*G&0EP4/1CBAU<1M5]YXK-I/QDGKCM'Y%_'\:9RKD@TR%%2F-L1%_BU=[
M4KEM7Y\Y?()2#_ K*=O7#?8 3ZZN;.W%;<.>,#>41-^29 2&32QC=P=E%CSV
MJ"0E'0O&9BZ#>9$X*"4[P% PX1GUE<?QG+;)J,+D2"9^UV%Q_B,M+: _X_5Q
MS8G2/!$QF!'S#==6_5*0KJ@#"0:FC>KV?^+4%=*!99 H.(6?BG_XLN*(TM"R
M/8JUNM)$1Y6TLRS-H; 2Q1,-6S2YFBMSS%YJ%BJ#KVC%^U8I* >ZIPG$1"GL
M@3G$"ZJ"SFD%NKHB]W*! Q_EG$K=E\948B6-WE6),W\0'@P3A!0=I(-F6.&J
MHJ3I#@XR>KNNVGZH0A",G$=U!V!(R>!Z7'G0<;T'8:G39W%I%=:B1V'&3(VA
M^"*=M<3Z<[2^T': I:3>"DF;!*S89SV<"I@L>+ VLD_ZPL!18X*H5"MIDH-O
MB^T76A6'4R*(SB6PZ.V*+>)#PAT7AJ1%B]XWD_Q@28&?O^61N+QX),(/9-=2
MF=JW!HL/M-E1S*D,FQWI*A C702R'J< 7UVDDC39RJI$<1T\>H#U*.KGRO=-
M$A)#[\"B.$KIJ;H/^ FXBQLJ=1%[F:F^=![JWKW-_9BDS$E1LE91*I'<B\G<
MW=Q."#QWC(ZP+#M.EZ3>F;D@E&<D9W:W;Q2JG!@:0RJ3Q-O%PT.1X8)SW]K<
M^8\RUXS@B4YB^[06^.< "\)KFFG##$^0@>B,"56E-5A50Z4T5-#AMXF_H^:Q
M:BEPF5()M(?_G[UW76XC.[:$_S."[U#ASV="B@!I45+?[)D3P59?+)_NTSJM
MMCWS_9DH  6R6@ *KBJ0#3_]Y%J9N2\%@%3WT86DX0C;(@E4[=JU=^Z\K%QK
M/;VHK+FAW"2A[WII:!N$T*/!USK[2 S=C02F"IP,.1C&R;#\=CF/D4_SP26Z
M8X_RHEF+ S2U+,8N0).NRFLNO47%/ \6D'$6D"NP V>P+ ABM<D10\> F1Q-
MHL$_SR%?U[K_$LP7(67 (YTX9#-QM=+F RV:9R,P>%9%J<4X>/..W'FK?I'3
MKQT3H\J^30<V;7T1'1:*_X_\6"EV*XOHI^7&XY>._3V_$K/51@<-KIFR<!)V
M=GQ$R]-,-"K\+9BMPXZ[8X_R N7]N5*#S.IVD4 $=R Y>7ZR]:#J8,VY5D9[
M88Y#=&2(RA?ESR '"JS:C[XOYW(:$#\9*.1&Q2LY6&OP@.,F?ZNK?EDNY(DN
M@8M93O60>+F<-O+WNGP\3!\X=)1\4G >\N2W'76C0*ELJ!_'C</+Z8.O$L&D
M(.$.!_-?7_^^^.R3)T,4^DA3I.A3C*A4?/;9T_A9.[="MEIO%UP _<;QT?/D
M*] @,W;HSTZ+;PTLBA>R'L\!$55MS)I0M:N:F>:K9GZE&5CCLXKL_?'11EN'
M;3J3(!!&3^%&_VS)7K[$6GN$^I .(>+"'L,,'LS(I%QW#,B0;@]&80M5QK\X
M<9\7+>3<1]RZDI4Y85/A&V*U$ ,:29S3\Y7Z:B+=='*#&/-]:'/TD8$?7QR
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MB(@Y("9 6K3^7"J23Y^?TPY:!A-$XZ!\GJ&6:ZHIB[$F#MR*1![[45'*UK[
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MXD]<%66PUJ<-&-KXYM@^.6_,=FPO],&F"3(O!E.<U;TC8>2;6)0+T*#72"$
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M/M C3*K%<K\_!%(V6<!O*O \65,'J03X!#-9[NN6[79AT-9%R(%OL4E>@JA
MTS<V$X$M+!$_AQAM[!=(G_NP%>[8HPRK)6\I:]_]6EW[0#YJ'73)1>=^ZH!9
M)IY$H4,&VNT<1^A@H9DO30\YR'M9GU%2H4-3TZ6<0/X=U9O:A'/2ZC)^7H<D
M)UJN!NTRFO?UOMN!,'%LND5#4WE5+4WU4F]*8C&>?DU[42X=AD^(6=^*S6"1
M&(^(Q/(]K-@<0IM#:'/;N#SLU\'LB/V+1W^&-!X]:/_=XT.)_2X>&A(_)!3E
MV^]2H;4FH1C_"F5G_5)Z((C9GC;BB=?KA1%F73:K%<O<<C9T&3.UN#N13K$O
MZ[FV0HL'4T\K55A,[G =^05E64F$TK3U/P.M]=9J*TC4PUK6TR=/GXDM9P?C
M2'F9NO1#?7-1T;7R0^KXZ+7$+0Q)7J>=X*QPK?6,H[I/&E-!_-H8C3QHZA*=
MY\MFW=%MLT9P:F6G12P=BW><EWX19;.TTF7@LDS>0U+BY$5UVAN<:96W=_#7
M?#JG18BW3[#1G,]L3.A#9]L[GHM%1PT;$S G!1U>QT'0N23M* A)YX GFLXW
MBWO4&T]UQ@?,%LFC =38RB<GSJ.4_DW<G&%=$NW/LW7'LUD/<KZP,F7I-._;
M@_F@B,D)5KC(]JMW=QQPC$"]K.M?/87C(^W1TUAZF5:;0[CA_LCVZAAOTI5%
M_)93Q$=?I/-A*?G(LIH#F[):C^<R/_QZIT33X?+*6?" ??1;:J"?'6J@[[8&
M>G:H@1[JC!\>G:72FF)')]6AG?WN/8KJH"+YE2J%)PHA8)&PWX+/9DD_9YO"
MI"-.E\"=Z4 JL;NL9R&;=S%OQG*\J<=8S,&!,RE7*L-T@M[9JIU4$2XFSHD3
M\$9?5-M'5=R%?/L+Y-,,&F;JY\R*:4XCQ/AT@C?$>BVAFT4M1CAKJ[EXD$U;
M\@FM98.M:5'71;ERNQIJ3S+8M:9CP*F]% ]&_)(P>$Z$3.2RPP-4TY1%TQY;
MN0(FEP!WT\?5/+JE)LPWT1N#[,7$)Y:=MLDZ)1'?DMR??D=;3:HZ)&0B0SNN
M8IE#C(L>$S0/R@)DQF_FU0G!;JII#YSU+GRLCT8\_$YAK2R/- I>Y]M1(#C8
M:RP=JJ4 75R8>D=UT1+0>5/"%WV*]7Q6SPV _WZXMP[[_[]'@0MBZLF;D155
M0OA7DS\'WP^,1\:3&RA9R^(KRU@:+C(Y$HI'7_WY^\=RU>.C;L%+JH&QC1+<
M[Q#B6$K3E]VNY6K+/7P7_U9F/?CJ>ILL_Z]^-^MI)+]E:M(6^:PV4[B C"I*
M2">><.S3_545\B!98_\R&,MTW5,\SL(76A-YQVFE0"S%](3A2%#>*R?<[8A"
MMQ_667A]/GRK/N# X7X^RE^1Z%!;+BMEN$=X.H)MG3H^776QB/0.;"0T_0HK
M!LP7>DA$)D8-'&6Y':AB#GGN^YSG?O\Q2?WO7RG60L?X.C*!@G-+21!VT81:
M*\\$(EN:MB0(7NXVIX1"J6PNK'M98O3%#W][^=7)V1<%*GG5HIY8 G6*U@2Z
M1!UH**T7$&2P]+=P(&FB*"BT:*&.W'K]YH2BWLPKQ?&=%N>3"0D8Z']]V^(;
M?ZLQ+W(DE>WD<I1ZX#N>4(=ACWDMCT,_E5U4?WW]^^+LD[/3+PHY->>P-V*F
MGCYY>J;CZECH<Q)$*US"=!4OSK_]$;/Q^>D7_^:Z"/CB4WSPZ9-G3\@@"_P'
M<W(R2:Y.WED[-AHLF5";RL2BI7S2K)>X$V;I^:>GG_Z;SS82W:"08.)P7<4A
MYB\FC4TB1QX492\J)X.=@/^&K9T=N-Y1C3=*G[5K>%A<(S_@<R?PXT^8EY5U
M.57)]?#:3X=M;'7'\J0-_$VUL6GO;($,9K2KJG38)N3>-M>@5]2*)5ENQ2.?
MX!Z4N_5QFOIM(<.:XD&I_^,17A(NX8;+:<W>M1 (G,2J;7 M' )A[P<4O:NF
M-@J@'3ZDO"ZH/$[%#>NM,A"RLFS?,?Y6>%!>C_9!A\X[BQ]OZ13Y5^N_OF^6
M][5LY0E!E&)I=:0TM]6"SC8H9^P3"8:G,N\?Z77CL3+76A:#A.[RD:Z\CN;4
M%W65[HU@@<D5-K5L -BW2UO()6!CRM8-E%II'5CXLA-<C,4^SVHEO5CSL\%,
M9V,^+0)C+)>Z+=[P;.;@.8.X/[RI; ,'9+A"!2E,MF>EL.XV;7AE*#Y?3UI6
M2P8G@0QE*A.;DI_IC;_5D\#?"=#@%N9K67C?.?#\R>D73P<'P1,_"((-DCMC
M$^?'P//33^4<\+K>F1X"3S^-J*J,_%T'XH2*P;[TWJ/>-F-9I=$0AM;S*'D^
MM!_:/QQZX*CD*N=WD QGXSY^2+6-.(HM?M2#K;G;MD:S#>[ED==='3Q+0R!F
MGF!;T^="=HS)Q.1<7I0_R\;AZ=12ALJ3 7)44@D+1YFM/OM*1MNGJ9/4@#D;
M7S4DG/</.R#8Y8V5&SFP,$1_17,%G1LX2U NUWU;*_]PA"\2UMA,-\K5('OZ
MTDT>_4A+428V.!_;P)Q\T[3]>AFLQTOC-<Z<R\'#[7$IO_J]CN*SST_/GN7V
M1%QFLR=BYWX.?I#BX/!-><WRK;/PK?$&AN0SF>M?+NMQK<#@Q.P\_;>=CI(>
M!J?&A;94C";<,0I=UN-U'[2;LQ==AX>JNZ$?A<)U.?<&7B^"TR.>K/O*R^'N
MZC&-K1Y07!W!M]29K*LV<U4;E1?7A7P2%O(@&YMZD.%(-")Z+([D76<WL+51
M*?" 9XL_4S^46: CEW&C,+M1FTI%N>9!9V#5-+6'J#T"\_;MA@/FZ"[FLO:)
MM\S*"7*JS&A%=G6C?7>H])Y%QP2G,B-;AT.2-HT<@JF!BZ$K"SS'1V8$)W-0
MTK,\(QNX!UV($N\G5ZS3#&VL/$5Y![.;BC=)>/ U^3KNZMZRN:'M+FR^XZ.
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MFNM=3Z;U .C .=<',6B ]Q&_EDEU:<F*/4:97@T:%F6;*BW4]CV( -2)VS$
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M'T51A+\#\UY_#6U!-OY_RA>E8QBEX^ MI_D38.A?/-]Q;_S%_@!9*]?]2?"
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M#7I3OS-I\HBX<O,]!BBA45!"'TZS^V.QBTV%R"OW?P"<L2.5/F=:8;$6KG2
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M*^Y; F66 L#F_LL/7[[6X/ ;C</F$ 8KN\ 1R3J?<RW?=.U:(2!0HR=,KY3
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MP*_NHM50(@)NHSCVU;J5V>BVRW4KUVE7 ?O$.CS@@.,6J,@G!ZC(NX6*?'&
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M04M?NS P[QP8=+V7=K(QV'!OO%S*6;9&F47IW^27HWU;#3ZJG5@DW.E(7TM
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MCJ8^M\'B.';%=J_#>X _4YB'&: LDX2<C6:C@-!-,EOX(; ,?3OB"68[6OU
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M4\Y(<5UNX:$RYB%A*C>TX0BY%<8VLEF 4*UBUS9BV2M/5>#4X/# #< \D%K
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MSB1-,["1B6P.69JX]V"&2#B8RHR[C,Y9(XJ!1-B^:7I=%Y$66-CB44^.D%6
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MEPYH(>0$:LL(*_)I:N(/(@"<_I)+MF'Y-+E:>CLE&;WB9=TZ[U8GIR9A"[*
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M_<OPY&@XLO(3!J>CLRL0T+T ;84 _98@OIG*VDE\%M8F8*+?E/$<4RI61O[
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M/6B-R@2 ?TF8LQ3_;<V0FPBC*82<0-!D4A /0F\ WMR*E)+^BZW^LT\4"VM
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M;X7T,93^T&'P%Q/3-]GRB%O!'@0?8"#O/KB2@AA,TIZ</2=;T^I>;G=6@E9
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MH4X0BNS;M" R:&YTJY> B(7I'>($F:Q;CFE1<\>@#8?AY"EL*"V[RGF:.3M
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M8$,W_W^"H?B]J4P&*^<=<]E+[0L<4RF(V2%<?G]=S"<V@S\2&8$8L63)_U5
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MGA\<'GQ HR$F:U^-$M[OE@*U06XTD$2>59+K!2H84!D@A]DU3@_> =HEN,5
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MW*2D/]$A6;1:(^=@&@*1# J&AT/EBRQ&]:,1+0,OB##="3/5Y2*F?'1EDS*
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M$-=()4-181-Q3"[*@2PYYHEO1>AU-2@P_?H F=CY 7"+":R&TQ4IQ,<A!LZ
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M=RJ$GXK7737F7N+;0S/'= P&*NL-+IH>SHCF<XX";7*.*Z-@-CZ<^?IO0XT
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M9(UO0)9C\Q^YDB>Z&0KF7L(8F&GS%6MB C_C^^ MT2YZABV39)A 5_B)PYF
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MK':>P.>2SPJCS*J@.3:IDY0'!,,I%I'V56&.B:\/EN:"/=K3T=A/W^M'A>F
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M[U#!Q, KGR+.Q>WK9SVUR^"1_D=X+ B>&N5#W&_CGO"[3U2F**H3=UP2KCH
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MO]181J"R!A[" 1V:(61N0K/[--P'E=BA<9@[D/C^KRP=D:K1Q**%IW*9#^F
M=U&NPW:KHOLLL#_[P>4#GR"-M>%^6H!>4C?)]3AUQZU*R-H@X])4MN?/96O#
M""&6573AF:JOE7OA<O1>NTBC\Y*.5U=Z&T_EB:_XG$@Y_&P;*5]JI/SHFXZ4
M/Q(!+\_!\M<X31X@7L3"'^FLKC=/LT@8Z"Q"7@+K03<MH8Q*76<C6"LKTO=I
M1L3@I$\+%M:]_-S38ZK0(PES$0^0";V)1B$IW8UO<L^;4D6S>K8M=$2LU<R=
M4 JQX4.F1RDR_8&1UE0BM=^L#E4X>UYD98^4&]3 S+ADG< _W3IS&:96FT7&
M<)/,M#9QK6Z S'H$EQ>QXDF! !UIFNJ:@ 4-=3S&A>,2<#X^CB26W*I>$0:C
M%$8&'LXGE&ESAH++F!.NI$6FT$;.Q5@ AJH>VO$]FF5-/WA>EYD-!VYJSD(^
MJPB=!T#4(>L+6#D+6FF0*Q""$[;:Q)O/'Y'Y)J5G]]&6<6Q,M")=!C3K;A#5
M2D"I!!Z=+-FDIM@S4[_6<7KG_(JKL&T>)#U6GI!3%RTLZ1I<[=,29;X+719G
M12>)U1F/P%1QP__[A^X/C_&Z[0RW,]ST&9[4%<PY2FS3&F3(Y>D\9F!"CTWV
M.)W6>8A6]S:7SXL^C*KDWOEQUTQA2U!/-\.F4/#"@N=^^B;%^$YC42:.$_=_
M^ 5-%]*E+D$U9%_EK.AIY<F?@Z_<O"^8;3-E_PO4F ?L=^,NW!?B7M.E7['N
M1Y?WN]R 9VE2YM_Q^J^*M/=)2C'4'37E^'XWX]T8^=?>?UUGP3]^";:;0IMR
MP59B5?;GW^EFO$%W/YGJV_T@XL"@L>U;454&O\L-^9 6]1SJY6[&X@I>4U0[
MN[G>Z1X<A=W#L[![?+S;H 2*"^/P\*=IQW=3%ML?.KZ-DN#Y4,_0_(Q/Y*?Y
MAVI_UN1O7^#!H]J#&6[@#[^@;VHU+_RJ!?TX]YF3YK4<GA^$!P<':[B<+S^?
M[6JVJ]FNYGM?#3\YZ[_KN-:G8^ KUP X^HG__L\@ G4& ]2+: (S$F:JJYV[
MXP\[QIET]#6#;^>WG=]V?MOY?6?S^SJA\I&3I>]]99/4N"KTK4Z"W]-A$ERE
MU^K38^[7;.MP):<Y0VEHF%BG,T=36 =*VTYM.[7MU!YU:H_!/58C![[.HIC*
MG]\(B;J=WW9^V_EMY_>]SF_E;JII<?%")9&.L9)JI[/[F)NTOF;$X>G6C-A.
M;3NU[=0>E7NLG/E_J47QBJNRV+#XH'O#!%YY,]E:%MOY;>>WG=]V?ALPO_]:
M,O[8&J%>_/ +6"X6#@)77@$W29/@K9H$G2ZAF1QN-*H3512]5=@N0('-IK,1
MMTLD9"$$5%DME-/J%]A,02_@;#%7TD!CY%Y'-J[$)5BV'R55A&IM&3N' "3F
M 9-0]7.24ADNY2AC2:_=3D89H0C;['?C(S^*][C=FOGN*8^L-[@M')Z>@JD1
M1L"+SV-L8 P$_4I?9XS1<TY4?10&91)C%?2@S#"UN-W*=*+ON+X<=E0ZQ9I+
M<L]:C@[G;^.T#GC?/K9;"]_/X!6URF4PQDG@P?E0L3G/)0QVHMW T@6"#6'_
M2X1]8Y0MP@JY@D'4.,VH*YX*/B7I7=)N<:E^+!!RA'AB2]T)$9HP3(9:Q;"D
M<:P*1"7@TG?^L(=X1;:U#A6V<R] @APB]!*$D8Y2ZG":1Y^#$5R/(0^Q$T7$
MK-HM)BL#7X-[\X!E!,M=!0&JS%U&FG#M^N;SSQ>F:?-*P,+6BG%^\.Z9;08]
M5I.0P;+@<L,^H'T)=#14_+6^Q7[/*NK[^'4>YA 2/'8@;VCA"S]RWUBPQR6A
MT"UU#QMPY<YKN')=X,T@+:B!_;N[Q'2?'P3/!6CD&6&\,T>G[_DNVVX1C&CQ
M7L<$4DI%8X*2 1(<V-KR<!>?AKSF( !^("P78>/ 6PA3 D1#;J$N!A:+S$&T
M$>J)V]34WW2"*44!16@CN4'<"'YC!O<;;"P,D0=OI .RHI_\7@+7ZK",/ S;
MK>O)LOHB;]L=/VR\NE=IVWAFUO0)4$9:C2/V#2A@+/$9UK;IDB"ICU*"OH-)
M'/]DL'#2LC (RDT7R-/"?MXD*/HMJ?BD4CU(:TE4,;02A>">#3U<-ZT-P?;L
M3?>:.%X()\TWM4 HJ@"EUGBEV/2UA7>/N$9S49$Y#S.QL\5,Q"^7AYEXO,5,
M7*$>[$R$=LNILP33QWX-U%0-!K_M*%'&3CY?O7Q.<'K Z&\T]IE 4XWM>RW@
MR4990 -NEOJL$$>:;)EV*QH$0QV"'J!#MMB"<9KG&O\?[XC&#TE)Z >WJ0&$
MC9);G1?DD!JG=ZARH)E($S C5YH?C"TF<W!'Z/P^UK/ &,8P&6!:62_*Z?HQ
M1I_]$UU*8&:=' 1]-5DNE/F7LJ:GIJ</%>7/IRF@ 60*<(L:( 6M*28P@A6\
M[>Y1>'IZ&AX?G#_8R/+T2X)NKEM<VS.#Z?Q%CEDX*P,N[3J7A!7I?*WC2-\:
M<'^4[WRQ<]'>Y# ])$B"%.4[*S<5[]O4527?K  ODZ,/AY$'Y/*B(],1%F)?
MWB%ONL9&('JT'_ B@IEK *&9"0@G*:4.P%-F"CRO$USJ430:PSI>9 1=_Q^=
M[M[!:1B\ YJQWSEOY_'I2>>XLX;>HR\Q_S<*3?/+0<V  .I^L6;5>N7@(]/Z
MTHIA!<O1-9GBCX$J^,YPZBOBU(_QRJHP>(PWUN7-8[SSF<<$'^4@D<\N'01R
MC<%^ZIOI&PH'4]89\.V?Z$I-G\*]#UJG_0.W]LG1A.[9R9EI>FCZ7[(>2+H:
MA1@V(#=EW>?W=0<^J[[+H%YT%\2,6I[KZ",FD,!]^12\ 'TS3L?<BL=PV;P<
M_T*U /B/N>ZQ1\(_Z<Q !CD/3TXV&-QIUK(.S_;/S[_@E3\]8@G)H]%J8\,A
M)M'N/!)=+2LY"4^.SL*3XS7.CN^>[)\=+CKV,DAG+I[!O:UMUY3UK_O\UE47
M>5&)3$REW6WUDJ<__*_!'UFB+J*CX*-. A\1D[C[X=-Q]PYP]DYX>OJ8Y8D/
M%4#[)Z>/R=S73B^81L AJCEZ.JHY#D^/UIABEK?U_]]<FV!-.98K<W[,3=];
M7WKXDJFM!0]Q7=C6?;O6>&I/=Q%?9E$O>*/OUGV'UGAJZW$-_U:3X(]RI++@
MO?I[K.)UW[4UGMK3W<8_L(WBOT#T?X1_K/LVK?'4UM4.QUX3]]GBC5F"OV*6
M8+!S:G(0'A4:!@VPT_"X<[2^1'*ZO["N7[>_EI5DN2U!>-AX]=NQPA*$^2;2
M>N0_O]?C3.<4^9F5-4@Y/U13T/EII1G#6YK]4IJ]+PM@[:X&1Q8W,N7>QANG
M$B6I<7B4YR4WWIX?8,5>T[U%.J+#EYSYN]@#P8[:Q>[C6?HY&L$,XDG0/=X_
M^8G3/1N3^U[!SES"L'$$HX(HN1D&'Z/XD\8MP%I/.V=JD'U5PC^#\S"X2/)R
MHH*7>0&O"8/W^C:-2YK"Q:W&!M__C%#AB%08O%689GRE)[TA7%[<W9WK^BP[
MG?W.O%EZON'0SO,UII/<Q.DUO UV%]N?OTYZ-,]?22@&K^(TS4+8(95C?ZEG
M943I1"$LL?=IJ$:P>6#"O'X=!I?O@F?IY^"P<P*+>Y^J?O !7@[TD&9%&L,J
MGF&*9#Z$=2'#"E[G,:A2N);>U%H.]L_GK>4WE14JH1Q,7L=;F&L1O$E[L.LK
MV.S^0R?X1SH,_H7QUDM5VDD"C>@ =,E(87& /\U_1GF1*=AD+AWW*.<YG$JF
MIW:[87^#?_X*-- YF+W-^L&KP 7@*JZ4(^VK7EK<@.H\E<C\>"LA!(#!0U?S
MNTJB'AQ(+QJ@\^1Q)\U][S,]4E%"&</(\KB0F4R'>Y@=UZC=)9XRP06*\Y_C
MMWIIQ?>\)LJ#WC_2A^]'\WW_YZ^X(;/N_4I5(?Z_FG1?H#*JNZV,6FYEU,DW
M71FU5;"_606[N[$*]FNJ'X-'$-RG&W:[A^'9\8%1LD&G(6EX%CD!W@TN"[T?
MO"GZ3ELV:#I13JHRE<=X0HMDL*F<I3^PJ(6N*)70V6>\DII^E(^I4SNVKO7+
MW\" ENG][-!].D<G8:=[;.8-NJC.X@F.94OA5._?992Q=+?S17"?<1;=HMP:
M WLF%!&N!D+U7V-B=F)KY[BLIZGT&^1T@;;\N+R.05](!P/8[^2F*E(1T67&
M3HHL/0E>EB 248G227 %TE,7P7\<G.UU#KTBG8/C\[/.Z7ZP247DJ[G32QWW
M_FMWC_?Y>]CO)3+-PXUEF@B"YEG(4R9$CB*WT6OA:]6FR)@><(X.$Q.HU1O-
MT("_+^K;WO:-O>U'&WO;I_+>&N[[\>'QZN_ZBAS_RP5UZQ[40-T.]RU\&P&S
M(4C!,!IS:-1 M7T '2U7/8=@8"*H[=9K.-4Q@FF"*?@M0@;.B2J^PO43FD"4
M _\@,,B <$6#%QIT52Q^/>Q0X7]7U&IVN^$S?=1IR7<-RN4%(XZ^UZ! %B%7
ME>XX[ @"!1T0DF!>7N=1/U)9A)4?J)V3>4_%\%+'[K -,CF^L<H0YJ+P3W&'
ME&7R17F?8ZE\BI*3L>?4S0V"T<%,U8B\LD E^G-/'% _=KIT3W99\4[+;!IQ
MQT$FANU6DB+ AV;<KEXZ@F&=W4'HFF*0-*!WX>BU*^S#:\@6P:2C+(A&(PU[
M!--FIA*,Z#!RQGA4,+,8OQ7O(VP@E_NS=Q'F 49%D<$NLC62EQ9^;+F8&W7B
M>S+\!F83T2]7NBABMK$NX.#Y7W2VE8 #'L7SE^_^ZQ_1+ZN]\9L#:?&.('O;
MK>Z)("OR'78!L)I.RM];^Q1V,PS L \/#TX0EZ+(HA[!B=1D%MB]/W;V03(!
M.?)G8-)F>:D2@D-&3!MS@D#G]@BO=7&G=>+0@2GM!280$AOJ,]RP3#W8P9N/
M4^L>_$R_;B(+^K[S\RYRA$$9(UIR$>4#X2)P$\V[S!K;K5ZLHA%9V66":*I!
MG +?,2 >CM6 P9_THC'P0V$ZR&K,YNP@FZB$"JY^[(2=PY.P>W*T?W"RB[_^
M Z?Z/NK?:*G-)V1?:Z&W6V#8HUV_'^S(.O]X_]O5KV9-P!809Q"TASUF"9;I
M3@P S'[P.@G(L\=HQZ.Q<3_\J?*^^K<]V8J;!>=]"^O*-/DZ^)AP0Y!.*)"$
MZ,@(BTJGF4RS4T8NZHE>XI\]OS=X$^7DHWE?QCHX/CD\WNGMAG+6M$@6WY80
M1BROX 3:K9F'C5R0Q R.3')&!5?E>,R_@P6Y7_K$T_P32SE )X2-8Z],GI)K
MAV6J4'SU!M$,[](2W5XVO&P0G\R%R!"2%W%[77P%!S3QXFN@//X-B;#]HU/O
M80.]?6P!4EE6(\)4E&8&D$K.A2F='$ZSMFX_N/0.B?"K&G<E=.M#H4YWEY8-
M,ERK7#-T;A\4#9@GT#6?)5(#W#VZ6723,EV464*7[/CT+#PZG(8P8A[BKYK%
M(+P+'AOHJ* _<_*J(=EV3SOAV<FI':C=J@)FFJM9?Y$[NB'<>[.S)\L$0GH\
MT6@/*N=K3J6WZ*0,<==<,R";3-AN&2!XVDT8$T.52 <>2UB]"'TJG&T0B+^K
MA!#Y!<>^B]'X#%2I[AE<*ZL37Y0W,(ZABVX5 $I("-CF"/Z99@0&KPEAWO,1
MD_APHN*0G3MA\..QN'GP/3]VS<>"^P1G%$]@)AJ!XQ(,^(A &L#;[/!R:<V$
M\&+=I=DG_'5/C;%G%'+A<9J#61C HO],;UGQ[YP:Q5_ _1?(;VFWS.2#.V "
MF28QZ2T6%Z*"! X*5%3R6V#,JK8]]*SLW&+"]51>ZC-O>)V<TI\PIF':[#''
MJ=BO^'5DA, Y#N":",9='O1+XJ@$O)OH/;*/5)+ SF>Y"-,%MV8?9':-CU8F
M$>)[ZGM_R,0$>@)CEO<I7<3>7!$DA!A&*(.8Q\KBG/:6/A15Q6X;\&&[;U.S
M8-DX'U?8P<RQY7C+X@536, >XGQF%&HP PQS6DG5$-9HMZ98KC%\"!(1;%"+
M(E[9A)5:,0_2F]=,C3<T1IAPBOA!X-1HUI4-6S,8ZAY!X>]9F7*IXPG&ER*D
M8;AS/W:.CL.CX^I->RW!*1SA#8Q@%214A<Y^<G=K3,(D*4?V@C$ MO )#)P1
M@Q6?PR%?UOKP]""J1P7L(]#)K*=#^Q;X!<;>^H1HB"H(A]X(QFY+2HN14JZ!
MJ_3K%%4/6 J)7<"MCQ&&\@LH[/"P&YX>-_#R*YY!C<*"1@(S_E#B&LC"F%L!
M_XXC-D)(<S\\$),QS0PV:4[.6(0GK?,][K##W0^&)+1ZH.**N"6-7PG*JX?
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MID_VN9?'^B=9XR.PURG@,.>2S4T5A=U.$83"91$A$5* )9-\=+AV]((X-HG
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M/S20Q\COC47Y$62[764DZ^9?6>9')*<BB$\*XJ#+*0_GTT>.X%I'D)LZ@H8
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MFLFU)WSM-9>HLNSOAK##]:]:Z+ (L=,@_OQMHX$+:"-:\)L6<C9:P#LKLK*
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M6:SF#YP&F0OD":(VE/CQ=QPI@>98\EU'F+N-$*;G^O6#'B@\.K8X+[ 5R<(
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MT]TFF33;D[O,0S,%<^7\$/I3ZV8F\N+)?\XN<ME*MIHO4J  NR1T"SB& NB
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MYFFG=?!PM4$]:#;BDV2W\KY3/&H_E4T@.X8)O4O,WQFAAPM%,7&*X7;/6 =
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MIW"_5R/<)+<F6K'];?ON>S!4!OU?/!%5M7@E2QC:1UF"_H.#6^@G]//0>N"
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M%AH4MV#!;^QHC4M\D-316"0,1<I,"$7*@,@/XT\XO62T-@@B[<S;UKZ9]B/
MB+V.Z22#U;V.9;:U@R>SU0^L1U.[8(4+Q1?W#B[$IR@BPN_HGHGE>$R/ $<Z
MW)A49/FE:(-(=(G$RKYPC42*UET!N]BK]#?:/KE[;/,\63GMZ?0H?W;]V]7S
M;X=$D,QG)'A<4F/"BEZ,0](NP#8FYA$5$6T2F_,M040AM6?09\$99$DP2.6B
MI/+'>2I7Q5QI&?S1[E_Z?W:M7.5LY\WY8VD%^6/4 XH.T,P$!RCR1^$6TQ3O
MS+-8Y,'%*WG?SEQX7TGROF40XBMYW^^'K^63AZI_?&F]*>\KS4C,;\#[=EV@
M896+ 8TIU-W101P[KN8*T[2O]=*XI278(ZYV.\(Y@X[G]N\ZRL@9S?(U\ZEG
MMM": *.U=,\;:FX_H'&-"5Y(X7J4A8YG4AU#:W/< =J3EZ12JS1&U]]/7><R
MJ->/JR^P"*?8I5DRR)A9.CZ56?W'@1LZRSYI)C"V'F:?>'WS4XR"Z_TFZO18
M[WG?[3>#6A.V^,@%M :$#(3E7,,7=FVW=?\ILA-8*DFRB]D':8SV6ZW<*']J
M^(6=^6U?J#DUOY"](*\19\S]$Y.VE?QA8_2MW^OD1@>/7:?PZ0M-$[<2YRE)
MH_E%GL'BG0\+^,*)H^F^#[2/BTN2%W?JLC.;&ZHFUW6!.[B>S\*+'=T>CF N
M%MRHENYW .9L==A?#/HEO_LP'/Y&=%+$NPL,.>BSD/.NQ2J);VO7X[/9W+ M
MX!,&BE''- WX,KP%E[YKF@%]8^!Z]S1A/KIG$IBB(3/*#.BKL.[4J;A-V"G&
MJ;:U?;,9:&U@W ZZ?#8W@$/A/E >-H99=UP0(7 ON^C(\=P!/.0SF=S4G?L,
MLCJJV&##\*:742R=%I^",(>JOZ--O#,=DT6ZT'@A_]S<()Y*GCU@;S:H[,3_
MV#1-FN"DW1!V6K[%VUJ-?B5#S@NY!.5=DH5CXN8\FIL;\6\8)@@:*] &NH\A
MYY[[!-(D,.VA-H8D*F&@SD\VBM(JL^>4G+(2O##:/3Z^,8H'I:O+L)+9S^C'
M)_:MC'YB4MC C.)QJR2A8#G>CK*XG2HK-S>ZEFT3;,-35B]41^>GSD@"11>)
M-7:=VHG[.3$)?@]>Q/\A=GJ$F<*Y7\EA\0\UQXC^0GDR\12\QZ.65:[UFCOA
M*>RE3'D:*GK5[!9\@-GM2MH!QL\QPJK(Y8Z,Q+/(UPY[TNI['A*I[2*GC=]C
MVCAQG=A)MVUW$'T.>2;,X=$BY@#,&BXX+#>[C=%P&GJ>F1X0(R9&85U]J/5
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M6OY974?ZO_3T%2;(80TIC9X)DE6[Z^L JP(SHE.'_#0N4F/JYS\XU/K 5^S
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MH$'+HKW=!@D0_L2\*MU>G\(R96UL/_!T:@.#1Z!US:#C@E!^-)E>%O9$B32
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MUM!AI*S>-TC(U_L[76*?VWRSB*UKJ!'GM O.2C9E%0;&RB-L.[VJ0QJ"BNH
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MHT56:4^[S\?5VLEY2[HN9ED[*L;6CF+KX[1V]FJ^/ES]:16)%(7M<\[^.>\
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M>\@Y@,][4>,RBR7C?3.EC.S7W=_N#H8>N^ 8*#+W@N^/C4!W!.'%CJZ0%N.
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M%_5)0_\A8MJSOO/$OP5[H-$,*G_^BY<ID9C*[-R5AHY1AJZHDY0XS]WV7.%
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MJ08""B?#2"MX/(S%PG0<AP;UPH],=9F-LBA)&!&^Y.]1K+>AI<R/K#VR6A8
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MU@AN"X)],YS$#A11@E]REH^SY[!^'# 38"BP6X0KCA[R(2HP/*=]7YZ),J?
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MJ-P\5]CL9,!0Y@NA[\'3P$P#)PYTCK$CJ%9$>(&G)X%O\##A=3:Z)T$@'P)
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M[J9&(65IH[*18PRV#ZGE](0&!P/^H4$SLQ#VPC@K8XIV%?S>&**=P6:J!+6
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M<%HS&#;3[E,<#EE4J&5T,S3N6T8SP_GI"4P)?1I+1SUG['S&22PVY#ZT8G-
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MZMQ0@;.9JU  23+V<PTT:ZW;1(,5M&FUR,3&B2TJ)RR6D_Q;G,1F+M-/0R9
M1C8WT5I#Y22C7Q;T QL1& #6W97RJT'EA^$&=)!-K+FE$W:E)>)1"T<]H/-=
M-B4]T&$AWJL+;U[B\Y%(W5Z3%+_GBL!C"X>D"0*)>A<5(:.M)ZLCNI]  "V2
M5A&>='@E5>X>/_/CT72R,QT1)X59E021]542GMJ .&J#[Z4-+J)I ]*,CI):
M=%26%$MDM#-@@4/.B1HG:K_3?U07(?R2;(9%%S?O^$>[\O?S*;<?VH T8Z.D
M'AL%Z^^Y+W]O-(&&=B6@HB<:IFYHE>$0AA\GT,( CC0QT3914 4&?1# GZ8D
M9,"?:& )Q,P"'X(A">R:%E0H^+7J"]*J)9RE&22$!1SR*.H"X;S0X]$8K\&8
M8S\@SKME6HXE(F,N;\HJ0&AJ<(VR.AA;%_4;^SG_A>"[!%6+"=$0*1GB]Z[I
M#&LK8UO[!KQ8(TC\Q"GC"I*]K%1#H&Q@&6599B$8?9>>]U0@1F,F<76I5MCW
M)ZI^N\+ZU9>VB8XC[" MHL[:50_4.1E\$T$#"OJY^(6P'3D!D!J<WP#NO:]J
M 3% UHAR?&_8:L#>L4H#/:<IRG(2=_?)303E+]=N4?V5>#)7O^GZ;,O;V<60
MF?R&>_&T!\BC/?"][ $JFCU F0Q';6L//-Z4RF+Q;L;OB3U F1Q*'>T!BSU
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ML/#_]^/,Z:?G,A1$+2.#]F;[GN*O?;N@=.\'-]UU/.SMV"^E1&8S).X6/$D
MHJ.ZG4S0O='>\G)1KLP_KFZ>\2AX#%[M:![FC/[6V&;4;[9DPC6_AGM>8N)$
M/Z;4I E>RN2 #5$H11VYBGN-BO00+8=ZU:G>=&QR"0?J.O*@:L^KW2RBUA/2
MH<ZF-E<DVIAGV%#8*1Q9#,])$GD>?+4!C3H@UGO+^UN^\RYQ3X^U0?)-UV9-
MJ<?(X*X(JXU15.BG%@_ZY1X>BFD,<<B![;YZ.=KP]_@%8-"K3TU"$E2F!"1D
MT;4(::MAN@$EY$$0PG[107QV'54$^M&M!F&'8Y35YTNN*_6IF80GWSV>9$9F
M-3/<R*&L9=E\LS%5UVQ,Z*?VEM>U*2&\">^SYCBA3,RJ=A=6U=I2+ B_&-6!
M?:GL2JFW+"X_<XO*["UW2P3*KG@?TC&C$BTRC+MF5+IUKO#>;WQTVZ.]B0QC
M^Q=8Q0XV(7#AFA#(7C0;S_,!DZWO3T)@3Z_]&,].*)YM+;^L:*V87G5#RP[3
MN!DWU,&]-$P^9*TOYK#BH?XG&+^+9#>.\[E,/A<T;A0TYOF5SSXVMZ20 _YH
M2H#05HZMPDX:B64\699\>ZZ+@[OFRY1(/J1LK.9K!1HWA%0V7$%J81$*1A:+
MQZ!QVG>YA0SQ"G 5,OEB0N%_#YER$:!L>$GQTU+WN3&?-@J[#^W>^[BFWRJ(
ME[J5@1<R%!$TLQHE G>\NX2L%* B<"JHE9)&[+326RZ;!5+J7+.R1*<2.PV&
M$E<\HL3%C1)7/*+$[2*D'Z35U#>FC[O&],,_MK=\K'1*)6+8$D9$0D']U7 T
MC=$D?3W@N:NN;;,)_/1$ ]O047V<7>JLL46SK?>@P_]D;_G<G.7NBP_B)UX*
M%/Y?G8"CO_D8_=]F\)DS^K_,-SM3_GWTF>-W'0:&4R^3CP.[_??M4@)9UY1
M=W;U\M0DGQZRA2,M'&J>(%H$W\T TWV)^-($6[S$(W00%K&IK-19.!R8[QAZ
MV/9A [5CF54O'Q>5Y[Q<3JB0;)5L<+.(7>R%=2V85'@\R!<CQ<ACN*"8PPL;
MX48"SX3P/=%_CI>U=3PAU:ORD#;YA$""ELMK_.V:G:@5HI_H*)BN@8#$Z*N
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M3/,IM:U.:4[@%_8N>#W4+*N#,9RK(@Z'\EA#4?E@905-A-8^HA5A8!*KJ)(
M"7;50JY-5X&?U89A5UJ/C>H97H*351"I:M.XX >TA: A/U *@Y<"#@"*Y<P
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M??6J-+M:YKM\$KAL\,U IBXT%:6!"1KH:29@VT$CI]5ZRY+P=+O,WLYN.KE
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M9W54%(.7 'W<&G;&M+2A.I:P4'NDY_665+].7E^7/VEYF.;Q&FL\6RO@M_1
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M.\TYL-]ALZV0].8'_[GK V K5__9<\X:;IF]+6^2BA W("?!L N@R")ND**
M.XT_(Q.Z+4VS\7]THEMZ_5\4T'W\?^&T#Z*J?Q>B)KD U[O#.C0M@-R3KXIJ
M0:]RV#\G2M[,6K<63+Q?:/EB]+%#]LL-5Q"-Y+WPP+;#B2>=D0]_3)'4?I;Z
M1 R[GSN;Q=J2@S=GX20>['IF^WP7@V(7Z]CLY?)-!):Z/+?%\* FTWQD"I("
MTWB?"'9Z OT$ZD1BAI3L2SE9@WZJLF%W+95XY [=*6;H0P3.0 Z&84&@:QC
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MEL/;DB%A):^4WFK(IC*('F 8^A,]L+_Y/-/TU6:IK.O?8P^=,_$P1@; CGE
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M31:_8-T&.1_C.W?_6"][L5[,&*&I6.@[X"5=6Z;'_=+9PPNOD.9NR!21/,1
M&QQ^"1D+/=\@6X8J++>VGRZLIZS*\D.*7]3_0]=?./Y#HWPKXS*MB,?K%.69
M!CJDS8E7?T1[Q_@U^: 5Z0\^21+2+U'XQG=XK=9RE4DQ)D5JQ2=*P!4<W,5<
M_]E.M/FHBY&V%=33.Y/,M00TY^J_D/YWNN)_[;9_37:9F S6?P/<8N 7ASW
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MR2E!'GW^WXH0"I[>+O<2"*_)&?A)/#)YZ3^4N[JN26:FI:C+G56)8*7CA_Y
M5T9@O$4!H>E(TBAJ6#\6=(?($<E1L\:1'[[)O;$(FQ/9S3X[?V>[2>3BD%9X
M-^4, ,$*+)V_*E68%D9_5/LN"N0E<'X( INEF4%H0G;>>?0A_=C!A':%[6J.
MFH8*X"O4BDW*-NP2O8!Y>EK.H8!IPUOWRU^]#C=/R@VX5<08=2B;"4X$GUP7
MH"= -A+MR_EK788R;,5LY6F68 CP.L+!VH.> L<Y?X%,]G=Y3\8.TW?2.KDN
M]/U-P=RBA4;*>T&+ PSW:'4+6 #8PM<Q5>EH/<-QG&=UQL0O4JVFH1PG9%IQ
M?+<J7/C>+=/R)[_UZUHWU+;9(R:.^HC0NMGTP+GL8Q[#.W2Q"CN(G9_SACCG
M& =3_I?<KBX;L =GE$K8#0F5#;:[[C&OZU!(F2_7ZG=3Q,R_$[.(BJI/;W[S
MP/&YMDK^P/U32G,J!G\^B6<8RO#0,-9(@6$+ FI<?_4ISR+#3#T]FH\.:C:G
M-+"?>/M9#'Z%^^=0-WR)WS-<N0(!-AW)C2>*YX"_HWMD2<J$ BXO1\S'Q<I-
MD9L[VTEA-&.:Q>B>*+U9X,+O1?8\EURVO_)TI\)M&>*1HFX4(<WK\J16N*_R
MJ<PYG\Q*N'K#'R7BZ]C ^OV6TJU>H<U&DL;E7!30Y;B3 18RQ_-4 ZO&H] ;
MYPGF4WF>8.<Y1W;&V9'8$)<;!B65T;LJPG<L:733BX:'H(XN4"Q9B=<P9,Z
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M?!J7L,5:8!U>6"1G1$%0MYCBSN=6H"^\_8>5T6V%5PUH0>2+^K&V,H;3F[>
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MJT:.F-TFANB];6S1^>#A='Z]X '[^_P+W2JQ2O]7%H-^BQ/C ?PN.P*/YO=
M8[U'SO&[T:SM*\Z& O.L0XZ:*O=[E)5H,=N*9GT0T7L&7IQ _3Q&MV*,Y/FP
MD92J8B>9-9"B>HYD/R40/QOY[#0KOT9PQ&WML,QO/3W%\53!@HH5&WM"U'Y9
M5>3J,X:YE9BK]*EGBF$CF4":9Y=\0QG*@=Z;\>K9U/-A$NXUWE7GC-<9N;.:
MSLS0RDH(MZ$>C''8 1K(S-G<G8PJJV/1OJ%.Q2Q>'3Y>;L-LQ)SCC_D?-D+R
MX2%9  UIEM:(SP. ^UT&1HT9,'*GR:-'2)&2=7KR5<( 57VQ3Q@[%765K'*
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M6+?(P CL\6"!IT_.;L!=S9F+:@'0;5 QA=(7M@J609JX]$;4%B;8/2I,>*%
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M1UVJ:Y&5BX5]XZ3X!M+'GGQR<GA >$@5P<&D&XFE')KQ2.S-/EHR68.X).;
MD)@IK_2#^9HX4^7/>AO^!)\S>#.:W3:E*+)"J?.0503I+<J$Y +%4P%/5)PA
MZ^Z.A RQ81X0A7*KMQT$,MXNR.P(ZY.ZJLJZH]_WW?.A**/.L^^E5K-Q6IF
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MO45G5,R,^,L>FYURU"YZS)G,X1I'5GIW"F"[EV1;,WDP4:A_<8"_U^8CFUP
MRG&L*,\MH.RPH_ I;WVYHO#RIN:<5TMK545$LR#!W)N\6*'K6M1[]^J,.0:4
M5$UPZW>B+ZFNX.>=".;:8(O5LY6UQEW>3DW5?..:)?EW!<;Z3MDZ/3II)YN=
MTLY+B1]&=SE>O,ME<Z--%L!=M9Q%AWX13;<>0ZX3+EB'+/%+$L]-F6X[L5J5
M*7DCRT;S3C#6V#>;6XD/1!?1;'UT *A^=^&=U'X?F<IGZ3.!X[LLK/)6/ V[
M%_,+8]T+G&_%ZD895, !W#*GI--#CB)EOP+,QQS48I3K4"Y1+ND-FW*PM 3-
ME?W^./'"SF+K4+BIQ]6$],^/H %KU2_0U&&[$B,PL:5;@)LV_Y,+-%78KN)S
M^*G$Z1;P@8WH6G[#^!SC71WV,A\Q)O0-WY;T"&HM]6/1MA?/,E7)R5_I;-W[
MX[.(R.8Q"KBR+)N:+-&-/62^6HB:RBK(/[J$"D;^1RDCDBI%OGH+N(Z<=KQQ
MCOU ,ZHOZO=7*4.CR_F:GPKR*C<$#8J8F+?)4TN!I#J&G7\ZJ;S6\=1)D?21
M=#?E=UW/_8]Q-%0;38:/0IYVL]4\?58/XI8B\:0D&G: $J@ZK(=@(X<C660+
MB8UTA]9\CO-YU(-9Q:7_E(0RZ\B8,56*)'&>:)@=:IA=][GXRY?.WE5O,U@M
M?W] P;Q9:E$.HQRK)<(; GMATS9R<KT2+DQ5R_)*]NQY,@&;!,@/=L!RBR@^
M2Y[F6#,;R@I7MST0D2^]G)+E$Y$'M6O[+B13?7^NMD8C-1&TETA#/F(9Q1ON
M(AZPE!]GD,'\P+/J9CBB,Z%]J=;"Z4NI"'ZT*C%ZG[(%JSKVIM9G6AM<8AK,
M]&[6K$2*&U5U[]QILS!7UMZ/LZ_V9%U(P>3C_F+#PZQKA.?R"K';NW@.?0]-
MWI&L? \_.>8WOY8L^,K1G*&-%LC]X%[W'J[_>"T'T@.A97*W@M\?O-!N?5\_
M^A3?I'N-ML%)O%MIX FVS>::?;4&?=JL4.]%6CCAQ' ]BR0FX!/E_1&)+W4P
MDP#\>CF9:.U)RD_ L?V,"'(VH <4L1#S*YV#B0_YR<J1<5?1DP6&<*5O6+SD
MK.NDDD;(TT;5(NJ8($)3K'<<[U;VC.365V?B!@J(/$PI._SXW2YH^HJ7\?>$
MOJ]X0FM':1MJC]X%OXQNCWHD5&HO($V9@S5+Q49P;S=F[5!D?;@DOG=<7X\/
MN@]+YS\R5<8UG>0M/YW^)D+0(JIS[UQ;(52;=J;R13E&S!L3 CGA,W[;,_W(
MOB'$BW<HD20OL_2">4H/V-^>&5@Z*W5VV1J3>E*2CY2K9+S >6M)\*$D311W
M/45[<8[K,^V59$_A!NK:HO$/W);M)[4<M#U/ T6]Z +Y9\AM\>6SB/CO/B+C
M,SQ,68/0%W5!N7(+J("GP<$(M]H^O']TM80+'1]JQOZC?!G;E!RK'QRC((-)
M+]\L7V^Z"6[9#,D2,6?=W<#\=7!A %!<CBF6\RAUM2&<)9]>^@ZK"]NW8^B2
M\WI>(J@8**BNB05\Z9)\QZ](,!FXFONV__ +&O:G!(EC>3'HXD7F.NSL$4N'
M,(,VM6H5GEDXJ]"*C8G%FZ0?;.[:N[*!:]'0_**>?E>U(N8__E<#"QF4@\XM
M"WON_K]XTRYYQRD##7Y<*^@$GYQ+)GBF;P?M2UY'2+#!Q6R_+FG^H:^_!!3
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M?NSG=,*Y)(C&<L/#ZV5T"_$DUG@':>3MAZ^>M\NS;%BIJL'$OIA]MNWK5K&
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M$&0BRP[K<5[BX,Q52E[JRQK#2Y)I[=#43U\7:PHS@#8^VF'I<)*&;5%6PR,
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MF(\:NQY/)O]@NWV\'V&1:S?9OK#N3!Q+6!E5_.*HN\.1T[DD5:<:22*$[0?
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M"VD])EE6])Y*7)E,&1EA6.T T8^-+U"A3 $%M[J)2=_+6)M Q 6*_V[,NS@
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MY0N2>V#JYR79$'+_$WUC.%??7R_4V$!;QI?>1:9=WG7>D$Z,P9'RODPU_D]
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M;W)T7S P,BYJ<&>ENV=44VL4+1I%1;J ="$J3:DJ36J.#02$"$@OD29"A(B
M1 F)@G2!(P@H"!'I3:0C+810%*1()P@D04":[*B$+23AYMQ[QWU_WH\WW@UC
M9(2Q]U[YUK?FFFO.S69_>I\".69A:FX*.7#@ .0VYP>R/PNY\M]O_U>O_X+\
MW\8XL-\)$3X*T3R@QG7@-.2@\ $NX0/[W1 H!'+@\/\Z ?*_7P<.<ATZ?(3[
M* \O'^>$AF.0@P>XN X>XCI\^- ASM%(SG'((>'#(J?.7SHB:N/)?3KX^(6G
M+_*/RE^N(8K9?@44M+P>1/'PBDM(2DDK*BF?.:NBK:.K=U'?X,K5:Z9FU\TM
M[&[9.S@Z.;MX^_C>\;OK'Q 2&O8P'/WH<?2SF-BX^(3$M/27&9E9KUYGORLH
M+"HN*2TKKZVK;VAL:O[8TD7J[NGM^_2Y?W1L?&)R:GJ&3*4M?E]:7OFQND;_
M]?O/-F,'_+O[7UX'(%S_)_7_U[R$.7D=/'2(ZQ#W?WD=.!C^WPG"APZ?.G]$
MY)(-MV>PZ.D+3X\>O_PBOX;((Z]E"XAY/?C**ZZ@356D_Y?:_\SL_UMB4?^_
M,OL_B?T_>9$A_%P'.,7C$H; (&PR+& ?0JZCP#?L ,V>?4@];O/LHC*( \([
M:^^>0Q?T6%*'1<!Z_RP31;K@:VH@[RGJ/H1[U6 E'C7XDU#I/^F]87!O52@[
M2$,AZNB\_=\MAN0^)*H"2UP ; :JXR<1-5M]KHC$IGT(;^ ?OF'9U2FYHV <
MQ9 E0NH>C!1/+E/$=VORH^]$L#1^1NKNSKP/G7Z?7]O2A-;TB3(_Y<C<VX=$
M%Q^  5<1Y"^")6X@OWZG)*Q>B'3_@>L!4ZU,A4-0O0"V.(SR!'H<@]P[A"/"
M891<A"@33E,-E*#L;*Y0AF4Q!I.I9(>!&Q\!W/,.58P3R%VPZL(NP*8B?2.I
M"ZFXHT:*BPGQ66$=B;L^(6ZNERJ^M3[!50$G_Q3>[SFAI"=V^Z-7=#"WE"]_
MOQ;SDKGL/TKOF@1+US80(I_K<S\>=:KM^_6D^1E4$3ZO*NFG=/D[\\H^Y/ )
M5GV;YAZ$W4VH]]OTHZ$#?PYWP2$!CEC!KT%!(O,P"8SUE%(T"<'?=NIC7]X'
M,+I/NO>I=YF[RZQ'1TZA>7D _LY'*UVG-UPT:,("$ QC"N]1)7H1,LP#])U-
M=Z4,NAYUH=O*D>J7^(=/*&I!=KO57:_OL7@]6W92^Q/3\BWFXGB;?CD)665F
M'+V6[5$45FS!^#V,PNED_UUAK(U>RSZ>>VG&*/A+'/_;PE)9$],[Y_^MY-+X
M9RX]!<DT-'($*FA=,^PA0L-.C^J+BZP:$T.,XQ13+RSX4$4I.@T51Q!N.^6_
M."S-RO_NB[\QT?:(-N=WN<&KTK2 &GGGO*JD!^&;JG7ZG9SB[_<G'ZH(POF!
MWK>Z!SH52NV&++V?^SS!1F+G\("]T+0EF^=C.+ "9]6:Z%5W)9O1OIDH$X C
M.8$41#S;L&VRDBE)OHH]U?ZQ$<114X_+:@SU!T:81TE,]&:W9/20B,4RGP,U
M'69743.IC->@_)XG1AB,W#/##N7I-X)) (H6DU)5CM;L863?:7KWODH\KGK=
M0WA*OOEKFV7QJLO/C$>%Z!S2[F1"J=/:X\CDS?<%Q7.N@P<W90B#=FR^2[2M
M>#S@N@\!-20287ZPF8_J&DSC/2.,(7T?0A3B70/F J2;XE#:PS,K</ %';>H
MF;HE4&]+=G%'RJFQOP%*">I9Z8+MX85HH6LI#-KR+^ZL'2TV?R^K00T3LJ>%
M"6(],S)_,((>HW _W\*>0XM,+F_:5+,EF/8=L5"1Z=5=9*VE-*A',\Z=FR_U
M;#IV1:_;4.!GFEMI:.[W1;_0:F  Z;%*'OKL/O.C*G)D4XF\E)=@WF%>.E,Q
M9TZ\MOH^[3&RL63[]9X+=A)V .8%BS)18A7@_'$RGX$M"J>S@D)=A8Z![S4%
M.8V>YN2.SG&L'0EUDK@,/$RN1N[$[D,<VNMK'>K'E)WD0C,I/4&U%OC434[_
MF^*(0N9$5FV#<._U5 :651CUY")9"\A@W[YX\0[_@X%?V9\YT<N?PH!K4#(B
M+T\-E(0W0R4QT+Z51&8<YQ .1XG! Q:IL^%L'@0@RDAFE1!\KX*OZ06])J?!
MJ1)T02\>:-V'W-V'')'UF.J"2AD%4ZN%*L (#OWT"O&"MCWU^Q A_\=W,J&6
M(Y79F_<F?S'G D3GW(>ZL8/.G.J,[$. *[-EF>*L^L)ZAU-7IW!U*YO:IQ6;
M#W0, ['+;CZ4=$%NM\/?L278?D13W$;8'@H,MZ$[;N#WKC$UP962N]6^$O%J
M3-%J53"')%"NWIWM1$<]W=:NH6?%X.H+:CL"#>#'?AAX(=1CWP;>B.I?[V<V
M?.2DQH$+)29M=O@$X@,S\U?;!840XMX-[%3Q7=F1\L&CS>!.<-!H]W5T3T\;
MD&4O0E+S?4%(T@35)9BB*3ML 1JK;A_B@R K,U3 "3H_&$)3:N>@<('O-EV;
MH4K#<Z'C*'Y)6&C [@Z)%8'XVD%"T;DZR<6YBWA^%_=9=.H_*;*HJWG[D'_H
MZOCXD\Y!?I!]R*T784'N-Z]+O4Y,+M_X:),Y4)YA+P6I.W>S^Y1AO-C?A+W'
M..)M&"4/#UBK^F_L0_RWR#(D:>5N*?7\MC$V+_J4,AA#S[%K;,D@#RTC(!PR
MTVS3+T;T,1(JM_<ATI^I<$'W]J+!]HZZ\)!C3PGRG!UHQ@'N$= 93GM7 !)]
MT+KN)K+$IC*'&/E 6!%80,G8SIAK&!SNW(<<!%.[YL4FC5!TD67&HM6ETG6V
M5%R/KHD(@'HMD/@-W4_'W()]Q:CMNA'^70 NP4 ]96K?)@X@<9# /!['YM5Z
MCUZGY<;UGF5>612"L(?G3[;3Q?%"R7]:(Q\'BI+V(:(F6B Y\@%4!JR^0?>=
MS(F@I0J@;?NWKM?2=6/V(4<9K57K[),C.JZY1YA<?_+6V4+&G!EVISH!<2.:
M,K49#HLK:#V:IP0_BKG8Y%RU0_FB;0J^9@ 'GW1QA_U[T-[=56S/>^\ !W-^
M.$HN ;#YJS""NX/GC)P"^H4%>*"K+:BS.*=L!X;1/48GG,5I2$T^,,%AH6=R
M\K2K)ZX4Y':B/WQ=TMY];L%CUF)5>$<5 2J%,T7[^SI?8,[7L^)P/M-,KN.J
M048:^Q (5FJ@J.V:N'YWC3FU-Y/ZL\!.=GQ'"VX\:I04KMC]P"B0>1M'Q'(J
M, OG]&_M5E>U+&=EEW&4G,^TA;A) E^U)QA-#Z<()I4O?%LU.0I4:MU@*X%E
M@+='VBH306TW[!(=1KY'1Q,O(*4S<_/186&!2)*$BUPR=18G!!':TJ3M0SA"
M <(4 EWI?(N.W9&H/5%J7]<P-SJ:QIT2]B-TT\PA4KYK7G+,=WP[T%K=T+RQ
M95R'NZFF(6]-%:F*;!UH+K"O;?RH>0RFAB7B =NMZ44VKPV5  6;&$9@?B3]
MRE70_?W=>5GZX-S.$Z-("O?7;9SPZHY+<<8AW3P3@/TT#"<VEYO<7>RNHWGR
M*>V\V_")3E/<&]PTDLW;0*L&SZ8R978X6.,99:L259@85B;,)S4>QVNB %;]
M)/_43)QTQ!W&_),G"N+OIQT(]J9I"D^O2B=7IU1.%-;@1&<12(/'TS-K(TYD
M<(LIR=J'*.WL/=Z'S/B"AON04K.D,UQ[6=6)N*#4V=\,3KM'/<"H CN]"^1%
MFM@6"18[KP[&%&+.CFRO0P^CA_L>N(/KKL!*8IMKL7^:/_;(5YTYEWX]@',=
MQ@83)I-T/73)('S&I]5RO=V$O+49P/X'1]E&_;V&[]3<@VW%$'8Y8]@*@IUG
MNG,NX30,T:3C$+L??W ?$HA+Q)^HQIS=T\>.2C1*([J@4!A)*/'QESS5]G'M
M=C^W^E@<#QC>Y9+U/%0ORP)@-(0JT 5?E%R!U**+??.0=_T8A.EH-B_WG@(G
M[#43.70ZC;"!H]^9HO5%M<DNJ@['L54Z$/SH/N+CE&1::Z"R^51,U4(<)NPM
M&.&^I\A(KW)RGT;R>>VZ_Y5P:,QJDF@)*D%Y,\4XT3R:.5SH!J,DF(WUY?'L
M0R;,Z*0Q[E\Z"1Q&?XUY,+$/\=X"581Z8-.MM)[!E;AT1AZH&C O.OHS>; ]
MMH*N3,Q63.V%'?PV>^G^0, I.J)+W:]/@BSXX=?9R5/[D&>/^T?<=:N\/W"Q
MSB,-;TW4#TI8C8=%NNS.6HW^R>$;A-N-HQ2=U#:T62;SKA7K Q4)O#W\XIDC
M \&&K4]/G&]+?F9[[5.12-GM<Q]/F7_C.T-)D[I5]DWJX1O\RQ/,:6@4%'C@
MMYE0Q/Z$!\RKR;[6^2C4(IYL1II"U*Z0!HW<E,D-/"::3@MWL28?K_K+Y]K]
M [I@4&5)K^P7&\:71M_.G4@W[>8:[>#"$3DE \QQ9-PB[LD^Y ZGAM"&$WD7
MP78ZK+N:"CT,!D"C<2="<XS#W:/Z&7\N<2?H[$/B6E Q&YMWZL>"\E3W-CUD
MI+K>J4\CX_GQ=5\]KV@=Y%G))UTH.Y!Q*;*T__6U8436X6;8(D<J'_J/:J#1
M,,!Y&%3,*$E1\QD-P\7O#D=UG/<G7^N2_+G!/$47);*-)C!\CQY$G^%.P$C)
M12_*B!0&C6+,2NI*7_57L#NF+O3+Q_>)7N\;^,OEY_\MGP?B&Z\&(4*"O+J?
M'_M;-3G_1W[J<6JFRES03H1BJZ6]F+SNVXRE+TLJH1GM?XE=&K\"34W^O*W6
MOVR,\B'_;64\957O0_Q29U)O LNY]!+:<8]CXTQ'%"[B[2IP5TZ>+K"TF9=E
MG%&U] T 0\PGY'K)ADGKZ/SL?<C&P$.''S/UJR5K2E.S&*'%!5ZF*8"+9893
MYJS545WSYT:U]R''P'#[6+Y249NOVV<.#V90HGX>U53/=DIQX5N/0%8\BG9U
MNR;6>3?NE]^>A;^),:L#%LAQ/.)C1+W)G76@B0@[)MH57/%M;L:<,U"BR%:L
M!D*<]NO3]JF;)FKT] 5)9:)#>O>.WM9*]P>7DM4MIK#6HG71(NIIASJH7S:T
M!2/BQ12'XT:_U[3("=&WV14T_?IELTO:#W>#.L+, Q5RI[NR/JR^4#OFK(#:
MF>D[8CL /LST.^$6<.=E&25@^16?CI$<]%QBAM2MX#@%;\,>I16-,,.]6G-H
M/UN6=4I+[CP=)=N%_I8E%$MYLR7<\R@\[A%#, .+6;A 4;MZGVFO-ADF9A(@
MZ#:LR0@=>_E&VMY[T!;6].O1U?-!9H=;-=_S_"A_*ZZ&YNHP8(9S=/'L/J0N
M?*.--D6+2PU,[['S1Y8Y,V% STNV(KUA+LG<X%JP;I*7<&@.,C9Q*3"(>:5T
M53=+,S!8MH2L&.LC1]J[C+G6 IH#,-I*]ZRD//XFH/D$ Z>YJ_#89_,ENY#,
M/V:9F4^<6Y[:@V\DA19LN;Z^]2]/]4H2FP>^)\<T895E]<'JP_NJ+F_1L&54
M7+P5%0GG 5M^!KJ,>= 53.0XM)BH:>2WB+NPIM]VY3@=S.Z?'#!K.;^J-;<Z
M17>;=7>^Y.?KO^RCK^2:-!"BMF-4G522X;/]8?H1%>!C58BZBJ]('S^EE'OQ
M<E!TLDNZ0V(P024)]9-I0>=*>/!>B:HIA.96_W3^#:K7R6U!>W=+=*)GK/^"
M-?03\B9ID=YP;MIBVLW4/\FNUR:63Z,(,4-3L2NGG[V9H5]=5P6C-,-JB^;H
M8S^-I.A!\U^V8&35=V  W?LOLS$M\ )4M&K>3EE5X06S\TF<9/5HZA-$_4)G
M*H<T%CB[SMUQ&HWJ49J<%)_X<S7-V+ '*RNRY(TX!KIL+D[\B;GC?#)E&0V%
MMZ1)F9 >A4C^%FPLVM/'<$\:&>K%ZJ"B$;R:]3R;F6=#(U+C.B0C#7UNBPEW
M9=_R/!CJGIC2=N^%E'W<[^2]!]AAEVJF:!(C&O3<NX3]DIW7E ^&]QH,-97[
M=QQOBKLYKFZD7HI^I(U,=NUL:M(;#0@WV(G&^!6OD5^><P[(.NBN,4^.A%F?
MUKIS>VO@@Y%BCWW THSAT"^UWOL5\0-EBS73!M,&(Z2QE^5VW;=LXVIS/>!A
M>N]<SK;V,,./T?V2382H'[[9]8(_1>F:3U>]@8\XD2O/0$?A+HP9:=HMTFG,
MB=G$C=#Z<N[O$+>00Z%WXL"2;>Z-&[D&_;\L%K[V<68HE+*PL40=$)+&>-%C
M"-%MQA4!'\ (JW&?KVV7RMKGJQ4KFY ^IT9"JVQ7A6;>YLX[!TX>G9=2G_?)
M=5'Y XTC'&L[1??NG)<$7U $/#2/H?5Z=MVD5^)T&AH(-:DWQ_S\Q0WS_<O)
M,P'BE'KK#O>EW#:2_YQTU&'L21S1M<T/29=GG&'AL:>()<DZ1OZ+\(-@H7_0
M+^O=@'7VP<GJ!>LT\[=/C#+3LA+=:ZXN7PO/OCA_ _H5!RK;R#/D6*]>1HX!
M3=?5FCM]]^X4_*N;Q_/MG&GP*KFM\N$E2[ZN:;>?#[I)LJY&O3Z_\BUNL>(F
M@/NY%A-E#4K5T+DA:_9.?7K)L/=FK9#(;_Z%7@]YX*_G_1HJDSO.Z&R?E/7M
M?(\\E$>UR.+2Y5O!+RM,A0LV %M2L^U-Z^=N=S_"[HSNZ:Y%6,HX!P4I1$V2
M>\FN.3E)KQU4D:YHFZ),_Z)_*X/?G:YK;54Y'65^DP<J@^'(]*@8]F?8"?;)
MNPM\;$F,<U)WAP[]8(#FN]4ZT*ZWQ>CQ.__'OD,UI9$<)>D!_,PIL1CQ?Q@>
M'BL:?F+TTJ$J:<-\E]\+G"'>IRH4O5 +[:[7N^"RCCM^SY7J%R?-\SS\ 2Q)
MK:1A:ILOC$>AIJ\0?7MM*ATN)T?V;9A>5WOA_3<,# E<3)WQZ\'7XC8-RWXT
MG0<CN@UZ5E*,] 4^M-:*SJ ->[/8?'3K1-D1;?\J,'*CL.D%9OJ]-N*XQ;NS
M-VP;(MZ<)4IB?BL/:O'[AE]N6Z,Y.%O8E;!G/3(%VQ^92BR'!&@WF/>8J@0V
M&1;]74A&7+\Q2WIO3'TO^JFV4@Z9U15KG@,^S;;6"9CZ?.'-^@72[7/V:U.%
M'54Q850/>\KZ1-MJK[FIT0AAY\JA^#6+^Y;'52[U?["_=[O\!=&1_.CS2O33
ML(M7H1O5O\0^HQV[#1R3,/K4+?&[>C8>=ST41^M9./,V\ZL)847KXC7STVYJ
M3YI>*35FZSDXW.[\+B+=,G[H],$'ETN5QY_H5P\;IY?X7FR^55QRJ>=GAD&M
MQ=K/!:&0W0(ACY33<K,"9^!\\<G\#N*AWXND7YZ_^#C,TT$@,N%WV:4&B3,-
M9THD0O[^^.]&&6'I**ZAA!5GPH5;OX31ZR.X14;0L]D7.E38/5D$*1AE6G,:
MSU@"["=ZXE)QGOAD/-1(A^9?OYW--SO\#"\)\Q^TZ#>V'MT=I1GV$ "]'EEX
METOQFTG@8^,8YAHMTL)\,]W* ;4QQ19\/<S4%V(T]%YBSX("8RDPZENLS$J)
MUT?N<1&A0U-=',T3U,2QDI1]R*P\6V"0GKI1LS@PFP/G8?K0'3>M@*9;X_<>
M#CZBCM&,?=S\6R9>VNJ]S,H6KR[U)V\7\HLIY!V=:ZQ,/7-G97.'*8QGC([#
M4 N@TO!&ZYX%F+3AOSA\#%19[(**>3>TQ%(1M'!2H-<^I!.K,2EU*N6\%\:[
M](=RW['5!]PY-QKHQ@W/LR1,A>H'F5\YRO0[HI[5EU2/F-YC\^"!1E6\&-,9
M;*(KP\$!&H[W;I:02;5834L[Z AXDT;O9I8934TM'#-"TC3%OJT*ESF/@+:G
M9%\2R)D[PO<)0(#$IO[B\ R"\8I52Z \1]1'7Z/BQ4!H+^X8]A33..Y6<W-]
MYBP-2HK8PQUFHH"4UXI??I%*_><5@*&,MYB;0-'2\X>9!18 (6E[N#$@TV7R
MS62;!%-4%\Z-([IQ]F]EBYS%6-K3 BLH)1LU<F4T?,SCP6<\8=1DCRVB@X%9
M)^RIP>8$)669?'6B\C\[GN@A<0R."@\IO3LI76^A_B?9ZCIW+Z<<#ZH[C6$,
MJW$")1Y:V_"DSA$4V%-9->$='TQN.W<IHMJ?K0<HY=*L[B7=0?K[33'-B]>E
M&^;ZZ],]/-R^>;@-:$^IR^,>$0 [Q"R?*2N:LS0\HAZQ:5@:\#!3>H5CLZ/)
ME5!!]?>HC<K"2:P:NL2:H]*1U.(7=YIL%;+TM- $V]&?Q;%?-31B7_A5N%\+
M6O=7QQTG (_$BU8X5;F*H^!W#0ZPHP&O^4W'AY!(N\7,$KE?6JGSQ:^>U4 :
MS=5F+U7;<[YED!"0'-'C(<^*WX?<AL9E=TN3!GQ#Z%LTH>AZ\S&;R6VH)/B4
M!@8"EO"6#_69ECD1A37-8')XR:J=Z^OM\S1939M8]7]=+,]P%^"(F;C:S!?Y
M&'U6)2P(*N+\ELX=WX8HP XB!']6TYH:V4-?C>0+?N"%.Q0Y_6O)GP:7^U@)
M9G62;V2=>V=VG"TQ7B7M6A9#<V&>8N50<: \GBD;4NQVEUR/%63E=9S#.#5U
M7%B33FZ,>7L%J&:, -ZS:V3?KNGK_UI1%IX1I-NNE;K>37J0>MR,^CZY=&U4
MO:>J.V%/?L\=1U2YA_-$S=@Q9('4KMR#B.,EI-0X%S^.ETC8;4C)11KM3O4D
MX[I;2I+M>K2TQ1LW#=%]O6Q=>F:TOV'/"N[.+$=)_U9P=3J&#>9L+L?%7"\
MKK!YB'MJV D3Z=JV=O %H.H.C\/5;^R&);?X_P:1BQ[5C]ZCP[NEGW\]/2 0
M1X(G.$HK=T5J./JY7VOS+W2S.JZ79&C^!]Q(U^BZ/^^8:SLTJ2SSRDOE:UE&
M;U+R#94"#9>T"@?[-VZRM+?YUA?:WN7^)#-=8YDW:&_6>^4,@3'93IT+;%G*
MMZ;#K^T6]5>:$U]A^J7ZNRSCBF('8#5EI;>^O/FMX_#LM\J'KDJ\R(J^RLN/
MN'P<:!"S @.N:9+O69=ET!&=&=V^3[C9XCO/KM3P<\L%N5S0OWO#MS.P$QO
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M.N8!YUUYWG\!L"* 9X8WENC0*Z BL-.-/=M6:VYDB,MG/@:E-%/#RIB(\_7
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M-L!< ,DH 14?T?8A3Q!R89J"/_#'4'\BS*LV.\Y@C$%D-3J*U(4_P3&%<+&
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M]?#]F?\!4$L! A0#%     @ ^(G<5MW3K#TB'P  W(8! !$
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M &5U9&$M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( /B)W%9R2F;OW@(
M (P6   *              "  5VU 0!E>#(Q+3$N:'1M4$L! A0#%     @
M^(G<5B1;O!$) P  G0T   H              ( !8[@! &5X,C,M,2YH=&U0
M2P$"% ,4    " #XB=Q6!KNCE"\#  #Z#P  "@              @ &4NP$
M97@R,RTR+FAT;5!+ 0(4 Q0    ( /B)W%8ZKF!^WP<  $<P   *
M      "  >N^ 0!E>#,Q+3$N:'1M4$L! A0#%     @ ^(G<5LI6C6KC!P
M="X   H              ( !\L8! &5X,S$M,BYH=&U02P$"% ,4    " #X
MB=Q6A OFY&H$   7%P  "@              @ ']S@$ 97@S,BTQ+FAT;5!+
M 0(4 Q0    ( /B)W%:&1(?B9 0   47   *              "  8_3 0!E
M>#,R+3(N:'1M4$L! A0#%     @ ^(G<5C0\@7F &0  <9<   D
M     ( !&]@! &5X-"TU+FAT;5!+ 0(4 Q0    ( /B)W%8W<0\609,# /*$
M(  ,              "  <+Q 0!F;W)M,3 M:RYH=&U02P$"% ,4    " #X
MB=Q6YNO'YND]   I2P  $               @ $MA04 9F]R;3$P+6M?,# Q
M+FIP9U!+ 0(4 Q0    ( /B)W%8DS?S2R(\  /"E   0              "
M 43#!0!F;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @ ^(G<5A%ZX#P'&
MW1@   X              ( !.E,& ')E<&]R=%\P,#$N:G!G4$L! A0#%
M  @ ^(G<5FEM']!10   #$(   X              ( !;6L& ')E<&]R=%\P
<,#(N:G!G4$L%!@     2 !( . 0  .JK!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
